FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Ryan, RJH Nitta, M Borger, D Iafrate, AJ Zukerberg, L Sohani, A Le, L AF Ryan, R. J. H. Nitta, M. Borger, D. Iafrate, A. J. Zukerberg, L. Sohani, A. Le, L. TI EZH2 Codon 641 Mutations Are Common in BCL2-Rearranged B Cell Lymphomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Ryan, R. J. H.; Nitta, M.; Borger, D.; Iafrate, A. J.; Zukerberg, L.; Sohani, A.; Le, L.] Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1355 BP 319A EP 319A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001011 ER PT J AU Rosado, FGN Tang, YW Hasserjian, RP McClain, C Wang, BY Mosse, CM AF Rosado, F. G. N. Tang, Y-W Hasserjian, R. P. McClain, C. Wang, B. Y. Mosse, C. M. TI Kikuchi's Lymphadenitis: Role of Parvovirus B-19, EBV, HHV-6, and HHV-8 Detected by PCR in a Multi-Institutional Review of 18 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Vanderbilt Univ, Med Ctr, Nashville, TN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NYU, New York, NY 10003 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1435 BP 338A EP 338A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001091 ER PT J AU McClintock, DS Lee, RE Oberg, CG Gudewicz, TM Gilbertson, JR AF McClintock, D. S. Lee, R. E. Oberg, C. G. Gudewicz, T. M. Gilbertson, J. R. TI Applying Computer Assisted Process Modeling To Improve Anatomic Pathology Workflows SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [McClintock, D. S.; Lee, R. E.; Oberg, C. G.; Gudewicz, T. M.; Gilbertson, J. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1446 BP 340A EP 341A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001102 ER PT J AU Kushner, YB Malik, FA Collins, AB Holmes, RK Smith, RN Colvin, RB AF Kushner, Y. B. Malik, F. A. Collins, A. B. Holmes, R. K. Smith, R. N. Colvin, R. B. TI Glomerular Endothelial Injury in Patients with Non-Renal Transplants: Are We Missing Subclinical Thrombotic Microangiopathy? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Kushner, Y. B.; Malik, F. A.; Collins, A. B.; Holmes, R. K.; Smith, R. N.; Colvin, R. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1472 BP 347A EP 347A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001128 ER PT J AU Das, KK Krings, G Pitman, MB Mino-Kenudson, M AF Das, K. K. Krings, G. Pitman, M. B. Mino-Kenudson, M. TI A Novel Monoclonal Antibody, mAb Das-1, Identifies a Colonic Phenotype and Is Specific for Intraductal Papillary Mucinous Neoplasm (IPMN) with a High Risk for Malignant Transformation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Das, K. K.; Krings, G.; Pitman, M. B.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1519 BP 358A EP 358A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001175 ER PT J AU Lisovsky, M Konstas, AA Hahn, PF Misdraji, J AF Lisovsky, M. Konstas, A. A. Hahn, P. F. Misdraji, J. TI Congenital Absence of Portal Vein (Abernethy Malformation): A Histopathologic Evaluation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1558 BP 367A EP 367A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001214 ER PT J AU Zhang, L Chari, S Smyrk, T Deshpande, V Kloppel, G Kojima, M Liu, X Longnecker, D Mino-Kenudson, M Notohara, K Rodriguez-Justo, M Srivastava, A Zamboni, G Zen, Y AF Zhang, L. Chari, S. Smyrk, T. Deshpande, V. Kloppel, G. Kojima, M. Liu, X. Longnecker, D. Mino-Kenudson, M. Notohara, K. Rodriguez-Justo, M. Srivastava, A. Zamboni, G. Zen, Y. TI Autoimmune Pancreatitis (AIP) Type 1 and Type 2: An International Consensus Study on Histopathologic Diagnostic Criteria SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Kiel, D-24098 Kiel, Germany. Natl Canc Ctr Hosp E, Kashiwa, Chiba, Japan. Cleveland Clin, Cleveland, OH USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Kurashiki Cent Hosp, Kurashiki, Okayama, Japan. UCL, London WC1E 6BT, England. Univ Verona, I-37100 Verona, Italy. Kings Coll London, London WC2R 2LS, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1599 BP 377A EP 377A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001255 ER PT J AU Katz, SG Fisher, JK Ligon, KL Walensky, LD AF Katz, S. G. Fisher, J. K. Ligon, K. L. Walensky, L. D. TI Neural Stem Cells Deficient in BAX and BAK Manifest Profound Hyperplasia and Tumorigenesis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Childrens Hosp Boston, Boston, MA USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1621 BP 382A EP 382A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001277 ER PT J AU Evans, A Fletcher, C French, C Jackman, D Lathan, C Sholl, L AF Evans, A. Fletcher, C. French, C. Jackman, D. Lathan, C. Sholl, L. TI Detection of NUT Midline Carcinoma in Retrospective Analysis of Thymic and Mediastinal Neoplasms. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1739 BP 408A EP 408A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001395 ER PT J AU Hariri, LP Mark, EJ Onozato, ML Yagi, Y Shea, B Digumarthy, S Fraire, A Matsubara, O Mino-Kenudsen, M AF Hariri, L. P. Mark, E. J. Onozato, M. L. Yagi, Y. Shea, B. Digumarthy, S. Fraire, A. Matsubara, O. Mino-Kenudsen, M. TI Histopathological Features of Acute Hypersensitivity Pneumonitis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Massachusetts, Mem Med Ctr, Worcester, MA 01605 USA. Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1750 BP 411A EP 411A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001406 ER PT J AU Hariri, LP Mino-Kenudsen, M Mark, EJ Applegate, MB Tearney, GJ Bouma, BE Suter, MJ AF Hariri, L. P. Mino-Kenudsen, M. Mark, E. J. Applegate, M. B. Tearney, G. J. Bouma, B. E. Suter, M. J. TI High-Resolution Volumetric Imaging of Lung Pathology: Improving Biopsy Sampling and Evaluation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Hariri, L. P.; Mino-Kenudsen, M.; Mark, E. J.; Applegate, M. B.; Tearney, G. J.; Bouma, B. E.; Suter, M. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1751 BP 411A EP 411A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001407 ER PT J AU Klepeis, VE Mark, EJ Dias-Santagata, D Iafrate, AJ Mino-Kenudson, M AF Klepeis, V. E. Mark, E. J. Dias-Santagata, D. Iafrate, A. J. Mino-Kenudson, M. TI Correlation of a Proposed Scoring System for Lung Adencoarcinoma with Molecular Alterations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Klepeis, V. E.; Mark, E. J.; Dias-Santagata, D.; Iafrate, A. J.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1768 BP 415A EP 416A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001424 ER PT J AU Kovach, AE Mark, EJ Mino-Kenudson, M AF Kovach, A. E. Mark, E. J. Mino-Kenudson, M. TI Expression of SOX2 and p63 Do Not Have Independent Prognostic Significance in Stage I Lung Adenocarcinoma. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Kovach, A. E.; Mark, E. J.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1770 BP 416A EP 416A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001426 ER PT J AU Matsubara, O Kobayashi, K Yamamoto, S Kikuchi, R Iwaya, K Nakatani, Y Kradin, RL Mark, EJ AF Matsubara, O. Kobayashi, K. Yamamoto, S. Kikuchi, R. Iwaya, K. Nakatani, Y. Kradin, R. L. Mark, E. J. TI Higher Metabolic Activity in Fibroblastic Foci of UIP Than in Buds of Fibrosis in Intra-Alveolar Buds in COP/BOOP. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Natl Def Med Coll, Saitama, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1778 BP 418A EP 418A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001434 ER PT J AU Nishino, M Mark, EJ Matsubara, O Medoff, BD O'Donnell, WJ Currier, PP Kradin, RL AF Nishino, M. Mark, E. J. Matsubara, O. Medoff, B. D. O'Donnell, W. J. Currier, P. F. Kradin, R. L. TI Variant Pulmonary Alveolar Proteinosis: A Syndrome with Distinct Clinical and Pathologic Features. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Natl Def Med Coll, Saitama, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1786 BP 420A EP 420A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001442 ER PT J AU Nishino, M Klepeis, VE Bergethon, K Mark, EJ Iafrate, AJ Mino-Kenudson, M AF Nishino, M. Klepeis, V. E. Bergethon, K. Mark, E. J. Iafrate, A. J. Mino-Kenudson, M. TI Histologic and Cytomorphologic Features of ALK-Rearranged Lung Adenocarcinomas. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Nishino, M.; Klepeis, V. E.; Bergethon, K.; Mark, E. J.; Iafrate, A. J.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1787 BP 420A EP 420A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001443 ER PT J AU Schwartz, B Hofer, M Lemieux, M Bauer, D Cameron, M West, N Agoston, E Ince, T Janeway, K Vargas, S Perez-Atayde, A Aster, J Sallan, S Kung, A Bradner, J French, C AF Schwartz, B. Hofer, M. Lemieux, M. Bauer, D. Cameron, M. West, N. Agoston, E. Ince, T. Janeway, K. Vargas, S. Perez-Atayde, A. Aster, J. Sallan, S. Kung, A. Bradner, J. French, C. TI Differentiation of NUT Midline Carcinoma in Humans and Mice by Epigenomic Reprogramming SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Childrens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1801 BP 423A EP 423A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001457 ER PT J AU Zhang, W Joshi, V Heon, S Gandhi, L Jackman, D Lindeman, N Sholl, L AF Zhang, W. Joshi, V. Heon, S. Gandhi, L. Jackman, D. Lindeman, N. Sholl, L. TI Phenotypic Correlates of ERBB2, BRAF and PIK3CA Mutations in Non-Small Cell Lung Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Partners Ctr Genom Med, Boston, MA USA. Massachussetts Gen Hosp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1828 BP 430A EP 430A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001484 ER PT J AU Martin, NE Sinnott, JA Finn, S Fedele, G Stampfer, MJ Andren, O Andersson, SO Mucci, L Loda, M AF Martin, N. E. Sinnott, J. A. Finn, S. Fedele, G. Stampfer, M. J. Andren, O. Andersson, S-O Mucci, L. Loda, M. TI Integrated Signature of PI3K Pathway Activation in Prostate Cancer. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Orebro Univ Hosp, Orebro, Sweden. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1892 BP 444A EP 445A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001547 ER PT J AU Ojesina, AI Kostic, A Jung, J Pedamallu, C Getz, G Maciejewski, J Shipp, M Cesarman, E Aster, J Meyerson, M AF Ojesina, A. I. Kostic, A. Jung, J. Pedamallu, C. Getz, G. Maciejewski, J. Shipp, M. Cesarman, E. Aster, J. Meyerson, M. TI Pathogen Discovery in Hematological Neoplasms and Inflammatory Diseases by High Throughput Sequencing of Human Tissues. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst MIT Anad Harvard, Cambridge, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Cleveland Clin, Cleveland, OH USA. Weill Cornell Med Coll, New York, NY USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1895 BP 445A EP 445A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001550 ER PT J AU Ackerman, KE Misra, M AF Ackerman, Kathryn E. Misra, Madhusmita TI Bone Health and the Female Athlete Triad in Adolescent Athletes SO PHYSICIAN AND SPORTSMEDICINE LA English DT Article DE athlete; adolescent; physical activity; bone density; bone microarchitecture; hormones; estrogen; hypogonadism; growth hormone; cortisol; leptin; nutrition; female athlete triad ID VITAMIN-D DEFICIENCY; GHRELIN STIMULATES PROLIFERATION; TRANSDERMAL ESTROGEN REPLACEMENT; OSTEOBLASTIC MC3T3-E1 CELLS; YOUNG-ADULT MEN; MINERAL DENSITY; ANOREXIA-NERVOSA; PHYSICAL-ACTIVITY; BODY-COMPOSITION; CORTICAL BONE AB Peak bone mass (PBM) is a negative predictor of osteoporosis and lifelong fracture risk. Because osteoporosis is such a prevalent disease with life-threatening consequences, it is important to try to maximize PBM. Adolescence is a critical period for bone acquisition. This article discusses some of the differences in male and female skeletal development and modifiable factors that enhance bone accrual in this age group, particularly in athletes. Hormonal influences, effects of physical activity, and nutritional contributions are included, with a focus on the adolescent athlete. Emphasis is placed on the importance of appropriate energy availability in this age group. We also review prevention and treatment strategies for the female athlete triad (ie, the inter-relationship of decreased energy availability, menstrual irregularity, and low bone density) in adolescents and athletic women. Recommendations for maximizing bone density in both male and female adolescents are discussed. C1 [Misra, Madhusmita] Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457, Boston, MA 02114 USA. [Ackerman, Kathryn E.; Misra, Madhusmita] Harvard Univ, Sch Med, Boston, MA USA. [Ackerman, Kathryn E.] Childrens Hosp, Div Sports Med, Boston, MA 02115 USA. [Misra, Madhusmita] Massachusetts Gen Hosp Children, Pediat Endocrine Unit, Boston, MA USA. RP Misra, M (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457, 55 Fruit St, Boston, MA 02114 USA. EM mmisra@partners.org FU National Institutes of Health [1 R01 HD060827-01A1] FX This work was supported in part by National Institutes of Health grant 1 R01 HD060827-01A1. NR 146 TC 12 Z9 12 U1 0 U2 36 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0091-3847 EI 2326-3660 J9 PHYSICIAN SPORTSMED JI Physician Sportsmed. PD FEB PY 2011 VL 39 IS 1 BP 131 EP 141 DI 10.3810/psm.2011.02.1871 PG 11 WC Primary Health Care; Orthopedics; Sport Sciences SC General & Internal Medicine; Orthopedics; Sport Sciences GA 764LN UT WOS:000290631100015 PM 21378496 ER PT J AU Nielsen, GP Rosenberg, AE O'Connell, JX Kattapuram, SV Schiller, AL AF Nielsen, G. Petur Rosenberg, Andrew E. O'Connell, John X. Kattapuram, Susan V. Schiller, Alan L. TI Tumors and diseases of the joint SO SEMINARS IN DIAGNOSTIC PATHOLOGY LA English DT Article DE Synovium; Tumors; Crystal deposition ID PIGMENTED VILLONODULAR SYNOVITIS; GIANT-CELL TUMOR; DIFFERENTIAL DIAGNOSTIC CONSIDERATIONS; EXTRASKELETAL MYXOID CHONDROSARCOMA; DIHYDRATE CRYSTAL-DEPOSITION; TENDON SHEATH; LIPOMA-ARBORESCENS; CALCIUM PYROPHOSPHATE; HEMOPHILIC ARTHROPATHY; MALIGNANT-TRANSFORMATION AB A variety of different diseases affect the synovium, including infection, noninfectious immunologic inflammatory conditions, degenerative arthroses, crystal deposits, trauma, and tumors. Tumors of the synovium are relatively uncommon. Any mesenchymal tumor may arise in the synovium, but most recapitulate its normal counterpart including synoviocytes, blood vessels, fat, and fibrous tissue. These tumors can arise in any synovial lined structures both within joints and in extraarticular locations. Most synovial tumors are benign. Malignant tumors are rare but important to recognize because many are aggressive and must be treated appropriately. Among common nonneoplastic conditions that affect the synovium and surrounding structures are crystal deposits such as monosodium urate crystals, calcium pyrophosphate dihydrate crystals, and hydroxyapatite crystals. These crystal deposits may be asymptomatic or cause severe pain or chronic joint destruction. Their accurate identification is important to guide appropriate therapy. (C) 2011 Elsevier Inc. All rights reserved. C1 [Nielsen, G. Petur; Rosenberg, Andrew E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. [O'Connell, John X.] CI Coady Associates, Dept Pathol, Surrey, BC, Canada. [Kattapuram, Susan V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Schiller, Alan L.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA. RP Nielsen, GP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. EM gnielsen@partners.org NR 103 TC 6 Z9 6 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0740-2570 EI 1930-1111 J9 SEMIN DIAGN PATHOL JI Semin. Diagn. Pathol. PD FEB PY 2011 VL 28 IS 1 BP 37 EP 52 DI 10.1053/j.semdp.2011.02.009 PG 16 WC Medical Laboratory Technology; Pathology SC Medical Laboratory Technology; Pathology GA 766ZG UT WOS:000290824500005 PM 21675376 ER PT J AU Rosenberg, AE Nielsen, GP Reith, J AF Rosenberg, Andrew E. Nielsen, G. Petur Reith, John TI Surgical pathology of joint prostheses SO SEMINARS IN DIAGNOSTIC PATHOLOGY LA English DT Article DE Prosthetic joint; Wear debris reaction; Hypersensitivity; Infection; Sarcoma ID HIP; WEAR; KNEE AB Joint arthroplasty is a commonly performed surgical procedure that provides significant benefit to the patient. The prosthetic devices are composed of combinations of polyethylene, ceramics, metal alloys, bone cement, and silicone and are associated with complications as well as eventual failure from wear and corrosion. The pathologic findings of these processes are complex and require accurate interpretation to help guide therapy and identify the underlying biological mechanisms. (C) 2011 Elsevier Inc. All rights reserved. C1 [Rosenberg, Andrew E.; Nielsen, G. Petur] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Reith, John] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA. RP Rosenberg, AE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. EM arosenberg@partners.org NR 16 TC 3 Z9 3 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0740-2570 J9 SEMIN DIAGN PATHOL JI Semin. Diagn. Pathol. PD FEB PY 2011 VL 28 IS 1 BP 65 EP 72 DI 10.1053/j.semdp.2011.02.005 PG 8 WC Medical Laboratory Technology; Pathology SC Medical Laboratory Technology; Pathology GA 766ZG UT WOS:000290824500007 PM 21675378 ER PT J AU Antonescu, CR Zhang, L Nielsen, GP Rosenberg, AE Dal Cin, P Fletcher, CD AF Antonescu, C. R. Zhang, L. Nielsen, G. P. Rosenberg, A. E. Dal Cin, P. Fletcher, C. D. TI Consistent t(1;10) Abnormality in Both Myxoinflammatory Fibroblastic Sarcoma (MIFS) and Hemosiderotic Fibrolipomatous Tumor (HFLT) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 21 BP 9A EP 9A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300022 ER PT J AU Kurzawa, PJ Nielsen, PG Kattapuram, S Hornicek, FJ Rosenberg, AE AF Kurzawa, P. J. Nielsen, P. G. Kattapuram, S. Hornicek, F. J. Rosenberg, A. E. TI Primary Myoepithelioma of Bone. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Great Poland Canc Ctr, Poznan, Wielkopolska, Poland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 57 BP 17A EP 17A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300058 ER PT J AU Yasir, S Nadji, A Kurzawa, P Nielsen, GP Rosenberg, A AF Yasir, S. Nadji, A. Kurzawa, P. Nielsen, G. P. Rosenberg, A. TI Expression of Epithelial Markers in Nodular Fasciitis and Fibromatosis: An Immunohistochemical Study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Univ Miami, Jackson Mem Hosp, Coral Gables, FL 33124 USA. Great Poland Canc Ctr, Poznan, Poland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 88 BP 24A EP 24A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300089 ER PT J AU Corben, AD Teo, C AbiRaad, R Bombonati, A Koerner, FC Taghian, A Brachtel, EF AF Corben, A. D. Teo, C. AbiRaad, R. Bombonati, A. Koerner, F. C. Taghian, A. Brachtel, E. F. TI Classifications of Pathological Response and Long-Term Follow-Up in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Tan Tock Seng Hosp, Singapore, Singapore. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 133 BP 34A EP 35A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282300134 ER PT J AU Corben, AD D'Arcy, C Abi-Raad, R Bombonati, A Taghian, A Akram, M Koerner, FC Eichhorn, JH Brachtel, EF AF Corben, A. D. D'Arcy, C. Abi-Raad, R. Bombonati, A. Taghian, A. Akram, M. Koerner, F. C. Eichhorn, J. H. Brachtel, E. F. TI Hormone Receptor and HER2 Profiles before and after Neoadjuvant Chemotherapy: Experience at Two Centers SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 135 BP 35A EP 35A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300136 ER PT J AU Eichhorn, JH Crothers, BA Wilbur, DC AF Eichhorn, J. H. Crothers, B. A. Wilbur, D. C. TI Gynecologic Telecytology Using Automated Local Image Selection with Remote Interpretation: The Results of a Phase 2 Prospective Trial SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 364 BP 89A EP 89A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300366 ER PT J AU Nishino, H Wilbur, D Tambouret, R AF Nishino, H. Wilbur, D. Tambouret, R. TI Utility of "Low-Grade Squamous Intraepithelial Lesion, Cannot Exclude High-Grade Squamous Intraepithelial Lesion" (LSIL-H) Usage as a Quality Assurance (QA) Measure SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Nishino, H.; Wilbur, D.; Tambouret, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 414 BP 100A EP 100A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300416 ER PT J AU Ono, J Yaeger, K Genevay, M Mino-Kenudson, M Brugge, WR Pitman, MB AF Ono, J. Yaeger, K. Genevay, M. Mino-Kenudson, M. Brugge, W. R. Pitman, M. B. TI Cytological Analysis of Small Branch-Duct IPMNS Provides a More Accurate Risk Assessment for Malignancy Than Symptoms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hosp Geneva, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 415 BP 100A EP 100A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300417 ER PT J AU Singh, RS Wang, HH AF Singh, R. S. Wang, H. H. TI Timing of Repeat Thyroid FNA in the Management of Thyroid Nodules SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 BIDMC, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 435 BP 105A EP 105A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300437 ER PT J AU Wang, H Michaels, PJ Cibas, ES Khurana, K Ali, SZ Bongiovanni, M Powers, CN Faquin, WC AF Wang, H. Michaels, P. J. Cibas, E. S. Khurana, K. Ali, S. Z. Bongiovanni, M. Powers, C. N. Faquin, W. C. TI FNAB of Secondary Neoplasms of the Thyroid Gland: A Multi-Institutional Study of 60 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Inst Pathol, Locarno, Switzerland. Virginia Commonwealth Univ, Richmond, VA 23284 USA. Johns Hopkins Univ, Baltimore, MD USA. SUNY Upstate Med Univ, Syracuse, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 451 BP 109A EP 109A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300453 ER PT J AU Baran, JL Duncan, LM AF Baran, J. L. Duncan, L. M. TI Definition and Categorization of Combined Melanocytic Nevi SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Baran, J. L.; Duncan, L. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 466 BP 112A EP 113A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282300468 ER PT J AU Brenn, T Grayson, W Frkovic-Grazio, S Mihm, MC Calonje, E McKee, PH AF Brenn, T. Grayson, W. Frkovic-Grazio, S. Mihm, M. C. Calonje, E. McKee, P. H. TI Melanoma in Childhood and Adolescence: Clinicopathologic Analysis of 64 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Western Gen Hosp, Edinburgh, Midlothian, Scotland. Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland. Natl Hlth Lab Serv, Johannesburg, South Africa. Univ Witwatersrand, Johannesburg, South Africa. Inst Oncol, Ljubljana, Slovenia. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Boston, MA 02115 USA. St Johns Inst Dermatol, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 468 BP 113A EP 113A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300470 ER PT J AU Linskey, K Kroshinsky, D Hoang, M AF Linskey, K. Kroshinsky, D. Hoang, M. TI Immunoglobulin-A Associated Small Vessel Vasculitis: A Ten-Year Experience at the Massachusetts General Hospital SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Linskey, K.; Kroshinsky, D.; Hoang, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 498 BP 120A EP 120A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300500 ER PT J AU Phadke, PA Rakheja, D Le, LP Selim, MA Kapur, P Davis, A Mihm, MC Hoang, MP AF Phadke, P. A. Rakheja, D. Le, L. P. Selim, M. A. Kapur, P. Davis, A. Mihm, M. C. Hoang, M. P. TI Proliferative Nodule Arising within Congenital Melanocytic Nevus: Histologic, Immunohistochemical and Molecular Analyses of 43 Cases. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 511 BP 123A EP 123A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300513 ER PT J AU Lee, RE McClintock, DS Ponce, CR Gilbertson, JR Dighe, AS Yagi, Y AF Lee, R. E. McClintock, D. S. Ponce, C. R. Gilbertson, J. R. Dighe, A. S. Yagi, Y. TI Educational Recuts on a Portable Hard Drive: A New Paradigm for Personal Slide Collections SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Lee, R. E.; McClintock, D. S.; Ponce, C. R.; Gilbertson, J. R.; Dighe, A. S.; Yagi, Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 545 BP 131A EP 131A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300547 ER PT J AU Kovach, AE Lam, Q Dias-Santagata, D Sadow, PM AF Kovach, A. E. Lam, Q. Dias-Santagata, D. Sadow, P. M. TI Molecular Analysis of Adrenal Cortical Carcinomas in Clinical and Histologic Context SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 577 BP 138A EP 138A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300579 ER PT J AU Fan, XS Chen, JY Feng, AN Wu, HY Gold, JS Huang, Q AF Fan, X. S. Chen, J. Y. Feng, A. N. Wu, H. Y. Gold, J. S. Huang, Q. TI HER2 Protein Over-Expression in Proximal and Distal Gastric Cancers: An Immunohistochemical and Clinicopathological Comparison Study of 957 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China. Harvard Univ, Sch Med, W Roxbury, MA USA. VA Boston Healthcare Syst, W Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 620 BP 148A EP 148A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300622 ER PT J AU Huang, Q Gold, JK Wu, HY Fan, XS Feng, AN Shi, J AF Huang, Q. Gold, J. K. Wu, H. Y. Fan, X. S. Feng, A. N. Shi, J. TI Pancreatic Acinar-Like Adenocarcinoma of the Proximal Stomach Involving the Esophagus in Chinese Patients: A Clinicopathological Study of 41 Cases from a Single High-Volume Hospital in China SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Nanjing Drum Tower Hosp, Nanjing, Peoples R China. VA Boston Healthcare Syst, W Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 640 BP 152A EP 152A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300642 ER PT J AU Kim, A Park, MK Kim, KB Kim, JY Shin, N Choi, KU Park, DY Lauwers, GY AF Kim, A. Park, M-K Kim, K-B Kim, J-Y Shin, N. Choi, K-U Park, D. Y. Lauwers, G. Y. TI P53 Expression and Proliferation Index Measured by Ki-67 Immunostaining in Gastric Pit Dysplasia. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Pusan Natl Univ Hosp, Pusan, South Korea. Pusan Natl Univ, Sch Med, Pusan, South Korea. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 654 BP 156A EP 156A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300656 ER PT J AU Lisovsky, M Mino-Kenudson, M Lefferts, J Courville, E Zaki, B Calvo, LN Hong, TS Tsongalis, GJ Lauwers, GY Srivastava, A AF Lisovsky, M. Mino-Kenudson, M. Lefferts, J. Courville, E. Zaki, B. Calvo, L. N. Hong, T. S. Tsongalis, G. J. Lauwers, G. Y. Srivastava, A. TI MGMT (O6-MethylguanineDNA Methyltransferase) Is Inactivated in a Significant Subset of Distal Esophageal Adenocarcinomas: Implications for Neoadjuvant Chemoradiation Therapy. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 660 BP 157A EP 157A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300662 ER PT J AU Lisovsky, M Jiang, Z Lauwers, GY AF Lisovsky, M. Jiang, Z. Lauwers, G. Y. TI Oncofetal Protein IMP3 as a Predictor of Prognosis in Gastric Adenocarcinoma. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH, Uzbekistan. UMassMem Med Ctr, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 659 BP 157A EP 157A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300661 ER PT J AU Nosho, K Dranoff, G Fuchs, C Ogino, S AF Nosho, K. Dranoff, G. Fuchs, C. Ogino, S. TI Tumor-Infiltrating CD45RO+-Cell Density, but Not CD3+, CD8+, or FOXP3+-Cell Density, Has a Prognostic Role in Colorectal Cancer, Independent of Molecular Features. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 672 BP 160A EP 160A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300674 ER PT J AU Ogino, S Tanaka, N Fuchs, C AF Ogino, S. Tanaka, N. Fuchs, C. TI Multivariate Negative Binomial Regression Identifies Length of Colorectal Resection, ProximalTumor Location,T3N0M0 Stage, Academic Setting, andTumor PIK3CA Mutation as Independent Predictors of Lymph Node Count SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 675 BP 160A EP 161A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282300677 ER PT J AU Ogino, S Fuchs, C Huttenhower, C AF Ogino, S. Fuchs, C. Huttenhower, C. TI LINE-1 Extreme Hypomethylator Is a New Distinct Molecular Subtype Associated with Young Age and Poor Prognosis: Bioinformatic Analysis of 1190 Colorectal Cancers SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 676 BP 161A EP 162A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282300678 ER PT J AU Rege, TA Wagner, AJ Corless, CL Hornick, JL AF Rege, T. A. Wagner, A. J. Corless, C. L. Hornick, J. L. TI "Pediatric-Type" Gastrointestinal Stromal Tumors in Adults: Distinctive Histology Predicts Genotype and Clinical Behavior SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 690 BP 165A EP 165A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300692 ER PT J AU Shimizu, M Aida, J Brown, IS Greenson, JK Jouret-Mourin, A Kawachi, H Lennerz, JK Nagata, K Takubo, K Vieth, M Lauwers, GY AF Shimizu, M. Aida, J. Brown, I. S. Greenson, J. K. Jouret-Mourin, A. Kawachi, H. Lennerz, J. K. Nagata, K. Takubo, K. Vieth, M. Lauwers, G. Y. TI Evaluation of Esophageal Biopsies for Squamous Intraepithelial Neoplasia: Differences between Japan and the West SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Saitama Med Univ, Int Med Ctr, Hidaka, Japan. Tokyo Metropolitan Inst Gerontol, Itabashi Ku, Tokyo, Japan. Sullivan Nicolaides Pathol, Brisbane, Qld, Australia. Univ Michigan, Ann Arbor, MI 48109 USA. Catholic Univ Louvain, B-1200 Brussels, Belgium. Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Klinikum Bayreuth, Bayreuth, Germany. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 701 BP 167A EP 167A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300703 ER PT J AU Virk, RK Lauwers, GY Deshpande, V AF Virk, R. K. Lauwers, G. Y. Deshpande, V. TI The Significance of IGG4 in Inflammatory Bowel Disease SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 UMass Mem Med Ctr, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 719 BP 172A EP 172A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300721 ER PT J AU Wang, H Chen, Y Deshpande, V AF Wang, H. Chen, Y. Deshpande, V. TI Heterogeneity in Signaling Pathways of Gastrointestinal Neuroendocrine Cell Tumors: A Critical Look at Notch Signaling Pathway SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Univ Delaware, Newark, DE USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 721 BP 172A EP 173A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282300723 ER PT J AU Berger, MF Lawrence, MS Demichelis, F Getz, G Rubin, MA Garraway, LA AF Berger, M. F. Lawrence, M. S. Demichelis, F. Getz, G. Rubin, M. A. Garraway, L. A. TI Characterization of Complex Chromosomal Aberrations in Primary Prostate Cancer Genomes SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Weill Cornell Med Coll, Prostate Genome Consortium, Broad Inst, Cambridge, MA USA. Weill Cornell Med Coll, New York, NY USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 752 BP 179A EP 179A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300754 ER PT J AU Flavin, R Hendrickson, W Krunz, L Judson, G Lis, R Bailey, D Fiorentino, M Finn, S Martin, N Stark, J Pettersson, A Sinnott, J Penny, K Fall, K Giovannucci, E Rubin, M Kantoff, P Stampfer, M Loda, M Mucci, L AF Flavin, R. Hendrickson, W. Krunz, L. Judson, G. Lis, R. Bailey, D. Fiorentino, M. Finn, S. Martin, N. Stark, J. Pettersson, A. Sinnott, J. Penny, K. Fall, K. Giovannucci, E. Rubin, M. Kantoff, P. Stampfer, M. Loda, M. Mucci, L. TI SPINK1 Protein Expression and Prostate Cancer Progression SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 810 BP 192A EP 192A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282300812 ER PT J AU He, W Cheville, JC Sadow, PM Gopalan, A Fine, SW Al-Ahmadie, HA Chen, Y Oliva, E Russo, P Reuter, VE Tickoo, SK AF He, W. Cheville, J. C. Sadow, P. M. Gopalan, A. Fine, S. W. Al-Ahmadie, H. A. Chen, Y. Oliva, E. Russo, P. Reuter, V. E. Tickoo, S. K. TI Pathologic Characteristics and Clinical Outcome of Renal Epithelioid Angiomyolipoma: A Multi-Institutional Experience Based on Primary Tumor Resections SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 4 Z9 4 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 829 BP 196A EP 197A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282300831 ER PT J AU Kao, CS Idrees, MT Young, RH Ulbright, TM AF Kao, C-S Idrees, M. T. Young, R. H. Ulbright, T. M. TI Solid Pattern of Testicular Yolk Sac Tumor: A Morphologic and Immunohistochemical Study of 52 Cases. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Indiana Univ Sch Med, Indianapolis, IN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 853 BP 202A EP 202A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301008 ER PT J AU Pettersson, A Flavin, R Stark, J Fiorentino, M Pollak, M Penney, K Sesso, HD Gleave, M Bismar, TA Perner, S Finn, S Rubin, MA Ma, J Giovannucci, E Stamper, M Kantoff, P Loda, M Mucci, L AF Pettersson, A. Flavin, R. Stark, J. Fiorentino, M. Pollak, M. Penney, K. Sesso, H. D. Gleave, M. Bismar, T. A. Perner, S. Finn, S. Rubin, M. A. Ma, J. Giovannucci, E. Stamper, M. Kantoff, P. Loda, M. Mucci, L. TI TMPRSS2:ERG Rearrangement and Markers of Metabolic Signaling Pathways Implicated in Prostate Carcinogenesis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Pettersson, A.; Flavin, R.; Stark, J.; Fiorentino, M.; Pollak, M.; Penney, K.; Sesso, H. D.; Gleave, M.; Bismar, T. A.; Perner, S.; Finn, S.; Rubin, M. A.; Ma, J.; Giovannucci, E.; Stamper, M.; Kantoff, P.; Loda, M.; Mucci, L.] Dana Farber Harvard Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 917 BP 217A EP 218A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282301072 ER PT J AU Ryan, RJ Wu, S Borger, D Lafrate, J Wu, CL Le, L AF Ryan, R. J. Wu, S. Borger, D. Lafrate, J. Wu, C-L Le, L. TI The Lymphoma-Associated EZH2 Codon 641 Mutation Is Not Detected in Localized Prostate Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Ryan, R. J.; Wu, S.; Borger, D.; Lafrate, J.; Wu, C-L; Le, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 933 BP 221A EP 221A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301088 ER PT J AU Stampfer, MJ Penney, K Sinnott, J Flavin, R Stark, J Finn, S Giovannucci, E Sesso, H Loda, M Mucci, L Fiorentino, M AF Stampfer, M. J. Penney, K. Sinnott, J. Flavin, R. Stark, J. Finn, S. Giovannucci, E. Sesso, H. Loda, M. Mucci, L. Fiorentino, M. TI Does Gleason Grade Progress over Time? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Stampfer, M. J.; Penney, K.; Sinnott, J.; Flavin, R.; Stark, J.; Finn, S.; Giovannucci, E.; Sesso, H.; Loda, M.; Mucci, L.; Fiorentino, M.] Dana Farber Harvard Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 952 BP 225A EP 225A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301107 ER PT J AU Stark, JR Finn, SP Ma, J Sinnott, JA Schumacher, F Lis, R Penney, KL Kasperzyk, JL Sesso, HD Stampfer, MJ Giovannucci, EL Loda, M Mucci, LA AF Stark, J. R. Finn, S. P. Ma, J. Sinnott, J. A. Schumacher, F. Lis, R. Penney, K. L. Kasperzyk, J. L. Sesso, H. D. Stampfer, M. J. Giovannucci, E. L. Loda, M. Mucci, L. A. TI Adiponectin Receptor 2 Expression Predicts Lethal Prostate Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Dublin, Trinity Coll, Dublin, Ireland. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Univ Calif Los Angeles, Keck Sch Med, Los Angeles, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 954 BP 226A EP 226A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301109 ER PT J AU Al-Agha, OM Huwait, HF Chow, C Yang, W Senz, JE Kalloger, SG Huntsman, DH Young, R Gilks, CB AF Al-Agha, O. M. Huwait, H. F. Chow, C. Yang, W. Senz, J. E. Kalloger, S. G. Huntsman, D. H. Young, R. Gilks, C. B. TI Anti-FOXL2 Antibody Is a Sensitive and Specific Diagnostic Marker for Ovarian Sex Cord-Stromal Tumors. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Vancouver Gen Hosp, Vancouver, BC, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 988 BP 234A EP 234A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301143 ER PT J AU Azueta, A Gatius, S Velasco, A Santacana, M Pallares, J Clarke, B Oliva, E Matias-Guiu, X AF Azueta, A. Gatius, S. Velasco, A. Santacana, M. Pallares, J. Clarke, B. Oliva, E. Matias-Guiu, X. TI Dedifferentiated Carcinoma of the Endometrium and the Ovary: A Molecular Study of 8 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Univ Lleida, IRB Lleida, Hosp Univ Arnau de Vilanova, Lleida, Spain. Massachusetts Gen Hosp, Boston, MA 02114 USA. Toronto Gen Hosp, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 999 BP 236A EP 236A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301154 ER PT J AU Biscuola, M De Vijver, KV Castilla, MA Romero-Perez, L Lopez-Garcia, MA Palacios, J Oliva, E AF Biscuola, M. De Vijver, K. Van Castilla, M. A. Romero-Perez, L. Lopez-Garcia, M. A. Palacios, J. Oliva, E. TI Molecular Alterations in Endometrial Carcinosarcomas (ECS) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Hosp Univ Virgen Rocio IBIS Inst Biomed Sevilla, Seville, Spain. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Romero-Perez, Laura/C-8314-2015; Castilla, M Angeles/C-9454-2015 OI Romero-Perez, Laura/0000-0003-3196-4382; NR 0 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1004 BP 237A EP 238A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282301159 ER PT J AU Castilla, MA Moreno-Bueno, G Romero-Perez, L Van De Vijver, K Biscuola, M Lopez-Garcia, MA Prat, J Matias-Guiu, X Cano, A Oliva, E Palacios, J AF Castilla, M. A. Moreno-Bueno, G. Romero-Perez, L. Van De Vijver, K. Biscuola, M. Lopez-Garcia, M. A. Prat, J. Matias-Guiu, X. Cano, A. Oliva, E. Palacios, J. TI Micro-RNA Signature of the Epithelial-Mesenchymal Transition in Endometrial Carcinosarcoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Hosp Univ Virgen Rocio IBIS, Seville, Spain. IdiPAZ Inst Invest La Paz, Inst Invest Biomed Alberto Sols CSIC UAM, Madrid, Spain. Massachusetts Gen Hosp, Boston, MA 02114 USA. Hosp San Pau, Barcelona, Spain. Hosp Arnau Vilanova, Lleida, Spain. RI Romero-Perez, Laura/C-8314-2015; Castilla, M Angeles/C-9454-2015 OI Romero-Perez, Laura/0000-0003-3196-4382; NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1015 BP 240A EP 240A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301170 ER PT J AU Chiang, S Gilks, B Huntsman, DG Oliva, E AF Chiang, S. Gilks, B. Huntsman, D. G. Oliva, E. TI Persistence of Serous Tubal Intraepithelial Carcinoma after Neo-Adjuvant Chemotherapy: Evidence Based Recommendations for Gross Evaluation of Interval Surgery Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. BC Canc Agcy, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1022 BP 241A EP 241A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301177 ER PT J AU Chiang, S Gilks, B Huntsman, DG Oliva, E AF Chiang, S. Gilks, B. Huntsman, D. G. Oliva, E. TI Immunohistochemical and Mutational Analysis of FOXL2 in Uterine Tumors Resembling Ovarian Sex-Cord Tumors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. BC Canc Agcy, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1021 BP 241A EP 241A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301176 ER PT J AU Chiang, S Ali, R Lee, CH Gilks, B Oliva, E AF Chiang, S. Ali, R. Lee, C-H Gilks, B. Oliva, E. TI Frequency of Known Translocations Detected by Fluorescence In Situ Hybridization in Endometrial and Endometrioid Stromal Tumors (ESTs): A Study of 57 Patients SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. BC Canc Agcy, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1020 BP 241A EP 241A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301175 ER PT J AU Gilks, CB Oliva, E Soslow, R AF Gilks, C. B. Oliva, E. Soslow, R. TI Poor Interobserver Reproducibility in the Diagnosis of High-Grade Endometrial Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Vancouver Gen Hosp, Vancouver, BC, Canada. BC Childrens & Womens Hosp, Vancouver, BC, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1049 BP 248A EP 248A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301204 ER PT J AU Karst, AM Levanon, K Duraisamy, S Liu, JF Hirsch, MS Drapkin, R AF Karst, A. M. Levanon, K. Duraisamy, S. Liu, J. F. Hirsch, M. S. Drapkin, R. TI Stathmin 1, a Marker of PI3K Pathway Activation and Regulator of Microtubule Dynamics, Is Expressed in Early Serous Ovarian Carcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Chaim Sheba Med Ctr, Sheba Canc Res Ctr, Ramat Gan, Israel. Brigham & Womens Hosp, Boston, MA 02115 USA. RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1064 BP 251A EP 251A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301219 ER PT J AU Karst, AM Levanon, K Hirsch, MS Drapkin, R AF Karst, A. M. Levanon, K. Hirsch, M. S. Drapkin, R. TI Transformation of Fallopian Tube Epithelial Cells Leads to High-Grade Tumor Formation in a Xenograft Mouse Model SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Chaim Sheba Med Ctr, Sheba Canc Res Ctr, Ramat Gan, Israel. Brigham & Womens Hosp, Ramat Gan, Israel. RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1063 BP 251A EP 251A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301218 ER PT J AU Lim, D Gilks, B Longacre, T Nucci, MR Soslow, RA Oliva, E AF Lim, D. Gilks, B. Longacre, T. Nucci, M. R. Soslow, R. A. Oliva, E. TI Interobserver Variability in the Interpretation of Tumor Cell Necrosis (TCN) in Uterine Leiomyosarcoma (LMS) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Natl Univ Hlth Syst, Singapore, Singapore. Vancouver Gen Hosp, Vancouver, BC, Canada. Stanford Univ, Stanford, CA 94305 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1086 BP 256A EP 256A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301241 ER PT J AU Lim, D Wang, WL Lee, CH Dodge, T Gilks, B Oliva, E AF Lim, D. Wang, W-L Lee, C-H Dodge, T. Gilks, B. Oliva, E. TI Old Versus New FIGO Staging Systems in Predicting Overall Survival in Patients with Uterine Leiomyosarcoma: A Study of 86 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Natl Univ Hlth Syst, Singapore, Singapore. Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. Vancouver Gen Hosp, Vancouver, BC, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1085 BP 256A EP 256A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301240 ER PT J AU Ning, G Laury, AR Quick, CM Hirsch, MS Drapkin, R Mehra, KK Mehrad, M McKeon, FD Crum, CP Xian, W AF Ning, G. Laury, A. R. Quick, C. M. Hirsch, M. S. Drapkin, R. Mehra, K. K. Mehrad, M. McKeon, F. D. Crum, C. P. Xian, W. TI Co-Ordinated Dysregulation of PAX2, ALDH1 and EZH2 in Tubal Serous Carcinogenesis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. St Lukes Roosevelt Hosp, New York, NY USA. Washington Univ, St Louis, MO USA. A Star Inst Med Biol, Singapore, Singapore. RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1110 BP 262A EP 262A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301265 ER PT J AU Tarragona, J Santacana, M Valls, J Oliva, E Palacios, J Matias-Guiu, X AF Tarragona, J. Santacana, M. Valls, J. Oliva, E. Palacios, J. Matias-Guiu, X. TI Stem Cell Marker Expression in Endometrial Carcinoma. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Univ Lleida, Hosp Univ Arnau de Vilanova, IRB Lleida, Lleida, Spain. Hosp Virgen del Rocio, Seville, Spain. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1140 BP 268A EP 268A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301295 ER PT J AU Zaino, R Zhu, J Abendroth, C Yemelyanova, A Oliva, E Lim, D Hagemann, IS Montone, K Delair, D Soslow, R AF Zaino, R. Zhu, J. Abendroth, C. Yemelyanova, A. Oliva, E. Lim, D. Hagemann, I. S. Montone, K. Delair, D. Soslow, R. TI Stage II Endometrial Carcinoma: Endocervical Gland Spread Is Not Reproducibly Distinguished from Endocervical Stromal Invasion SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Hershey Med Ctr, Hershey, PA 17033 USA. Johns Hopkins Med Ctr, Baltimore, MD USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. U Penn, Philadelphia, PA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1157 BP 272A EP 272A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301312 ER PT J AU Courville, EL Lew, M Sadow, PM AF Courville, E. L. Lew, M. Sadow, P. M. TI Retrospective Review of Tonsil Specimens: Experiential Assessment of a Clinical Practice. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1178 BP 277A EP 277A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301333 ER PT J AU Carvajal, A Sua, L Silva, N Pittaluga, S Royo, C Sargent, RL Climent, F Jacobs, SA Delabie, J Naresh, K Bagg, A Harris, NL Swerdlow, SH Jaffe, ES Campo, E AF Carvajal, A. Sua, L. Silva, N. Pittaluga, S. Royo, C. Sargent, R. L. Climent, F. Jacobs, S. A. Delabie, J. Naresh, K. Bagg, A. Harris, N. L. Swerdlow, S. H. Jaffe, E. S. Campo, E. TI "In Situ" Mantle Cell Lymphoma (MCL), an Incidental Finding with an Indolent Clinical Course. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Hosp Clin Barcelona, Barcelona, Spain. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. Oslo Univ Hosp, Oslo, Norway. Hammersmith Hosp, London, England. Hosp Univ Penn, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NCI, Bethesda, MD 20892 USA. RI Royo, Cristina/H-3193-2015 OI Royo, Cristina/0000-0002-1214-4656 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1228 BP 289A EP 289A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301383 ER PT J AU Chiu, A Chen, YB Pinkus, GS Hasserjian, RP AF Chiu, A. Chen, Y-B Pinkus, G. S. Hasserjian, R. P. TI Acute Graft-Versus-Host Disease Is Associated with Increased Bone Remodeling and Impaired B-Cell Development Suggesting Effects on the Osteoblastic Niche. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1237 BP 291A EP 291A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301392 ER PT J AU Hasserjian, RP Chi, YO Hu, Y Kluk, M Attar, E Wang, SA AF Hasserjian, R. P. Chi, Y. Ok Hu, Y. Kluk, M. Attar, E. Wang, S. A. TI Therapy-Related Myelodysplastic Syndrome (MDS) Lacking High-Risk Karyotype Resembles De Novo Disease and Differs from Conventional Therapy-Related MDS SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. UMass Med Ctr, Worcester, MA USA. UT MD Anderson Canc Ctr, Houston, TX USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1275 BP 300A EP 300A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301430 ER PT J AU Katz, SG LaBelle, JL Godes, M Fisher, JK Bird, GH Walensky, LD AF Katz, S. G. LaBelle, J. L. Godes, M. Fisher, J. K. Bird, G. H. Walensky, L. D. TI Stapled BIM BH3 Helix Restores Apoptosis in BIM-Null Mantle Cell Lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1295 BP 304A EP 305A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282301450 ER PT J AU Nardi, V Kluk, M Attar, E Winkfield, K Hasserjian, RP AF Nardi, V. Kluk, M. Attar, E. Winkfield, K. Hasserjian, R. P. TI AML and MDS Following Radiation Therapy Are Similar to De Novo Disease and Differ from Other Therapy-Related Myeloid Neoplasms. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1322 BP 310A EP 311A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282301477 ER PT J AU Nardi, V Rochelle-Keyes, H Peterson, T Loda, M Rosina, L Raje, N Sohani, AR Sabatini, DM Hasserjian, RP AF Nardi, V. Rochelle-Keyes, H. Peterson, T. Loda, M. Rosina, L. Raje, N. Sohani, A. R. Sabatini, D. M. Hasserjian, R. P. TI Activation of the PI3K/Akt Pathway in Plasma Cell Myeloma Is Associated with MAF and DEPTOR Overexpression and Favorable Response to Therapy. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Whitehead Inst, Cambridge, MA 02142 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1323 BP 311A EP 311A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301478 ER PT J AU Rosado, FGN Tang, YW Hasserjian, RP McClain, C Wang, BY Mosse, CM AF Rosado, F. G. N. Tang, Y-W Hasserjian, R. P. McClain, C. Wang, B. Y. Mosse, C. M. TI Kikuchi's Lymphadenitis: Role of Parvovirus B-19, EBV, HHV-6, and HHV-8 Detected by PCR in a Multi-Institutional Review of 18 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Vanderbilt Univ, Med Ctr, Nashville, TN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NYU, New York, NY 10003 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1435 BP 338A EP 338A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301590 ER PT J AU McClintock, DS Lee, RE Oberg, CG Gudewicz, TM Gilbertson, JR AF McClintock, D. S. Lee, R. E. Oberg, C. G. Gudewicz, T. M. Gilbertson, J. R. TI Applying Computer Assisted Process Modeling To Improve Anatomic Pathology Workflows. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [McClintock, D. S.; Lee, R. E.; Oberg, C. G.; Gudewicz, T. M.; Gilbertson, J. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1446 BP 340A EP 341A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282301601 ER PT J AU Kushner, YB Malik, FA Collins, AB Holmes, RK Smith, RN Colvin, RB AF Kushner, Y. B. Malik, F. A. Collins, A. B. Holmes, R. K. Smith, R. N. Colvin, R. B. TI Glomerular Endothelial Injury in Patients with Non-Renal Transplants: Are We Missing Subclinical Thrombotic Microangiopathy? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Kushner, Y. B.; Malik, F. A.; Collins, A. B.; Holmes, R. K.; Smith, R. N.; Colvin, R. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1472 BP 347A EP 347A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301627 ER PT J AU Das, KK Krings, G Pitman, MB Mino-Kenudson, M AF Das, K. K. Krings, G. Pitman, M. B. Mino-Kenudson, M. TI A Novel Monoclonal Antibody, mAb Das-1, Identifies a Colonic Phenotype and Is Specific for Intraductal Papillary Mucinous Neoplasm (IPMN) with a High Risk for Malignant Transformation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Das, K. K.; Krings, G.; Pitman, M. B.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1519 BP 358A EP 358A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301674 ER PT J AU Lisovsky, M Konstas, AA Hahn, PF Misdraji, J AF Lisovsky, M. Konstas, A. A. Hahn, P. F. Misdraji, J. TI Congenital Absence of Portal Vein (Abernethy Malformation): A Histopathologic Evaluation. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1558 BP 367A EP 367A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302004 ER PT J AU Zhang, L Chari, S Smyrk, T Deshpande, V Kloppel, G Kojima, M Liu, X Longnecker, D Mino-Kenudson, M Notohara, K Rodriguez-Justo, M Srivastava, A Zamboni, G Zen, Y AF Zhang, L. Chari, S. Smyrk, T. Deshpande, V. Kloppel, G. Kojima, M. Liu, X. Longnecker, D. Mino-Kenudson, M. Notohara, K. Rodriguez-Justo, M. Srivastava, A. Zamboni, G. Zen, Y. TI Autoimmune Pancreatitis (AIP) Type 1 and Type 2: An International Consensus Study on Histopathologic Diagnostic Criteria SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Kiel, D-24098 Kiel, Germany. Natl Canc Ctr Hosp, Kashiwa, Chiba, Japan. Cleveland Clin, Cleveland, OH 44106 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Kurashiki Cent Hosp, Okayama, Japan. UCL, London WC1E 6BT, England. Univ Verona, I-37100 Verona, Italy. Kings Coll London, London WC2R 2LS, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1599 BP 377A EP 377A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302045 ER PT J AU Katz, SG Fisher, JK Ligon, KL Walensky, LD AF Katz, S. G. Fisher, J. K. Ligon, K. L. Walensky, L. D. TI Neural Stem Cells Deficient in BAX and BAK Manifest Profound Hyperplasia and Tumorigenesis. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp Boston, Boston, MA USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1621 BP 382A EP 382A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302067 ER PT J AU Evans, A Fletcher, C French, C Jackman, D Lathan, C Sholl, L AF Evans, A. Fletcher, C. French, C. Jackman, D. Lathan, C. Sholl, L. TI Detection of NUT Midline Carcinoma in Retrospective Analysis of Thymic and Mediastinal Neoplasms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1739 BP 408A EP 408A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302185 ER PT J AU Hariri, LP Mino-Kenudsen, M Mark, EJ Applegate, MB Tearney, GJ Bouma, BE Suter, MJ AF Hariri, L. P. Mino-Kenudsen, M. Mark, E. J. Applegate, M. B. Tearney, G. J. Bouma, B. E. Suter, M. J. TI High-Resolution Volumetric Imaging of Lung Pathology: Improving Biopsy Sampling and Evaluation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Hariri, L. P.; Mino-Kenudsen, M.; Mark, E. J.; Applegate, M. B.; Tearney, G. J.; Bouma, B. E.; Suter, M. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1751 BP 411A EP 411A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302197 ER PT J AU Hariri, LP Mark, EJ Onozato, ML Yagi, Y Shea, B Digumarthy, S Fraire, A Matsubara, O Mino-Kenudsen, M AF Hariri, L. P. Mark, E. J. Onozato, M. L. Yagi, Y. Shea, B. Digumarthy, S. Fraire, A. Matsubara, O. Mino-Kenudsen, M. TI Histopathological Features of Acute Hypersensitivity Pneumonitis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Massachusetts Mem Med Ctr, Worcester, MA USA. Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1750 BP 411A EP 411A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302196 ER PT J AU Klepeis, VE Mark, EL Dias-Santagata, D Iafrate, AJ Mino-Kenudson, H AF Klepeis, V. E. Mark, E. L. Dias-Santagata, D. Iafrate, A. J. Mino-Kenudson, H. TI Correlation of a Proposed Scoring System for Lung Adencoarcinoma with Molecular Alterations SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Klepeis, V. E.; Mark, E. L.; Dias-Santagata, D.; Iafrate, A. J.; Mino-Kenudson, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1768 BP 415A EP 416A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282302214 ER PT J AU Kovach, AE Mark, EJ Mino-Kenudson, M AF Kovach, A. E. Mark, E. J. Mino-Kenudson, M. TI Expression of SOX2 and p63 Do Not Have Independent Prognostic Significance in Stage I Lung Adenocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Kovach, A. E.; Mark, E. J.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1770 BP 416A EP 416A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302216 ER PT J AU Matsubara, O Kobayashi, K Yamamoto, S Kikuchi, R Iwaya, K Nakatani, Y Kradin, RL Mark, EJ AF Matsubara, O. Kobayashi, K. Yamamoto, S. Kikuchi, R. Iwaya, K. Nakatani, Y. Kradin, R. L. Mark, E. J. TI Higher Metabolic Activity in Fibroblastic Foci of VIP Than in Buds of Fibrosis in Intra-Alveolar Buds in COP/BOOP SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1778 BP 418A EP 418A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302224 ER PT J AU Nishino, M Klepeis, VE Bergethon, K Mark, EJ Iafrate, AJ Mino-Kenudson, M AF Nishino, M. Klepeis, V. E. Bergethon, K. Mark, E. J. Iafrate, A. J. Mino-Kenudson, M. TI Histologic and Cytomorphologic Features of ALK-Rearranged Lung Adenocarcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Nishino, M.; Klepeis, V. E.; Bergethon, K.; Mark, E. J.; Iafrate, A. J.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1787 BP 420A EP 420A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302233 ER PT J AU Nishino, M Mark, EJ Matsubara, O Medoff, BD O'Donnell, WJ Currier, PF Kradin, RL AF Nishino, M. Mark, E. J. Matsubara, O. Medoff, B. D. O'Donnell, W. J. Currier, P. F. Kradin, R. L. TI Variant Pulmonary Alveolar Proteinosis: A Syndrome with Distinct Clinical and Pathologic Features SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1786 BP 420A EP 420A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302232 ER PT J AU Schwartz, B Hofer, M Lemieux, M Bauer, D Cameron, H West, N Agoston, E Ince, T Janeway, K Vargas, S Perez-Atayde, A Aster, J Sallan, S Kung, A Bradner, J French, C AF Schwartz, B. Hofer, M. Lemieux, M. Bauer, D. Cameron, H. West, N. Agoston, E. Ince, T. Janeway, K. Vargas, S. Perez-Atayde, A. Aster, J. Sallan, S. Kung, A. Bradner, J. French, C. TI Differentiation of NUT Midline Carcinoma in Humans and Mice by Epigenomic Reprogramming SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1801 BP 423A EP 423A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302247 ER PT J AU Zhang, W Joshi, V Heon, S Gandhi, L Jackman, D Lindeman, N Sholl, L AF Zhang, W. Joshi, V. Heon, S. Gandhi, L. Jackman, D. Lindeman, N. Sholl, L. TI Phenotypic Correlates of ERBB2, BRAF and PIK3CA Mutations in Non-Small Cell Lung Cancer. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Partners Ctr Genom Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1828 BP 430A EP 430A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302274 ER PT J AU Martin, NE Sinnott, JA Finn, S Fedele, G Stampfer, MJ Andren, O Andersson, SO Mucci, L Loda, M AF Martin, N. E. Sinnott, J. A. Finn, S. Fedele, G. Stampfer, M. J. Andren, O. Andersson, S-O Mucci, L. Loda, M. TI Integrated Signature of PI3K Pathway Activation in Prostate Cancer. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Orebro Univ Hosp, Orebro, Sweden. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1892 BP 444A EP 445A PG 2 WC Pathology SC Pathology GA 720LN UT WOS:000287282302337 ER PT J AU Ojesina, AI Kostic, A Jung, J Pedamallu, C Getz, G Maciejewski, J Shipp, M Cesarman, E Aster, J Meyerson, M AF Ojesina, A. I. Kostic, A. Jung, J. Pedamallu, C. Getz, G. Maciejewski, J. Shipp, M. Cesarman, E. Aster, J. Meyerson, M. TI Pathogen Discovery in Hematological Neoplasms and Inflammatory Diseases by High Throughput Sequencing of Human Tissues. SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst & Harvard, Cambridge, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Cleveland Clin, Cleveland, OH USA. Weill Cornell Med Coll, New York, NY USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1895 BP 445A EP 445A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302340 ER PT J AU Benvenga, S Itri, E Hauser, P De Tolla, L Yu, SF Testa, G Pappalardo, MA Trimarchi, F Amato, A AF Benvenga, Salvatore Itri, Elenora Hauser, Peter De Tolla, Louis Yu, Sui-Foh Testa, Giuseppe Pappalardo, Maria Angela Trimarchi, Francesco Amato, Antonino TI Gender Differences in Locomotor and Stereotypic Behavior Associated With L-Carnitine Treatment in Mice SO GENDER MEDICINE LA English DT Article DE gender differences; L-carnitine; locomotor activity; stereotypic activity ID ACETYL-L-CARNITINE; CATION/CARNITINE TRANSPORTER FAMILY; ORGANIC CATION TRANSPORTERS; THYROID-HORMONE ACTION; RAT-BRAIN; SEXUAL-DIFFERENTIATION; PALMITOYLTRANSFERASE-I; CHAKRAGATI MOUSE; AGED RATS; OLD RATS AB Background: The carnitines exert neuroprotective and neuromodulatory actions, and carnitine supplementation increases locomotor activity (LMA) in experimental animals. Methods: We measured 13 indexes of LMA and 3 indexes of stereotypic activity (STA) in adult male and female caged mice. In a randomized 4-week trial, 10 males and 10 females received SO mg/kg body weight PO L-carnitine, and another 10 males and 10 females received placebo. Results: Compared with placebo-treated females, placebo-treated males had a greater number of stereotypies (NSTs), stereotypy counts (STCs), stereotypy time (STT), and right front time (RFT), but smaller total distance traveled (TDT), margin distance (MD), number of vertical movements (NVMs), and left rear time (LRT). Compared with placebo-treated males, carnitine-treated males had greater horizontal activity (HA), movement time (MT), NVM, STT, TDT, SIC, MD, LRT, and clockwise revolutions (CRs), but smaller left front time (LFT) and RFT. Compared with placebo-treated females, carnitine-treated females had greater NST, STC, STT, LFT, and RFT, but smaller NM, HA, NVM, VA, MT, anticlockwise revolutions (ACRs), CR, TDT, and MD; right rear time (RRT) remained statistically insignificant across all comparisons. Conclusions: In summary, L-carnitine caused gender differences to persist for STC, diminish for NST and STT, disappear for LRT and NVM, change in the opposite direction for TDT and MD, appear de novo for HA, VA, NM, MT, and LFT, and remain absent for RRT and ACR. Some indexes of LMA and STA are sexually dimorphic in adult mice, and L-carnitine differentially maintains, diminishes/cancels, inverts, or creates the sexual dimorphism of particular indexes. (Gend Med. 2011;8:1-13) (C) 2011 Elsevier HS Journals, Inc. All rights reserved. C1 [Benvenga, Salvatore; Itri, Elenora; Pappalardo, Maria Angela; Trimarchi, Francesco] Univ Messina, Sez Endocrinol, Dipartimento Clin Sperimentale Med & Farmacol, Messina, Italy. [Benvenga, Salvatore] AOU Policlin G Martino, Programma Endocrinol Mol Clin, Messina, Italy. [Hauser, Peter] Oregon Hlth & Sci Univ, NW Hepatitis C Resource Ctr, VA Med Ctr, Res & Dev Serv & Behav Hlth & Clin, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Div Neurosci, Portland VA Med Ctr, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, JENS Lab, Portland VA Med Ctr, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Dept Behav Neurosci, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Div Gastroenterol, Portland, OR 97201 USA. [De Tolla, Louis; Yu, Sui-Foh] Univ Maryland, Sch Med, Comparat Med Program & Vet Resources, Baltimore, MD 21201 USA. [Testa, Giuseppe; Amato, Antonino] Sigma Tau Res, Gaithersburg, MD USA. RP Benvenga, S (reprint author), Univ Messina Policlin, Sez Endocrinol, Dip Clin Sperimentale Med & Farmacol, 4 Piano, I-98125 Messina, Italy. EM s.benvenga@me.nettuno.it FU Ministero dell'Universita e della Ricerca, Rome, Italy [2004062391_01]; Sigma-Tau Research, Inc, Gaithersburg, Maryland FX This work was funded in part by the Ministero dell'Universita e della Ricerca, Rome, Italy, (PRIN2004 project 2004062391_01) and in part by Sigma-Tau Research, Inc, Gaithersburg, Maryland. The authors have indicated that they have no other conflicts of interest regarding the content of this article. NR 44 TC 1 Z9 1 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1550-8579 J9 GENDER MED JI Gend. Med. PD FEB PY 2011 VL 8 IS 1 BP 1 EP 13 DI 10.1016/j.genm.2011.02.003 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 761CB UT WOS:000290371400001 PM 21497767 ER PT J AU Yang, E Nucifora, PG Melhem, ER AF Yang, Edward Nucifora, Paolo G. Melhem, Elias R. TI Diffusion MR Imaging: Basic Principles SO NEUROIMAGING CLINICS OF NORTH AMERICA LA English DT Article DE MRI; Diffusion MRI; Diffusion tensor imaging; Clinical neurology ID WHITE-MATTER TRACTS; ANISOTROPIC WATER DIFFUSION; VOXEL-BASED MORPHOMETRY; CENTRAL-NERVOUS-SYSTEM; NORMAL-APPEARING WHITE; AMYOTROPHIC-LATERAL-SCLEROSIS; DEFORMATION-BASED MORPHOMETRY; INTRAVOXEL INCOHERENT MOTION; AXON DIAMETER DISTRIBUTION; HIGH-FIELD-STRENGTH AB From their origin as simple techniques primarily used for detecting acute cerebral ischemia, diffusion MR imaging techniques have rapidly evolved into a versatile set of tools that provide the only noninvasive means of characterizing brain microstructure and connectivity, becoming a mainstay of both clinical and investigational brain MR imaging. In this article, the basic principles required for understanding diffusion MR imaging techniques are reviewed with clinical neuroradiologists in mind. C1 [Yang, Edward; Nucifora, Paolo G.; Melhem, Elias R.] Univ Penn, Hosp Univ Penn, Sch Med, Div Neuroradiol,Dept Radiol, Philadelphia, PA 19104 USA. [Nucifora, Paolo G.] Vet Affairs Med Ctr, Philadelphia, PA USA. RP Melhem, ER (reprint author), Univ Penn, Hosp Univ Penn, Sch Med, Div Neuroradiol,Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. EM Elias.melhem@uphs.upenn.edu RI Melhem, Elias/E-5205-2013 NR 212 TC 11 Z9 15 U1 2 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1052-5149 J9 NEUROIMAG CLIN N AM JI Neuroimaging Clin. N. Am. PD FEB PY 2011 VL 21 IS 1 BP 1 EP + DI 10.1016/j.nic.2011.02.001 PG 26 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 757ZJ UT WOS:000290128200002 PM 21477749 ER PT J AU Yoo, AJ Gonzalez, RG AF Yoo, Albert J. Gonzalez, R. Gilberto TI Clinical Applications of Diffusion MR Imaging for Acute Ischemic Stroke SO NEUROIMAGING CLINICS OF NORTH AMERICA LA English DT Article DE Diffusion MR imaging; Acute ischemic stroke; Intravenous reperfusion therapy; Intra-arterial reperfusion therapy ID TISSUE-PLASMINOGEN-ACTIVATOR; SYMPTOMATIC INTRACEREBRAL HEMORRHAGE; RANDOMIZED CONTROLLED-TRIAL; CEREBRAL-ARTERY INFARCTION; COOPERATIVE ACUTE STROKE; ACUTE HEMISPHERIC STROKE; ACUTE BRAIN ISCHEMIA; MAGNETIC-RESONANCE; INTRAARTERIAL THROMBOLYSIS; SCALE SCORE AB Diffusion magnetic resonance imaging is the best imaging tool for detecting acute ischemic brain injury. Studies have shown its high accuracy for delineating irreversible tissue damage within the first few hours after stroke onset; however, the true value of any diagnostic tool is whether it can be used to guide clinical management. This review discusses the role of diffusion imaging in the evaluation of the patient with acute ischemic stroke, and how this role is influenced by other important stroke-related variables, including the level of vessel occlusion and the clinical deficit. The review focuses on decision-making for intravenous and intra-arterial reperfusion therapies. C1 [Yoo, Albert J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Diagnost & Intervent Neuroradiol, Boston, MA 02114 USA. [Gonzalez, R. Gilberto] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroradiol Div, Boston, MA 02114 USA. RP Yoo, AJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Diagnost & Intervent Neuroradiol, 55 Fruit St,Gray 241, Boston, MA 02114 USA. EM ajyoo@partners.org FU NIH/NINDS [NS050041] FX Supported in part by NIH/NINDS grant NS050041 to RGG. NR 123 TC 5 Z9 8 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1052-5149 J9 NEUROIMAG CLIN N AM JI Neuroimaging Clin. N. Am. PD FEB PY 2011 VL 21 IS 1 BP 51 EP + DI 10.1016/j.nic.2011.02.002 PG 20 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 757ZJ UT WOS:000290128200004 PM 21477751 ER PT J AU Liao, Y Schmidt, RL Walton, ZE Tang, AH AF Liao, Yang Schmidt, Rebecca L. Walton, Zandra E. Tang, Amy H. TI SIAH-dependent proteolysis modulates focal adhesion, cell junction, and cell motility in response to oncogenic K-RAS activation in human cancer cells SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Meeting Abstract C1 [Liao, Yang] Mayo Clin, Coll Med, Rochester, MN USA. [Schmidt, Rebecca L.] Natl Jewish Med & Res Ctr, Denver, CO USA. [Walton, Zandra E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Tang, Amy H.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PD FEB PY 2011 VL 28 IS 2 BP 179 EP 179 PG 1 WC Oncology SC Oncology GA 753RB UT WOS:000289796200072 ER PT J AU Mortazavi, F Rettig, MB Dubinett, SM AF Mortazavi, Fariborz (Fred) Rettig, Matthew B. Dubinett, Steven M. TI c-Crk proto-oncogene and TGF-beta signaling pathway contribute to transcriptional repression of p120ctn in non-small cell lung cancer cells SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Meeting Abstract C1 [Mortazavi, Fariborz (Fred); Rettig, Matthew B.] Univ Calif Los Angeles, W Los Angeles VA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PD FEB PY 2011 VL 28 IS 2 BP 186 EP 186 PG 1 WC Oncology SC Oncology GA 753RB UT WOS:000289796200094 ER PT J AU Chung, I Masamune, A Bardeesy, N Zetter, B AF Chung, Ivy Masamune, Atsushi Bardeesy, Nabeel Zetter, Bruce TI Secretion from stellate cells induces epithelial-mesenchymal transition in pancreatic cancer SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Meeting Abstract C1 [Chung, Ivy; Zetter, Bruce] Childrens Hosp, Boston, MA 02115 USA. [Masamune, Atsushi] Tohoku Univ, Grad Sch Med, Sendai, Miyagi 980, Japan. [Bardeesy, Nabeel] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PD FEB PY 2011 VL 28 IS 2 BP 202 EP 203 PG 2 WC Oncology SC Oncology GA 753RB UT WOS:000289796200141 ER PT J AU Kradin, RL AF Kradin, Richard L. TI Placebo Response: A Consideration of its Role in Therapeutics SO CURRENT PSYCHIATRY REPORTS LA English DT Article DE Placebo response; Placebo effects; Therapeutics; Reward system; Dopamine; Antidepressants; Child development ID RANDOMIZED CONTROLLED-TRIAL; POWERFUL PLACEBO; CLINICAL-TRIALS; DOUBLE-BLIND; PSYCHOTHERAPY; MECHANISM; SURGERY AB Placebo effects are a potentially inherent element in all treatment responses, and as such, they play a critical role in determining what is "therapeutic." However, the placebo response is also an area of substantial controversy. In the present review, the scientific issues that influence placebo effects are elucidated. The evolution of the concept of placebo and how this has affected its historical importance in therapeutics is considered. The importance of placebo responses in psychiatry and psychotherapy is specifically examined, and recent progress in determining the cognitive and neurobiological bases of placebo effects is reviewed. Finally, it is argued that the placebo response is a cardinal mind-body pathway that promotes salutogenesis and that evidence suggests its relationship to central nervous system activities that are responsible for the concomitant development of positive affects and somatic procedural memories that govern states of mind/body wellbeing during maternal-infant attachment. C1 [Kradin, Richard L.] Massachusetts Gen Hosp, Dept Pathol & Med, Boston, MA 02114 USA. [Kradin, Richard L.] Massachusetts Gen Hosp, Ctr Psychoanalyt Studies, Boston, MA 02114 USA. RP Kradin, RL (reprint author), Massachusetts Gen Hosp, Dept Pathol & Med, Warren 253, Boston, MA 02114 USA. EM rkradin@partners.org NR 41 TC 3 Z9 3 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD FEB PY 2011 VL 13 IS 1 BP 37 EP 42 DI 10.1007/s11920-010-0158-y PG 6 WC Psychiatry SC Psychiatry GA 752ZP UT WOS:000289734300007 PM 20878506 ER PT J AU Peron, EP Marcum, ZA Boyce, R Hanlon, JT Handler, SM AF Peron, Emily P. Marcum, Zachary A. Boyce, Richard Hanlon, Joseph T. Handler, Steven M. TI Year in Review: Medication Mishaps in the Elderly SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Editorial Material DE adverse drug events; aged; drug monitoring; medication adherence; medication errors; suboptimal prescribing. ID ADVERSE DRUG-REACTIONS; POTENTIALLY INAPPROPRIATE MEDICATIONS; CLINICAL DECISION-SUPPORT; NURSING-HOME RESIDENTS; COMPREHENSIVE GERIATRIC ASSESSMENT; PROTON-PUMP INHIBITORS; PROVIDER ORDER ENTRY; OLDER-ADULTS; HOSPITALIZED-PATIENTS; EXPLICIT CRITERIA AB Objective: This paper reviews articles from 2010 that examined medication mishaps (ie, medication errors and adverse drug events [ADEs]) in the elderly. Methods: The MEDLINE and EMBASE databases were searched for English-language articles published in 2010 using a combination of search terms including medication errors, medication adherence, medication compliance, suboptimal prescribing, monitoring, adverse drug events, adverse drug withdrawal events, therapeutic failures, and aged. A manual search of the reference lists of the identified articles and the authors' article files, book chapters, and recent reviews was conducted to identify additional publications. Five studies of note were selected for annotation and critique. From the literature search, this paper also generated a selected bibliography of manuscripts published in 2010 (excluding those previously published in the American Journal of Geriatric Pharmacotherapy or by one of the authors) that address various types of medication errors and ADEs in the elderly. Results: Three studies focused on types of medication errors. One study examined underuse (due to prescribing) as a type of medication error. This before-and-after study from the Netherlands reported that those who received comprehensive geriatric assessments had a reduction in the rate of undertreatment of chronic conditions by over one third (from 32.9% to 22.3%, P < 0.05). A second study focused on reducing medication errors due to the prescribing of potentially inappropriate medications. This quasi-experimental study found that a computerized provider order entry clinical decision support system decreased the number of potentially inappropriate medications ordered for patients 65 years of age who were hospitalized (11.56 before to 9.94 orders per day after, P < 0.001). The third medication error study was a cross-sectional phone survey of managed-care elders, which found that more blacks than whites had low antihypertensive medication adherence as per a self-reported measure (18.4% vs 12.3%, respectively; P < 0.001). Moreover, blacks used more complementary and alternative medicine (CAM) than whites for the treatment of hypertension (30.5% vs 24.7%, respectively; P = 0.005). In multivariable analyses stratified by race, blacks who used CAM were more likely than. those who did not to have low antihypertensive medication adherence (prevalence rate ratio = 1.56; 95% CI, 1.14-2.15; P = 0.006). The remaining two studies addressed some form of medication-related adverse patient events. A case-control study of Medicare Advantage patients revealed for the first time that the use of skeletal muscle relaxants was associated significantly with an increased fracture risk (adjusted odds ratio = 1.40; 95% CI, 1.15-1.72; P < 0.001). This increased risk was even more pronounced with the concomitant use of benzodiazepines. Finally, a randomized controlled trial across 16 centers in France used a 1-week educational intervention about high-risk medications and ADEs directed at rehabilitation health care teams. Results indicated that the rate of ADEs in the intervention group was lower than that in the usual care group (22% vs 36%, respectively, P = 0.004). Conclusion: Information from these studies may advance health professionals' understanding of medication errors and ADEs and may help guide research and clinical practices in years to come. (Am J Geriatr Pharmacother. 2011;9: 1-10) (C) 2011 Published by Elsevier HS Journals, Inc. C1 [Peron, Emily P.; Marcum, Zachary A.; Hanlon, Joseph T.; Handler, Steven M.] Univ Pittsburgh, Dept Med, Sch Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Boyce, Richard; Hanlon, Joseph T.; Handler, Steven M.] Univ Pittsburgh, Dept Biomed Informat, Sch Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.; Handler, Steven M.] Vet Affairs Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.; Handler, Steven M.] Vet Affairs Pittsburgh Hlth Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Med Geriatr, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu OI Handler, Steven/0000-0002-3940-3224 FU AHRQ HHS [K12 HS019461, R01 HS017695, R01 HS018721]; NIA NIH HHS [K07 AG033174, K07AG033174, P30 AG024827, P30AG024827, R01 AG027017, R01 AG034056, R01AG027017, R01AG034056, R56 AG027017, R56AG027017, T32 AG021885]; NIMH NIH HHS [R34 MH082682]; NINR NIH HHS [R01 NR010135] NR 111 TC 6 Z9 6 U1 4 U2 13 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2011 VL 9 IS 1 BP 1 EP 10 DI 10.1016/j.amjopharm.2011.01.003 PG 10 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 754PA UT WOS:000289866600001 PM 21459304 ER PT J AU Aspinall, SL Zhao, XH Good, CB Stone, RA Boresi, J Cox, S Bartholomew, C Jansen, D Guterman, S Patino, M Rivera-Miranda, G Burlingame, M Frazer, J Sellers, J Steele, VS Witt, L Cunningham, FE AF Aspinall, Sherrie L. Zhao, Xinhua Good, Chester B. Stone, Roslyn A. Boresi, Joy Cox, Sarah Bartholomew, Chad Jansen, David Guterman, Sarah Patino, Mauricio Rivera-Miranda, Giselle Burlingame, Mark Frazer, Justin Sellers, Janelle Steele, Valerie Stanard Witt, Lauri Cunningham, Francesca E. TI Intervention to Decrease Glyburide Use in Elderly Patients With Renal Insufficiency SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Article DE elderly; diabetes mellitus; glyburide; outcome assessment; renal insufficiency ID DIABETIC-PATIENTS; HYPOGLYCEMIA; SULFONYLUREAS; THERAPY; DISEASE; DRUGS AB Objectives: The objectives of this study were to describe changes in glyburide prescribing in cohorts that were and were not targeted by a risk reduction project, assess factors associated with glyburide discontinuation, and evaluate changes in glycated hemoglobin (ie, HbA(1c)) levels and rates of serious hypoglycemia. Methods: This historical cohort study included a targeted cohort of 4368 outpatient veterans aged years with active prescriptions for glyburide between April 1, 2007 and June 30, 2007 and serum creatinine (SCr)>= 2 mg/dL and a nontargeted cohort of 1886 outpatients meeting these same criteria between July I, 2007 and September 3, 2007. The intervention in the risk reduction project took place on September 4, 2007 and entailed giving regional pharmacy leaders information about the increased risk of hypoglycemia with glyburide and the list of targeted patients for follow up with providers. For each patient, the study period was the time between the date they first met the eligibility criteria and March 31, 2008. All data were obtained from Veterans Affairs (VA) administrative databases. The primary outcome was the discontinuation of glyburide. Secondary outcomes were the change in HbA(1c) after stopping glyburide and the rate of serious hypoglycemia after intervention. Results: Incidence rate ratios (IRRs) for glyburide discontinuation in targeted versus nontargeted cohorts were statistically significantly elevated in September (IRR 2.1; 95% CI 1.7-2.5), October (IRR 1.3; 95% CI 1.1-1.6), and November 2007 (IRR 1.4; 95% CI 1.1-1.7). The intervention, black race, SCr, Charlson comorbidity score, new glyburide use, and VA region were independently associated with discontinuation. Among patients in the targeted cohort who discontinued glyburide, mean (SD) HbA(1c) at baseline and after discontinuation were 7.17% (1.35%), and 7.22% (1.34%), respectively (P = 0.36). The hypoglycemia rates/1000 person-days were 0.093 before the intervention and 0.070 afterwards (P = 0.10). Conclusion: A one-time intervention in a risk reduction project decreased glyburide use over a 3-month period in elderly outpatients with renal insufficiency without compromising glucose control. (Am J Geriatr Pharmacother. 2011;9:58-68) Published by Elsevier HS Journals, Inc. C1 [Aspinall, Sherrie L.; Zhao, Xinhua; Good, Chester B.; Stone, Roslyn A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Aspinall, Sherrie L.; Zhao, Xinhua; Good, Chester B.; Cunningham, Francesca E.] VA Ctr Medicat Safety, Hines, IL USA. [Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Boresi, Joy; Jansen, David] St Louis VA Med Ctr, St Louis, MO USA. [Cox, Sarah; Witt, Lauri] Kansas City VA Med Ctr, Kansas City, MO USA. [Bartholomew, Chad; Sellers, Janelle] VA Nebraska Western Iowa Hlth Care Syst, Grand Isl, NE USA. [Guterman, Sarah; Burlingame, Mark] N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA. [Patino, Mauricio; Steele, Valerie Stanard] Bay Pines VA Hlth Care Syst, Bay Pines, FL USA. [Rivera-Miranda, Giselle] VA Caribbean Healthcare Syst, San Juan, PR USA. [Frazer, Justin] VA Eastern Kansas Hlth Care Syst, Topeka, KS USA. RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA. EM sherrie.aspinall@va.gov NR 20 TC 11 Z9 11 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2011 VL 9 IS 1 BP 58 EP 68 DI 10.1016/j.amjopharm.2011.02.001 PG 11 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 754PA UT WOS:000289866600006 PM 21459309 ER PT J AU Prentice, JC Fincke, BG Miller, DR Pizer, SD AF Prentice, Julia C. Fincke, B. Graeme Miller, Donald R. Pizer, Steven D. TI Outpatient Wait Time and Diabetes Care Quality Improvement SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CASE-MANAGEMENT; HEALTH-CARE; GLYCEMIC CONTROL; DISEASE; STRATEGIES; MORTALITY; ACCESS; TRIAL; RISK AB Objective: To examine the relationship between glycated hemoglobin (A1C) levels and the number of days spent waiting for primary care appointments. Study Design: Retrospective observational study that relied on Department of Veterans Affairs (VA) utilization data and Medicare claims data from 2001 to 2003. The outcome was A1C levels. The main explanatory variable of interest was facility-level primary care wait times measured in days. Methods: Heckman selection models simultaneously predicted the presence of an A1C value and its level. Models were risk adjusted for prior individual health status. Separate models were estimated on the entire sample and on subsamples stratified by baseline A1C levels. Results: Veterans who visited VA facilities with wait times of longer than 32.5 days had small significant increases in A1C levels of 0.14 percentage point for the whole sample, 0.07 percentage point for patients with baseline A1C levels less than 7%, 0.11 percentage point for patients with baseline A1C levels between 7% and 8%, and 0.18 percentage point for patients with baseline A1C levels greater than 8%. Conclusions: Decreasing wait times has the potential to reduce A1C levels by 0.18 percentage point for patients with baseline A1C levels exceeding 8%. This effect is roughly one-third of what is achieved with the most successful existing quality improvement strategies. Ensuring timely access to outpatient care could be an important addition to future diabetes care quality improvement programs. (Am J Manag Care. 2011; 17(2): e43-e54) C1 [Prentice, Julia C.; Fincke, B. Graeme; Miller, Donald R.] US Dept Vet Affairs, Ctr Hlth Qual Outcomes & Econ Res, Boston, MA 02130 USA. Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Prentice, JC (reprint author), US Dept Vet Affairs, Ctr Hlth Qual Outcomes & Econ Res, 150 S Huntington Ave,Mail Stop 152H, Boston, MA 02130 USA. EM julia.prentice@va.gov FU Health Services Research and Development Service, Department of Veterans Affairs [IAD-06-112, IIR 04-233]; Health Care Financing and Organization Initiative under the Robert Wood Johnson Foundation [62967] FX Funding Source: Funding for this research was provided by grants IAD-06-112 and IIR 04-233 from the Health Services Research and Development Service, Department of Veterans Affairs, and by grant 62967 from the Health Care Financing and Organization Initiative under the Robert Wood Johnson Foundation. NR 31 TC 0 Z9 0 U1 0 U2 1 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD FEB PY 2011 VL 17 IS 2 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 747XR UT WOS:000289355100003 ER PT J AU Oujiri, J Hakeem, A Pack, Q Holland, R Meyers, D Hildebrand, C Bridges, A Roach, MA Vogelman, B AF Oujiri, James Hakeem, Abdul Pack, Quinn Holland, Robert Meyers, David Hildebrand, Christopher Bridges, Alan Roach, Mary A. Vogelman, Bennett TI Resident-initiated interventions to improve inpatient heart-failure management SO BMJ QUALITY & SAFETY LA English DT Article ID ELECTRONIC HEALTH RECORD; ACUTE MYOCARDIAL-INFARCTION; CLINICAL DECISION-SUPPORT; QUALITY-OF-CARE; IMPLEMENTATION; PERFORMANCE; INDICATORS; MORTALITY; SYSTEMS; SAFETY AB Background: Third-year internal medicine residents participating in a quality improvement rotation identified gaps between the Joint Commission's ORYX quality guidelines and clinical practices for the inpatient management of heart failure (HF) at the William S. Middleton Memorial Veterans Hospital. Residents focused on the performance metrics associated with tobacco-cessation counselling documentation, ejection fraction assessment and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker prescriptions. Methods: After analysing data collected by the External Peer Review Program, residents reviewed the institution's admissions and discharge processes with the aim of improving quality and compliance. In redesigning these processes, residents created an admissions template and a discharge face sheet, and compared specific ORYX measure compliance rates before and after institution-wide implementation. Results: Following implementation of the tobacco-cessation admissions template, 100% of HF patients who used tobacco received documented cessation counselling, compared with 59% prior to intervention (p<0.01, n=32). Following implementation of the mandatory discharge face sheet, 97% of HF patients (compared with 92% preintervention, p>0.05) received comprehensive discharge instruction; LV function assessment went from 98% to 100% (p>0.05); and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker prescription for left ventricular systolic dysfunction at discharge (or documentation of a contra-indication) went from 82% to 100% (p<0.01, n=48). Discussion: By implementing a standardised admissions template and a mandatory discharge face sheet, the hospital improved its processes of documentation and increased adherence to quality-performance measures. By strengthening residents' learning and commitment to quality improvement, the hospital created a foundation for future changes in the systems that affect patient care. C1 [Oujiri, James; Holland, Robert; Meyers, David; Hildebrand, Christopher; Bridges, Alan] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Oujiri, James; Roach, Mary A.; Vogelman, Bennett] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Hakeem, Abdul] Univ Cincinnati, Coll Med, Div Cardiovasc Dis, Cincinnati, OH USA. [Pack, Quinn] Div Cardiovasc Dis, Detroit, MI USA. RP Vogelman, B (reprint author), Internal Med Residency Program, Educ Program Off, Suite 5000,1685 Highland Ave, Madison, WI 53705 USA. EM bsv@medicine.wisc.edu FU Medical Education and Research Committee (MERC) of the University of Wisconsin-Madison School of Medicine and Public Health; Residency Review Committee for Internal Medicine; William S Middleton Memorial Veterans Administration Hospital; NIH [1 UL1RR025011] FX Completion of this paper was made possible by a grant from the Medical Education and Research Committee (MERC) of the University of Wisconsin-Madison School of Medicine and Public Health as well as by the support of the Education Innovation Project of the Residency Review Committee for Internal Medicine, of which we are a participating residency. These QI projects received widespread support from the William S Middleton Memorial Veterans Administration Hospital, especially the director, D Thompson, and personnel in the Information Technology, Pharmacy, Nursing, and Organisation Improvement departments. Results of these projects were shared at the Association of Program Directors in Internal Medicine (APDIM) meeting in April, 2009. We also wish to acknowledge the support of the University of Wisconsin Institute for Clinical and Translational Research, funded through an NIH Clinical and Translational Science Award (CTSA), grant no 1 UL1RR025011. NR 18 TC 3 Z9 3 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD FEB PY 2011 VL 20 IS 2 BP 181 EP 186 DI 10.1136/bmjqs.2009.039339 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 752WT UT WOS:000289726900012 PM 21303773 ER PT J AU Dimopoulos, MA Mitsiades, CS Anderson, KC Richardson, PG AF Dimopoulos, Meletios-Athanassios Mitsiades, Constantine S. Anderson, Kenneth C. Richardson, Paul G. TI Tanespimycin as Antitumor Therapy SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Review DE 17-AAG; Heat shock protein; HSP90; Multiple myeloma; Tanespimycin ID PHASE-I TRIAL; REFRACTORY ADVANCED CANCERS; HSP90 INHIBITOR 17-AAG; MULTIPLE-MYELOMA CELLS; HUMAN BREAST-CANCER; SHOCK-PROTEIN 90; LEUKEMIA-CELLS; ADULT PATIENTS; SOLID TUMORS; AML CELLS AB Background: The 90 kDa heat shock protein (HSP90), which facilitates proper folding and stability of numerous signaling molecules involved in growth control, cell survival, and development, has been implicated in malignant processes. Like its parent compound geldanamycin, tanespimycin binds to HSP90 and causes antineoplastic effects in vitro and in vivo. Materials and Methods: All relevant published papers identified through searches of PubMed and abstracts from major recent hematology and oncology meetings were reviewed as of October 2009. Results: Different formulations and schedules of tanespimycin monotherapy and combination therapy have been tested in several phase I studies in patients with solid tumors or multiple myeloma (MM). No responses have been reported in studies of tanespimycin monotherapy in patients with metastatic melanoma. Tanespimycin given in combination with trastuzumab in patients with metastatic breast cancer induced a partial response in 24% of patients. Single-agent tanespimycin showed activity in MM and in combination with bortezomib, 27% of patients achieved minor response or better (48% bortezomib-naive patients, 22% bortezomib-pretreated patients, 13% bortezomib-refractory patients). Conclusion: Tanespimycin represents a promising new agent for the treatment of relapsed/refractory MM. Results of ongoing and future trials will determine the role of tanespimycin both in MM and other malignancies, including breast cancer. C1 [Dimopoulos, Meletios-Athanassios] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, Athens 11528, Greece. [Mitsiades, Constantine S.; Anderson, Kenneth C.; Richardson, Paul G.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. [Mitsiades, Constantine S.; Anderson, Kenneth C.; Richardson, Paul G.] Harvard Univ, Sch Med, Boston, MA USA. RP Dimopoulos, MA (reprint author), Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, 80 Vas Sofias Ave, Athens 11528, Greece. EM mdimop@med.uoa.gr FU Bristol-Myers Squibb; Amgen Pharmaceuticals; AVEO Pharma; EMD Serono; Sunesis Pharmaceuticals; Celgene Corporation; Novartis; Millennium Pharmaceuticals FX The authors thank Monica Nicosia, PhD, and AOI Communications, L.P., for editorial assistance, supported by funding from Bristol-Myers Squibb. Editorial support for this review manuscript was funded in part by Bristol-Myers Squibb. Please note that the authors were fully responsible for both content and writing the paper, and did not receive compensation for their effort.; Dr. Dimopoulos has participated on an Advisory Board for Bristol-Myers Squibb. Dr. Mitsiades is a consultant for Millennium Pharmaceuticals and Novartis. Bristol-Myers Squibb, Merck & Co., and Pharmion. He has received research funding from Amgen Pharmaceuticals, AVEO Pharma, EMD Serono, and Sunesis Pharmaceuticals. He has received honoraria from Millennium Pharmaceuticals, Novartis, Bristol-Myers Squibb, Merck & Co., and Pharmion. lie has received royalties from patents from PharmaMar. Dr. Anderson is a consultant for Celgene Corporation, Novartis, Millennium Pharmaceuticals, and Bristol-Myers Squibb. He has received research funding from Celgene Corporation, Novartis, Millennium Pharmaceuticals, and Bristol-Myers Squibb, and he has received honoraria from Celgene Corporation, Novartis, Millennium Pharmaceuticals, and Bristol-Myers Squibb. Dr. Richardson is on the speakers bureau for Millennium Pharmaceuticals and Celgene Corporation, and has received research funding from Millennium Pharmaceuticals. NR 50 TC 11 Z9 14 U1 0 U2 5 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 17 EP 22 DI 10.3816/CLML.2011.n.002 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600002 PM 21454186 ER PT J AU Treon, SP Merlini, G Morra, E Patterson, CJ Stone, MJ AF Treon, Steven P. Merlini, Giampaolo Morra, Enrica Patterson, Christopher J. Stone, Marvin J. TI Report From the Sixth International Workshop on Waldenstrom's Macroglobulinemia SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Editorial Material ID CONSENSUS PANEL RECOMMENDATIONS; CRITERIA C1 [Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Merlini, Giampaolo] Fdn IRCCS Policlin San Matteo, Pavia, Italy. [Merlini, Giampaolo] Univ Pavia, I-27100 Pavia, Italy. [Morra, Enrica] Osped Niguarda Ca Granda, Milan, Italy. [Stone, Marvin J.] Baylor Sammons Canc Ctr, Dallas, TX USA. RP Treon, SP (reprint author), Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, M547,44 Binney St, Boston, MA 02115 USA. EM steven_treon@dfci.harvard.edu OI Merlini, Giampaolo/0000-0001-7680-3254 NR 52 TC 2 Z9 2 U1 0 U2 1 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 69 EP 73 DI 10.3816/CLML.2011.n.010 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600011 ER PT J AU Sacco, A Maiso, P Azab, A Azab, F Zhang, Y Liu, Y Ngo, HT Morgan, B Quang, P Issa, G Ghobrial, IM Roccaro, AM AF Sacco, Antonio Maiso, Patricia Azab, Abdelkareem Azab, Feda Zhang, Yong Liu, Yang Ngo, Hai T. Morgan, Brittany Quang, Phong Issa, Ghayas Ghobrial, Irene M. Roccaro, Aldo M. TI Key Role of MicroRNAs in Waldenstrom's Macroglobulinemia Pathogenesis SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Article; Proceedings Paper CT 6th International Workshop on Waldenstroms Macroglobulinemia CY OCT 06-10, 2010 CL Venice, ITALY ID MULTIPLE-MYELOMA; HUMAN CANCERS; GENE; MODULATION; EXPRESSION; THERAPY; EZH2; 3B AB Epigenetics represent heritable changes in gene expression that are not due to any alteration in the DNA sequence. One of the best-known epigenetic markers is histone acetylation, which has been shown to be deregulated in neoplastic diseases, including B-cell malignancies, such as Waldenstrom's Macroglobulinemia (WM), a low-grade B-cell lymphoma characterized by the presence of lymphoplasmacytic cells in the bone marrow and a serum monoclonal immunoglobulin M in the circulation. It has been recently demonstrated that microRNAs may be responsible for modulating histone acetylation in WM cells, thus providing the preclinical evidences for using microRNA-based therapeutic strategies in this disease. C1 [Roccaro, Aldo M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Roccaro, AM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM aldo_roccaro@dfci.harvard.edu RI Sacco, Antonio/K-4681-2016; OI Sacco, Antonio/0000-0003-2945-9416; Roccaro, Aldo/0000-0002-1872-5128; Maiso, Patricia/0000-0003-3745-1924 NR 23 TC 0 Z9 0 U1 0 U2 0 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 109 EP 111 DI 10.3816/CLML.2011.n.022 PG 3 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600023 PM 21454206 ER PT J AU Ghobrial, IM Zhang, Y Liu, Y Ngo, H Azab, F Sacco, A Azab, A Maiso, P Morgan, B Quang, P Issa, G Roccaro, A AF Ghobrial, Irene M. Zhang, Yong Liu, Yang Hai Ngo Azab, Feda Sacco, Antonio Azab, Abdelkareem Maiso, Patricia Morgan, Brittany Phong Quang Issa, Ghayas Roccaro, Aldo TI The Bone Marrow Niche in Waldenstrom's Macroglobulinemia SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Article; Proceedings Paper CT 6th International Workshop on Waldenstroms Macroglobulinemia CY OCT 06-10, 2010 CL Venice, ITALY ID MULTIPLE-MYELOMA; CELL; MICROENVIRONMENT; THERAPIES AB The widespread involvement of the bone marrow with tumor cells indicates that there is continuous cell trafficking of WM cells in and out of the bone marrow leading to cell dissemination in the bone marrow and in the lymph nodes in many patients with WM. The interaction of the WM cells with the bone marrow is critical for the regulation of cell proliferation, cell cycle, drug resistance as well as cell dissemination and trafficking. Advances in understanding the interaction of the tumor clone with the BM microenvironment have led to the development of therapeutic agents that not only target the tumor clone but also regulate the bone marrow microenvironment. Here, we review the role of the cellular and liquid bone marrow compartments in the regulation of cell proliferation and dissemination in WM. C1 [Ghobrial, Irene M.; Zhang, Yong; Liu, Yang; Hai Ngo; Azab, Feda; Sacco, Antonio; Azab, Abdelkareem; Maiso, Patricia; Morgan, Brittany; Phong Quang; Issa, Ghayas; Roccaro, Aldo] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM irene_ghobrial@dfci.harvard.edu RI Sacco, Antonio/K-4681-2016; OI Sacco, Antonio/0000-0003-2945-9416; Roccaro, Aldo/0000-0002-1872-5128; Maiso, Patricia/0000-0003-3745-1924 NR 24 TC 0 Z9 0 U1 0 U2 2 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 118 EP 120 DI 10.3816/CLML.2011.n.025 PG 3 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600026 PM 21454209 ER PT J AU Treon, SP Hanzis, C Tripsas, C Ioakimidis, L Patterson, CJ Manning, RJ Sheehy, P AF Treon, Steven P. Hanzis, Christina Tripsas, Christina Ioakimidis, Leukothea Patterson, Christopher J. Manning, Robert J. Sheehy, Patricia TI Bendamustine Therapy in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Article; Proceedings Paper CT 6th International Workshop on Waldenstroms Macroglobulinemia CY OCT 06-10, 2010 CL Venice, ITALY ID NON-HODGKINS-LYMPHOMA; PHASE-II MULTICENTER; INDOLENT B-CELL; INTERNATIONAL WORKSHOP; PLUS RITUXIMAB; MANTLE CELL; RECOMMENDATIONS; FLUDARABINE; UPDATE AB We report the treatment outcome for 30 relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients following bendamustine-containing therapy. Treatment consisted of bendamustine (90 mg/m(2) I.V. on days 1, 2) and rituximab (375 mg/m(2) I.V. on either day 1 or 2) for 24 patients. Si,: rituximab-intolerant patients received bendamustine alone (n = 4) or with ofatumumab (1000 mg IV. on day 1; n = 2). Each cycle was 4 weeks, and median number of treatment cycles was 5. At best response, median serum IgM declined from 3980 to 698 mg/dL (P < .0001), and hematocrit rose from 31.9% to 36.6% (P = .0002). Overall response rate was 83.3%, with 5 VGPR and 20 PR. The median estimated progression-free survival for all patients was 13.2 months. Overall therapy was well tolerated. Prolonged myelosuppression was more common in patients who received prior nucleoside analogues. Bendamustine is active and produces durable responses in previously treated WM, both as monotherapy and with CD20-directed monoclonal antibodies. C1 [Treon, Steven P.; Hanzis, Christina; Tripsas, Christina; Ioakimidis, Leukothea; Patterson, Christopher J.; Manning, Robert J.; Sheehy, Patricia] Harvard Univ, Dana Farber Canc Inst, Bing Ctr Wildenstroms Macroglobulinemia, Sch Med, Boston, MA 02115 USA. RP Treon, SP (reprint author), Harvard Univ, Dana Farber Canc Inst, Bing Ctr Wildenstroms Macroglobulinemia, Sch Med, M547,44 Binney St, Boston, MA 02115 USA. EM steven_treon@dfci.harvard.edu NR 14 TC 37 Z9 39 U1 0 U2 2 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 133 EP 135 DI 10.3816/CLML.2011.n.030 PG 3 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600031 PM 21454214 ER PT J AU Sun, JY Xu, LA Tseng, H Ciccarelli, B Fulciniti, M Hunter, ZR Maghsoudi, K Hatjiharissi, E Zhou, YS Yang, GA Zhu, BA Liu, X Gong, P Ioakimidis, L Sheehy, P Patterson, CJ Munshi, NC O'Connor, OA Treon, SP AF Sun, Jenny Y. Xu, Lian Tseng, Hsuyi Ciccarelli, Bryan Fulciniti, Mariateresa Hunter, Zachary R. Maghsoudi, Kaveh Hatjiharissi, Evdoxia Zhou, Yangsheng Yang, Guang Zhu, Biao Liu, Xia Gong, P. Ioakimidis, Leukothea Sheehy, Patricia Patterson, Christopher J. Munshi, Nikhil C. O'Connor, Owen A. Treon, Steven P. TI Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Article; Proceedings Paper CT 6th International Workshop on Waldenstroms Macroglobulinemia CY OCT 06-10, 2010 CL Venice, ITALY ID MULTIPLE-MYELOMA; CELLS; INDUCTION; LYMPHOMA AB We studied the role of histone deacetylase inhibitors in Waldenstrom's macroglobulinemia (WM). Gene expression profiling of bone marrow CD19+ cells from 30 patients and 10 healthy donors showed overexpression of HDAC4, HDAC9, and Sirt5, with validation of HDAC9 overexpression by q-PCR in primary and BCWM.1 cells. Suberoylanilide hydroxamic acid, trichostatin A, panobinostat, and sirtinol demonstrated dose-dependent killing of BCWM.1 cells. TSA showed the greatest potency with IC50 of 70 nM. Importantly, HDAC9 activity was decreased following TSA treatment suggesting an essential role for this HDAC in WM therapy. The combination of bortezomib plus HDAC inhibitors resulted in at least additive tumor cell killing in BCWM.1 cells. TSA and bortezomib-induced apoptosis depended on a similar set of caspase activation, whereas their effect on cell cycle regulators was distinctly different. These results provided a framework for examining HDAC inhibitors as monotherapy, as well as combination therapy with bortezomib in WM. C1 [Treon, Steven P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. NYU, Langone Canc Ctr, New York, NY USA. RP Treon, SP (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, M547,44 Binney St, Boston, MA 02115 USA. EM steven_treon@dfci.harvard.edu RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 23 TC 6 Z9 7 U1 0 U2 7 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 152 EP 156 DI 10.3816/CLML.2011.n.036 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600037 PM 21454220 ER PT J AU Ciccarelli, BT Patterson, CJ Hunter, ZR Hanzis, C Ioakimidis, L Manning, R Yang, GA Xu, LA Zhou, Y Sun, J Liu, X Tseng, HY Cao, Y Sheehy, P Rodig, SJ Treon, SP AF Ciccarelli, Bryan T. Patterson, Christopher J. Hunter, Zachary R. Hanzis, Christina Ioakimidis, Leukothea Manning, Robert Yang, Guang Xu, Lian Zhou, Yangsheng Sun, Jenny Liu, Xia Tseng, Hsiuyi Cao, Yang Sheehy, Patricia Rodig, Scott J. Treon, Steven P. TI Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated With Anemia in Waldenstrom's Macroglobulinemia SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Article; Proceedings Paper CT 6th International Workshop on Waldenstroms Macroglobulinemia CY OCT 06-10, 2010 CL Venice, ITALY ID HUMAN MONOCYTES; IRON; FERROPORTIN; INTERNALIZATION; REUTILIZATION; EXPRESSION; BINDING; IL-6 AB Waldenstrom's macroglobulinemia (WM) patients often present with anemia as their primary disease manifestation that may be related to hepcidin, an important regulator of iron homeostasis. We therefore determined hepcidin levels in 53 WM patients, and 20 age-matched healthy patient donors by hepcidin-25 ELISA. Serum hepcidin levels were elevated in WM patients versus healthy patients (P = .04), and correlated with BM disease involvement (P = .004), beta-2-microglobulin levels (P = .029), and inversely with hemoglobin (P = .05). No correlation with serum iron indices was observed, though in patients with high hepcidin levels, increased iron deposition in bone marrow macrophages was observed. Importantly, hepcidin transcripts and protein were produced by primary WM cells. Hepcidin levels correlated with serum IL-6 (P < .001) and C-Reactive Protein (P = .033) levels. The results of this study implicate hepcidin as a contributor to anemia in WM, and suggest that an iron re-utilization defect accompanies hepcidin overproduction leading to its sequestration in WM patients. C1 [Treon, Steven P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Treon, SP (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, M547,44 Binney St, Boston, MA 02115 USA. EM steven_treon@dfci.harvard.edu RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 18 TC 12 Z9 12 U1 0 U2 1 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 160 EP 163 DI 10.3816/CLML.2011.n.038 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600039 PM 21454222 ER PT J AU Leleu, X Koulieris, E Maltezas, D Itzykson, R Xie, WL Manier, S Dulery, R Boyle, E Gauthier, J Poulain, S Tatiana, T Panayiotidis, P Bradwell, AR Harding, S Leblond, V Kyrtsonis, MC Ghobrial, IM AF Leleu, Xavier Koulieris, Efstathios Maltezas, Dimitrios Itzykson, Raphael Xie, Wanling Manier, Salomon Dulery, Remy Boyle, Eilleen Gauthier, Jordan Poulain, Stephanie Tatiana, Tzenou Panayiotidis, Panayiotis Bradwell, Arthur R. Harding, Stephen Leblond, Veronique Kyrtsonis, Marie-Christine Ghobrial, Irene M. TI Novel M-Component Based Biomarkers in Waldenstrom's Macroglobulinemia SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Article; Proceedings Paper CT 6th International Workshop on Waldenstroms Macroglobulinemia CY OCT 06-10, 2010 CL Venice, ITALY ID FREE LIGHT-CHAINS; MULTIPLE-MYELOMA; SERUM AB Waldenstrom's macroglobulinemia (WM) is an indolent B-cell lymphoma of the lymphoplasmacytic type accompanied by a serum IgM component. However, conventional IgM quantification lacks sensitivity, does not precisely reflect tumor burden of WM, and, although being the main marker for monitoring response to treatment, may not be accurate. New serum M-component based biomarkers were developed for routine practice in recent years, such as the Freelite (R) test and more recently the Hevylite test (R). Studies have shown that Free lite was a prognostic marker for time to treatment in WM that helps monitoring disease response or progression. Hevylite measures IgMkappa and IgMlambda, separately, and might provide true quantitative measurement of the IgM M-spike. Although current data are preliminary, Hevylite (R) might replace the current technique to measure IgM M-spike in the years to come. We summarize herein studies conducted to delineate the role of these tests in WM. C1 [Xie, Wanling; Ghobrial, Irene M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Leleu, Xavier; Manier, Salomon; Dulery, Remy; Boyle, Eilleen; Gauthier, Jordan; Poulain, Stephanie] CHRU, Hop Huriez, Serv Malad Sang, Lille, France. [Koulieris, Efstathios; Maltezas, Dimitrios; Tatiana, Tzenou; Panayiotidis, Panayiotis; Kyrtsonis, Marie-Christine] Laikon Univ Hosp, Dept Propedeut Internal Med & Hematol 1, Athens 11527, Greece. [Xie, Wanling; Ghobrial, Irene M.] Harvard Univ, Sch Med, Boston, MA USA. [Itzykson, Raphael; Leblond, Veronique] Hop La Pitie Salpetriere, APHP, Serv Hematol, Paris, France. [Bradwell, Arthur R.] Univ Birmingham, Sch Med, Dept Immun & Infect, Birmingham B15 2TT, W Midlands, England. RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM mck@ath.forthnet.gr; irene_ghobrial@dfci.harvard.edu OI Itzykson, Raphael/0000-0003-2139-6262; Bradwell, Arthur/0000-0002-1562-1606 NR 13 TC 16 Z9 18 U1 0 U2 5 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 164 EP 167 DI 10.3816/CLML.2011.n.039 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600040 PM 21454223 ER PT J AU Varadarajan, KM Rubash, HE Li, GA AF Varadarajan, Kartik M. Rubash, Harry E. Li, Guoan TI Are Current Total Knee Arthroplasty Implants Designed to Restore Normal Trochlear Groove Anatomy? SO JOURNAL OF ARTHROPLASTY LA English DT Article DE patellar tracking; trochlear groove geometry; total knee arthroplasty; virtual TKA; knee biomechanics ID PATELLOFEMORAL JOINT; FEMORAL COMPONENT; PATELLA; TRACKING; COMPLICATIONS; REPLACEMENT; CONTACT; FORCES; MODELS AB Biomechanical studies have shown that external rotation of the femoral TKA component improves patellar tracking but does not restore it to physiologic values. We hypothesized that this could be due to differences in the trochlear groove geometry of TKA and normal knees. This was investigated via a virtual TKA procedure that mounted femoral components on to 3-dimensional models of healthy femurs, followed by measurement of the trochlear geometry before and after the simulated TKA. The results showed that (1) external rotation of the component brought the trochlear groove closer to normal anatomy than no external rotation; (2) however, even with external rotation, the trochlear anatomy was only partially restored to normal. Further work is needed to determine implications for patellofemoral complications observed with current TKA designs. C1 [Varadarajan, Kartik M.; Rubash, Harry E.; Li, Guoan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab, Boston, MA 02114 USA. [Varadarajan, Kartik M.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. RP Li, GA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA. FU Department of Orthopedic Surgery, Massachusetts General Hospital FX This study was made possible through research grant received from the Department of Orthopedic Surgery, Massachusetts General Hospital. The authors would also like to thank Dr Jong-Keun Seon for technical assistance with the virtual TKA procedure. NR 41 TC 14 Z9 14 U1 0 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD FEB PY 2011 VL 26 IS 2 BP 274 EP 281 DI 10.1016/j.arth.2009.12.009 PG 8 WC Orthopedics SC Orthopedics GA 718JK UT WOS:000287117100018 PM 20171042 ER PT J AU Gray, LR Gabuzda, D Cowley, D Ellett, A Chiavaroli, L Wesselingh, SL Churchill, MJ Gorry, PR AF Gray, Lachlan R. Gabuzda, Dana Cowley, Daniel Ellett, Anne Chiavaroli, Lisa Wesselingh, Steven L. Churchill, Melissa J. Gorry, Paul R. TI CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE HIV-1; Dementia; Nef; Neurotropism; CNS; Lymphoid; CD4; MHC-1 ID IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTIOUS MOLECULAR CLONE; CEREBROSPINAL-FLUID; DILEUCINE MOTIF; DELETED HIV-1; CELL; PROTEIN; ENTRY; REPLICATION; DEMENTIA AB Human immunodeficiency virus type 1 (HIV-1) nef undergoes adaptive evolution in the central nervous system (CNS), reflecting altered requirements for HIV-1 replication in macrophages/microglia and brain-specific immune selection pressures. The role of Nef in HIV-1 neurotropism and pathogenesis of HIV-associated dementia (HAD) is unclear. In this study, we characterized 82 nef alleles cloned from brain, cerebral spinal fluid, spinal cord, and blood/lymphoid tissue-derived HIV-1 isolates from seven subjects with HAD. CNS isolate-derived nef alleles were genetically compartmentalized and had reduced sequence diversity compared to those from lymphoid tissue isolates. Defective nef alleles predominated in a brain-derived isolate from one of the seven subjects (MACS2-br). The ability of Nef to down-modulate CD4 and MHC class 1 (MHC-1) was generally conserved among nef alleles from both CNS and lymphoid tissues. However, the potency of CD4 and MHC-1 down-modulation was variable, which was associated with sequence alterations known to influence these Nef functions. These results suggest that CD4 and MHC-1 down-modulations are highly conserved functions among nef alleles from CNS- and lymphoid tissue-derived HIV-1 isolates that may contribute to viral replication and escape from immune surveillance in the CNS. C1 [Gray, Lachlan R.; Cowley, Daniel; Ellett, Anne; Chiavaroli, Lisa; Churchill, Melissa J.; Gorry, Paul R.] Burnet Inst, Ctr Virol, Melbourne, Vic 3004, Australia. [Gray, Lachlan R.; Gorry, Paul R.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia. [Gray, Lachlan R.; Wesselingh, Steven L.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia. [Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Gabuzda, Dana] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Cowley, Daniel; Wesselingh, Steven L.; Churchill, Melissa J.; Gorry, Paul R.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia. RP Churchill, MJ (reprint author), Burnet Inst, Ctr Virol, 85 Commercial Rd, Melbourne, Vic 3004, Australia. EM churchil@burnet.edu.au; gorry@burnet.edu.au OI Gray, Lachlan/0000-0002-9894-1049 FU Australian National Health and Medical Research Council (NHMRC) [433915, 433920]; NHMRC [358399]; Burnet Institute; [MH083588] FX This study was supported, in part, from project grants from the Australian National Health and Medical Research Council (NHMRC) to PRG (433915) and MJC (433920) and a multi-center program grant from the NHMRC to SLW (358399). We thank T. Spellman for advice with statistics. LRG and DC were supported by the NHMRC Dora Lush Biomedical Research Scholarships. DG was supported by MH083588. PRG is a recipient of an NHMRC Level 2 Biomedical Career Development Award. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. NR 38 TC 19 Z9 19 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD FEB PY 2011 VL 17 IS 1 BP 82 EP 91 DI 10.1007/s13365-010-0001-6 PG 10 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 750XA UT WOS:000289580200010 PM 21165790 ER PT J AU Shah, K AF Shah, Khalid TI Engineered Diagnostic and Therapeutic Stem Cells for Cancer SO TISSUE ENGINEERING PART A LA English DT Meeting Abstract CT 4th Congress on Regenerative Biology and Medicine CY OCT 13-15, 2010 CL Stuttgart, GERMANY C1 [Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol & Neurol, Boston, MA 02129 USA. EM kshah@helix.mgh.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 J9 TISSUE ENG PT A JI Tissue Eng. Part A PD FEB PY 2011 VL 17 IS 3-4 BP 543 EP 543 PG 1 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA 712JB UT WOS:000286661600056 ER PT J AU Clark, SW Dang, TA Toth, G Pride, GL Greenberg, B Warnack, W AF Clark, Stephen W. Dang, Toan Toth, Gabor Pride, Glenn L. Greenberg, Benjamin Warnack, Worthy TI Carotid Cavernous Fistula Imitating Brainstem Glioma SO ARCHIVES OF NEUROLOGY LA English DT Editorial Material ID CONGESTION C1 [Clark, Stephen W.] Massachusetts Gen Hosp, Div Neurooncol, Dept Neurol, Boston, MA 02114 USA. [Clark, Stephen W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Dang, Toan; Greenberg, Benjamin; Warnack, Worthy] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA. [Toth, Gabor; Pride, Glenn L.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA. RP Clark, SW (reprint author), Massachusetts Gen Hosp, Div Neurooncol, Dept Neurol, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM stephenwclark2@gmail.com OI Greenberg, Benjamin/0000-0002-2091-8201 NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD FEB PY 2011 VL 68 IS 2 BP 256 EP 257 DI 10.1001/archneurol.2010.366 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 721CY UT WOS:000287330300016 PM 21320994 ER PT J AU Barnes, DE Yaffe, K AF Barnes, Deborah E. Yaffe, Kristine TI Accuracy of Summary Risk Score for Prediction of Alzheimer Disease: Better Than Demographics Alone? SO ARCHIVES OF NEUROLOGY LA English DT Letter ID DEMENTIA RISK C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Barnes, DE (reprint author), 4150 Clement St,151R, San Francisco, CA 94121 USA. EM deborah.barnes@ucsf.edu NR 5 TC 2 Z9 2 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD FEB PY 2011 VL 68 IS 2 BP 268 EP 268 DI 10.1001/archneurol.2011.4 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 721CY UT WOS:000287330300022 PM 21321000 ER PT J AU McElroy, SL Frye, MA Hellemann, G Altshuler, L Leverich, GS Suppes, T Keck, PE Nolen, WA Kupka, R Post, RM AF McElroy, Susan L. Frye, Mark A. Hellemann, Gerhard Altshuler, Lori Leverich, Gabriele S. Suppes, Trisha Keck, Paul E. Nolen, Willem A. Kupka, Ralph Post, Robert M. TI Prevalence and correlates of eating disorders in 875 patients with bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Eating disorders; Bipolar disorder; Binge ID COMORBIDITY SURVEY REPLICATION; TREATMENT ENHANCEMENT PROGRAM; ANOREXIA-NERVOSA; STEP-BD; PSYCHIATRIC-DISORDERS; METABOLIC SYNDROME; CO-MORBIDITY; I-DISORDER; SPECTRUM; ILLNESS AB Objective: Relatively little is known about the co-occurrence of bipolar and eating disorders. We therefore assessed the prevalence and clinical correlates of eating disorders in 875 patients with bipolar disorder. Method: 875 outpatients with DSM-IV bipolar I or II disorder were evaluated with structured diagnostic interviews and clinician- and self-administered questionnaires to determine bipolar and eating disorder diagnoses, other comorbid Axis I disorder diagnoses, and demographic and historical illness characteristics. Results: 125 (14.3%) patients met DSM-IV criteria for at least one comorbid lifetime Axis I eating disorder, with binge eating disorder (N = 77) being more common than bulimia nervosa (n = 42) and anorexia nervosa (N = 27). There were no significant eating disorder comorbidity differences between bipolar I and bipolar II patients. Presence of a lifetime comorbid eating disorder was associated with female gender, younger age, earlier age of onset of mood symptoms and of bipolar disorder, presentation in a mixed episode, greater number of prior mood episodes, history of rapid cycling and suicide attempts, greater mean BMI, obesity and severe obesity, and family history of depression, bipolar disorder, alcoholism, and drug abuse. When the three eating disorder groups were compared, lifetime anorexia nervosa was associated with normal weight and a lifetime anxiety disorder, lifetime bulimia nervosa was associated with overweight, and lifetime binge eating disorder was associated with obesity and severe obesity. Conclusions: Patients with bipolar disorder, especially women, not infrequently have comorbid eating disorders, and this comorbidity is associated with an earlier age of onset and more severe course of bipolar illness. (C) 2010 Elsevier B.V. All rights reserved. C1 [McElroy, Susan L.; Keck, Paul E.] Craig & Frances Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.; Keck, Paul E.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA. [Hellemann, Gerhard; Altshuler, Lori] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Altshuler, Lori] VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA. [Leverich, Gabriele S.; Post, Robert M.] Bipolar Collaborat Network, Bethesda, MD USA. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Bipolar Disorder Res Program, Palo Alto, CA USA. [Nolen, Willem A.] Univ Groningen, Dept Psychiat, Univ Med Ctr Groningen, Groningen, Netherlands. [Kupka, Ralph] Altrech Inst Mental Hlth Care, Utrecht, Netherlands. [Post, Robert M.] George Washington Sch Med, Washington, DC USA. RP McElroy, SL (reprint author), Linder Ctr HOPE, 4075 Old Western Row Rd, Mason, OH 45040 USA. EM susan.mcelroy@lindnercenter.org RI Nolen, Willem/E-9006-2014 FU Astra Zeneca Pharmaceuticals; National Institute of Mental Health (NIMH); Pfizer; Pharma Solutions (CNS Drug Supplement); Wolters Kluwer; Theodore and Vada Stanley Foundation FX T Suppes receives honoraria and/or research support from Astra Zeneca Pharmaceuticals, National Institute of Mental Health (NIMH), Pfizer, Pharma Solutions (CNS Drug Supplement), and Wolters Kluwer.; Supported by a generous grant from The Theodore and Vada Stanley Foundation. NR 49 TC 58 Z9 58 U1 7 U2 21 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2011 VL 128 IS 3 BP 191 EP 198 DI 10.1016/j.jad.2010.06.037 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 743JG UT WOS:000289014000002 PM 20674033 ER PT J AU Bhambhvani, P Scott, J Heo, J Iskandrian, A AF Bhambhvani, Pradeep Scott, Johnny Heo, Jaekyeong Iskandrian, Ami TI Unusual intrathoracic activity of Tc-99m sestamibi in a patient with chest pains SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article ID MYOCARDIAL-PERFUSION SCINTIGRAPHY; EMISSION COMPUTED-TOMOGRAPHY; INTESTINAL ACTIVITY; SPECT C1 [Bhambhvani, Pradeep; Scott, Johnny; Iskandrian, Ami] Univ Alabama, Dept Radiol, Birmingham, AL 35294 USA. [Scott, Johnny] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Heo, Jaekyeong; Iskandrian, Ami] Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Scott, Johnny] Birmingham VA Med Ctr, Dept Nucl Med, Birmingham, AL USA. RP Bhambhvani, P (reprint author), Univ Alabama, Dept Radiol, Birmingham, AL 35294 USA. EM pbhambhvani@uabmc.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2011 VL 18 IS 1 BP 185 EP 186 DI 10.1007/s12350-010-9289-0 PG 2 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 745LK UT WOS:000289166700022 PM 20848255 ER PT J AU Pilch, PF Meshulam, T Ding, SY Liu, LB AF Pilch, Paul F. Meshulam, Tova Ding, Shiying Liu, Libin TI Caveolae and lipid trafficking in adipocytes SO CLINICAL LIPIDOLOGY LA English DT Review DE adipocyte; caveolin; cavin; cholesterol; fatty acid; lipid droplet ID DEPRIVATION-RESPONSE-GENE; TRANSCRIPT RELEASE FACTOR; FAST FLIP-FLOP; PLASMA-MEMBRANE; FATTY-ACID; BINDING PROTEIN; POLYMERASE-I; GENERALIZED LIPODYSTROPHY; CHOLESTEROL EFFLUX; ENDOTHELIAL-CELLS AB The abundance of caveolae in adipocytes suggests a possible cell-specific role for these structures, and because these cells take up and release fatty acids as their quantitatively most robust activity, modulation of fatty acid movement is one such role that is supported by substantial in vitro and in vivo data. In addition, caveolae are particularly rich in cholesterol and sphingolipids, and indeed, fat cells harbor more cholesterol than any other tissue. In this article, we review the role of adipocyte caveolae with regard to these important lipid classes. C1 [Pilch, Paul F.; Meshulam, Tova; Ding, Shiying; Liu, Libin] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA. [Pilch, Paul F.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Liu, Libin] Joslin Diabet Ctr, Boston, MA 02215 USA. RP Pilch, PF (reprint author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA. FU NIH [DK-30425, DK-56935] FX This work is supported by NIH grants DK-30425 and DK-56935. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 108 TC 11 Z9 11 U1 0 U2 6 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-4299 J9 CLIN LIPIDOL JI Clin. Lipidol. PD FEB PY 2011 VL 6 IS 1 BP 49 EP 58 DI 10.2217/CLP.10.80 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 741DX UT WOS:000288844400010 PM 21625349 ER PT J AU Dodson, TB AF Dodson, Thomas B. TI Estimating Survival, Like Placing Implants, Must be Done Right SO INTERNATIONAL JOURNAL OF PERIODONTICS & RESTORATIVE DENTISTRY LA English DT Editorial Material C1 [Dodson, Thomas B.] Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA. [Dodson, Thomas B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Ctr Appl Clin Invest, Boston, MA 02114 USA. RP Dodson, TB (reprint author), Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, 188 Longwood Ave, Boston, MA 02115 USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU QUINTESSENCE PUBLISHING CO INC PI HANOVER PARK PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA SN 0198-7569 EI 1945-3388 J9 INT J PERIODONT REST JI Int. J. Periodontics Restor. Dent. PD FEB PY 2011 VL 31 IS 1 BP 7 EP 8 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 739OZ UT WOS:000288728800001 ER PT J AU Zisook, S Reynolds, CF Pies, R Simon, NM Lebowitz, B Shear, MK AF Zisook, Sidney Reynolds, Charles F., III Pies, Ronald Simon, Naomi M. Lebowitz, Barry Shear, M. Katherine TI Back to "Normal Bereavement" Reply SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Letter ID MAJOR DEPRESSION; COMPLICATED GRIEF; DIFFER; DSM C1 [Zisook, Sidney] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Zisook, Sidney] San Diego VA Healthcare Syst, San Diego, CA USA. [Reynolds, Charles F., III] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15260 USA. [Reynolds, Charles F., III] Univ Pittsburgh, Grad Sch Publ Hlth, Western Psychiat Inst & Clin, Dept Community & Behav Hlth Sci, Pittsburgh, PA USA. [Pies, Ronald] Tufts Univ, Sch Med, Dept Psychiat, Boston, MA 02111 USA. [Pies, Ronald] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. [Simon, Naomi M.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Simon, Naomi M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lebowitz, Barry] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Shear, M. Katherine] Columbia Univ, Sch Social Work, New York, NY USA. [Shear, M. Katherine] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. RP Zisook, S (reprint author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. EM szisook@ucsd.edu NR 12 TC 0 Z9 0 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD FEB PY 2011 VL 72 IS 2 BP 260 EP 261 DI 10.4088/JCP.10lr06493ablu PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 729WR UT WOS:000287985400018 ER PT J AU Akiyama, Y Caucheteux, SM Vernochet, C Iwamoto, Y Tanaka, K Kanellopoulos-Langevin, C Benichou, G AF Akiyama, Yoshinobu Caucheteux, Stephane M. Vernochet, Cecile Iwamoto, Yoshiko Tanaka, Katsunori Kanellopoulos-Langevin, Colette Benichou, Gilles TI Transplantation Tolerance to a Single Noninherited MHC Class I Maternal Alloantigen Studied in a TCR-Transgenic Mouse Model SO JOURNAL OF IMMUNOLOGY LA English DT Article ID SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION; T-CELLS; HLA ANTIGENS; PROLONGED SURVIVAL; HOST-DISEASE; SKIN-GRAFTS; MICE; FETAL; INDUCTION AB The mechanisms underlying tolerance to noninherited maternal Ags (NIMA) are not fully understood. In this study, we designed a double-transgenic model in which all the offspring's CD8(+) T cells corresponded to a single clone recognizing the K(b) MHC class I protein. In contrast, the mother and the father of the offspring differed by the expression of a single Ag, K(b), that served as NIMA. We investigated the influence of NIMA exposure on the offspring thymic T cell selection during ontogeny and on its peripheral T cell response during adulthood. We observed that anti-K(b) thymocytes were exposed to NIMA and became activated during fetal life but were not deleted. Strikingly, adult mice exposed to NIMA accepted permanently K(b+) heart allografts despite the presence of normal levels of anti-K(b) TCR transgenic T cells. Transplant tolerance was associated with a lack of a proinflammatory alloreactive T cell response and an activation/expansion of T cells producing IL-4 and IL-10. In addition, we observed that tolerance to NIMA K(b) was abrogated via depletion of CD4(+) but not CD8(+) T cells and could be transferred to naive nonexposed mice via adoptive transfer of CD4(+)CD25(high) T cell expressing Foxp3 isolated from NIMA mice. The Journal of Immunology, 2011, 186: 1442-1449. C1 [Akiyama, Yoshinobu; Iwamoto, Yoshiko; Tanaka, Katsunori; Benichou, Gilles] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA. [Caucheteux, Stephane M.; Vernochet, Cecile; Kanellopoulos-Langevin, Colette] CNRS, Lab Inflammat Gestat & Autoimmun, Inst Jacques Monod, F-75205 Paris 13, France. [Caucheteux, Stephane M.; Vernochet, Cecile; Kanellopoulos-Langevin, Colette] Univ Paris Diderot, F-75205 Paris 13, France. RP Benichou, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Thier 807,55 Fruit St, Boston, MA 02114 USA. EM kanellopoulos.colette@ijm.univ-paris-diderot.fr; gbenichou@partners.org FU National Institute of Child Health and Human Development, National Institutes of Health [RO1HD050484, K02AI53103]; French Ministry of Education and Research; Fondation pour la Recherche Medicale and Ligue contre le Cancer; North Atlantic Treaty Organization Science Program FX This work was supported by the National Institute of Child Health and Human Development, National Institutes of Health (Grants RO1HD050484 and K02AI53103 to GB), the French Ministry of Education and Research (to S.M.C. and CV), the Fondation pour la Recherche Medicale and Ligue contre le Cancer (to S.M.C.), and a North Atlantic Treaty Organization Science Program collaborative grant (to G.B. and C.K.-L.). NR 45 TC 7 Z9 7 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD FEB 1 PY 2011 VL 186 IS 3 BP 1442 EP 1449 DI 10.4049/jimmunol.1003023 PG 8 WC Immunology SC Immunology GA 708RE UT WOS:000286381200022 PM 21178009 ER PT J AU Makin-Byrd, K Gifford, E McCutcheon, S Glynn, S AF Makin-Byrd, Kerry Gifford, Elizabeth McCutcheon, Susan Glynn, Shirley TI Family and Couples Treatment for Newly Returning Veterans SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE family; couples; treatment; veteran; military ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-ILLNESS; LED EDUCATION; SCHIZOPHRENIA; IMPACT; INTERVENTION; DEPLOYMENT; COMBAT; PSYCHOEDUCATION; SATISFACTION AB Civilian psychologists are being called on to assist the thousands of service members returning from Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF). Newly returning veterans are at risk for depression, posttraumatic stress disorder, and alcohol use disorders. In addition, veteran partners and families are at increased risk for stress and conflict. The following article provides clinicians with information on the impact of military service on the veteran and the family, then reviews ongoing family services available to veterans through the Veterans Health Administration (VHA). Finally, we describe recovery-oriented implications for practicing psychologists when treating veterans and their families. C1 [Makin-Byrd, Kerry] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Palo Alto, CA USA. [Makin-Byrd, Kerry] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Gifford, Elizabeth] Vet Hlth Adm, Menlo Pk, CA USA. [McCutcheon, Susan] Dept Vet Affairs, Off Mental Hlth Serv, Washington, DC USA. [Glynn, Shirley] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Glynn, Shirley] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Gifford, Elizabeth] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. RP Makin-Byrd, K (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat MPD 152, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Kerry.Makin-Byrd@va.gov OI Makin-Byrd, Kerry/0000-0003-0670-3826 NR 57 TC 17 Z9 17 U1 4 U2 10 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD FEB PY 2011 VL 42 IS 1 SI SI BP 47 EP 55 DI 10.1037/a0022292 PG 9 WC Psychology, Multidisciplinary SC Psychology GA 733TE UT WOS:000288285100007 ER PT J AU Sautter, FJ Armelie, AP Glynn, SM Wielt, DB AF Sautter, Frederic J. Armelie, Aaron P. Glynn, Shirley M. Wielt, Dustin B. TI The Development of a Couple-Based Treatment for PTSD in Returning Veterans SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE couple therapy; posttraumatic stress disorder; behavior therapy; psychotherapy; relationship problem ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; MALE VIETNAM VETERANS; SOCIAL SUPPORT; SYMPTOMS; THERAPY; IRAQ; AFGHANISTAN; EXPOSURE; METAANALYSIS AB Military personnel deployed in Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) show high levels of emotional distress and posttraumatic stress disorder (PTSD), and these deployment-related problems may be expected to have a devastating impact on their relationships. It is urgent that researchers develop couple-based treatments to reduce PTSD in OEF/OIF veterans and to reduce PTSD-related relationship problems. This article describes the development of a novel couple-based treatment for PTSD, called Structured Approach Therapy (SAT), that uses empathic communication training and stress inoculation procedures to help couples improve their ability to cope with trauma-related anxiety and a multicomponent emotion activation program to help couples reduce emotional numbing. The theoretical basis of the SAT Treatment Model is described, and the various treatment components are presented. The authors recommend that couple-based interventions be used to provide OEF/OIF veterans and their partners with empathic communication skills to discuss their thoughts and feelings about deployment and with dyadic coping skills to confront trauma-related aversive emotions and emotional numbing and return intimacy to their lives. C1 [Sautter, Frederic J.; Armelie, Aaron P.; Wielt, Dustin B.] SE Louisiana Vet Hlth Care Syst, New Orleans, LA USA. [Glynn, Shirley M.] W Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Sautter, FJ (reprint author), Tulane Univ, Dept Psychiat & Behav Sci, Sch Med, 1440 Canal St TB 53, New Orleans, LA 70112 USA. EM fredericsautter@msn.com NR 39 TC 14 Z9 14 U1 2 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD FEB PY 2011 VL 42 IS 1 SI SI BP 63 EP 69 DI 10.1037/a0022323 PG 7 WC Psychology, Multidisciplinary SC Psychology GA 733TE UT WOS:000288285100009 ER PT J AU Terrio, HP Nelson, LA Betthauser, LM Harwood, JE Brenner, LA AF Terrio, Heidi P. Nelson, Lonnie A. Betthauser, Lisa M. Harwood, Jeri E. Brenner, Lisa A. TI Postdeployment Traumatic Brain Injury Screening Questions: Sensitivity, Specificity, and Predictive Values in Returning Soldiers SO REHABILITATION PSYCHOLOGY LA English DT Article DE concussion; military; postdeployment; screening; traumatic brain injury ID POSTTRAUMATIC-STRESS-DISORDER; IRAQ; IDENTIFICATION; RELIABILITY; AFGHANISTAN; POPULATION; DEPRESSION; DEPLOYMENT; SYMPTOMS; VALIDITY AB Objective: To evaluate the sensitivity, specificity, and predictive values of Post-Deployment Health Assessment traumatic brain injury (TBI) screening questions employed by the Department of Defense (DOD). Participants: Complete data was obtained from 3,072 soldiers upon return from a 15-month deployment to Iraq. Method: Comparisons were made between responses to the DOD four-item screener and a brief structured clinical interview for likely deployment-related TBI history. The interview process was facilitated using responses to the Warrior Administered Retrospective Casualty Assessment Tool (WARCAT). Results: The sensitivity and specificity of the DOD screening tool (positive response to all four items) in comparison to the clinician-confirmed diagnosis was 60% and 96%, respectively. The sensitivity increased to 80%, with a slight decrease in specificity to 93%, for positive TBI screening when affirmative responses to questions 1 and 2 only were included. Conclusions: Affirmative responses to questions 1 and 2 of the DOD TBI screening tool demonstrated higher sensitivity for clinician-diagnosed deployment-related TBI. These two items perform better than positive responses to all four questions; the criteria presently being used for documentation and referral of a deployment-related TBI. These findings support further exploration of TBI screening and assessment procedures. C1 [Terrio, Heidi P.] Evans Army Community Hosp, Def & Vet Brain Injury Ctr, Dept Deployment Hlth, Ft Carson, CO USA. [Betthauser, Lisa M.] Univ Colorado Denver, Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA. [Harwood, Jeri E.] Univ Colorado Denver, Dept Pediat, Sch Med, Denver, CO USA. [Brenner, Lisa A.] Univ Colorado Denver, Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, Sch Med, Denver, CO USA. [Brenner, Lisa A.] Univ Colorado Denver, Dept Psychiat, Sch Med, Denver, CO USA. [Brenner, Lisa A.] Univ Colorado Denver, Dept Neurol, Sch Med, Denver, CO USA. [Brenner, Lisa A.] Univ Colorado Denver, Dept Phys Med & Rehabil, Sch Med, Denver, CO USA. RP Terrio, HP (reprint author), USA, Western Reg Med Command, Bldg 2006,Liggett Ave,Room 317,Mail Stop 109,Box, Jblm, WA 98433 USA. EM heidi.terrio@amedd.army.mil NR 32 TC 21 Z9 21 U1 0 U2 1 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD FEB PY 2011 VL 56 IS 1 BP 26 EP 31 DI 10.1037/a0022685 PG 6 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA 735LZ UT WOS:000288417400003 PM 21401283 ER PT J AU Shapiro, LJ Stewart, SE AF Shapiro, Leslie J. Stewart, S. Evelyn TI Pathological guilt: A persistent yet overlooked treatment factor in obsessive-compulsive disorder SO ANNALS OF CLINICAL PSYCHIATRY LA English DT Review DE OCD; guilt; state; trait; moral; responsibility ID INFLATED RESPONSIBILITY; RIGHT EXPERIENCES; TRAUMATIC EVENTS; PTSD SYMPTOMS; SHAME; DEPRESSION; SCRUPULOSITY; EXPOSURE; ACTIVATION; ADDICTION AB BACKGROUND: Guilt appears to be a factor that may increase the severity of obsessive-compulsive disorder (OCD) and negatively impact treatment outcomes. However, researchers and clinicians have paid little attention to addressing guilt in OCD treatment. Because guilt is an important perpetuating and mediating factor for OCD symptoms and the development of guilt-specific strategies may yield improved treatment outcomes, we hypothesized that a review of the relevant literature may provide important guidance for the field. METHODS: To identify existing scientific contributions across psychological, biologic, and theological disciplines, we conducted a systematic review of the literature on the topic of pathological guilt (PG) in OCD. RESULTS: Fourteen studies focusing on both PG and OCD were identified. The content of these papers consistently reflected the theme that guilt plays a significant role in OCD and obsessive-compulsive symptoms. CONCLUSIONS: The potential influence and moderating effects of guilt require more focused attention in the clinical management of OCD. Development of routine standardized measures and treatment protocols targeting the role of guilt in OCD, in addition to consultation with clergy or other appropriate community resources, would provide valuable contributions to the literature. Addressing this affective component related to OCD may lead to improved treatment outcomes and fewer relapses for this debilitating and frequently chronic illness. C1 [Shapiro, Leslie J.; Stewart, S. Evelyn] McLean Hosp, OCD Inst, Belmont, MA 02478 USA. [Stewart, S. Evelyn] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Shapiro, LJ (reprint author), McLean Hosp, OCD Inst, 115 Mill St, Belmont, MA 02478 USA. EM lshapiro@mclean.harvard.edu RI Stewart, Evelyn/K-6961-2014 NR 60 TC 22 Z9 22 U1 0 U2 13 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 1040-1237 J9 ANN CLIN PSYCHIATRY JI Ann. Clin. Psychiatry PD FEB PY 2011 VL 23 IS 1 BP 63 EP 70 PG 8 WC Psychiatry SC Psychiatry GA 725AB UT WOS:000287616500009 PM 21318197 ER PT J AU Bhengu, BR Ncama, BP McInerney, PA Wantland, DJ Nicholas, PK Corless, IB McGibbon, CA Davis, SM Nicholas, TP Ros, AV AF Bhengu, Busisiwe R. Ncama, Busisiwe P. McInerney, Patricia A. Wantland, Dean J. Nicholas, Patrice K. Corless, Inge B. McGibbon, Chris A. Davis, Sheila M. Nicholas, Thomas P. Ros, Ana Viamonte TI Symptoms experienced by HIV-infected Individuals on antiretroviral therapy in KwaZulu-Natal, South Africa SO APPLIED NURSING RESEARCH LA English DT Article ID SELF-CARE; MEDICATION ADHERENCE; HIV/AIDS PATIENTS; MANAGEMENT; STRATEGIES; PROGRAM; DISEASE; PEOPLE; LIFE AB Symptom management in HIV/AIDS is a critical issue that influences the quality of life of those living with the disease. Although the goals of treating the numbers living with HIV/AIDS have not yet been achieved, availability of antiretroviral therapies (ARVs) has been expanded to many clinical settings in KwaZulu-Natal, the epicenter of HIV infection in South Africa. The South African Department of Health (2007) estimates indicate that 5.54 million South Africans are living with HIV/AIDS, whereas UNAIDS (2007) estimates suggest that 18.8% of the population in South Africa is affected. Because the symptom experience may influence adherence to ARVs and quality of life, this study focused on the prevalence of symptoms reported by patients (N = 149) diagnosed with HIV/AIDS and adherence to medications and appointments. Self-report data were obtained from this community-based sample of HIV-infected patients who received care in outpatient clinics in Durban, KwaZulu-Natal, South Africa. With an average of three side effects, the most frequently reported by the study participants were fatigue/tiredness (41%), rashes (40%), headaches (32%), insomnia (31%), sadness (24%), disturbing dreams (23%), numbness (22%), pain (22%), and self-appearance (20%). On a scale of 1 to 10 (10 being worst possible), those with symptoms reported an average intensity of 4.2 (SD = 2.0), and the degree to which symptoms affected activity levels was 3.2 (SD = 2.2). Although intensity of symptoms and effects on activity levels were strongly correlated (r = .78, p < .001), there were no significant relationships between adherence and the intensity of symptoms or the relationship of symptoms with activity levels. Logistic regression analyses indicate that the presence of a greater number of symptoms was not associated with greater adherence (odds ratio = 2.27, 95% confidence interval = 0.60-8.70, ns). However, those who reported higher adherence were 1.5 times more likely to report greater physical health than low adherers = .04). High adherers were also 1.6 times more likely to report greater psychological health than low adherers = .03). This suggests that further study is needed to investigate adherence motivations for those living with HIV/AIDS in South Africa because adherence seems not to be linked to the frequency of symptoms or limitations on activity related to symptoms. (C) 2011 Elsevier Inc. All rights reserved. C1 [Nicholas, Patrice K.; Corless, Inge B.] MGH Inst Hlth Profess, Boston, MA 02129 USA. [Bhengu, Busisiwe R.; Ncama, Busisiwe P.; McInerney, Patricia A.] Univ KwaZulu Natal, ZA-4041 Durban, South Africa. [Wantland, Dean J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Nicholas, Patrice K.; Nicholas, Thomas P.] Brigham & Womens Hosp, Boston, MA 02120 USA. [McGibbon, Chris A.] Univ New Brunswick, Fredericton, NB E3B 5A3, Canada. [Davis, Sheila M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Davis, Sheila M.] Harvard Univ, Sch Med, Div Aids, Boston, MA 02115 USA. [Ros, Ana Viamonte] State Florida, Dept Hlth, Tallahassee, FL 32303 USA. RP Nicholas, PK (reprint author), MGH Inst Hlth Profess, Grad Program Nursing, Boston, MA 02120 USA. EM pnicholas@partners.org OI Corless, Inge/0000-0003-0438-2037 NR 32 TC 7 Z9 7 U1 3 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0897-1897 J9 APPL NURS RES JI Appl. Nurs. Res. PD FEB PY 2011 VL 24 IS 1 BP 1 EP 9 DI 10.1016/j.apnr.2009.01.001 PG 9 WC Nursing SC Nursing GA 722WG UT WOS:000287465400001 PM 20974052 ER PT J AU Kettl, P AF Kettl, Paul TI Exploring the Mental Life and Home Life of Children: The Role of a Television History SO CHILD AND ADOLESCENT MENTAL HEALTH LA English DT Article DE Television; video entertainment; child evaluation ID CHILDHOOD OBESITY; MEDIA AB Background: Media entertainment is a pervasive presence in the lives of our children. It presents a series of stories that a child can select as important or intriguing to him or her. Method: A good history of television and media viewing uses this omnipresent influence in a child's life to attempt to gain insight into the child's hopes and fears as well as information concerning the structure of the home. Conclusion: It is a useful exercise that could be done with each new child patient, and could provide a quick means to assess the child's thoughts as well as assessing the child's home environment. C1 Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA 19104 USA. RP Kettl, P (reprint author), Philadelphia VA Med Ctr, Behav Hlth Serv, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM paul.kettl@va.gov NR 12 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1475-357X J9 CHILD ADOL MENT H-UK JI Child Adolesc. Ment. Health PD FEB PY 2011 VL 16 IS 1 BP 60 EP 62 DI 10.1111/j.1475-3588.2010.00573.x PG 3 WC Psychology, Clinical; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 727RH UT WOS:000287818400009 ER PT J AU Case, MAB AF Case, Mary Ann B. TI Oncology Nurse Navigator: Ensuring Safe Passage SO CLINICAL JOURNAL OF ONCOLOGY NURSING LA English DT Article ID BREAST-CANCER; OLDER WOMEN; PATIENT NAVIGATION; CASE MANAGERS; CARE; PERCEPTIONS AB The purpose of this integrative review is to explore the presence of the oncology nurse as navigator on measurable patient outcomes. Eighteen primary nursing research studies were found using combinations of the following key words: advocate, cancer, case manager, coach, certification, guide, navigator, nurse, oncology, patient navigator, pivot nurse, and continuity of care. Nurse researchers identified nursing-sensitive patient outcomes related to the time to diagnosis and appropriate treatment, effect on mood states, satisfaction, support, continuity of care, and cost outcomes. Navigator roles are expanding globally, and nurses should continue to embrace opportunities to ensure the safe passage of patients with cancer along the entire trajectory of illness and to evaluate the implications for educational preparation, research, and practice of navigators of all kinds. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Case, MAB (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM mabcase@gmail.com NR 36 TC 16 Z9 16 U1 2 U2 12 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 1092-1095 J9 CLIN J ONCOL NURS JI Clin. J. Oncol. Nurs. PD FEB PY 2011 VL 15 IS 1 BP 33 EP 40 DI 10.1188/11.CJON.33-40 PG 8 WC Oncology; Nursing SC Oncology; Nursing GA 724DW UT WOS:000287557300008 PM 21278039 ER PT J AU Specht, MW Woods, DW Piacentini, J Scahill, L Wilhelm, S Peterson, AL Chang, S Kepley, H Deckersbach, T Flessner, C Buzzella, BA McGuire, JF Levi-Pearl, S Walkup, JT AF Specht, Matt W. Woods, Douglas W. Piacentini, John Scahill, Lawrence Wilhelm, Sabine Peterson, Alan L. Chang, Susanna Kepley, Hayden Deckersbach, Thilo Flessner, Christopher Buzzella, Brian A. McGuire, Joseph F. Levi-Pearl, Sue Walkup, John T. TI Clinical Characteristics of Children and Adolescents with a Primary Tic Disorder SO JOURNAL OF DEVELOPMENTAL AND PHYSICAL DISABILITIES LA English DT Article DE Tourette's disorder; Tics; Comorbid; Anxiety; Impairment ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; GLOBAL ASSESSMENT SCALE; TOURETTES-DISORDER; DOUBLE-BLIND; SOCIAL ACCEPTABILITY; INTERVIEW SCHEDULE; BEHAVIOR-THERAPY; PARENT VERSIONS; DSM-IV AB The clinical characteristics and rates of co-occurring psychiatric conditions in youth seeking treatment for a chronic tic disorder (CTD) were examined. Children and adolescents (N = 126) with a primary CTD diagnosis were recruited for a randomized controlled treatment trial. An expert clinician established diagnostic status via semi-structured interview. Participants were male (78.6%), Caucasians (84.9%), mean age 11.7 years (SD = 2.3) with moderate-to-severe tics who met criteria for Tourette's disorder (93.7%). Common co-occurring conditions included attention-deficit/hyperactivity disorder (ADHD; 26%), social phobia (21%), generalized anxiety disorder (20%), and obsessive-compulsive disorder (OCD; 19%). Motor and vocal tics with greater intensity, complexity, and interference were associated with increased impairment. Youth with a CTD seeking treatment for tics should be evaluated for non-OCD anxiety disorders in addition to ADHD and OCD. Despite the presence of co-occurring conditions, children with more forceful, complex, and/or directly interfering tics may seek treatment to reduce tic severity. C1 [Specht, Matt W.; Kepley, Hayden; Walkup, John T.] Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA. [Woods, Douglas W.; Flessner, Christopher] Univ Wisconsin, Dept Psychol, Milwaukee, WI 53201 USA. [Piacentini, John; Chang, Susanna; Buzzella, Brian A.] Univ Calif Los Angeles, Neuropsychiart Hosp, Div Child & Adolescent Psychiat, Los Angeles, CA USA. [Scahill, Lawrence; McGuire, Joseph F.] Yale Univ, Sch Nursing, Ctr Child Study, New Haven, CT 06536 USA. [Wilhelm, Sabine; Deckersbach, Thilo] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Levi-Pearl, Sue] Tourette Syndrome Assoc, Bayside, NY USA. RP Specht, MW (reprint author), Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, 600 N Wolfe St CMSC 314, Baltimore, MD 21287 USA. EM mspecht1@jhmi.edu RI Piacentini, John/C-4645-2011; Flessner, Christopher/K-1483-2015; OI Scahill, Lawrence/0000-0001-5073-1707 FU NCRR NIH HHS [UL1 RR024139]; NIMH NIH HHS [R01 MH069877, R01 MH070802] NR 47 TC 20 Z9 20 U1 6 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1056-263X J9 J DEV PHYS DISABIL JI J. Dev. Phys. Disabil. PD FEB PY 2011 VL 23 IS 1 BP 15 EP 31 DI 10.1007/s10882-010-9223-z PG 17 WC Rehabilitation SC Rehabilitation GA 719ZB UT WOS:000287248900003 PM 24999300 ER PT J AU Kossida, T Rigopoulos, D Katsambas, A Anderson, RR AF Kossida, Theodora Rigopoulos, Dimitrios Katsambas, Andreas Anderson, R. Rox TI OPTIMAL TATTOO REMOVAL IN ONE TREATMENT SESSION WITH NANOSECOND-DOMAIN LASER PULSES SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract C1 Univ Athens, Sch Med, A Syggros Skin Dis Hosp, Athens 11528, Greece. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2011 VL 43 SU 23 MA 76 BP 930 EP 930 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 735EK UT WOS:000288396000071 ER PT J AU Shofner, J Tannous, Z Avram, M AF Shofner, Joshua Tannous, Zeina Avram, Mathew TI QUALITY CONTROL AND THE PULSED DYE LASER: WHEN NOT TO TREAT SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract C1 [Shofner, Joshua; Tannous, Zeina; Avram, Mathew] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2011 VL 43 SU 23 MA 75 BP 930 EP 930 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 735EK UT WOS:000288396000070 ER PT J AU Ortiz, A Avram, M AF Ortiz, Arisa Avram, Mathew TI REDISTRIBUTION OF INK FOLLOWING LASER TATTOO REMOVAL SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract C1 Univ Calif Irvine, Irvine, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2011 VL 43 SU 23 MA 78 BP 931 EP 931 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 735EK UT WOS:000288396000073 ER PT J AU Chuang, G Avram, M Tannous, Z AF Chuang, Gary Avram, Mathew Tannous, Zeina TI ULCERATION OF MATURE SURGICAL SCARS FROM NON-ABLATIVE 1,550 NM FRACTIONAL LASER TREATMENTS ASSOCIATED WITH INTRA-LESIONAL LIDOCAINE INJECTIONS SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract C1 [Chuang, Gary; Avram, Mathew; Tannous, Zeina] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2011 VL 43 SU 23 MA 89 BP 934 EP 935 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 735EK UT WOS:000288396000083 ER PT J AU Town, G Ash, C Dierickx, C Haedersdal, M Fritz, K AF Town, Godfrey Ash, Caerwyn Dierickx, Christine Haedersdal, Merete Fritz, Klaus TI GUIDELINES ON THE SAFETY OF LIGHT-BASED HOME-USE DEVICES FROM THE EUROPEAN SOCIETY FOR LASER DERMATOLOGY SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract C1 Swansea Metropolitan Univ, Global Acad, Univ Wales, Swansea, W Glam, Wales. Ghent Univ Hosp, B-9000 Ghent, Belgium. Massachusetts Gen Hosp, Boston, MA 02114 USA. European Soc Laser Dermatol, Landau, Germany. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2011 VL 43 SU 23 MA 113 BP 942 EP 942 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 735EK UT WOS:000288396000106 ER PT J AU Hamblin, M Xuan, WJ Wu, QH Huang, YY Sharma, SK Kharkwal, GB AF Hamblin, Michael Xuan, Weijun Wu, Qiuhe Huang, Ying-Ying Sharma, Sulbha K. Kharkwal, Gitika B. TI IN VITRO AND IN VIVO STUDIES OF LLLT FOR TRAUMATIC BRAIN INJURY SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract C1 [Hamblin, Michael; Xuan, Weijun; Wu, Qiuhe; Huang, Ying-Ying; Sharma, Sulbha K.; Kharkwal, Gitika B.] Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, Sch Med,MIT, Boston, MA USA. RI Huang, Ying-ying/G-3153-2011 OI Huang, Ying-ying/0000-0003-3066-6981 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2011 VL 43 SU 23 MA 149 BP 951 EP 951 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 735EK UT WOS:000288396000134 ER PT J AU Zhou, GY Li, PP Li, GL Pang, Y Sheb, LY Xu, Q Gu, JH Zhu, XY Hamblin, MR AF Zhou, Guoyu Li, Pingping Li, Guolin Pang, Yan Sheb, Lingyue Xu, Qing Gu, Jizhong Zhu, Xinyuan Hamblin, Michael R. TI IN VITRO STUDY OF THE PHOTODYNAMIC THERAPY OF NANO-PHOTOSENSITIZER ON HUMAN ORAL TONGUE CANCER CAL-27 CELLS SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract C1 Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Coll Stomatol, Shanghai 200030, Peoples R China. Shanghai Res Inst Stomatol, Shanghai Key Lab Stomatol, Shanghai, Peoples R China. Haerbin Med Univ, Affiliated Hosp 1, Haerbin, Peoples R China. Shanghai Jiao Tong Univ, Coll Chem & Chem Technol, Shanghai 200030, Peoples R China. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2011 VL 43 SU 23 MA 168 BP 956 EP 956 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 735EK UT WOS:000288396000149 ER PT J AU Mimiaga, MJ Reisner, SL Bland, SE Driscoll, MA Cranston, K Isenberg, D VanDerwarker, R Mayer, KH AF Mimiaga, Matthew J. Reisner, Sari L. Bland, Sean E. Driscoll, Maura A. Cranston, Kevin Isenberg, Deborah VanDerwarker, Rodney Mayer, Kenneth H. TI Sex Parties among Urban MSM: An Emerging Culture and HIV Risk Environment SO AIDS AND BEHAVIOR LA English DT Article DE MSM; HIV; Sex party; Prevention; Group sex event ID NEW-YORK-CITY; MOBILE VAN SERVICES; BISEXUAL MEN; GAY MEN; SENSATION SEEKING; MASSACHUSETTS MEN; STIMULANT USE; POSITIVE GAY; DRUG-USE; BEHAVIOR AB Private sex parties are an emerging risk environment for HIV among men who have sex with men (MSM). In 2009, 103 participants who reported attending at least one sex party in Massachusetts in the prior 12 months completed an in-depth, interviewer-administered quantitative assessment. Multivariable logistic regression analyses were conducted to examine associations with having engaged in one or more serodiscordant unprotected anal sex (SDUAS) acts at the most recent sex party attended. Nearly one-third (32%) of the sample reported engaging in SDUAS at the most recent sex party attended. Adjusting for age, race/ethnicity, and educational attainment, variables associated with an increased odds of engaging in SDUAS at the most recent sex party were: total number of unprotected anal receptive sex acts at sex parties in the past 12 months, self-perception of being at-risk for transmitting or acquiring HIV, and sexual sensation seeking. Examined in the same model, if condoms were provided/available at the most recent sex party attended, participants were at a decreased odds of engaging in SDUAS at that sex party. The majority (80%) expressed an interest in HIV prevention activities for MSM who attend sex parties. HIV prevention interventions are needed to reach MSM who attend sex parties and should take into account individual and contextual factors that may contribute to sexual risk. Environmental factors in the sex party setting, in particular the presence and availability of condoms, may potentially mitigate individual-level factors such as unprotected anal sex. C1 [Mimiaga, Matthew J.; Reisner, Sari L.; Bland, Sean E.; VanDerwarker, Rodney; Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA 02215 USA. [Mimiaga, Matthew J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Mimiaga, Matthew J.; Reisner, Sari L.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Driscoll, Maura A.; Cranston, Kevin; Isenberg, Deborah] Massachusetts Dept Publ Hlth, Boston, MA 01060 USA. [Mayer, Kenneth H.] Brown Med Sch, Providence, RI 02912 USA. [Mayer, Kenneth H.] Miriam Hosp, Providence, RI 02906 USA. RP Mimiaga, MJ (reprint author), Fenway Hlth, Fenway Inst, 1340 Boylston St, Boston, MA 02215 USA. EM mmimiaga@fenwayhealth.org NR 51 TC 18 Z9 18 U1 2 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD FEB PY 2011 VL 15 IS 2 BP 305 EP 318 DI 10.1007/s10461-010-9809-6 PG 14 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 715YX UT WOS:000286932800007 PM 20838870 ER PT J AU Simoni, JM Safren, SA Manhart, LE Lyda, K Grossman, CI Rao, D Mimiaga, MJ Wong, FY Catz, SL Blank, MB DiClemente, R Wilson, IB AF Simoni, Jane M. Safren, Steven A. Manhart, Lisa E. Lyda, Karen Grossman, Cynthia I. Rao, Deepa Mimiaga, Matthew J. Wong, Frank Y. Catz, Sheryl L. Blank, Michael B. DiClemente, Ralph Wilson, Ira B. TI Challenges in Addressing Depression in HIV Research: Assessment, Cultural Context, and Methods SO AIDS AND BEHAVIOR LA English DT Article DE HIV/AIDS; Depression; Research methods; Measurement ID HUMAN-IMMUNODEFICIENCY-VIRUS; QUALITY-OF-LIFE; SUBSTANCE USE DISORDERS; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; RANDOMIZED CONTROLLED-TRIAL; POSITIVE PREGNANT-WOMEN; MAJOR DEPRESSION; INFECTED INDIVIDUALS; PRIMARY-CARE; GAY MEN AB Depression is one of the most common co-morbidities of HIV infection. It negatively impacts self-care, quality of life, and biomedical outcomes among people living with HIV (PLWH) and may interfere with their ability to benefit from health promotion interventions. State-of-the-science research among PLWH, therefore, must address depression. To guide researchers, we describe the main diagnostic, screening, and symptom-rating measures of depression, offering suggestions for selecting the most appropriate instrument. We also address cultural considerations in the assessment of depression among PLWH, emphasizing the need to consider measurement equivalence and offering strategies for developing measures that are valid cross-culturally. Finally, acknowledging the high prevalence of depression among PLWH, we provide guidance to researchers on incorporating depression into the theoretical framework of their studies and employing procedures that account for participants with depression. C1 [Simoni, Jane M.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Safren, Steven A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Manhart, Lisa E.] UW Ctr AIDS & STD, Dept Epidemiol, Seattle, WA USA. [Lyda, Karen] Univ Colorado Denver, Univ Colorado Hosp, Sch Med, Div Infect Dis, Aurora, CO USA. [Grossman, Cynthia I.] NIMH, Ctr Mental Hlth Res AIDS, Bethesda, MD 20892 USA. [Rao, Deepa] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Mimiaga, Matthew J.] Fenway Community Hlth, Boston, MA USA. [Wong, Frank Y.; DiClemente, Ralph] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Catz, Sheryl L.] Grp Hlth Res Inst, Seattle, WA USA. [Blank, Michael B.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Wilson, Ira B.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. RP Simoni, JM (reprint author), Univ Washington, Dept Psychol, Box 351525, Seattle, WA 98195 USA. EM jsimoni@uw.edu RI Wilson, Ira/F-9190-2016; OI Wilson, Ira/0000-0002-0246-738X; Simoni, Jane/0000-0002-8711-1576 FU NIAID NIH HHS [P30 AI027757, P30 AI027757-18]; NIMH NIH HHS [K23 MH084551, K23 MH084551-05, K23 MH084551-06, K24 MH092242] NR 142 TC 31 Z9 31 U1 9 U2 15 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD FEB PY 2011 VL 15 IS 2 BP 376 EP 388 DI 10.1007/s10461-010-9836-3 PG 13 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 715YX UT WOS:000286932800014 PM 21046221 ER PT J AU Stone, RM AF Stone, R. M. TI FLT3 Inhibitors in Acute Myeloid Leukemia: An Update SO ANNALS OF HEMATOLOGY LA English DT Meeting Abstract ID ACUTE MYELOGENOUS LEUKEMIA; RISK MYELODYSPLASTIC SYNDROME; INTERNAL TANDEM DUPLICATIONS; TYROSINE KINASE INHIBITOR; MUTANT FLT3; WILD-TYPE; MUTATIONS; PKC412; AML; ANTAGONIST C1 [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 19 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0939-5555 J9 ANN HEMATOL JI Ann. Hematol. PD FEB PY 2011 VL 90 SU 1 BP S70 EP S72 PG 3 WC Hematology SC Hematology GA 727XH UT WOS:000287836000080 ER PT J AU Hur, W Gray, NS AF Hur, Wooyoung Gray, Nathanael S. TI Small molecule modulators of antioxidant response pathway SO CURRENT OPINION IN CHEMICAL BIOLOGY LA English DT Review ID ALPHA-LIPOIC ACID; DRUG-METABOLIZING-ENZYMES; NRF2 TRANSCRIPTION FACTOR; OXIDATIVE STRESS; HEME OXYGENASE-1; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CARNOSIC ACID; ADIPOCYTE DIFFERENTIATION; PHENOLIC ANTIOXIDANTS; GLUTATHIONE SYNTHESIS AB Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor that regulates Antioxidant Response Element (ARE)-mediated transcription of a plethora of antioxidant and protective genes to counteract the harmful effects of reactive oxygen species or environmental carcinogens. Studies have demonstrated that pre-emptive activation of the Nrf2-ARE pathway reinforces the cellular defense mechanism against oxidative stress and leads to protection in a variety of disease models. Non-carcinogenic ARE inducers have been identified from a variety of chemical classes that enhance the transcriptional activity of Nrf2 through S-alkylation of reactive cysteines within the cellular redox sensor protein Keap1 (Kelch-like ECH associated protein 1). Here we review the currently known small molecule ARE inducers and their reported biological activities in various models. C1 [Hur, Wooyoung; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Hur, Wooyoung; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP Gray, NS (reprint author), Dana Farber Canc Inst, Dept Canc Biol, 250 Longwood Ave, Boston, MA 02115 USA. EM Nathanael_Gray@dfci.harvard.edu NR 81 TC 86 Z9 89 U1 4 U2 25 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1367-5931 J9 CURR OPIN CHEM BIOL JI Curr. Opin. Chem. Biol. PD FEB PY 2011 VL 15 IS 1 BP 162 EP 173 DI 10.1016/j.cbpa.2010.12.009 PG 12 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 734SG UT WOS:000288357400020 PM 21195017 ER PT J AU Goy, ER Ganzini, L AF Goy, Elizabeth R. Ganzini, Linda TI Prevalence and Natural History of Neuropsychiatric Syndromes in Veteran Hospice Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Hospice; veterans; mental disorders; anxiety; depression; suicide; delirium; alcohol abuse; insomnia ID ILL CANCER-PATIENTS; TERMINALLY-ILL; DEPRESSION; DISORDERS; CARE AB Context. Prospective studies are needed to adequately describe the overall impact of neuropsychiatric syndromes on the course of hospice enrollment in outpatient settings. Objectives. To determine the prevalence and natural history of delirium, cognitive impairment, alcohol abuse, anxiety, depression, and suicidal ideation (SI) in community-dwelling veteran hospice patients. Methods. Home hospice patients were visited regularly from enrollment until their deaths, study withdrawal, or discharge from hospice. Family caregivers gave consent for those with Mini-Mental State Examination (MMSE) scores less than or equal to 23. Measures included the Structured Clinical Interview for DSM-IV for depression (past and current) and alcohol abuse; the Hospital Anxiety and Depression Scale; MMSE; and Confusion Assessment Method (CAM). A clinician-rated CAM item documented sleep disturbance, and participants were asked about SI at each visit. Results. The median length of hospice enrollment was 81 days. Of 88 participants, 77 (88%) experienced at least one neuropsychiatric syndrome. Cognitive impairment was prevalent, with 60 (68%) registering MMSE less than or equal to 23 at least once. More than half of the participants developed delirium; the proportion with delirium, any cognitive impairment, sleep disturbance, or any neuropsychiatric syndrome increased significantly from first to last study visit. Twelve (14%) participants had SI during the study, and 30 (34%) participants were affected by depression overall. Sixteen patients who were not depressed on admission subsequently developed depression. Anxiety was present in 14 (16%) on at least one study visit. Active alcohol abuse remained relatively stable (8%) across visits. Conclusions. Psychiatric syndromes are highly prevalent in hospice patients. Systematic case finding of psychiatric disorders may be necessary to improve quality of life in the last months of life. J Pain Symptom Manage 2011;41:394-401. Published by Elsevier Inc. on behalf of U.S. Cancer Pain Relief Committee. C1 [Ganzini, Linda] Portland VA Med Ctr, Div Mental Hlth, Portland, OR 97207 USA. Portland VA Med Ctr, Hlth Serv Res & Dev Program, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, Div Mental Hlth, R&D 66,POB 1034, Portland, OR 97207 USA. EM linda.ganzini@va.gov FU Department of Veterans Affairs; Veterans Health Administration Clinical Sciences Research and Development Program; Health Services Research and Development Program FX This article is based on work supported by the Department of Veterans Affairs, Veterans Health Administration Clinical Sciences Research and Development Program and Health Services Research and Development Program. NR 14 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2011 VL 41 IS 2 BP 394 EP 401 DI 10.1016/j.jpainsymman.2010.04.015 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 736ZW UT WOS:000288536300009 PM 20869843 ER PT J AU Reinke, LF Slatore, CG Udris, EM Moss, BR Johnson, EA Au, DH AF Reinke, Lynn F. Slatore, Christopher G. Udris, Edmunds M. Moss, Brianna R. Johnson, Eric A. Au, David H. TI The Association of Depression and Preferences for Life-Sustaining Treatments in Veterans with Chronic Obstructive Pulmonary Disease SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Chronic obstructive pulmonary disease; COPD; depression; life-sustaining preferences; cardiopulmonary resuscitation; CPR ID QUALITY-OF-LIFE; SERIOUSLY ILL PATIENTS; RESPIRATORY QUESTIONNAIRE; ADVANCED CANCER; SCREENING-TEST; PREVALENCE; HEALTH; END; MORTALITY; COPD AB Context. Depressive symptoms are common among patients with chronic obstructive pulmonary disease (COPD) and may modify patients' preferences for life-sustaining therapy. Examining the relationship between patient preferences for life-sustaining treatments and depressive symptoms is important for clinicians engaging in end-of-life care discussions. Objectives. To assess whether a history of depression or active depressive symptoms is associated with preferences for life-sustaining therapies among veterans with COPD. Methods. This was a cross-sectional study of 376 veterans who participated in a randomized trial to improve the occurrence and quality of end-of-life communication between providers and patients. Depressive symptoms were assessed by self-reported history and the Mental Health Index-5 survey. Preferences for mechanical ventilation (MV) and cardiopulmonary resuscitation (CPR) were assessed using standardized instruments. Multivariate logistic regression was conducted to adjust for potential confounding factors. Results. Participants were older men with severe COPD. A substantial proportion of participants noted that they would want MV (64.2%) or CPR (77.8%). Depressive history and active symptoms were not associated with preferences for MV and CPR either before or after adjusting for confounding variables. Conclusion. Depressive history and active symptoms among veterans with severe COPD were not associated with their decisions for life-sustaining treatments. Clinicians caring for patients with COPD should understand the importance of assessing and treating patients with depressive symptoms, yet recognize that depressive symptoms may not be predictive of a patient declining life-sustaining treatments. J Pain Symptom Manage 2011;41:402-411. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Reinke, Lynn F.; Udris, Edmunds M.; Moss, Brianna R.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv R&D, Seattle, WA 98101 USA. [Au, David H.] Univ Washington, Dept Med, Seattle, WA USA. [Johnson, Eric A.] Grp Hlth Res Inst, Seattle, WA USA. [Slatore, Christopher G.] Portland VA Med Ctr, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. RP Reinke, LF (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv R&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM reinkl@u.washington.edu OI Slatore, Christopher/0000-0003-0958-8122 FU Department of Veterans Affairs [IIR 02-292] FX Funding for this study was provided by the Health Services Research and Development Program, Department of Veterans Affairs (IIR 02-292). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The authors declare no conflicts of interest. NR 34 TC 8 Z9 10 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2011 VL 41 IS 2 BP 402 EP 411 DI 10.1016/j.jpainsymman.2010.05.012 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 736ZW UT WOS:000288536300010 PM 21145201 ER PT J AU O'Byrne, K Rosell, R Baas, P Kerr, K Taron, M Mok, TSK Janne, P Blackhall, F Ciardiello, F Felip, E Stahel, RA AF O'Byrne, K. Rosell, R. Baas, P. Kerr, K. Taron, M. Mok, T. S. K. Janne, P. Blackhall, F. Ciardiello, F. Felip, E. Stahel, R. A. TI The Lugano Consensus on pathology and molecular testing SO LUNG CANCER LA English DT Meeting Abstract C1 [O'Byrne, K.] St James Hosp, Dublin, Ireland. [O'Byrne, K.] Trinity Coll Dublin, Dublin, Ireland. [Rosell, R.] Inst Catala Oncol, Med Oncol Serv, Badalona, Spain. [Baas, P.] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands. [Kerr, K.] Aberdeen Royal Infirm, Aberdeen, Scotland. [Taron, M.] Inst Catala Oncol, Med Oncol Serv, Barcelona, Spain. [Mok, T. S. K.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China. [Janne, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Blackhall, F.] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England. [Ciardiello, F.] Univ Naples 2, Internist Clin, Naples, Italy. [Felip, E.] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain. [Stahel, R. A.] Univ Zurich Hosp, Div Oncol, CH-8091 Zurich, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 J9 LUNG CANCER JI Lung Cancer PD FEB PY 2011 VL 71 SU 2 BP S4 EP S4 DI 10.1016/S0169-5002(11)70142-8 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 735LV UT WOS:000288417000006 ER PT J AU Weintraub, D AF Weintraub, Daniel TI A Failure to Communicate: Preliminary Evidence for Cortico-striatal Dysconnection with Pathological Gambling in Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Editorial Material ID IMPULSE CONTROL; BEHAVIORS C1 [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu NR 14 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB 1 PY 2011 VL 26 IS 2 BP 193 EP 194 DI 10.1002/mds.23532 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 736AL UT WOS:000288461800001 PM 21412827 ER PT J AU Amstadter, AB Richardson, L Meyer, A Sawyer, G Kilpatrick, DG Trinh, LT Lam, TT Nguyen, TT Tran, T La, TB Tran, TH Tran, DT Gaboury, M Acierno, R AF Amstadter, Ananda B. Richardson, Lisa Meyer, Alicia Sawyer, Genelle Kilpatrick, Dean G. Trinh Luong Tran Lam Tu Trung Nguyen Thanh Tam Tran Tuan La Thi Buoi Tran Thu Ha Tran Duc Thach Gaboury, Mario Acierno, Ron TI Prevalence and correlates of probable adolescent mental health problems reported by parents in Vietnam SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Adolescents; Vietnam; Mental Health; Epidemiology ID DIFFICULTIES-QUESTIONNAIRE SDQ; DEVELOPING-COUNTRIES; CHILD-PSYCHIATRY; DSM-IV; STRENGTHS; DISORDERS; GENDER; PSYCHOPATHOLOGY; COMORBIDITY; VERSION AB The purpose of the present study was to estimate the prevalence of probable mental health problems in an epidemiologic study of Vietnamese adolescents. A secondary aim was to examine the correlates of probable mental health caseness. Interviewers visited 1,914 households that were randomly selected to participate in a multi-agency study of mental health in select provinces of Vietnam. Semi-structured interviews assessed adolescent mental health problems using the Strengths and Difficulties Questionnaire (SDQ) parent informant version, and additionally the interviewers collected information on demographic variables (age, gender, ethnic group, religious affiliation, social capital). The final sample included data on 1,368 adolescents (aged 11-18 years). The average score on the total problem composite of the SDQ scale was 6.66 (SD = 4.89), and 9.1% of the sample was considered a case (n = 124). Bivariate analyses were conducted to determine which demographic variables were related to the SDQ case/non-case score. All variables except gender were significant in bivariate analyses, and therefore were entered into a logistic regression. Results indicated that age, religion, and wealth remained significant predictors of probable caseness. Overall, prevalence estimates of mental health problems generated by the SDQ were consistent with those reported in the US and other Western and non-Western samples. Results of the current study suggest some concordance of risk and protective factors between Western and Vietnamese youth (i.e., age and SES). C1 [Amstadter, Ananda B.] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Acierno, Ron] Ralph H Johnson VA Med Ctr, Dept Psychiat & Behav Sci, Charleston, SC USA. [Gaboury, Mario] Oskar Schindler Humanities Fdn, New Haven, CT USA. [Tran Tuan; La Thi Buoi; Tran Thu Ha; Tran Duc Thach] Res & Training Ctr Community Dev, Vong St Hanoi, Vietnam. [Nguyen Thanh Tam] Vietnam Vet Amer Fdn, Washington, DC USA. [Lam Tu Trung] Da Nang Mental Hlth Hosp, Da Nang, Vietnam. [Trinh Luong Tran] Hlth Dept Da Nang City, Da Nang, Vietnam. RP Amstadter, AB (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Dept Psychiat & Behav Sci, 250852,67 President St, Charleston, SC 29425 USA. EM amstadt@musc.edu RI Tran, Thach/H-7734-2014 OI Tran, Thach/0000-0002-4686-8601 NR 35 TC 9 Z9 10 U1 1 U2 4 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD FEB PY 2011 VL 46 IS 2 BP 95 EP 100 DI 10.1007/s00127-009-0172-8 PG 6 WC Psychiatry SC Psychiatry GA 718DA UT WOS:000287099000002 PM 20012859 ER PT J AU Barnes, DE AF Barnes, Deborah E. TI The Mediterranean Diet: Good for the Heart = Good for the Brain? SO ANNALS OF NEUROLOGY LA English DT Editorial Material ID ALZHEIMERS-DISEASE; COGNITIVE DECLINE; RANDOMIZED-TRIAL; STYLE DIET; RISK; INTERVENTION; PREVENTION; DEMENTIA; ADHERENCE; MORTALITY C1 [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. NR 26 TC 3 Z9 4 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD FEB PY 2011 VL 69 IS 2 BP 226 EP 228 DI 10.1002/ana.22376 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 733TD UT WOS:000288284900002 PM 21387364 ER PT J AU Fogh, S Hirsch, AE Langmead, JP Goldberg, SI Rosenberg, CL Taghian, AG Powell, SN Kachnic, LA AF Fogh, Shannon Hirsch, Ariel E. Langmead, Jon P. Goldberg, Saveli I. Rosenberg, Carol L. Taghian, Alphonse G. Powell, Simon N. Kachnic, Lisa A. TI Use of Tamoxifen With Postsurgical Irradiation May Improve Survival in Estrogen and Progesterone Receptor-Positive Male Breast Cancer SO CLINICAL BREAST CANCER LA English DT Article DE Adjuvant therapy; Radiation therapy ID PROGNOSTIC-FACTORS; CARCINOMA; MEN; THERAPY; WOMEN; LUMPECTOMY; STATISTICS; EXPERIENCE; RADIATION; FEMALE AB Background: The purpose of this study is to assess the impact of adjuvant therapy on survival in males with nonmetastatic breast cancer. Materials and Methods: A retrospective analysis of male breast cancers treated between 1990 and 2003 was performed. Age, estrogen and progesterone receptor (ER/PgR) status, tumor histology and stage, and details of surgical and adjuvant therapy were recorded. Five and ten-year overall survival (OS) and disease-free survival (DFS) were calculated using the actuarial Kaplan-Meier method with comparisons made using the log-rank test. Results: Forty-two men received treatment for nonmetastatic breast cancer; median age, 62 years (range, 2490 years). All tumors were ER and PgR positive. Twenty-one received tamoxifen (50%), 18 chemotherapy (43%), and 11 radiation (26%). Median follow-up was 8 years (range, 3-18 years). Five and ten-year OS in patients who received tamoxifen and radiation was 100%, compared with 81% and 65%, respectively, with tamoxifen alone (P = .06), 92% and 83% radiation alone (P = .05), and 85% and 65% without adjuvant therapy (P = .03). Five- and 10-year DFS was 100% and 83.3% with tamoxifen and radiation, 90% and 70% with tamoxifen alone (P = .45), 50% and 50% with radiation alone (P = .05), and 80.8% and 67.9% without adjuvant therapy (P = .27). Adjuvant chemotherapy, either alone or in combination with Tamoxifen and/or radiation, did not significantly improve OS or DFS. Conclusion: This series suggests an important role for adjuvant tamoxifen and radiation in the management of ER- and PgR-positive nonmetastatic male breast cancer. Larger, multicenter datasets are warranted for this rare disease to validate these results. C1 [Fogh, Shannon; Hirsch, Ariel E.; Kachnic, Lisa A.] Boston Univ, Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. [Goldberg, Saveli I.; Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Rosenberg, Carol L.] Boston Univ, Med Ctr, Dept Med Oncol, Boston, MA 02215 USA. [Powell, Simon N.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA. RP Fogh, S (reprint author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, 111 S 11th St, Philadelphia, PA 19107 USA. EM shannonfogh@jeffersonhospital.org NR 38 TC 12 Z9 13 U1 1 U2 3 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1526-8209 J9 CLIN BREAST CANCER JI Clin. Breast Cancer PD FEB PY 2011 VL 11 IS 1 BP 39 EP 45 DI 10.3816/CBC.2011.n.007 PG 7 WC Oncology SC Oncology GA 732LV UT WOS:000288187600006 PM 21421521 ER PT J AU Girish, S Gupta, M Wang, B Lu, D Krop, I Vogel, C Burris, H Yi, J Saad, O Tong, B Klencke, B Agresta, S Chu, W Joshi, A AF Girish, S. Gupta, M. Wang, B. Lu, D. Krop, I. Vogel, C. Burris, H. Yi, J. Saad, O. Tong, B. Klencke, B. Agresta, S. Chu, W. Joshi, A. TI CLINICAL PHARMACOLOGY OF T-DM1: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) IN DEVELOPMENT FOR THE TREATMENT OF HER2-POSITIVE (HER2+) CANCER SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Meeting Abstract CT 112th Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics CY MAR 02-05, 2011 CL Dallas, TX SP Amer Soc Clin Pharmacol & Therapeut C1 [Girish, S.; Gupta, M.; Wang, B.; Lu, D.; Yi, J.; Saad, O.; Tong, B.; Klencke, B.; Agresta, S.; Chu, W.; Joshi, A.] Genentech Inc, San Francisco, CA 94080 USA. [Krop, I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Vogel, C.] Lynn Canc Inst, Boca Raton, FL USA. [Burris, H.] Sarah Cannon Canc Ctr, Nashville, TN USA. NR 0 TC 3 Z9 3 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD FEB PY 2011 VL 89 SU 1 BP S12 EP S12 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 712DE UT WOS:000286644100036 ER PT J AU Lu, D Gupta, M Wang, B Joshi, A Theil, F Krop, I Burris, H Yi, J Girish, S AF Lu, D. Gupta, M. Wang, B. Joshi, A. Theil, F. Krop, I. Burris, H. Yi, J. Girish, S. TI AN INTEGRATED POPULATION PHARMACOKINETIC MODEL FOR A FIRST-IN-CLASS HER2 TARGETED ANTIBODYDRUG CONJUGATE TRASTUZUMAB-DM1 (T-DM1): SIMULTANEOUS MODELING OF T-DM1 AND TOTAL TRASTUZUMAB PHARMACOKINETICS IN HEAVILY PRETREATED HER2+METASTATIC BREAST CANCER PATIENTS. SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Meeting Abstract CT 112th Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics CY MAR 02-05, 2011 CL Dallas, TX SP Amer Soc Clin Pharmacol & Therapeut C1 [Lu, D.; Gupta, M.; Wang, B.; Joshi, A.; Theil, F.; Yi, J.; Girish, S.] Genentech Inc, San Francisco, CA 94080 USA. [Krop, I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Burris, H.] Sarah Cannon Res Inst, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD FEB PY 2011 VL 89 SU 1 BP S54 EP S54 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 712DE UT WOS:000286644100171 ER PT J AU Iovieno, N van Nieuwenhuizen, A Clain, A Baer, L Nierenberg, AA AF Iovieno, Nadia van Nieuwenhuizen, Adrienne Clain, Alisabet Baer, Lee Nierenberg, Andrew A. TI RESIDUAL SYMPTOMS AFTER REMISSION OF MAJOR DEPRESSIVE DISORDER WITH FLUOXETINE AND RISK OF RELAPSE SO DEPRESSION AND ANXIETY LA English DT Article DE major depression; residual symptoms; remission; relapse; SSRI ID ANTIDEPRESSANT RESPONSE; SEXUAL DYSFUNCTION; SLEEP DISTURBANCE; RATING-SCALE; YOUNG-ADULTS; INSOMNIA; OUTPATIENTS; PREVALENCE; ANXIETY; MULTICENTER AB Background: Many patients with major depressive disorder (MDD) who achieve full remission after antidepressant treatment still have residual depressive symptoms. In this study, we assess the type and frequency of residual symptoms and their relationship to subsequent depressive relapses after remission of major depression with fluoxetine. Method: Five hundred seventy-six patients with MDD were openly treated with fluoxetine for 12 weeks. Those who responded underwent random assignment, under double-blind conditions, to continue taking fluoxetine or to switch to placebo for 52 weeks or until relapse. The presence of residual symptoms in patients who achieved remission at the end of the acute phase (N=203) was assessed using the 28-item Hamilton Depression Rating Scale. Survival analysis was used to examine the effect of residual symptoms on relapse in remitters. Results: More than 90% of patients who met criteria for remission had at least one residual depressive symptom (median = 4). The most common were sleep disturbances (insomnia 48.2%, hypersomnia 35.9%) and anxiety (52.7%). The most common individual symptom was middle insomnia (33.5%). No statistically or clinically significant differences in baseline variables were found between remitters- with and without residual symptoms. The presence of residual symptoms, the presence of residual insomnia and the global number of residual symptoms did not predict relapse during the continuation phase of the study. Conclusion: The great majority of patients with remission of MDD after treatment with fluoxetine continue to experience selected residual depressive symptoms. The presence of residual symptoms is not significantly associated with an increased risk of relapse. Depression and Anxiety 28:137-144, 2011. (C) 2010 Wiley-Liss, Inc. C1 [Iovieno, Nadia; van Nieuwenhuizen, Adrienne; Clain, Alisabet; Baer, Lee; Nierenberg, Andrew A.] Harvard Univ, Depress Clin & Res Program, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Iovieno, Nadia] Univ Pisa, Dept Psychiat, Pisa, Italy. RP Iovieno, N (reprint author), Harvard Univ, Depress Clin & Res Program, Sch Med, Massachusetts Gen Hosp, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM niovieno@partners.org FU NIMH; PamLabs; Pfizer Pharmaceuticals; Shire FX The authors disclose the following financial relationships within the past 3 years: Contract grant sponsors: NIMH, PamLabs, Pfizer Pharmaceuticals; Shire. NR 44 TC 30 Z9 32 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD FEB PY 2011 VL 28 IS 2 BP 137 EP 144 DI 10.1002/da.20768 PG 8 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 716WV UT WOS:000287005100005 PM 21284066 ER PT J AU Burgess, JF Maciejewski, ML Bryson, CL Chapko, M Fortney, JC Perkins, M Sharp, ND Liu, CF AF Burgess, James F., Jr. Maciejewski, Matthew L. Bryson, Chris L. Chapko, Michael Fortney, John C. Perkins, Mark Sharp, Nancy D. Liu, Chuan-Fen TI IMPORTANCE OF HEALTH SYSTEM CONTEXT FOR EVALUATING UTILIZATION PATTERNS ACROSS SYSTEMS SO HEALTH ECONOMICS LA English DT Article DE primary care; utilization; data-generating processes; public sector; private sector; veterans ID PROSPECTIVE-PAYMENT SYSTEM; ADMINISTRATIVE DATA; VETERANS-AFFAIRS; QUALITY MEASURES; MEDICARE CLAIMS; CARE; ACCURACY; CONCORDANCE; OUTCOMES; RECORD AB Measuring health services provided to patients can be difficult when patients see providers across multiple health systems and all visits are rarely captured in a single data source covering all systems where patients receive care. Studies that account for only one system will omit the out-of-system health-care use at the patient level. Combining data across systems and comparing utilization patterns across health systems creates complications for both aggregation and accuracy because data-generating processes (DGPs) tend to vary across systems. We develop a hybrid methodology for aggregation across systems, drawing on the strengths of the DGP in each system, and demonstrate its validity for answering research questions requiring cross-system assessments of health-care utilization. Positive and negative predictive probabilities can be useful to assess the impact of the hybrid methodology. We illustrate these issues comparing public sector (administrative records from the US Department of Veterans Affairs system) and private sector (billing records from the US Medicare system) patient level data to identify primary-care utilization. Understanding the context of a particular health system and its effect on the DGP is important in conducting effective valid evaluations. Published in 2010 by John Wiley & Sons, Ltd. C1 [Burgess, James F., Jr.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Dept Vet Affairs, Boston, MA USA. [Burgess, James F., Jr.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Maciejewski, Matthew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA. [Bryson, Chris L.; Chapko, Michael; Perkins, Mark; Sharp, Nancy D.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA. [Bryson, Chris L.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. [Chapko, Michael; Sharp, Nancy D.; Liu, Chuan-Fen] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. [Fortney, John C.] VA Cent Arkansas Vet Healthcare Syst, S Cent Mental Illness Res Educ & Clin Ctr, Little Rock, AR USA. [Fortney, John C.] VA Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, Little Rock, AR USA. [Fortney, John C.] Univ Arkansas Med Sci, Dept Psychiat & Behav Sci, Div Hlth Serv Res, Little Rock, AR 72205 USA. RP Burgess, JF (reprint author), VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Dept Vet Affairs, Boston, MA USA. EM burgess@world.std.com OI Burgess, James/0000-0002-6646-7071 FU Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs [IIR 04-292] FX This work was supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs, project number IIR 04-292. The views expressed are those of the authors and do not reflect the views of the Department of Veterans Affairs, Boston University, Duke University, the University of Arkansas for Medical Sciences, or the University of Washington. Institutional ethical approval for the study was obtained separately at each VA research site and no conflicts of interest exist for any author regarding this study. NR 39 TC 10 Z9 10 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1057-9230 J9 HEALTH ECON JI Health Econ. PD FEB PY 2011 VL 20 IS 2 BP 239 EP 251 DI 10.1002/hec.1588 PG 13 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 714XN UT WOS:000286845100008 PM 20169587 ER PT J AU Narla, A Hurst, SN Ebert, BL AF Narla, Anupama Hurst, Slater N. Ebert, Benjamin L. TI Ribosome defects in disorders of erythropoiesis SO INTERNATIONAL JOURNAL OF HEMATOLOGY LA English DT Article DE Myelodysplastic syndrome; Diamond-Blackfan anemia; p53 ID DIAMOND-BLACKFAN ANEMIA; PROTEIN S19; EXTRARIBOSOMAL FUNCTIONS; MYELODYSPLASTIC SYNDROME; ERYTHROID DEVELOPMENT; P53 FUNCTION; MOUSE MODEL; GENE; MDM2; RNA AB Over the past decade, genetic lesions that cause ribosome dysfunction have been identified in both congenital and acquired human disorders. These discoveries have established a new category of disorders, known as ribosomopathies, in which the primary pathophysiology is related to impaired ribosome function. The protoptypical disorders are Diamond-Blackfan anemia, a congenital bone marrow failure syndrome, and the 5q- syndrome, a subtype of myelodysplastic syndrome. In both of these disorders, impaired ribosome function causes a severe macrocytic anemia. In this review, we will discuss the evidence that defects in ribosomal biogenesis cause the hematologic phenotype of Diamond-Blackfan anemia and the 5q- syndrome. We will also explore the potential mechanisms by which a ribosomal defect, which would be expected to have widespread consequences, may lead to specific defects in erythropoiesis. C1 [Narla, Anupama; Hurst, Slater N.; Ebert, Benjamin L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Narla, Anupama; Ebert, Benjamin L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Narla, Anupama] Childrens Hosp, Dept Med, Boston, MA 02115 USA. [Ebert, Benjamin L.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Ebert, BL (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Karp Res Bldg,CHRB 05-211,1 Blackfan Circle, Boston, MA 02115 USA. EM bebert@partners.org FU NHLBI NIH HHS [R01 HL082945] NR 55 TC 18 Z9 18 U1 0 U2 4 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 0925-5710 J9 INT J HEMATOL JI Int. J. Hematol. PD FEB PY 2011 VL 93 IS 2 BP 144 EP 149 DI 10.1007/s12185-011-0776-0 PG 6 WC Hematology SC Hematology GA 730IT UT WOS:000288027700002 PM 21279816 ER PT J AU Japuntich, SJ Piper, ME Leventhal, AM Bolt, DM Baker, TB AF Japuntich, Sandra J. Piper, Megan E. Leventhal, Adam M. Bolt, Daniel M. Baker, Timothy B. TI The Effect of Five Smoking Cessation Pharmacotherapies on Smoking Cessation Milestones SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE smoking cessation; pharmacotherapy; medication; relapse; milestones ID NICOTINE GUM; FOLLOW-BACK; RELAPSE; BUPROPION; SMOKERS; PLACEBO; TRIAL; ENVIRONMENTS; RELIABILITY; ABSTINENCE AB Objective: Most smoking cessation studies have used long-term abstinence as their primary outcome measure. Recent research has suggested that long-term abstinence may be an insensitive index of important smoking cessation mechanisms. The goal of the current study was to examine the effects of 5 smoking cessation pharmacotherapies using Shiffman et al.'s (2006) approach of examining the effect of smoking cessation medications on 3 process markers of cessation or smoking cessation milestones: initial abstinence, lapse, and the lapse relapse transition. Method: The current study (N = 1,504: 58.2% female and 41.8% male; 83.9% Caucasian, 13.6% African American, 2.5% other races) examined the effect of 5 smoking cessation pharmacotherapy treatments versus placebo (bupropion, nicotine lozenge, nicotine patch, bupropion + lozenge, patch + lozenge) on Shiffman et al.'s smoking cessation milestones over 8 weeks following a quit attempt. Results: Results show that all 5 medication conditions decreased rates of failure to achieve initial abstinence and most (with the exception of the nicotine lozenge) decreased lapse risk; however, only the nicotine patch and bupropion + lozenge conditions affected the lapse relapse transition. Conclusions: These findings demonstrate that medications are effective at aiding initial abstinence and decreasing lapse risk but that they generally do not decrease relapse risk following a lapse. The analysis of cessation milestones sheds light on important impediments to long-term smoking abstinence, suggests potential mechanisms of action of smoking cessation pharmacotherapies, and identifies targets for future treatment development. C1 [Japuntich, Sandra J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Japuntich, Sandra J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. [Japuntich, Sandra J.; Piper, Megan E.; Baker, Timothy B.] Univ Wisconsin, Dept Med, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Bolt, Daniel M.] Univ Wisconsin Madison, Dept Educ Psychol, Madison, WI USA. RP Japuntich, SJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM sjapuntich@partners.org FU NCI NIH HHS [K05 CA139871-01, 1K05CA139871, K05 CA139871-03, K05 CA139871]; NCRR NIH HHS [M01 RR003186-215535, UL1 RR025011, M01 RR03186, M01 RR003186, KL2 RR025012-04, KL2 RR025012-01, 1KL2RR025012-01, KL2 RR025012]; NIDA NIH HHS [P50 DA019706-08, K08 DA025041-01A1, K08 DA025041-03, K08DA025041, P50 DA019706-06, R01 DA026831, P50 DA019706, K08 DA025041] NR 28 TC 26 Z9 26 U1 2 U2 6 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD FEB PY 2011 VL 79 IS 1 BP 34 EP 42 DI 10.1037/a0022154 PG 9 WC Psychology, Clinical SC Psychology GA 714ZD UT WOS:000286849300004 PM 21261432 ER PT J AU Goodman, M Patil, U Triebwasser, J Hoffman, P Weinstein, ZA New, A AF Goodman, Marianne Patil, Uday Triebwasser, Joseph Hoffman, Perry Weinstein, Zachary A. New, Antonia TI PARENTAL BURDEN ASSOCIATED WITH BORDERLINE PERSONALITY DISORDER IN FEMALE OFFSPRING SO JOURNAL OF PERSONALITY DISORDERS LA English DT Article ID MENTAL-ILLNESS; PSYCHOLOGICAL DISTRESS; FAMILY-MEMBERS; RELATIVES; DEPRESSION; EXPERIENCE; INVENTORY; APPRAISAL; COMMUNITY; SYMPTOMS AB To identify aspects of parental burden associated with borderline personality disorder (BPD), an anonymous internet survey linked to BPD support websites was developed for parents to complete on their BPD offspring and unaffected siblings. The questions cover aspects of the child's life from pregnancy through young adulthood, and query about the impact of the child's BPD on six domains of the parent's life, including physical and emotional health, marriage, job, standard of living, social life, and career trajectory. Additionally, financial burden was assessed with questions pertaining to insurance and out-of pocket costs associated with the BPD disorder. BPD offspring were identified by meeting diagnostic criteria embedded within the survey and having been given a diagnosis of BPD by a professional at some point in their life. We report on 233 female offspring meeting strict criteria for BPD. Parents of daughters with BPD endorsed varying levels of impact on the six domains comprising burden with the largest impact on emotional health which was impacted in over 88% of the respondents. Over 50% of parents endorsed four or greater of the six burden items. Particular aspects of the offspring's BPD symptom profile correlated with intensity of parental burden included including problems in adolescence with acting out behavior (p < .000), property destruction (.003), delusional symptoms (.007), and hallucinatory symptoms (.008). A subgroup of respondents provided data on specific financial expenses. The average and median out-of-pocket expense was $60,087, and $10,000. Insurance costs totaled an average of $108,251 with a mean of $20,000. The average cost per year after diagnosis was $14,606 out-of-pocket and $45,573 billed to insurance. The median cost per year after diagnosis was $3,667 out-of-pocket, and $12,500 billed to insurance. After adjusting for household income, a female proband who had been raped incurred roughly $40,000 more in BPD-related costs, while a diagnosis of conduct disorder led to about $50,000 in additional costs. Parents of female offspring with BPD experience burden in multiple domains of their life and many have incurred substantial financial expense. Increasing awareness of co-morbid conditions in the BPD proband that significantly increase parental burden may be indicators for the provision of increased family support. C1 [Goodman, Marianne; Patil, Uday; Triebwasser, Joseph; Hoffman, Perry; Weinstein, Zachary A.; New, Antonia] Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Goodman, M (reprint author), Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Marianne.Goodman@va.gov NR 34 TC 10 Z9 11 U1 2 U2 12 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0885-579X J9 J PERS DISORD JI J. Pers. Disord. PD FEB PY 2011 VL 25 IS 1 BP 59 EP 74 PG 16 WC Psychiatry SC Psychiatry GA 717RB UT WOS:000287064000005 PM 21309623 ER PT J AU Ibrahimi, OA Sakamoto, FH Tannous, Z Anderson, RR AF Ibrahimi, Omar A. Sakamoto, Fernanda H. Tannous, Zeina Anderson, R. Rox TI 755 nm Alexandrite Laser for the Reduction of Tumor Burden in Basal Cell Nevus Syndrome SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE non-melanoma skin cancer; basal cell carcinoma; angiogenesis ID PULSED DYE-LASER; PHOTODYNAMIC THERAPY; CARCINOMA SYNDROME; ANGIOGENESIS; MICROSCOPY; ACID AB Background and Objective: Basal Cell Nevus syndrome (BCNS) is characterized by numerous basal cell carcinomas (BCCs). Multiple treatments with the pulsed dye laser (PDL) have been shown, in small studies, to be effective for the treatment of superficial and nodular BCCs. Like PDL, the alexandrite laser can be vessel-selective, but has the added advantage of deeper tissue penetration. We evaluated the utility of the alexandrite laser in reducing the tumor burden in BCNS with a single treatment. Study Design/Materials and Methods: A case report and review of the literature are presented. A 45-year-old man with BCNS and a history of radiation therapy presented with an extraordinarily high tumor burden (> 250 BCCs). As a compassionate measure to reduce the tumor burden, we investigated the utility of a single treatment of the long-pulsed 755 nm alexandrite laser to several BCC lesions. The treated lesions were evaluated at 2-month and 7-month clinical follow-up. Histopathologic analysis of a treated lesion was performed at 7-month clinical follow-up. Results: At 2-month, and 7-month clinical follow-up, 15 of 18 treated lesions or about 83% of the alexandrite laser treated lesions showed a complete clinical response and appeared as hypopigmented areas with scarring. Histopathologic analysis of a treated lesion at 7-month clinical follow-up showed no evidence of residual tumor. Conclusions: The long-pulsed alexandrite laser may be helpful in significantly reducing tumor burden in difficult to manage BCNS patients with a single treatment. This provides a facile and practical treatment alternative for the management of challenging cases of BCNS. The limitation of this study is that it is a single case observation. Larger, prospective studies are needed to confirm these observations. Lasers Surg. Med. 43:68-71, 2011. (C) 2011 Wiley-Liss, Inc. C1 Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Ibrahimi, OA (reprint author), 55 Fruit St,BH 616, Boston, MA 02114 USA. EM omar.ibrahimi@gmail.com FU USAF FX This article was presented at the 2010 ASLMS annual meeting in Phoenix, AZ under the support of a USAF travel grant. NR 16 TC 9 Z9 10 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2011 VL 43 IS 2 BP 68 EP 71 DI 10.1002/lsm.20953 PG 4 WC Dermatology; Surgery SC Dermatology; Surgery GA 732II UT WOS:000288177800003 PM 21384386 ER PT J AU Konnikov, N Avram, M Jarell, A Tannous, Z AF Konnikov, Nellie Avram, Mathew Jarell, Abel Tannous, Zeina TI Pulsed Dye Laser as a Novel Non-Surgical Treatment for Basal Cell Carcinomas: Response and Follow Up 12-21 Months After Treatment SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE pulsed dye laser; basal cell carcinoma; follow up; non-invasive ID NONMELANOMA SKIN-CANCER; THERAPY; MOHS AB Background and Objective: We showed previously that pulsed dye laser (PDL) is a potentially effective therapy for BCCs < 15 mm on trunk and extremities. To follow-up, we conducted a study based on optimized parameters and expanded the duration of the study to at least 1 year after treatment. Materials and Methods: Fourteen patients with 20 biopsy-proven BCCs on trunk and extremities, 8-35 mm in diameter, were treated. Each BCC received four consecutive PDL treatments at 3-4 week intervals. A 4 mm margin of clinically normal skin was also treated. Standardized photography was performed prior to each treatment and follow up visit. Patients were asked to consent for standard excision or at least scouting biopsies after treatment completion. Results: Complete clinical response was seen with 19 of 20 treated BCCs, regardless of size and histologic subtype. One did not respond completely to therapy. All remaining 19 BCCs were followed between 12 and 21 months (median = 18 months) after the last PDL treatment. Of these 19 BCCs, only one recurred at 17 months follow up. The remaining 18 BCCs did not show any clinical signs of residual or recurrent tumor at 12-21 months follow-up. Overall, 90% (18/20 tumors) of treated BCCs in this study showed no clinical or histologic evidence of BCC more than 12 months after PDL treatment. Additionally, 18/19 (95%) BCCs less than or equal to 17 mm showed no evidence of residual or recurrent tumor clinically or on histology 12-21 months post-laser treatment. Conclusions: PDL treatment of BCC represents a novel, quick, and relatively non-painful treatment that does not usually produce scar and may represent an alternative treatment for certain types of BCC in the appropriate clinical setting. This study confirms prior findings regarding the efficacy of PDL in the treatment of BCC, with longer follow-up period. Lasers Surg. Med. 43:72-78, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Konnikov, Nellie; Tannous, Zeina] Boston Vet Affairs Hlth Care Syst, Dept Dermatol, Boston, MA 02130 USA. [Avram, Mathew; Tannous, Zeina] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA. [Jarell, Abel] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94115 USA. [Jarell, Abel] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA. RP Tannous, Z (reprint author), Boston Vet Affairs Hlth Care Syst, Dept Dermatol, Jamaica Plains Campus, Boston, MA 02130 USA. EM ztannous1@hotmail.com NR 15 TC 13 Z9 13 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2011 VL 43 IS 2 BP 72 EP 78 DI 10.1002/lsm.21035 PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA 732II UT WOS:000288177800004 PM 21384387 ER PT J AU Samson, F Hyde, KL Bertone, A Soulieres, I Mendrek, A Ahad, P Mottron, L Zeffiro, TA AF Samson, Fabienne Hyde, Krista L. Bertone, Armando Soulieres, Isabelle Mendrek, Adrianna Ahad, Pierre Mottron, Laurent Zeffiro, Thomas A. TI Atypical processing of auditory temporal complexity in autistics SO NEUROPSYCHOLOGIA LA English DT Article DE Auditory cortex; Enhanced perceptual functioning model; Functional magnetic resonance imaging ID EVENT-RELATED POTENTIALS; ASPERGER-SYNDROME; MACAQUE MONKEYS; DIAGNOSTIC INTERVIEW; ABSOLUTE PITCH; SPEECH SOUNDS; CORTEX; CHILDREN; PERCEPTION; FMRI AB Autistics exhibit a contrasting combination of auditory behavior, with enhanced pitch processing abilities often coexisting with reduced orienting towards complex speech sounds. Based on an analogous dissociation observed in vision, we expected that autistics' auditory behavior with respect to complex sound processing may result from atypical activity in non-primary auditory cortex. We employed fMRI to explore the neural basis of complex non-social sound processing in 15 autistic and 13 non-autistics, using a factorial design in which auditory stimuli varied in spectral and temporal complexity. Spectral complexity was modulated by varying the harmonic content, whereas temporal complexity was modulated by varying frequency modulation depth. The detection task was performed similarly by autistics and non-autistics. In both groups, increasing spectral or temporal complexity was associated with activity increases in primary (Heschl's gyrus) and non-primary (anterolateral and posterior superior temporal gyrus) auditory cortex Activity was right-lateralized for spectral and left-lateralized for temporal complexity. Increasing temporal complexity was associated with greater activity in anterolateral superior temporal gyrus in non-autistics and greater effects in Heschl's gyrus in autistics. While we observed similar hierarchical functional organization for auditory processing in both groups, autistics exhibited diminished activity in non-primary auditory cortex and increased activity in primary auditory cortex in response to the presentation of temporally, but not of spectrally complex sounds. Greater temporal complexity effects in regions sensitive to acoustic features and reduced temporal complexity effects in regions sensitive to more abstract sound features could represent a greater focus towards perceptual aspects of speech sounds in autism. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Samson, Fabienne; Bertone, Armando; Soulieres, Isabelle; Mottron, Laurent] CETEDUM, Montreal, PQ, Canada. [Samson, Fabienne; Bertone, Armando; Mendrek, Adrianna; Mottron, Laurent] Univ Montreal, Dept Psychiat, Ctr Rech Fernand Seguin, Montreal, PQ H3C 3J7, Canada. [Hyde, Krista L.; Ahad, Pierre] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada. [Soulieres, Isabelle; Zeffiro, Thomas A.] Massachusetts Gen Hosp, Dept Psychiat, Neural Syst Grp, Boston, MA 02114 USA. [Soulieres, Isabelle] Massachusetts Gen Hosp, Athinoula A Martin Ctr Biomed Imaging, Boston, MA 02114 USA. RP Mottron, L (reprint author), Hop Riviere des Prairies, 7070 Blvd Perras, Montreal, PQ H1E 1A4, Canada. EM mottronl@istar.ca FU Canadian Institutes for Health Research [MOP-84243]; Natural Sciences and Engineering Research Council of Canada; Autism Research Training fellowship FX This work was supported by Canadian Institutes for Health Research [Grant MOP-84243] to L.M., as well as a doctoral award from Natural Sciences and Engineering Research Council of Canada and an Autism Research Training fellowship to F.S. The authors report no biomedical financial interests or potential conflicts of interest. NR 102 TC 26 Z9 26 U1 2 U2 20 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 EI 1873-3514 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD FEB PY 2011 VL 49 IS 3 BP 546 EP 555 DI 10.1016/j.neuropsychologia.2010.12.033 PG 10 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 728YH UT WOS:000287909900027 PM 21192958 ER PT J AU Muir, ER Duong, TQ AF Muir, Eric R. Duong, Timothy Q. TI MRI of retinal and choroidal blood flow with laminar resolution SO NMR IN BIOMEDICINE LA English DT Article DE perfusion; arterial spin labeling (ASL); high-resolution MRI; isoflurane; ketamine; xylazine; retinal diseases; ophthalmology ID OPTICAL COHERENCE TOMOGRAPHY; HYDROGEN CLEARANCE; AUTONOMIC INNERVATION; FUNCTIONAL MRI; RATS; EYE; DEGENERATION; CAT; MICROSPHERES; COEFFICIENT AB The retina is nourished by two distinct circulations: the retinal vessels within the inner retina and the choroidal vessels behind the neural retina. The outer nuclear layer and the inner and outer segments of the photoreceptors in between are avascular. The aim of this study was to determine whether arterial spin labeling MRI could provide sufficient resolution to differentiate between quantitative retinal blood flow (rBF) and choroidal blood flow (chBF), and whether this technique is sufficiently sensitive to detect vascular-specific blood flow (BF) changes modulated by anesthetics. Arterial spin labeling MRI was performed at 42 x 42 x 400 mu m(3) in the mouse retina at 7 T, and was used to investigate the effects of isoflurane and ketamine/xylazine anesthesia on rBF and chBF. MRI yielded unambiguous differentiation of rBF, chBF and the avascular layer in between. Under isoflurane, chBF was 7.7 +/- 2.1 mL/g/min and rBF was 1.3 +/- 0.44 mL/g/min (mean +/- SD, n = 7, p < 0.01). Under ketamine/xylazine anesthesia in the same animals, chBF was 4.3 +/- 1.9 mL/g/min and rBF was 0.88 +/- 0.22 mL/g/min (p < 0.01). Under ketamine/xylazine anesthesia, rBF was lower by 29% (P < 0.01) and chBF by 42% (P < 0.01) relative to isoflurane. This study demonstrates, for the first time, the quantitative imaging of rBF and chBF in vivo, providing a new method to study basal values and alterations of rBF and chBF. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Ophthalmol, San Antonio, TX 78229 USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Radiol, San Antonio, TX 78229 USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Physiol, San Antonio, TX 78229 USA. [Muir, Eric R.] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA. [Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008; Muir, Eric/H-8830-2013 FU National Eye Institute/National Institutes of Health [R01 EY018855, R01 EY014211]; Department of Veterans Affairs; National Institutes of Health [T32EB005969] FX This work was supported in part by the National Eye Institute/National Institutes of Health (R01 EY018855 and R01 EY014211) and the Department of Veterans Affairs (VA MERIT Award). ERM was supported in part by National Institutes of Health T32EB005969. NR 47 TC 30 Z9 32 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0952-3480 EI 1099-1492 J9 NMR BIOMED JI NMR Biomed. PD FEB PY 2011 VL 24 IS 2 BP 216 EP 223 DI 10.1002/nbm.1576 PG 8 WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy GA 732SG UT WOS:000288209300013 PM 20821409 ER PT J AU Vogt, D AF Vogt, Dawne TI Mental Health-Related Beliefs as a Barrier to Service Use for Military Personnel and Veterans: A Review SO PSYCHIATRIC SERVICES LA English DT Article ID PERCEIVED STIGMA; WOMEN VETERANS; ILLNESS STIGMA; PSYCHIATRIC STIGMA; CARE UTILIZATION; FEMALE VETERANS; HELP-SEEKING; SELF-ESTEEM; UNMET NEED; ATTITUDES AB Objective: Although military personnel are at high risk of mental health problems, research findings indicate that many military personnel and veterans do not seek needed mental health care. Thus it is critical to identify factors that interfere with the use of mental health services for this population, and where possible, intervene to reduce barriers to care. The overarching goal of this review was to examine what is known with regard to concerns about public stigma and personal beliefs about mental illness and mental health treatment as potential barriers to service use in military and veteran populations and to provide recommendations for future research on this topic. Methods: Fifteen empirical articles on mental health beliefs and service use were identified via a review of the military and veteran literature included in PsycINFO and PubMed databases. Results: Although results suggest that mental health beliefs may be an important predictor of service use for this population, several gaps were identified in the current literature. Limitations include a lack of attention to the association between mental health beliefs and service use, a limited focus on personal beliefs about mental illness and mental health treatment, and the application of measures of mental health beliefs with questionable or undocumented psychometric properties. Conclusions: Studies that attend to these important issues and that examine mental health beliefs in the broader context within which decisions about seeking health care are made can be used to best target resources to engage military personnel and veterans in health care. (Psychiatric Services 62:135-142, 2011) C1 [Vogt, Dawne] Boston Univ, Sch Med, Div Psychiat, Boston, MA 02215 USA. RP Vogt, D (reprint author), US Dept Vet Affairs Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave 116B-5, Boston, MA 02116 USA. EM dawne.vogt@va.gov FU VA Health Sciences Research and Development Service [DHI 06-225-2]; National Center for Posttraumatic Stress Disorder; Massachusetts Veterans Epidemiological Research and Information Center (MAVERIC) FX This research was supported in part by grant DHI 06-225-2 from the VA Health Sciences Research and Development Service ("Stigma, Gender, and Other Barriers to VHA Use for OEF/OIF Veterans"). Additional support was provided by the National Center for Posttraumatic Stress Disorder and the Massachusetts Veterans Epidemiological Research and Information Center (MAVERIC). NR 68 TC 103 Z9 103 U1 2 U2 19 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD FEB PY 2011 VL 62 IS 2 BP 135 EP 142 DI 10.1176/appi.ps.62.2.135 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 714KW UT WOS:000286809500006 PM 21285091 ER PT J AU Lee, JA Zierler, BK Liu, CF Chapko, MK AF Lee, Jung-Ah Zierler, Brenda K. Liu, Chuan-Fen Chapko, Michael K. TI Cost-Effective Diagnostic Strategies in Patients With a High, Intermediate, or Low Clinical Probability of Pulmonary Embolism SO VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE cost-effectiveness analysis; pulmonary embolism; diagnosis; clinical probability; D-dimer; multislice computer tomographic angiography; venous duplex ultrasonography ID HELICAL COMPUTED-TOMOGRAPHY; DEEP VENOUS THROMBOSIS; D-DIMER; SPIRAL CT; MANAGEMENT; THROMBOEMBOLISM; MODEL; ULTRASONOGRAPHY; ANGIOGRAPHY; OUTPATIENTS AB Rapid quantitative D-dimer assays (DD), lower extremity venous duplex ultrasonography (US), and multislice computed tomographic (CT) angiography have been shown to have adequate sensitivities and specificities for diagnostic purpose. The purpose of this study was to evaluate cost-effectiveness of diagnostic strategies for pulmonary embolism (PE) in patients with a high, intermediate, or low clinical probability of PE. A formal cost-effectiveness analysis for the diagnosis of PE was performed. The main outcome measure for effectiveness was 3-month expected survival. The strategy of DD followed by CT was cost-effective and had the lowest cost per life saved for all patients suspected with PE. The conventional strategy including ventilation and perfusion lung scanning followed by pulmonary angiography (PA) or CT was not cost-effective. The leg US after CT was not also cost-effective. In clinical practice, the individual patient's condition should be considered when choosing appropriate diagnostic tests. C1 [Lee, Jung-Ah] Univ Calif Irvine, Coll Hlth Sci, Program Nursing Sci, Irvine, CA 92697 USA. [Zierler, Brenda K.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Zierler, Brenda K.; Liu, Chuan-Fen; Chapko, Michael K.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Liu, Chuan-Fen; Chapko, Michael K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. RP Lee, JA (reprint author), Univ Calif Irvine, Coll Hlth Sci, Program Nursing Sci, 205B Irvine Hall, Irvine, CA 92697 USA. EM jungahl@uci.edu FU Agency for Healthcare Research and Quality [1 U18 HS015898] FX The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This project was partially supported by the Agency for Healthcare Research and Quality: The Partnerships in Patient Safety grant number 1 U18 HS015898. (Principal Investigator: Brenda K. Zierler, PhD). NR 52 TC 3 Z9 3 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1538-5744 J9 VASC ENDOVASC SURG JI Vasc. Endovasc. Surg. PD FEB PY 2011 VL 45 IS 2 BP 113 EP 121 DI 10.1177/1538574410380472 PG 9 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 733TJ UT WOS:000288285600001 PM 20810405 ER PT J AU Javed, U Deedwania, PC Bhatt, DL Cannon, CP Dai, D Hernandez, AF Peterson, ED Fonarow, GC AF Javed, Usman Deedwania, Prakash C. Bhatt, Deepak L. Cannon, Christopher P. Dai, David Hernandez, Adrian F. Peterson, Eric D. Fonarow, Gregg C. TI Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG) (vol 160, pg 1130, 2010) SO AMERICAN HEART JOURNAL LA English DT Correction ID ELEVATION MYOCARDIAL-INFARCTION; TO-Z TRIAL; UNSTABLE ANGINA; ARTERY-DISEASE; RAT HEARTS; ASSOCIATION; MORTALITY; EFFICACY; CRUSADE; STATINS AB Objectives The study aimed to analyze the use of intensive lipid-lowering therapy (I-LLT) at discharge in a broad population of patients hospitalized with acute coronary syndrome (ACS). Background Early and intensive statin therapy in ACS has been shown to reduce cardiovascular morbidity and mortality. Utilization and predictors of I-LLT among hospitalized ACS patients are not known. Methods The GWTG database was analyzed for ACS-related hospitalizations from 2005 to 2009. The use of I-LLT (defined as dose of statin or combination therapy likely to produce >50% reductions in low-density lipoprotein [LDL]) and less intensive lipid-lowering therapy (LI-LLT) at discharge was assessed. Baseline characteristics and temporal trends in LLT were compared in these 2 treatment groups. Results Of 65,396 patients receiving LLT, only 25,036 (38.3%) were treated with an I-LLT regimen. Mean total cholesterol, LDL, and triglycerides were significantly higher in the I-LLT group. Even among those with LDL>130 mg/dL, 50% or less received I-LLT. Predictors of I-LLT at discharge included LLT before admission, hyperlipidemia, prior coronary artery disease, increasing body mass index, and in-hospital percutaneous coronary intervention. Although there was some temporal improvement in the rate of I-LLT from 2005 to 2007, a decline in use of I-LLT was noted in 2008 and 2009. This was attributed to a sharp reduction in use of ezetimibe in combination with statin, without corresponding increases in intensive statin monotherapy. Conclusions In a large cohort of patients admitted with ACS, most of the eligible patients were not discharged on I-LLT. These data suggest the need for better implementation of guideline-recommended intensive statin therapy in patients with ACS. (Am Heart J 2011;161:418-424.e3.) C1 [Javed, Usman; Deedwania, Prakash C.] Univ Calif, San Francisco Fresno Med Educ Program, Fresno, CA USA. [Bhatt, Deepak L.; Cannon, Christopher P.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA. [Bhatt, Deepak L.; Cannon, Christopher P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Dai, David; Hernandez, Adrian F.; Peterson, Eric D.] Duke Univ, Med Ctr, Durham, NC USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles Sch Med, Los Angeles, CA USA. RP Deedwania, PC (reprint author), UCSF Program Fresno, Cardiol Sect, 2615 E Clinton Ave 111, Fresno, CA 93703 USA. EM deed1@sbcglobal.net NR 28 TC 10 Z9 12 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD FEB PY 2011 VL 161 IS 2 BP 418 EP U580 DI 10.1016/j.ahj.2010.12.014 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 719FX UT WOS:000287188000030 PM 21404720 ER PT J AU Kudel, I Cotton, S Szaflarski, M Holmes, WC Tsevat, J AF Kudel, Ian Cotton, Sian Szaflarski, Magda Holmes, William C. Tsevat, Joel TI Spirituality and Religiosity in Patients with HIV: A Test and Expansion of a Model SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE Religious beliefs; Spirituality; Utilities; Quality of life; Coping ID QUALITY-OF-LIFE; DEPRESSIVE SYMPTOMS; IMMUNE STATUS; OLDER ADULTS; HIV/AIDS; HEALTH; DISTRESS; PEOPLE; WOMEN; VALIDATION AB A causal model developed by Koenig suggests that higher levels of spirituality and religiosity effect intermediary variables and eventually result in better mental health, which then positively affects physical function. Using structural equation modeling, we tested the model and expanded versions that use self-report data of patients with HIV (n = 345). All models demonstrated good overall fit with significant parameters. The final model found that increased spirituality/religiosity predicted increased religious coping, which influenced social support. Social support, in turn, positively influenced depressed mood (as a measure of mental health); depressed mood affected fatigue; and both variables predicted self-reported physical function. These three variables predicted health rating/utility for one's health state. Additional analyses found that two covariates, religiosity and race, differentially predicted spirituality/religiosity and religious coping. In patients with HIV, an expanded version of Koenig's model found that increased spirituality/religiosity is positively associated with self-reported outcomes. C1 [Kudel, Ian; Tsevat, Joel] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA. [Kudel, Ian; Cotton, Sian; Szaflarski, Magda; Tsevat, Joel] Univ Cincinnati, Cincinnati, OH USA. [Holmes, William C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Holmes, William C.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Tsevat, Joel] Univ Cincinnati, Coll Med, Dept Publ Hlth Sci, Cincinnati, OH USA. RP Kudel, I (reprint author), Cincinnati Vet Affairs Med Ctr, 3200 Vine St, Cincinnati, OH USA. EM ian.kudel2@va.gov OI Szaflarski, Magdalena/0000-0002-6228-1405 FU NCCIH NIH HHS [K24AT001676, R01 AT01147]; NICHD NIH HHS [K23HD052639] NR 54 TC 15 Z9 16 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD FEB PY 2011 VL 41 IS 1 BP 92 EP 103 DI 10.1007/s12160-010-9229-x PG 12 WC Psychology, Multidisciplinary SC Psychology GA 717KB UT WOS:000287041400009 PM 21103963 ER PT J AU Kim, JY Rosenberg, ES AF Kim, Ji Yeon Rosenberg, Eric S. TI The Sum of the Parts Is Greater Than the Whole: Reducing Blood Culture Contamination SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID RANDOMIZED-TRIAL; VENIPUNCTURE; RATES C1 [Rosenberg, Eric S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Rosenberg, ES (reprint author), Massachusetts Gen Hosp, Gray J-504,55 Fruit St, Boston, MA 02114 USA. EM erosenberg1@partners.org NR 15 TC 2 Z9 2 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 1 PY 2011 VL 154 IS 3 BP 202 EP + DI 10.7326/0003-4819-154-3-201102010-00010 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 713HY UT WOS:000286729200008 PM 21282700 ER PT J AU Yoon, SS AF Yoon, Sam S. TI How Closely Should We Follow Gastric Cancer Patients Following Surgical Resection? SO ANNALS OF SURGICAL ONCOLOGY LA English DT Editorial Material ID CURATIVE RESECTION; CHEMOTHERAPY; METAANALYSIS C1 [Yoon, Sam S.] Harvard Univ, Sch Med, Dept Surg, Div Surg Oncol,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Yoon, Sam S.] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA. RP Yoon, SS (reprint author), Harvard Univ, Sch Med, Dept Surg, Div Surg Oncol,Massachusetts Gen Hosp, Boston, MA 02115 USA. EM syoon@partners.org NR 16 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2011 VL 18 IS 2 BP 311 EP 313 DI 10.1245/s10434-010-1416-2 PG 3 WC Oncology; Surgery SC Oncology; Surgery GA 716AZ UT WOS:000286938600004 PM 21125338 ER PT J AU Pandalai, PK Dominguez, FJ Michaelson, J Tanabe, KK AF Pandalai, Prakash K. Dominguez, Francisco J. Michaelson, James Tanabe, Kenneth K. TI Clinical Value of Radiographic Staging in Patients Diagnosed With AJCC Stage III Melanoma SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 63rd Annual Meeting of the Society-of-Surgical-Oncology CY MAR 05-07, 2010 CL St Louis, MO SP Soc Surg Oncol ID POSITRON-EMISSION-TOMOGRAPHY; SENTINEL NODE BIOPSY; AMERICAN JOINT COMMITTEE; COMPUTED-TOMOGRAPHY; MALIGNANT-MELANOMA; PROGNOSTIC-FACTORS; FOLLOW-UP; METASTASES; RECURRENCE; UTILITY AB Patients with American Joint Committee on Cancer (AJCC) stage III melanoma represent patients with high risk of systemic relapse. This study evaluates the clinical utility of standardized radiographic staging. Consecutive asymptomatic patients underwent standardized radiographic staging workup within 6 weeks of diagnosis. True- and false-positive rates and number of additional examinations generated after a positive initial report were quantified. All suspicious findings were further studied by biopsy and/or by clinical or radiologic assessment. Fifty-eight patients underwent complete radiographic staging. Nineteen (33%) had ulcerated primary tumors. Forty-two patients (73%) presented with clinically negative lymph nodes that were positive on sentinel lymph node biopsy. Lymph node involvement was classified as N1a in 54%, N2a in 19%, N2b in 3%, and N3 in 22% of patients. Among 204 staging examinations in 58 patients, 52 (25%) were initially reported as positive. Three percent of all examinations proved truly positive; 23% were falsely positive. Analyzed per patient, in 37 (64%) of 58 patients, at least one examination was initially reported as positive. However, only 3 patients (5%) had a true-positive and 34 (59%) had at least one false-positive report. The positive reports of the staging scans generated 45 additional examinations (0.78 per patient). Radiographic staging in asymptomatic patients with stage III melanoma detects a low number of patients with unsuspected systemic disease. The ratio of falsely to truly positive is approximately 11:1. Radiographic screening should only be considered in patients with high-risk prognostic features or symptoms, or in the context of clinical trials. C1 [Pandalai, Prakash K.; Dominguez, Francisco J.; Michaelson, James; Tanabe, Kenneth K.] Massachusetts Gen Hosp, Dept Surg, Div Surg Oncol, Boston, MA 02114 USA. [Pandalai, Prakash K.; Dominguez, Francisco J.; Michaelson, James; Tanabe, Kenneth K.] Harvard Univ, Sch Med, Boston, MA USA. RP Tanabe, KK (reprint author), Massachusetts Gen Hosp, Dept Surg, Div Surg Oncol, Boston, MA 02114 USA. EM ktanabe@partners.org NR 21 TC 11 Z9 11 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2011 VL 18 IS 2 BP 506 EP 513 DI 10.1245/s10434-010-1272-0 PG 8 WC Oncology; Surgery SC Oncology; Surgery GA 716AZ UT WOS:000286938600033 PM 20734149 ER PT J AU Adler, JT AF Adler, Joel T. TI Reply to "25-Hydroxyvitamin D Status Does Not Affect Intraoperative Parathyroid Hormone Dynamics in Patients With Primary Hyperparathyroidism," by Agarwal et al. SO ANNALS OF SURGICAL ONCOLOGY LA English DT Letter C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Adler, JT (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. EM joeladler@gmail.com OI Adler, Joel/0000-0001-8190-3444 NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2011 VL 18 IS 2 BP 602 EP 602 DI 10.1245/s10434-010-1411-7 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 716AZ UT WOS:000286938600049 ER PT J AU Levack, M Berger, D Sylla, P Rattner, D Bordeianou, L AF Levack, Melissa Berger, David Sylla, Patricia Rattner, David Bordeianou, Liliana TI Laparoscopy Decreases Anastomotic Leak Rate in Sigmoid Colectomy for Diverticulitis SO ARCHIVES OF SURGERY LA English DT Article ID QUALITY-OF-LIFE; COLON-CANCER; ASSISTED COLECTOMY; RANDOMIZED TRIAL; DISEASE; RESECTION; MULTICENTER; MANAGEMENT; SURGERY; COMORBIDITY AB Background: Early studies comparing laparoscopic and open operations for diverticulitis failed to show any advantages of the laparoscopic approach. Our study compared the 30-day postoperative outcomes of laparoscopic and open sigmoid colectomy for diverticulitis by surgeons who had performed 20 or more laparoscopic colectomies before the study period. Hypothesis: Patients who undergo an elective laparoscopic operation for diverticulitis have reduced postoperative complications compared with patients who have a traditional open operation. Design: Retrospective analysis. Setting: Academic medical center. Patients: A total of 249 patients who underwent elective open (n = 127) or laparoscopic (n = 122) sigmoid colectomy with primary anastomosis for diverticulitis between July 1, 2001, and February 1, 2008. Main Outcome Measures: Combined rates of free and contained anastomotic leaks.A logistic regression model was used to determine predictors of anastomotic leaks while controlling for significant differences between study groups. Results: Patients who underwent laparoscopic or open operations were similar in age, sex, history of diagnosed intraabdominal abscess (9.4% vs 12.3%), and history of preoperative percutaneous abscess drainage (3.9% vs 4.9%). Patients who underwent the open procedure had a higher Charlson comorbidity index (1.6 vs 1.2; P = .04), and those who underwent laparoscopy more frequently underwent splenic flexure mobilization (82.8% vs 26.7%; P < .001). Patients who underwent a laparoscopy had lower rates of anastomotic leaks (2.4% vs 8.2%; P = .04).This finding held true on logistic regression analysis (odds ratio, 0.67; 95% confidence interval, 0.008-0.567; P = .01), even when controlling for age, Charlson comorbidity index, splenic flexure mobilization, and length of resected bowel. Conclusion: Anastomotic leaks occurred less frequently after laparoscopic sigmoid colectomy performed by experienced laparoscopic colorectal surgeons. C1 [Bordeianou, Liliana] Massachusetts Gen Hosp, Div Gastrointestinal Surg, Colon & Rectal Surg Program, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Bordeianou, L (reprint author), Massachusetts Gen Hosp, Div Gastrointestinal Surg, Colon & Rectal Surg Program, 15 Parkman St,Bldg ACC 460, Boston, MA 02114 USA. EM lbordeianou@partners.org NR 34 TC 20 Z9 20 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD FEB PY 2011 VL 146 IS 2 BP 207 EP 210 DI 10.1001/archsurg.2010.325 PG 4 WC Surgery SC Surgery GA 723WE UT WOS:000287537200022 PM 21339434 ER PT J AU Brunstein, CG Carter, S Fuchs, EJ Karanes, C Devine, S Aljitawi, O Cutler, C Ballen, KK Thompson, J O'Donnell, PV Eapen, M AF Brunstein, C. G. Carter, S. Fuchs, E. J. Karanes, C. Devine, S. Aljitawi, O. Cutler, C. Ballen, K. K. Thompson, J. O'Donnell, P., V Eapen, M. TI PHASE II TRIAL OF NON-MYELOABLATIVE CONDITIONING (NST) DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION (DUCBT) FROM UNRELATED DONORS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: RESULTS OF BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK (BMT CTN) PROTOCOL 0604 SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Brunstein, C. G.] Univ Minnesota, Minneapolis, MN USA. [Carter, S.; Thompson, J.] Emmes Corp, Rockville, MD USA. [Fuchs, E. J.] Johns Hopkins Univ, Baltimore, MD USA. [Karanes, C.] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Devine, S.] Ohio State Univ, Columbus, OH 43210 USA. [Aljitawi, O.] Univ Kansas, Kansas City, KS USA. [Cutler, C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ballen, K. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [O'Donnell, P., V] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Eapen, M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 4 BP S151 EP S151 DI 10.1016/j.bbmt.2010.12.006 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500005 ER PT J AU Chen, YB Driscoll, J McAfee, SL Spitzer, TR Rosenberg, E Moss, R Fang, F Marty, FM AF Chen, Y. -B Driscoll, J. McAfee, S. L. Spitzer, T. R. Rosenberg, E. Moss, R. Fang, F. Marty, F. M. TI TREATMENT OF PARAINFLUENZA 3 INFECTION WITH DAS181 IN A PATIENT AFTER ALLOGENEIC STEM CELL TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Chen, Y. -B; Driscoll, J.; McAfee, S. L.; Spitzer, T. R.; Rosenberg, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Moss, R.; Fang, F.] NexBio Inc, San Diego, CA USA. [Marty, F. M.] Brigham & Womens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 338 BP S276 EP S277 DI 10.1016/j.bbmt.2010.12.372 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500338 ER PT J AU Chen, YB Sun, L Kim, H Alyea, EP Armand, P Attar, EC Ballen, KK Cutler, C Dey, BR Koreth, J McAfee, SL Spitzer, TR Antin, JH Soiffer, RJ Ho, VT AF Chen, Y-B Sun, L. Kim, H. Alyea, E. P. Armand, P. Attar, E. C. Ballen, K. K. Cutler, C. Dey, B. R. Koreth, J. McAfee, S. L. Spitzer, T. R. Antin, J. H. Soiffer, R. J. Ho, V. T. TI INCREASING THE DOSE OF BUSULFAN RESULTS IN LOWER RELAPSE RATES AND HIGHER NON-RELAPSE MORTALITY IN PATIENTS WITH MDS/AML UNDERGOING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Chen, Y-B; Attar, E. C.; Ballen, K. K.; Dey, B. R.; McAfee, S. L.; Spitzer, T. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sun, L.; Kim, H.; Alyea, E. P.; Armand, P.; Cutler, C.; Koreth, J.; Antin, J. H.; Soiffer, R. J.; Ho, V. T.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 8 BP S153 EP S153 DI 10.1016/j.bbmt.2010.12.011 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500009 ER PT J AU Cutler, C Kim, HT Sun, L Sese, D Kao, G Vasquez, M Armand, P Koreth, J Ho, VT Alyea, E Soiffer, RJ Bellen, K Ritz, J Milford, E Antin, JH AF Cutler, C. Kim, H. T. Sun, L. Sese, D. Kao, G. Vasquez, M. Armand, P. Koreth, J. Ho, V. T. Alyea, E. Soiffer, R. J. Bellen, K. Ritz, J. Milford, E. Antin, J. H. TI ANTI-HLA ANTIBODIES PREDICT GRAFT FAILURE, TIME TO ENGRAFTMENT AND UMBILICAL CORD UNIT DOMINANCE IN DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Cutler, C.; Kim, H. T.; Sun, L.; Kao, G.; Vasquez, M.; Armand, P.; Koreth, J.; Ho, V. T.; Alyea, E.; Soiffer, R. J.; Bellen, K.; Ritz, J.; Antin, J. H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sese, D.; Milford, E.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 197 BP S225 EP S226 DI 10.1016/j.bbmt.2010.12.223 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500197 ER PT J AU Cutler, CS Desponts, C Robbins, D North, TE Goessling, W Kao, G Ritz, J Ballen, KK Antin, JH Spitzer, TR Soiffer-Chen, YBA Ho, VT Armand, P Koreth, J Alyea, E McAfee, S Dey, BR Shoemaker, D Multani, PS AF Cutler, C. S. Desponts, C. Robbins, D. North, T. E. Goessling, W. Kao, G. Ritz, J. Ballen, K. K. Antin, J. H. Spitzer, T. R. Soiffer-Chen, Y-B A. Ho, V. T. Armand, P. Koreth, J. Alyea, E. McAfee, S. Dey, B. R. Shoemaker, D. Multani, P. S. TI EX VIVO TREATMENT OF HEMATOPOIETIC STEM CELLS WITH 16,16-DIMETHYL PROSTAGLANDIN E2 (FT1050) IMPROVES ENGRAFTMENT AND HEMATOPOIETIC RECONSTITUTION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Cutler, C. S.; Kao, G.; Ritz, J.; Antin, J. H.; Soiffer-Chen, Y-B A.; Ho, V. T.; Armand, P.; Koreth, J.; Alyea, E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ballen, K. K.; Spitzer, T. R.; Soiffer-Chen, Y-B A.; McAfee, S.; Dey, B. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Desponts, C.; Robbins, D.; Shoemaker, D.; Multani, P. S.] Fate Therapeut, San Diego, CA USA. [North, T. E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Goessling, W.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 198 BP S226 EP S226 DI 10.1016/j.bbmt.2010.12.224 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500198 ER PT J AU Duran-Struuck, R Crepeau, R Matar, A Pathiraja, V Horner, B Robson, S Fishman, J Spitzer, T Sachs, D Huang, C AF Duran-Struuck, R. Crepeau, R. Matar, A. Pathiraja, V Horner, B. Robson, S. Fishman, J. Spitzer, T. Sachs, D. Huang, C. TI IMPACT OF DONOR STEM CELL MOBILIZATION REACTIONS ON REDUCED INTENSITY HAPLOIDENTICAL HCT OUTCOMES IN MINIATURE SWINE SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Duran-Struuck, R.; Crepeau, R.; Matar, A.; Pathiraja, V; Horner, B.; Fishman, J.; Spitzer, T.; Sachs, D.; Huang, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Robson, S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 451 BP S317 EP S317 DI 10.1016/j.bbmt.2010.12.487 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500451 ER PT J AU Gaumer, C Holland, D Emmert, A AF Gaumer, C. Holland, D. Emmert, A. TI EFFORTS TO MANAGE AND REDUCE DISCHARGE PHARMACY CRISES AMONG HIGH RISK HSCT PATIENTS SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Gaumer, C.; Holland, D.; Emmert, A.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 575 BP S359 EP S359 DI 10.1016/j.bbmt.2010.12.614 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500575 ER PT J AU Hainz, U Stevenson, K Ho, VT Alonso, A Goldstein, NR Lokko, N Sievers, Q Brusic, AM Zhang, W Pasek, M Zeng, W Choi, J Brown, JR Canning, CM Koreth, J Cutler, C Armand, P Antin, JH Sasada, T Ritz, J Dranoff, G Soiffer, RJ Alyea, EP Wu, CJ AF Hainz, U. Stevenson, K. Ho, V. T. Alonso, A. Goldstein, N. R. Lokko, N. Sievers, Q. Brusic, A. M. Zhang, W. Pasek, M. Zeng, W. Choi, J. Brown, J. R. Canning, C. M. Koreth, J. Cutler, C. Armand, P. Antin, J. H. Sasada, T. Ritz, J. Dranoff, G. Soiffer, R. J. Alyea, E. P. Wu, C. J. TI EARLY POST-TRANSPLANT WHOLE TUMOR CELL VACCINATION ELICITS ANTI-TUMOR T CELL RESPONSES IN PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Hainz, U.; Stevenson, K.; Ho, V. T.; Alonso, A.; Goldstein, N. R.; Lokko, N.; Sievers, Q.; Brusic, A. M.; Zhang, W.; Pasek, M.; Zeng, W.; Choi, J.; Brown, J. R.; Canning, C. M.; Koreth, J.; Cutler, C.; Armand, P.; Antin, J. H.; Sasada, T.; Ritz, J.; Dranoff, G.; Soiffer, R. J.; Alyea, E. P.; Wu, C. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 46 BP S169 EP S169 DI 10.1016/j.bbmt.2010.12.052 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500047 ER PT J AU Holland, AM Zakrzewski, JL Fletcher, AL Smith, OM Suh, D King, CG Yim, NL Rao, UK Brill, J van den Brink, MR AF Holland, A. M. Zakrzewski, J. L. Fletcher, A. L. Smith, O. M. Suh, D. King, C. G. Yim, N. L. Rao, U. K. Brill, J. van den Brink, M. R. TI EXTRATHYMIC SITES DRIVE THYMUS-INDEPENDENT DEVELOPMENT OF FUNCTIONAL T CELLS AFTER BONE MARROW TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Holland, A. M.; Zakrzewski, J. L.; Smith, O. M.; Suh, D.; King, C. G.; Yim, N. L.; Rao, U. K.; Brill, J.; van den Brink, M. R.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Holland, A. M.] Weill Cornell Grad Sch Med Sci, New York, NY USA. [Fletcher, A. L.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 222 BP S235 EP S236 DI 10.1016/j.bbmt.2010.12.249 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500222 ER PT J AU Inamoto, Y Kurland, BF Chai, S Heffernan, MJ Martin, PJ Flowers, MED Carpenter, PA Cutler, C Jacobsohn, D Jagasia, M Johnston, L Vogelsang, GB Pavletic, SZ Lee, SJ AF Inamoto, Y. Kurland, B. F. Chai, S. Heffernan, M. J. Martin, P. J. Flowers, M. E. D. Carpenter, P. A. Cutler, C. Jacobsohn, D. Jagasia, M. Johnston, L. Vogelsang, G. B. Pavletic, S. Z. Lee, S. J. TI EVALUATION OF SCALES CORRELATED WITH CLINICIAN AND PATIENT-PERCEIVED SYMPTOM CHANGE IN OCULAR GRAFT-VERSUS-HOST DISEASE: RESULTS FROM THE CHRONIC GVHD CONSORTIUM SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Inamoto, Y.; Kurland, B. F.; Chai, S.; Heffernan, M. J.; Martin, P. J.; Flowers, M. E. D.; Carpenter, P. A.; Lee, S. J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Cutler, C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jacobsohn, D.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Jagasia, M.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Johnston, L.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Vogelsang, G. B.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Pavletic, S. Z.] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 63 BP S175 EP S176 DI 10.1016/j.bbmt.2010.12.073 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500064 ER PT J AU Ion, DI Stevenson, KE Woo, SB Antin, JH Soiffer, RJ Treister, NS AF Ion, D. I. Stevenson, K. E. Woo, S. -B Antin, J. H. Soiffer, R. J. Treister, N. S. TI CHARACTERIZATION OF ORAL INVOLVEMENT IN ACUTE-GRAFT-VERSUS-HOST DISEASE SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Ion, D. I.; Woo, S. -B; Treister, N. S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Stevenson, K. E.; Antin, J. H.; Soiffer, R. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Woo, S. -B; Treister, N. S.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. [Antin, J. H.; Soiffer, R. J.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 449 BP S316 EP S316 DI 10.1016/j.bbmt.2010.12.485 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500449 ER PT J AU Jacobson, C Turki, A McDonough, S Stevenson, K Kim, H Herrera, M Reynolds, C Alyea, E Ho, V Koreth, J Soiffer, R Antin, J Ballen, K Cutler, C Ritz, J AF Jacobson, C. Turki, A. McDonough, S. Stevenson, K. Kim, H. Herrera, M. Reynolds, C. Alyea, E. Ho, V Koreth, J. Soiffer, R. Antin, J. Ballen, K. Cutler, C. Ritz, J. TI IMMUNE RECONSTITUTION AFTER DOUBLE UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION: COMPARISON WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Jacobson, C.; Turki, A.; McDonough, S.; Stevenson, K.; Kim, H.; Herrera, M.; Reynolds, C.; Alyea, E.; Ho, V; Koreth, J.; Soiffer, R.; Antin, J.; Cutler, C.; Ritz, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ballen, K.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 215 BP S233 EP S233 DI 10.1016/j.bbmt.2010.12.242 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500215 ER PT J AU Kawano, Y Kim, HT Matsuoka, KI Smith, R Lazo-Kallanian, S Daley, J Ho, VT Cutler, C Koreth, J Alyea, EP Antin, JH Soiffer, RJ Ritz, J AF Kawano, Y. Kim, H. T. Matsuoka, K. -, I Smith, R. Lazo-Kallanian, S. Daley, J. Ho, V. T. Cutler, C. Koreth, J. Alyea, E. P. Antin, J. H. Soiffer, R. J. Ritz, J. TI TELOMERASE ACTIVITY IN REGULATORY T CELLS IS INVERSELY ASSOCIATED WITH SEVERITY OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Kawano, Y.; Kim, H. T.; Matsuoka, K. -, I; Smith, R.; Lazo-Kallanian, S.; Daley, J.; Ho, V. T.; Cutler, C.; Koreth, J.; Alyea, E. P.; Antin, J. H.; Soiffer, R. J.; Ritz, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 477 BP S325 EP S325 DI 10.1016/j.bbmt.2010.12.514 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500477 ER PT J AU King, BS Ellis, M Schott, DM Kostaras, PM Emmert, AE AF King, B. S. Ellis, M. Schott, D. M. Kostaras, P. M. Emmert, A. E. TI ASSESSMENT AND REVISION OF PATIENT SCHEDULING FOR HSCT RELATED APHERESIS AND CELL PROCESSING TO REDUCE OVER-ALLOCATION AND UNDERUTILIZATION OF RESOURCES SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [King, B. S.; Ellis, M.; Schott, D. M.; Kostaras, P. M.; Emmert, A. E.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 576 BP S359 EP S360 DI 10.1016/j.bbmt.2010.12.615 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500576 ER PT J AU Koreth, J Stevenson, KE Kim, HT Bindra, B McDonough, S Ho, VT Cutler, CS Armand, P Soiffer, RJ Antin, JH Ritz, J Alyea, EP AF Koreth, J. Stevenson, K. E. Kim, H. T. Bindra, B. McDonough, S. Ho, V. T. Cutler, C. S. Armand, P. Soiffer, R. J. Antin, J. H. Ritz, J. Alyea, E. P. TI A PROSPECTIVE PHASE I/II TRIAL OF BORTEZOMIB-BASED GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS IN HLA-MISMATCHED UNRELATED DONOR REDUCED-INTENSITY CONDITIONING HEMATOPOIETIC STEM CELL TRANSPLANTATION: ENCOURAGING SAFETY, EFFICACY, AND SURVIVAL SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Koreth, J.; Stevenson, K. E.; Kim, H. T.; Bindra, B.; McDonough, S.; Ho, V. T.; Cutler, C. S.; Armand, P.; Soiffer, R. J.; Antin, J. H.; Ritz, J.; Alyea, E. P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 38 BP S165 EP S166 DI 10.1016/j.bbmt.2010.12.044 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500039 ER PT J AU Kostaras, PM Emmert, AE AF Kostaras, P. M. Emmert, A. E. TI INTEGRATING HSCT EVALUATION-PHASE ACTIVITIES TO REDUCE COST AND STREAMLINE WORKFLOW SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Kostaras, P. M.; Emmert, A. E.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 574 BP S359 EP S359 DI 10.1016/j.bbmt.2010.12.613 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500574 ER PT J AU Leen, AM Bollard, CM Mendizabal, A Shpall, EJ Szabolcs, P Antin, JH Kapoor, N Pai, SY Grilley, B Gee, AP Brenner, MK Rooney, CM Heslop, HE AF Leen, A. M. Bollard, C. M. Mendizabal, A. Shpall, E. J. Szabolcs, P. Antin, J. H. Kapoor, N. Pai, S-Y Grilley, B. Gee, A. P. Brenner, M. K. Rooney, C. M. Heslop, H. E. TI MOST CLOSELY HLA-MATCHED ALLOGENEIC VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES (CTL) TO TREAT PERSISTENT REACTIVATION OR INFECTION WITH ADENOVIRUS, CMV AND EBV AFTER HEMOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Leen, A. M.; Bollard, C. M.; Grilley, B.; Gee, A. P.; Brenner, M. K.; Rooney, C. M.; Heslop, H. E.] Texas Childrens Hosp, Baylor Coll Med, Methodist Hosp, Houston, TX 77030 USA. [Mendizabal, A.] EMMES Corp, Rockville, MD USA. [Shpall, E. J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Szabolcs, P.] Duke Univ, Med Ctr, Durham, NC USA. [Kapoor, N.] USC, Childrens Hosp Los Angeles, Keck Sch Med, Los Angeles, CA USA. [Pai, S-Y] Childrens Hosp, Dana Faber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 6 BP S151 EP S152 DI 10.1016/j.bbmt.2010.12.008 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500007 ER PT J AU Lightdale, JR Tran, CM Randolph, AG Jiang, H Colon, A Houlahan, KE Sloan, S Lehmann, LE AF Lightdale, J. R. Tran, C. M. Randolph, A. G. Jiang, H. Colon, A. Houlahan, K. E. Sloan, S. Lehmann, L. E. TI IMPACT OF A PRUDENT (c) CONSERVATIVE RED BLOOD CELL TRANSFUSION STRATEGY IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Tran, C. M.; Colon, A.] Childrens Hosp, Phys Org, Boston, MA 02115 USA. [Houlahan, K. E.; Lehmann, L. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 308 BP S266 EP S266 DI 10.1016/j.bbmt.2010.12.339 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500308 ER PT J AU Pidala, J Kurland, B Chai, X Majhail, N Weisdorf, D Pavletic, S Cutler, C Arai, S Jagasia, M Palmer, J Lee, SJ AF Pidala, J. Kurland, B. Chai, X. Majhail, N. Weisdorf, D. Pavletic, S. Cutler, C. Arai, S. Jagasia, M. Palmer, J. Lee, S. J. TI CHRONIC GVHD SEVERITY AND SENSITIVITY TO CHANGE IN PATIENT-REPORTED QUALITY OF LIFE: RESULTS FROM THE CHRONIC GVHD CONSORTIUM SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Pidala, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Kurland, B.; Chai, X.; Lee, S. J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Majhail, N.; Weisdorf, D.] Univ Minnesota, Minneapolis, MN 55455 USA. [Pavletic, S.] NCI, Bethesda, MD 20892 USA. [Cutler, C.] Dana Farber Canc Inst, Boston, MA USA. [Arai, S.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Jagasia, M.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Palmer, J.] Med Coll Wisconsin, Milwaukee, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 229 BP S238 EP S238 DI 10.1016/j.bbmt.2010.12.257 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500229 ER PT J AU Postow, M Kim, HT Sun, L Koreth, J Armand, P Cutler, C Alyea, EP Antin, JH Soiffer, RJ Ho, VT AF Postow, M. Kim, H. T. Sun, L. Koreth, J. Armand, P. Cutler, C. Alyea, E. P. Antin, J. H. Soiffer, R. J. Ho, V. T. TI PHILADELPHIA CHROMOSOME IS NOT AN ADVERSE PROGNOSTIC FACTOR IN ACUTE LYMPHOBLASTIC LEUKEMIA AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Postow, M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Kim, H. T.; Sun, L.; Koreth, J.; Armand, P.; Cutler, C.; Alyea, E. P.; Antin, J. H.; Soiffer, R. J.; Ho, V. T.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 247 BP S244 EP S245 DI 10.1016/j.bbmt.2010.12.276 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500247 ER PT J AU Sturtevant, OJ Schott, DM Brzezinski, P Marston, E Gatzos, L Barbetti, S Canning, C Kao, G Antin, J Soiffer, R Ritz, J AF Sturtevant, O. J. Schott, D. M. Brzezinski, P. Marston, E. Gatzos, L. Barbetti, S. Canning, C. Kao, G. Antin, J. Soiffer, R. Ritz, J. TI BIOTHERAPY ORDER ENTRY (BOE) - ELECTRONIC PHYSICIAN ORDERS FOR CELLULAR THERAPY PRODUCTS SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Sturtevant, O. J.; Schott, D. M.; Brzezinski, P.; Kao, G.; Antin, J.; Soiffer, R.; Ritz, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Marston, E.; Gatzos, L.; Barbetti, S.] Partners Healthcare Inc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 174 BP S217 EP S217 DI 10.1016/j.bbmt.2010.12.197 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500175 ER PT J AU Toro, JJ Varadarajan, P Schneider, DL Lee, S Chao, JH Frye, BL Neumon, B Haile, DJ Freytes, CO AF Toro, J. J. Varadarajan, P. Schneider, D. L. Lee, S. Chao, J. -H Frye, B. L. Neumon, B. Haile, D. J. Freytes, C. O. TI ORAL AND SYSTEMIC COMPLICATIONS OF MYELOMA PATIENTS WITH BISPHOSPHONATE-INDUCED OSTEONECROSIS OF THE JAW: A CASE-CONTROL STUDY SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Toro, J. J.; Schneider, D. L.; Lee, S.; Chao, J. -H; Frye, B. L.; Neumon, B.; Haile, D. J.; Freytes, C. O.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Toro, J. J.; Varadarajan, P.; Freytes, C. O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 334 BP S275 EP S275 DI 10.1016/j.bbmt.2010.12.368 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500334 ER PT J AU Whitley, KE Williams, T Muriel, AC Lehmann, LE Duncan, CN AF Whitley, K. E. Williams, T. Muriel, A. C. Lehmann, L. E. Duncan, C. N. TI THE USE OF PSYCHOTROPIC MEDICATIONS IN PEDIATRIC STEM CELL TRANSPLANT PATIENTS SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem CY FEB 17-21, 2011 CL Honolulu, HI SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res C1 [Whitley, K. E.; Williams, T.; Muriel, A. C.; Lehmann, L. E.; Duncan, C. N.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2011 VL 17 IS 2 SU 2 MA 346 BP S279 EP S279 DI 10.1016/j.bbmt.2010.12.380 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 721JX UT WOS:000287350500346 ER PT J AU Jakupcak, M Varra, EM AF Jakupcak, Matthew Varra, Edward M. TI Treating Iraq and Afghanistan War Veterans With PTSD Who Are at High Risk for Suicide SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; VIETNAM COMBAT VETERANS; BORDERLINE PERSONALITY-DISORDER; COGNITIVE PROCESSING THERAPY; DIALECTICAL BEHAVIOR-THERAPY; HEALTH-CARE; PSYCHIATRIC-DISORDERS; SEEKING SAFETY; US-VETERANS AB Iraq and Afghanistan War veterans diagnosed with psychiatric disorders commit suicide at a higher rate than the general population (Kang & Bullman, 2008). Posttraumatic stress disorder (PTSD) has been identified as a risk factor for suicide in veterans (Bullman & Kang, 1994) and is the most common mental disorder among Iraq and Afghanistan veterans presenting for treatment at Veterans Affairs (VA) facilities (Kang, 2009). Therefore, it is critical for health providers to identify veterans with PTSD who are at high risk for suicide in order to more effectively intervene to promote safety, stabilization, and reduce psychiatric symptoms. In the following paper; we discuss risk for suicide in veterans with PTSD and application of cognitive behavioral therapies to reduce suicidality in high-risk patients. We also discuss pertinent clinical issues common to treating Iraq and Afghanistan War veterans with PTSD. C1 [Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Deployment Hlth Clin, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA 98108 USA. [Varra, Edward M.] VA Puget Sound Hlth Care Syst, PTSD Outpatient Clin, Seattle, WA 98108 USA. RP Jakupcak, M (reprint author), VA Puget Sound Hlth Care Syst, Deployment Hlth Clin, VISN Mental Illness Res Educ & Clin Ctr 20, 1660 S Columbian Way, Seattle, WA 98108 USA. EM matthew.jakupcak@va.gov NR 70 TC 12 Z9 12 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD FEB PY 2011 VL 18 IS 1 BP 85 EP 97 DI 10.1016/j.cbpra.2009.08.007 PG 13 WC Psychology, Clinical SC Psychology GA 712EV UT WOS:000286648400011 ER PT J AU Steenkamp, MM Litz, BT Gray, MJ Lebowitz, L Nash, W Conoscenti, L Amidon, A Lang, A AF Steenkamp, Maria M. Litz, Brett T. Gray, Matt J. Lebowitz, Leslie Nash, William Conoscenti, Lauren Amidon, Amy Lang, Ariel TI A Brief Exposure-Based Intervention for Service Members With PTSD SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; COGNITIVE-PROCESSING THERAPY; WAR ZONE STRESSORS; IRAQ WAR; COMPLICATED GRIEF; COMBAT VETERANS; GUILT; BEREAVEMENT; SYMPTOMS AB The growing number of service members in need of mental health care requires that empirically based interventions be tailored to the unique demands and exigencies of this population. We discuss a 6-session intervention for combat-related PTSD designed to foster willingness to engage with and disclose difficult deployment memories through a combination of imaginal exposure and subsequent cognitive restructuring and meaning-making strategies. Care corrective elements of existing PTSD treatments are incorporated and expanded, including techniques designed to specifically address traumatic loss and moral conflict. C1 [Steenkamp, Maria M.; Litz, Brett T.] Boston Univ, Boston, MA 02215 USA. [Litz, Brett T.; Conoscenti, Lauren] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Gray, Matt J.] Univ Wyoming, Laramie, WY 82071 USA. [Amidon, Amy; Lang, Ariel] Univ Calif San Diego, San Diego, CA 92103 USA. [Lang, Ariel] VA San Diego Healthcare Syst, San Diego, CA USA. RP Steenkamp, MM (reprint author), Boston Univ, 648 Beacon St,5th Floor, Boston, MA 02215 USA. EM msteen@bu.edu NR 44 TC 35 Z9 35 U1 3 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD FEB PY 2011 VL 18 IS 1 BP 98 EP 107 DI 10.1016/j.cbpra.2009.08.006 PG 10 WC Psychology, Clinical SC Psychology GA 712EV UT WOS:000286648400012 ER PT J AU Sayers, SL AF Sayers, Steven L. TI Family Reintegration Difficulties and Couples Therapy for Military Veterans and Their Spouses SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; COGNITIVE-PROCESSING THERAPY; IRAQI FREEDOM VETERANS; MALE VIETNAM VETERANS; US ARMY SOLDIERS; MARITAL-THERAPY; DOMESTIC VIOLENCE; DEPLOYMENT; INTERVENTIONS AB There is compelling evidence that mental health problems complicate the process of family reintegration of military service members after a wartime deployment. Couples in which one spouse has recently returned from military deployment in Iraq or Afghanistan and are experiencing marital problems can present a significant treatment challenge. There is little empirical evidence regarding effective treatments for this population, and these couples tend to exhibit a wide range of difficulties, including the following: conflicts about reintegration, problems with posttraumatic stress disorder and/or depression, chronic injury, infidelity, and personal and social challenges associated with rejoining civilian life Behavioral couples therapy provides a useful framework for intervention with these couples, combined with individual treatment and education about the impact of combat deployment. This paper discusses considerations for integrating these treatment approaches and future clinical and research needs for these couples. C1 [Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Sayers, Steven L.] Univ Penn, Philadelphia, PA 19104 USA. RP Sayers, SL (reprint author), Philadelphia Vet Affairs Med Ctr, MIRECC 116,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM steven.sayers@va.gov NR 52 TC 24 Z9 24 U1 6 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD FEB PY 2011 VL 18 IS 1 BP 108 EP 119 DI 10.1016/j.cbpra.2010.03.002 PG 12 WC Psychology, Clinical SC Psychology GA 712EV UT WOS:000286648400013 ER PT J AU Keane, TM AF Keane, Terence M. TI Responding to the Psychological Needs of OEF-OIF Military: A Commentary on Progress in Treatment Development SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; OPERATION IRAQI FREEDOM; MARITAL SATISFACTION; IMPLOSIVE-THERAPY; LEARNING-THEORY; SYMPTOMS; VETERANS; AFGHANISTAN; INFORMATION; EXPOSURE AB America's involvement in the wars in Afghanistan and Iraq (i.e., OEF-OIF) is entering its 9th year with casualties exceeding 5,000 American deaths and many times that number with serious physical injuries. Epidemiological surveys and mental health screening concurrent with service and at the point of discharge provide us with important information on the psychological status of those directly involved in the military action. Support to mental health professionals coming primarily from the Department of Defense, the Department of Veterans Affairs, and the National Institutes of Health provided an important catalyst in the development of psychological treatments aimed specifically at the presenting problems of service men and women and their families. This special series highlights the impressive growth in treatments developed for OEF-OIF military and demonstrates the wide-ranging nature of the treatments that are now available for testing and use in assisting those most affected by the war. The creativity of these research teams in addressing the needs of these service men and women inspires continuing work in this area that will undoubtedly enhance mental health services available to the general population in the near term. C1 [Keane, Terence M.] VA Boston Healthcare Syst, ACOS Res, Res 151, Natl Ctr Posttraumat Stress Disorder, Boston, MA 02130 USA. [Keane, Terence M.] Boston Univ, Sch Med, Boston, MA 02215 USA. RP Keane, TM (reprint author), VA Boston Healthcare Syst, ACOS Res, Res 151, Natl Ctr Posttraumat Stress Disorder, 150 S Huntington Ave, Boston, MA 02130 USA. EM terry.keane@va.gov NR 35 TC 3 Z9 3 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD FEB PY 2011 VL 18 IS 1 BP 144 EP 148 DI 10.1016/j.cbpra.2010.07.001 PG 5 WC Psychology, Clinical SC Psychology GA 712EV UT WOS:000286648400016 ER PT J AU Wang, ZH Bordas, V Deisboeck, TS AF Wang, Zhihui Bordas, Veronika Deisboeck, Thomas S. TI Discovering Molecular Targets in Cancer With Multiscale Modeling SO DRUG DEVELOPMENT RESEARCH LA English DT Article DE computational modeling; multiscale; epidermal growth factor receptor; non-small cell lung cancer; signaling pathway ID CELL LUNG-CANCER; EPIDERMAL-GROWTH-FACTOR; SENSITIVITY-ANALYSIS; FACTOR RECEPTOR; SYSTEMS BIOLOGY; MULTICOMPONENT THERAPEUTICS; DRUG DISCOVERY; CROSS-SCALE; INHIBITOR; NETWORKS AB Multiscale modeling is being recognized increasingly as a promising research area in computational cancer systems biology. In the present review, exemplified by two pioneering studies, we attempt to explain why and how such a multiscale approach paired with an innovative cross-scale analytical technique can be useful in identifying high-value molecular therapeutic targets. This novel, integrated approach has the potential to offer a more effective in silico framework for target discovery and represents an important technical step toward systems medicine. Drug Dev Res 72: 45-52, 2011. (C) 2010 Wiley-Liss, Inc. C1 [Wang, Zhihui; Deisboeck, Thomas S.] Massachusetts Gen Hosp, Harvard MIT HST, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Bordas, Veronika] Harvard Univ, Dept Appl Math, Cambridge, MA 02138 USA. RP Deisboeck, TS (reprint author), Massachusetts Gen Hosp E 2301, Harvard MIT HST, Complex Biosyst Modeling Lab, Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St, Charlestown, MA 02129 USA. EM deisboec@helix.mgh.harvard.edu FU National Institutes of Health [CA 113004]; Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging; Department of Radiology, Massachusetts General Hospital FX Grant sponsor: National Institutes of Health; Grant number: CA 113004; Grant sponsors: Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging; Department of Radiology, Massachusetts General Hospital. NR 49 TC 6 Z9 6 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4391 J9 DRUG DEVELOP RES JI Drug Dev. Res. PD FEB PY 2011 VL 72 IS 1 SI SI BP 45 EP 52 DI 10.1002/ddr.20401 PG 8 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 730LZ UT WOS:000288036100006 PM 21572568 ER PT J AU Merriam, GR Koenig, JI AF Merriam, George R. Koenig, James I. TI Stress Hypogonadism: Not Everything That Suppresses Must Converge SO ENDOCRINOLOGY LA English DT Editorial Material ID INSULIN-INDUCED HYPOGLYCEMIA; LUTEINIZING-HORMONE; FEMALE RATS; OREXIN-A; AREA; PROJECTIONS; SECRETION; NEURONS; IMMUNOREACTIVITY; INTEGRATION C1 [Merriam, George R.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98493 USA. [Merriam, George R.] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Seattle, WA 98493 USA. [Merriam, George R.] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Tacoma, WA 98493 USA. [Merriam, George R.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA. [Koenig, James I.] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA. [Koenig, James I.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21228 USA. RP Merriam, GR (reprint author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98493 USA. NR 16 TC 1 Z9 1 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 2011 VL 152 IS 2 BP 340 EP 342 DI 10.1210/en.2010-1405 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 709FA UT WOS:000286422100002 PM 21252178 ER PT J AU Fargo, KN Foecking, EM Jones, KJ AF Fargo, Keith N. Foecking, Eileen M. Jones, Kathryn J. TI Muscle Matters-Dendrites Grow Up SO ENDOCRINOLOGY LA English DT Editorial Material ID MOSAIC ANDROGEN INSENSITIVITY; SPINAL NUCLEUS; PERINEAL MOTONEURONS; RECEPTOR PROTEIN; MALE RATS; TESTOSTERONE; EXPRESSION; BULBOCAVERNOSUS; MORPHOLOGY; ACCUMULATION C1 [Fargo, Keith N.; Foecking, Eileen M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA. [Foecking, Eileen M.] Loyola Univ Chicago, Stritch Sch Med, Dept Otolaryngol Head & Neck Surg, Maywood, IL 60153 USA. [Fargo, Keith N.] Loyola Univ Chicago, Stritch Sch Med, Inst Neurosci, Maywood, IL 60153 USA. [Jones, Kathryn J.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA. [Jones, Kathryn J.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA. RP Fargo, KN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 23 TC 0 Z9 0 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 2011 VL 152 IS 2 BP 346 EP 348 DI 10.1210/en.2010-1413 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 709FA UT WOS:000286422100004 PM 21252180 ER PT J AU Miller, JW Cole, AJ AF Miller, John W. Cole, Andrew J. TI Is it necessary to define the ictal onset zone with EEG prior to performing resective epilepsy surgery? SO EPILEPSY & BEHAVIOR LA English DT Review DE Epilepsy surgery; Video EEG monitoring; MRI; Ictal localization ID HIGH-FREQUENCY OSCILLATIONS; TEMPORAL-LOBE EPILEPSY; PROGNOSTIC-FACTORS; NORMAL MRI; SEIZURES; HIPPOCAMPAL; LOCALIZATION; LOBECTOMY; SCLEROSIS; SURFACE AB When evaluating candidates for neurosurgical treatment for medically intractable epilepsy, is it always necessary to define the region of seizure onset with EEG? A simple answer to this question is not possible. There are specific situations where surgery is commonly performed without clear EEG ictal localization, and other situations where electrical localization is mandatory. However, opinions differ in many other situations. What are the core issues for determining when EEG localization is necessary? Neuroimaging is imperfect. It does not always accurately identify the site of seizure origination, because seizures do not always arise from visible structural lesions. EEG localization is also imperfect, as well as expensive and time consuming. Sometimes the site of origin is not identified, or a region of spread is misidentified as site of origin. False localization and lateralization can occur. Finally, epilepsy surgery is imperfect. It can produce life-changing results, but it carries risk, and surgical failure is not rare. The limitations of these methods, and the high stakes of epilepsy surgery imply that we should be very cautious to omit EEG studies. The desire to improve access to epilepsy surgery, and to minimize the expense and risk from inpatient EEG studies, must be weighed against the possibility of an ineffective resection. To improve outcomes, improvements in both neuroimaging and EEG techniques are needed. (C) 2010 Elsevier Inc. All rights reserved. C1 [Miller, John W.] Univ Washington, Sch Med, Dept Neurol & Neurol Surg, UW Reg Epilepsy Ctr, Seattle, WA 98104 USA. [Cole, Andrew J.] Massachusetts Gen Hosp, MGH Epilepsy Serv, Boston, MA 02114 USA. [Cole, Andrew J.] Harvard Univ, Sch Med, Boston, MA USA. RP Miller, JW (reprint author), Univ Washington, Sch Med, Dept Neurol & Neurol Surg, UW Reg Epilepsy Ctr, Box 359745,325 9th Ave, Seattle, WA 98104 USA. EM millerjw@u.washington.edu NR 24 TC 5 Z9 5 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD FEB PY 2011 VL 20 IS 2 BP 178 EP 181 DI 10.1016/j.yebeh.2010.08.024 PG 4 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 727WN UT WOS:000287833700006 PM 20888304 ER PT J AU Hughes, KC Shin, LM AF Hughes, Katherine C. Shin, Lisa M. TI Functional neuroimaging studies of post-traumatic stress disorder SO EXPERT REVIEW OF NEUROTHERAPEUTICS LA English DT Review DE amygdala; gyrus cinguli; hippocampus; insula; limbic system; magnetic resonance imaging; MRI; neuroimaging; positron emission tomography; post-traumatic stress disorders ID CEREBRAL-BLOOD-FLOW; CHILDHOOD SEXUAL-ABUSE; SCRIPT-DRIVEN IMAGERY; POSITRON-EMISSION-TOMOGRAPHY; SMALLER HIPPOCAMPAL VOLUME; BENZODIAZEPINE-RECEPTOR BINDING; ANTERIOR CINGULATE FUNCTION; COGNITIVE-BEHAVIOR THERAPY; INTIMATE PARTNER VIOLENCE; MEDIAL PREFRONTAL CORTEX AB Post-traumatic stress disorder (PTSD) is a significant problem that can affect individuals who have been exposed to a traumatic event or events, such as combat, violent crime or childhood abuse. Over the past several years, neuroimaging studies of PTSD have focused on elucidating the brain circuits that mediate this disorder. In this article, we will briefly introduce some of the methods used in functional neuroimaging studies of PTSD. We will then review functional neuroimaging studies that have reported significant findings in the amygdala, medial prefrontal cortex, hippocampus and insula. Finally, we will suggest future directions for research. C1 [Hughes, Katherine C.; Shin, Lisa M.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA. [Hughes, Katherine C.; Shin, Lisa M.] Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. RP Shin, LM (reprint author), Tufts Univ, Dept Psychol, 490 Boston Ave, Medford, MA 02155 USA. EM lisa.shin@tufts.edu FU NIMH NIH HHS [R01 MH054636, R01 MH054636-10A1] NR 115 TC 82 Z9 86 U1 5 U2 22 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7175 J9 EXPERT REV NEUROTHER JI Expert Rev. Neurother. PD FEB PY 2011 VL 11 IS 2 BP 275 EP 285 DI 10.1586/ERN.10.198 PG 11 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 727TB UT WOS:000287823400016 PM 21306214 ER PT J AU Marques, L Robinaugh, DJ LeBlanc, NJ Hinton, D AF Marques, Luana Robinaugh, Donald J. LeBlanc, Nicole J. Hinton, Devon TI Cross-cultural variations in the prevalence and presentation of anxiety disorders SO EXPERT REVIEW OF NEUROTHERAPEUTICS LA English DT Review DE anxiety disorders; culture; phenomenology; prevalence; race/ethnicity ID NATIONAL COMORBIDITY SURVEY; POSTTRAUMATIC-STRESS-DISORDER; SOCIAL PHOBIA SYMPTOMS; DSM-IV DISORDERS; MENTAL-DISORDERS; PANIC DISORDER; EPIDEMIOLOGIC SURVEY; 12-MONTH PREVALENCE; SURVEY REPLICATION; PSYCHIATRIC-DISORDERS AB Considerable cross-cultural variation exists in the prevalence and presentation of the anxiety disorders as defined by the fourth edition of the Diagnostic and Statistical Manual. Researchers debate whether this variation represents cultural differences in the phenomenology of universal disorders or the existence of unique culturally constructed disorders. This article reviews recent literature on the prevalence and presentation of five anxiety disorders: generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobia and post-traumatic stress disorder, both across countries and within the USA. This article indicates that certain anxiety disorders (e.g., generalized anxiety disorder and panic disorder) may vary greatly in rate across cultural groups. It indicates that the clinical presentation of anxiety disorders, with respect to symptom presentation and the interpretation of symptoms, varies across cultures. A difference in catastrophic cognitions about anxiety symptoms across cultures is hypothesized to be a key aspect of cross-cultural variation in the anxiety disorders. Future research directions are suggested. C1 [Marques, Luana; LeBlanc, Nicole J.; Hinton, Devon] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Anxiety & Traumat Stress Disorders, Boston, MA 02114 USA. [Robinaugh, Donald J.] Harvard Univ, Dept Psychol, Boston, MA 02114 USA. RP Marques, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Anxiety & Traumat Stress Disorders, 1 Bowdoin Sq, Boston, MA 02114 USA. EM lmarques@partners.org NR 89 TC 22 Z9 23 U1 8 U2 35 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7175 J9 EXPERT REV NEUROTHER JI Expert Rev. Neurother. PD FEB PY 2011 VL 11 IS 2 BP 313 EP 322 DI 10.1586/ERN.10.122 PG 10 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 727TB UT WOS:000287823400019 PM 21306217 ER PT J AU Malik, SM Nevin, DT Cohen, S Hunt, JL Palazzo, JP AF Malik, Sajjad M. Nevin, Daniel T. Cohen, Sidney Hunt, Jennifer L. Palazzo, Juan P. TI Assessment of Immunohistochemistry for p16(INK4) and High-Risk HPV DNA by In Situ Hybridization in Esophageal Squamous Cell Carcinoma SO INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE esophageal squamous cell carcinoma; HPV; in situ hybridization; p16; immunohistochemistry ID HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL-CANCER; LOW-PREVALENCE; UNITED-STATES; EXPRESSION; P16; WORLDWIDE; PROTEIN; LESIONS AB The role of high-risk human papillomavirus (HPV) in the pathogenesis of esophageal squamous cell carcinoma (ESCC) remains unclear. p16(INK4) is used as a surrogate marker to detect HPV-related tumors but has had discrepant results in ESCC. In this study, 32 cases of ESCC were examined to determine the relationship between p16(INK4) expression and high-risk HPV.All the tumors were stained by immunohistochemistry for p16(INK4). Tumors having p16(INK4) nuclear and/or nuclear and cytoplasmic expression were considered positive.Tumors positive for p16(INK4) expression were tested for high-risk HPV by in situ hybridization (ISH). In all, 20 cases of ESCC (63%) showed only cytoplasmic staining for p16(INK4), and 11 cases (34%) showed both cytoplasmic and nuclear staining for p16(INK4); 4 cases (13%) showed no staining for p16(INK4). None of the p16(INK4)-positive cases were positive for high-risk HPV by ISH.These results indicate that p16(INK4) expression in ESCC does not correlate with the presence of high-risk HPV DNA by ISH. High-risk HPV does not seem to play a major role in the carcinogenesis of ESCC in low-risk areas. C1 [Palazzo, Juan P.] Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA. [Hunt, Jennifer L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Palazzo, JP (reprint author), Thomas Jefferson Univ Hosp, Dept Pathol, 132 S 10th St,Room 263 Main Bldg, Philadelphia, PA 19107 USA. EM juan.palazzo@jefferson.edu NR 27 TC 11 Z9 11 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1066-8969 J9 INT J SURG PATHOL JI Int. J. Surg. Pathol. PD FEB PY 2011 VL 19 IS 1 BP 31 EP 34 DI 10.1177/1066896910382005 PG 4 WC Pathology; Surgery SC Pathology; Surgery GA 709OY UT WOS:000286451200005 PM 21087981 ER PT J AU Pineles, SL Mostoufi, SM Ready, CB Street, AE Griffin, MG Resick, PA AF Pineles, Suzanne L. Mostoufi, Sheeva M. Ready, C. Beth Street, Amy E. Griffin, Michael G. Resick, Patricia A. TI Trauma Reactivity, Avoidant Coping, and PTSD Symptoms: A Moderating Relationship? SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE posttraumatic stress disorder; avoidance; coping; psychophysiology; heart rate ID POSTTRAUMATIC-STRESS-DISORDER; INFORMATION; SCALE AB In the immediate aftermath of a traumatic event, many individuals experience physiological reactivity in response to reminders of the traumatic event that typically lessens over time. However, an overreliance on avoidant coping strategies may interfere with the natural recovery process, particularly for those who are highly reactive to trauma reminders. In the current investigation, we examined avoidant coping as a moderator of the association between heart rate reactivity to a trauma monologue measured shortly after a traumatic event and severity of posttraumatic stress disorder (PTSD) symptoms measured several months later. Fifty-five female survivors of assault completed PTSD diagnostic interviews and a self-report coping measure and participated in a trauma monologue procedure that included continuous heart rate measurement. These procedures were completed within 1 month of the assault and again 3 months postassault. After we controlled for the effect of initial symptom levels, the interaction of heart rate reactivity to the trauma monologue and avoidant coping measured at Time 1 was associated with PTSD symptom severity at Time 2. Individuals who are relatively highly reliant on avoidant coping strategies and relatively highly reactive to trauma reminders may be at greatest risk of maintaining or potentially increasing their PTSD symptoms within the first few months following the trauma. These findings may help inform early intervention efforts for survivors of traumatic events. C1 [Pineles, Suzanne L.; Mostoufi, Sheeva M.; Ready, C. Beth; Street, Amy E.; Resick, Patricia A.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA. [Pineles, Suzanne L.; Street, Amy E.; Resick, Patricia A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Griffin, Michael G.] Univ Missouri St Louis, Dept Psychol, St Louis, MO USA. [Resick, Patricia A.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. RP Pineles, SL (reprint author), VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, 150 S Huntington Ave, Boston, MA 02130 USA. EM Suzanne.Pineles@va.gov FU NIMH NIH HHS [R01 MH046992, R01 MH046992-02, R01-MH46992] NR 23 TC 38 Z9 38 U1 5 U2 16 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2011 VL 120 IS 1 BP 240 EP 246 DI 10.1037/a0022123 PG 7 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA 717VB UT WOS:000287074400022 PM 21319932 ER PT J AU Tsatsanis, KD Noens, ILJ Illmann, CL Pauls, DL Volkmar, FR Schultz, RT Klin, A AF Tsatsanis, Katherine D. Noens, Ilse L. J. Illmann, Cornelia L. Pauls, David L. Volkmar, Fred R. Schultz, Robert T. Klin, Ami TI Managing Complexity: Impact of Organization and Processing Style on Nonverbal Memory in Autism Spectrum Disorders SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE ROCF; ASD; Episodic memory; Information processing; Weak central coherence; Executive functioning ID OBSESSIVE-COMPULSIVE DISORDER; HIGH-FUNCTIONING AUTISM; VISUOSPATIAL ANALYSIS; DEVELOPMENTAL-TRENDS; CHILDREN; FIGURE; PERFORMANCE; ADHD; INDIVIDUALS; ADOLESCENTS AB The contributions of cognitive style and organization to processing and recalling a complex novel stimulus were examined by comparing the Rey Osterrieth Complex Figure (ROCF) test performance of children, adolescents, and adults with ASD to clinical controls (CC) and non-impaired controls (NC) using the Developmental Scoring System. The ROCF task involves a complex structure with strong organizational or integrative processing demands. The individuals with ASD relied on a predominantly part-oriented strategy to cope with the complexity of the task and did not make the typical developmental shift to a configurational approach. Both processing style and organization (whether pieces of information were perceived as connected to one another in a meaningful way) contributed to structural recall in the ASD group. C1 [Tsatsanis, Katherine D.; Volkmar, Fred R.; Klin, Ami] Yale Child Study Ctr, New Haven, CT 06520 USA. [Noens, Ilse L. J.; Illmann, Cornelia L.; Pauls, David L.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Noens, Ilse L. J.] Katholieke Univ Leuven, Parenting & Special Educ Res Grp, B-3000 Louvain, Belgium. [Noens, Ilse L. J.] Katholieke Univ Leuven, Leuven Autism Res Org, B-3000 Louvain, Belgium. [Schultz, Robert T.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RP Tsatsanis, KD (reprint author), Yale Child Study Ctr, 230 S Frontage Rd, New Haven, CT 06520 USA. EM katherine.tsatsanis@yale.edu; Ilse.Noens@ped.kuleuven.be FU NICHD NIH HHS [U19HD35482]; NIMH NIH HHS [MH000508]; NINDS NIH HHS [NS16648] NR 42 TC 5 Z9 5 U1 6 U2 24 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD FEB PY 2011 VL 41 IS 2 BP 135 EP 147 DI 10.1007/s10803-010-1139-z PG 13 WC Psychology, Developmental SC Psychology GA 708WH UT WOS:000286394500001 PM 21128108 ER PT J AU Osawa, R Williams, KL Singh, N AF Osawa, Ryosuke Williams, Kristi L. Singh, Nina TI The inflammasome regulatory pathway and infections: Role in pathophysiology and clinical implications SO JOURNAL OF INFECTION LA English DT Review DE Innate immunity; Inflammasome; Infection; IL-1 beta ID INTERLEUKIN-1-BETA CONVERTING-ENZYME; FAMILIAL MEDITERRANEAN FEVER; CRYPTOCOCCUS-NEOFORMANS INFECTION; LEGIONELLA-PNEUMOPHILA INFECTION; COLD AUTOINFLAMMATORY SYNDROME; PATHOGEN CANDIDA-ALBICANS; MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; ANTHRAX LETHAL TOXIN; HOST-DEFENSE AB The innate immune system serves to generate immediate host defenses against pathogens. Advance in the mechanism of innate immunity has provided new insights into host-pathogen microbial interactions. The cytosolic multi-protein complex called the inflammasome, which regulates the caspase-1 dependent processing of inflammatory cytokines IL-1 beta and IL-18, is critical for the innate defense against pathogens. We summarize the current knowledge regarding the regulatory functions of the inflammasome in the pathogenesis of infections by various microbes (e.g., bacteria, fungi, viruses, and protozoa), and discuss its potential application in a clinical setting. Understanding of the unique role of the inflammasome signaling pathway in initiating and regulating inflammation is pivotal for the development of innovative approaches to optimize management of these infections. (C) 2010 The British Infection Association. Published by Elsevier Ltd. All rights reserved. C1 [Singh, Nina] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Dept Med, Pittsburgh, PA 15240 USA. [Osawa, Ryosuke; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. [Williams, Kristi L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Dept Med, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu FU Southeast Regional Center of Excellence for Emerging Infections and Biodefense (SERCEB); NIH [R56 AI089756]; Center for Comparative Biology of Vulnerable Populations (CCBVP) FX KLW was supported by grants from Southeast Regional Center of Excellence for Emerging Infections and Biodefense (SERCEB) and Center for Comparative Biology of Vulnerable Populations (CCBVP), and the NIH (R56 AI089756). NR 134 TC 15 Z9 16 U1 1 U2 5 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 J9 J INFECTION JI J. Infect. PD FEB PY 2011 VL 62 IS 2 BP 119 EP 129 DI 10.1016/j.jinf.2010.10.002 PG 11 WC Infectious Diseases SC Infectious Diseases GA 716NR UT WOS:000286981200002 PM 20950647 ER PT J AU Adams, JM AF Adams, Jeffrey M. TI The Emergence of Nurse Executive Influence in Practice An Interview With Joyce Clifford SO JOURNAL OF NURSING ADMINISTRATION LA English DT Editorial Material AB This department highlights nursing leaders who have demonstrated the ability to inspire and lead change. This competency is seen in the ability to create, structure, and implement organizational change through strategic vision, risk taking, and effective communication. In this article, the author showcases the work of Joyce Clifford, PhD, RN, FAAN. C1 Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, Boston, MA 02114 USA. RP Adams, JM (reprint author), Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, 275 Cambridge St,POB 4, Boston, MA 02114 USA. EM jadams9@partners.org NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD FEB PY 2011 VL 41 IS 2 BP 55 EP 57 DI 10.1097/NNA.0b013e31820594db PG 3 WC Nursing SC Nursing GA 711IT UT WOS:000286584700003 ER PT J AU Gorlin, A Susarla, SM Chatburn, J Jiang, YD AF Gorlin, Andrew Susarla, Srinivas M. Chatburn, Jennifer Jiang, Yandong TI Use of a Second Fiberoptic Bronchoscope to Guide Oral Fiberoptic Intubation in 2 Patients With Existing Vocal Cord Injury SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID DIFFICULT AIRWAY; MANAGEMENT C1 [Gorlin, Andrew; Chatburn, Jennifer; Jiang, Yandong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Susarla, Srinivas M.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. RP Jiang, YD (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM yjiang@partners.org OI Susarla, Srinivas/0000-0003-0155-8260 NR 8 TC 1 Z9 1 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD FEB PY 2011 VL 69 IS 2 BP 546 EP 550 DI 10.1016/j.joms.2010.09.012 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 716VV UT WOS:000287002500035 PM 21238850 ER PT J AU Boggess, KA Espinola, JA Moss, K Beck, J Offenbacher, S Camargo, CA AF Boggess, Kim A. Espinola, Janice A. Moss, Kevin Beck, Jim Offenbacher, Steven Camargo, Carlos A., Jr. TI Vitamin D Status and Periodontal Disease Among Pregnant Women SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Periodontal diseases; pregnancy; vitamin D ID ADULTS 30 YEARS; SERUM CONCENTRATIONS; UNITED-STATES; CIRCULATING 25-HYDROXYVITAMIN-D; PRETERM DELIVERY; CUTTING EDGE; RISK; AGE; ASSOCIATION; INFECTIONS AB Background: Maternal periodontal disease is found in <= 40% of pregnant women and is associated with adverse pregnancy outcomes. Vitamin D deficiency may play a role in periodontal disease and tooth loss, and insufficient vitamin D status is common among pregnant women. The objective of this study is to examine the relationship between maternal vitamin D status and periodontal disease. Methods: A case-control study was conducted. Cases were defined as pregnant women with clinical moderate to severe periodontal disease; controls were pregnant women who were periodontally healthy. Maternal data were chart abstracted and serum was collected between 14 and 26 weeks of gestation. Serum 25-hydroxyvitamin D (25[OH]D) levels were measured using liquid chromatography tandem mass spectrometry. Median serum 25(OH)D levels and prevalence of vitamin D insufficiency (defined as <75 nmol/l) were compared between cases and controls. The odds ratio and 95% confidence interval for moderate to severe periodontal disease among women with vitamin D insufficiency was calculated using multivariable logistic regression, adjusting for maternal race, season of blood draw, and other potential confounders. Results: A total of 117 cases were compared to 118 controls. Cases had lower median 25(OH)D levels than controls (59 versus 100 nmol/l; P<0.001) and were more likely to have vitamin D insufficiency (65% versus 29%; P<0.001). The adjusted odds ratio (95% confidence interval) for moderate to severe periodontal disease among women with vitamin D insufficiency was 2.1 (0.99 to 4.5). Conclusions: Vitamin D insufficiency (serum 25[OH]D <75 nmol/l) is associated with maternal periodontal disease during pregnancy. Vitamin D supplementation represents a potential therapeutic strategy to improve maternal oral health. J Periodontol 2011;82:195-200. C1 [Boggess, Kim A.] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC 27599 USA. [Espinola, Janice A.; Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. [Moss, Kevin; Beck, Jim] Univ N Carolina, Dept Dent Ecol, Chapel Hill, NC 27599 USA. [Offenbacher, Steven] Univ N Carolina, Dept Periodontol, Chapel Hill, NC 27599 USA. RP Boggess, KA (reprint author), Univ N Carolina, Dept Obstet & Gynecol, Campus Box 7570,3010 Old Clin Bldg, Chapel Hill, NC 27599 USA. EM kboggess@med.unc.edu FU Massachusetts General Hospital Center for D-receptor Activation Research FX This article was funded by the Massachusetts General Hospital Center for D-receptor Activation Research. The authors report no conflicts of interest related to this study. NR 40 TC 30 Z9 30 U1 3 U2 8 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD FEB PY 2011 VL 82 IS 2 BP 195 EP 200 DI 10.1902/JOP.2010.100384 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 716YG UT WOS:000287008800002 PM 20809861 ER PT J AU Ligibel, JA AF Ligibel, Jennifer A. TI Role of Adjuvant and Posttreatment Exercise Programs in Breast Health SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article DE Exercise; physical activity; breast cancer; adjuvant ID INDUCED MAMMARY CARCINOGENESIS; RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY; CANCER SURVIVORS; POSTMENOPAUSAL WOMEN; GROWTH-FACTORS; C-PEPTIDE; RISK; INSULIN; METAANALYSIS AB Growing evidence suggests that physical activity may be an important part of survivorship care for women with a history of breast cancer. Observational evidence suggests that women who are physically active after breast cancer diagnosis have a 30% to 50% lower risk of breast cancer recurrence, breast cancer death, and overall death compared with sedentary individuals. Although randomized controlled trials have not been performed to test the ability of exercise to improve outcomes in women with early-stage breast cancer, many small intervention studies have shown the safety and potential benefits of exercise in the adjuvant and posttreatment settings. These studies have shown that physical activity can be performed safely both during and after adjuvant treatment for breast cancer, and that women who increase physical activity in these settings experience improvements in fitness, strength, quality of life, and other end points. Although more research is needed to fully define the role of exercise in breast cancer survivors, the many proven benefits of physical activity have led the American Cancer Society and American College of Sports Medicine to encourage regular participation in moderate-intensity recreational activity for most breast cancer survivors. This article reviews the growing evidence that exercise could be an important part of breast cancer survivorship, and describes current exercise guidelines for breast cancer survivors. (JNCCN 2011;9:251-256) C1 [Ligibel, Jennifer A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ligibel, Jennifer A.] Harvard Univ, Sch Med, Boston, MA USA. RP Ligibel, JA (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM jligibel@partners.org NR 34 TC 6 Z9 6 U1 1 U2 2 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD FEB PY 2011 VL 9 IS 2 BP 251 EP 256 PG 6 WC Oncology SC Oncology GA 729IU UT WOS:000287942900006 PM 21310846 ER PT J AU Burstein, HJ AF Burstein, Harold J. TI Take Your Medicine SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Editorial Material C1 [Burstein, Harold J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Burstein, Harold J.] Dana Farber Canc Inst, Boston, MA USA. [Burstein, Harold J.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Burstein, HJ (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD FEB PY 2011 VL 9 SU 3 BP S1 EP S1 PG 1 WC Oncology SC Oncology GA 729IV UT WOS:000287943000001 PM 21357661 ER PT J AU Durant, RW Legedza, AT Marcantonio, ER Freeman, MB Landon, BE AF Durant, Raegan W. Legedza, Anna T. Marcantonio, Edward R. Freeman, Marcie B. Landon, Bruce E. TI Different Types of Distrust in Clinical Research Among Whites and African Americans SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE trust; clinical research ID HEALTH-CARE-SYSTEM; MEDICAL-RESEARCH; RACIAL-DIFFERENCES; PARTICIPATION; TRIALS; TRUST; RACE; ATTITUDES; WILLINGNESS; PERCEPTIONS AB Background: African Americans are thought to be more distrustful of clinical research compared to elderly whites, but it is unknown whether specific types of distrust in clinical research, such as interpersonal or societal distrust, vary according to race. The primary objective was to identify racial differences in interpersonal or societal distrust in clinical research among African Americans and whites. Methods: Seven hundred seventy-six older African Americans and whites were surveyed about their interpersonal and societal distrust using a 7-item index of distrust in clinical research. We combined the 2 societal distrust items into a societal distrust subscale. We also assessed trust in primary care physicians, access to care, health/functional status, previous exposure to clinical research, awareness of the Tuskegee Syphilis Study, perceived discrimination in health care, and sociodemographic characteristics. Results: High societal distrust was more common among African Americans compared to whites (21% vs 7% in the top quartile of the societal distrust, p < .0001), but there were no racial differences in responses to the individual interpersonal distrust index items. In sequentially built multivariable analyses, the relationship between African American race and societal distrust (odds ratio, 2.2; 95% CI, 1.2-3.7) was not completely explained by other factors such as trust in one's physician, previous discrimination, or awareness of the Tuskegee Syphilis Study. Conclusions: Racial differences according to the type of distrust in clinical research may warrant assessing specific types of distrust separately among racially diverse populations in future studies. C1 [Durant, Raegan W.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL 35205 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Legedza, Anna T.] Vertex Pharmaceut, Biometr Dept, Cambridge, MA USA. [Marcantonio, Edward R.; Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Freeman, Marcie B.] Inst Aging Res, Boston, MA USA. [Landon, Bruce E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. RP Durant, RW (reprint author), Univ Alabama Birmingham, Div Prevent Med, 1717 11th Ave S,MT 607, Birmingham, AL 35205 USA. EM rdurant@dopm.uab.edu FU Health Resources and Services Administration [2 T32 HP11001-15]; National Institute on Aging [5 P01 AG04390]; Older Americans Independence Center [2 P60 AG08812]; Massachusetts Alzheimer's Disease Research Center [2 P50 AG05134] FX Supported by a grants from the Health Resources and Services Administration (2 T32 HP11001-15), National Institute on Aging (5 P01 AG04390), Older Americans Independence Center (2 P60 AG08812), and Massachusetts Alzheimer's Disease Research Center (2 P50 AG05134). NR 25 TC 18 Z9 20 U1 3 U2 14 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 EI 1943-4693 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD FEB PY 2011 VL 103 IS 2 BP 123 EP 130 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 728YI UT WOS:000287910000005 PM 21443064 ER PT J AU Stone, JH AF Stone, John H. TI BLISS! Lupus learns its lessons SO LANCET LA English DT Editorial Material ID ERYTHEMATOSUS; INDEX C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Rheumatol Unit, Boston, MA 02114 USA. RP Stone, JH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Rheumatol Unit, Boston, MA 02114 USA. EM jhstone@partners.org NR 6 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD FEB-MAR PY 2011 VL 377 IS 9767 BP 693 EP 694 DI 10.1016/S0140-6736(10)61546-2 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 729JQ UT WOS:000287946000004 PM 21296404 ER PT J AU Singer, SJ Burgers, J Friedberg, M Rosenthal, MB Leape, L Schneider, E AF Singer, Sara J. Burgers, Jako Friedberg, Mark Rosenthal, Meredith B. Leape, Lucian Schneider, Eric TI Defining and Measuring Integrated Patient Care: Promoting the Next Frontier in Health Care Delivery SO MEDICAL CARE RESEARCH AND REVIEW LA English DT Article DE integration; coordination; patient centeredness; delivery system reform; integrated patient care ID PROVIDER ORGANIZATIONS; MEDICAL HOME; COLLABORATION; COMMUNICATION; READMISSIONS; PERFORMANCE; EXPERIENCE; MANAGEMENT; QUALITY; SYSTEMS AB Integration of care is emerging as a central challenge of health care delivery, particularly for patients with multiple, complex chronic conditions. The authors argue that the concept of "integrated patient care" would benefit from further clarification regarding (a) the object of integration and (b) its essential components, particularly when constructing measures. To address these issues, the authors propose a definition of integrated patient care that distinguishes it from integrated delivery organizations, acknowledging that integrated organizational structures and processes may fail to produce integrated patient care. The definition emphasizes patients' central role as active participants in managing their own health by including patient centeredness as a key element of integrated patient care. Measures based on the proposed definition will enable empirical assessment of the potential relationships between the integration of organizations, the integration of patient care, and patient outcomes, providing valuable guidance to health systems reformers. C1 [Singer, Sara J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Singer, Sara J.] Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. [Burgers, Jako] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. [Friedberg, Mark] RAND Corp, Santa Monica, CA USA. [Schneider, Eric] RAND, Boston, MA USA. RP Singer, SJ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA. EM ssinger@hsph.harvard.edu OI Rosenthal, Meredith/0000-0003-3410-0184; Schneider, Eric/0000-0002-1132-5084 FU Kaiser Permanente Institute for Health Policy; Harkness fellowship; Commonwealth Fund FX The authors disclosed that they received the following support for their research and/or authorship of this article: Financial support of these activities was generously provided by the Kaiser Permanente Institute for Health Policy. Support for Jako Burgers was provided through a 2008-2009 Harkness fellowship, supported by the Commonwealth Fund. NR 48 TC 69 Z9 71 U1 2 U2 21 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-5587 J9 MED CARE RES REV JI Med. Care Res. Rev. PD FEB PY 2011 VL 68 IS 1 BP 112 EP 127 DI 10.1177/1077558710371485 PG 16 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 709FC UT WOS:000286422300008 PM 20555018 ER PT J AU Kontos, EZ Viswanath, K AF Kontos, Emily Z. Viswanath, K. TI Cancer-related direct-to-consumer advertising: a critical review SO NATURE REVIEWS CANCER LA English DT Review ID PRESCRIPTION DRUG ADVERTISEMENTS; MANAGED CARE ORGANIZATION; HEREDITARY BREAST; OVARIAN-CANCER; GENETIC TESTS; INFORMATION; HEALTH; IMPACT; PHYSICIANS; STATEMENT AB The direct-to-consumer advertising (DTCA) phenomenon has received attention because of its attempt to reach out to consumers by bypassing important gatekeepers such as physicians. The emergence of new information platforms and the introduction of genetic tests directly to the consumer have heightened the concern with DTCA and its potential consequences. These effects of DTCA are particularly important given the communication inequalities among social groups, with class, race and ethnicity influencing how people access, seek, process and act on information. This Science and Society article reviews the major issues regarding general and cancer-related DTCA and also offers data from a national survey in the United States as an example of the communication inequalities in genetic testing awareness. C1 [Kontos, Emily Z.; Viswanath, K.] Harvard Univ, Sch Publ Hlth, Lung Canc Dispar Ctr, Dept Soc Human Dev & Hlth, Boston, MA 02215 USA. [Viswanath, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Viswanath, K (reprint author), Harvard Univ, Sch Publ Hlth, Lung Canc Dispar Ctr, Dept Soc Human Dev & Hlth, 401 Pk Dr,Room 403F, Boston, MA 02215 USA. EM vish_viswanath@dfci.harvard.edu FU Dana-Farber/Harvard Cancer Center FX The authors would like to thank the Dana-Farber/Harvard Cancer Center for support to K.V. NR 58 TC 22 Z9 23 U1 0 U2 16 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-175X J9 NAT REV CANCER JI Nat. Rev. Cancer PD FEB PY 2011 VL 11 IS 2 BP 142 EP 150 DI 10.1038/nrc2999 PG 9 WC Oncology SC Oncology GA 710JC UT WOS:000286506700014 PM 21258398 ER PT J AU Gerding, DN Johnson, S AF Gerding, Dale N. Johnson, Stuart TI CLOSTRIDIUM DIFFICILE INFECTION IN 2010 Advances in pathogenesis, diagnosis and management of CDI SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY LA English DT Editorial Material ID TOXIN-B; STRAIN C1 [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Johnson, Stuart] Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA. RP Gerding, DN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Bldg 1,Room C344,5000 S 5th Ave, Hines, IL 60141 USA. EM dale.gerding2@va.gov NR 10 TC 8 Z9 8 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5045 J9 NAT REV GASTRO HEPAT JI Nat. Rev. Gastroenterol. Hepatol. PD FEB PY 2011 VL 8 IS 2 BP 67 EP 68 DI 10.1038/nrgastro.2010.215 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 716LL UT WOS:000286970000001 PM 21293502 ER PT J AU Greer, D Scripko, P Bartscher, J Sims, J Camargo, E Singhal, A Furie, K AF Greer, David Scripko, Patricia Bartscher, James Sims, John Camargo, Erica Singhal, Aneesh Furie, Karen TI Serial MRI Changes in Comatose Cardiac Arrest Patients SO NEUROCRITICAL CARE LA English DT Article DE Cardiac arrest; Coma; Neuroimaging; Prognosis; DWI; MRI ID CEREBRAL-ISCHEMIA; DIFFUSION MRI; WHITE-MATTER; BRAIN-INJURY; PREDICTION; SURVIVORS; ENCEPHALOPATHY; RESUSCITATION; INFARCTION; STROKE AB Neuroimaging may prove useful in identifying cardiac arrest patients destined for a poor recovery, as certain patterns have been associated with a poor outcome. However, MRI changes evolve temporally and spatially, which may lead to misinterpretation and misclassification of patients. Eight comatose patients following cardiac arrest underwent diffusion-weighted imaging (DWI) at two time points, and one patient underwent DWI at three time points. Each of the prespecified areas of each study were read as either "normal" or "abnormal" by two stroke neurologists. Neurological examinations, including GCS scores, were recorded on days 0, 1, 3, and 7. Outcomes were determined by the modified Rankin Scale (mRS), with poor outcome defined as mRS score a parts per thousand yen4 at 6 months. In the acute (< 24 h) period, two patients exhibited changes on DWI and FLAIR in the cerebellum and basal ganglia. In the early subacute period (days 1-5), cortical abnormalities predominated, with a shift to more white matter changes in the late subacute period (days 6-12). We observed more widespread imaging abnormalities in patients with poor outcomes, and partial or full resolution of DWI abnormalities in the two patients with good outcomes. MRI patterns after global hypoxic-ischemic injury follow a characteristic pattern with variable acute changes in the cortex, basal ganglia, and cerebellum, followed by predominantly cortical and white matter changes in the early and late subacute periods. Diffuse, persistent widespread changes on MRI may help to predict poor outcome. C1 [Greer, David] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06530 USA. [Scripko, Patricia; Bartscher, James; Sims, John; Camargo, Erica; Singhal, Aneesh; Furie, Karen] Massachusetts Gen Hosp, Stroke Serv, Boston, MA 02114 USA. RP Greer, D (reprint author), Yale Univ, Sch Med, Dept Neurol, 15 York St, New Haven, CT 06530 USA. EM david.greer@yale.edu NR 28 TC 16 Z9 17 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 J9 NEUROCRIT CARE JI Neurocrit. Care PD FEB PY 2011 VL 14 IS 1 BP 61 EP 67 DI 10.1007/s12028-010-9457-8 PG 7 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA 708WF UT WOS:000286394300010 PM 20931362 ER PT J AU Kacmarek, RM AF Kacmarek, Robert M. TI Proportional Assist Ventilation and Neurally Adjusted Ventilatory Assist SO RESPIRATORY CARE LA English DT Article DE patient-ventilator synchrony; assisted ventilation; work of breathing; diaphragmatic electromyogram; EMG ID PRESSURE-SUPPORT VENTILATION; ACUTE RESPIRATORY-FAILURE; OBSTRUCTIVE PULMONARY-DISEASE; BIRTH-WEIGHT INFANTS; CRITICALLY-ILL PATIENTS; END-EXPIRATORY PRESSURE; ACUTE LUNG INJURY; MECHANICAL VENTILATION; BREATHING PATTERN; GAIN FACTORS AB Patient-ventilator synchrony is a common problem with all patients actively triggering the mechanical ventilator. In many cases synchrony can be improved by vigilant adjustments by the managing clinician. However, in most institutions clinicians are not able to spend the time necessary to ensure synchrony in all patients. Proportional assist ventilation (PAY) and neurally adjusted ventilatory assist (NAVA) were both developed to improve patient-ventilator synchrony by proportionally unloading ventilatory effort and turning control of the ventilatory pattern over to the patient. This paper discusses PAV's and NAVA's theory of operation, general process of application, and the supporting literature. C1 [Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Anesthesiol, Boston, MA 02114 USA. [Kacmarek, Robert M.] Harvard Univ, Sch Med, Boston, MA USA. RP Kacmarek, RM (reprint author), Massachusetts Gen Hosp, Dept Anesthesiol, Ellison 401,55 Fruit St, Boston, MA 02114 USA. EM rkacmarek@partners.org NR 71 TC 28 Z9 33 U1 0 U2 6 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD FEB PY 2011 VL 56 IS 2 SI SI BP 140 EP 148 DI 10.4187/respcare.01021 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 729NY UT WOS:000287958700004 PM 21333175 ER PT J AU Hess, DR AF Hess, Dean R. TI Patient-Ventilator Interaction During Noninvasive Ventilation SO RESPIRATORY CARE LA English DT Article DE asynchrony; noninvasive ventilation; mechanical ventilation; patient-ventilator interactions ID ADAPTIVE SERVO-VENTILATION; POSITIVE-PRESSURE VENTILATION; CHEYNE-STOKES RESPIRATION; CONGESTIVE-HEART-FAILURE; INSPIRATORY FLOW-RATE; CENTRAL SLEEP-APNEA; OBSTRUCTIVE PULMONARY-DISEASE; SUPPORT VENTILATION; MECHANICAL VENTILATION; AIRWAY PRESSURE AB There is arguably more evidence to support the use of noninvasive ventilation (NIV) than any other practice related to the care of patients with acute respiratory failure. Despite this strong evidence base, NIV seems to be under-utilized and the failure rate (need for intubation) may be as high as 40%. Some of these failures potentially relate to asynchrony, although the relationship between asynchrony and NIV failure has not been well studied. Good NW tolerance has been associated with success of NW, and improved comfort has been associated with better synchrony. In one study a high rate of asynchrony occurred in 43% of patients during NIV. Asynchrony is commonly associated with leaks. Thus, reducing the leak related to the interface and using a ventilator with good leak compensation should reduce the rate of asynchrony. Asynchronies can also be related to the underlying disease process. This paper reviews issues related to asynchrony during NW and suggests strategies that might be used to correct asynchrony when it occurs. C1 Harvard Univ, Resp Care Serv, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Hess, DR (reprint author), Harvard Univ, Resp Care Serv, Massachusetts Gen Hosp, Sch Med, Ellison 401,55 Fruit St, Boston, MA 02114 USA. EM dhess@partners.org NR 89 TC 27 Z9 28 U1 0 U2 9 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD FEB PY 2011 VL 56 IS 2 SI SI BP 153 EP 165 DI 10.4187/respcare.01049 PG 13 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 729NY UT WOS:000287958700006 PM 21333176 ER PT J AU Ko, CW Mhsa, JAD Green, P Baldwin, LM AF Ko, Cynthia W. Mhsa, Jason A. DominitzMd Green, Pam Baldwin, Laura-Mae TI Effect of Annual Colonoscopy Volume and Years in Practice on Polyp Detection and Removal Reply SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter ID ADENOMA DETECTION C1 [Ko, Cynthia W.; Mhsa, Jason A. DominitzMd] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Mhsa, Jason A. DominitzMd] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Green, Pam; Baldwin, Laura-Mae] Univ Washington, Dept Family Med, Seattle, WA 98195 USA. RP Ko, CW (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. NR 3 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD FEB PY 2011 VL 124 IS 2 BP E17 EP E18 DI 10.1016/j.amjmed.2010.09.010 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 725PO UT WOS:000287658100009 ER PT J AU Johnson, JM Moonis, G Green, GE Carmody, R Burbank, HN AF Johnson, J. M. Moonis, G. Green, G. E. Carmody, R. Burbank, H. N. TI Syndromes of the First and Second Branchial Arches, Part 2: Syndromes SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Review ID TREACHER-COLLINS-SYNDROME; AURICULO-CONDYLAR SYNDROME; 22Q11.2 DELETION SYNDROME; PIERRE-ROBIN-SEQUENCE; QUESTION MARK EAR; HEMIFACIAL MICROSOMIA; STICKLER-SYNDROME; CLEFT-PALATE; ANOMALIES; DIAGNOSIS AB A variety of congenital syndromes affecting the face occur due to defects involving the first and second BAs. Radiographic evaluation of craniofacial deformities is necessary to define aberrant anatomy, plan surgical procedures, and evaluate the effects of craniofacial growth and surgical reconstructions. High-resolution CT has proved vital in determining the nature and extent of these syndromes. The radiologic evaluation of syndromes of the first and second BA should begin first by studying a series of isolated defects (cleft lip with or without CP, micrognathia, and EAC atresia) that compose the major features of these syndromes and allow a more specific diagnosis. After discussion of these defects and the associated embryology, we discuss PRS, HFM, ACS, TCS, Stickler syndrome, and VCFS. C1 [Johnson, J. M.; Burbank, H. N.] Fletcher Allen Hlth Care, Dept Radiol, Div Neuroradiol, Burlington, VT 05401 USA. [Moonis, G.] Harvard Univ, Sch Med, Dept Radiol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Med, Mass Eye & Ear Infirm, Boston, MA 02115 USA. [Green, G. E.] Univ Michigan, Dept Pediat Otolaryngol, Ann Arbor, MI 48109 USA. [Carmody, R.] Univ Arizona, Dept Radiol, Div Neuroradiol, Tucson, AZ 85724 USA. RP Johnson, JM (reprint author), Fletcher Allen Hlth Care, Dept Radiol, Div Neuroradiol, 111 Colchester Ave, Burlington, VT 05401 USA. EM Jason.Johnson@vtmednet.org NR 63 TC 8 Z9 10 U1 1 U2 11 PU AMER SOC NEURORADIOLOGY PI OAK BROOK PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA SN 0195-6108 J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD FEB PY 2011 VL 32 IS 2 BP 230 EP 237 DI 10.3174/ajnr.A2073 PG 8 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 727CX UT WOS:000287776200004 PM 20360348 ER PT J AU Mohamed, FB Hunter, LN Barakat, N Liu, CSJ Sair, H Samdani, AF Betz, RR Faro, SH Gaughan, J Mulcahey, MJ AF Mohamed, F. B. Hunter, L. N. Barakat, N. Liu, C. -S. J. Sair, H. Samdani, A. F. Betz, R. R. Faro, S. H. Gaughan, J. Mulcahey, M. J. TI Diffusion Tensor Imaging of the Pediatric Spinal Cord at 1.5T: Preliminary Results SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID NEUROLOGICAL CLASSIFICATION; INTERNATIONAL STANDARDS; INJURY; CHILDREN; CORRELATE; AGE AB BACKGROUND AND PURPOSE: Recent studies suggest that pediatric subjects as old as 8-years-of-age may have difficulty with the ISNCSCI examinations. Our aim was to investigate DTI parameters of healthy spinal cord in children with noncervical IS for comparison with children with SCI and to prospectively evaluate reliability measures of DTI and to correlate the measures obtained in children with SCI with the ISNCSCI. MATERIALS AND METHODS: Five controls with thoracic and lumbar IS and 5 children with cervical SCI were imaged twice by using a single-shot echo-planar diffusion-weighted sequence. Axial imaging was performed to cover the entire cervical spinal cord in controls. For the SCI subjects, 2 vertebral bodies above and below the injury were imaged. FA and D values were obtained at different levels of the cervical spinal cord. All subjects with SCI had undergone ISNCSCI clinical examinations. Statistical analysis was performed to access differences of the DTI indices between the controls and SCI subjects, reproducibility measurements, and correlations between DTI and ISNCSCI. RESULTS: Subjects with SCI showed reduced FA and increased D values compared with controls. Test-retest reproducibility showed good ICC coefficients in all the DTI index values among controls (>= 0.9), while the SCI group showed moderate ICC (>= 0.77). There were statistically significant correlations between the various DTI indices and ISNCSCI scores. CONCLUSIONS: Preliminary DTI indices in children were determined and showed good reproducibility. Reduced FA and increased D values were seen in children with SCI in comparison with controls and showed good clinical correlation with ISNCSCI examinations. C1 [Mohamed, F. B.; Barakat, N.; Liu, C. -S. J.; Faro, S. H.] Temple Univ, Sch Med, Dept Radiol, Philadelphia, PA 19140 USA. [Gaughan, J.] Temple Univ, Sch Med, Biostat Consulting Ctr, Philadelphia, PA 19140 USA. [Hunter, L. N.; Samdani, A. F.; Betz, R. R.; Mulcahey, M. J.] Shriners Hosp Children, Philadelphia, PA USA. [Sair, H.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Mohamed, FB (reprint author), Temple Univ, Sch Med, Dept Radiol, 3401 N Broad St, Philadelphia, PA 19140 USA. EM feroze@temple.edu FU Shriners Hospitals for Children [8956] FX The study was funded by the Shriners Hospitals for Children, grant 8956. (M.J.M., Principal Investigator). NR 18 TC 22 Z9 23 U1 0 U2 3 PU AMER SOC NEURORADIOLOGY PI OAK BROOK PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA SN 0195-6108 J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD FEB PY 2011 VL 32 IS 2 BP 339 EP 345 DI 10.3174/ajnr.A2334 PG 7 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 727CX UT WOS:000287776200022 PM 21233227 ER PT J AU Kuschner, WG AF Kuschner, Ware G. TI Palliative Care for Pulmonary Patients SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter C1 [Kuschner, Ware G.] US Dept Vet Affairs, Palo Alto, CA USA. [Kuschner, Ware G.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Kuschner, WG (reprint author), US Dept Vet Affairs, Palo Alto, CA USA. NR 1 TC 0 Z9 0 U1 0 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2011 VL 183 IS 3 BP 416 EP 416 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 720QD UT WOS:000287294300025 PM 21288868 ER PT J AU Abujudeh, HH Kaewlai, R McMahon, PM Binder, W Novelline, RA Gazelle, GS Thrall, JH AF Abujudeh, Hani H. Kaewlai, Rathachai McMahon, Pamela M. Binder, William Novelline, Robert A. Gazelle, G. Scott Thrall, James H. TI Abdominopelvic CT Increases Diagnostic Certainty and Guides Management Decisions: A Prospective Investigation of 584 Patients in a Large Academic Medical Center SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE acute abdomen; CT; diagnostic imaging; emergency department; physician diagnostic certainty; sensitivity and specificity ID ACUTE ABDOMINAL-PAIN; EMERGENCY-DEPARTMENT; COMPUTED-TOMOGRAPHY; IMPACT AB OBJECTIVE. The objective of our study was to prospectively determine how CT affects physicians' diagnostic certainty and management decisions in the setting of patients with nontraumatic abdominal complaints presenting to the emergency department. SUBJECTS AND METHODS. We included 584 patients presenting with nontraumatic abdominal complaints to the emergency department from November 2006 through February 2008. Emergency department clinicians were prospectively surveyed both before abdominal CT (pre-CT) and after abdominal CT (post-CT) to determine the leading diagnosis, the diagnostic certainty, and the management decisions. Changes were assessed by Fisher's exact test and the log likelihood ratio. RESULTS. The most common diagnoses were renal colic (119/584, 20.4%) and intestinal obstruction (80/584, 13.7%). CT altered the leading diagnosis in 49% of the patients (284/584, p < 0.00001) and increased mean physician diagnostic certainty from 70.5% (pre-CT) to 92.2% (post-CT) (p < 0.001; log likelihood ratio, 2.48). The management plan was changed by CT in 42% (244/583) (p < 0.0001). Physicians planned to admit 75.3% of the patients (440/584) to the hospital before CT; that plan was changed to hospital discharge with follow-up in 24.1% of patients (106/440) after CT. Surgery was planned for 79 patients before CT, whereas hospital discharge was planned for 25.3% of these patients (20/79) after CT. CONCLUSION. In the management of patients presenting to the emergency department with nontraumatic abdominal complaints, CT changes the leading diagnosis, increases diagnostic certainty, and changes potential patient management decisions. C1 [Abujudeh, Hani H.; Kaewlai, Rathachai; McMahon, Pamela M.; Novelline, Robert A.; Gazelle, G. Scott; Thrall, James H.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Abujudeh, Hani H.; Kaewlai, Rathachai; McMahon, Pamela M.; Binder, William; Novelline, Robert A.; Gazelle, G. Scott; Thrall, James H.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [McMahon, Pamela M.; Gazelle, G. Scott] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Binder, William] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Abujudeh, HH (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Founders 213D, Boston, MA 02114 USA. EM habujudeh@partners.org OI Kaewlai, Rathachai/0000-0002-0650-9380 NR 27 TC 30 Z9 30 U1 0 U2 4 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2011 VL 196 IS 2 BP 238 EP 243 DI 10.2214/AJR.10.4467 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 718OZ UT WOS:000287135600002 PM 21257870 ER PT J AU Pectasides, M Kalva, SP AF Pectasides, Melina Kalva, Sanjeeva P. TI Diabetes Revealed: Multisystem Danger SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE diabetes; fatty infiltration; imaging; obesity; polycystic ovary disease; pregnancy ID FATTY LIVER-DISEASE; POLYCYSTIC-OVARY-SYNDROME; MULTIDETECTOR-ROW CT; MACROVESICULAR HEPATIC STEATOSIS; PERIPHERAL ARTERIAL-DISEASE; RENAL PAPILLARY NECROSIS; LYMPH-NODE METASTASES; ENDOMETRIAL CANCER; 3-DIMENSIONAL ULTRASONOGRAPHY; TRANSVAGINAL ULTRASONOGRAPHY AB OBJECTIVE. The purpose of this article is to review the role of diagnostic imaging in the evaluation of women with diabetes. CONCLUSION. Diabetic patients present a challenging population for the performance of various imaging studies and special considerations need to be made to obtain adequate studies. Imaging plays a significant role in assessing the multisystem morbidity of diabetes. Furthermore, diabetes in women may have some unique features and consequences and imaging studies can aid in the correct management of these patients. C1 [Pectasides, Melina; Kalva, Sanjeeva P.] Massachusetts Gen Hosp, Dept Imaging, Boston, MA 02114 USA. [Pectasides, Melina; Kalva, Sanjeeva P.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. RP Kalva, SP (reprint author), Massachusetts Gen Hosp, Dept Imaging, 55 Fruit St,GRB 297, Boston, MA 02114 USA. EM skalva@partners.org NR 110 TC 1 Z9 1 U1 0 U2 2 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2011 VL 196 IS 2 BP 274 EP 286 DI 10.2214/AJR.10.5922 PG 13 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 718OZ UT WOS:000287135600009 PM 21257877 ER PT J AU Boland, GWL AF Boland, Giles W. L. TI Adrenal Imaging: Why, When, What, and How? Part 3. The Algorithmic Approach to Definitive Characterization of the Adrenal Incidentaloma SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE adrenal; biopsy; CT; MRI; PET/CT ID MASSES; CT; MALIGNANCY; LESIONS; PET/CT C1 [Boland, Giles W. L.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Boland, Giles W. L.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Boland, GWL (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,White 270, Boston, MA 02114 USA. EM gboland@partners.org NR 7 TC 16 Z9 17 U1 0 U2 4 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2011 VL 196 IS 2 BP W109 EP W111 DI 10.2214/AJR.10.4206 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 718OZ UT WOS:000287135600038 PM 21257849 ER PT J AU McDonald, AG Dal Cin, P Ganguly, A Campbell, S Imai, Y Rosenberg, AE Oliva, E AF McDonald, Anna Greene Dal Cin, Paola Ganguly, Aniruddha Campbell, Sharon Imai, Yuki Rosenberg, Andrew E. Oliva, Esther TI Liposarcoma Arising in Uterine Lipoleiomyoma: A Report of 3 Cases and Review of the Literature SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Review DE liposarcoma; myxoid; pleomorphic; lipoleiomyoma; uterus ID INFLAMMATORY MYOFIBROBLASTIC TUMOR; GIANT-CELLS; YOUNG WOMAN; UTERUS; LEIOMYOSARCOMA; LEIOMYOMA; CHROMOSOMES; FEATURES; LIPOMAS; SARCOMA AB Background: Primary sarcomas of the uterus are uncommon, leiomyosarcoma being the most frequent. Most uterine sarcomas arise de novo, with malignant transformation of a benign mesenchymal tumor being a very rare event, and is reported only in leiomyomata. Design: The clinicopathologic features of 3 uterine liposarcomas arising in association with a lipoleiomyoma were studied. Immunohistochemistry for desmin, h-caldesmon, S100, and MDM2, and fluorescence in situ hybridization for the t(12;16) (q13;p11) were performed in all cases. Result: Patients ranged in age from 49 to 70 (mean, 59) years. The tumors were centered in the myometrium, ranged in size from 10 to 18.5 cm, and showed a gelatinous cut surface with foci of necrosis. On microscopic examination, the tumors had well-circumscribed pushing margins. One neoplasm was uniformly hypocellular with a prominent myxoid background, and a striking delicate vascular network. Another neoplasm showed alternating hypocellular (myxoid) and hypercellular areas, whereas the third tumor was uniformly hypercellular with a hyalinized background. In the myxoid areas, the cells were small and spindle with oval nuclei and inconspicuous nucleoli. In the hypercellular areas, the cells were pleomorphic with large, hyperchromatic nuclei. Mitotic activity ranged from <3 to 7/10 high-power fields. Lipoblasts were present in all tumors but were more common in the hypercellular areas. Two tumors merged imperceptibly with a lipoleiomyoma (1 typical and 1 with bizarre nuclei), whereas the third tumor showed an infarcted area composed of ghost mature adipocytes admixed with hyalinized smooth muscle most consistent with an infarcted lipoleiomyoma. Tumors were classified as myxoid, mixed myxoid and pleomorphic, and pleomorphic liposarcoma, respectively. The benign and malignant adipose components were positive for S100, whereas the benign smooth muscle component stained for desmin and h-caldesmon. MDM2 immunostain was positive in the 2 cases with a pleomorphic liposarcoma component. Fluorescence in situ hybridization analysis was successfully completed in only 1 of 3 tumors (pure pleomorphic liposarcoma), which failed to show the t(12;16) and HMAG2 amplification. The patients are alive and well 1, 2, and 20 years after initial surgery with no adjuvant therapy. Conclusions: Primary liposarcomas of the uterus are extremely rare and are most likely to arise from malignant transformation of a lipoleiomyoma. These tumors should be added to the differential diagnosis of benign lipomatous tumors, myxoid mesenchymal tumors, and malignant mixed Mullerian tumors (if pleomorphic) of the uterus. C1 [McDonald, Anna Greene; Ganguly, Aniruddha; Campbell, Sharon; Rosenberg, Andrew E.; Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Dal Cin, Paola] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Imai, Yuki] Kobe City Gen Hosp, Dept Pathol, Kobe, Hyogo, Japan. RP Oliva, E (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 2, Boston, MA 02114 USA. EM eoliva@partners.org NR 46 TC 7 Z9 9 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD FEB PY 2011 VL 35 IS 2 BP 221 EP 227 DI 10.1097/PAS.0b013e31820414f7 PG 7 WC Pathology; Surgery SC Pathology; Surgery GA 711IC UT WOS:000286581700006 PM 21263242 ER PT J AU McCluggage, WG Hirschowitz, L Wilson, GE Oliva, E Soslow, RA Zaino, RJ AF McCluggage, W. Glenn Hirschowitz, Lynn Wilson, Godfrey E. Oliva, Esther Soslow, Robert A. Zaino, Richard J. TI Significant Variation in the Assessment of Cervical Involvement in Endometrial Carcinoma: An Interobserver Variation Study SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE endometrial carcinoma; cervical involvement; interobserver variation ID REPRODUCIBILITY; CANCER; WOMEN; ADENOCARCINOMA; CLASSIFICATION; HYPERPLASIA; SPECIMENS; SURVIVAL; EMPHASIS; PATTERN AB The histologic assessment of cervical involvement in endometrial carcinoma may be problematic for a number of reasons, but an accurate evaluation of this is important for correct staging, dictating the need for adjuvant therapy, and prognostication. In this study, we assessed interobserver variation in the evaluation of cervical involvement in hysterectomy specimens of endometrial carcinoma among 6 specialist gynecologic pathologists. Seventy-six cases of endometrial carcinoma enriched for cases exhibiting some perceived issue in the assessment of cervical involvement were used. In all the cases, a single slide of the primary tumor in the uterine corpus and a single slide of the cervix were circulated among the 6 participants who filled in a proforma. On the basis of the responses, the tumors were staged according to the 1988 International Federation of Gynecology and Obstetrics (FIGO) staging system (I, IIA, IIB) and the 2009 FIGO staging system (I, II). Using the 1988 FIGO staging system, the unweighted and weighted kappa values between individual observers ranged from 0.3115 to 0.6139 (average 0.4675) and from 0.3492 to 0.6533 (average 0.5065), respectively. The k values between observers for the 2009 FIGO staging system ranged from 0.3481 to 0.6862 (average 0.4908). Although enriched for problematic cases, our study shows that there is at most a fair-to-good agreement among specialist gynecologic pathologists in the assessment of cervical involvement in endometrial carcinoma. Problematic factors include determination of the junction between the lower uterine segment and upper endocervix, the distinction between "floaters" and true cervical glandular involvement, the distinction between cervical glandular involvement and stromal involvement, and the distinction between cervical glandular involvement and reactive nonneoplastic lesions of the endocervical glands. There is a need for specialist pathology groups dealing with gynecologic cancers to develop and disseminate recommendations regarding the assessment of cervical involvement in endometrial carcinoma. C1 [McCluggage, W. Glenn] Royal Grp Hosp Trust, Dept Pathol, Belfast BT12 6BA, Antrim, North Ireland. [Hirschowitz, Lynn] Birmingham Womens Hosp, Dept Pathol, Birmingham, AL USA. [Wilson, Godfrey E.] Cent Manchester Univ Hosp NHS Fdn Trust, Dept Pathol, Manchester, Lancs, England. [Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA. [Zaino, Richard J.] Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA USA. RP McCluggage, WG (reprint author), Royal Grp Hosp Trust, Dept Pathol, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland. EM glenn.mccluggage@belfasttrust.hscni.net OI Soslow, Robert/0000-0002-7269-5898 NR 21 TC 14 Z9 15 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD FEB PY 2011 VL 35 IS 2 BP 289 EP 294 DI 10.1097/PAS.0b013e3182073ac0 PG 6 WC Pathology; Surgery SC Pathology; Surgery GA 711IC UT WOS:000286581700014 PM 21263250 ER PT J AU Krodel, DJ Eikermann, M AF Krodel, David J. Eikermann, Matthias TI Acute Postoperative Negative-pressure Pulmonary Edema Reply SO ANESTHESIOLOGY LA English DT Letter ID GENIOGLOSSUS; ANTAGONISM C1 [Krodel, David J.; Eikermann, Matthias] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02163 USA. [Krodel, David J.; Eikermann, Matthias] Univ Duisburg Essen, Essen, Germany. RP Krodel, DJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02163 USA. EM meikermann@partners.org NR 7 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-3022 J9 ANESTHESIOLOGY JI Anesthesiology PD FEB PY 2011 VL 114 IS 2 BP 462 EP 462 DI 10.1097/ALN.0b013e3182075071 PG 1 WC Anesthesiology SC Anesthesiology GA 711JE UT WOS:000286586200030 ER PT J AU Romley, JA Jena, AB Goldman, DP AF Romley, John A. Jena, Anupam B. Goldman, Dana P. TI Hospital Spending and Inpatient Mortality: Evidence From California An Observational Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID REGIONAL-VARIATIONS; HEALTH-CARE; QUALITY; INTENSITY; SURVIVAL; OUTCOMES; ALWAYS AB Background: Evidence shows that high Medicare spending is not associated with better health outcomes at a regional level and that high spending in hospitals is not associated with better process quality. The relationship between hospital spending and inpatient mortality is less well understood. Objective: To determine the association between hospital spending and risk-adjusted inpatient mortality. Design: Retrospective cohort study. Setting: Database of discharge records from 1999 to 2008 for 208 California hospitals included in The Dartmouth Atlas of Health Care. Patients: 2 545 352 patients hospitalized during 1999 to 2008 with 1 of 6 major medical conditions. Measurements: Inpatient mortality rates among patients admitted to hospitals with varying levels of end-of-life hospital spending. Results: For each of 6 diagnoses at admission-acute myocardial infarction, congestive heart failure, acute stroke, gastrointestinal hemorrhage, hip fracture, and pneumonia-patient admission to higher-spending hospitals was associated with lower risk-adjusted inpatient mortality. During 1999 to 2003, for example, patients admitted with acute myocardial infarction to California hospitals in the highest quintile of hospital spending had lower inpatient mortality than did those admitted to hospitals in the lowest quintile (odds ratio, 0.862 [95% CI, 0.742 to 0.983]). Predicted inpatient deaths would increase by 1831 if all patients admitted with acute myocardial infarction were cared for in hospitals in the lowest quintile of spending rather than the highest. The association between hospital spending and inpatient mortality did not vary by region or hospital size. Limitation: Unobserved predictors of mortality create uncertainty about whether greater inpatient hospital spending leads to lower inpatient mortality. Conclusion: Hospitals that spend more have lower inpatient mortality for 6 common medical conditions. C1 Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Dept Neurol, Los Angeles, CA 90089 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Romley, JA (reprint author), Univ So Calif, Schaeffer Ctr, Dept Neurol, 650 Childs Way, Los Angeles, CA 90089 USA. FU National Institute on Aging [1R03AG031990-A1]; Roybal Center for Health Policy Simulation [P30AG024968] FX Dr. Romley received support from the National Institute on Aging (1R03AG031990-A1), and Dr. Goldman was supported by the Roybal Center for Health Policy Simulation (P30AG024968). NR 27 TC 47 Z9 47 U1 0 U2 4 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 1 PY 2011 VL 154 IS 3 BP 160 EP + DI 10.7326/0003-4819-154-3-201102010-00005 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 713HY UT WOS:000286729200003 PM 21282695 ER PT J AU Bellmunt, J Choueiri, TK Schutz, FAB Rosenberg, JE AF Bellmunt, J. Choueiri, T. K. Schutz, F. A. B. Rosenberg, J. E. TI Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls SO ANNALS OF ONCOLOGY LA English DT Editorial Material ID TRANSITIONAL-CELL CARCINOMA; PLATINUM-CONTAINING REGIMEN; PROGNOSTIC-FACTORS; UROTHELIAL TRACT; VINFLUNINE; GEMCITABINE; PACLITAXEL; THERAPY C1 [Bellmunt, J.] Univ Hosp Mar, Dept Med Oncol, Inst Municipal Invest Med, Barcelona, Spain. [Choueiri, T. K.; Schutz, F. A. B.; Rosenberg, J. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Choueiri, T. K.; Schutz, F. A. B.; Rosenberg, J. E.] Harvard Univ, Sch Med, Boston, MA USA. RP Bellmunt, J (reprint author), Univ Hosp Mar, Dept Med Oncol, Inst Municipal Invest Med, Barcelona, Spain. EM joaquim.bellmunt@gmail.com NR 14 TC 7 Z9 7 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2011 VL 22 IS 2 BP 245 EP 247 DI 10.1093/annonc/mdq684 PG 3 WC Oncology SC Oncology GA 712NL UT WOS:000286673400001 PM 21278220 ER PT J AU Egede, LE Gebregziabher, M Hunt, KJ Axon, RN Echols, C Gilbert, GE Mauldin, PD AF Egede, Leonard E. Gebregziabher, Mulugeta Hunt, Kelly J. Axon, Robert N. Echols, Carrae Gilbert, Gregory E. Mauldin, Patrick D. TI Regional, Geographic, and Ethnic Differences in Medication Adherence Among Adults with Type 2 Diabetes SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE cohort; diabetes mellitus; health disparities; medication adherence ID ORAL HYPOGLYCEMIC AGENTS; BLOOD-GLUCOSE CONTROL; GLYCEMIC CONTROL; HEALTH-CARE; RETROSPECTIVE COHORT; URBAN VETERANS; UNITED-STATES; POPULATION; INSULIN; COMPLICATIONS AB BACKGROUND: Medication adherence, a critical component of glycemic control for patients with type 2 diabetes, differs by race/ethnicity. However, few studies have examined regional and rural/urban differences in medication adherence and whether racial/ethnic differences persist after controlling for these differences. OBJECTIVE: To examine regional, rural/urban, and racial/ethnic differences in medication adherence in a national sample of veterans with type 2 diabetes. METHODS: We performed a cohort study of a national sample of veterans with diabetes (N = 690,968) receiving prescriptions for insulin or oral hypoglycemic agents in 2002. Patients were followed until death, loss to follow-up, or through December 2006. We calculated the annual medication possession ratio (MPR) for each veteran across 4 groups of medication users: individuals using (1) insulin only, (2) oral hypoglycemic agents only, (3) insulin combined with hypoglycemic agents, and (4) insulin or oral hypoglycemic agents (primary analysis). RESULTS: In longitudinal models for the primary analysis, adjusting for relevant covariates and time trends, MPR was significantly lower among non-Hispanic blacks (NHBs), Hispanics, and individuals with other/missing/unknown race/ethnicity (6.07%, 1.76%, and 2.83% lower, respectively) relative to non-Hispanic whites (NHWs). MPR was also 2.0% higher in rural versus urban veterans and 1.28% higher in the mid-Atlantic, 2.04% higher in the Midwest, and 0.76% lower in the West, relative to the South. There was a significant race/ethnicity and urban/rural interaction. In NHWs and NHBs, MPR was 1.91% and 2.00% higher, respectively, in rural versus urban veterans; in contrast, in Hispanics, MPR was 1.0% lower in rural veterans relative to urban veterans. CONCLUSIONS: In a national longitudinal cohort of veterans with type 2 diabetes, we found significant regional, rural/urban, and racial/ethnic differences in MPR. Rural/urban residence modified the effect of race/ethnicity on MPR. Recognition of these differences can enable clinicians to better allocate resources and target quality improvement programs. C1 [Egede, Leonard E.; Gebregziabher, Mulugeta; Hunt, Kelly J.; Axon, Robert N.; Echols, Carrae; Gilbert, Gregory E.; Mauldin, Patrick D.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta; Hunt, Kelly J.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Mauldin, Patrick D.] S Carolina Coll Pharm, Dept Clin Pharm & Outcome Sci, Charleston, SC USA. RP Egede, LE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. EM egedel@musc.edu RI Gilbert, Gregory/C-7735-2016; OI Gilbert, Gregory/0000-0003-0879-5496; Gebregziabher, Mulugeta/0000-0002-4826-481X FU Veterans Health Administration Health Services Research and Development (HSRD) program [IIR-06-219] FX This study was supported by grant IIR-06-219 funded by the Veterans Health Administration Health Services Research and Development (HSR&D) program. The funding agency did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 54 TC 19 Z9 19 U1 2 U2 6 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD FEB PY 2011 VL 45 IS 2 BP 169 EP 178 DI 10.1345/aph.1P442 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 725GV UT WOS:000287634100004 PM 21304026 ER PT J AU Koopmann, MC Kudsk, KA Szotkowski, MJ Rees, SM AF Koopmann, Matthew C. Kudsk, Kenneth A. Szotkowski, Molly J. Rees, Susan M. TI A Team-Based Protocol and Electromagnetic Technology Eliminate Feeding Tube Placement Complications SO ANNALS OF SURGERY LA English DT Article ID WRONG-SITE SURGERY; CRITICALLY-ILL; PREVENTION; INSTRUMENTS; PATTERNS; SPONGES; EVENTS; SAFETY AB Objective: To examine whether feeding tube placement into high-risk patients using a team-based protocol and electromagnetic tube tracking reduces complications associated with blind tube placement and to evaluate safety of blind tube placement in alert, low-risk patients. Background: Approximately 1.2 million feeding tubes with stylets are placed annually in the US. Serious complications during placement exceed the rates of retained sponges and wrong site surgery. Several suggested solutions to the problem have been proposed but none completely eliminate the serious complications and many are neither cost-effective nor practical. Methods: In a retrospective, single center study, we compared complications after bedside feeding tube placement using a blind technique in 2005 to a hospital protocol mandating tube placement in high-risk patients by a Tube Team in 2007 using electromagnetic tracking. Outcome variables included airway placement, pneumothorax, death, and radiology resource utilization. Results: The Tube Team protocol eliminated airway tube placement (0 of 1154 vs. 20 of 1822, P < 0.001), pneumothorax (0/715 vs. 11/1822, P = 0.009), and all mortality whereas improving placement (83.9% success vs. 60.5%, P<0.001) in high-risk patients compared to the 2005 study. The number of x-rays obtained per tube (1.07 +/- 0.01 vs. 1.49 +/- 0.026, P < 0.001) and need for fluoroscopy (2.1% vs. 10.9%, P < 0.001) significantly dropped with the Tube Team. A final comparison was made to low-risk patients considered acceptable for blind tube placement in 2007 due to their alertness and ability to cooperate and provide feedback during tube placement. Although no mortality occurred during blind placement in low risk, alert patients, blind placement resulted in significantly increased airway placement (3/143, p = 0.001) and pneumothorax (2 of 143, P = 0.01) compared to the Tube Team protocol. Most patients who would have required fluoroscopic placement of feeding tube due to failed blind technique had successful placement by the Team avoiding fluoroscopy. Conclusion: Feeding tube placement by a dedicated team using electromagnetic tracking eliminates the morbidity and mortality of this common hospital procedure. Blind placement is not acceptable in awake, alert patients. C1 [Koopmann, Matthew C.; Kudsk, Kenneth A.; Szotkowski, Molly J.] William S Middleton Mem Vet Adm Med Ctr, Dept Surg, Madison, WI USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Rees, Susan M.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Clin Sci Ctr H4 736, 600 Highland Ave, Madison, WI 53706 USA. EM kudsk@surgery.wisc.edu FU Department of Surgery of the University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin FX The authors declare no conflict of interest. There was no financial sponsorship of this trial. The equipment was purchased by the University of Wisconsin-Madison Hospitals and Clinics. Salary support for the Tube Team members was assumed by the Department of Surgery of the University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin. Neither Viasys nor any other industry source provided sponsorship-financial or otherwise-nor did they have any involvement in the design and conduct of the study, collection, management, analysis, or interpretation of the data. No sponsorship is provided in the preparation, review, or approval of the manuscript. NR 18 TC 12 Z9 12 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD FEB PY 2011 VL 253 IS 2 BP 297 EP 302 DI 10.1097/SLA.0b013e318208f550 PG 6 WC Surgery SC Surgery GA 708OV UT WOS:000286374400014 ER PT J AU Hammon, RJ Lin, HW Sadow, PM Lin, DT Rocco, JW AF Hammon, Rebecca J. Lin, Harrison W. Sadow, Peter M. Lin, Derrick T. Rocco, James W. TI Pathology Quiz Case 1 Angiosarcoma SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Editorial Material ID PHASE-II; RECURRENT; SARCOMAS; NECK; HEAD C1 [Hammon, Rebecca J.; Lin, Harrison W.; Sadow, Peter M.; Lin, Derrick T.; Rocco, James W.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Hammon, Rebecca J.; Lin, Harrison W.; Lin, Derrick T.; Rocco, James W.] Harvard Univ, Sch Med, Boston, MA USA. [Sadow, Peter M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Hammon, RJ (reprint author), Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD FEB PY 2011 VL 137 IS 2 BP 197 EP + PG 3 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 723WB UT WOS:000287536900018 ER PT J AU Hata, Y Nakao, S Kohno, R Oba, K Kita, T Miura, M Sassa, Y Schering, A Ishibashi, T AF Hata, Yasuaki Nakao, Shintaro Kohno, Ri-ichiro Oba, Kumiyo Kita, Takeshi Miura, Muneki Sassa, Yukio Schering, Alexander Ishibashi, Tatsuro TI Role of tumour necrosis factor-alpha (TNF alpha) in the functional properties of hyalocytes SO BRITISH JOURNAL OF OPHTHALMOLOGY LA English DT Article ID PROLIFERATIVE VITREORETINAL DISEASES; ENDOTHELIAL GROWTH-FACTOR; COLLAGEN GEL CONTRACTION; PIGMENT EPITHELIAL-CELLS; PARS-PLANA VITRECTOMY; RHO-KINASE PATHWAY; DIABETIC-RETINOPATHY; UVEITIS; NEOVASCULARIZATION; INVOLVEMENT AB Background/aim Tumour necrosis factor-alpha (TNF alpha) is an inflammatory cytokine that is upregulated in various vitreoretinal diseases including uveitis and diabetic retinopathy. Recently, our studies have indicated that hyalocytes contribute to the pathogenesis of these diseases. However, the impact of TNF alpha on the functional properties of hyalocytes is unknown. Methods Hyalocytes were isolated from bovine eyes. Cellular proliferation, migration and gel contraction in response to TNF alpha and the other inflammatory cytokines were analysed by thymidine uptake, Boyden's chamber assay and collagen gel contraction assay, respectively. Furthermore, we estimated the effect of dexamethasone on these properties of hyalocytes. Results TNF alpha promoted proliferation, migration and gel contraction by hyalocytes. Dexamethasone inhibited TNF alpha-induced proliferation but not migration. Dexamethasone did not inhibit TNF alpha-induced gel contraction but further increased contraction. Furthermore, dexamethasone inhibited TNF alpha-induced extracellular signal-related kinase (ERK) 1/2 phosphorylation in hyalocytes. Conclusion This study indicates that TNF alpha in vitreous and retina causes activation of hyalocytes, and the activated hyalocytes contribute to the pathogenesis of inflammatory vitreoretinal diseases. Steroid treatment appears to inhibit the activation of hyalocytes in the early stages of the diseases, but might have adverse effects in the late stage through membrane contraction. C1 [Hata, Yasuaki; Nakao, Shintaro; Kohno, Ri-ichiro; Oba, Kumiyo; Kita, Takeshi; Miura, Muneki; Sassa, Yukio; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan. [Schering, Alexander] Harvard Univ, Sch Med, Dept Ophthalmol, Angiogenesis Lab,Massachusetts Eye & Ear Infirm, Boston, MA USA. RP Ishibashi, T (reprint author), Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan. EM ishi@med.kyushu-u.ac.jp RI Sassa, Yukio/H-6339-2012 FU Ministry of Education, Science, Sports and Culture, Japan [21592233] FX The study was supported in part by grants from the Ministry of Education, Science, Sports and Culture, Japan (Grant-in-Aid for Scientific Research #21592233). NR 24 TC 2 Z9 2 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0007-1161 J9 BRIT J OPHTHALMOL JI Br. J. Ophthalmol. PD FEB PY 2011 VL 95 IS 2 BP 261 EP 265 DI 10.1136/bjo.2010.190322 PG 5 WC Ophthalmology SC Ophthalmology GA 709RI UT WOS:000286458700023 PM 21030411 ER PT J AU Miller, KW Orser, BA Roth, SH AF Miller, Keith W. Orser, Beverley A. Roth, Sheldon H. TI Mechanisms of anesthesia: past, present, and a glimpse into the future SO CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE LA English DT Editorial Material C1 [Orser, Beverley A.] Univ Toronto, Dept Anesthesia, Toronto, ON M5S 1A8, Canada. [Orser, Beverley A.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada. [Miller, Keith W.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Miller, Keith W.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Orser, Beverley A.] Sunnybrook Hlth Sci Ctr, Dept Anesthesia, Toronto, ON M4N 3M5, Canada. [Roth, Sheldon H.] Univ Calgary, Dept Physiol, Hotchkiss Brain Inst, Calgary, AB, Canada. [Roth, Sheldon H.] Univ Calgary, Dept Pharmacol, Hotchkiss Brain Inst, Calgary, AB, Canada. [Roth, Sheldon H.] Univ Calgary, Dept Anesthesiol, Hotchkiss Brain Inst, Calgary, AB, Canada. RP Orser, BA (reprint author), Univ Toronto, Dept Anesthesia, Rm 3318,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada. EM beverley.orser@utoronto.ca NR 14 TC 2 Z9 2 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0832-610X J9 CAN J ANESTH JI Can. J. Anesth. PD FEB PY 2011 VL 58 IS 2 BP 131 EP 134 DI 10.1007/s12630-010-9433-y PG 4 WC Anesthesiology SC Anesthesiology GA 726XR UT WOS:000287760900002 PM 21165729 ER PT J AU Kolandaivelu, K Bhatt, DL AF Kolandaivelu, Kumaran Bhatt, Deepak L. TI Antiplatelet Therapy in Coronary Heart Disease Prevention SO CARDIOLOGY CLINICS LA English DT Article DE Antiplatelet; Prevention; Cardiovascular; Coronary ID ADVERSE CARDIOVASCULAR EVENTS; ST-SEGMENT ELEVATION; LOW-DOSE ASPIRIN; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIALS; COLLABORATIVE METAANALYSIS; ANTITHROMBOTIC THERAPY; SECONDARY PREVENTION; PLATELET INHIBITION; VASCULAR-DISEASE AB Platelets are central to the pathogenesis of coronary heart disease (CHD). An ever-growing number of antiplatelet therapies used in different doses and combinations have helped manage atherothrombosis, both acutely and in primary and secondary prevention. Despite modern therapy, nearly 800,000 individuals suffer annually from an initial coronary event in the United States alone; almost 500,000 experience a recurrent event. This review provides a current appraisal of antiplatelet drug use in CHD prevention and discusses key barriers to achieving its full potential in real-world practice. C1 [Bhatt, Deepak L.] VA Boston Healthcare Syst, Div Cardiol, Boston, MA 02132 USA. [Kolandaivelu, Kumaran] Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA. [Kolandaivelu, Kumaran] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Integrated Intervent Cardiovasc Program, Boston, MA 02115 USA. [Bhatt, Deepak L.] VA Boston Healthcare Syst, Integrated Intervent Cardiovasc Program, Boston, MA 02132 USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Bhatt, DL (reprint author), VA Boston Healthcare Syst, Div Cardiol, 1400 VFW Pkwy, Boston, MA 02132 USA. EM dlbhattmd@post.harvard.edu FU Astra Zeneca; Bristol-Myers Squibb; Eisai; Sanofi Aventis; Medicines Company FX Conflicts of interest: D.L. Bhatt declares research grant support from Astra Zeneca, Bristol-Myers Squibb, Eisai, Sanofi Aventis, and The Medicines Company. K.K. declares no competing interests. NR 77 TC 3 Z9 5 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8651 J9 CARDIOL CLIN JI Cardiol. Clin. PD FEB PY 2011 VL 29 IS 1 BP 71 EP + DI 10.1016/j.ccl.2010.10.001 PG 16 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 725LU UT WOS:000287647000007 PM 21257101 ER PT J AU Longmore, RB Yeh, RW Kennedy, KF Anderson, HV White, CJ Longmore, LS Rosenfield, K Ho, KKL Spertus, JA AF Longmore, Ryan B. Yeh, Robert W. Kennedy, Kevin F. Anderson, H. Vernon White, Christopher J. Longmore, Lance S. Rosenfield, Kenneth Ho, Kalon K. L. Spertus, John A. TI Clinical Referral Patterns for Carotid Artery Stenting Versus Carotid Endarterectomy Results From the Carotid Artery Revascularization and Endarterectomy Registry SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE carotid artery stenting; carotid stenosis; carotid stenting; endovascular surgery; stroke ID PROPENSITY-SCORE METHODS; RECURRENT STENOSIS; CARE REGISTRY; STROKE; RISK; ANGIOPLASTY; DEATH; PREDICTORS; TRIAL AB Background-Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are alternative strategies for stroke prevention in patients with atherosclerotic carotid disease. Although randomized clinical trials are the gold standard for assessing the relative benefits of different treatments, observational research is necessary for determining "real-world" effectiveness. Current recommendations limit the application of CAS to high-risk patients, undermining the ability to "balance" the characteristics of patients treated with either approach. We compared the clinical profiles of patients referred for CAS versus CEA in a large national database. Methods and Results-Clinical characteristics of 12 701 patients referred for CAS or CEA in the National Cardiovascular Data Registry-Carotid Artery Revascularization and Endarterectomy were compared for 44 clinical and demographic variables. To investigate the comparability of CAS and CEA patients, we stratified the cohort into quintiles of the propensity score for referral for CAS. Among 8069 patients referred for CAS and 4632 referred for CEA, the CAS patients had significantly more comorbidities. Whereas the propensity model balanced most covariates, the pooled standardized differences (>= 10%) suggested persistent imbalance for ischemic heart disease, recent myocardial infarction, and restenosis of prior CAS/CEA, all of which were more common in the CAS group. After stratification of propensity scores by quintile, CEA patients comprised only 14% of the upper 2 quintiles. Conclusions-Characteristics of patients referred for CAS differ markedly from those referred for CEA. Because of extreme clinical disparities between these patients, generalizable comparative effectiveness analyses of observational data will be difficult. (Circ Cardiovasc Interv. 2011; 4: 88-94.) C1 [Longmore, Ryan B.; Kennedy, Kevin F.; Spertus, John A.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Yeh, Robert W.; Rosenfield, Kenneth] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Anderson, H. Vernon] Univ Texas Med Sch Houston, Houston, TX USA. [White, Christopher J.] Ochsner Heart & Vasc Inst, New Orleans, LA USA. [Longmore, Lance S.] Univ Missouri, Kansas City, MO 64110 USA. [Ho, Kalon K. L.] Harvard Univ, Sch Med, Boston, MA USA. RP Longmore, RB (reprint author), Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA. EM Ryan.Longmore@gmail.com RI White, Christopher/J-6686-2012 OI White, Christopher/0000-0001-8618-7539 FU American College of Cardiology Foundation; Boston Scientific; Abbot Vascular; Bard Peripheral Vascular; Cordis Endovascular; ev3 Inc FX This study was supported by The American College of Cardiology Foundation.; Dr John Spertus received a contract from the American College of Cardiology Foundation to serve as an analytic center for NCDR. Dr Christopher White received a principal investigator/research grant for the CABANA trial and served on the consultant/advisory board for Boston Scientific. Dr Kenneth Rosenfield received a research grants from Abbot Vascular, Bard Peripheral Vascular, Cordis Endovascular, and ev3 Inc and honoraria from VIVA Physicians; he has ownership interest in Contego Medical, LLC, and Lumen Biomedical and served on the consultant/ advisory board for Abbot Vascular. NR 21 TC 19 Z9 19 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7640 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD FEB PY 2011 VL 4 IS 1 BP 88 EP U132 DI 10.1161/CIRCINTERVENTIONS.110.958843 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 721KJ UT WOS:000287351700014 PM 21224465 ER PT J AU Perez, DL Diamond, EL Castro, CM Diaz, A Buonanno, F Nogueira, RG Sheth, K AF Perez, David L. Diamond, Eli L. Castro, Cesar M. Diaz, Andres Buonanno, Ferdinando Nogueira, Raul G. Sheth, Kevin TI Factor XIII deficiency related recurrent spontaneous intracerebral hemorrhage: A case and literature review SO CLINICAL NEUROLOGY AND NEUROSURGERY LA English DT Review DE Intracerebral hemorrhage; Factor XIII; Replacement therapy; Recurrent multifocal bleeding ID INTRACRANIAL HEMORRHAGE; YOUNG-ADULTS; MANAGEMENT; UPDATE; STROKE AB Spontaneous intracerebral hemorrhage (ICH) in young adults under 50 years of age is an uncommon occurrence associated with considerable morbidity and mortality. The differential diagnosis of ICH in this population differs from that of older individuals and includes vascular, toxic, inflammatory, oncologic, infectious and hematologic conditions. We present a case based observation of a spontaneous and recurrent ICH in a 25-year-old female secondary to undetected Factor XIII (FXIII) deficiency with no prior associated stigmata of hematologic disturbance admitted to a tertiary care neuroscience intensive care unit (NICU). Our patient was admitted after spontaneous development of left thalamic hemorrhage with ventricular extension. Initial management included external drain placement (EVD) and fresh frozen plasma administration. Diagnostic evaluation was unrevealing including CT angiography, magnetic resonance imaging (MRI) with venography, conventional cerebral angiogram, and hematologic and rheumatologic screens. Our patient recovered but represented 6 months later with five foci of spontaneous ICH. She underwent vascular, infectious, oncologic, hematologic, and rheumatologic evaluations. She expired secondary to ICH expansion with uncal herniation. The results of our investigation revealed markedly diminished FXIII activity. The pathophysiology, diagnosis and treatment of this disease are reviewed. FXIII deficiency should be considered in a case of cryptogenic ICH presenting with multifocal, recurrent ICH and a normal coagulation profile. Early diagnosis and initiation of factor replacement therapy offer the best strategies to reduce the morbidities associated with this disease. (C) 2010 Elsevier B.V. All rights reserved. C1 [Perez, David L.; Diamond, Eli L.; Buonanno, Ferdinando; Nogueira, Raul G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Perez, David L.; Diamond, Eli L.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Castro, Cesar M.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. [Diaz, Andres] Hosp Univ Fdn Santa Fe Bogota, Neurol Sect, Bogota, Colombia. [Sheth, Kevin] Univ Maryland, Dept Neurol & Neurosurg, Baltimore, MA USA. RP Perez, DL (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. EM david.lperez@gmail.com NR 27 TC 14 Z9 15 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0303-8467 J9 CLIN NEUROL NEUROSUR JI Clin. Neurol. Neurosurg. PD FEB PY 2011 VL 113 IS 2 BP 142 EP 145 DI 10.1016/j.clineuro.2010.09.003 PG 4 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 720NR UT WOS:000287287900014 PM 20950938 ER PT J AU Kuschner, WG AF Kuschner, Ware G. TI Passive leg raising for monitoring volume status and predicting fluid responsiveness SO CRITICAL CARE MEDICINE LA English DT Letter ID CRITICALLY-ILL C1 [Kuschner, Ware G.] Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA. [Kuschner, Ware G.] US Dept Vet Affairs, Med Serv, Pulm & Crit Care Med Sect, Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Kuschner, WG (reprint author), Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA. NR 6 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2011 VL 39 IS 2 BP 420 EP 420 DI 10.1097/CCM.0b013e3181fd6936 PG 1 WC Critical Care Medicine SC General & Internal Medicine GA 709GN UT WOS:000286426400040 PM 21248535 ER PT J AU Abu Dayyeh, BK Yang, M Dienstag, JL Chung, RT AF Abu Dayyeh, Barham K. Yang, May Dienstag, Jules L. Chung, Raymond T. TI The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Renin-angiotensin system; ACE inhibitors; Angiotensin receptor blockers; Liver fibrosis; Hypertension; Diabetes ID HEPATIC STELLATE CELLS; AT1 RECEPTOR ANTAGONIST; NONALCOHOLIC STEATOHEPATITIS; RATS; LOSARTAN; CCL4; TRANSPLANTATION; ACTIVATION; MARKERS; MICE AB Therapies that can slow the progression of liver fibrosis in chronic liver disease are needed. Evidence suggests that the renin-angiotensin system (RAS) contributes to inflammation and fibrosis in chronic liver disease. Both animal and limited human studies have shown that RAS inhibition with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor-1 [AT-1] blockers (ARBs) has antifibrogenic properties. In this study, we evaluated the effects of continuous ACEi/ARB use for 3.5 years on histological liver fibrosis progression in the HALT-C Trial cohort. In the HALT-C Trial, subjects with chronic hepatitis C and advanced hepatic fibrosis (Ishak stage a parts per thousand yen3) underwent serial liver biopsies at baseline, 1.5 years, and 3.5 years after randomization. The primary outcome was a a parts per thousand yen2-point increase in Ishak fibrosis score in at least one of the two serial biopsies. Sixty-six subjects were continuously taking ACEi/ARBs over the observation period, 126 were taking other antihypertensive medications, and 343 subjects took no antihypertensive medications. The three groups were similar in baseline fibrosis scores, and the two groups being treated with antihypertensives were taking a similar number of antihypertensive medications. Fibrosis progression occurred in 33.3% of the ACEi/ARB group, 32.5% of the other antihypertensive medications group, and in 25.7% of subjects taking no antihypertensive medications. No significant associations between a parts per thousand yen2-point increases in fibrosis scores and continuous ACEi/ARB use were apparent at either 1.5 or 3.5 years in diabetes-adjusted and unadjusted odds ratios. ACEi/ARB therapy did not retard the progression of hepatic fibrosis. C1 [Abu Dayyeh, Barham K.; Dienstag, Jules L.; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA. [Yang, May] New England Res Inst, Watertown, MA 02472 USA. RP Chung, RT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Warren 1007C,55 Fruit St, Boston, MA 02114 USA. EM babudayyeh@partners.org; MYang@neriscience.com; jdienstag@partners.org; rtchung@partners.org FU National Institute of Diabetes & Digestive & Kidney Diseases; National Institute of Allergy and Infectious Diseases (NIAID); National Cancer Institute; National Center for Minority Health and Health Disparities; National Center for Research Resources, National Institutes of Health; Hoffmann-La Roche, Inc.; National Institutes of Health; University of Massachusetts Medical Center, Worcester, MA [N01-DK-9-2326]; University of Connecticut Health Center, Farmington, CT [M01RR-06192]; Saint Louis University School of Medicine, St Louis, MO [N01-DK-9-2324]; Massachusetts General Hospital, Boston, MA (Harvard Clinical and Translational Science Center) [N01-DK-9-2319, M01RR-01066, 1 UL1 RR025758-01]; University of Colorado Denver, School of Medicine, Aurora, CO [N01-DK-9-2327, M01RR-00051, 1 UL1 RR 025780-01]; University of California-Irvine, Irvine, CA [N01-DK-9-2320, M01RR-00827]; University of Texas Southwestern Medical Center, Dallas, TX (North and Central Texas Clinical and Translational Science Initiative) [N01-DK-9-2321, M01RR-00633, 1 UL1 RR024982-01]; University of Southern California, Los Angeles, CA [N01-DK-9-2325, M01RR-00043]; University of Michigan Medical Center, Ann Arbor, MI [N01-DK-9-2323, M01RR-00042, 1 UL1 RR024986]; Virginia Commonwealth University Health System, Richmond, VA [N01-DK-9-2322, M01RR-00065]; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; National Institute of Diabetes and Digestive and Kidney Diseases, Division of Digestive Diseases and Nutrition, Bethesda, MD; University of Washington, Seattle, WA [N01-DK-9-2318]; New England Research Institutes, Watertown, MA [N01-DK-9-2328] FX This study was supported by the National Institute of Diabetes & Digestive & Kidney Diseases (contract numbers are listed below). Additional support was provided by the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute, the National Center for Minority Health and Health Disparities and by General Clinical Research Center and Clinical and Translational Science Center grants from the National Center for Research Resources, National Institutes of Health (grant numbers are listed below). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Additional funding to conduct this study was supplied by Hoffmann-La Roche, Inc., through a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health. In addition to the authors of this manuscript, the following individuals were instrumental in the planning, conduct and/or care of patients enrolled in this study at each of the participating institutions as follows: University of Massachusetts Medical Center, Worcester, MA: (Contract N01-DK-9-2326) Gyongyi Szabo, MD, Barbara F. Banner, MD, Maureen Cormier, RN, Donna Giansiracusa, RN. University of Connecticut Health Center, Farmington, CT: (Grant M01RR-06192) Herbert L. Bonkovsky, MD, Gloria Borders, RN, Michelle Kelley, RN, ANP. Saint Louis University School of Medicine, St Louis, MO: (Contract N01-DK-9-2324) Adrian M. Di Bisceglie, MD, Bruce Bacon, MD, Brent Neuschwander-Tetri, MD, Elizabeth M. Brunt, MD, Debra King, RN. Massachusetts General Hospital, Boston, MA: (Contract N01-DK-9-2319, Grant M01RR-01066; Grant 1 UL1 RR025758-01, Harvard Clinical and Translational Science Center) Andrea E. Reid, MD, Atul K. Bhan, MD, Wallis A. Molchen, David P. Lundmark. University of Colorado Denver, School of Medicine, Aurora, CO: (Contract N01-DK-9-2327, Grant M01RR-00051, Grant 1 UL1 RR 025780-01), Gregory T. Everson, MD, Thomas Trouillot, MD, Marcelo Kugelmas, MD, S. Russell Nash, MD, Jennifer DeSanto, RN, Carol McKinley, RN. University of California-Irvine, Irvine, CA: (Contract N01-DK-9-2320, Grant M01RR-00827) Timothy R. Morgan, MD, John C. Hoefs, MD, John R. Craig, MD, M. Mazen Jamal, MD, MPH, Muhammad Sheikh, MD, Choon Park, RN. University of Texas Southwestern Medical Center, Dallas, TX: (Contract N01-DK-9-2321, Grant M01RR-00633, Grant 1 UL1 RR024982-01, North and Central Texas Clinical and Translational Science Initiative) William M. Lee, MD, Thomas E. Rogers, MD, Peter F. Malet, MD, Janel Shelton, Nicole Crowder, LVN, Rivka Elbein, RN, BSN, Nancy Liston, MPH. University of Southern California, Los Angeles, CA: (Contract N01-DK-9-2325, Grant M01RR-00043) Karen L. Lindsay, MD, MMM, Sugantha Govindarajan, MD, Carol B. Jones, RN, Susan L. Milstein, RN. University of Michigan Medical Center, Ann Arbor, MI: (Contract N01-DK-9-2323, Grant M01RR-00042, Grant 1 UL1 RR024986, Michigan Center for Clinical and Health Research) Anna S. Lok, MD, Robert J. Fontana, MD, Joel K. Greenson, MD, Pamela A. Richtmyer, LPN, CCRC, R. Tess Bonham, BS. Virginia Commonwealth University Health System, Richmond, VA: (Contract N01-DK-9-2322, Grant M01RR-00065) Mitchell L. Shiffman, MD, Richard K. Sterling, MD, MSc, Melissa J. Contos, MD, A. Scott Mills, MD, Charlotte Hofmann, RN, Paula Smith, RN. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD: Marc G. Ghany, MD, T.; Jake Liang, MD, Dvid Kleiner, MD, PhD, Yoon Park, RN, Elenita Rivera, RN, Vanessa Haynes-Williams, RN. National Institute of Diabetes and Digestive and Kidney Diseases, Division of Digestive Diseases and Nutrition, Bethesda, MD: James E. Everhart, MD, Leonard B. Seeff, MD, Patricia R. Robuck, PhD, Jay H. Hoofnagle, MD, Elizabeth C. Wright, PhD. University of Washington, Seattle, WA: (Contract N01-DK-9-2318) Chihiro Morishima, MD, David R. Gretch, MD, PhD, Minjun Chung Apodaca, BS, ASCP, Rohit Shankar, BC, ASCP, Natalia Antonov, M. Ed. New England Research Institutes, Watertown, MA: (Contract N01-DK-9-2328) Kristin K. Snow, MSc, ScD, Anne M. Stoddard, ScD, Teresa M. Curto, MSW, MPH. Armed Forces Institute of Pathology, Washington, DC: Zachary D. Goodman, MD, PhD. Data and Safety Monitoring Board Members: (Chair) Gary L. Davis, MD, Guadalupe Garcia-Tsao, MD, Michael Kutner, PhD, Stanley M. Lemon, MD, Robert P. Perrillo, MD. NR 22 TC 27 Z9 27 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD FEB PY 2011 VL 56 IS 2 BP 564 EP 568 DI 10.1007/s10620-010-1507-8 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 712KF UT WOS:000286664900039 PM 21136163 ER PT J AU Eliott, D Salehi-Had, H Plous, OZ AF Eliott, D. Salehi-Had, H. Plous, O. Z. TI Adenocarcinoma of the esophagus presenting as choroidal metastasis SO DISEASES OF THE ESOPHAGUS LA English DT Article DE adenocarcinoma; choroidal; esophagus; eye; metastasis ID PHOTODYNAMIC THERAPY; EYE; EPIDEMIOLOGY; CARCINOMA; CANCER; ORBIT AB P>Adenocarcinoma of the esophagus is an exceedingly rare cause of choroidal metastasis. We report the case of a 48-year-old Caucasian male with a 2-month history of decreased vision and dysphagia. Ophthalmologic examination revealed bilateral choroidal masses and an exudative retinal detachment in the left eye. Gastroduodenoscopy revealed a circumferential mass in the distal esophagus at 30 cm extending into and involving the gastroesophageal junction. Endoscopic biopsy disclosed an invasive, poorly differentiated adenocarcinoma. Systemic workup revealed widespread metastatic changes in the pericardium, liver, and left adrenal gland, and a right pleural effusion. The patient's condition rapidly deteriorated, and he passed away 40 days after initial presentation. To our knowledge, this represents the first case of choroidal metastasis as the initial manifestation of esophageal adenocarcinoma. C1 [Eliott, D.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. [Salehi-Had, H.] Univ So Calif, Keck Sch Med, Doheny Retina Inst, Los Angeles, CA 90033 USA. [Plous, O. Z.] Florida Retina Consultants, Lakeland, FL USA. RP Eliott, D (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM dean_eliott@meei.harvard.edu NR 17 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1120-8694 J9 DIS ESOPHAGUS JI Dis. Esophagus PD FEB PY 2011 VL 24 IS 2 BP E16 EP E18 DI 10.1111/j.1442-2050.2010.01170.x PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 726EB UT WOS:000287700500002 PM 21309919 ER PT J AU Lawson, EA Eddy, KT Donoho, D Misra, M Miller, KK Meenaghan, E Lydecker, J Herzog, D Klibanski, A AF Lawson, Elizabeth A. Eddy, Kamryn T. Donoho, Daniel Misra, Madhusmita Miller, Karen K. Meenaghan, Erinne Lydecker, Janet Herzog, David Klibanski, Anne TI Appetite-regulating hormones cortisol and peptide YY are associated with disordered eating psychopathology, independent of body mass index SO EUROPEAN JOURNAL OF ENDOCRINOLOGY LA English DT Article ID FUNCTIONAL HYPOTHALAMIC-AMENORRHEA; PITUITARY-ADRENAL-AXIS; QUESTIONNAIRE EDE-Q; COGNITIVE DIETARY RESTRAINT; ANOREXIA-NERVOSA; ADOLESCENT GIRLS; SECRETORY DYNAMICS; ELEVATED GHRELIN; BULIMIA-NERVOSA; NEUROPEPTIDE-Y AB Objective: Disordered eating occurs in women at both weight extremes of anorexia nervosa (AN) and obesity. Cortisol, peptide YY (PYY), leptin, and ghrelin are hormones involved in appetite and feeding behavior that vary with weight and body fat. Abnormal levels of these hormones have been reported in women with AN, functional hypothalamic amenorrhea (HA), and obesity. The relationship between appetite-regulating hormones and disordered eating psychopathology is unknown. We therefore studied the relationship between orexigenic and anorexigenic hormones and disordered eating psychopathology in women across a range of weights. Design: A cross-sectional study of 65 women, 18-45 years: 16 with AN, 12 normal-weight with HA, 17 overweight or obese, and 20 normal-weight in good health. Methods: Two validated measures of disordered eating psychopathology, the Eating Disorders Examination-Questionnaire (EDE-Q) and Eating Disorders Inventory-2 (EDI-2), were administered. Fasting PYY, leptin, and ghrelin levels were measured; cortisol levels were pooled from serum samples obtained every 20 min from 2000 to 0800 h. Results: Cortisol and PYY levels were positively associated with disordered eating psychopathology including restraint, eating concerns, and body image disturbance, independent of body mass index (BMI). Although leptin levels were negatively associated with disordered eating psychopathology, these relationships were not significant after controlling for BMI. Ghrelin levels were generally not associated with EDE-Q or EDI-2 scores. Conclusions: Higher levels of cortisol and PYY are associated with disordered eating psychopathology independent of BMI in women across the weight spectrum, suggesting that abnormalities in appetite regulation may be associated with specific eating disorder pathologies. European Journal of Endocrinology 164 253-261 C1 [Lawson, Elizabeth A.; Donoho, Daniel; Misra, Madhusmita; Miller, Karen K.; Meenaghan, Erinne; Lydecker, Janet; Klibanski, Anne] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Eddy, Kamryn T.; Herzog, David] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Eddy, Kamryn T.; Herzog, David] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02114 USA. RP Lawson, EA (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B, Boston, MA 02114 USA. EM ealawson@partners.org RI Lydecker, Janet/B-3349-2016 OI Lydecker, Janet/0000-0001-6425-514X FU Bioenvision; NIH [M01 RR01066, UL1 RR025758, P30-DK040561]; Harvard/MIT Health Sciences and Technology - Beth Israel Deaconess Medical Center; Pfizer Inc.; Merck Co. FX This study was supported by the investigator-initiated grant from Bioenvision; NIH: M01 RR01066, UL1 RR025758, and P30-DK040561; The Clinical Investigator Training Program: Harvard/MIT Health Sciences and Technology - Beth Israel Deaconess Medical Center, in collaboration with Pfizer Inc. and Merck & Co. NR 48 TC 26 Z9 27 U1 1 U2 11 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0804-4643 EI 1479-683X J9 EUR J ENDOCRINOL JI Eur. J. Endocrinol. PD FEB PY 2011 VL 164 IS 2 BP 253 EP 261 DI 10.1530/EJE-10-0523 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 707UY UT WOS:000286315500014 PM 21098684 ER PT J AU Sbrocchi, AM Rauch, F Lawson, ML Hadjiyannakis, S Lawrence, S Bastepe, M Juppner, H Ward, LM AF Sbrocchi, Anne Marie Rauch, Frank Lawson, Margaret L. Hadjiyannakis, Stasia Lawrence, Sarah Bastepe, Murat Jueppner, Harald Ward, Leanne Marie TI Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis SO EUROPEAN JOURNAL OF ENDOCRINOLOGY LA English DT Article ID PARATHYROID-HORMONE 1-34; MINERAL DENSITY; SKELETAL RESPONSIVENESS; GNAS LOCUS; IB; DISEASE; PREVENTION; DIAGNOSIS; GROWTH; CELLS AB Objective: Pseudohypoparathyroidism (PHP) is a heterogeneous disorder characterized by hypocalcemia and hyperphosphatemia resulting from selective renal resistance to parathyroid hormone (PTH). One autosomal dominant form of PHP type 1b (PHP-Ib) is most frequently caused by a maternally inherited 3-kb deletion within STX16, the gene encoding syntaxin 16. To date, increased bone mineral density (BMD) has been described only in PHP type 1a, and there is a lack of detailed information on bone histomorphometry in PHP-Ib. The objective of this report was to present trans-iliac static and dynamic histomorphometry in two brothers with the 3-kb deletion in the STX16 region and elevated BMD. Design: Observational study of two brothers (age 18.0 and 22.7 years) with the 3-kb STX16 deletion and increased BMD. Results: The brothers had elevated PTH (146 pg/ml (15.6 pmol/l) and 102 pg/ml (10.9 pmol/l); normal: 10-64 pg/ml (1.1-6.8 pmol/l)) and striking osteosclerosis (lumbar spine areal BMD Z-scores: +5.4 and +4.9). Bone histomorphometry showed marked elevations in cortical width for both brothers (241 and 209% of the mean result expected for age), with elevations in the bone formation rate on the endocortical (119 and 260% of the healthy mean) and trabecular (220 and 190% of mean) surfaces. Conclusion: Our findings suggest that PTH in this PHP-Ib genotype can increase cortical thickness due to its anabolic effect on endocortical bone, and underscore the heterogeneity in the skeletal phenotype among patients with PHP-Ib. European Journal of Endocrinology 164 295-301 C1 [Sbrocchi, Anne Marie; Lawson, Margaret L.; Hadjiyannakis, Stasia; Lawrence, Sarah; Ward, Leanne Marie] Childrens Hosp Eastern Ontario, Div Endocrinol & Metab, Pediat Bone Hlth Clin Program, Ottawa, ON K1H 8L1, Canada. [Sbrocchi, Anne Marie; Lawson, Margaret L.; Hadjiyannakis, Stasia; Lawrence, Sarah; Ward, Leanne Marie] Childrens Hosp Eastern Ontario, Div Endocrinol & Metab, Res Program, Ottawa, ON K1H 8L1, Canada. [Rauch, Frank] Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada. [Bastepe, Murat; Jueppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Bastepe, Murat; Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Ward, LM (reprint author), Childrens Hosp Eastern Ontario, Div Endocrinol & Metab, Pediat Bone Hlth Clin Program, 401 Smyth Rd,RI Rm 250 A, Ottawa, ON K1H 8L1, Canada. EM lward@cheo.on.ca OI Lawson, Margaret/0000-0002-2370-9552 FU Canadian Institutes for Health Research; Canadian Child Health Clinician Scientist Career Enhancement Award FX Dr L M Ward is supported by a Canadian Institutes for Health Research New Investigator Award and a Canadian Child Health Clinician Scientist Career Enhancement Award. NR 30 TC 9 Z9 9 U1 0 U2 1 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0804-4643 J9 EUR J ENDOCRINOL JI Eur. J. Endocrinol. PD FEB PY 2011 VL 164 IS 2 BP 295 EP 301 DI 10.1530/EJE-10-0795 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 707UY UT WOS:000286315500019 PM 21062889 ER PT J AU Koyama, MS Stein, JF Stoodley, CJ Hansen, PC AF Koyama, Maki S. Stein, John F. Stoodley, Catherine J. Hansen, Peter C. TI Functional MRI evidence for the importance of visual short-term memory in logographic reading SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE attention; Japanese; lateral occipital complex; logographic Kanji vs; syllabic Kana; superior intraparietal sulcus; visual complexity ID WORD FORM AREA; POSTERIOR PARIETAL CORTEX; LATERAL OCCIPITAL COMPLEX; SUPERIOR TEMPORAL GYRUS; WORKING-MEMORY; DEVELOPMENTAL DYSLEXIA; PHONOLOGICAL AWARENESS; INTRAPARIETAL SULCUS; FUSIFORM GYRUS; NEURAL SYSTEM AB Logographic symbols are visually complex, and thus children's abilities for visual short-term memory (VSTM) predict their reading competence in logographic systems. In the present study, we investigated the importance of VSTM in logographic reading in adults, both behaviorally and by means of fMRI. Outside the scanner, VSTM predicted logographic Kanji reading in native Japanese adults (n = 45), a finding consistent with previous observations in Japanese children. In the scanner, participants (n = 15) were asked to perform a visual one-back task. For this fMRI experiment, we took advantage of the unique linguistic characteristic of the Japanese writing system, whereby syllabic Kana and logographic Kanji can share the same sound and meaning, but differ only in the complexity of their visual features. Kanji elicited greater activation than Kana in the cerebellum and two regions associated with VSTM, the lateral occipital complex and the superior intraparietal sulcus, bilaterally. The same regions elicited the highest activation during the control condition (an unfamiliar, unpronounceable script to the participants), presumably due to the increased VSTM demands for processing the control script. In addition, individual differences in VSTM performance (outside the scanner) significantly predicted blood oxygen level-dependent signal changes in the identified VSTM regions, during the Kanji and control conditions, but not during the Kana condition. VSTM appears to play an important role in reading logographic words, even in skilled adults, as evidenced at the behavioral and neural level, most likely due to the increased VSTM/visual attention demands necessary for processing complex visual features inherent in logographic symbols. C1 [Koyama, Maki S.] NYU, Ctr Child Study, Phyllis Green & Randolph Cowen Inst Pediat Neuros, New York, NY 10016 USA. [Koyama, Maki S.; Stein, John F.; Stoodley, Catherine J.; Hansen, Peter C.] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England. [Stoodley, Catherine J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Stoodley, Catherine J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Hansen, Peter C.] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England. RP Koyama, MS (reprint author), NYU, Ctr Child Study, Phyllis Green & Randolph Cowen Inst Pediat Neuros, 550 1St Ave, New York, NY 10016 USA. EM makisophiakoyama@gmail.com RI Hansen, Peter/F-3163-2010; Stoodley, Catherine/P-2081-2016; OI Hansen, Peter/0000-0002-4948-1007; Stoodley, Catherine/0000-0003-2629-0213; Stein, John/0000-0001-5843-8986 FU Oxford-Kobe scholarship; Dyslexia Research Trust FX This study was part of the doctoral research of M. S. K., which was conducted at the University of Oxford, and supported by an Oxford-Kobe scholarship and the Dyslexia Research Trust. NR 73 TC 7 Z9 7 U1 1 U2 12 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD FEB PY 2011 VL 33 IS 3 BP 539 EP 548 DI 10.1111/j.1460-9568.2010.07534.x PG 10 WC Neurosciences SC Neurosciences & Neurology GA 713XD UT WOS:000286769800016 PM 21175881 ER PT J AU von Campenhausen, S Winter, Y Silva, ARE Sampaio, C Ruzicka, E Barone, P Poewe, W Guekht, A Mateus, C Pfeiffer, KP Berger, K Skoupa, J Botzel, K Geiger-Gritsch, S Siebert, U Balzer-Geldsetzer, M Oertel, WH Dodel, R Reese, JP AF von Campenhausen, Sonja Winter, Yaroslav Rodrigues e Silva, Antonio Sampaio, Christina Ruzicka, Evzen Barone, Paolo Poewe, Werner Guekht, Alla Mateus, Ceu Pfeiffer, Karl-P. Berger, Karin Skoupa, Jana Boetzel, Kai Geiger-Gritsch, Sabine Siebert, Uwe Balzer-Geldsetzer, Monika Oertel, Wolfgang H. Dodel, Richard Reese, Jens P. TI Costs of illness and care in Parkinson's Disease: An evaluation in six countries SO EUROPEAN NEUROPSYCHOPHARMACOLOGY LA English DT Article DE Parkinson's Disease; Cost; Cost-of-illness; Care; Economic burden; Europe ID QUALITY-OF-LIFE; CAREGIVER-BURDEN; ECONOMIC-IMPACT; EUROPE; COHORT; GERMANY; SEVERITY AB We investigated the costs of Parkinson's Disease (PD) in 486 patients based on a survey conducted in six countries. Economic data were collected over a 6-month period and presented from the societal perspective. The total mean costs per patient ranged from EUR 2620 to EUR 9820. Direct costs totalled about 60% to 70% and indirect costs about 30% to 40% of total costs. The proportions of costs components of PD vary notably; variations were due to differences in country-specific health system characteristics, macro economic conditions, as well as frequencies of resource use and price differences. However, inpatient care, long-term care and medication were identified as the major expenditures in the investigated countries. (C) 2010 Elsevier B.V. and ECNP. All rights reserved. C1 [von Campenhausen, Sonja; Winter, Yaroslav; Rodrigues e Silva, Antonio; Balzer-Geldsetzer, Monika; Oertel, Wolfgang H.; Dodel, Richard; Reese, Jens P.] Univ Marburg, Dept Neurol, D-35039 Marburg, Germany. [von Campenhausen, Sonja; Boetzel, Kai] Univ Munich, Dept Neurol, D-8000 Munich, Germany. [Sampaio, Christina] Lisboa Med Univ, Dept Neurol, Lisbon, Portugal. [Ruzicka, Evzen; Skoupa, Jana] Charles Univ Prague, Dept Neurol, Prague, Czech Republic. [Barone, Paolo] Napoli Frederico II Univ, Dept Neurol, Naples, Italy. [Poewe, Werner] Innsbruck Med Univ, Dept Neurol, Innsbruck, Austria. [Guekht, Alla] Russian State Med Univ, Dept Neurol, Moscow 117437, Russia. [Mateus, Ceu] Natl Sch Publ Hlth, Lisbon, Portugal. [Pfeiffer, Karl-P.] Innsbruck Med Univ, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria. [Berger, Karin] Med Econ Res Grp, Munich, Germany. [Geiger-Gritsch, Sabine; Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth, Inst Publ Hlth Med Decis Making & Hlth Technol As, Hall In Tirol, Austria. [Siebert, Uwe] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Siebert, Uwe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA. RP Dodel, R (reprint author), Univ Marburg, Dept Neurol, Rudolf Bultmann Str 8, D-35039 Marburg, Germany. EM dodel@med.uni-marburg.de RI Mateus, Ceu/J-2554-2012 OI Mateus, Ceu/0000-0001-6219-219X NR 58 TC 21 Z9 21 U1 2 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-977X J9 EUR NEUROPSYCHOPHARM JI Eur. Neuropsychopharmacol. PD FEB PY 2011 VL 21 IS 2 BP 180 EP 191 DI 10.1016/j.euroneuro.2010.08.002 PG 12 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 725BJ UT WOS:000287619900006 PM 20888737 ER PT J AU El-Serag, HB Graham, DY AF El-Serag, Hashem B. Graham, David Y. TI Routine Polypectomy for Colorectal Polyps and Ablation for Barrett's Esophagus Are Intellectually the Same SO GASTROENTEROLOGY LA English DT Editorial Material ID CANCER; SURVEILLANCE; MORTALITY C1 [El-Serag, Hashem B.; Graham, David Y.] Houston VA Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [El-Serag, Hashem B.; Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston VA Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. NR 12 TC 15 Z9 15 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2011 VL 140 IS 2 BP 386 EP 388 DI 10.1053/j.gastro.2010.12.019 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 711LR UT WOS:000286593600012 PM 21172329 ER PT J AU Malik, WQ Truccolo, W Brown, EN Hochberg, LR AF Malik, Wasim Q. Truccolo, Wilson Brown, Emery N. Hochberg, Leigh R. TI Efficient Decoding With Steady-State Kalman Filter in Neural Interface Systems SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Article DE Brain-computer interfaces (BCI); brain-machine interfaces (BMI); Kalman filter; motor cortex; neural decoding; paralysis; spinal cord injury; state-space models; tetraplegia ID POSTERIOR PARIETAL CORTEX; BRAIN-MACHINE INTERFACES; PRIMARY MOTOR CORTEX; MOVEMENT; TETRAPLEGIA; HUMANS; TRAJECTORIES; PERFORMANCE; PRIMATES; SIGNALS AB The Kalman filter is commonly used in neural interface systems to decode neural activity and estimate the desired movement kinematics. We analyze a low-complexity Kalman filter implementation in which the filter gain is approximated by its steady-state form, computed offline before real-time decoding commences. We evaluate its performance using human motor cortical spike train data obtained from an intracortical recording array as part of an ongoing pilot clinical trial. We demonstrate that the standard Kalman filter gain converges to within 95% of the steady-state filter gain in 1.5 +/- 0.5 s (mean +/- s.d.). The difference in the intended movement velocity decoded by the two filters vanishes within 5 s, with a correlation coefficient of 0.99 between the two decoded velocities over the session length. We also find that the steady-state Kalman filter reduces the computational load (algorithm execution time) for decoding the firing rates of 25 +/- 3 single units by a factor of 7.0 +/- 0.9. We expect that the gain in computational efficiency will be much higher in systems with larger neural ensembles. The steady-state filter can thus provide substantial runtime efficiency at little cost in terms of estimation accuracy. This far more efficient neural decoding approach will facilitate the practical implementation of future large-dimensional, multisignal neural interface systems. C1 [Malik, Wasim Q.; Brown, Emery N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Malik, Wasim Q.; Hochberg, Leigh R.] Brown Univ, Sch Engn, Providence, RI 02912 USA. [Malik, Wasim Q.; Truccolo, Wilson; Hochberg, Leigh R.] Brown Univ, Inst Brain Res, Providence, RI 02912 USA. [Malik, Wasim Q.; Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Hochberg, Leigh R.] Rehabil R&D Serv, Ctr Restorat & Regenerat Med, US Dept Vet Affairs, Providence, RI 02908 USA. [Truccolo, Wilson] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Truccolo, Wilson; Hochberg, Leigh R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. [Brown, Emery N.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Malik, WQ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. EM wmalik@partners.org; wilson_truccolo@brown.edu; enb@neu-rostat.mit.edu; leigh_hochberg@brown.edu RI Malik, Wasim/C-9982-2011 FU National Institutes of Health (NIH) [R01 DC009899, RC1 HD063931, N01 HD053403, 5K01 NS057389, DP1 OD003646, R01 EB006385]; Office of Research and Development, Rehabilitation R&D Service, U.S. Department of Veterans Affairs; Deane Institute for Integrated Research on Atrial Fibrillation and Stroke; Massachusetts General Hospital; Doris Duke Charitable Foundation; Massachusetts General and Spaulding Rehabilitation Hospitals FX Manuscript received December 05, 2009, revised May 18, 2010; accepted September 17, 2010. Date of publication November 15, 2010; date of current version February 09, 2011. This work was supported in part by the National Institutes of Health (NIH) under Grant R01 DC009899, Grant RC1 HD063931, Grant N01 HD053403, Grant 5K01 NS057389, Grant DP1 OD003646, and Grant R01 EB006385; in part by the Office of Research and Development, Rehabilitation R&D Service, U.S. Department of Veterans Affairs; in part by the Deane Institute for Integrated Research on Atrial Fibrillation and Stroke, Massachusetts General Hospital; and in part by the Doris Duke Charitable Foundation. The work of L. R. Hochberg was supported by the Massachusetts General and Spaulding Rehabilitation Hospitals, which in turn received clinical trial support from Cyberkinetics Neurotechnology Systems, Inc. Cyberkinetics ceased operation in 2009. The BrainGate pilot clinical trials are now directed by Massachusetts General Hospital. NR 40 TC 25 Z9 25 U1 0 U2 11 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1534-4320 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD FEB PY 2011 VL 19 IS 1 BP 25 EP 34 DI 10.1109/TNSRE.2010.2092443 PG 10 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA 718CG UT WOS:000287096900004 PM 21078582 ER PT J AU Rosenthal, A Ntziachristos, V Razansky, D AF Rosenthal, Amir Ntziachristos, Vasilis Razansky, Daniel TI Optoacoustic Methods for Frequency Calibration of Ultrasonic Sensors SO IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL LA English DT Article ID OPTICAL INTERFEROMETRY; IN-VIVO; HYDROPHONES; TOMOGRAPHY; RECIPROCITY AB The frequency response of ultrasonic detectors is commonly calibrated by finding their sensitivity to incident plane waves at discrete frequencies. For certain applications, such as the emerging field of optoacoustic tomography, it is the response to point sources emitting broadband spectra that needs to be found instead. Although these two distinct sensitivity characteristics are interchangeable in the case of a flat detector and a point source at infinity, it is not the case for detectors with size considerably larger than the acoustic wavelength of interest or those having a focused aperture. Such geometries, which are common in optoacoustics, require direct calibration of the acoustic detector using a point source placed in the relevant position. In this paper, we report on novel cross-validating optoacoustic methods for measuring the frequency response of wideband acoustic sensors. The approach developed does not require pre-calibrated hydrophones and therefore can be readily adopted in any existing optoacoustic measurement configuration. The methods are successfully confirmed experimentally by measuring the frequency response of a common piezoelectric detector having a cylindrically focused shape. C1 [Rosenthal, Amir; Ntziachristos, Vasilis; Razansky, Daniel] Tech Univ Munich, IBMI, Neuherberg, Germany. [Rosenthal, Amir; Ntziachristos, Vasilis; Razansky, Daniel] Helmholtz Ctr Munich, Neuherberg, Germany. [Rosenthal, Amir] Massachusetts Gen Hosp, Cardiovasc Res Ctr CVRC, Boston, MA 02114 USA. [Rosenthal, Amir] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Rosenthal, Amir] Harvard Univ, Sch Med, Boston, MA USA. RP Rosenthal, A (reprint author), Tech Univ Munich, IBMI, Neuherberg, Germany. EM eeamir@gmail.com RI Rosenthal, Amir/C-8650-2014; OI Razansky, Daniel/0000-0001-8676-0964 FU European Community [235689]; German Research Foundation (DFG) [RA 1848/1]; European Research Council; BMBF FX A.R. acknowledges the financial support of the European Community's Seventh Framework Programme (FP7/2007-2013 under grant agreement number 235689). D. R. acknowledges support from the German Research Foundation (DFG) Research Grant (RA 1848/1) and the European Research Council Starting Grant. V. N. acknowledges financial support from the European Research Council Advanced Investigator Award, and the BMBF's Innovation in Medicine Award. NR 20 TC 28 Z9 28 U1 0 U2 9 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0885-3010 J9 IEEE T ULTRASON FERR JI IEEE Trans. Ultrason. Ferroelectr. Freq. Control PD FEB PY 2011 VL 58 IS 2 BP 316 EP 326 DI 10.1109/TUFFC.2011.1809 PG 11 WC Acoustics; Engineering, Electrical & Electronic SC Acoustics; Engineering GA 725TY UT WOS:000287670200006 PM 21342817 ER PT J AU Cox, KM Goel, S O'Connell, RL Boyer, M Beale, PJ Simes, RJ Stockler, MR AF Cox, K. M. Goel, S. O'Connell, R. L. Boyer, M. Beale, P. J. Simes, R. J. Stockler, M. R. TI Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin SO INTERNAL MEDICINE JOURNAL LA English DT Article DE cisplatin; outpatient; inpatient; patient preference; health services ID INFUSION CHEMOTHERAPY; PROGNOSTIC-FACTORS; CANCER; NAUSEA; NEPHROTOXICITY; TOXICITY AB Background/Aims: Treatment with high-dose cisplatin (HDC) previously required inpatient (IP) admission with overnight hospitalization, but recently practice has shifted to outpatient (OP) therapy. We aimed to determine whether it is preferable to give HDC as an IP or OP using a two-period cross-over trial. Methods: Eligible patients were starting chemotherapy with >= 2 cycles of HDC (>= 100 mg/dose) and were suitable for OP treatment. All patients received an IP cycle and OP cycle: the order was randomly allocated. Pre-hydration, anti-emetics and chemotherapy were identical for IP and OP. Post-hydration varied by group (3 L normal saline (NS) for IP, 2 L NS for OP). The primary outcome was patient preference for IP versus OP treatment. Secondary outcomes included aspects of health-related quality of life, adverse events (dose delays and reductions, elevated creatinine and unplanned readmissions) and resource use. Results: Fifty-nine patients were randomized, 53 completed two cycles of HDC. Most patients preferred OP treatment (36 vs 13, P = 0.002). There were no significant differences in patients' ratings of nausea, vomiting, fatigue, anxiety, depression or overall quality of life. Adverse events were few and unrelated to IP versus OP treatment. Nursing time was longer for IP than OP (163 vs 104 min, P < 0.001). Conclusion: OP treatment was preferred by most patients, appeared safe and used less resources. C1 [Cox, K. M.; Goel, S.; Boyer, M.; Beale, P. J.; Simes, R. J.; Stockler, M. R.] Royal Prince Alfred Hosp, Sydney Canc Ctr, Sydney, NSW, Australia. [O'Connell, R. L.; Simes, R. J.; Stockler, M. R.] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 2006, Australia. [Beale, P. J.; Stockler, M. R.] Concord Repatriat Gen Hosp, Sydney Canc Ctr, Sydney, NSW, Australia. RP Goel, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Edwin L Steele Lab Tumor Biol, Cox 7,100 Blossom St, Boston, MA 02114 USA. EM shom.goel@gmail.com RI Simes, Robert/P-1497-2014; Stockler, Martin/N-3859-2016 OI Stockler, Martin/0000-0003-3793-8724 NR 17 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1444-0903 J9 INTERN MED J JI Intern. Med. J. PD FEB PY 2011 VL 41 IS 2 BP 172 EP 178 DI 10.1111/j.1445-5994.2010.02201.x PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 726UM UT WOS:000287751900007 PM 20214694 ER PT J AU Lipsky, BA Itani, KMF Weigelt, JA Joseph, W Paap, CM Reisman, A Myers, DE Huang, DB AF Lipsky, Benjamin A. Itani, Kamal M. F. Weigelt, John A. Joseph, Warren Paap, Christopher M. Reisman, Arlene Myers, Daniela E. Huang, David B. TI The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Complicated skin and skin structure infection; Diabetes mellitus; Linezolid; Methicillin-resistant Staphylococcus aureus; Vancomycin ID FOOT INFECTIONS; SOFT-TISSUE; VANCOMYCIN; PENETRATION; BACTEREMIA AB Objective: To compare outcomes of treating complicated skin and skin structure infections (cSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA) with linezolid versus vancomycin in diabetic and non-diabetic patients. Methods: We pooled data from three prospective clinical trials in which 1056 patients were randomized to receive either linezolid (intravenous (IV) or oral) or vancomycin (IV) every 12 h, for 7-28 days. Results: Diabetic (n = 349) and non-diabetic patients (n = 707) had comparable demographics and comorbidities. Clinical success rates were lower in diabetic than in non-diabetic patients (72.3% and 85.8%, respectively). Overall, non-diabetic patients had a shorter adjusted mean length of stay (LOS) compared with diabetic patients (8.2 and 10.7 days, respectively; p < 0.0001). Among diabetic patients, rates were comparable with linezolid and vancomycin treatment for clinical success (74% and 71%, respectively) and microbiological success (60% and 54%, respectively). Among non-diabetic patients, clinical and microbiological success rates were higher in linezolid-than in vancomycin-treated patients (90% and 81%, respectively, and 78% and 65%, respectively). Rates of drug-related adverse events were comparable in diabetic and non-diabetic patients and with linezolid and vancomycin treatment. Adjusted mean LOS was shorter with linezolid than with vancomycin treatment in diabetic patients (9.5 and 11.7 days, respectively; p = 0.03) and non-diabetic patients (7.6 and 8.9 days, respectively; p = 0.02). Conclusions: Clinical success rates were lower in diabetic than non-diabetic patients with cSSSI caused by MRSA. Comparing linezolid and vancomycin, clinical and microbiological success rates were comparable in diabetic patients, but were better for linezolid than for vancomycin in non-diabetic patients. (C) 2010 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [Lipsky, Benjamin A.] VA Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98108 USA. [Lipsky, Benjamin A.] Univ Washington, Sch Med, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. [Itani, Kamal M. F.] Boston VA Hlth Care Syst, Boston, MA USA. [Itani, Kamal M. F.] Boston Univ, Boston, MA 02215 USA. [Weigelt, John A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Joseph, Warren] Roxborough Mem Hosp, Philadelphia, PA USA. [Paap, Christopher M.; Reisman, Arlene; Myers, Daniela E.; Huang, David B.] Pfizer Inc, New York, NY USA. RP Lipsky, BA (reprint author), VA Puget Sound Hlth Care Syst, Med Serv, 1880 S Columbian Way,S-111-GIMC, Seattle, WA 98108 USA. EM balipsky@uw.edu OI Lipsky, Benjamin A./0000-0001-9886-5114 FU Pfizer Inc. FX This study was sponsored by Pfizer Inc. All authors collaborated in the development of the study design, in the collection, analysis, and interpretation of study data, in the writing of the manuscript, and in the decision to submit the manuscript for publication. Editorial support for this manuscript (technical writing) was provided by E.M. Wells of PAREXEL and was funded by Pfizer Inc. NR 19 TC 16 Z9 18 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD FEB PY 2011 VL 15 IS 2 BP E140 EP E146 DI 10.1016/j.ijid.2010.10.003 PG 7 WC Infectious Diseases SC Infectious Diseases GA 715WR UT WOS:000286924100006 PM 21134775 ER PT J AU Mamtani, M Chatterjee, N Mishra, A Soni, R Jawahirani, A Das, K Rughwani, V Shrivastava, M Kulkarni, H AF Mamtani, M. Chatterjee, N. Mishra, A. Soni, R. Jawahirani, A. Das, K. Rughwani, V. Shrivastava, M. Kulkarni, H. TI Hemoglobin F levels influence the results of NESTROFT: replication in two surveys SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY LA English DT Letter ID CELL OSMOTIC FRAGILITY; BETA-THALASSEMIA; INFANTS; NEWBORNS; PRETERM C1 [Mamtani, M.; Kulkarni, H.] Lata Med Res Fdn, Nagpur, Maharashtra, India. [Mamtani, M.; Kulkarni, H.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Mamtani, M.; Kulkarni, H.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & Infect HIV 1, San Antonio, TX USA. [Chatterjee, N.; Mishra, A.; Soni, R.; Shrivastava, M.] Bhopal Mem Hosp & Res Ctr, Thalassaemia Unit, Dept Transfus Med, Bhopal, India. [Jawahirani, A.; Rughwani, V.] Thalassemia Soc India, Nagpur, Maharashtra, India. [Das, K.] Anthropol Survey India, Nagpur, Maharashtra, India. RP Mamtani, M (reprint author), Lata Med Res Fdn, Nagpur, Maharashtra, India. EM hemant_kulkarnius@yahoo.com NR 13 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1751-5521 J9 INT J LAB HEMATOL JI Int. J. Lab. Hematol. PD FEB PY 2011 VL 33 IS 1 BP 113 EP 115 DI 10.1111/j.1751-553X.2010.01252.x PG 3 WC Hematology SC Hematology GA 704KW UT WOS:000286052900014 PM 20633055 ER PT J AU Kradin, RL AF Kradin, Richard L. TI Psychosomatic disorders: the canalization of mind into matter SO JOURNAL OF ANALYTICAL PSYCHOLOGY LA English DT Article DE Charcot; genetics; mind/body interaction; placebo response complex; psychosomatic dysfunction ID CHRONIC-FATIGUE-SYNDROME; MYALGIC ENCEPHALOMYELITIS; SOMATIZATION; ABUSE; SELF AB Psychosomatic disorders represent a therapeutic conundrum. Despite compelling evidence to suggest the integrity of mind and body, humans are famously prone to experiencing them as separate. This paper explores the scientific challenges posed by psychosomatic disorders and how changing cultural notions contribute to their perplexing presentations. Excerpts of cases from patients with chronic pelvic pain, chronic fatigue, and a factitious disorder are presented as examples of the challenges that these patients pose in analysis. An explanatory model of mind/body interaction based on early maternal-infant interactions and the placebo response complex is proposed as the basis for how psychosomatic pathologies may develop. Finally, therapeutic approaches to the psychological treatment of patients with psychosomatic issues are considered. C1 [Kradin, Richard L.] Massachusetts Gen Hosp, MGH Ctr Psychoanalyt Studies, Boston, MA 02114 USA. [Kradin, Richard L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Kradin, Richard L.] CG Jung Inst, Boston, MA USA. [Kradin, Richard L.] Pacifica Grad Sch, Carpinteria, CA USA. RP Kradin, RL (reprint author), Massachusetts Gen Hosp, MGH Ctr Psychoanalyt Studies, Boston, MA 02114 USA. EM rkradin@partners.org NR 40 TC 1 Z9 1 U1 0 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0021-8774 J9 J ANAL PSYCHOL JI J. Anal. Psychol. PD FEB PY 2011 VL 56 IS 1 BP 37 EP 55 DI 10.1111/j.1468-5922.2010.01889.x PG 19 WC Psychology, Psychoanalysis SC Psychology GA 707AJ UT WOS:000286258600003 PM 21241293 ER PT J AU Troughton, RW Ritzema, J Eigler, NL Melton, IC Krum, H Adamson, PB Kar, S Shah, PK Whiting, JS Heywood, JT Rosero, S Singh, JP Saxon, L Matthews, R Crozier, IG Abraham, WT AF Troughton, Richard W. Ritzema, Jay Eigler, Neal L. Melton, Iain C. Krum, Henry Adamson, Philip B. Kar, Saibal Shah, Prediman K. Whiting, James S. Heywood, J. Thomas Rosero, Spencer Singh, Jagmeet P. Saxon, Leslie Matthews, Ray Crozier, Ian G. Abraham, William T. CA HOMEOSTASIS Investigators TI Direct Left Atrial Pressure Monitoring in Severe Heart Failure: Long-Term Sensor Performance SO JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH LA English DT Article DE Heart failure; Hemodynamics; Implantable devices ID HEMODYNAMIC MONITOR; WEDGE AB We report the stability, accuracy, and development history of a new left atrial pressure (LAP) sensing system in ambulatory heart failure (HF) patients. A total of 84 patients with advanced HF underwent percutaneous transseptal implantation of the pressure sensor. Quarterly noninvasive calibration by modified Valsalva maneuver was achieved in all patients, and 96.5% of calibration sessions were successful with a reproducibility of 1.2 mmHg. Absolute sensor drift was maximal after 3 months at 4.7 mmHg (95% CI, 3.2-6.2 mmHg) and remained stable through 48 months. LAP was highly correlated with simultaneous pulmonary wedge pressure at 3 and 12 months (r = 0.98, average difference of 0.8 +/- 4.0 mmHg). Freedom from device failure was 95% (n = 37) at 2 years and 88% (n = 12) at 4 years. Causes of failure were identified and mitigated with 100% freedom from device failure and less severe anomalies in the last 41 consecutive patients (p = 0.005). Accurate and reliable LAP measurement using a chronic implanted monitoring system is safe and feasible in patients with advanced heart failure. C1 [Troughton, Richard W.] Univ Otago, Dept Med, Christchurch 8140, New Zealand. [Troughton, Richard W.; Ritzema, Jay; Melton, Iain C.; Crozier, Ian G.] Christchurch Hosp, Dept Cardiol, Christchurch, New Zealand. [Krum, Henry] Alfred Hosp, Melbourne, Australia. [Adamson, Philip B.] Oklahoma Cardiovasc Res Grp, Oklahoma City, OK USA. [Eigler, Neal L.; Kar, Saibal; Shah, Prediman K.; Whiting, James S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Heywood, J. Thomas] Scripps Hosp, La Jolla, CA USA. [Rosero, Spencer] Univ Rochester, Rochester, NY USA. [Saxon, Leslie; Matthews, Ray] Univ So Calif, Los Angeles, CA USA. [Singh, Jagmeet P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Abraham, William T.] Ohio State Univ, Columbus, OH 43210 USA. RP Troughton, RW (reprint author), Univ Otago, Dept Med, POB 4345, Christchurch 8140, New Zealand. EM Richard.Troughton@cdhb.govt.nz FU St Jude Medical, CRMD, Sylmar California FX We thank the study coordinators for their hard work and attention to detail. The study was sponsored by St Jude Medical, CRMD, Sylmar California. NR 21 TC 33 Z9 33 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1937-5387 J9 J CARDIOVASC TRANSL JI J. Cardiovasc. Transl. Res. PD FEB PY 2011 VL 4 IS 1 SI SI BP 3 EP 13 DI 10.1007/s12265-010-9229-z PG 11 WC Cardiac & Cardiovascular Systems; Medicine, Research & Experimental SC Cardiovascular System & Cardiology; Research & Experimental Medicine GA 705CM UT WOS:000286106400002 PM 20945124 ER PT J AU Bloch, MJ Basile, JN AF Bloch, Michael J. Basile, Jan N. TI Patient Self-management Improves Blood Pressure Control SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article C1 [Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Risk Reduct Ctr,St Marys Reg Med Ctr, Reno, NV 89503 USA. [Basile, Jan N.] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Bloch, MJ (reprint author), Univ Nevada, Sch Med, Dept Internal Med, Risk Reduct Ctr,St Marys Reg Med Ctr, 645 N Arlington St,Suite 460, Reno, NV 89503 USA. EM mbloch@aol.com NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD FEB PY 2011 VL 13 IS 2 BP 138 EP 140 DI 10.1111/j.1751-7176.2010.00400.x PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 711ZE UT WOS:000286630100010 PM 21272203 ER PT J AU Brown, WV Goldberg, RB Lopes-Virella, M Reaven, P AF Brown, W. Virgil Goldberg, Ronald B. Lopes-Virella, Maria Reaven, Peter TI Reducing vascular disease risk in the type 2 diabetic patientt SO JOURNAL OF CLINICAL LIPIDOLOGY LA English DT Editorial Material C1 [Brown, W. Virgil] Emory Univ, Sch Med, Atlanta, GA 30033 USA. [Goldberg, Ronald B.] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Diabet Res Inst, Miami, FL 33136 USA. [Lopes-Virella, Maria] Med Univ S Carolina, Charleston, SC 29425 USA. [Lopes-Virella, Maria] Ralph H Johnson VA Med Ctr, Nutr Support Team, Charleston, SC USA. [Reaven, Peter] Arizona State Univ, Phoenix, AZ USA. [Reaven, Peter] Univ Arizona, Phoenix, AZ USA. RP Brown, WV (reprint author), Emory Univ, Sch Med, 1670 Clairmont Rd, Atlanta, GA 30033 USA. EM editorjel@yahoo.corn NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-2874 J9 J CLIN LIPIDOL JI J. Clin. Lipidol. PD FEB PY 2011 VL 5 IS 1 BP 3 EP 11 DI 10.1016/j.jacl.2010.11.005 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 716XD UT WOS:000287005900002 PM 21262501 ER PT J AU Rogg, JG De Neve, JW Huang, C Brown, D Jang, IK Chang, YC Marill, K Parry, B Hoffmann, U Nagurney, JT AF Rogg, Jonathan G. De Neve, Jan-Walter Huang, Calvin Brown, David Jang, Ik-Kyung Chang, Yuchiao Marill, Keith Parry, Blair Hoffmann, Udo Nagurney, John T. TI THE TRIPLE WORK-UP FOR EMERGENCY DEPARTMENT PATIENTS WITH ACUTE CHEST PAIN: HOW OFTEN DOES IT OCCUR? SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE acute coronary syndrome; pulmonary embolus; aortic dissection; chest pain ID ACUTE AORTIC DISSECTION; ACUTE CORONARY SYNDROMES; ACUTE MYOCARDIAL-INFARCTION; SUSPECTED PULMONARY-EMBOLISM; D-DIMER; COMPUTED-TOMOGRAPHY; DIAGNOSTIC-ACCURACY; MANAGEMENT; MALPERFUSION; ISCHEMIA AB Objectives: To measure the degree of overlap and diagnostic yield for evaluations of acute coronary syndrome (ACS), pulmonary embolism (PE), and aortic dissection (AD) among Emergency Department (ED) patients. Methods: We conducted a cross-sectional descriptive study of consecutive adult patients seen in the ED of a 78,000-annual-visit urban academic medical center. Patients who had received at least one of eight of the tests used in our ED to diagnose these three diseases were identified through three methods, and a final study population list was created. Overlap of evaluations and diagnostic yields were calculated by simple descriptive statistics. Results: Over a 2-week period, 626 patient encounters among 622 unique patients were identified. Among these 626 visits, 139 (22%) included diagnostic tests for more than one of the three diagnoses of interest. The majority of these multiple tests were for ACS plus PE (n = 121, 87% of all multiple tests), whereas a minority of patients received tests for ACS plus AD (n = 14, 10% of all multiple tests) or for.the "triple work-up" of ACS plus PE plus AD (n = 4, 2.9% of all multiple tests). Conclusion: Although the "triple work-up" evaluation for ACS, PE, and AD is relatively uncommon, a significant number of ED patients who are evaluated for at least one of these three major chest pain syndromes receive simultaneous testing for one of the others. (C) 2011 Elsevier Inc. C1 [Rogg, Jonathan G.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [De Neve, Jan-Walter] Univ Brussels, Fac Med, Brussels, Belgium. [Huang, Calvin] Harvard Affiliated Emergency Med Residency, Boston, MA USA. [Brown, David; Marill, Keith; Parry, Blair; Nagurney, John T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Jang, Ik-Kyung] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. [Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Nagurney, JT (reprint author), MGH Clin 115, 55 Fruit St,0 Emerson Pl,Suite 3B, Boston, MA 02114 USA. RI De Neve, Jan-Walter/D-7547-2017 OI De Neve, Jan-Walter/0000-0003-0090-8249 NR 43 TC 7 Z9 7 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD FEB PY 2011 VL 40 IS 2 BP 128 EP 134 DI 10.1016/j.jemermed.2008.02.031 PG 7 WC Emergency Medicine SC Emergency Medicine GA 722XO UT WOS:000287468800002 PM 18790585 ER PT J AU Krauss, WC Shah, S Shah, S Thomas, SH AF Krauss, William C. Shah, Sachita Shah, Sachin Thomas, Stephen H. TI FENTANYL IN THE OUT-OF-HOSPITAL SETTING: VARIABLES ASSOCIATED WITH HYPOTENSION AND HYPOXEMIA SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE analgesia; Emergency Medical Services; pain control; fentanyl ID PAIN MANAGEMENT; TRAUMA PATIENTS; EMERGENCY-DEPARTMENT; INTRANASAL FENTANYL; PEDIATRIC TRAUMA; ANALGESIA; MORPHINE; PROGRAM; RELIEF; SAFETY AB Background: Previous out-of-hospital fentanyl analgesia studies are limited by retrospective nature or low numbers. Study Objectives: This study sought to prospectively assess fentanyl safety in a large out-of-hospital group, to identify variables associated with post-fentanyl hypotension (HN; systolic blood pressure [SBP] < 90) or hypoxemia (HX; Spo(2) < 90%). Methods: As part of a new protocol requiring documentation of pen-dose vital signs and adverse effects associated with fentanyl bolus doses, our Emergency Medical Services helicopter service assessed 500 consecutive patients receiving fentanyl from July through September 2006. By a priori plan, we assessed HN and HX descriptively (median with interquartile range, exact confidence intervals [CIs]) and with multivariate regression. Results: In 1055 patients, post-fentanyl HN was noted 52 times (4.9%), being a continuation of pre-fentanyl HN in 24 patients (46.2%); HN was new in 28 patients (2.7% of 1055, 95% CI 1.8-3.8%). Regression showed no association between dependent variables HN (assessed for 1055 doses) or HX (528 doses in non-intubated) and independent variables age, diagnosis, gender, scene/inter-facility mission, dose, or total transport dose. Pre-and post-fentanyl SpO(2) means were unchanged: 98.8% (95% CI 98.5-98.9) vs. 98.6% (95% CI 98.3-99.0), respectively. Post-fentanyl HN was seen in patients with pre-fentanyl intubation (odds ratio [OR] 5.3, p = 0.002) and with pre-fentanyl low SBP (OR 40, p < 0.001). Conclusion: In a closely monitored out-of-hospital population, fentanyl incurs a low risk of significant hypoxemia. The risk of fentanyl-associated hypotension is also very low, but difficult to predict in the absence of acuity markers such as preexisting hypotension. (C) 2011 Elsevier Inc. C1 [Krauss, William C.; Shah, Sachita; Thomas, Stephen H.] Brigham & Womens Hosp, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Shah, Sachin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Krauss, WC (reprint author), Brigham & Womens Hosp, Massachusetts Gen Hosp, 75 Francis St, Boston, MA 02115 USA. NR 31 TC 7 Z9 7 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD FEB PY 2011 VL 40 IS 2 BP 182 EP 187 DI 10.1016/j.jemermed.2009.02.009 PG 6 WC Emergency Medicine SC Emergency Medicine GA 722XO UT WOS:000287468800012 PM 19327928 ER PT J AU Tsoulfas, G Kawai, T Elias, N Ko, SC Agorastou, P Cosimi, AB Hertl, M AF Tsoulfas, Georgios Kawai, Tatsuo Elias, Nahel Ko, S. C. Agorastou, Polyxeni Cosimi, A. Benedict Hertl, Martin TI Long-term experience with liver transplantation for hepatocellular carcinoma SO JOURNAL OF GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT 8th Congress of the European-Hepato-Pancreato-Biliary-Association CY JUN 18-20, 2009 CL Athens, GREECE SP European Hepato Pancreato Biliary Assoc DE Liver transplantation; Hepatocellular carcinoma; MELD system ID WAITING-LIST; ALLOCATION SYSTEM; CIRRHOTIC LIVERS; UNITED-STATES; SURVIVAL; IMPACT; CHEMOEMBOLIZATION; RESECTION; DISEASE; POLICY AB The effect of the model for end-stage liver disease (MELD) system on the post-transplant survival of patients with hepatocellular carcinoma (HCC) has not been fully elucidated. Our objective is to review the results of liver transplantation (LT) for HCC at the Massachusetts General Hospital over a period of 12 years, with special emphasis on the effect of the MELD system. A retrospective review of 73 patients who underwent liver transplantation for HCC between 1995 and 2007. Outcome measures included demographics, tumor stage at explant, patient survival, and tumor recurrence. On pathologic review of the explanted liver, 12.3% of patients were classified as stage I; 42.5% as stage II, 21.9% as stage III, and 23.3% as stage IV. The overall actual survival rate was 85% at 1 year, 82% at 3 years, 73% at 5 years, and 66% at 10 years. Overall tumor recurrence was 11%. Survival rates were higher after the MELD system (5 year survival 60% before MELD vs. 85% after MELD). Recurrence decreased from 21% to 7.5%. We showed improved survival for HCC after LT over the last 12 years, and especially improved survival and decreased recurrence in the time since the implementation of the MELD system. C1 [Tsoulfas, Georgios; Kawai, Tatsuo; Elias, Nahel; Ko, S. C.; Agorastou, Polyxeni; Cosimi, A. Benedict; Hertl, Martin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Transplantat Unit, Boston, MA USA. RP Tsoulfas, G (reprint author), 66 Tsimiski St, Thessaloniki 54622, Greece. EM tsoulfasg@msn.com RI Tsoulfas, Georgios/K-4801-2012 OI Tsoulfas, Georgios/0000-0001-5043-7962 NR 31 TC 8 Z9 8 U1 0 U2 2 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 0944-1174 J9 J GASTROENTEROL JI J. Gastroenterol. PD FEB PY 2011 VL 46 IS 2 BP 249 EP 256 DI 10.1007/s00535-010-0302-9 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 723TF UT WOS:000287529200014 PM 20711612 ER PT J AU Dhaliwal, G AF Dhaliwal, Gurpreet TI Going with Your Gut SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE clinical reasoning; decision making; intuition; pattern recognition ID REASONING STRATEGIES; PHYSICIANS; DIAGNOSIS; MODEL C1 [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Dhaliwal, G (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. EM gurpreet.dhaliwal@ucsf.edu NR 22 TC 4 Z9 4 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2011 VL 26 IS 2 BP 107 EP 109 DI 10.1007/s11606-010-1578-4 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 725TK UT WOS:000287668800003 PM 21104451 ER PT J AU Peltan, ID Wright, DE AF Peltan, Ithan D. Wright, Douglas E. TI The Return of Bedside Rounds SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Letter C1 [Peltan, Ithan D.; Wright, Douglas E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Peltan, ID (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA. EM ipeltan@post.harvard.edu OI Peltan, Ithan/0000-0003-1730-234X NR 5 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2011 VL 26 IS 2 BP 113 EP 113 DI 10.1007/s11606-010-1564-x PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 725TK UT WOS:000287668800005 PM 21061080 ER PT J AU Guitton, TG Van der Werf, HJ Ring, D AF Guitton, Thierry G. Van der Werf, Huub J. Ring, David TI Quantitative Measurements of the Coronoid in Healthy Adult Patients SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE Computed tomography; morphology; predict; quantitative; coronoid ID RADIAL HEAD; DISLOCATIONS; FRACTURES; ELBOW; ULNA AB Purpose We investigated the hypothesis that a quantitative 3-dimensional computed tomography (CT) modeling technique that can measure size, shape, and proximal articular surface area can be used to develop formulas that could predict the volume and proximal surface area of the intact coronoid based on anatomical and demographic data available in patients with fracture of the coronoid process. Methods We used a consecutive series of 50 CT scans with a slice thickness of 1.25 mm or less obtained in patients with fracture of the distal humerus, but no injury to the coronoid, to create 3-dimensional models. The volume and articular surface area of the coronoid were measured, and predictive formulas were based on anatomical measurements. We calculated gender using multiple linear regression. Results There were significant correlations between total coronoid volume and coronoid articular surface area for coronoid width, radial neck diameter, radial head diameter, height, weight, and gender. Multiple linear regression modeling with the factors radial head diameter, radial neck diameter, coronoid width, height, weight, and gender resulted in formulas that could account for 71.8% of the variation in coronoid volume and 66.2% of the variation in coronoid articular surface area. The average relative percent difference was 1.32% for the coronoid volume and 0.68% for the coronoid articular surface area. Conclusions The volume and articular surface area of the coronoid can be estimated based on anatomical measurements and gender. This may lead to better estimates of lost fragments when modeling the fractured coronoid and CT scan of the opposite limb is not available. (J Hand Surg 2011;36A:232-237. Copyright (C) 2011 by the American Society for Surgery of the Hand. All rights reserved.) C1 [Guitton, Thierry G.; Van der Werf, Huub J.; Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hand & Upper Extrem Serv,Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org OI Guitton, Thierry/0000-0002-2599-1985 FU Joint Active Systems; Biomet; Stryker; Orthopaedic Trauma Association; Hand Innovations; Wright Medical; Skeletal Dynamics; AO North America FX D.R. received study-specific grants from Joint Active Systems, Biomet, Stryker, and the Orthopaedic Trauma Association. He is a consultant for Wright Medical, Tomier, Acumed, Skeletal Dynamics, Joint Active Systems, and Biomet. He receives honoraria from AO North America and AO International. He receives royalties from Hand Innovations, Wright Medical, and Skeletal Dynamics. He has stock options in Illuminos and Mimedex. He received funding for Hand Surgery Fellowship from AO North America. He is a deputy editor for The Journal of Hand Surgery and for Hand and Wrist, Journal of Orthopaedic Trauma. He is an assistant editor for Journal of Shoulder and Elbow Surgery. NR 9 TC 12 Z9 12 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD FEB PY 2011 VL 36A IS 2 BP 232 EP 237 DI 10.1016/j.jhsa.2010.11.002 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 716EM UT WOS:000286951900005 PM 21276886 ER PT J AU Gordon, CR AF Gordon, Chad R. TI Social Networking Among Upper Extremity Patients SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Letter ID FACE; PROGRAM C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA 02115 USA. RP Gordon, CR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA 02115 USA. NR 6 TC 1 Z9 1 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD FEB PY 2011 VL 36A IS 2 BP 367 EP 367 DI 10.1016/j.jhsa.2010.11.018 PG 1 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 716EM UT WOS:000286951900028 PM 21276904 ER PT J AU Bailey, EE Kroshinsky, D AF Bailey, Elizabeth E. Kroshinsky, Daniela TI Diagnostic guidelines for cellulitis: Recommendations based on a retrospective analysis of cellulitis admissions to Massachusetts General Hospital SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 69th Annual Meeting of the American-Academy-of-Dermatology CY FEB 04-08, 2011 CL New Orleans, LA SP Amer Acad Dermatol C1 [Bailey, Elizabeth E.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Kroshinsky, Daniela] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD FEB PY 2011 VL 64 IS 2 SU 1 BP AB12 EP AB12 PG 1 WC Dermatology SC Dermatology GA 714AY UT WOS:000286780500045 ER PT J AU Diehl, J Liang, LJ Aquino, L Chiu, M AF Diehl, Joseph Liang, Li-Jung Aquino, Lisa Chiu, Melvin TI Association between Mohs surgery wait times and surgical defect size in patients with squamous cell or basal cell carcinoma of the skin SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 69th Annual Meeting of the American-Academy-of-Dermatology CY FEB 04-08, 2011 CL New Orleans, LA SP Amer Acad Dermatol C1 [Diehl, Joseph; Chiu, Melvin] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA. [Liang, Li-Jung] W Los Angeles Vet Adm Med Ctr, Los Angeles, CA 90073 USA. [Aquino, Lisa] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD FEB PY 2011 VL 64 IS 2 SU 1 BP AB1 EP AB1 PG 1 WC Dermatology SC Dermatology GA 714AY UT WOS:000286780500004 ER PT J AU Hagele, T Cheng, C Kvedar, J Konda, S Pugliese, S AF Hagele, Thomas Cheng, Carol Kvedar, Joseph Konda, Sailesh Pugliese, Silvina TI DermHub: A comprehensive dermatology-focused patient education resource and social community SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Meeting Abstract CT 69th Annual Meeting of the American-Academy-of-Dermatology CY FEB 04-08, 2011 CL New Orleans, LA SP Amer Acad Dermatol C1 [Hagele, Thomas] Wright State Univ, Boonshoft Sch Med, Dayton, OH 45435 USA. [Cheng, Carol] Boston Univ, Sch Med, Boston, MA 02118 USA. [Kvedar, Joseph] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Konda, Sailesh] Boston Univ, Med Ctr, Boston, MA USA. [Pugliese, Silvina] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD FEB PY 2011 VL 64 IS 2 SU 1 BP AB78 EP AB78 PG 1 WC Dermatology SC Dermatology GA 714AY UT WOS:000286780500305 ER PT J AU Baddour, LM Epstein, AE Erickson, CC Knight, BP Levison, ME Lockhart, PB Masoudi, FA Okum, EJ Wilson, WR Beerman, LB Bolger, AF Estes, NAM Gewitz, M Newburger, JW Schron, EB Taubert, KA AF Baddour, Larry M. Epstein, Andrew E. Erickson, Christopher C. Knight, Bradley P. Levison, Matthew E. Lockhart, Peter B. Masoudi, Frederick A. Okum, Eric J. Wilson, Walter R. Beerman, Lee B. Bolger, Ann F. Estes, N. A. Mark, III Gewitz, Michael Newburger, Jane W. Schron, Eleanor B. Taubert, Kathryn A. CA Council Cardiovasc Disease Young Council Cardiovasc Surg & Anesthe Council Cardiovasc Nursing Council Clinical Cardiology Interdisciplinary Council Quality TI A summary of the update on cardiovascular implantable electronic device infections and their management A scientific statement from the American Heart Association SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE American Heart Association scientific statements; infection; device; cardiovascular implantable electronic device; pacemaker; defibrillator; endocarditis; bacteremia; antibiotic prophylaxis ID COAGULASE-NEGATIVE STAPHYLOCOCCI; PERMANENT PACEMAKER IMPLANTATION; ANTIBIOTIC-PROPHYLAXIS; CARDIOVERTER-DEFIBRILLATORS; ANTIMICROBIAL PROPHYLAXIS; ENDOCARDIAL PACEMAKER; SUSTAINED BACTEREMIA; AUREUS BACTEREMIA; DENTAL PROCEDURES; LEAD EXTRACTION AB Background. The purpose of this statement is to update the recommendations by the American Heart Association (AHA) for cardiovascular implantable electronic device (CIED) infections and their management, which were last published in 2003. Methods and Results. The AHA commissioned this scientific statement to educate clinicians about CIED infections, provide explicit recommendations for the care of patients with suspected or established CIED infections and highlight areas of needed research. The recommendations in this statement reflect analyses of relevant literature, to include recent advances in our understanding of the epidemiology, risk factors, microbiology, management and prevention of CIED infections. Conclusion. There are no scientific data to support the use of antimicrobial prophylaxis for dental or other invasive procedures. Clinical Implications. The concerns about life-threatening drug reactions, the development of resistant strains of bacterial pathogens, medicolegal issues and cost to the health care system are, thus, avoided. C1 [Baddour, Larry M.] Carolinas Med Ctr, Dept Oral Med, Charlotte, NC 28232 USA. [Baddour, Larry M.; Wilson, Walter R.] Mayo Clin, Div Infect Dis, Coll Med, Rochester, MN USA. [Epstein, Andrew E.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Epstein, Andrew E.] Univ Penn, Div Cardiovasc, Philadelphia, PA 19104 USA. [Erickson, Christopher C.] Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE USA. [Erickson, Christopher C.] Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE USA. [Erickson, Christopher C.] Creighton Univ, Sch Med, Dept Pediat, Omaha, NE 68178 USA. [Erickson, Christopher C.] Childrens Hosp & Med Ctr, Omaha, NE USA. [Knight, Bradley P.] NW Med Ctr, Div Cardiol, Chicago, IL USA. [Levison, Matthew E.] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA. [Levison, Matthew E.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA. [Masoudi, Frederick A.] Denver Hlth Med Ctr, Div Cardiol, Denver, CO USA. [Okum, Eric J.] Cardiac Vasc & Thorac Surg, Cincinnati, OH USA. [Beerman, Lee B.] Univ Pittsburgh, Div Pediat Cardiol, Childrens Hosp Pittsburgh, Ctr Med, Pittsburgh, PA 15260 USA. [Bolger, Ann F.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Bolger, Ann F.] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA USA. [Estes, N. A. Mark, III] Tufts Med Ctr, Cardiac Arrhythmia Serv, Boston, MA USA. [Gewitz, Michael] Maria Fareri Childrens Hosp, Westchester Med Ctr, Valhalla, NY USA. [Gewitz, Michael] New York Med Coll, Valhalla, NY 10595 USA. [Newburger, Jane W.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA. [Schron, Eleanor B.] NEI, Vis Res Program, Natl Inst Hlth, Rockville, MD USA. [Taubert, Kathryn A.] World Heart Federat, Geneva, NY USA. RP Lockhart, PB (reprint author), Carolinas Med Ctr, Dept Oral Med, POB 32861, Charlotte, NC 28232 USA. EM Peter.Lockhart@carolinashealthcare.org FU St. Jude Medical, St. Paul, Minn; Boston Scientific, Natick, Mass FX Dr. Erickson has received a research grant from St. Jude Medical, St. Paul, Minn. Dr. Estes has received research support from Boston Scientific, Natick, Mass.; is a consultant to Boston Scientific; and has received honoraria from Boston Scientific and St. Jude Medical. None of the other authors reported any disclosures. NR 69 TC 15 Z9 16 U1 0 U2 1 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD FEB PY 2011 VL 142 IS 2 BP 159 EP 165 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 716UU UT WOS:000286999800017 PM 21282681 ER PT J AU Krug, LM Crawford, J Ettinger, DS Shapiro, GI Spigel, D Reiman, T Temel, JS Michelson, GC Young, DY Hoch, U Adelman, DC AF Krug, Lee M. Crawford, Jeffrey Ettinger, David S. Shapiro, Geoffrey I. Spigel, David Reiman, Tony Temel, Jennifer S. Michelson, Glenn C. Young, Donald Y. Hoch, Ute Adelman, Daniel C. TI Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Small cell lung cancer; Voreloxin; Quinolone; Phase II ID FORMERLY SNS-595; SOLID TUMORS AB Introduction: Voreloxin is an anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, causing double-strand breaks in DNA, irreversible G2 arrest, and rapid onset of apoptosis. Based on preclinical activity of voreloxin in chemoresistant tumors, early phase I clinical activity, and a mechanism of action similar to other topoisomerase II inhibitors such as the anthracyclines and etoposide, this phase II trial was undertaken as second-line treatment of small cell lung cancer (SCLC). Methods: Patients with extensive stage SCLC previously treated with one prior chemotherapy regimen were eligible. Patients with chemotherapy-sensitive or chemotherapy-refractory disease were considered as separate cohorts. Voreloxin (48 mg/m(2)) was administered on the first day of each 21-day cycle for up to six cycles. The primary end point was objective response rate. Results: Fifty-five patients were enrolled including 28 with refractory SCLC and 27 with sensitive SCLC; 47 were evaluable for response. Three patients with sensitive SCLC had an objective response, including one complete response and two partial responses (11% response rate based on intent to treat). No patients in the refractory cohort had a response. The primary grade 3 toxicity was neutropenia. Conclusion: Voreloxin has minimal activity in relapsed SCLC when administered at 48 mg/m(2) in a 3-week schedule. C1 [Krug, Lee M.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA. [Crawford, Jeffrey] Duke Univ, Med Ctr, Dept Med, Raleigh, NC USA. [Ettinger, David S.] Sidney Kimmel Canc Ctr Johns Hopkins, Dept Med, Baltimore, MD USA. [Shapiro, Geoffrey I.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA. [Spigel, David] Sarah Cannon Res Inst, Nashville, TN USA. [Reiman, Tony] St Johns Hosp, Dept Med, St John, NB, Canada. [Temel, Jennifer S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Michelson, Glenn C.; Young, Donald Y.] Sunesis Pharmaceut Inc, San Francisco, CA USA. [Hoch, Ute] Nektar Therapeut, San Carlos, CA USA. [Adelman, Daniel C.] Alvine Pharmaceut Inc, San Carlos, CA USA. RP Krug, LM (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA. EM krugl@mskcc.org FU Sunesis Pharmaceuticals, Inc., South San Francisco, CA FX Supported by Sunesis Pharmaceuticals, Inc., South San Francisco, CA. NR 10 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD FEB PY 2011 VL 6 IS 2 BP 384 EP 386 DI 10.1097/JTO.0b013e318200e509 PG 3 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 709SG UT WOS:000286461100019 PM 21252718 ER PT J AU Delgado-Borrego, A Kamegaya, Y Jordan, SH Agrawal, S Valim, C Chung, RT AF Delgado-Borrego, A. Kamegaya, Y. Jordan, S. H. Agrawal, S. Valim, C. Chung, R. T. TI HCV synergizes with body weight in the promotion of insulin resistance SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE diabetes; HCV; hepatitis C; insulin resistance; synergy ID HEPATITIS-C VIRUS; TUMOR-NECROSIS-FACTOR; DEPENDENT DIABETES-MELLITUS; LIVER-TRANSPLANT RECIPIENTS; FACTOR-ALPHA; EXTRAHEPATIC MANIFESTATIONS; INCREASED PREVALENCE; OVERWEIGHT PATIENTS; RISK-FACTORS; INFECTION AB Hepatitis C virus (HCV) infection appears to contribute to the development of insulin resistance (IR). Among the multiple determinants of IR, body mass index (BMI) is the most important. We investigated the contribution of HCV to BMI-associated IR using a transgenic mouse model expressing HCV core protein. Eight transgenic and five nontransgenic littermate controls were evaluated. Glucose and insulin tolerance tests (ITT) were performed on two separate occasions. Multivariate linear mixed modelling was used to evaluate and compare the effect of weight on IR between HCV core transgenic and nontransgenic controls. There were no statistically significant differences in glucose or ITT (P = 0.58 and P = 0.59, respectively) between the two groups, and no difference in median weights between transgenic and control mice (P = 0.11). However, there was greater variance in the distributions of Tg when compared to nontransgenic mice for both glucose and insulin tolerance. When evaluating this closely, a differential contribution of weight to IR curves between these groups was noted (P = 0.05). Among nontransgenic mice, IR curves for mice of different weights were comparable, however, for transgenic mice, higher weights resulted in larger levels of IR curves with slower decay. In all animals, steatosis was absent or minimal. We conclude that weight has a greater effect on IR in HCV core expressing transgenic mice than littermate controls. HCV therefore synergizes with weight in the promotion of IR. Steatosis was not a prerequisite for the development of IR, implying that HCV's effects on IR may be independent of steatosis. C1 [Delgado-Borrego, A.; Kamegaya, Y.; Jordan, S. H.; Agrawal, S.; Chung, R. T.] Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Boston, MA 02114 USA. [Delgado-Borrego, A.] Childrens Hosp, Dept Med, Gastroenterol & Nutr Unit, Boston, MA 02115 USA. [Delgado-Borrego, A.] Univ Miami, Div Gastroenterol & Nutr, Miami, FL USA. [Delgado-Borrego, A.] Univ Miami, Dept Pediat, Div Pediat Clin Res, Miami, FL 33152 USA. [Valim, C.] Childrens Hosp, Div Biostat, Clin Res Program, Boston, MA 02115 USA. RP Chung, RT (reprint author), Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, 55 Fruit St GI Unit,Warren 1007, Boston, MA 02114 USA. EM rtchung@partners.org FU Robert Wood Johnson Foundation; [NIH T32 DK07477]; [NIH K08 DK070022]; [NIH DK57857]; [DK78772] FX This work was supported by: NIH T32 DK07477 (ADB), NIH K08 DK070022(ADB), NIH DK57857 (RTC), DK78772 (RTC) and the Robert Wood Johnson Foundation (ADB). NR 46 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD FEB PY 2011 VL 18 IS 2 BP 135 EP 141 DI 10.1111/j.1365-2893.2010.01291.x PG 7 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 706ZV UT WOS:000286257200008 PM 20497310 ER PT J AU Antonescu, CR Zhang, L Nielsen, GP Rosenberg, AE Dal Cin, P Fletcher, CD AF Antonescu, C. R. Zhang, L. Nielsen, G. P. Rosenberg, A. E. Dal Cin, P. Fletcher, C. D. TI Consistent t(1;10) Abnormality in Both Myxoinflammatory Fibroblastic Sarcoma (MIFS) and Hemosiderotic Fibrolipomatous Tumor (HFLT) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 21 BP 9A EP 9A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400022 ER PT J AU Kurzawa, PJ Nielsen, PG Kattapuram, S Hornicek, FJ Rosenberg, AE AF Kurzawa, P. J. Nielsen, P. G. Kattapuram, S. Hornicek, F. J. Rosenberg, A. E. TI Primary Myoepithelloma of Bone SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Great Poland Canc Ctr, Poznan, Wielkopolska, Poland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 57 BP 17A EP 17A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400058 ER PT J AU Yasir, S Nadji, M Kurzawa, P Nielsen, GP Rosenberg, A AF Yasir, S. Nadji, M. Kurzawa, P. Nielsen, G. P. Rosenberg, A. TI Expression of Epithelial Markers in Nodular Fasciitis and Fibromatosis: An Immunohistochemical Study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Univ Miami, Jackson Mem Hosp, Coral Gables, FL 33124 USA. Great Poland Canc Ctr, Poznan, Poland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 88 BP 24A EP 24A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400089 ER PT J AU Corben, AD Teo, C AbiRaad, R Bombonati, A Koerner, FC Taghian, A Brachtel, EF AF Corben, A. D. Teo, C. AbiRaad, R. Bombonati, A. Koerner, F. C. Taghian, A. Brachtel, E. F. TI Classifications of Pathological Response and Long-Term Follow-Up in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Tan Tock Seng Hosp, Singapore, Singapore. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 133 BP 34A EP 35A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400134 ER PT J AU Corben, AD D'Arcy, C Abi-Raad, R Bombonati, A Taghian, A Akram, M Koerner, FC Eichhorn, JH Brachtel, EF AF Corben, A. D. D'Arcy, C. Abi-Raad, R. Bombonati, A. Taghian, A. Akram, M. Koerner, F. C. Eichhorn, J. H. Brachtel, E. F. TI Hormone Receptor and HER2 Profiles before and after Neoadjuvant Chemotherapy: Experience at Two Centers SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 135 BP 35A EP 35A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400136 ER PT J AU Eichhorn, JH Crothers, BA Wilbur, DC AF Eichhorn, J. H. Crothers, B. A. Wilbur, D. C. TI Gynecologic Telecytology Using Automated Local Image Selection with Remote Interpretation: The Results of a Phase 2 Prospective Trial SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 364 BP 89A EP 89A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400366 ER PT J AU Nishino, H Wilbur, D Tambouret, R AF Nishino, H. Wilbur, D. Tambouret, R. TI Utility of "Low-Grade Squamous Intraepithelial Lesion, Cannot Exclude High-Grade Squamous Intraepithelial Lesion" (LSIL-H) Usage as a Quality Assurance (QA) Measure SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Nishino, H.; Wilbur, D.; Tambouret, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 414 BP 100A EP 100A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400416 ER PT J AU Ono, J Yaeger, K Genevay, M Mino-Kenudson, M Brugge, WR Pitman, MB AF Ono, J. Yaeger, K. Genevay, M. Mino-Kenudson, M. Brugge, W. R. Pitman, M. B. TI Cytological Analysis of Small Branch-Duct IPMNS Provides a More Accurate Risk Assessment for Malignancy Than Symptoms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hosp Geneva, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 415 BP 100A EP 100A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400417 ER PT J AU Singh, RS Wang, HH AF Singh, R. S. Wang, H. H. TI Timing of Repeat Thyroid FNA in the Management of Thyroid Nodules SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 BIDMC, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 435 BP 105A EP 105A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400437 ER PT J AU Wang, H Michaels, PJ Cibas, ES Khurana, K Ali, SZ Bongiovanni, M Powers, CN Faquin, WC AF Wang, H. Michaels, P. J. Cibas, E. S. Khurana, K. Ali, S. Z. Bongiovanni, M. Powers, C. N. Faquin, W. C. TI FNAB of Secondary Neoplasms of the Thyroid Gland: A Multi-Institutional Study of 60 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Virginia Commonwealth Univ, Richmond, VA 23284 USA. Inst Pathol, Locarno, Switzerland. Johns Hopkins Univ, Baltimore, MD USA. SUNY Upstate Med Univ, Syracuse, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 451 BP 109A EP 109A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400453 ER PT J AU Baran, JL Duncan, LM AF Baran, J. L. Duncan, L. M. TI Definition and Categorization of Combined Melanocytic Nevi SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Baran, J. L.; Duncan, L. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 466 BP 112A EP 113A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400468 ER PT J AU Brenn, T Grayson, W Frkovic-Grazio, S Mihm, MC Calonje, E Mckee, PH AF Brenn, T. Grayson, W. Frkovic-Grazio, S. Mihm, M. C. Calonje, E. McKee, P. H. TI Melanoma in Childhood and Adolescence: Clinicopathologic Analysis of 64 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland. Western Gen Hosp, Edinburgh, Midlothian, Scotland. Univ Witwatersrand, Johannesburg, South Africa. Natl Hlth Lab Serv, Johannesburg, South Africa. Inst Oncol, Ljubljana, Slovenia. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. St Johns Inst Dermatol, London, England. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 468 BP 113A EP 113A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400470 ER PT J AU Linskey, K Kroshinsky, D Hoang, M AF Linskey, K. Kroshinsky, D. Hoang, M. TI Immunoglobulin-A Associated Small Vessel Vasculitis: A Ten-Year Experience at the Massachusetts General Hospital SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Linskey, K.; Kroshinsky, D.; Hoang, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 498 BP 120A EP 120A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400500 ER PT J AU Phadke, PA Rakheja, D Le, LP Selim, MA Kapur, P Davis, A Mihm, MC AF Phadke, P. A. Rakheja, D. Le, L. P. Selim, M. A. Kapur, P. Davis, A. Mihm, M. C. TI Proliferative Nodule Arising within Congenital Melanocytic Nevus: Histologic, Immunohistochemical and Molecular Analyses of 43 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 511 BP 123A EP 123A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400513 ER PT J AU Lee, RE McClintock, DS Ponce, CR Gilbertson, JR Dighe, AS Yagi, Y AF Lee, R. E. McClintock, D. S. Ponce, C. R. Gilbertson, J. R. Dighe, A. S. Yagi, Y. TI Educational Recuts on a Portable Hard Drive: A New Paradigm for Personal Slide Collections SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Lee, R. E.; McClintock, D. S.; Ponce, C. R.; Gilbertson, J. R.; Dighe, A. S.; Yagi, Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 545 BP 131A EP 131A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 716ZG UT WOS:000287011400547 ER PT J AU Lorch, JH Goloubeva, O Haddad, RI Cullen, K Sarlis, N Tishler, R Tan, M Fasciano, J Sammartino, DE Posner, MR AF Lorch, Jochen H. Goloubeva, Olga Haddad, Robert I. Cullen, Kevin Sarlis, Nicholas Tishler, Roy Tan, Ming Fasciano, John Sammartino, Daniel E. Posner, Marshall R. CA TAX 324 Study Grp TI Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial SO LANCET ONCOLOGY LA English DT Article ID III TRIAL; OROPHARYNGEAL CANCER; HUMAN-PAPILLOMAVIRUS; RADIATION-THERAPY; CARCINOMA; RADIOTHERAPY; CONCURRENT; LARYNX; PRESERVATION; SURVIVAL AB Background At a minimum follow-up of 2 years, the TAX 324 study showed a significant survival benefit of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) versus cisplatin and fluorouracil (PF) in locally advanced head and neck cancer. We report the long-term results at 5 years' minimum follow-up. Methods TAX 324 was a randomised, open-label phase 3 trial comparing three cycles of TPF induction chemotherapy (docetaxel 75 mg/m(2), followed by intravenous cisplatin 100 mg/m2 and fluorouracil 1000 mg/m2 per day, administered as a continuous 24-h infusion for 4 days) with three cycles of PF (intravenous cisplatin 100 mg/m2, followed by fluorouracil 1000 mg/m2 per day as a continuous 24-h infusion for 5 days) in patients with stage III or IV squamous-cell carcinoma of the head or neck. Both regimens were followed by 7 weeks of chemoradiotherapy with concomitant weekly carboplatin. Randomisation was done centrally with the use of a biased-coin minimisation technique. At study entry, patients were stratified according to the site of the primary tumour, nodal status (N0 or N1 vs N2 or N3), and institution. For this long-term analysis, data as of Dec 1,2008, were gathered retrospectively from patients' medical records. Overall and progression-free survival were the primary endpoints. Tracheostomy and dependence on a gastric feeding tube were used as surrogate measures for treatment-related long-term toxicity. The intention-to-treat analysis included data from all 501 patients (255 TPF, 246 PF); data from the initial analysis in 2005 were used for 61 patients who were lost to follow-up. TAX 324 was registered at ClinicalTrials.gov, NCT00273546. Findings Median follow-up was 72.2 months (95% CI 68.8-75.5). Overall survival was significantly better after treatment with TPF versus PF (hazard ratio [HR] 0.74, 95% CI 0.58-0.94), with an estimated 5-year survival of 52% in patients treated with TPF and 42% in those receiving PF. Median survival was 70.6 months (95% CI 49.0-89-0) in the TPF group versus 34.8 months (22.6-48.0) in the PF group (p=0.014). Progression-free survival was also significantly better in patients treated with TPF (median 38.1 months, 95% CI 19.3-66.1, vs 13.2 months, 10.6-20-7; HR 0.75,95% CI 0.60-0.94). We detected no significant difference in dependence on gastric feeding tubes and tracheostomies between treatment groups. In the TPF group, three (3%) of 91 patients remained feeding-tube dependent, compared with eight (11%) of 71 patients in the PF group. Six (7%) of 92 patients had tracheostomies in the TPF group, versus eight (11%) of 71 in the PF group. Interpretation Induction chemotherapy with TPF provides long-term survival benefit compared with PF in locally advanced head and neck cancer. Patients who are candidates for induction chemotherapy should be treated with TPF. C1 [Lorch, Jochen H.; Haddad, Robert I.; Tishler, Roy; Fasciano, John; Sammartino, Daniel E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goloubeva, Olga; Tan, Ming] Univ Maryland, Div Biostat, Marlene & Stewart Greenebaum Canc Ctr, Med Sch Teaching Facil, Baltimore, MD 21201 USA. [Cullen, Kevin] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Sarlis, Nicholas] Sanofi Aventis US, Dept Med Affairs, Oncol Business Unit, US Pharmaceut Operat, Bridgewater, NJ USA. [Fasciano, John] Morgan Stanley Smith Barney, Boston, MA USA. [Posner, Marshall R.] Mt Sinai Sch Med, Div Hematol Med Oncol, Tisch Canc Inst, New York, NY USA. RP Lorch, JH (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM jochen_lorch@dfci.harvard.edu FU Sanofi-Aventis; Bristol-Myers Squibb; Biovex FX MT's academic institution has received research support from Sanofi-Aventis. KC has received travel support from Sanofi-Aventis and his academic institution has received research support from Sanofi-Aventis. RT has received consultancy honoraria and speakers' fees from Sanofi-Aventis. RIH has received consultancy fees from Sanofi-Aventis and Bristol-Myers Squibb. NS was an employee of Sanofi-Aventis until September, 2010 and holds stock in Sanofi-Aventis. MRP has received consultancy fees for participating in data safety and monitoring boards for GlaxoSmithKline, Amgen, Merck-EMD, and Novartis. He has participated in advisory boards for Pfizer and has received consultancy fees from Biovex. He holds patents with Allopexx and has received royalties. His academic institution has received research funding from Sanofi-Aventis. He has received honoraria for lectures at American Society of Clinical Oncology meetings. JHL, OG, JF, and DES declared no conflicts of interest NR 23 TC 140 Z9 150 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD FEB PY 2011 VL 12 IS 2 BP 153 EP 159 DI 10.1016/S1420-2045(10)20279-5 PG 7 WC Oncology SC Oncology GA 720NB UT WOS:000287286300022 PM 21233014 ER PT J AU Hebert, PL Chassin, MR Howell, EA AF Hebert, Paul L. Chassin, Mark R. Howell, Elizabeth A. TI The Contribution of Geography to Black/White Differences in the Use of Low Neonatal Mortality Hospitals in New York City SO MEDICAL CARE LA English DT Article DE neonatal mortality; distance; quality; geography ID RESIDENTIAL SEGREGATION; INFANT-MORTALITY; BIRTH-WEIGHT; CARE PHYSICIANS; UNITED-STATES; HEALTH; DISPARITIES; POLICIES AB Background: Racial differences in the use of high-quality hospital care contribute to racial disparities in mortality for very low birth weight (VLBW) neonates. Objectives: We explored the role that geographic distribution of hospitals plays in the racial disparity in the use of top-tier hospitals by mothers of VLBW neonates in New York City. Research Design: Retrospective analysis of Vital Statistics and administrative databases. Subjects: VLBW deliveries in New York City from 1996 to 2001 to non-Hispanic Black (n = 4947) and non-Hispanic White (n = 1615) mothers. Results: Black mothers were less likely to deliver in a top-tier hospitals (White = 44%, Black = 28%; P < 0.001) and top-tier hospitals were less likely to be located in Black mothers' neighborhoods (White = 40%, Black = 33%; P < 0.001). Distance, however, did not contribute to the disparity in use of top-tier hospitals. Non-Hispanic Black mothers lived marginally closer to a top-tier hospital than non-Hispanic White mothers (0.65 miles closer; P < 0.001), and mothers of both the races often bypassed their neighborhood hospital (Black = 62% bypassed, White = 71%; P < 0.001). Inattention to recommended prenatal behaviors was associated with using a closer hospital, suggesting that geographic proximity was most important to mothers of vulnerable neonates. Purported measures of hospital quality such as Neonatal Intensive Care Unit level and volume were more strongly associated with use of hospital for White mothers than for Black mothers. Conclusions: The influence of geography on the use of top-tier hospitals for mothers of VLBW neonates is complex. Other personal and hospital characteristics, not just distance or geography, also influenced hospital use in New York City. C1 [Hebert, Paul L.] VA Puget Sound Hlth Care Syst, VA HSR&D, Seattle, WA 98101 USA. [Hebert, Paul L.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Chassin, Mark R.] Joint Commiss, Off President, Oak Brook Terrace, IL USA. [Howell, Elizabeth A.] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA. [Howell, Elizabeth A.] Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY USA. [Howell, Elizabeth A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Hebert, PL (reprint author), VA Puget Sound Hlth Care Syst, VA HSR&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Paul.Hebert2@va.gov FU Agency for Health Care Research and Quality; Commonwealth Fund FX Supported by Agency for Health Care Research and Quality and The Commonwealth Fund. NR 21 TC 4 Z9 4 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD FEB PY 2011 VL 49 IS 2 BP 200 EP 206 DI 10.1097/MLR.0b013e3182019144 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 706BR UT WOS:000286191000012 PM 21239954 ER PT J AU Seco, J Depauw, N AF Seco, Joao Depauw, Nicolas TI Proof of principle study of the use of a CMOS active pixel sensor for proton radiography SO MEDICAL PHYSICS LA English DT Article ID THERAPY AB Purpose: Proof of principle study of the use of a CMOS active pixel sensor (APS) in producing proton radiographic images using the proton beam at the Massachusetts General Hospital (MGH). Methods: A CMOS APS, previously tested for use in s-ray radiation therapy applications, was used for proton beam radiographic imaging at the MGH. Two different setups were used as a proof of principle that CMOS can be used as proton imaging device: (i) a pen with two metal screws to assess spatial resolution of the CMOS and (ii) a phantom with lung tissue, bone tissue, and water to assess tissue contrast of the CMOS. The sensor was then traversed by a double scattered monoenergetic proton beam at 117 MeV, and the energy deposition inside the detector was recorded to assess its energy response. Conventional x-ray images with similar setup at voltages of 70 kVp and proton images using commercial Gafchromic EBT 2 and Kodak X-Omat V films were also taken for comparison purposes. Results: Images were successfully acquired and compared to x-ray kVp and proton EBT2/X-Omat film images. The spatial resolution of the CMOS detector image is subjectively comparable to the EBT2 and Kodak X-Omat V film images obtained at the same object-detector distance. X-rays have apparent higher spatial resolution than the CMOS. However, further studies with different commercial films using proton beam irradiation demonstrate that the distance of the detector to the object is important to the amount of proton scatter contributing to the proton image. Proton images obtained with films at different distances from the source indicate that proton scatter significantly affects the CMOS image quality. Conclusion: Proton radiographic images were successfully acquired at MGH using a CMOS active pixel sensor detector. The CMOS demonstrated spatial resolution subjectively comparable to films at the same object-detector distance. Further work will be done in order to establish the spatial and energy resolution of the CMOS detector for protons. The development and use of CMOS in proton radiography could allow in vivo proton range checks, patient setup QA, and real-time tumor tracking. (c) 2011 American Association of Physicists in Medicine. [DOI: 10.1118/1.3496327] C1 [Seco, Joao; Depauw, Nicolas] Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. RP Seco, J (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. EM jseco@partners.org RI Seco, Joao/J-4451-2012 NR 10 TC 17 Z9 17 U1 0 U2 8 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2011 VL 38 IS 2 BP 622 EP 623 DI 10.1118/1.3496327 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 716DI UT WOS:000286945000009 PM 21452699 ER PT J AU Bradford, LS Schorge, JO AF Bradford, Leslie S. Schorge, John O. TI CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much? SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Editorial Material ID BRCA2 MUTATION CARRIERS; OVARIAN-CANCER; FALLOPIAN-TUBE; BREAST; WOMEN C1 [Bradford, Leslie S.; Schorge, John O.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02114 USA. RP Bradford, LS (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02114 USA. NR 17 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD FEB PY 2011 VL 18 IS 2 BP 123 EP 124 DI 10.1097/gme.0b013e31820246da PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 711XA UT WOS:000286623500003 PM 21191312 ER PT J AU Lee, HJ AF Lee, Ho Joon TI Antimullerian hormone as a potential predictor for the late menopausal transition SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Editorial Material ID ANTI-MULLERIAN HORMONE; ASSISTED REPRODUCTIVE TECHNOLOGY; FOLLICLE RECRUITMENT; OVARIAN RESERVE; SERUM-LEVELS; MARKER; GROWTH; WOMEN C1 Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynaecol, Boston, MA 02114 USA. RP Lee, HJ (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynaecol, Boston, MA 02114 USA. NR 24 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD FEB PY 2011 VL 18 IS 2 BP 125 EP 126 DI 10.1097/gme.0b013e318204e23f PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 711XA UT WOS:000286623500004 PM 21245773 ER PT J AU Barisoni, L Jennette, C Colvin, R Bragat, A Castelli, J Sitaraman, S Boudes, P AF Barisoni, Laura Jennette, Charles Colvin, Robert Bragat, Alexander Castelli, Jeff Sitaraman, Sheela Boudes, Pol TI Novel quantitative method to evaluate GL-3 inclusions in renal peritubular capillaries (PTCs) in patients with Fabry disease (FD) by virtual microscopy (VM) SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 7th Annual World Symposium of the Lysosomal-Disease-Network CY FEB 16-18, 2011 CL Las Vegas, NV SP Lysosomal Dis Network C1 [Barisoni, Laura] NYU, Med Ctr, New York, NY 10016 USA. [Jennette, Charles] Univ N Carolina, Chapel Hill, NC USA. [Colvin, Robert] Massachusetts Gen Hosp, Boston, MA 02114 USA. OI Bragat, Alexander/0000-0002-0993-9896 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2011 VL 102 IS 2 BP S7 EP S7 DI 10.1016/j.ymgme.2010.11.022 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 715CW UT WOS:000286859000041 ER PT J AU Bley, A Tifft, C Kahn, S Eichler, F AF Bley, Annette Tifft, Cynthia Kahn, Susan Eichler, Florian TI Natural history of infantile GM2 gangliosidosis - Survey of 97 patients SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 7th Annual World Symposium of the Lysosomal-Disease-Network CY FEB 16-18, 2011 CL Las Vegas, NV SP Lysosomal Dis Network C1 [Bley, Annette; Eichler, Florian] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tifft, Cynthia] NHGRI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2011 VL 102 IS 2 BP S9 EP S9 DI 10.1016/j.ymgme.2010.11.028 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 715CW UT WOS:000286859000047 ER PT J AU Kamath, R Lukina, E Watman, N Dragosky, M Iastrebner, M Pastores, GM Arreguin, EA Rosenbaum, H Phillips, M Kaper, M Puga, AC Peterschmitt, MJ Rosenthal, DI AF Kamath, Ravi Lukina, Elena Watman, Nora Dragosky, Marta Iastrebner, Marcelo Pastores, Gregory M. Arreguin, Elsa Avila Rosenbaum, Hanna Phillips, Mici Kaper, Mathilde Puga, Ana Cristina Peterschmitt, M. Judith Rosenthal, Daniel I. TI Improvements in skeletal manifestations in gaucher disease Type 1 patients receiving oral eliglustat during a phase 2 trial SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 7th Annual World Symposium of the Lysosomal-Disease-Network CY FEB 16-18, 2011 CL Las Vegas, NV SP Lysosomal Dis Network C1 [Kamath, Ravi; Rosenthal, Daniel I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lukina, Elena] Russian Acad Med Sci, Moscow, Russia. [Watman, Nora] Hosp Ramos Mejia, Buenos Aires, DF, Argentina. [Dragosky, Marta; Iastrebner, Marcelo] Inst Argentino Diagnost & Tratamiento, Buenos Aires, DF, Argentina. [Pastores, Gregory M.] NYU, New York, NY USA. [Arreguin, Elsa Avila] Hosp Especialidades Ctr Med La Raza, Inst Mexicano Seguro Social, Mexico City, DF, Mexico. [Rosenbaum, Hanna] Rambam Med Ctr, Haifa, Israel. [Phillips, Mici] Shaare Zedek Med Ctr, Jerusalem, Israel. [Kaper, Mathilde; Puga, Ana Cristina; Peterschmitt, M. Judith] Genzyme Corp, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2011 VL 102 IS 2 BP S23 EP S23 DI 10.1016/j.ymgme.2010.11.078 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 715CW UT WOS:000286859000096 ER PT J AU Sims, K Clarke, V Hung, G Martin, D AF Sims, Katherine Clarke, Virginia Hung, Gregory Martin, Dana TI A new pain assessment tool for Fabry disease SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 7th Annual World Symposium of the Lysosomal-Disease-Network CY FEB 16-18, 2011 CL Las Vegas, NV SP Lysosomal Dis Network C1 [Sims, Katherine; Clarke, Virginia] Massachusetts Gen Hosp, Cambridge, MA USA. [Hung, Gregory] Massachusetts Coll Pharm & Hlth Sci Genyzme Corp, Worcester, MA USA. [Martin, Dana] Genzyme Corp, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2011 VL 102 IS 2 BP S42 EP S42 DI 10.1016/j.ymgme.2010.11.140 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 715CW UT WOS:000286859000157 ER PT J AU Utz, J Eichler, FS Ziegler, RS Diethelm-Okita, BM LeDuc, RL Whitley, CB AF Utz, Jeanine Eichler, Florian S. Ziegler, Richard S. Diethelm-Okita, Brenda M. LeDuc, Renee L. Whitley, Chester B. TI A natural history of hexosaminidase deficiency SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 7th Annual World Symposium of the Lysosomal-Disease-Network CY FEB 16-18, 2011 CL Las Vegas, NV SP Lysosomal Dis Network C1 [Utz, Jeanine; Ziegler, Richard S.; Diethelm-Okita, Brenda M.; Whitley, Chester B.] Univ Minnesota, Minneapolis, MN USA. [Eichler, Florian S.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02114 USA. [LeDuc, Renee L.] Data Management & Coordinating Ctr, Tampa, FL 33612 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2011 VL 102 IS 2 BP S43 EP S43 DI 10.1016/j.ymgme.2010.11.144 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 715CW UT WOS:000286859000161 ER PT J AU Suzuki, Y St Onge, RP Mani, R King, OD Heilbut, A Labunskyy, VM Chen, WD Pham, L Zhang, LV Tong, AHY Nislow, C Giaever, G Gladyshev, VN Vidal, M Schow, P Lehar, J Roth, FP AF Suzuki, Yo St Onge, Robert P. Mani, Ramamurthy King, Oliver D. Heilbut, Adrian Labunskyy, Vyacheslav M. Chen, Weidong Pham, Linda Zhang, Lan V. Tong, Amy H. Y. Nislow, Corey Giaever, Guri Gladyshev, Vadim N. Vidal, Marc Schow, Peter Lehar, Joseph Roth, Frederick P. TI Knocking out multigene redundancies via cycles of sexual assortment and fluorescence selection SO NATURE METHODS LA English DT Article ID SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; GENE DISRUPTION; ABC TRANSPORTERS; DRUG-RESISTANCE; MAMMALIAN-CELLS; BUDDING YEAST; EXPRESSION; DELETION; GENOME AB Phenotypes that might otherwise reveal a gene's function can be obscured by genes with overlapping function. This phenomenon is best known within gene families, in which an important shared function may only be revealed by mutating all family members. Here we describe the 'green monster' technology that enables precise deletion of many genes. In this method, a population of deletion strains with each deletion marked by an inducible green fluorescent protein reporter gene, is subjected to repeated rounds of mating, meiosis and flow-cytometric enrichment. This results in the aggregation of multiple deletion loci in single cells. The green monster strategy is potentially applicable to assembling other engineered alterations in any species with sex or alternative means of allelic assortment. To test the technology, we generated a single broadly drug-sensitive strain of Saccharomyces cerevisiae bearing precise deletions of all 16 ATP-binding cassette transporters within clades associated with multidrug resistance. C1 [Suzuki, Yo; Mani, Ramamurthy; King, Oliver D.; Chen, Weidong; Pham, Linda; Zhang, Lan V.; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [St Onge, Robert P.] Stanford Genome Technol Ctr, Palo Alto, CA USA. [Heilbut, Adrian; Lehar, Joseph] Boston Univ, Bioinformat Program, Boston, MA 02215 USA. [Labunskyy, Vyacheslav M.; Gladyshev, Vadim N.] Harvard Univ, Sch Med, Div Genet, Brigham & Womens Hosp, Boston, MA 02115 USA. [Tong, Amy H. Y.] Univ Hong Kong, Genome Res Ctr, Pokfulam, Hong Kong, Peoples R China. [Giaever, Guri] Univ Toronto, Dept Pharmaceut Sci, Dept Mol Genet, Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada. [Vidal, Marc; Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. [Schow, Peter] Dana Farber Canc Inst, Flow Cytometry Core Facil, Boston, MA 02115 USA. RP Suzuki, Y (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. EM ysuzuki@jcvi.org; fritz_roth@hms.harvard.edu RI Giaever, Guri/D-3930-2009; Heilbut, Adrian/J-9427-2012; Gladyshev, Vadim/A-9894-2013; Roth, Frederick/H-6308-2011; OI Heilbut, Adrian/0000-0002-8169-7967; Roth, Frederick/0000-0002-6628-649X; Nislow, Corey/0000-0002-4016-8874 FU US National Institutes of Health [R01 HG003224, R21 CA130266]; National Institutes of Health-National Human Genome Research Institute FX This work was supported by US National Institutes of Health grants R01 HG003224 and R21 CA130266 to F. P. R. O.D.K. was supported by a National Research Service Award fellowship from the National Institutes of Health-National Human Genome Research Institute. Micrographs were generated at Nikon Imaging Center at Harvard Medical School. We are grateful for yeast strains from C. Boone (University of Toronto) and A. Goffeau (Universite catholique de Louvain), and for advice and assistance from M. Al-Shawi, B.J. Andrews, C. Baisden, R. Balasubramanian, W. Bender, C. Boone, R. Brost, S. Buratowski, D. Chowdhury, G. M. Church, D. Coen, E. Craig, E. Elion, M. Fenerjian, D. Gibson, J. Glass, A. Goffeau, R. Grene, C. Hutchison, S. Iwase, M. Johnston, B. Karas, K. Kono, K. Kuchler, J. Li, D. Morgan, S. Moye-Rowley, J. Murai, S. Oliver, F. Ozbek, Y. Pan, D. Pellman, A. Ramon, J. Rine, A. Rowat, P. Silver, H. Smith, M. Springer, K. Struhl, C. Tagwerker, M. Takahashi, B. Turcotte, D. Weitz and S. Yoshida; members of the Roth Lab, especially M. Tasan, J. Mellor, J. Komisarof, J. MacKay, A. Derti and S. Komili; and members of the Dana-Farber Center for Cancer Systems Biology, especially P. Braun, A. Dricot, D. Hill, Q. Li and H. Yu. NR 34 TC 28 Z9 28 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 EI 1548-7105 J9 NAT METHODS JI Nat. Methods PD FEB PY 2011 VL 8 IS 2 BP 159 EP U87 DI 10.1038/NMETH.1550 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 712GQ UT WOS:000286654600014 PM 21217751 ER PT J AU Livhits, M Mercado, C Yermilov, I Parikh, JA Dutson, E Mehran, A Ko, CY Shekelle, PG Gibbons, MM AF Livhits, M. Mercado, C. Yermilov, I. Parikh, J. A. Dutson, E. Mehran, A. Ko, C. Y. Shekelle, P. G. Gibbons, M. M. TI Is social support associated with greater weight loss after bariatric surgery?: a systematic review SO OBESITY REVIEWS LA English DT Article DE Bariatric surgery; social support; support group; weight loss ID Y GASTRIC BYPASS; PREDICTING SUCCESS; BEHAVIORAL-FACTORS; FOLLOW-UP; GASTROPLASTY; ATTENDANCE; OBESITY AB Social support may be associated with increased weight loss after bariatric surgery. The objective of this article is to determine impact of post-operative support groups and other forms of social support on weight loss after bariatric surgery. MEDLINE search (1988-2009) was completed using MeSH terms including bariatric procedures and a spectrum of patient factors with potential relationship to weight loss outcomes. Of the 934 screened studies, 10 reported on social support and weight loss outcomes. Five studies reported on support groups and five studies reported on other forms of social support (such as perceived family support or number of confidants) and degree of post-operative weight loss (total n = 735 patients). All studies found a positive association between post-operative support groups and weight loss. One study found a positive association between marital status (being single) and weight loss, while three studies found a non-significant positive trend and one study was inconclusive. Support group attendance after bariatric surgery is associated with greater post-operative weight loss. Further research is necessary to determine the impact of other forms of social support. These factors should be addressed in prospective studies of weight loss following bariatric surgery, as they may represent ways to improve post-operative outcomes. C1 [Livhits, M.; Mercado, C.; Yermilov, I.; Parikh, J. A.; Dutson, E.; Mehran, A.; Ko, C. Y.; Shekelle, P. G.; Gibbons, M. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Livhits, M.; Yermilov, I.; Parikh, J. A.; Ko, C. Y.; Shekelle, P. G.; Gibbons, M. M.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Gibbons, M. M.] Olive View UCLA, Dept Surg, Sylmar, CA USA. RP Livhits, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,72-215 CHS, Los Angeles, CA 90095 USA. EM mlivhits@mednet.ucla.edu FU Robert Wood Johnson Physician Faculty Scholars programme; VA Department of Surgery FX We would like to acknowledge the VA Department of Surgery for providing support for Dr Livhits and Dr Maggard. Dr Maggard's time was also supported in part by a grant from the Robert Wood Johnson Physician Faculty Scholars programme. NR 29 TC 48 Z9 48 U1 3 U2 25 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1467-7881 J9 OBES REV JI Obes. Rev. PD FEB PY 2011 VL 12 IS 2 BP 142 EP 148 DI 10.1111/j.1467-789X.2010.00720.x PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 725RE UT WOS:000287662800007 PM 20158617 ER PT J AU Goldberg, RM Ryan, DP AF Goldberg, Richard M. Ryan, David P. TI Scan? Cure? Sure! SO ONCOLOGIST LA English DT Editorial Material ID COLORECTAL-CANCER; FOLLOW-UP; PRACTICE GUIDELINE; SURVIVAL; FLUOROURACIL; SURVEILLANCE; CARCINOMA; RESECTION; SURGERY; TRIAL AB PRESENTATION OF THE CASE A 61-year-old man undergoes a sigmoid colectomy for a T3N1 ( two of 18 nodes) adenocarcinoma of the sigmoid colon. He recovers well and receives 6 months of adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) uneventfully. At his first follow-up visit, the oncologist recommended every 3 month visits for a physical, liver function tests, and carcinoembryonic antigen (CEA) measurement; every 6 month chest, abdomen, and pelvic computed tomography (CT) scans for 3 years; and aspirin, vitamin D supplementation, and exercise. Is CT scanning appropriate in the follow-up of colon cancer patients? ( This case was presented at Massachusetts General Hospital Cancer Center.) C1 [Goldberg, Richard M.] Univ N Carolina, Chapel Hill, NC 27515 USA. [Ryan, David P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Goldberg, RM (reprint author), Univ N Carolina, Chapel Hill, NC 27515 USA. RI Inov Farmaceutica, Inct/K-2313-2013; Goldberg , Richard/M-1311-2013 NR 14 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PD FEB PY 2011 VL 16 IS 2 BP 254 EP 256 DI 10.1634/theoncologist.2011-0014 PG 3 WC Oncology SC Oncology GA 726DL UT WOS:000287698900015 PM 21349952 ER PT J AU Moskowitz, SM Emerson, JC McNamara, S Shell, RD Orenstein, DM Rosenbluth, D Katz, MF Ahrens, R Hornick, D Joseph, PM Gibson, RL Aitken, ML Benton, WW Burns, JL AF Moskowitz, Samuel M. Emerson, Julia C. McNamara, Sharon Shell, Richard D. Orenstein, David M. Rosenbluth, Daniel Katz, Marcia F. Ahrens, Richard Hornick, Douglas Joseph, Patricia M. Gibson, Ronald L. Aitken, Moira L. Benton, Wade W. Burns, Jane L. TI Randomized Trial of Biofilm Testing to Select Antibiotics for Cystic Fibrosis Airway Infection SO PEDIATRIC PULMONOLOGY LA English DT Article DE Pseudomonas aeruginosa; intravenous antibiotics; antibiotic resistance; antibiotic susceptibility testing; broth microdilution testing; inhibitory quotient; sputum bacterial density; lung function ID PSEUDOMONAS-AERUGINOSA; BACTERIAL BIOFILMS; UNITED-STATES; TOBRAMYCIN; SUSCEPTIBILITIES; EXACERBATIONS; SPUTUM; MICROBIOLOGY; RESISTANCE; REGIMENS AB Rationale: In cystic fibrosis (CF), conventional antibiotic susceptibility results correlate poorly with clinical outcomes. We hypothesized that biofilm testing would more accurately reflect the susceptibilities of bacteria infecting CF airways. Methods: A multicenter randomized pilot trial was conducted to assess the efficacy and safety of using biofilm susceptibility testing of Pseudomonas aeruginosa sputum isolates to guide antibiotic regimens for chronic airway infections in clinically stable adolescent and adult CF patients. Thirty-nine participants were randomized to biofilm or conventional treatment groups; 14-day courses of two antibiotics were selected according to an activity-based algorithm using the corresponding susceptibility results. Results: Of the agents tested, meropenem was most active against biofilm-grown bacteria, and was included in regimens for about half of each study group. For 19 of 39 randomized participants, randomization to the other study group would not have changed the antibiotic classes of the assigned regimen. Study groups were comparable at baseline, and had similar mean decreases in bacterial density, measured in log, 0 colony forming units per gram of sputum (biofilm, -2.94 [SD 2.83] vs. conventional, -3.27 [SD 3.09]), and mean increases in forced expiratory volume in 1 sec, measured in liters (0.18 [SD 0.20] vs. 0.12 [SD 0.22]). Conclusions: In this pilot study, antibiotic regimens based on biofilm testing did not differ significantly from regimens based on conventional testing in terms of microbiological and clinical responses. The predictive value of biofilm testing may nonetheless warrant evaluation in an adequately powered clinical trial in younger CF patients or those experiencing acute pulmonary exacerbation. Pediatr Pulmonol. 2011; 46:184-192. (C) 2011 Wiley-Liss, Inc. C1 [Moskowitz, Samuel M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Moskowitz, Samuel M.; Emerson, Julia C.; Gibson, Ronald L.; Burns, Jane L.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. [Moskowitz, Samuel M.; Emerson, Julia C.; McNamara, Sharon; Gibson, Ronald L.; Benton, Wade W.; Burns, Jane L.] Seattle Childrens Hosp, Seattle, WA USA. [Shell, Richard D.] Nationwide Childrens Hosp, Div Pulm Med, Columbus, OH USA. [Orenstein, David M.] UPMC, Childrens Hosp Pittsburgh, Div Pulm Med, Pittsburgh, PA USA. [Rosenbluth, Daniel] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA. [Rosenbluth, Daniel] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA. [Katz, Marcia F.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Ahrens, Richard] Univ Iowa, Dept Pediat, Carver Coll Med, Iowa City, IA 52242 USA. [Hornick, Douglas] Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA. [Joseph, Patricia M.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA. [Aitken, Moira L.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Moskowitz, SM (reprint author), MGH Div Pediat Pulm Med, 175 Cambridge St, Boston, MA 02114 USA. EM smoskowitz@partners.org FU Cystic Fibrosis Foundation [BURNS03A0]; Clinical and Translational Science Center; National Center for Research Resources [UL1 RR025014]; University of Washington, Seattle [M01 RR000037]; Ohio State University, Columbus [UL1 RR025755, M01 RR000034]; University of Pittsburgh [UL1 RR024153, M01 RR000084]; Washington University, St. Louis [UL1 RR024992, M01 RR000036]; Baylor College of Medicine, Houston [M01 RR000188]; University of Iowa [UL1 RR024979, M01 RR000059]; University of Cincinnati [UL1 RR026314]; Children's Hospital Medical Center, Cincinnati [M01 RR008084]; National Heart Lung and Blood Institute [K08HL067903]; Gilead Sciences for clinical research; Boehringer-Ingelheim Pharmaceuticals; Transave; Vertex for clinical research; PTC Pharmaceuticals; Vertex; Pharmaxis for clinical research; KaloBios; Chiesi for clinical research; Cystic Fibrosis Foundation; National Institutes of Health FX The authors acknowledge the vital work of the Biofilm Study Research Coordinators: Laura Raterman and Terri Johnson, Nationwide Children's Hospital, Columbus, OH; Elizabeth Hartigan, Children's Hospital of Pittsburgh of UPMC, PA; Mary Boyle, Washington University School of Medicine, St. Louis, MO; Suzanne Cummings, Baylor College of Medicine, Houston, TX; Mary Teresi and Cheri Lux, University of Iowa, Iowa City, IA; Melenie Meyers, University Hospital, Cincinnati, OH; and Alan Genatossio, Seattle Children's Research Institute, Seattle, WA. The authors thank the following for their contributions to the study: Jessica Foster, Janine Jijina, Maxine Smith, Molly Andrina, Emily Sasnett, Jenny Stapp, Anne Marie Buccat, Adam Griffith, Morty Cohen, Lucas Hoffman, Chris Goss, Bonnie Ramsey, Wayne Morgan, and Option Care, Inc. (now Walgreens-OptionCare). This study was supported through a Clinical Research Grant from the Cystic Fibrosis Foundation (BURNS03A0), as well as Clinical and Translational Science Center and General Clinical Research Center Awards from the National Center for Research Resources (UL1 RR025014 and M01 RR000037-University of Washington, Seattle; UL1 RR025755 and M01 RR000034- Ohio State University, Columbus; UL1 RR024153 and M01 RR000084 University of Pittsburgh; UL1 RR024992 and M01 RR000036-Washington University, St. Louis; M01 RR000188-Baylor College of Medicine, Houston; UL1 RR024979 and M01 RR000059 University of :Iowa; UL1 RR026314 University of Cincinnati; and M01 RR008084 Children's Hospital Medical Center, Cincinnati). S.M.M. was supported in part through a Clinician Scientist Career Development Award from the National Heart Lung and Blood Institute (K08HL067903). Potential conflict of interest: S.M.M. serves as a consultant to Kala Pharmaceuticals, and has received honoraria from the France Foundation for speaking engagements. J.C.E., no conflict. S.McN., no conflict R.D.S., no conflict. D.M.O., no conflict. D.R., no conflict. M.F.K. has received honoraria from Novartis, Genentech, and Gilead Sciences for speaking engagements and consulting, and has received funding from Gilead Sciences for clinical research. R.A. has received funding from Gilead Sciences, Boehringer-Ingelheim Pharmaceuticals, Transave, and Vertex for clinical research. D.H. has received honoraria from Pfizer and Boehringer-Ingelheim Pharmaceuticals for speaking engagements, and serves on advisory boards for Pfizer and Genentech. P.M.J., no conflict. R.L.G. has received funding from Gilead Sciences for clinical research. M.L.A. has received honoraria from the CF Foundation for speaking engagements, and has received funding from Transave, PTC Pharmaceuticals, Vertex, and Pharmaxis for clinical research. W.W.B. is an employee of Actelion Pharmaceuticals. J.L.B. has received funding from Transave, Gilead Sciences, Vertex, KaloBios, and Chiesi for clinical research. Contributions of authors: S.M.M., J.C.E., and J.L.B. wrote the manuscript, and S.McN., R.D.S., D.M.O., -D.R., M.F.K., R.A., P.M.J., and R.L.G. edited it. S.M.M., J.C.E., and J.L.B. had full access to all of the data in the study and take full responsibility for the integrity of all of the data and the accuracy of the data analysis, including all adverse effects. This work was performed at Barnes Jewish Hospital (St. Louis), Baylor College of Medicine (Houston), Children's Hospital of Pittsburgh of UPMC, Nationwide Children's Hospital (Columbus), Seattle Children's Hospital, University Hospital (Cincinnati), and University of Iowa Hospitals and Clinics (Iowa City).; Cystic Fibrosis Foundation; National Institutes of Health NR 30 TC 25 Z9 25 U1 0 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD FEB PY 2011 VL 46 IS 2 BP 184 EP 192 DI 10.1002/ppul.21350 PG 9 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 717SS UT WOS:000287068300013 PM 20963843 ER PT J AU Powe, CE Puopolo, KM Newburg, DS Lonnerdal, B Chen, C Allen, M Merewood, A Worden, S Welt, CK AF Powe, Camille E. Puopolo, Karen M. Newburg, David S. Loennerdal, Bo Chen, Ceng Allen, Maureen Merewood, Anne Worden, Susan Welt, Corrine K. TI Effects of Recombinant Human Prolactin on Breast Milk Composition SO PEDIATRICS LA English DT Article DE breastfeeding; prolactin; nutrition; premature; neonate ID BIRTH-WEIGHT INFANTS; ALPHA-LACTALBUMIN; MAMMARY-GLAND; NECROTIZING ENTEROCOLITIS; SERUM PROLACTIN; HUMAN LACTATION; TERM INFANTS; SIALIC-ACID; 1ST YEAR; WOMEN AB OBJECTIVE: The objective of this study was to determine the impact of recombinant human prolactin (r-hPRL) on the nutritional and immunologic composition of breast milk. METHODS: We conducted 2 trials of r-hPRL treatment. In the first study, mothers with documented prolactin deficiency were given r-hPRL every 12 hours in a 28-day, open-label trial. In the second study, mothers with lactation insufficiency that developed while they were pumping breast milk for their preterm infants were given r-hPRL daily in a 7-day, double-blind, placebo-controlled trial. Breast milk characteristics were compared before and during 7 days of treatment. RESULTS: Among subjects treated with r-hPRL (N = 11), milk volumes (73 +/- 36 to 146 +/- 54 mL/day; P < .001) and milk lactose levels (155 +/- 15 to 184 +/- 8 mmol/L; P = .01) increased, whereas milk sodium levels decreased (12.1 +/- 2.0 to 8.3 +/- 0.5 mmol/L; P = .02). Milk calcium levels increased in subjects treated with r-hPRL twice daily (2.8 +/- 0.6 to 5.0 +/- 0.9 mmol/L; P = .03). Total neutral (1.5 +/- 0.3 to 2.5 +/- 0.4 g/L; P = .04) and acidic (33 +/- 4 to 60 +/- 6 mg/L; P = .02) oligosaccharide levels increased in r-hPRL-treated subjects, whereas total daily milk immunoglobulin A secretionwas unchanged. CONCLUSIONS: r-hPRL treatment increased milk volume and induced changes in milk composition similar to those that occur during normal lactogenesis. r-hPRL also increased antimicrobially active oligosaccharide concentrations. These effects were achieved for women with both prolactin deficiency and lactation insufficiency. Pediatrics 2011;127:e359-e366 C1 [Powe, Camille E.; Welt, Corrine K.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. [Powe, Camille E.; Puopolo, Karen M.; Newburg, David S.; Chen, Ceng; Welt, Corrine K.] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA. [Puopolo, Karen M.; Allen, Maureen] Brigham & Womens Hosp, Dept Newborn Med, Boston, MA 02115 USA. [Newburg, David S.; Chen, Ceng] Massachusetts Gen Hosp Children, Pediat Gastroenterol & Nutr Unit, Boston, MA USA. [Worden, Susan] Massachusetts Gen Hosp Children, Dept Pediat, Boston, MA USA. [Loennerdal, Bo] Univ Calif Davis, Coll Agr & Environm Sci, Dept Nutr, Davis, CA 95616 USA. [Merewood, Anne] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA. RP Welt, CK (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, BHX 511,55 Fruit St, Boston, MA 02114 USA. EM cwelt@partners.org OI Welt, Corrine/0000-0002-8219-5504; Merewood, Anne/0000-0002-7802-9028 FU Genzyme; Food and Drug Administration [FD-R-003014]; March of Dimes Birth Defects Foundation [6-FY04-76]; National Center for Research Resources General Clinical Research Center [M01-RR-01066] FX The recombinant human prolactin was provided by Genzyme. Dr Welt received an unrestricted grant from Genzyme. Genzyme was not involved in study design, subject recruitment, data analysis, or manuscript preparation.; This work was supported by the Food and Drug Administration (grant FD-R-003014), the March of Dimes Birth Defects Foundation (research grant 6-FY04-76), and the National Center for Research Resources General Clinical Research Centers Program (grant M01-RR-01066). NR 57 TC 5 Z9 5 U1 0 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2011 VL 127 IS 2 BP E359 EP E366 DI 10.1542/peds.2010-1627 PG 8 WC Pediatrics SC Pediatrics GA 714JF UT WOS:000286805200014 PM 21262884 ER PT J AU Yu, DT Seger, DL Lasser, KE Karson, AS Fiskio, JM Seger, AC Bates, DW AF Yu, Donghui Tony Seger, Diane L. Lasser, Karen E. Karson, Andrew S. Fiskio, Julie M. Seger, Andrew C. Bates, David W. TI Impact of implementing alerts about medication black-box warnings in electronic health records SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE drug-drug interactions; drug-laboratory interactions; drug-disease interactions; drug-pregnancy interactions; electronic prescribing; alert; drug safety ID ADVERSE DRUG EVENTS; PHYSICIAN ORDER ENTRY; HOSPITALIZED-PATIENTS; AMBULATORY-CARE; ERRORS; PREVENTION; OUTCOMES; SUPPORT; RATES AB Background The Food and Drug Administration issues black-box warnings (BBWs) regarding medications with serious risks, yet physician adherence to the warnings is low. Methods We evaluated the impact of delivering BBW-based alerts about drug-drug, drug-disease, and drug-laboratory interactions for prescription medications in outpatients in an electronic health record with clinical decision support. We compared the frequency of non-adherence to all BBWs about drug-drug, drug-disease, and drug-laboratory interactions for 30 drugs/drug classes, and by individual drugs/drug groups with BBWs between the pre- and post-intervention periods. We used multivariate analysis to identify independent risk factors for non-adherence to BBWs. Results There was a slightly higher frequency of non-adherence to BBWs after the intervention (4.8% vs. 5.1%, p = 0.045). In multivariate analyses, after adjustment for patient and provider characteristics and site of care, medications prescribed during the pre-intervention period were less likely to violate BBWs compared to those prescribed during the post-intervention period (OR 0.67, 95% CI, 0.47-0.96). However, black-box warning violations did decrease after the intervention for BBWs about drug-drug interactions (6.1% vs. 1.8%, p < 0.0001) and drug-pregnancy interactions (5.1% vs. 3.6%, p = 0.01). Conclusions Ambulatory care computerized order entry with prescribing alerts about BBWs did not improve clinicians' overall adherence to BBWs, though it did improve adherence for specific clinically important subcategories. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Bates, David W.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gen Internal Med & Primary Care,Dept Med, Boston, MA 02120 USA. [Yu, Donghui Tony; Seger, Diane L.; Fiskio, Julie M.; Seger, Andrew C.; Bates, David W.] Partners HealthCare Syst, Dept Informat Syst, Wellesley, MA USA. [Seger, Andrew C.] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA. [Karson, Andrew S.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA 02120 USA. [Lasser, Karen E.] Boston Univ, Sch Med, Boston Med Ctr, Dept Med, Boston, MA 02118 USA. RP Bates, DW (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gen Internal Med & Primary Care,Dept Med, 1620 Tremont St, Boston, MA 02120 USA. EM dbates@partners.org OI Lasser, Karen/0000-0003-3777-6075 FU Partners Information Systems Research Council, Partners HealthCare System, Boston, MA FX This study was supported by grant from Partners Information Systems Research Council, Partners HealthCare System, Boston, MA. The funding sponsor had no role in study design, conduct, analysis, interpretation of the data, or preparation, review or approval of the manuscript. The authors thank Hanna M. Seidling, PhD, and Jennifer Boehne, PharmD for their comments on draft of this article. NR 35 TC 15 Z9 15 U1 5 U2 8 PU WILEY PERIODICALS, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD FEB PY 2011 VL 20 IS 2 BP 192 EP 202 DI 10.1002/pds.2088 PG 11 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 726JH UT WOS:000287716100011 PM 21254291 ER PT J AU Gordon, CR AF Gordon, Chad R. TI Sequential Heart and Composite Tissue Allotransplantation in Rats SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Letter ID TRANSPLANTATION C1 Harvard Univ, Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Sch Med, Boston, MA 02114 USA. RP Gordon, CR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Sch Med, 15 Parkman St,WACC 435, Boston, MA 02114 USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD FEB PY 2011 VL 127 IS 2 BP 1021 EP 1022 DI 10.1097/PRS.0b013e318200b051 PG 2 WC Surgery SC Surgery GA 715XJ UT WOS:000286928100102 PM 21285847 ER PT J AU Wu, CS Chen, YF Gartenberg, MR AF Wu, Ching-Shyi Chen, Yu-Fan Gartenberg, Marc R. TI Targeted Sister Chromatid Cohesion by Sir2 SO PLOS GENETICS LA English DT Article ID BUDDING YEAST CHROMOSOMES; SACCHAROMYCES-CEREVISIAE; SILENT CHROMATIN; GENE-EXPRESSION; ROBERTS-SYNDROME; RIBOSOMAL DNA; RDNA REPEATS; RENT COMPLEX; MEIOSIS-I; S-PHASE AB The protein complex known as cohesin binds pericentric regions and other sites of eukaryotic genomes to mediate cohesion of sister chromatids. In budding yeast Saccharomyces cerevisiae, cohesin also binds silent chromatin, a repressive chromatin structure that functionally resembles heterochromatin of higher eukaryotes. We developed a protein-targeting assay to investigate the mechanistic basis for cohesion of silent chromatin domains. Individual silencing factors were tethered to sites where pairing of sister chromatids could be evaluated by fluorescence microscopy. We report that the evolutionarily conserved Sir2 histone deacetylase, an essential silent chromatin component, was both necessary and sufficient for cohesion. The cohesin genes were required, but the Sir2 deacetylase activity and other silencing factors were not. Binding of cohesin to silent chromatin was achieved with a small carboxyl terminal fragment of Sir2. Taken together, these data define a unique role for Sir2 in cohesion of silent chromatin that is distinct from the enzyme's role as a histone deacetylase. C1 [Wu, Ching-Shyi; Chen, Yu-Fan; Gartenberg, Marc R.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA. [Gartenberg, Marc R.] Canc Inst New Jersey, New Brunswick, NJ USA. RP Wu, CS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Charlestown, MA USA. EM gartenbe@umdnj.edu OI Wu, Ching-Shyi/0000-0001-9800-9844; Gartenberg, Marc/0000-0003-0713-7993 FU NIH [GM51402]; March of Dimes [1-FY08-481] FX This research was supported by grants from NIH (GM51402) and the March of Dimes (1-FY08-481). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 78 TC 20 Z9 21 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD FEB PY 2011 VL 7 IS 2 AR e1002000 DI 10.1371/journal.pgen.1002000 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA 726CV UT WOS:000287697300034 PM 21304892 ER PT J AU Osorio, Y Travi, BL Renslo, AR Peniche, AG Melby, PC AF Osorio, Yaneth Travi, Bruno L. Renslo, Adam R. Peniche, Alex G. Melby, Peter C. TI Identification of Small Molecule Lead Compounds for Visceral Leishmaniasis Using a Novel Ex Vivo Splenic Explant Model System SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID INDIAN KALA-AZAR; ANTILEISHMANIAL ACTIVITY; PLASMODIUM-FALCIPARUM; INTERFERON-GAMMA; T-CELLS; DRUG; DONOVANI; INFECTION; CYTOTOXICITY; CHEMOTHERAPY AB Background: New drugs are needed to treat visceral leishmaniasis (VL) because the current therapies are toxic, expensive, and parasite resistance may weaken drug efficacy. We established a novel ex vivo splenic explant culture system from hamsters infected with luciferase-transfected Leishmania donovani to screen chemical compounds for anti-leishmanial activity. Methodology/Principal Findings: This model has advantages over in vitro systems in that it: 1) includes the whole cellular population involved in the host-parasite interaction; 2) is initiated at a stage of infection when the immunosuppressive mechanisms that lead to progressive VL are evident; 3) involves the intracellular form of Leishmania; 4) supports parasite replication that can be easily quantified by detection of parasite-expressed luciferase; 5) is adaptable to a high-throughput screening format; and 6) can be used to identify compounds that have both direct and indirect anti-parasitic activity. The assay showed excellent discrimination between positive (amphotericin B) and negative (vehicle) controls with a Z' Factor >0.8. A duplicate screen of 4 chemical libraries containing 4,035 compounds identified 202 hits (5.0%) with a Z score of < -1.96 (p<0.05). Eighty-four (2.1%) of the hits were classified as lead compounds based on the in vitro therapeutic index (ratio of the compound concentration causing 50% cytotoxicity in the HepG(2) cell line to the concentration that caused 50% reduction in the parasite load). Sixty-nine (82%) of the lead compounds were previously unknown to have anti-leishmanial activity. The most frequently identified lead compounds were classified as quinoline-containing compounds (14%), alkaloids (10%), aromatics (11%), terpenes (8%), phenothiazines (7%) and furans (5%). Conclusions/Significance: The ex vivo splenic explant model provides a powerful approach to identify new compounds active against L. donovani within the pathophysiologic environment of the infected spleen. Further in vivo evaluation and chemical optimization of these lead compounds may generate new candidates for preclinical studies of treatment for VL. C1 [Osorio, Yaneth; Travi, Bruno L.; Peniche, Alex G.; Melby, Peter C.] Res Serv, Dept Vet Affairs Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Osorio, Yaneth; Travi, Bruno L.; Peniche, Alex G.; Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Renslo, Adam R.] Univ Calif San Francisco, Small Mol Discovery Ctr, Sandler Ctr Basic Res Parasit Dis, San Francisco, CA 94143 USA. [Renslo, Adam R.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA. [Melby, Peter C.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA. RP Osorio, Y (reprint author), Univ Texas Med Branch, Ctr Trop Dis, Dept Internal Med, Galveston, TX 77555 USA. EM pcmelby@utmb.edu OI Renslo, Adam/0000-0002-1240-2846 FU Department of Defense, Air Force [FA7014-07-C-0034] FX This work was funded by Department of Defense, Air Force Contract No. FA7014-07-C-0034 (P.C. Melby P.I.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 59 TC 26 Z9 26 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2011 VL 5 IS 2 AR e962 DI 10.1371/journal.pntd.0000962 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 726CQ UT WOS:000287696700012 PM 21358812 ER PT J AU Baish, JW Stylianopoulos, T Lanning, RM Kamoun, WS Fukumura, D Munn, LL Jain, RK AF Baish, James W. Stylianopoulos, Triantafyllos Lanning, Ryan M. Kamoun, Walid S. Fukumura, Dai Munn, Lance L. Jain, Rakesh K. TI Scaling rules for diffusive drug delivery in tumor and normal tissues SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE antiangiogenesis; cancer; fractal dimension; percolation; transport ID VASCULAR NORMALIZATION; ANTIANGIOGENIC THERAPY; PRESSURE; GROWTH; MICROSCOPY; CANCER; MODEL; ANGIOGENESIS; ARCHITECTURE; BRAIN AB Delivery of blood-borne molecules and nanoparticles from the vasculature to cells in the tissue differs dramatically between tumor and normal tissues due to differences in their vascular architectures. Here we show that two simple measures of vascular geometry-delta(max) and lambda-readily obtained from vascular images, capture these differences and link vascular structure to delivery in both tissue types. The longest time needed to bring materials to their destination scales with the square of delta(max), the maximum distance in the tissue from the nearest blood vessel, whereas., a measure of the shape of the spaces between vessels, determines the rate of delivery for shorter times. Our results are useful for evaluating how new therapeutic agents that inhibit or stimulate vascular growth alter the functional efficiency of the vasculature and more broadly for analysis of diffusion in irregularly shaped domains. C1 [Baish, James W.] Bucknell Univ, Dept Mech, Lewisburg, PA 17837 USA. [Baish, James W.] Bucknell Univ, Dept Biomed Engn, Lewisburg, PA 17837 USA. [Stylianopoulos, Triantafyllos; Lanning, Ryan M.; Kamoun, Walid S.; Fukumura, Dai; Munn, Lance L.; Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Stylianopoulos, Triantafyllos; Lanning, Ryan M.; Kamoun, Walid S.; Fukumura, Dai; Munn, Lance L.; Jain, Rakesh K.] Massachusetts Gen Hosp, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA. RP Baish, JW (reprint author), Bucknell Univ, Dept Mech, Lewisburg, PA 17837 USA. EM baish@bucknell.edu; jain@steele.mgh.harvard.edu RI Munn, Lance/L-3950-2016; OI Munn, Lance/0000-0003-0698-7232; Stylianopoulos, Triantafyllos/0000-0002-3093-1696 FU US National Cancer Institute [R15-CA094119, R15-CA074366, R01-CA96915, R01-CA85140, R01-CA115767, R01-CA126642, P01-CA80124]; US Department of Defense [W81XWH-10-1-0016, W81XWH-06-1-0436] FX The authors thank Dan Duda, Joseph Tranquillo, and Michael Prince for their insightful comments on the manuscript. This study was supported in part by US National Cancer Institute Grants R15-CA094119 and R15-CA074366 (J.W.B.); R01-CA96915 (D.F.); and R01-CA85140, R01-CA115767, R01-CA126642, and P01-CA80124 (R.K.J.). R.K.J. is a recipient of an Innovator Award from US Department of Defense Breast Cancer Research Program (W81XWH-10-1-0016). T.S. was a Susan G. Komen fellow (KG091281). R.M.L. was supported in part by US Department of Defense Breast Cancer Research Program Fellowship W81XWH-06-1-0436. NR 29 TC 62 Z9 62 U1 2 U2 27 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 1 PY 2011 VL 108 IS 5 BP 1799 EP 1803 DI 10.1073/pnas.1018154108 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 714JA UT WOS:000286804700013 PM 21224417 ER PT J AU Jennings-Antipov, LD Song, LK Collier, RJ AF Jennings-Antipov, Laura D. Song, Likai Collier, R. John TI Interactions of anthrax lethal factor with protective antigen defined by site-directed spin labeling SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID PORE FORMATION; TOXIN PORE; PROTEIN TRANSLOCATION; EDEMA FACTOR; PHENYLALANINE CLAMP; CRYSTAL-STRUCTURE; RECEPTOR; BINDING; MUTATIONS; COMPLEXES AB The protective antigen (PA) moiety of anthrax toxin forms oligomeric pores that translocate the enzymatic moieties of the toxin -lethal factor (LF) and edema factor (EF)-across the endosomal membrane of mammalian cells. Here we describe site-directed spin-labeling studies that identify interactions of LF with the prepore and pore conformations of PA. Our results reveal a direct interaction between the extreme N terminus of LF (residues 2-5) and the F-clamp, a structure within the lumen of the pore that catalyzes translocation. Also, consistent with a recent crystallographic model, we find that, upon binding of the translocation substrate to PA, LF helix alpha 1 separates from helices alpha 2 and alpha 3 and binds in the a-clamp of PA. These interactions, together with the binding of the globular part of the N-terminal domain of LF to domain 1' of PA, indicate that LF interacts with the PA pore at three distinct sites. Our findings elucidate the state from which translocation of LF and EF proceeds through the PA pore. C1 [Jennings-Antipov, Laura D.; Collier, R. John] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. [Song, Likai] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Song, Likai] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. RP Collier, RJ (reprint author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. EM jcollier@hms.harvard.edu OI Collier, R John/0000-0002-2427-4239 FU National Institutes of Health (NIH) [AI057159, AI022021] FX We thank Dr. Robin Ross and Lauren Perry of the Biomolecule Production Core of New England Regional Center of Excellence, supported by National Institutes of Health (NIH) Grant AI057159, for helping with bacterial growth and expression of proteins. We also thank Prof. Blythe Janowiak (St. Louis University, St. Louis, MO) for supplying plasmids, Prof. Bryan Krantz, Geoffrey Feld, and colleagues for allowing access to the PA prepore-LFN crystal structure coordinates ahead of print, and Prof. Ellis Reinherz for providing time on the Bruker EMX spectrometer. This work was supported by NIH Grant AI022021 (to R.J.C.). NR 38 TC 17 Z9 17 U1 0 U2 3 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 1 PY 2011 VL 108 IS 5 BP 1868 EP 1873 DI 10.1073/pnas.1018965108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 714JA UT WOS:000286804700025 PM 21262847 ER PT J AU Sansregret, L Vadnais, C Livingstone, J Kwiatkowski, N Awan, A Cadieux, C Leduy, L Hallett, MT Nepveu, A AF Sansregret, Laurent Vadnais, Charles Livingstone, Julie Kwiatkowski, Nicholas Awan, Arif Cadieux, Chantal Leduy, Lam Hallett, Michael T. Nepveu, Alain TI Cut homeobox 1 causes chromosomal instability by promoting bipolar division after cytokinesis failure SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE tetraploidy; transcription factor; spindle assembly checkpoint ID EXTRA CENTROSOMES; TRANSCRIPTION FACTOR; HUMAN-CELLS; CANCER; ANEUPLOIDY; ISOFORM; TISSUE; EXPRESSION; MECHANISM; CUX1 AB Cell populations able to generate a large repertoire of genetic variants have increased potential to generate tumor cells that survive through the multiple selection steps involved in tumor progression. A mechanism for the generation of aneuploid cancer cells involves passage through a tetraploid stage. Supernumerary centrosomes, however, can lead to multipolar mitosis and cell death. Using tissue culture and transgenic mouse models of breast cancer, we report that Cut homeobox 1 (CUX1) causes chromosomal instability by activating a transcriptional program that prevents multipolar divisions and enables the survival of tetraploid cells that evolve to become genetically unstable and tumorigenic. Transcriptional targets of CUX1 involved in DNA replication and bipolar mitosis defined a gene expression signature that, across 12 breast cancer gene expression datasets, was associated with poor clinical outcome. The signature not only was higher in breast tumor subtypes of worse prognosis, like the basal-like and HER2(+) subtypes, but also identified poor outcome among estrogen receptor-positive/node-negative tumors, a subgroup considered to be at lower risk. The CUX1 signature therefore represents a unique criterion to stratify patients and provides insight into the molecular determinants of poor clinical outcome. C1 [Sansregret, Laurent; Vadnais, Charles; Livingstone, Julie; Awan, Arif; Cadieux, Chantal; Leduy, Lam; Hallett, Michael T.; Nepveu, Alain] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada. [Sansregret, Laurent; Vadnais, Charles; Awan, Arif; Cadieux, Chantal; Nepveu, Alain] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada. [Nepveu, Alain] McGill Univ, Dept Oncol, Montreal, PQ H3A 1A3, Canada. [Nepveu, Alain] McGill Univ, Dept Med, Montreal, PQ H3A 1A3, Canada. [Kwiatkowski, Nicholas] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Kwiatkowski, Nicholas] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Livingstone, Julie; Hallett, Michael T.] McGill Univ, McGill Ctr Bioinformat, Quebec City, PQ H3G 0B1, Canada. RP Nepveu, A (reprint author), McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada. EM alain.nepveu@mcgill.ca OI Livingstone, Julie/0000-0002-8424-3768 FU Canadian Institutes of Heath Research; Fonds de la Recherche en Sante du Quebec; Department of Defense; Canadian Cancer Society [019389] FX We thank Dr. M. Petronczki for sharing reagents; Dr. J. Gannon for anti-p21 and p53 antibodies; and Ginette Berube and Maria Drossos for expert technical assistance. L.S., C.V., and C.C. were supported by studentships from, respectively, the Canadian Institutes of Heath Research, the Fonds de la Recherche en Sante du Quebec, and the Department of Defense Breast Cancer Research Program. This research was supported by Grant 019389 from the Canadian Cancer Society (to A.N.). NR 23 TC 15 Z9 15 U1 0 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 1 PY 2011 VL 108 IS 5 BP 1949 EP 1954 DI 10.1073/pnas.1008403108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 714JA UT WOS:000286804700039 PM 21245318 ER PT J AU Zha, S Jiang, WX Fujiwara, Y Patel, H Goff, PH Brush, JW Dubois, RL Alt, FW AF Zha, Shan Jiang, Wenxia Fujiwara, Yuko Patel, Harin Goff, Peter H. Brush, James W. Dubois, Richard L. Alt, Frederick W. TI Ataxia telangiectasia-mutated protein and DNA-dependent protein kinase have complementary V(D)J recombination functions SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE DNA repair; DNA double-strand break repair ID SIGNAL JOINT FORMATION; INCREASED GENOMIC INSTABILITY; CATALYTIC SUBUNIT; BREAK REPAIR; CODING JOINT; PKCS; ATM; CELLS; IMMUNODEFICIENCY; PHOSPHORYLATION AB Antigen receptor variable region exons are assembled during lymphocyte development from variable (V), diversity (D), and joining (J) gene segments. Each germ-line gene segment is flanked by recombination signal sequences (RSs). Recombination-activating gene endonuclease initiates V(D)J recombination by cleaving a pair of gene segments at their junction with flanking RSs to generate covalently sealed (hairpinned) coding ends (CEs) and blunt 5'-phosphorylated RS ends (SEs). Subsequently, nonhomologous end joining (NHEJ) opens, processes, and fuses CEs to form coding joins (CJs) and precisely joins SEs to form signal joins (SJs). DNA-dependent protein kinase catalytic subunit (DNA-PKcs) activates Artemis endonuclease to open and process hairpinned CEs before their fusion into CJs by other NHEJ factors. Although DNA-PKcs is absolutely required for CJs, SJs are formed to variable degrees and with variable fidelity in different DNA-PKcs-deficient cell types. Thus, other factors may compensate for DNA-PKcs function in SJ formation. DNA-PKcs and the ataxia telangiectasia-mutated (ATM) kinase are members of the same family, and they share common substrates in the DNA damage response. Although ATM deficiency compromises chromosomal V(D)J CJ formation, it has no reported role in SJ formation in normal cells. Here, we report that DNA-PKcs and ATM have redundant functions in SJ formation. Thus, combined DNA-PKcs and ATM deficiency during V(D)J recombination leads to accumulation of unjoined SEs and lack of SJ fidelity. Moreover, treatment of DNA-PKcs-or ATM-deficient cells, respectively, with specific kinase inhibitors for ATM or DNA-PKcs recapitulates SJ defects, indicating that the overlapping V(D)J recombination functions of ATM and DNA-PKcs are mediated through their kinase activities. C1 [Zha, Shan; Fujiwara, Yuko; Patel, Harin; Goff, Peter H.; Brush, James W.; Alt, Frederick W.] Childrens Hosp, Howard Hughes Med Inst, Immune Dis Inst, Boston, MA 02115 USA. [Zha, Shan; Fujiwara, Yuko; Patel, Harin; Goff, Peter H.; Brush, James W.; Alt, Frederick W.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Zha, Shan; Jiang, Wenxia; Dubois, Richard L.] Columbia Univ, Dept Pediat, Dept Pathol & Cell Biol, Inst Canc Genet, New York, NY 10032 USA. RP Zha, S (reprint author), Childrens Hosp, Howard Hughes Med Inst, Immune Dis Inst, Boston, MA 02115 USA. EM sz2296@columbia.edu; alt@enders.tch.harvard.edu FU Leukemia and Lymphoma Society; St. Baldrick Foundation; Dr. John Driscoll Jr. Children's Medical Award; National Institutes of Health [CA092625, CA109901, AI0762190] FX We thank Drs. David G. Schatz, Barry Sleckman, and Michael R. Lieber for critical review of this manuscript. We thank Drs. Kevin Otipoby and Klaus Rajewsky for their help on Tat-cre purification and transduction. We also thank Tiffany Borjeson, Nicole Stokes, Lisa Acquaviva, and Peiyi Huang for technical assistant. S.Z. is supported by the Leukemia and Lymphoma Society, St. Baldrick Foundation, and the Dr. John Driscoll Jr. Children's Medical Award. F. W. A. is a Howard Hughes Medical Institute investigator. This work was supported by National Institutes of Health Grants CA092625, CA109901, and AI0762190 (to F.W.A). NR 39 TC 37 Z9 39 U1 1 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 1 PY 2011 VL 108 IS 5 BP 2028 EP 2033 DI 10.1073/pnas.1019293108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 714JA UT WOS:000286804700053 PM 21245310 ER PT J AU Cheng, YK Beroukhim, R Levine, RL Mellinghoff, IK Michor, F AF Cheng, Yu-Kang Beroukhim, Rameen Levine, Ross L. Mellinghoff, Ingo K. Michor, Franziska TI Many tumor types follow the monoclonal model of tumor initiation Reply SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Letter ID CANCER C1 [Cheng, Yu-Kang; Michor, Franziska] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Cheng, Yu-Kang; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Cheng, Yu-Kang] Weill Cornell Med Coll, Tri Inst Training Program Computat Biol & Med, New York, NY 10065 USA. [Cheng, Yu-Kang] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA. [Beroukhim, Rameen] Dana Farber Canc Inst, Dept Canc Biol, Cambridge, MA 02139 USA. [Beroukhim, Rameen] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02139 USA. [Levine, Ross L.; Mellinghoff, Ingo K.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA. RP Michor, F (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. EM michor@jimmy.harvard.edu NR 6 TC 1 Z9 1 U1 0 U2 3 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 1 PY 2011 VL 108 IS 5 BP E16 EP E16 DI 10.1073/pnas.1018584108 PG 1 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 714JA UT WOS:000286804700002 ER PT J AU Porkka-Heiskanen, T Kalinchuk, AV AF Porkka-Heiskanen, Tarja Kalinchuk, Anna V. TI Adenosine as a sleep factor SO SLEEP AND BIOLOGICAL RHYTHMS LA English DT Review DE adenosine; basal forebrain; hypothalamus; prolonged wakefulness; recovery sleep ID CHOLINERGIC BASAL FOREBRAIN; CENTRAL-NERVOUS-SYSTEM; EYE-MOVEMENT SLEEP; PROLONGED WAKEFULNESS; TUBEROMAMMILLARY NUCLEUS; EXTRACELLULAR ADENOSINE; RETICULAR-FORMATION; SUBSEQUENT SLEEP; BEHAVIORAL STATE; INCREASES SLEEP AB What puts us to sleep? This question has bothered the mankind for thousands of years, but we still have no definite answer. After abandoning philosophical and religious explanations, science has adopted this question and started to examine it with experimental methods. Two early pioneers in this field, Dr. Ishimori from Japan and Drs. Pieron and Legendre from France developed the concept of hypnotoxin - a factor that accumulates during waking and puts animals and humans to sleep. They were able to show that, indeed, during deprivation of sleep, something accumulates in body - something that can be removed and will induce sleep in another individual. Later research has identified many substances that affect sleep. One of them is adenosine, which fulfils the criteria of a physiologic sleep factor. C1 [Porkka-Heiskanen, Tarja] Univ Helsinki, Inst Biomed, Biomedicum Helsinki, FIN-00014 Helsinki, Finland. [Kalinchuk, Anna V.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA. RP Porkka-Heiskanen, T (reprint author), Univ Helsinki, Inst Biomed, Biomedicum Helsinki, FIN-00014 Helsinki, Finland. EM porkka@cc.helsinki.fi OI Stenberg, Tarja/0000-0003-1843-7625 FU Academy of Finland FX This work was supported by a grant from Academy of Finland. NR 53 TC 1 Z9 1 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1446-9235 J9 SLEEP BIOL RHYTHMS JI Sleep Biol. Rhythms PD FEB PY 2011 VL 9 SU 1 BP 18 EP 23 DI 10.1111/j.1479-8425.2010.00472.x PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 726EM UT WOS:000287701800004 ER PT J AU Steeves, JD Kramer, JK Fawcett, JW Cragg, J Lammertse, DP Blight, AR Marino, RJ Ditunno, JF Coleman, WP Geisler, FH Guest, J Jones, L Burns, S Schubert, M van Hedel, HJA Curt, A AF Steeves, J. D. Kramer, J. K. Fawcett, J. W. Cragg, J. Lammertse, D. P. Blight, A. R. Marino, R. J. Ditunno, J. F., Jr. Coleman, W. P. Geisler, F. H. Guest, J. Jones, L. Burns, S. Schubert, M. van Hedel, H. J. A. Curt, A. CA EMSCI Study Grp TI Extent of spontaneous motor recovery after traumatic cervical sensorimotor complete spinal cord injury SO SPINAL CORD LA English DT Article DE assessment; clinical trial; outcomes; neurological recovery; upper extremity motor score; motor level ID CLINICAL-TRIALS; ICCP PANEL; INCOMPLETE TETRAPLEGIA; OUTCOME MEASURES; GUIDELINES; CONDUCT; STRENGTH; RELIABILITY; MULTICENTER; STANDARDS AB Study design: Retrospective, longitudinal analysis of motor recovery data from individuals with cervical (C4-C7) sensorimotor complete spinal cord injury (SCI) according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). Objectives: To analyze the extent and patterns of spontaneous motor recovery over the first year after traumatic cervical sensorimotor complete SCI. Methods: Datasets from the European multicenter study about SCI (EMSCI) and the Sygen randomized clinical trial were examined for conversion of American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade, change in upper extremity motor score (UEMS) or motor level, as well as relationships between these measures. Results: There were no overall differences between the EMSCI and Sygen datasets in motor recovery patterns. After 1 year, up to 70% of subjects spontaneously recovered at least one motor level, but only 30% recovered two or more motor levels, with lesser values at intermediate time points. AIS grade conversion did not significantly influence motor level changes. At 1 year, the average spontaneous improvement in bilateral UEMS was 10-11 motor points. There was only moderate relationship between a change in UEMS and a change in cervical motor level (r(2)=0.30, P<0.05). Regardless of initial cervical motor level, most individuals recover a similar number of motor points or motor levels. Conclusion: Careful tracking of cervical motor recovery outcomes may provide the necessary sensitivity and accuracy to reliably detect a subtle, but meaningful treatment effect after sensorimotor complete cervical SCI. The distribution of the UEMS change may be more important functionally than the total UEMS recovered. Spinal Cord (2011) 49, 257-265; doi:10.1038/sc.2010.99; published online 17 August 2010 C1 [Steeves, J. D.; Kramer, J. K.; Cragg, J.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, ICORD, Vancouver, BC V5Z 1M9, Canada. [Fawcett, J. W.] Univ Cambridge, Ctr Brain Repair, Cambridge, England. [Lammertse, D. P.] Craig Hosp, Englewood, CO USA. [Blight, A. R.] Acorda Therapeut, Hawthorne, NY USA. [Marino, R. J.; Ditunno, J. F., Jr.] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA. [Coleman, W. P.] WPCMath, Buffalo, NY USA. [Geisler, F. H.] Rush Copley Med Ctr, Illinois Neurospine Ctr, Aurora, CO USA. [Guest, J.] Neurol Surg & Miami Project Cure Paralysis, Miami, FL USA. [Jones, L.] Geron Corp, Menlo Pk, CA USA. [Burns, S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Schubert, M.; van Hedel, H. J. A.; Curt, A.] Balgrist Univ Hosp, Spinal Cord Injury Ctr, Zurich, Switzerland. RP Steeves, JD (reprint author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, ICORD, 818 W 10th Ave, Vancouver, BC V5Z 1M9, Canada. EM steeves@icord.org OI Lammertse, Daniel/0000-0003-4590-2481; van Hedel, Hubertus/0000-0002-9577-5049; Marino, Ralph/0000-0003-2670-4113; Fawcett, James/0000-0002-7990-4568 FU ICCP; SCOPE; International Foundation for Research in Paraplegia, Zurich, Switzerland (IFP, Zurich) FX The support of ICCP (http://www.campaignforcure.org) and SCOPE (http://www.scopesci.org) is gratefully acknowledged. We are grateful for the constructive suggestions of Jose Zariffa. John Kramer is a doctoral trainee of the Canadian Institute of Health Research and Michael Smith Foundation for Health Research. EMSCI is supported by the International Foundation for Research in Paraplegia, Zurich, Switzerland (IFP, Zurich). NR 29 TC 48 Z9 49 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD FEB PY 2011 VL 49 IS 2 BP 257 EP 265 DI 10.1038/sc.2010.99 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 716LZ UT WOS:000286971600016 PM 20714334 ER PT J AU Frisbie, JH Sharma, GVRK AF Frisbie, J. H. Sharma, G. V. R. K. TI Recurrent, massive pulmonary embolism in chronic myelopathy: a case report SO SPINAL CORD LA English DT Article DE pulmonary embolism; thromboembolism; spinal cord injury; paraplegia; right bundle branch block ID SPINAL-CORD-INJURY AB Study design: Case report. Objectives: The aim of this report was to describe an example of pulmonary embolism (PE), recently suggested to be highly prevalent in persons with chronic spinal cord lesions. Setting: Veterans Affairs Hospital, Boston, MA, USA. Methods: Chart review. Results: A 60-year-old man with paraplegia, T10 motor complete, underwent laminectomy for correction of an arteriovenous malformation. After 41 days, he sustained a massive PE-suggested by right bundle branch block (RBBB) on an electrocardiogram (ECG) and diagnosed by perfusion lung scanning. He was treated with anticoagulants, the lung scan and RBBB resolving within 1 month of initiating treatment. After 5 years, he developed vertebral osteomyelitis at L5-S1 and was treated with antibiotics and bed rest. After 7 days, he was mobilized to a wheelchair, and during a transfer back to bed, he developed anxiety, dyspnea, fluctuating consciousness, low blood pressure and RBBB, absent by ECG 4 days earlier. He expired 20 min after onset of symptoms. The autopsy revealed a fresh thromboembolus occluding both main stem branches of the pulmonary artery. Conclusion: Massive PE after surgery in a patient with chronic paraplegia recurred 5 years later in association with severe infection and mobilization after bed rest, which resulted in death. Spinal Cord (2011) 49, 318-320; doi:10.1038/sc.2010.54; published online 18 May 2010 C1 [Frisbie, J. H.] VA Boston Healthcare Syst, Res Serv, Boston, MA USA. [Frisbie, J. H.; Sharma, G. V. R. K.] Harvard Univ, Sch Med, Boston, MA USA. [Sharma, G. V. R. K.] VA Boston Healthcare Syst, Med Serv, Boston, MA USA. RP Frisbie, JH (reprint author), 832 Woodland Dr, Mahtomedi, MN 55115 USA. EM jfrisbie@comcast.com NR 5 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD FEB PY 2011 VL 49 IS 2 BP 318 EP 320 DI 10.1038/sc.2010.54 PG 3 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 716LZ UT WOS:000286971600026 PM 20479769 ER PT J AU Furie, K AF Furie, Karen TI Introduction to Advances in Stroke 2011 SO STROKE LA English DT Editorial Material DE acute stroke; advances; neuroimaging; neurointerventional; stroke; stroke prevention C1 [Furie, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Furie, K (reprint author), J Philip Kistler MGH Stroke Res Ctr, 175 Cambridge St,Suite 300, Boston, MA 02114 USA. EM kfurie@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD FEB PY 2011 VL 42 IS 2 BP 282 EP 282 DI 10.1161/STROKEAHA.110.610956 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 710KB UT WOS:000286509400012 ER PT J AU Li, JH Udayasankar, UK Tang, XY Toth, TL Small, WC Kalra, MK AF Li, Jianhai Udayasankar, Unni K. Tang, Xiangyang Toth, Thomas L. Small, William C. Kalra, Mannudeep K. TI Patient Size Compensated Automatic Tube Current Modulation in Multi-detector Row CT of the Abdomen and Pelvis SO ACADEMIC RADIOLOGY LA English DT Article DE MDCT; PSC-AutomA; image quality; radiation dose ID Z-AXIS MODULATION; EXPOSURE CONTROL; DOSE REDUCTION; IMAGE QUALITY; OPTIMIZATION; PHANTOM; MDCT AB Rationale and Purpose: To evaluate the performance of a patient size-compensated automatic tube current modulation (PSC-AutomA) technique from the perspectives of image quality and radiation dose in multi-detector-row computed tomography (MDCT) scan of the abdomen and pelvis. Materials and Methods: Institutional review board approval was obtained and the study was Health Insurance Portability and Accountability Act-compliant. One hundred and seventeen patients (mean age: 48.8 years; range: 17-89 years; male/female: 57/60) underwent abdominal-pelvic CT scan on a 64-slice MDCT using the noise indexes (NI) recommended by the PSC-AutomA technique. Two radiologists independently evaluated all examinations for noise, streak artifacts, and diagnostic acceptability at the dome of liver, porta hepatis, and the upper margin of acetabulum. The CT dose index (CTDI) volume and effective dose of the CT performed using a recommended NI were compared to the CT performed using a fixed NI of 12. Statistical analysis of the data was performed with nonparametric tests. Results: The NI recommended by the PSC-AutomA technique was strongly correlated with patient size (r = 0.98, P < .001) with a mean NI of 14.2 HU. The recommended NI of 98.2% (115/117) patients was different from the fixed NI of 12. Approximately 71.8% (84/117) subjects were scanned with a NI higher than 12, whereas 26.5% (31/117) subjects were scanned with a NI lower than 12. All examinations (100%; 117/117) were graded as possessing diagnostic image quality. Compared with the CT performed by using a fixed NI 12, the overall CTDI and effective dose reduction by the PSC-AutomA technique were 11.1% and 11.8%, respectively. Conclusion: The PSC-AutomA technique can recommend an appropriate NI in MDCT scan of the abdomen and pelvis according to patient size, allowing a balanced optimization of both radiation dose and image quality, simultaneously. C1 [Li, Jianhai; Udayasankar, Unni K.; Tang, Xiangyang; Small, William C.] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA. [Toth, Thomas L.] Gen Elect Healthcare, Waukesha, WI USA. [Kalra, Mannudeep K.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Small, WC (reprint author), Emory Univ, Sch Med, Dept Radiol, 1364 Clifton Rd NE, Atlanta, GA 30322 USA. EM wsmall@emory.edu FU GE Healthcare Technologies, Waukesha, WI FX From the Department of Radiology, Emory University School of Medicine, 1364 Clifton Road NE, Atlanta, GA 30322 (J.L., U.K.U., X.T., W.C.S.); General Electric Healthcare, Waukesha, WI (T.L.T.); Department of Radiology, Massachusetts General Hospital, Charlestown, Boston, MA (M.K.K.). Received July 29, 2010; accepted September 17, 2010. This study was partly supported by a research grant from GE Healthcare Technologies, Waukesha, WI. Address correspondence to: W.C.S. e-mail: wsmall@emory.edu NR 23 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD FEB PY 2011 VL 18 IS 2 BP 205 EP 211 DI 10.1016/j.acra.2010.09.014 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 712XI UT WOS:000286699200011 PM 21075016 ER PT J AU Kremen, SA Mendez, MF Tsai, PH Teng, E AF Kremen, Sarah A. Mendez, Mario F. Tsai, Po-Heng Teng, Edmond TI Extrapyramidal Signs in the Primary Progressive Aphasias SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE primary progressive aphasia; parkinsonism; progressive nonfluent aphasia; semantic dementia; logopenic aphasia ID FRONTOTEMPORAL LOBAR DEGENERATION; CORTICOBASAL DEGENERATION; NONFLUENT APHASIA; SUPRANUCLEAR PALSY; CLINICOPATHOLOGICAL CORRELATIONS; GLUCOSE-METABOLISM; ALZHEIMER-DISEASE; 3 VARIANTS; DEMENTIA; PATHOLOGY AB Background: Extrapyramidal signs (EPS) may vary across 3 major subtypes of primary progressive aphasia (PPA): progressive nonfluent aphasia (PNFA), semantic dementia (SD), and progressive logopenic aphasia (PLA). Methods: We reviewed initial neurological examinations from a clinical PPA cohort (PNFA = 49, SD = 26, PLA = 28) to determine the prevalence of specific categories of EPS. Results: The presence of any EPS was more common in PNFA (38.8%) and PLA (35.7%) than in SD (3.8%). The PNFA group exhibited the highest prevalence of bradykinesia (PNFA: 22.4%, SD: 3.8%, PLA: 0.0%) and rigidity (PNFA: 30.6%, SD: 0.0%, PLA: 10.7%). Calculated positive likelihood ratios indicated bradykinesia (12.1) or rigidity (5.5) was more strongly associated with PNFA than other PPAs. Conclusion: These findings suggest that on initial presentation, specific EPS may help distinguish PPA subtypes when linguistic and/or neuroimaging profiles are indistinct. Moreover, EPS could represent a marker of underlying tauopathy, linking clinical presentation to neuropathology in PPA. C1 [Kremen, Sarah A.] Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Kremen, Sarah A.; Mendez, Mario F.; Tsai, Po-Heng; Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. [Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Kremen, SA (reprint author), Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, David Geffen Sch Med, Dept Neurol, 10911 Weyburn Ave,2nd Fl, Los Angeles, CA 90095 USA. EM skremen@ucla.edu FU VA Special Fellowship FX The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: supported by a VA Special Fellowship for Geriatric Neurology (to S.A.K.)]). NR 40 TC 10 Z9 10 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD FEB PY 2011 VL 26 IS 1 BP 72 EP 77 DI 10.1177/1533317510391239 PG 6 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA 713WZ UT WOS:000286769400010 PM 21282281 ER PT J AU Uthamalingam, S Patvardhan, EA Subramanian, S Ahmed, W Martin, W Daley, M Capodilupo, R AF Uthamalingam, Shanmugam Patvardhan, Eshan A. Subramanian, Sharath Ahmed, Waleed Martin, William Daley, Marilyn Capodilupo, Robert TI Utility of the Neutrophil to Lymphocyte Ratio in Predicting Long-Term Outcomes. in Acute Decompensated Heart Failure SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE CORONARY SYNDROMES; MYOCARDIAL-INFARCTION; MORTALITY; COUNT; RISK; MYELOPEROXIDASE; DYSFUNCTION; CYTOKINES; ADMISSION; MARKERS AB Neutrophil-to-lymphocyte ratio (NLR) has been associated with poor outcomes in patients with acute coronary syndromes. However, its role for risk stratification in acute decompensated heart failure (ADHF) has not been well described. In this study, 1,212 consecutive patients admitted with ADHF who had total white blood cell and differential counts measured at admission were analyzed. The patients were divided into tertiles according to NLR. The association between NLR and white blood cell types with all-cause mortality was assessed using Cox regression analysis. During a median follow-up period of 26 months, a total of 284 patients (23.4%) had died, and a positive trend between death and NLR was observed; 32.8%, 23.2%, and 14.2% of deaths occurred in the higher, middle, and lower tertiles, respectively (p < 0.001). After adjusting for confounding factors, multivariate analysis demonstrated that patients in the higher NLR tertile had the highest mortality (adjusted hazard ratio 2.23, 95% confidence interval (CI) 1.63 to 3.02, p < 0.001), followed by those in the middle tertile (adjusted hazard ratio 1.62, 95% CI 1.16 to 2.23, p = 0.001). Furthermore, tertiles of NLR were superior in predicting long-term mortality compared with white blood cell, neutrophil, and relative lymphocyte counts. Patients in the higher NLR tertile (adjusted odds ratio 3.46, 95% CI 2.11 to 5.68, p < 0.001) had a significantly higher 30-day readmission rate. In conclusion, higher NLR, an emerging marker of inflammation, is associated with an increased risk for long-term mortality in patients admitted with ADHF. NLR is a readily available inexpensive marker to aid in the risk stratification of patients with ADHF. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:433-438) C1 [Uthamalingam, Shanmugam] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Subramanian, Sharath; Ahmed, Waleed] Massachusetts Gen Hosp, Cardiac MRI PET CT Program, Boston, MA 02114 USA. [Patvardhan, Eshan A.] Tufts Med Ctr, Div Cardiol, Boston, MA USA. [Uthamalingam, Shanmugam; Ahmed, Waleed; Martin, William; Daley, Marilyn; Capodilupo, Robert] New England Heart Inst, Manchester, NH USA. RP Uthamalingam, S (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. EM suthamalingam@partners.org NR 27 TC 104 Z9 107 U1 1 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD FEB 1 PY 2011 VL 107 IS 3 BP 433 EP 438 DI 10.1016/j.amjcard.2010.09.039 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 718EK UT WOS:000287103600017 PM 21257011 ER PT J AU Prodhan, P Sharoor-Karni, S Lin, J Noviski, N AF Prodhan, Parthak Sharoor-Karni, Sarit Lin, James Noviski, Natan TI Predictors of respiratory failure among previously healthy children with respiratory syncytial virus infection SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID INTENSIVE-CARE-UNIT; RISK-FACTORS; YOUNG-CHILDREN; MECHANICAL VENTILATION; TRACT INFECTION; US CHILDREN; INFANTS; BRONCHIOLITIS; HOSPITALIZATION; SEVERITY AB Background: Respiratory syncytial virus (RSV)-related disease is the leading cause of hospitalization among infants, with approximately 7% to 21% of these patients developing acute respiratory failure. Objective: The aim of this study was to identify clinical variables at initial presentation in the emergency department (ED) that may predict the subsequent need for mechanical ventilation among previously healthy, RSV-infected children who require pediatric intensive care unit (PICU) hospitalization. Study design: This is a retrospective study of 67 previously healthy, RSV-infected patients admitted from January 1997 to March 2000 to the PICU. The primary outcome for this study was the need for mechanical ventilation. The relationship between clinical variables at initial ED presentation and the need for mechanical ventilation were explored using univariate and multiple logistic regression analysis. Results: On multivariate analysis, the presence of lethargy (odds ratio [OR], 12.2; P = .005), grunting (OR, 9.3; P = .01), and a PaCO(2) 65 mm Hg or greater (OR, 11.8; P = .013) were clinical factors at initial presentation in the ED associated with the subsequent need for mechanical ventilation among the study cohort. A developmental model that included lethargy, grunting, and a PaCO(2) of 65 mm Hg or greater performed well as a prediction model. The developmental model had a sensitivity of 71%, specificity of 96%, a positive predictive value of 86%, and a negative predictive value of 91%. Conclusions: The presence of lethargy, grunting, and a PaCO(2) of 65 mm Hg or greater at initial presentation in the ED were predictive for the subsequent need for mechanical ventilation in previously healthy, RSV-infected children admitted to the PICU. (C) 2011 Elsevier Inc. All rights reserved. C1 [Noviski, Natan] Massachusetts Gen Hosp, Div Pediat, Boston, MA 02114 USA. [Prodhan, Parthak] Coll Med Univ, Div Pediat Crit Care & Cardiol, Little Rock, AR 72202 USA. [Sharoor-Karni, Sarit] Shaarei Tzedek Med Ctr, Pediat Crit Care Unit, IL-91031 Jerusalem, Israel. [Lin, James] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Pediat Crit Care, Los Angeles, CA 90095 USA. RP Noviski, N (reprint author), Massachusetts Gen Hosp, Div Pediat, Boston, MA 02114 USA. EM nnoviski@partners.org NR 31 TC 6 Z9 6 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD FEB PY 2011 VL 29 IS 2 BP 168 EP 173 DI 10.1016/j.ajem.2009.08.020 PG 6 WC Emergency Medicine SC Emergency Medicine GA 718QG UT WOS:000287139800006 PM 20825782 ER PT J AU Church, S Robinson, TN Angles, EM Tran, ZV Wallace, JI AF Church, Skotti Robinson, Thomas N. Angles, Erik M. Tran, Zung V. Wallace, Jeffrey I. TI Postoperative falls in the acute hospital setting: characteristics, risk factors, and outcomes in males SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Hospital falls; Geriatric surgery; Elderly; Hospital-acquired condition ID DELIRIUM; INJURIES; CLASSIFICATION; CIRCUMSTANCES; PREVENTION; PREDICTORS; SYSTEM AB BACKGROUND: Hospital falls are an important cause of morbidity in older surgical patients. The objectives of this study were to describe the characteristics, risk factors, and outcomes for postoperative falls. METHODS: A retrospective study was performed on patients who were admitted to the hospital for more than 23 hours after surgery. Patients who fell within 30 days of their surgery were considered to have experienced a postoperative fall. RESULTS: Over 5 years and 9,625 inpatient surgical procedures, 154 patients experienced 190 falls. Injuries resulting from postoperative falls included major injury (hip fracture), less than 1%; injury requiring intervention, 2%; injury not requiring intervention, 27%; and no injury, 70%. Variables associated with postoperative falls included older age, functional dependence, lower albumin level, and higher American Society of Anesthesia score. CONCLUSIONS: One or more postoperative falls occurred in 1.6% of surgical inpatients and can lead to significant morbidity. Recognition of fall risk factors will help design postoperative fall prevention programs by identifying patients at highest risk for postoperative falls. Published by Elsevier Inc. C1 [Church, Skotti; Robinson, Thomas N.; Angles, Erik M.] Univ Colorado Denver, Sch Med, Hlth Sci Ctr, Dept Surg, Aurora, CO 80045 USA. [Robinson, Thomas N.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA. [Tran, Zung V.] Univ Colorado Denver, Sch Med, Dept Biometr, Aurora, CO 80045 USA. [Wallace, Jeffrey I.] Univ Colorado Denver, Sch Med, Dept Geriatr Med, Aurora, CO 80045 USA. RP Robinson, TN (reprint author), Univ Colorado Denver, Sch Med, Hlth Sci Ctr, Dept Surg, Mail Stop C313,12631 E 17th Ave,POB 6511, Aurora, CO 80045 USA. EM thomas.robinson@ucdenver.edu OI Tran, Zung/0000-0002-9322-9562 FU American Geriatric Society FX This work was supported by the American Geriatric Society's Jahnigen Scholars Award (T.N.R.) and the American Geriatric Society Geriatrics for Specialty Residents Award (T.N.R. and J.I.W.). NR 22 TC 15 Z9 15 U1 1 U2 6 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD FEB PY 2011 VL 201 IS 2 BP 197 EP 202 DI 10.1016/j.amjsurg.2009.12.013 PG 6 WC Surgery SC Surgery GA 722KE UT WOS:000287430300010 PM 20851375 ER PT J AU Sreeramoju, P Porbandarwalla, NS Arango, J Latham, K Dent, DL Stewart, RM Patterson, JE AF Sreeramoju, Pranavi Porbandarwalla, Nabilla S. Arango, Jorge Latham, Kerry Dent, Daniel L. Stewart, Ronald M. Patterson, Jan E. TI Recurrent skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus requiring operative debridement SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Staphylococcal skin infections; Staphylococcus aureus; Staphylococcal infections; Abscess; Methicillin-resistant Staphylococcus aureus; Epidemiology; Risk factors; Recurrence ID RISK-FACTORS; EMERGENCY-DEPARTMENT; DOUBLE-BLIND; ABSCESSES; CHILDREN AB BACKGROUND: The aim of this study was to examine clinical factors associated with the recurrence of community-onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. METHODS: An observational case-comparison study based on a retrospective review of medical records was conducted in a public health system. All patients with community-onset skin and soft tissue infections caused by methicillin-resistant S aureus who underwent operative debridement from January 1999 to December 2003 were included. The outcome of interest was recurrence within 1 year. RESULTS: Two hundred fifty-three patients met the criteria for inclusion. Fifty-three (21%) patients returned with recurrent episodes. These patients were compared with 200 patients (79%) who did not develop recurrence. On multivariate analysis, factors independently predictive of recurrence were medical history of abscess requiring surgical debridement within the previous year (adjusted odds ratio, 2.6; 95% confidence interval, 1.4-5.0; P = .002) and obesity (adjusted odds ratio, 3.4; 95% confidence interval, 1.4-8.8; P = .008). CONCLUSIONS: Patients with obesity or histories of methicillin-resistant S aureus infection are at significantly increased risk for recurrent soft tissue infection. (C) 2011 Elsevier Inc. All rights reserved. C1 [Sreeramoju, Pranavi] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA. [Porbandarwalla, Nabilla S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. [Arango, Jorge; Dent, Daniel L.; Stewart, Ronald M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX USA. [Latham, Kerry] Dept Surg, Keesler AFB, MS USA. [Patterson, Jan E.] S Texas Vet Healthcare Syst, Dept Med, San Antonio, TX USA. RP Sreeramoju, P (reprint author), Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA. EM pranavi.sreeramoju@utsouthwestern.edu NR 19 TC 24 Z9 25 U1 0 U2 4 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD FEB PY 2011 VL 201 IS 2 BP 216 EP 220 DI 10.1016/j.amjsurg.2009.12.024 PG 5 WC Surgery SC Surgery GA 722KE UT WOS:000287430300013 PM 20832054 ER PT J AU Lee, JJ Hsia, RY AF Lee, Jennifer J. Hsia, Renee Y. TI IMAGES IN EMERGENCY MEDICINE Cryptococcus neoformans SO ANNALS OF EMERGENCY MEDICINE LA English DT Editorial Material C1 [Lee, Jennifer J.] Harvard Univ, Sch Med, Dept Dermatol, Beth Israel Deaconness Med Ctr, Boston, MA 02115 USA. [Hsia, Renee Y.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Emergency Med, San Francisco, CA USA. RP Lee, JJ (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Beth Israel Deaconness Med Ctr, Boston, MA 02115 USA. NR 3 TC 2 Z9 2 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD FEB PY 2011 VL 57 IS 2 BP 100 EP + DI 10.1016/j.annemergmed.2010.01.019 PG 2 WC Emergency Medicine SC Emergency Medicine GA 722WB UT WOS:000287464900005 PM 21251522 ER PT J AU Delgado, MK Acosta, CD Ginde, AA Wang, NE Strehlow, MC Khandwala, YS Camargo, CA AF Delgado, M. Kit Acosta, Colleen D. Ginde, Adit A. Wang, N. Ewen Strehlow, Matthew C. Khandwala, Yash S. Camargo, Carlos A., Jr. TI National Survey of Preventive Health Services in US Emergency Departments SO ANNALS OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT American-College-of-Emergency-Physicians Scientific Assembly CY OCT, 2009 CL Boston, MA SP Amer Coll Emergency Phys ID PUBLIC-HEALTH; HIGH-RISK; CARE; MEDICINE AB Study objective: We describe the availability of preventive health services in US emergency departments (EDs), as well as ED directors' preferred service and perceptions of barriers to offering preventive services. Methods: Using the 2007 National Emergency Department Inventory (NEDI)-USA, we randomly sampled 350 (7%) of 4,874 EDs. We surveyed directors of these EDs to determine the availability of (1) screening and referral programs for alcohol, tobacco, geriatric falls, intimate partner violence, HIV, diabetes, and hypertension; (2) vaccination programs for influenza and pneumococcus; and (3) linkage programs to primary care and health insurance. ED directors were asked to select the service they would most like to implement and to rate 5 potential barriers to offering preventive services. Results: Two hundred seventy-seven EDs (80%) responded across 46 states. Availability of services ranged from 66% for intimate partner violence screening to 19% for HIV screening. ED directors wanted to implement primary care linkage most (17%) and HIV screening least (2%). ED directors "agreed/strongly agreed" that the following are barriers to ED preventive care: cost (74%), increased patient length of stay (64%), lack of follow-up (60%), resource shifting leading to worse patient outcomes (53%), and philosophical opposition (27%). Conclusion: Most US EDs offer preventive services, but availability and ED director preference for type of service vary greatly. The majority of EDs do not routinely offer Centers for Disease Control and Prevention recommended HIV screening. Most ED directors are not philosophically opposed to offering preventive services but are concerned with added costs, effects on ED operations, and potential lack of follow-up. [Ann Emerg Med. 2011;57:104-108.] C1 [Delgado, M. Kit] Stanford Univ, Sch Med, Ctr Hlth Policy Primary Care & Outcomes Res, Palo Alto, CA 94304 USA. [Delgado, M. Kit; Acosta, Colleen D.; Wang, N. Ewen; Strehlow, Matthew C.; Khandwala, Yash S.] Stanford Univ, Sch Med, Div Emergency Med, Palo Alto, CA 94304 USA. [Ginde, Adit A.] Univ Colorado, Denver Sch Med, Dept Emergency Med, Aurora, CO USA. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. RP Delgado, MK (reprint author), Ctr Primary Care & Outcomes Res, 117 Encina Commons, Stanford, CA 94305 USA. EM kdelgado@stanford.edu RI Siry, Bonnie/D-7189-2017 FU AHRQ HHS [T32HS00028, T32 HS000028]; NICHD NIH HHS [1K23HD051595-01A2, K23 HD051595] NR 11 TC 24 Z9 25 U1 0 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD FEB PY 2011 VL 57 IS 2 BP 104 EP 108 DI 10.1016/j.annemergmed.2010.07.015 PG 5 WC Emergency Medicine SC Emergency Medicine GA 722WB UT WOS:000287464900007 PM 20889237 ER PT J AU Zeitels, SM de Alarcon, A Burns, JA Lopez-Guerra, G Hillman, RE AF Zeitels, Steven M. de Alarcon, Alessandro Burns, James A. Lopez-Guerra, Gerardo Hillman, Robert E. TI Posterior Glottic Diastasis: Mechanically Deceptive and Often Overlooked SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE cricoid cartilage; dysphonia; hoarseness; intubation; laryngofissure; laryngoplasty; larynx; stenosis; vocal cord; vocal fold ID VOCAL FOLD PARALYSIS; STENOSIS AB Dysphonia secondary to posterior glottic aerodynamic incompetence can often be recognizable acoustically, but difficult to document visually. This mechanical impairment in posterior glottic closure is the result of injury caused by airway instrumentation. The difficulty of recognition of this entity is due to posterior supraglottic soft tissue that obscures the complete view during posterior glottic adduction, the lack of a structural organization of the cricoarytenoid region injury that leads to this disorder, and the lack of nomenclature. A retrospective assessment was done on 3 patients who underwent surgical reconstruction to correct posterior phonatory incompetence subsequent to laryngotracheal intubation. All 3 had sustained an injury to the cricoarytenoid joints, and 2 of the 3 had undergone paraglottic space medialization laryngoplasty that failed to solve the posterior glottic insufficiency. New procedures were designed and performed in these patients to correct the posterior glottic incompetence and are described: laryngofissure and partial posterior cricoid resection, endoscopic pharyngoepiglottic-aryepiglottic fold advancement-rotation flap with interarytenoid interposition, and interarytenoid submucosal implant augmentation. Although the academic literature is replete with reports describing stenosis resulting from impaired cricoarytenoid joint abduction, the term glottic diastasis provides nomenclature for the inability to normally adduct the arytenoid cartilages. The initial experience with surgical reconstruction is preliminary, but encouraging. C1 [Zeitels, Steven M.; Burns, James A.; Lopez-Guerra, Gerardo; Hillman, Robert E.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA. [Zeitels, Steven M.; Burns, James A.; Lopez-Guerra, Gerardo; Hillman, Robert E.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [de Alarcon, Alessandro] Univ Cincinnati, Coll Med, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH USA. [de Alarcon, Alessandro] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. RP Zeitels, SM (reprint author), Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, 1 Bowdoin Sq,11th Floor, Boston, MA 02114 USA. FU Eugene B. Casey Foundation; Institute of Laryngology and Voice Restoration FX This work was supported in part by the Eugene B. Casey Foundation and the Institute of Laryngology and Voice Restoration. NR 20 TC 3 Z9 3 U1 0 U2 2 PU ANNALS PUBL CO PI ST LOUIS PA 4507 LACLEDE AVE, ST LOUIS, MO 63108 USA SN 0003-4894 J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD FEB PY 2011 VL 120 IS 2 BP 71 EP 80 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA 720JP UT WOS:000287277300001 PM 21391417 ER PT J AU Lott, DG Russell, JO Khariwala, SS Dan, O Strome, M AF Lott, David G. Russell, Jonathon O. Khariwala, Samir S. Dan, Olivia Strome, Marshall TI Ten-Month Laryngeal Allograft Survival With Use of Pulsed Everolimus and Anti-alpha beta T-Cell Receptor Antibody Immunosuppression SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE alpha beta T-cell receptor; everolimus; immunosuppression; laryngeal transplantation ID RAT MODEL; IN-VIVO; TRANSPLANTATION; CANCER; INDUCTION; TOLERANCE; REJECTION; GROWTH AB Objectives: The risks of daily immunosuppression limit the use of laryngeal transplantation as a reconstructive option. Pulsed immunosuppressive dosing can lessen these risks. The study objective was to develop a long-term pulsing regimen that minimizes exposure to immunosuppressive agents. Methods: Rat laryngeal transplantation was performed. Everolimus (1 mg/kg per day) and anti-alpha beta T-cell receptor (TCR) antibodies (250 mu g) were given for 7 days beginning I day before transplantation and for 5 days beginning on day 90 after transplantation. On day 180, group I (n = 5) received the initial regimen for 3 days, and group 2 (n = 5) received everolimus (1 mg/kg per day) until euthanization, which occurred when parathyroid hormone (PTH) levels dropped to less than 11 pg/mL or at 300 days. Results: Four of the 5 rats in group I had normal PTH levels at 300 days. The PTH level for I rat was less than 11 pg/mL at 270 days. In group 2, none of the 5 rats had normal PTH levels at 300 days. Two had PTH levels below 11 pg/mL at 270 days, and 3 had PTH levels below 11 pg/mL at 300 days. The allografts that survived beyond 300 days had an essentially normal histologic appearance. Conclusions: Pulsed immunosuppression prevented allograft rejection for ID months and was more effective than daily everolimus. Short-term perioperative therapy followed by pulsed, tapered dosing is a viable alternative to traditional regimens and may decrease associated risks. C1 [Lott, David G.; Russell, Jonathon O.; Khariwala, Samir S.; Dan, Olivia; Strome, Marshall] Cleveland Clin, Head & Neck Inst, Cleveland, OH 44106 USA. RP Lott, DG (reprint author), Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, 1 Bowdoin Sq,11th Floor, Boston, MA 02114 USA. NR 23 TC 2 Z9 2 U1 0 U2 2 PU ANNALS PUBL CO PI ST LOUIS PA 4507 LACLEDE AVE, ST LOUIS, MO 63108 USA SN 0003-4894 J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD FEB PY 2011 VL 120 IS 2 BP 131 EP 136 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 720JP UT WOS:000287277300010 PM 21391426 ER PT J AU Gupta, SR Phan, IT Suhler, EB AF Gupta, Seema R. Phan, Isabella T. Suhler, Eric B. TI Successful Treatment of Refractory Sympathetic Ophthalmia in a Child With Infliximab SO ARCHIVES OF OPHTHALMOLOGY LA English DT Letter ID UVEITIS; THERAPY C1 [Gupta, Seema R.; Phan, Isabella T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. RP Suhler, EB (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM suhlere@ohsu.edu NR 6 TC 11 Z9 11 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD FEB PY 2011 VL 129 IS 2 BP 250 EP 252 DI 10.1001/archophthalmol.2010.358 PG 3 WC Ophthalmology SC Ophthalmology GA 721CQ UT WOS:000287329500025 PM 21320978 ER PT J AU Masia, R Mino-Kenudson, M Warshaw, AL Pitman, MB Misdraji, J AF Masia, Ricard Mino-Kenudson, Mari Warshaw, Andrew L. Pitman, Martha B. Misdraji, Joseph TI Pancreatic Mucinous Cystic Neoplasm of the Main Pancreatic Duct SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID EXPRESSION; CYSTADENOMA; CONSENSUS; PROFILE AB Mucinous cystic neoplasm and intraductal papillary mucinous neoplasm are 2 types of cystic pancreatic mucinous tumors, each with its own distinct clinicopathologic features and pathogenetic mechanisms. We report here an unusual pancreatic mucinous neoplasm with features of both a mucinous cystic neoplasm and an intraductal papillary mucinous neoplasm in a 40-year-old woman who underwent total pancreatectomy. The endoscopic retrograde cholangiopancreatogram and gross examination demonstrated a mucin-producing intraductal neoplasm involving the length of the main pancreatic duct, typical of main duct intraductal papillary mucinous neoplasm, but histology of the main duct showed involvement by a biphasic tumor composed of columnar epithelium overlying ovarian-type stroma, characteristic of a mucinous cystic neoplasm. Immunohistochemistry confirmed that the stromal cells expressed estrogen and progesterone receptors, inhibin, and calretinin. Pancreatic mucinous cystic neoplasm involving the entire main pancreatic duct has not, to our knowledge, been previously reported. (Arch Pathol Lab Med. 2011;135:264-267) C1 [Masia, Ricard; Mino-Kenudson, Mari; Pitman, Martha B.; Misdraji, Joseph] Massachusetts Gen Hosp, Dept Pathol & Lab Med, Boston, MA 02114 USA. [Warshaw, Andrew L.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Misdraji, J (reprint author), Massachusetts Gen Hosp, Dept Pathol & Lab Med, 55 Fruit St,Warren Bldg 105F, Boston, MA 02114 USA. EM jmisdraji@partners.org NR 15 TC 4 Z9 4 U1 0 U2 2 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD FEB PY 2011 VL 135 IS 2 BP 264 EP 267 PG 4 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 722KG UT WOS:000287430500021 PM 21284448 ER PT J AU Zamani, P Kinlay, S AF Zamani, Payman Kinlay, Scott TI Long-Term Risk of Clinical Events From Stenting Side Branches of Coronary Bifurcation Lesions With Drug-Eluting and Bare-Metal Stents: An Observational Meta-Analysis SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article ID OFF-LABEL USE; FOLLOW-UP; CRUSH TECHNIQUE; PERCUTANEOUS TREATMENT; MYOCARDIAL-INFARCTION; PROSPECTIVE REGISTRY; RANDOMIZED-TRIAL; ARTERY-DISEASE; OUTCOMES; THROMBOSIS AB Objectives: To compare the long-term risks of coronary bifurcation lesions treated with side-branch stenting using drug-eluting versus bare-metal stents. Background: Side-branch stenting is an off-label practice, but when needed, the incidence of late adverse events may differ between drug-eluting and bare-metal stents. Methods: We systematically searched PubMed, and the National Institutes of Health and Cochrane Registries for studies of coronary bifurcation stenting reporting clinical outcomes over at least 5 months. Data were extracted and cross checked independently by two investigators for inclusion in an observational meta-analysis. Clinical outcomes included major adverse clinical events (MACE), death, myocardial infarction, target vessel revascularization (TVR), and definite stent thrombosis. We used random-effects models and meta-regression in 6,825 subjects from 42 studies. Results: Most (79%) of the heterogeneity in MACE between treatment groups was explained by differences in stent type, side-branch stenting, and length of follow-up. Compared with drug-eluting stents without side-branch stenting, drug-eluting stents with side-branch stenting had a 3% higher incidence of myocardial infarction [95% confidence interval (CI) = 0.3%, 5%, P < 0.05], but no significant increase in MACE, death, TVR, or stent thrombosis. Bare-metal stenting without side-branch stenting had 10% (95% CI = 3%, 16%, P < 0.01) higher MACE, and 10% (95% CI = 4%, 17%, P < 0.01) higher TVR, whereas bare-metal side-branch stenting had 31% (95% CI = 23%, 39%, P < 0.001) higher MACE, and 19% (95% CI = 10%, 28%, P < 0.001) higher TVR. Conclusions: Side-branch stenting has a much smaller impact on long-term MACE with drug-eluting stents compared with bare-metal stents. Although this study does not support routine side-branch stenting, when side-branch stenting is required, drug-eluting stents are associated with less adverse outcomes. (C) 2011 Wiley-Liss, Inc. C1 [Kinlay, Scott] VA Boston Healthcare Syst, Div Cardiovasc, W Roxbury, MA 02132 USA. Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Kinlay, S (reprint author), VA Boston Healthcare Syst, Div Cardiovasc, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM scott.kinlay@va.gov FU Office of Enrichment Programs, Harvard Medical School FX Grant sponsor: Office of Enrichment Programs, Harvard Medical School (to P.Z.) NR 68 TC 11 Z9 11 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD FEB 1 PY 2011 VL 77 IS 2 BP 202 EP 212 DI 10.1002/ccd.22750 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 718EC UT WOS:000287102500008 PM 20824754 ER PT J AU Gomez, JE Clatworthy, A Hung, DT AF Gomez, James E. Clatworthy, Anne Hung, Deborah T. TI Probing bacterial pathogenesis with genetics, genomics, and chemical biology: past, present, and future approaches SO CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Review ID SIGNATURE-TAGGED MUTAGENESIS; VIVO EXPRESSION TECHNOLOGY; TRANSPOSON MUTANT LIBRARY; DIFFERENTIAL FLUORESCENCE INDUCTION; VIBRIO-CHOLERAE VIRULENCE; SMALL-MOLECULE INHIBITORS; MYCOBACTERIUM-TUBERCULOSIS; STAPHYLOCOCCUS-AUREUS; PSEUDOMONAS-AERUGINOSA; ESSENTIAL GENES AB Classical genetic approaches for studying bacterial pathogenesis have provided a solid foundation for our current understanding of microbial physiology and the interactions between pathogen and host. During the past decade however, advances in several arenas have expanded the ways in which the biology of pathogens can be studied. This review discussed the impact of these advances on bacterial genetics, including the application of genomics and chemical biology to the study of pathogenesis.Juvenile neuronal ceroid lipofuscinosis (Batten disease) is a neurodegenerative disorder caused by mutation in CLN3. Defective autophagy and concomitant accumulation of autofluorescence enriched with mitochondrial ATP synthase subunit c were previously discovered in Cln3 mutant knock-in mice. In this study, we show that treatment with lithium reduces numbers of LC3-positive autophagosomes and accumulation of LC3-II in Cln3 mutant knock-in cerebellar cells (CbCln3 Delta ex7/8/Delta ex7/8). Lithium, an inhibitor of GSK3 and IMPase, reduces the accumulation of mitochondrial ATP synthase subunit c and autofluorescence in CbCln3 Delta ex7/8/Delta ex7/8 cells, and mitigates the abnormal subcellular distribution of acidic vesicles in the cells. L690,330, an IMPase inhibitor, is as effective as lithium in restoring autophagy in CbCln3 Delta ex7/8/Delta ex7/8 cells. Moreover, lithium or down-regulation of IMPase expression protects CbCln3 Delta ex7/8/Delta ex7/8 cells from cell death induced by amino acid deprivation. These results suggest that lithium overcomes the autophagic defect in CbCln3 Delta ex7/8/Delta ex7/8 cerebellar cells probably through IMPase, thereby reducing their vulnerability to cell death. C1 [Chang, Jae-Woong; Choi, Hyunwoo; Jung, Yong-Keun] Seoul Natl Univ, Sch Biol Sci, BioMAX Inst, Creat Res Initiat CRI Accelerat Res Lab, Seoul 151747, South Korea. [Cotman, Susan L.] Massachusetts Gen Hosp, Mol Neurogenet Unit, Boston, MA 02114 USA. [Cotman, Susan L.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Jung, YK (reprint author), Seoul Natl Univ, Sch Biol Sci, BioMAX Inst, Creat Res Initiat CRI Accelerat Res Lab, 599 Gwanak Ro, Seoul 151747, South Korea. EM ykjung@snu.ac.kr FU Korean Government (MOEHRD) [KRF-2007-355-C00032]; Korea Research Foundation; Harvard Neurodiscovery Center; Massachusetts Alzheimer's Disease Research Center, USA FX The authors thank Dr D. Pearce (University of Rochester, USA) for providing lymphoblastoid cell lines (homozygous 1.02-kb deletion) from JNCL patients and whole brains from Cln3 knock-out mice, Dr T. Ohnishi (RIKEN Brain Science Institute, Japan) for providing IMPase1 and IMPase2 antibodies and Ms P. Wolf (Massachusetts General Hospital, Boston) for technical assistance. Dr J. W. Chang was supported by a Korea Research Foundation Grant funded by the Korean Government (MOEHRD) [KRF-2007-355-C00032]. This work was supported by grants from CRI-Acceleration Research, Brain Research of the 21C Frontier Research Program and Global Research laboratory funded by the Korea Research Foundation (to Y. K. Jung) and by the Harvard Neurodiscovery Center and the Massachusetts Alzheimer's Disease Research Center, USA (to S. L. Cotman). NR 38 TC 13 Z9 13 U1 0 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD FEB PY 2011 VL 116 IS 4 BP 659 EP 668 DI 10.1111/j.1471-4159.2010.07158.x PG 10 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 715MK UT WOS:000286888400018 PM 21175620 ER PT J AU Naliboff, BD Wu, SM Schieffer, B Bolus, R Pham, Q Baria, A Aragaki, D Van Vort, W Davis, F Shekelle, P AF Naliboff, Bruce D. Wu, Stephen M. Schieffer, Beatrix Bolus, Roger Pham, Quynh Baria, Ariel Aragaki, Dixie Van Vort, Walter Davis, Frederick Shekelle, Paul TI A Randomized Trial of 2 Prescription Strategies for Opioid Treatment of Chronic Nonmalignant Pain SO JOURNAL OF PAIN LA English DT Article DE Chronic noncancer pain; opioid medications; substance abuse; addiction; medication misuse ID CHRONIC NONCANCER PAIN; BACK-PAIN; ADDICTION; EFFICACY; THERAPY; ABUSE AB The use of opioid medications for treating chronic noncancer pain is growing; however, there is a lack of good evidence regarding their long-term effectiveness, association with substance abuse, and proper prescribing guidelines. The current study directly compares for the first time in a randomized trial the effectiveness of a conservative, hold the line (Stable Dose) prescribing strategy for opioid medications with a more liberal dose escalation (Escalating Dose) approach. This 2-arm, parallel, randomized pragmatic clinical trial followed 135 patients referred to a specialty pain clinic at a Veterans Affairs Hospital for 12 months (94% male and 74% with musculoskeletal pain). Primary outcomes included monthly or quarterly evaluations of pain severity, pain relief from medications, pain-related functional disability, and opioid misuse behaviors. All subjects received identical pain treatment except for the application of treatment group specific strategies for opioid prescriptions. No group differences were found for primary outcomes of usual pain or functional disability although the Escalating Dose group did show a small but significantly larger increase in self-rated pain relief from medications. About 27% of patients were discharged over the course of the study due to opioid misuse/noncompliance, but there were no group differences in rate of opioid misuse. Perspective: The results of this study demonstrate that even in carefully selected patients there is a significant risk of problematic opioid misuse. Although in general there were no statistically significant differences in the primary outcomes between groups, the escalating dose strategy did lead to small improvements in self-reported acute relief from medications without an increase in opioid misuse, compared to the stable dose strategy. (C) 2011 by the American Pain Society C1 [Naliboff, Bruce D.] VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA. [Naliboff, Bruce D.; Wu, Stephen M.; Bolus, Roger] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Naliboff, Bruce D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Pham, Quynh; Aragaki, Dixie; Shekelle, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Naliboff, BD (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Bldg 115,Rm 107,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM naliboff@ucla.edu FU Department of Veterans Affairs, Health Services Research and Development FX Grant support provided by Department of Veterans Affairs, Health Services Research and Development. NR 21 TC 24 Z9 24 U1 0 U2 3 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD FEB PY 2011 VL 12 IS 2 BP 288 EP 296 DI 10.1016/j.jpain.2010.09.003 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 722IW UT WOS:000287426900016 PM 21111684 ER PT J AU Enguidanos, S Kogan, AC Lorenz, K Taylor, G AF Enguidanos, Susan Kogan, Alexis Coulourides Lorenz, Karl Taylor, George TI Use of Role Model Stories to Overcome Barriers to Hospice among African Americans SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID ETHNIC-DIFFERENCES; RACIAL-DIFFERENCES; OLDER-ADULTS; DEATH; CARE; SERVICES; WOMEN; INTERVENTION; ASSOCIATIONS; DISCUSSIONS AB Objectives: To test a brochure comprising hospice patient role model stories aimed at improving attitudes and knowledge of hospice among older African Americans. Design: Pre-post community-based study. Setting: Community-based organizations including senior centers, community exercise programs, churches, and senior care management services in greater Los Angeles area. Participants: Seventy-one African Americans aged 65 and older. Intervention: Hospice brochure containing theoretically driven role model stories portraying African Americans' experience with hospice, their initial attitudes and beliefs about hospice, factors influencing their enrollment in the program, and outcomes following enrollment. Measurements: Change from baseline in attitudes toward, knowledge of, and intentions to enroll in hospice. Results: Mean knowledge scores (range, 0-9) increased from 5.76 (standard deviation [SD] = 2.12) at pretest to 6.95 (SD = 1.90) at posttest (t = -6.14, p < 0.001). Average attitude toward hospice (range, 12-72) improved 12.5% from 41.16 (SD = 5.20) to 46.29 (SD = 5.45) (t = -7.52, p < 0.001). Intentions to enroll a family member in hospice increased from 84.5% to 92.9% (p = 0.002) and intentions to seek hospice care for themselves increased from 83.1% to 95.8% (p < 0.001). Conclusion: This small pre-post pilot study found that exposure to a hospice brochure containing theoretically driven, culturally parallel, role model stories was effective in improving knowledge of and attitudes toward hospice as well as intentions to enroll a family member or self in hospice care. Further study is needed to determine the impact of using this brochure within a clinical setting. C1 [Enguidanos, Susan; Kogan, Alexis Coulourides] Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90089 USA. [Enguidanos, Susan; Taylor, George] Partners Care Fdn, San Fernando, CA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. RP Enguidanos, S (reprint author), Univ So Calif, Davis Sch Gerontol, 3715 McClintock Ave,Gero 228-B, Los Angeles, CA 90089 USA. EM Enguidan@usc.edu OI Enguidanos, Susan/0000-0002-5112-288X FU PacifiCare/United Healthcare FX This research was supported by a grant from PacifiCare/United Healthcare. NR 36 TC 12 Z9 12 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2011 VL 14 IS 2 BP 161 EP 168 DI 10.1089/jpm.2010.0380 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 719UM UT WOS:000287236200011 PM 21265628 ER PT J AU Jackson, V AF Jackson, Vicki TI "Knowing'' Your Learners and Providing Feedback SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Editorial Material C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Jackson, V (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM VJackson@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2011 VL 14 IS 2 BP 231 EP 231 DI 10.1089/jpm.2010.9731 PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 719UM UT WOS:000287236200020 PM 21314575 ER PT J AU Thomas, JD Arnold, RM AF Thomas, Jane DeLima Arnold, Robert M. TI Giving Feedback SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID MEDICAL-EDUCATION; CLINICAL-PERFORMANCE; FORMATIVE FEEDBACK; STUDENTS; FACULTY; PERCEPTIONS; RESIDENTS; BEHAVIOR; SKILLS AB Background: Giving feedback is a core element of medical education, one that is gaining attention but with a thin evidence base to guide medical educators. This review provides a definition of feedback and its purpose, selectively reviews the literature regarding educators' and learners' attitudes toward feedback, and provides an algorithm for giving feedback. Discussion: The authors discuss the parallels between giving feedback and breaking bad news, emphasizing the importance of titrating the amount of information given, attending to affect, and making a plan for next steps. Special considerations for giving feedback in palliative care are highlighted, including the effect of heightened emotion in the clinical encounter and the difficulties of giving feedback about communication skills. C1 [Thomas, Jane DeLima] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. [Arnold, Robert M.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. RP Thomas, JD (reprint author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 44 Binney St, Boston, MA 02115 USA. EM jdelima@partners.org FU Division of State, Community, and Public Health; Bureau of Health Professions (BHPr); Health Resources and Services Administration (HRSA); Department of Health and Human Services (DHHS) [K01 HP 00077]; Geriatric Academic Career Award FX Dr. Thomas' work on this project was supported by funds from the Division of State, Community, and Public Health, Bureau of Health Professions (BHPr), Health Resources and Services Administration (HRSA), Department of Health and Human Services (DHHS), under grant K01 HP 00077, Geriatric Academic Career Award. The information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by the BHPr, HRSA, DHHS or the U. S. Government. NR 36 TC 12 Z9 12 U1 0 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2011 VL 14 IS 2 BP 233 EP 239 DI 10.1089/jpm.2010.0093 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 719UM UT WOS:000287236200021 PM 21314576 ER PT J AU Chittenden, EH Blinderman, CD AF Chittenden, Eva H. Blinderman, Craig D. TI Case Discussions in Palliative Medicine Introduction SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Editorial Material C1 [Chittenden, Eva H.] Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA. [Blinderman, Craig D.] Columbia Univ, Adult Palliat Med, Dept Anesthesiol, New York, NY 10032 USA. RP Chittenden, EH (reprint author), Massachusetts Gen Hosp, Palliat Care Serv, 55 Fruit St,Founders 600, Boston, MA 02114 USA. EM echittenden@partners.org; cdb21@columbia.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2011 VL 14 IS 2 BP 249 EP 249 DI 10.1089/jpm.2010.9728 PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 719UM UT WOS:000287236200027 ER PT J AU Francisco, IFS Werner, L Regan, MM Garnick, MB Bubley, G DeWolf, WC AF Francisco, Ignacio F. San Werner, Lillian Regan, Meredith M. Garnick, Marc B. Bubley, Glenn DeWolf, William C. TI Risk Stratification and Validation of Prostate Specific Antigen Density as Independent Predictor of Progression in Men With Low Risk Prostate Cancer During Active Surveillance SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; prostate-specific antigen; biopsy; risk ID EXPECTANT MANAGEMENT; CURATIVE INTENT; BIOPSY; EXPERIENCE AB Purpose: We assessed risk stratification in patients with low grade prostate cancer managed by active surveillance using a 20-core saturation biopsy technique. Materials and Methods: A total of 135 consecutive patients with low risk prostate cancer were prospectively entered in an active surveillance program in a 10-year period. The study entrance requirement and progression definition followed Epstein criteria using only pathological parameters, ie fewer than 3 positive cores, Gleason score 6 or less and 50% or less of any single core involved. All patients were monitored by restaging 20-core saturation biopsy every 12 to 18 months. A total of 120 patients with at least 1 rebiopsy form the basis of this report. Results: Of the cohort 30% progressed during a median of 2.4 years. Three multivariate analyses were performed. The first analysis used variables only at diagnosis biopsy and revealed that prostate specific antigen density greater than 0.08 ng/ml/cc and prostate cancer family history were significant predictors of progression. When combined in a 3-level risk factor score, they were significant (p = 0.003). The second multivariate analysis considered changes in characteristics between diagnosis biopsy and first rebiopsy. Prostate specific antigen velocity along with prostate specific antigen density and family history highly predicted progression according to a 4-level risk factor score (p < 0.0001). The third multivariate analysis validated the previously reported prostate specific antigen density cutoff of 0.08 ng/ml/cc at first rebiopsy as a significant predictor of subsequent progression (HR 3.16, 95% CI 1.12, 8.93; p = 0.03). Conclusions: Risk factor stratification can be used to significantly predict the outcome in patients on active surveillance. Prostate specific antigen density 0.08 ng/ml/cc at first rebiopsy was validated as a significant predictor of subsequent progression. C1 [Francisco, Ignacio F. San; DeWolf, William C.] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA. [Garnick, Marc B.; Bubley, Glenn] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA. [Werner, Lillian; Regan, Meredith M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Francisco, Ignacio F. San] Pontificia Univ Catolica Chile, Dept Urol, Santiago, Chile. RP DeWolf, WC (reprint author), Beth Israel Deaconess Med Ctr, Div Urol Surg, 330 Brookline Ave, Boston, MA 02215 USA. EM wdewolf@bidmc.harvard.edu FU Hershey Family Fund FX Supported by the Hershey Family Fund. NR 17 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD FEB PY 2011 VL 185 IS 2 BP 471 EP 476 DI 10.1016/j.juro.2010.09.115 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 704JH UT WOS:000286047500032 ER PT J AU Jensen, JK Hallen, J Lund, T Madsen, LH Grieg, Z Januzzi, JL Atar, D AF Jensen, Jesper K. Hallen, Jonas Lund, Terje Madsen, Lene Helleskov Grieg, Zanina Januzzi, James L., Jr. Atar, Dan TI Troponin I degradation in serum of patients with acute ischemic stroke SO SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION LA English DT Article ID MYOCARDIAL-INFARCTION; ELEVATION AB Background. Although troponin is a cornerstone biomarker in the assessment and management of patients with acute coronary syndrome, much remains to be learned about the biology of this widely used biomarker, including its post-release modification. Degradation of troponin following release in patients with acute coronary syndrome has been described; however whether such post-release modification occurs in other non-acute coronary syndrome states remains unknown. The aim of this study was to define troponin degradation in patients with acute ischemic stroke. Materials and methods. Troponin I (cTnI) was measured daily during the first 5 days of admission in 244 patients with acute ischemic stroke. Western blot analysis was performed using anti-cTnI antibodies and compared with serum concentrations of cTnI in seven patients and one patient with myocardial infarction (positive control). Results. Elevated levels of troponin were detected in 25 (10 %) patients; in all, both intact cTnI and cTnI degradation products were detected, with up to seven degradation fragments found. Samples with the highest total cTnI levels gave the strongest and most numerous western-blotting bands. All fragments were comparable with the degradation pattern of the positive control in terms of position. Conclusions. Immunoblotting of blood samples from patients with acute ischemic stroke reveals similar degradation patterns of cTnI as has been described in patients with acute myocardial infarction. The biological ramification and potential clinical impact of this finding bears further scrutiny. C1 [Jensen, Jesper K.] Odense Univ Hosp, Dept Cardiol, DK-5000 Odense C, Denmark. [Hallen, Jonas; Grieg, Zanina] Oslo Univ Hosp Aker, Dept Cardiol, Oslo, Norway. [Lund, Terje] Oslo Univ Hosp, Dept Endocrinol, Hormone Lab, Oslo, Norway. [Madsen, Lene Helleskov] Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark. [Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Atar, Dan] Oslo Univ Hosp Ulleval, Dept Cardiol, Oslo, Norway. [Atar, Dan] Univ Oslo, Fac Med, Inst Clin Med, N-0316 Oslo, Norway. RP Jensen, JK (reprint author), Odense Univ Hosp, Dept Cardiol, DK-5000 Odense C, Denmark. EM jesperkjensen@dadlnet.dk FU Danish Heart Foundation, Copenhagen, Denmark; South-Eastern Norway Regional Health Authority; Aker University Hospital Research Foundation; Center for Heart Failure Research, Oslo, Norway; Siemens, US; Roche, US FX Dr Jensen was supported by grants from the Danish Heart Foundation, Copenhagen, Denmark.; Dr Hallen was supported by grants from the South-Eastern Norway Regional Health Authority, Aker University Hospital Research Foundation and Center for Heart Failure Research, Oslo, Norway.; Dr Januzzi was supported by grants from Siemens, US and Roche, US. NR 16 TC 3 Z9 4 U1 1 U2 3 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0036-5513 EI 1502-7686 J9 SCAND J CLIN LAB INV JI Scand. J. Clin. Lab. Invest. PD FEB PY 2011 VL 71 IS 1 BP 74 EP 80 DI 10.3109/00365513.2010.542485 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 714QW UT WOS:000286825100011 PM 21214502 ER PT J AU Nestel, D Walker, K Simon, R Aggarwal, R Andreatta, P AF Nestel, Debra Walker, Katie Simon, Robert Aggarwal, Raj Andreatta, Pamela TI Nontechnical Skills An Inaccurate and Unhelpful Descriptor? SO SIMULATION IN HEALTHCARE LA English DT Editorial Material DE Nontechnical skills; Human factors; Simulation-based education; Leadership; Teamwork; Communication; Decision making ID SURGEONS; SYSTEM; TEAMS C1 [Nestel, Debra] Monash Univ, Fac Med Nursing & Hlth Sci, Gippsland Med Sch, Melbourne, Vic 3004, Australia. [Walker, Katie] Natl Hlth Workforce Taskforce, Dept Hlth & Ageing, Melbourne, Vic, Australia. [Simon, Robert] Massachusetts Gen Hosp, Ctr Med Simulat, Boston, MA 02114 USA. [Simon, Robert] Harvard Univ, Sch Med, Boston, MA USA. [Aggarwal, Raj] Univ London Imperial Coll Sci Technol & Med, Div Surg, Dept Surg & Canc, London, England. [Andreatta, Pamela] Univ Michigan, Dept Med Educ, Clin Simulat Ctr, Dearborn, MI USA. RP Nestel, D (reprint author), Monash Univ, Fac Med Nursing & Hlth Sci, Gippsland Med Sch, Melbourne, Vic 3004, Australia. EM debra.nestel@monash.edu NR 8 TC 17 Z9 17 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-2332 J9 SIMUL HEALTHC JI Simul. Healthc. PD FEB PY 2011 VL 6 IS 1 BP 2 EP 3 DI 10.1097/SIH.0b013e3182069587 PG 2 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 717VX UT WOS:000287076600002 PM 21330843 ER PT J AU Hu, JC Prasad, SM Gu, XM Williams, SB Lipsitz, SR Nguyen, PL Choueiri, TK Choi, WW D'Amico, AV AF Hu, Jim C. Prasad, Sandip M. Gu, Xiangmei Williams, Stephen B. Lipsitz, Stuart R. Nguyen, Paul L. Choueiri, Toni K. Choi, Wesley W. D'Amico, Anthony V. TI Determinants of Performing Radical Prostatectomy Pelvic Lymph Node Dissection and the Number of Lymph Nodes Removed in Elderly Men SO UROLOGY LA English DT Article ID CANCER; OUTCOMES; LYMPHADENECTOMY; COMPLICATIONS; SURGERY; UPDATE; EXTENT AB OBJECTIVE Controversy persists regarding the adequacy of pelvic lymph node dissection (PLND) and cancer control when comparing minimally invasive radical prostatectomy (MIRP) and open radical prostatectomy (RRP). We characterized determinants of performance and extent of PLND during radical prostatectomy in elderly men. METHODS A population-based study was conducted comprised of 5448 men >= 65 years undergoing RRP and MIRP during 2004 to 2006 from Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked data. Multivariable logistic regression was used to assess the effect of demographic and tumor characteristics, surgical approach, and surgeon volume on the likelihood of performing PLND. RESULTS PLND was performed for 87.6% vs. 38.3% of men undergoing RRP vs. MIRP (P < .001). Among RRP, 82.6% vs. 4.6% underwent extended vs. limited PLND, with a median yield of 4 vs. 3 lymph nodes (P < .001). Median MIRP PLND yield was 3 lymph nodes. In adjusted analyses, men undergoing RRP vs. MIRP (odds ratio [OR] 16.7; 95% confidence interval [CI], 11.1-25.0), those with few vs. multiple comorbidities (OR 1.4, 95% CI 1.02-1.91), intermediate (OR 1.87; 95% CI 1.48-2.37), and high (OR 2.77; 95% CI 2.02-3.78) vs. low-risk features, and men treated by high-volume surgeons (OR 1.008; 95% CI 1.004-1.011) were more likely to undergo PLND. Conversely, Hispanic (OR 0.68, 95% CI 0.49-0.96) vs. white men were less likely to undergo PLND. CONCLUSIONS Independent of tumor characteristics, men undergoing RRP vs. MIRP were more likely to undergo PLND with greater lymph node yield and racial variation observed. Further studies are needed to determine the appropriate use of PLND. UROLOGY 77: 402-406, 2011. (C) 2011 Elsevier Inc. C1 [Hu, Jim C.] Brigham & Womens Hosp, Div Urol Surg, Boston, MA 02115 USA. Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. RP Hu, JC (reprint author), Brigham & Womens Hosp, Div Urol Surg, 75 Francis St, Boston, MA 02115 USA. EM jhu2@partners.org FU Department of Defense [W81XWH-08-1-0283] FX This study was funded by a Department of Defense Physician Training Award, W81XWH-08-1-0283, granted to Dr Hu. NR 25 TC 24 Z9 24 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD FEB PY 2011 VL 77 IS 2 DI 10.1016/j.urology.2010.05.015 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 715XG UT WOS:000286927700037 PM 20719365 ER PT J AU Porter, MP Gore, JL Wright, JL AF Porter, Michael P. Gore, John L. Wright, Jonathan L. TI Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study SO WORLD JOURNAL OF UROLOGY LA English DT Article DE Bladder cancer; Outcomes; Mortality; Survival; Hospital volume AB Hospital cystectomy volume has been associated with in-hospital perioperative mortality in previous studies. In this study, we examine the relationship between hospital cystectomy volume and 90-day mortality in a population-based cohort of patients undergoing cystectomy for bladder cancer. We performed a retrospective cohort study using population from the State of Washington Comprehensive Hospital Abstract Reporting System (CHARS) database. We examined the association between hospital cystectomy volume (categorized into volume tertiles) and cumulative 90-day mortality in patients undergoing cystectomy for bladder cancer. Multivariate regression was used to adjust for patient age, comorbid disease, year of surgery, and gender. Standard errors were clustered by discharge hospital. We identified 823 patients who underwent cystectomy for bladder cancer at 39 unique hospitals in 2003-2007. The unadjusted cumulative 90-day cumulative mortality was 5.4, 6.9, and 8.4% for patients discharged from hospitals in the high, medium, and low volume tertiles, respectively (P = 0.35). In the multivariate analysis, the patients undergoing cystectomy who were discharged from hospitals in the highest volume tertile had a lower risk of death in the first 90 days postoperatively compared to patients discharged from hospitals in the low volume tertile, though the finding was not statistically significant (OR = 0.68, 95% CI 0.29-1.56). Ninety-day cumulative mortality after cystectomy for bladder cancer is significant and may be associated with hospital cystectomy volume. C1 [Porter, Michael P.; Wright, Jonathan L.] VA Puget Sound Hlth Care Syst, Div Urol, Seattle, WA 98108 USA. [Porter, Michael P.; Gore, John L.; Wright, Jonathan L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. RP Porter, MP (reprint author), VA Puget Sound Hlth Care Syst, Div Urol, 1660 S Columbian Way,S-112-GU, Seattle, WA 98108 USA. EM mporter@u.washington.edu OI Gore, John/0000-0002-2847-5062 FU VA Puget Sound Health Care System, Seattle, Washington FX This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. NR 0 TC 12 Z9 12 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0724-4983 J9 WORLD J UROL JI World J. Urol. PD FEB PY 2011 VL 29 IS 1 BP 73 EP 77 DI 10.1007/s00345-010-0626-3 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 709TX UT WOS:000286465400011 PM 21132553 ER PT J AU Howland, J Rohsenow, DJ Arnedt, JT Bliss, CA Hunt, SK Calise, TV Heeren, T Winter, M Littlefield, C Gottlieb, DJ AF Howland, Jonathan Rohsenow, Damaris J. Arnedt, J. Todd Bliss, Caleb A. Hunt, Sarah K. Calise, Tamara Vehige Heeren, Timothy Winter, Michael Littlefield, Caroline Gottlieb, Daniel J. TI The acute effects of caffeinated versus non-caffeinated alcoholic beverage on driving performance and attention/reaction time SO ADDICTION LA English DT Article DE Alcohol; attention; caffeine; driving; energy drinks; reaction time ID ENERGY DRINK CONSUMPTION; INDUCED IMPAIRMENT; COLLEGE-STUDENTS; PROLONGED WAKEFULNESS; MENSTRUAL-CYCLE; EXPECTANCIES; INTOXICATION; INGESTION; RESPONSES; COCKTAILS AB Aims Marketing that promotes mixing caffeinated 'energy' drinks with alcoholic beverages (e.g. Red Bull with vodka) targets young drinkers and conveys the expectation that caffeine will offset the sedating effects of alcohol and enhance alertness. Such beliefs could result in unwarranted risk taking (e.g. driving while intoxicated). The aim of this study was to assess the acute effects of caffeinated versus non-caffeinated alcoholic beverages on a simulated driving task and attention/reaction time. Design We conducted a 2 x 2 between-groups randomized trial in which participants were randomized to one of four conditions: beer and non-alcoholic beer, with and without caffeine added. Caffeine was added in the same proportion as found in a commercially available caffeinated beer (69 mg/12 oz of beer at 4.8% alc. by vol). Participants Participants were 127 non-dependent, heavy episodic, young adult drinkers (age 21-30) who were college students or recent graduates. The target breath alcohol level was 0.12 g%. Measures Driving performance was assessed with a driving simulator; sustained attention/reaction with the Psychomotor Vigilance Task (PVT). Findings Across the driving and attention/reaction time we found main effects for alcohol, with alcohol significantly impairing driving and sustained attention/reaction time, with mainly large statistical effects; however, the addition of caffeine had no main or interaction effects on performance. Conclusion The addition of caffeine to alcohol does not appear to enhance driving or sustained attention/reaction time performance relative to alcohol alone. C1 [Howland, Jonathan] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA. [Howland, Jonathan] Boston Univ, Sch Med, Dept Emergency Med, Boston, MA 02118 USA. [Rohsenow, Damaris J.] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Arnedt, J. Todd] Univ Michigan, Sch Med, Sleep & Chronophysiol Lab, Ann Arbor, MI USA. [Gottlieb, Daniel J.] VA Boston Healthcare Syst, W Roxbury, MA USA. RP Howland, J (reprint author), Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, 801 Massachusetts Ave,Crosstown Ctr 3rd Floor, Boston, MA 02118 USA. EM jhowl@bu.edu OI Howland, Jonathan/0000-0001-8079-1188; Heeren, Timothy/0000-0001-5643-3559 FU Centers for Disease Control and Prevention (CDC) [1R49CE000946]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [M01 RR00533] FX We wish to acknowledge Sigmund Gurnick whose energy, enthusiasm and sense of humor contributed to the completion of this study. 'Ziggy' died of cancer at age 23 before the preparation of this report. He is greatly missed by his friends and colleagues. This research was supported by a grant from the Centers for Disease Control and Prevention (CDC), grant no. 1R49CE000946 and by the National Center for Research Resources (NCRR), grant no. M01 RR00533, a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or CDC. NR 36 TC 33 Z9 33 U1 2 U2 34 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0965-2140 J9 ADDICTION JI Addiction PD FEB PY 2011 VL 106 IS 2 BP 335 EP 341 DI 10.1111/j.1360-0443.2010.03219.x PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 702UV UT WOS:000285922300019 PM 21134017 ER PT J AU Martins, PN AF Martins, Paulo N. TI Effects of Organ Donor Age on Alloresponse SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Letter ID ADHESION MOLECULES; IMMUNE-RESPONSE; TRANSPLANTATION; IMMUNOGENICITY C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02163 USA. RP Martins, PN (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02163 USA. EM pnmartins@partners.org NR 10 TC 0 Z9 0 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD FEB PY 2011 VL 57 IS 2 BP 353 EP 354 DI 10.1053/j.ajkd.2010.11.012 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 708OK UT WOS:000286372700027 PM 21251547 ER PT J AU Jakobiec, FA Zakka, FR AF Jakobiec, Frederick A. Zakka, Fouad R. TI A Reappraisal of Eyelid Eccrine and Apocrine Hidrocystomas: Microanatomic and Immunohistochemical Studies of 40 Lesions SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID SWEAT GLAND TUMORS; FOCAL DERMAL HYPOPLASIA; TRICHLOROACETIC-ACID; CLINICAL-DIAGNOSIS; CELL CARCINOMA; GOLTZ-SYNDROME; MULTIPLE; DIFFERENTIATION; CYSTADENOMA; SKIN AB PURPOSE: To establish reliable criteria for diagnosing eyelid eccrine and apocrine hidrocystomas. DESIGN: Retrospective clinicopathologic and immunohistochemical study. METHODS: Twenty-two specimens of normal portions of eyelids were evaluated to establish the distribution and microanatomy of eccrine and apocrine glands. Immunostaining for cytokeratin 7 (CK7), gross cystic disease fluid protein-15 (GCDFP-15), alpha-smooth muscle actin (alpha-SMA), epithelial membrane antigen (EMA), and carcinoembryonic antigen (CEA) was performed on these tissues and on 40 lesions in 33 patients diagnosed with eccrine or apocrine hidrocystomas by unaided light microscopy. RESULTS: Eccrine glands were not present in the eyelid margins, the lower half of the upper eyelid pretarsal skin, or the pretarsal lower eyelid skin. Apocrine glands were restricted to the eyelid margins and canthi where the cysts were located. GCDFP-15, CK7, and alpha-SMA immunoreacted with the eccrine secretory coils but not their ducts; apocrine gland secretory spirals also stained positively for these markers throughout their extended courses, but not their short terminal ducts. Positivity was found in 37 of 40 hidrocystomas for alpha-SMA and 19 for GCDFP-15; lesions tested for CK7 displayed positivity. CONCLUSIONS: Alpha-SMA-, CK7-, and/or GCDFP-15-positive apocrine hidrocystomas were the only type discovered in this series and arose from glandular secretory spirals within the marginal, perimarginal, or canthal skin. Three lesions did not stain for alpha-SMA, initially suggesting an absent myoepithelium and therefore an eccrine ductal origin; they manifested CK7 positivity, however, another characteristic of the apocrine secretory spiral but not ducts. Our findings disprove the contention that eccrine predominate over apocrine hidrocystomas in the eyelids. (Am J Ophthalmol 2011;151:358-374. (C) 2011 by Elsevier Inc. All rights reserved.) C1 [Jakobiec, Frederick A.] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Dept Ophthalmol, Boston, MA 02114 USA. [Jakobiec, Frederick A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM Fred_Jakobiec@meei.harvard.edu NR 95 TC 16 Z9 16 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD FEB PY 2011 VL 151 IS 2 BP 358 EP 374 DI 10.1016/j.ajo.2010.08.028 PG 17 WC Ophthalmology SC Ophthalmology GA 712ZX UT WOS:000286705900026 PM 21168812 ER PT J AU Kenney, PA Wszolek, MF Rieger-Christ, KM Neto, BS Gould, JJ Harty, NJ Mosquera, JM Zeheb, R Loda, M Darling, DS Libertino, JA Summerhayes, IC AF Kenney, Patrick A. Wszolek, Matthew F. Rieger-Christ, Kimberly M. Silva Neto, Brasil Gould, Justin J. Harty, Niall J. Mosquera, Juan Miguel Zeheb, Ron Loda, Massimo Darling, Douglas S. Libertino, John A. Summerhayes, Ian C. TI Novel ZEB1 expression in bladder tumorigenesis SO BJU INTERNATIONAL LA English DT Article DE ZEB1; bladder cancer; microRNA ID EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR ZEB1; MIR-200 FAMILY; E-CADHERIN; TUMOR PROGRESSION; AGGRESSIVE DISEASE; THERAPEUTIC TARGET; TWIST EXPRESSION; REPRESSORS ZEB1; CANCER-CELLS AB Epithelial-mesenchymal transition (EMT) is involved in tumor progression where the underlying cellular changes associated with EMT have been identified in in vitro models and confirmed in a limited number of in vivo studies. ZEB1, which targets E-cadherin repression, is a transcriptional regulator that has been implicated in EMT, and is associated with uterine and colorectal cancers. Regulation of ZEB1 expression has been shown to involve different microRNAs (miRNAs), identifying a potential role for miRNA in EMT. In the present study we have identified novel expression of ZEB1 in bladder tumours and shown a role for ZEB1 in enhanced migration and invasion potential in in vitro assays. Confirmation of ZEB1 expression in bladder tumours was shown in tissue microarrays (TMAs). OBJECTIVE To evaluate ZEB1 expression in bladder tumorigenesis and define a possible role for this transcription factor in urothelial carcinomas of the bladder (UCBs). MATERIALS and METHODS Five hundred and fifty-eight samples were assembled in 10 tissue microarrays (TMAs; 263 non-muscle-invasive Ta/T1/Tis, 295 muscle-invasive T2-T4). All tumours were transitional cell carcinomas (TCCs) and processed for immunohistochemistry to assess nuclear ZEB1 expression. Expression levels of ZEB1 were modulated in bladder carcinoma cell lines CUBIII or UM-UC-3 after forced expression or shRNA knockdown, respectively. Protein expression levels were determined using western blot analysis and transfectants were assessed for migration and invasion potential in standard in vitro assays. RESULTS Nuclear ZEB1 expression was recorded in 22.8% of non-muscle-invasive UCBs and 21.7% of muscle-invasive UCBs, including 24.1% grade I/II and 21.1% grade III tumours, and absent in normal bladder mucosa. No significant correlation was observed for tumour stage and grade, nodal involvement, vascular invasion, metastasis and overall or cancer-specific survival. The introduction or knockdown of ZEB1 expression in bladder carcinoma cell lines showed enhanced or reduced migration and invasive potential, respectively. Changes in ZEB1 expression were accompanied by altered microRNA (miRNA) expression underlying events linked to epithelial-mesenchymal transition (EMT). CONCLUSION The results in the present study showed novel expression of ZEB1 in bladder cancer in the absence of a link to clinical variables of change, including metastasis and survival. However, in vitro assays showed enhanced or reduced migration and invasion after the introduction or reduction of ZEB1, respectively, in transfected bladder cell lines. Modulation in expression of ZEB1 was closely linked to changes in the miR-200 family along with alternative known prognostic indicators of bladder tumour progression. C1 [Rieger-Christ, Kimberly M.; Silva Neto, Brasil; Summerhayes, Ian C.] Lahey Clin Med Ctr, Cell & Mol Biol Lab, Robert E Wise MD Res & Educ Inst, Burlington, MA 01805 USA. [Kenney, Patrick A.; Wszolek, Matthew F.; Rieger-Christ, Kimberly M.; Silva Neto, Brasil; Gould, Justin J.; Harty, Niall J.; Libertino, John A.; Summerhayes, Ian C.] Lahey Clin Fdn, Dept Urol, Burlington, MA USA. [Zeheb, Ron] Lahey Clin Fdn, Dept Pathol, Burlington, MA USA. [Mosquera, Juan Miguel; Loda, Massimo] Dana Farber Canc Ctr, Dept Pathol, Boston, MA USA. [Darling, Douglas S.] Univ Louisville, Sch Med, Louisville, KY 40292 USA. [Silva Neto, Brasil] Hosp Clin Porto Alegre, Fac Med UFRGS, Porto Alegre, RS, Brazil. RP Summerhayes, IC (reprint author), Lahey Clin Med Ctr, Cell & Mol Biol Lab, Robert E Wise MD Res & Educ Inst, 31 Mall Rd, Burlington, MA 01805 USA. EM Ian.C.Summerhayes@lahey.org FU CAPES/Brazil; R.E. Wise Research and Education Institute FX None declared. Source of Funding: B.S.N. was sponsored by CAPES/Brazil and a grant from the R.E. Wise Research and Education Institute. NR 38 TC 28 Z9 30 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1464-4096 J9 BJU INT JI BJU Int. PD FEB PY 2011 VL 107 IS 4 BP 656 EP 663 DI 10.1111/j.1464-410X.2010.09489.x PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 713WE UT WOS:000286767300021 PM 20735391 ER PT J AU Greenberg, DB AF Greenberg, Donna B. TI The Signal of Suicide Rates Seen From a Distance in Patients With Pancreatic Cancer SO CANCER LA English DT Editorial Material ID TERMINALLY-ILL; DEPRESSION; DEATH; DESIRE C1 [Greenberg, Donna B.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Greenberg, Donna B.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Greenberg, Donna B.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Greenberg, DB (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,WRN 605, Boston, MA 02114 USA. EM dgreenberg@partners.org NR 20 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2011 VL 117 IS 3 BP 446 EP 448 DI 10.1002/cncr.25419 PG 3 WC Oncology SC Oncology GA 709JC UT WOS:000286433300006 PM 21254047 ER PT J AU Oh, WK Vargas, R Jacobus, S Leitzel, K Regan, MM Hamer, P Pierce, K Brown-Shimer, S Carney, W Ali, SM Kantoff, PW Lipton, A AF Oh, William K. Vargas, Roberto Jacobus, Susanna Leitzel, Kim Regan, Meredith M. Hamer, Peter Pierce, Karen Brown-Shimer, Sheryl Carney, Walter Ali, Suhail M. Kantoff, Philip W. Lipton, Allan TI Elevated Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Predict Decreased Survival in Castration-Resistant Prostate Cancer Patients SO CANCER LA English DT Article DE castration resistant prostate cancer; TIMP-1; plasma; prognostic marker; survival ID METASTATIC BREAST-CANCER; MATRIX METALLOPROTEINASES; COLORECTAL-CANCER; DISTANT METASTASES; EXPRESSION; TIMP-1; CARCINOMA; CELLS; APOPTOSIS; GROWTH AB BACKGROUND. Tissue inhibitor of metalloproteinase-1 (TIMP-1) has paradoxical multifunctional roles in tumorigenesis: inhibition of the catalytic activity of matrix metalloproteinases and apoptosis as well as promotion of angiogenesis and tumor growth. Elevated TIMP-1 levels have been associated with a poorer prognosis in multiple cancers. METHODS. Ethylenediaminetetraacetic acid plasma TIMP-1 was determined in 362 castration-resistant prostate cancer (PC) patients using a TIMP-1 enzyme-linked immunosorbent assay. All patients with castration-resistant PC and available plasma were identified from an institutional database. Overall survival was analyzed using the Kaplan-Meier method and Cox modeling on plasma TIMP-1 tertiles. RESULTS. Patients were evaluated in pilot (n = 60) and primary (n = 302) sets. Median follow-up from diagnosis was 5.8 and 6.6 years, respectively. Median plasma TIMP-1 levels were 335 and 183 ng/mL in the pilot and primary sets, respectively. Overall survival was significantly shorter with each higher tertile of TIMP-1 in both datasets (P<.001). For the primary cohort, hazard ratio of (HR) death and median survival by plasma TIMP-1 tertile levels were: low, HR 1.0, 43 months; middle, HR 1.7, 27 months; high, HR 2.4, 19 months. In the primary set, significant covariates in the adjusted Cox regression model were: TIMP-1 level (mid or high vs low tertile), prostate-specific antigen (>20 vs <= 20 ng/mL), alkaline phosphatase (>102 vs <= 102 U/L), Eastern Cooperative Oncology Group performance status (1 + vs 0), and Gleason score (7 or 8 vs <= 6). CONCLUSIONS. Elevated plasma TIMP-1 levels predicted decreased survival in metastatic castration-resistant PC patients, independent of known prognostic markers. Cancer 2011;117:517-25. (C) 2010 American Cancer Society. C1 [Oh, William K.; Kantoff, Philip W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. [Vargas, Roberto; Leitzel, Kim; Ali, Suhail M.; Lipton, Allan] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA. [Jacobus, Susanna; Regan, Meredith M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Hamer, Peter; Pierce, Karen; Brown-Shimer, Sheryl; Carney, Walter] Oncogene Sci Siemens Healthcare Diagnost, Cambridge, MA USA. [Ali, Suhail M.] Lebanon VA Med Ctr, Lebanon, PA USA. RP Oh, WK (reprint author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1079, New York, NY 10029 USA. EM william.oh@mssm.edu RI Oh, William/B-9163-2012 OI Oh, William/0000-0001-5113-8147 FU Bing Sound Wong Fund for Prostate Cancer Research; Louis DiGiovanni Research Fund; Gelb Center for Translational Research; Oncogene Science/Siemens Healthcare Diagnostics FX Supported by the Bing Sound Wong Fund for Prostate Cancer Research and the Louis DiGiovanni Research Fund (both to W.K.O.), Gelb Center for Translational Research (W.K.O., P. W. K.), and Oncogene Science/Siemens Healthcare Diagnostics (K.L., A.L.) NR 39 TC 18 Z9 20 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2011 VL 117 IS 3 BP 517 EP 525 DI 10.1002/cncr.25394 PG 9 WC Oncology SC Oncology GA 709JC UT WOS:000286433300016 PM 20862742 ER PT J AU Choueiri, TK D'Amico, AV Chen, MH AF Choueiri, Toni K. D'Amico, Anthony V. Chen, Ming-Hui TI Reply to Impact of Postoperative Prostate-Specific Antigen Disease Recurrence and the Use of Salvage Therapy on the Risk of Death SO CANCER LA English DT Letter ID BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; SURVIVAL; MEN C1 [Choueiri, Toni K.; D'Amico, Anthony V.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Med Sch, Boston, MA 02115 USA. [Chen, Ming-Hui] Univ Connecticut, Storrs, CT USA. RP Choueiri, TK (reprint author), Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Med Sch, Boston, MA 02115 USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2011 VL 117 IS 3 BP 656 EP 656 DI 10.1002/cncr.25404 PG 1 WC Oncology SC Oncology GA 709JC UT WOS:000286433300033 ER PT J AU Sacks, DB Nathan, DM Lachin, JM AF Sacks, David B. Nathan, David M. Lachin, John M. TI Gaps in the Glycation Gap Hypothesis SO CLINICAL CHEMISTRY LA English DT Editorial Material ID BLOOD-GLUCOSE CONTROL; BIOLOGICAL VARIATION; COMPLICATIONS; HBA(1C); RISK; GLYCOHEMOGLOBIN; FRUCTOSAMINE; NEPHROPATHY; DISCORDANCE; ASSAY C1 [Sacks, David B.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Sacks, David B.; Nathan, David M.] Harvard Univ, Sch Med, Boston, MA USA. [Nathan, David M.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA. [Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD USA. RP Sacks, DB (reprint author), Dept Lab Med, 10 Ctr Dr,Bldg 10,Room 2C427, Bethesda, MD 20892 USA. OI Lachin, John/0000-0001-9838-2841; Sacks, David/0000-0003-3100-0735 FU NCRR NIH HHS [UL1 RR025014] NR 19 TC 14 Z9 15 U1 0 U2 1 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD FEB PY 2011 VL 57 IS 2 BP 150 EP 152 DI 10.1373/clinchem.2010.158071 PG 3 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 712GD UT WOS:000286653000002 PM 21127149 ER PT J AU Nathan, DM Steffes, MW Sun, WJ Rynders, GP Lachin, JM AF Nathan, David M. Steffes, Michael W. Sun, Wanjie Rynders, Gregory P. Lachin, John M. TI Determining Stability of Stored Samples Retrospectively: The Validation of Glycated Albumin SO CLINICAL CHEMISTRY LA English DT Article ID DIABETES INTERVENTIONS; COMPLICATIONS TRIAL; HEMOGLOBIN; EPIDEMIOLOGY; TYPE-1 AB BACKGROUND: Determining the stability of stored samples for assays that were not available at the time of original collection is problematic. To assess sample stability for a relatively new assay of glycated albumin (GA), we first measured GA in fresh samples and in samples stored for 19-23 years. We then compared the regression of the contemporaneous glycohemoglobin (Hb A(1c)) values against the GA results from fresh vs stored samples, reasoning that similar slopes and intercepts would provide strong, albeit indirect, support for the stability of the stored samples for GA measurements. METHODS: We assayed 90 samples frozen for 19-23 years and 90 fresh samples from participants in the Diabetes Control and Complications trial cohort for GA. Hb A(1c) was measured contemporaneously in fresh samples at each time period. A single normal-errors linear model regressed the Hb A(1c) values on the GA, with an additional effect for collection period (fresh vs stored for GA) and the interaction of period and GA. RESULTS: Analysis of the regressions lines between GA and Hb A(1c) revealed intercepts (3.69 and 2.97 for the fresh and stored samples, respectively) and slopes (0.198 vs 0.187) that were not significantly different (P = 0.182 and P = 0.639, respectively). CONCLUSIONS: This simple approach can be used to assess the stability of stored samples in new assays. Samples stored for as long as 23 years are suitable for the GA assay. (C) 2010 American Association for Clinical Chemistry C1 [Nathan, David M.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA. [Nathan, David M.] Harvard Univ, Sch Med, Boston, MA USA. [Steffes, Michael W.; Rynders, Gregory P.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Sun, Wanjie; Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD USA. RP Nathan, DM (reprint author), MGH Diabet Ctr, 50 Staniford St,Suite 340, Boston, MA 02114 USA. EM dnathan@partners.org OI Lachin, John/0000-0001-9838-2841 FU Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases; National Eye Institute; National Institute of Neurological Disorders and Stroke; General Clinical Research Centers Program; Clinical and Translation Science Centers Program; National Center for Research Resources; Genentech; National Institute of Diabetes and Digestive and Kidney Diseases; Lifescan; Roche; Aventis; Eli Lilly; OmniPod; Can-Am; B-D; Animas; Medtronic; Medtronic Minimed; Bayer FX The DCCT/EDIC project is supported by contracts with the Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases, National Eye Institute, National Institute of Neurological Disorders and Stroke, General Clinical Research Centers Program, Clinical and Translation Science Centers Program, National Center for Research Resources, and Genentech through a Cooperative Research and Development Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases. Lifescan, Roche, Aventis, Eli Lilly, OmniPod, Can-Am, B-D, Animas, Medtronic, Medtronic Minimed, Bayer (donation 1 time in 2008), and Omron contributed free or discounted supplies and/or equipment. The current ancillary study received support in the form of donated assay kits from Asahi Kasei Pharma Corporation. NR 11 TC 21 Z9 23 U1 0 U2 5 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD FEB PY 2011 VL 57 IS 2 BP 286 EP 290 DI 10.1373/clinchem.2010.150250 PG 5 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 712GD UT WOS:000286653000023 PM 21030684 ER PT J AU Goldfine, AB Gerwien, RW Kolberg, JA O'Shea, S Hamren, S Hein, GP Xu, XMM Patti, ME AF Goldfine, Allison B. Gerwien, Robert W. Kolberg, Janice A. O'Shea, Sheila Hamren, Sarah Hein, Glenn P. Xu, Xiaomei M. Patti, Mary Elizabeth TI Biomarkers in Fasting Serum to Estimate Glucose Tolerance, Insulin Sensitivity, and Insulin Secretion SO CLINICAL CHEMISTRY LA English DT Article ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; BETA-CELL DYSFUNCTION; RISK-FACTORS; DIABETES-MELLITUS; ELEVATED LEVELS; TYPE-2; RESISTANCE; INTERVENTION; POPULATION; INDEXES AB BACKGROUND: Biomarkers for estimating reduced glucose tolerance, insulin sensitivity, or impaired insulin secretion would be clinically useful, since these physiologic measures are important in the pathogenesis of type 2 diabetes mellitus. METHODS: We conducted a cross-sectional study in which 94 individuals, of whom 84 had 1 or more risk factors and 10 had no known risk factors for diabetes, underwent oral glucose tolerance testing. We measured 34 protein biomarkers associated with diabetes risk in 250-mu L fasting serum samples. We applied multiple regression selection techniques to identify the most informative biomarkers and develop multivariate models to estimate glucose tolerance, insulin sensitivity, and insulin secretion. The ability of the glucose tolerance model to discriminate between diabetic individuals and those with impaired or normal glucose tolerance was evaluated by area under the ROC curve (AUC) analysis. RESULTS: Of the at-risk participants, 25 (30%) were found to have impaired glucose tolerance, and 11 (13%) diabetes. Using molecular counting technology, we assessed multiple biomarkers with high accuracy in small volume samples. Multivariate biomarker models derived from fasting samples correlated strongly with 2-h postload glucose tolerance (R(2) = 0.45, P < 0.0001), composite insulin sensitivity index (R(2) = 0.91, P < 0.0001), and insulin secretion (R(2) = 0.45, P < 0.0001). Additionally, the glucose tolerance model provided strong discrimination between diabetes vs impaired or normal glucose tolerance (AUC 0.89) and between diabetes and impaired glucose tolerance vs normal tolerance (AUC 0.78). CONCLUSIONS: Biomarkers in fasting blood samples may be useful in estimating glucose tolerance, insulin sensitivity, and insulin secretion. (C) 2010 American Association for Clinical Chemistry C1 [Goldfine, Allison B.; O'Shea, Sheila; Patti, Mary Elizabeth] Joslin Diabet Ctr, Boston, MA 02215 USA. [Gerwien, Robert W.; Kolberg, Janice A.; Hamren, Sarah; Hein, Glenn P.; Xu, Xiaomei M.] Tethys Biosci, Emeryville, CA USA. RP Goldfine, AB (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM allison.goldfine@joslin.harvard.edu FU Tethys Bioscience; NIH [DK-062948, DK070648, DK-060837, DERC P30-DK-36836, GCRC M01-RR-001032]; American Diabetes Association [06-CD-07]; Lilly Foundation FX A.B. Goldfine, Tethys Bioscience, NIH grants DK-062948 and DK070648, and American Diabetes Association Career Development Award (06-CD-07); M. E. Patti, NIH grant DK-060837 and the Lilly Foundation. This study was supported by NIH grants DERC P30-DK-36836 and GCRC M01-RR-001032 (Joslin Diabetes Center). NR 26 TC 10 Z9 10 U1 0 U2 2 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD FEB PY 2011 VL 57 IS 2 BP 326 EP 337 DI 10.1373/clinchem.2010.156133 PG 12 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 712GD UT WOS:000286653000028 PM 21149503 ER PT J AU Dyer, GSM Blazar, PE AF Dyer, George S. M. Blazar, Philip E. TI Rheumatoid Elbow SO HAND CLINICS LA English DT Article DE Rheumatoid arthritis; Elbow; Elbow degeneration; Total elbow arthroplasty ID FOLLOW-UP; ARTHROSCOPIC SYNOVECTOMY; ARTHRITIS; ARTHROPLASTY; REPLACEMENT; KUDO; INJECTION; JOINT AB The elbow is often involved in the progression of rheumatoid arthritis. Because of the elbow's unique role in maneuvering and positioning the hand in space, loss of normal elbow motion, loss of stability, or increased pain with the use of the elbow are all significant sources of impairment in patients with rheumatoid arthritis. The improvements in disease-modifying medications have greatly diminished the prevalence of severe elbow degeneration among patients with rheumatoid arthritis. However, it hasn't been eliminated. In this article the authors discuss strategies for managing it. C1 [Dyer, George S. M.] Harvard Univ, Brigham & Womens Hosp, Hand Upper Extrem Serv, Sch Med,Dept Orthopaed Surg, Boston, MA 02115 USA. [Dyer, George S. M.; Blazar, Philip E.] VA Boston Healthcare, Jamaica Plain, MA 02130 USA. RP Dyer, GSM (reprint author), Harvard Univ, Brigham & Womens Hosp, Hand Upper Extrem Serv, Sch Med,Dept Orthopaed Surg, 75 Francis St, Boston, MA 02115 USA. EM GDYER@PARTNERS.ORG NR 24 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0712 EI 1558-1969 J9 HAND CLIN JI Hand Clin. PD FEB PY 2011 VL 27 IS 1 BP 43 EP + DI 10.1016/j.hcl.2010.10.003 PG 7 WC Orthopedics SC Orthopedics GA 710SL UT WOS:000286534000007 PM 21176799 ER PT J AU Dyer, GSM Simmons, BP AF Dyer, George S. M. Simmons, Barry P. TI Rheumatoid Thumb SO HAND CLINICS LA English DT Article DE Rheumatoid arthritis; MCP joint; Surgical management; Arthroplasty ID SWAN-NECK DEFORMITY; ARTHRITIS; ARTHROPLASTY AB The hand is the main tactile sensory organ and is uniquely designed for fine motor activities. Any deviation from the normal architecture or limitation from a painful condition may lead to disability. Rheumatoid arthritis (RA) is fundamentally an inflammatory disease of the soft tissues. Deformities of the thumb arise from abnormal stretching of ligament and capsular structures as well as from ruptures and subluxations of the tendons. This article provides an overview of the types of deformities associated with, and surgical management of, RA of the thumb. C1 [Dyer, George S. M.; Simmons, Barry P.] Harvard Univ, Brigham & Womens Hosp, Hand Upper Extrem Serv, Sch Med,Dept Orthopaed Surg, Boston, MA 02115 USA. [Dyer, George S. M.] VA Boston Healthcare, Jamaica Plain, MA 02130 USA. RP Dyer, GSM (reprint author), Harvard Univ, Brigham & Womens Hosp, Hand Upper Extrem Serv, Sch Med,Dept Orthopaed Surg, 75 Francis St, Boston, MA 02115 USA. EM GDYER@PARTNERS.ORG NR 10 TC 3 Z9 3 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0712 J9 HAND CLIN JI Hand Clin. PD FEB PY 2011 VL 27 IS 1 BP 73 EP + DI 10.1016/j.hcl.2010.10.001 PG 6 WC Orthopedics SC Orthopedics GA 710SL UT WOS:000286534000010 PM 21176802 ER PT J AU Duque, C Stipp, RN Wang, B Smith, DJ Hofling, JF Kuramitsu, HK Duncan, MJ Mattos-Graner, RO AF Duque, Cristiane Stipp, Rafael N. Wang, Bing Smith, Daniel J. Hoefling, Jose F. Kuramitsu, Howard K. Duncan, Margaret J. Mattos-Graner, Renata O. TI Downregulation of GbpB, a Component of the VicRK Regulon, Affects Biofilm Formation and Cell Surface Characteristics of Streptococcus mutans SO INFECTION AND IMMUNITY LA English DT Article ID GLUCAN-BINDING-PROTEIN; YYCF RESPONSE-REGULATOR; GROUP-B STREPTOCOCCUS; STAPHYLOCOCCUS-AUREUS; OXIDATIVE STRESS; FUNCTIONAL-ANALYSIS; GENETIC COMPETENCE; MUREIN HYDROLASE; PNEUMONIAE R6; EXPRESSION AB The virulence of the dental caries pathogen Streptococcus mutans relies in part on the sucrose-dependent synthesis of and interaction with glucan, a major component of the extracellular matrix of tooth biofilms. However, the mechanisms by which secreted and/or cell-associated glucan-binding proteins (Gbps) produced by S. mutans participate in biofilm growth remain to be elucidated. In this study, we further investigate GbpB, an essential immunodominant protein with similarity to murein hydrolases. A conditional knockdown mutant that expressed gbpB antisense RNA under the control of a tetracycline-inducible promoter was constructed in strain UA159 (UACA2) and used to investigate the effects of GbpB depletion on biofilm formation and cell surface-associated characteristics. Additionally, regulation of gbpB by the two-component system VicRK was investigated, and phenotypic analysis of a vicK mutant (UAvicK) was performed. GbpB was directly regulated by VicR, and several phenotypic changes were comparable between UACA2 and UAvicK, although differences between these strains existed. It was established that GbpB depletion impaired initial phases of sucrose-dependent biofilm formation, while exogenous native GbpB partially restored the biofilm phenotype. Several cellular traits were significantly affected by GbpB depletion, including altered cell shape, decreased autolysis, increased cell hydrophobicity, and sensitivity to antibiotics and osmotic and oxidative stresses. These data provide the first experimental evidence for GbpB participation in sucrose-dependent biofilm formation and in cell surface properties. C1 [Duque, Cristiane; Stipp, Rafael N.; Hoefling, Jose F.; Mattos-Graner, Renata O.] Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Oral Diag, BR-13414903 Sao Paulo, Brazil. [Wang, Bing; Kuramitsu, Howard K.] SUNY Buffalo, Dept Oral Biol, Buffalo, NY 14260 USA. [Smith, Daniel J.] Forsyth Inst, Dept Immunol, Boston, MA USA. [Duncan, Margaret J.] Forsyth Inst, Dept Mol Genet, Boston, MA USA. RP Mattos-Graner, RO (reprint author), Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Oral Diag, Av Limeira 901, BR-13414903 Sao Paulo, Brazil. EM rmgraner@fop.unicamp.br RI Mattos-Graner, Renata/C-9410-2012; Duque, Cristiane/G-9505-2012 OI Mattos-Graner, Renata/0000-0001-8309-8135; FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [07/56100-2, 02/07156-1, 05/55775-0, 06/55933-8]; [R01 DE15931]; [R37 DE06153] FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; grants 07/56100-2 and 02/07156-1). C. D. was supported by FAPESP (grant 05/55775-0). R.N.S. was supported by FAPESP (06/55933-8). M.J.D. was supported by grants R01 DE15931 and R37 DE06153. D.J.S. was supported by grant R37 DE06153. NR 55 TC 27 Z9 28 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD FEB PY 2011 VL 79 IS 2 BP 786 EP 796 DI 10.1128/IAI.00725-10 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 709SP UT WOS:000286462000024 PM 21078847 ER PT J AU Lim, K Small, W Portelance, L Creutzberg, C Jurgenliemk-Schulz, IM Mundt, A Mell, LK Mayr, N Viswanathan, A Jhingran, A Erickson, B De Los Santos, J Gaffney, D Yashar, C Beriwal, S Wolfson, A Taylor, A Bosch, W El Naqa, I Fyles, A AF Lim, Karen Small, William, Jr. Portelance, Lorraine Creutzberg, Carien Jurgenliemk-Schulz, Ina M. Mundt, Arno Mell, Loren K. Mayr, Nina Viswanathan, Akila Jhingran, Anuja Erickson, Beth De Los Santos, Jennifer Gaffney, David Yashar, Catheryn Beriwal, Sushil Wolfson, Aaron Taylor, Alexandra Bosch, Walter El Naqa, Issam Fyles, Anthony CA Gyn IMRT Consortium TI CONSENSUS GUIDELINES FOR DELINEATION OF CLINICAL TARGET VOLUME FOR INTENSITY-MODULATED PELVIC RADIOTHERAPY FOR THE DEFINITIVE TREATMENT OF CERVIX CANCER SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Intensity-modulated radiotherapy; Cervical cancer; Guidelines; CTV ID RADICAL VAGINAL TRACHELECTOMY; RADIATION-THERAPY; EXTENDED-FIELD; GASTROINTESTINAL TOXICITY; CONCURRENT CISPLATIN; GYNECOLOGICAL CANCER; ORGAN MOVEMENT; LYMPH-NODES; CARCINOMA; IMRT AB Purpose: Accurate target definition is vitally important for definitive treatment of cervix cancer with intensity-modulated radiotherapy (IMRT), yet a definition of clinical target volume (CTV) remains variable within the literature. The aim of this study was to develop a consensus CTV definition in preparation for a Phase 2 clinical trial being planned by the Radiation Therapy Oncology Group. Methods and Materials: A guidelines consensus working group meeting was convened in June 2008 for the purposes of developing target definition guidelines fir IMRT for the intact cervix. A draft document of recommendations for CTV definition was created and used to aid in contouring a clinical case. The clinical case was then analyzed for consistency and clarity of target delineation using an expectation maximization algorithm for simultaneous truth and performance level estimation (STAPLE), with kappa statistics as a measure of agreement between participants. Results: Nineteen experts in gynecological radiation oncology generated contours on axial magnetic resonance images of the pelvis. Substantial STAPLE agreement sensitivity and specificity values were seen for gross tumor volume (GTV) delineation (0.84 and 0.96, respectively) with a kappa statistic of 0.68 (p < 0.0001). Agreement for delineation of cervix, uterus, vagina, and parametria was moderate. Conclusions: This report provides guidelines for CTV definition in the definitive cervix cancer setting for the purposes of IMRT, building on previously published guidelines for IMRT in the postoperative setting. (C) 2011 Elsevier Inc. C1 [Lim, Karen; Fyles, Anthony] Univ Hlth Network, Princess Margaret Hosp, Radiat Med Program, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada. [Small, William, Jr.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Dept Radiat Oncol, Chicago, IL 60611 USA. [Portelance, Lorraine] McGill Univ, Dept Radiat Oncol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada. [Creutzberg, Carien] Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands. [Jurgenliemk-Schulz, Ina M.] Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands. [Mundt, Arno; Mell, Loren K.; Yashar, Catheryn] Univ Calif San Diego, Sch Med, Dept Radiat Oncol, La Jolla, CA 92093 USA. [Mayr, Nina] Ohio State Univ, Dept Radiat Med, Columbus, OH 43210 USA. [Viswanathan, Akila] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Viswanathan, Akila] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Jhingran, Anuja] Univ Texas Houston, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Erickson, Beth] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA. [De Los Santos, Jennifer] Univ Alabama, Dept Radiat Oncol, Birmingham, AL USA. [Gaffney, David] Univ Utah, Huntsman Canc Inst, Dept Radiat Oncol, Salt Lake City, UT USA. [Beriwal, Sushil] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Radiat Oncol, Pittsburgh, PA USA. [Wolfson, Aaron] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA. [Taylor, Alexandra] Hammersmith Hosp, Dept Radiotherapy, London, England. [Bosch, Walter; El Naqa, Issam] Washington Univ, Sch Med, St Louis, MO USA. RP Fyles, A (reprint author), Univ Hlth Network, Princess Margaret Hosp, Radiat Med Program, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada. EM Anthony.Fyles@rmp.uhn.on.ca RI Beriwal, Sushil/J-6404-2012; OI Viswanathan, Akila/0000-0002-2003-0392; Mell, Loren/0000-0003-2277-6080; Fyles, Anthony/0000-0002-3633-2483 FU NCI NIH HHS [U24 CA081647] NR 34 TC 118 Z9 130 U1 2 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD FEB 1 PY 2011 VL 79 IS 2 BP 348 EP 355 DI 10.1016/j.ijrobp.2009.10.075 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 709OW UT WOS:000286451000005 PM 20472347 ER PT J AU Zukotynski, KA Fahey, FH Kocak, M Alavi, A Wong, TZ Treves, ST Shulkin, BL Haas-Kogan, DA Geyer, JR Vajapeyam, S Boyett, JM Kun, LE Poussaint, TY AF Zukotynski, Katherine A. Fahey, Frederic H. Kocak, Mehmet Alavi, Abass Wong, Terence Z. Treves, S. Ted Shulkin, Barry L. Haas-Kogan, Daphne A. Geyer, Jeffrey R. Vajapeyam, Sridhar Boyett, James M. Kun, Larry E. Poussaint, Tina Young TI Evaluation of F-18-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain Stem Glioma: A Report from the Pediatric Brain Tumor Consortium SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE pediatric; brain stem glioma; F-18-FDG PET; MRI; diffusion; enhancement; perfusion; brain tumor ID POSITRON-EMISSION-TOMOGRAPHY; FDG-PET; PONTINE GLIOMAS; LOW-GRADE; CHILDREN; FLUORODEOXYGLUCOSE; STRATEGIES; C-11-METHIONINE; ASTROCYTOMA; PREDICTION AB The purpose of this study was to assess F-18-FDG uptake in children with a newly diagnosed diffuse intrinsic brain stem glioma (BSG) and to investigate associations with progression-free survival (PFS), overall survival (OS), and MRI indices. Methods: Two Pediatric Brain Tumor Consortium (PBTC) therapeutic trials in children with newly diagnosed BSG were designed to test radiation therapy combined with molecularly targeted agents (PBTC-007: phase I/II study of gefitinib; PBTC-014: phase I/II study of tipifarnib). Baseline brain F-18-FDG PET scans were obtained in 40 children in these trials. Images were evaluated by consensus between 2 PET experts for intensity and uniformity of tracer uptake. Associations of F-18-FDG uptake intensity and uniformity with both PFS and OS, as well as associations with tumor MRI indices at baseline (tumor volume on fluid-attenuated inversion recovery, baseline intratumoral enhancement, diffusion and perfusion values), were evaluated. Results: In most of the children, BSG F-18-FDG uptake was less than gray-matter uptake. Survival was poor, irrespective of intensity of F-18-FDG uptake, with no association between intensity of F-18-FDG uptake and PFS or OS. However, hyperintense F-18-FDG uptake in the tumor, compared with gray matter, suggested poorer survival rates. Patients with F-18-FDG uptake in 50% or more of the tumor had shorter PFS and OS than did patients with F-18-FDG uptake in less than 50% of the tumor. There was some evidence that tumors with higher F-18-FDG uptake were more likely to show enhancement, and when the diffusion ratio was lower, the uniformity of F-18-FDG uptake appeared higher. Conclusion: Children with BSG for which F-18-FDG uptake involves at least half the tumor appear to have poorer survival than children with uptake in less than 50% of the tumor. A larger independent study is needed to verify this hypothesis. Intense tracer uptake in the tumors, compared with gray matter, suggests decreased survival. Higher F-18-FDG uptake within the tumor was associated with enhancement on MR images. Increased tumor cellularity as reflected by restricted MRI diffusion may be associated with increased F-18-FDG uniformity throughout the tumor. C1 [Fahey, Frederic H.; Treves, S. Ted; Vajapeyam, Sridhar; Poussaint, Tina Young] Childrens Hosp Boston, Dept Radiol, Boston, MA 02115 USA. [Zukotynski, Katherine A.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA. [Zukotynski, Katherine A.; Fahey, Frederic H.; Treves, S. Ted; Vajapeyam, Sridhar; Poussaint, Tina Young] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Kocak, Mehmet; Boyett, James M.] St Jude Childrens Hosp, Dept Biostat, Memphis, TN 38105 USA. [Alavi, Abass] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Wong, Terence Z.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA. [Shulkin, Barry L.; Kun, Larry E.] St Jude Childrens Hosp, Dept Radiol Sci, Memphis, TN 38105 USA. [Haas-Kogan, Daphne A.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA. [Geyer, Jeffrey R.] Childrens Hosp & Reg Med Ctr, Dept Hematol Oncol, Seattle, WA USA. RP Poussaint, TY (reprint author), Childrens Hosp Boston, Dept Radiol, 300 Longwood Ave, Boston, MA 02115 USA. EM tina.poussaint@childrens.harvard.edu OI Kocak, Mehmet/0000-0002-3386-1734 FU NIH [U01 CA81457]; Pediatric Brain Tumor Consortium Foundation (PBTCF); Pediatric Brain Tumor Foundation of the United States (PBTFUS); American Lebanese Syrian Associated Charities FX We acknowledge the other-site PET physicians, including Drs. Randall Hawkins (University of California, San Francisco), James Mountz (Children's Hospital of Pittsburgh), Satoshi Minoshima (Seattle Children's Hospital), David Earl-Graef (Children's National), Stewart Spies (Children's Memorial), and John Butman (National Institutes of Health). We acknowledge Cynthia Dube for manuscript preparation. This work was supported in part by NIH grant U01 CA81457 for the Pediatric Brain Tumor Consortium (PBTC), the Pediatric Brain Tumor Consortium Foundation (PBTCF), the Pediatric Brain Tumor Foundation of the United States (PBTFUS), and American Lebanese Syrian Associated Charities. NR 36 TC 19 Z9 19 U1 1 U2 2 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD FEB 1 PY 2011 VL 52 IS 2 BP 188 EP 195 DI 10.2967/jnumed.110.081463 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 711ME UT WOS:000286594900007 PM 21233173 ER PT J AU Fett, N Werth, VP AF Fett, Nicole Werth, Victoria P. TI Update on morphea Part I. Epidemiology, clinical presentation, and pathogenesis SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE autoimmune connective tissue disorder; fibrosing disorders; localized scleroderma; morphea; scleroderma; systemic sclerosis ID SCLEROSUS-ET-ATROPHICUS; OF-THE-LITERATURE; BORRELIA-BURGDORFERI INFECTION; JUVENILE LOCALIZED SCLERODERMA; DISABLING PANSCLEROTIC MORPHEA; PROGRESSIVE FACIAL HEMIATROPHY; POLYMERASE-CHAIN-REACTION; SYSTEMIC-SCLEROSIS; RAYNAUDS-PHENOMENON; EN-COUP AB Morphea, also known as localized scleroderma, is a rare fibrosing disorder of the skin and underlying tissues. Morphea is differentiated from systemic sclerosis based on the absence of sclerodactyly, Raynaud phenomenon, and nailfold capillary changes. Patients with morphea commonly have systemic symptoms, such as malaise, fatigue, arthralgias, and myalgias, as well as positive autoantibody serologies. However, involvement of morphea is almost uniformly limited to those tissues derived from the mesoderm. The underlying pathogenesis of morphea is incompletely understood at this time, but ultimately results in an imbalance of collagen production and destruction. (J Am Acad Dermatol 2011;64:217-28.) C1 [Fett, Nicole] Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Fett, N (reprint author), Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Ste 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM Nicole.Fett@uphs.upenn.edu FU Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; National Institutes of Health [NIH K24-AR 02207] FX Supported in part by a Merit Review Grant from the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, and by the National Institutes of Health (grant NIH K24-AR 02207) to Dr Werth. NR 75 TC 75 Z9 79 U1 1 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD FEB PY 2011 VL 64 IS 2 BP 217 EP 228 DI 10.1016/j.jaad.2010.05.045 PG 12 WC Dermatology SC Dermatology GA 714AX UT WOS:000286780400001 PM 21238823 ER PT J AU Otsuji, Y Sakata, R Kubota, K Takeuchi, M Levine, RA Tei, C AF Otsuji, Yutaka Sakata, Ryuzo Kubota, Kayoko Takeuchi, Masaaki Levine, Robert A. Tei, Chuwa TI FUNCTIONAL MITRAL STENOSIS AFTER SURGICAL ANNULOPLASTY FOR ISCHEMIC MITRAL REGURGITATION: IMPORTANCE OF SUBVALVULAR TETHERING IN THE MECHANISM AND DYNAMIC DETERIORATION DURING EXERTION Reply SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Letter C1 [Otsuji, Yutaka; Takeuchi, Masaaki] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan. [Sakata, Ryuzo] Kyoto Univ, Kyoto, Japan. [Kubota, Kayoko; Tei, Chuwa] Kagoshima Univ, Kagoshima 890, Japan. [Levine, Robert A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Otsuji, Y (reprint author), Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan. NR 6 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD FEB PY 2011 VL 141 IS 2 BP 602 EP 603 DI 10.1016/j.jtcvs.2010.10.018 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 706MP UT WOS:000286222800062 ER PT J AU Amory, JK Bush, MA Zhi, H Caricofe, RB Matsumoto, AM Swerdloff, RS Wang, C Clark, RV AF Amory, John K. Bush, Mark A. Zhi, Hui Caricofe, Ralph B. Matsumoto, Alvin M. Swerdloff, Ronald S. Wang, Christina Clark, Richard V. TI Oral Testosterone With and Without Concomitant Inhibition of 5 alpha-Reductase by Dutasteride in Hypogonadal Men for 28 Days SO JOURNAL OF UROLOGY LA English DT Article DE testis; hypogonadism; administration; oral; testosterone; dutasteride ID BONE-MINERAL DENSITY; LEAN BODY-MASS; PROSTATE-CANCER; OLDER MEN; EXOGENOUS TESTOSTERONE; SERUM TESTOSTERONE; PLUS DUTASTERIDE; SEXUAL FUNCTION; REPLACEMENT; FINASTERIDE AB Purpose: Co-administration of the 5 alpha-reductase inhibitor dutasteride increases the oral testosterone bioavailability in men with experimentally induced hypogonadism. We examined oral testosterone with and without dutasteride administration in hypogonadal men for 28 days. Materials and Methods: We randomly assigned 43 hypogonadal men to twice daily oral doses of 150, 250 or 400 mg testosterone with 0.25 mg dutasteride, 400 mg testosterone alone or 0.25 mg dutasteride alone for 28 days in a multicenter study. Subjects underwent pharmacokinetic profiling of serum hormones on days 1 and 28. A total of 32 men completed all study procedures. Results: Serum testosterone increased in all groups on testosterone compared with that in the dutasteride only group. At the 400 mg dose the combination of testosterone and dutasteride resulted in average testosterone concentrations that were 2.7 and 4.6 times higher than in the testosterone only group on days 1 and 28, respectively (p < 0.01). On day 28 average testosterone was 20% to 30% lower in all groups on testosterone and dutasteride, and 50% lower in the testosterone only group compared with day 1. Serum dihydrotestosterone was suppressed in all groups on dutasteride and increased in the testosterone only group. Conclusions: Oral testosterone administration resulted in a therapeutic serum testosterone concentration in hypogonadal men. Dutasteride improved the oral bioavailability of testosterone while suppressing dihydrotestosterone. Compared with day 1, testosterone was decreased after 28 days of administration. Additional study is warranted of oral testosterone with dutasteride for testosterone deficiency. C1 [Clark, Richard V.] GlaxoSmithKline Res & Dev Ltd, Metab Discovery Med, Muscle Metab DPU, Metab Pathways CEDD, Res Triangle Pk, NC 27709 USA. [Amory, John K.] Univ Washington, Seattle, WA 98195 USA. [Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Swerdloff, Ronald S.; Wang, Christina] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Swerdloff, Ronald S.; Wang, Christina] Los Angeles Biomed Res Inst, Torrance, CA USA. RP Clark, RV (reprint author), GlaxoSmithKline Res & Dev Ltd, Metab Discovery Med, Muscle Metab DPU, Metab Pathways CEDD, 5 Moore Dr,N2-3212,POB 13398, Res Triangle Pk, NC 27709 USA. FU GlaxoSmithKline; National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development [U54 HD 042454]; National Institutes of Health [M01-RR-00037, M01-RR-00425] FX Supported by GlaxoSmithKline (JKA, AM, CW, RSS), National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development Grant U54 HD 042454 (JKA), and National Institutes of Health Grants M01-RR-00037 and M01-RR-00425. NR 29 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 EI 1527-3792 J9 J UROLOGY JI J. Urol. PD FEB PY 2011 VL 185 IS 2 BP 626 EP 632 DI 10.1016/j.juro.2010.09.089 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 704JH UT WOS:000286047500085 PM 21168874 ER PT J AU Coutinho, AC Krishnaraj, A Pires, CE Bittencourt, LK Guimaraes, AR AF Coutinho, Antonio C., Jr. Krishnaraj, Arun Pires, Cintia E. Bittencourt, Leonardo K. Guimaraes, Alexander R. TI Pelvic Applications of Diffusion Magnetic Resonance Images SO MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA LA English DT Article DE MR imaging; Pelvic; Diffusion; Neoplasms; Uterus; Ovaries; Prostate; Rectum ID HIGH-B-VALUE; UTERINE ENDOMETRIAL CANCER; TOTAL MESORECTAL EXCISION; URINARY-BLADDER CANCER; ADVANCED RECTAL-CANCER; MR-IMAGING FINDINGS; PROSTATE-CANCER; WEIGHTED MRI; OVARIAN-CANCER; PREOPERATIVE RADIOTHERAPY AB Diffusion-weighted imaging (DWI) is a powerful imaging technique in neuroimaging; its value in abdominal and pelvic imaging has only recently been appreciated as a result of improvements in magnetic resonance imaging technology. There is growing interest in the use of DWI for evaluating pathology in the pelvis. Its ability to noninvasively characterize tissues and to depict changes at a cellular level allows DWI to be an effective complement to conventional sequences of pelvic imaging, especially in oncologic patients. The addition of DWI may obviate contrast material in those with renal insufficiency or contrast material allergy. C1 [Coutinho, Antonio C., Jr.; Pires, Cintia E.; Bittencourt, Leonardo K.] CDPI, BR-22640902 Rio De Janeiro, Brazil. [Krishnaraj, Arun; Guimaraes, Alexander R.] Harvard Univ, Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, Dept Radiol,Med Sch, Boston, MA 02114 USA. [Bittencourt, Leonardo K.] Univ Fed Rio de Janeiro, Dept Radiol, Rio De Janeiro, Brazil. [Bittencourt, Leonardo K.] Carlos Bittencourt Diagnost Imagem, Rio De Janeiro, Brazil. [Guimaraes, Alexander R.] Harvard Univ, Massachusetts Gen Hosp, MIT, Martinos Ctr Biomed Imaging,Dept Radiol,Med Sch, Cambridge, MA 02139 USA. RP Coutinho, AC (reprint author), CDPI, Av Amer 4666,Sala 325, BR-22640902 Rio De Janeiro, Brazil. EM antoniocoutinhojr@yahoo.com.br NR 90 TC 7 Z9 8 U1 3 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1064-9689 J9 MAGN RESON IMAGING C JI Magn. Reson. Imaging Clin. N. Am. PD FEB PY 2011 VL 19 IS 1 BP 133 EP + DI 10.1016/j.mric.2010.10.003 PG 26 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 701GH UT WOS:000285805900008 PM 21129639 ER PT J AU Higgins, MJ Baselga, J AF Higgins, Michaela J. Baselga, Jose TI Novel targets and therapies for a personalized approach SO NATURE REVIEWS CLINICAL ONCOLOGY LA English DT Editorial Material ID METASTATIC BREAST-CANCER; BEVACIZUMAB AB 2010 has been another prolific year in breast cancer research with a number of original observations bringing us closer to personalized care. studies with novel targeted agents in defined breast cancer subgroups have revealed exciting developments and highlight the importance of patient selection. C1 [Higgins, Michaela J.; Baselga, Jose] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Baselga, J (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Laurence House, Boston, MA 02114 USA. EM jbaselga@partners.org NR 10 TC 13 Z9 13 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4774 J9 NAT REV CLIN ONCOL JI Nat. Rev. Clin. Oncol. PD FEB PY 2011 VL 8 IS 2 BP 65 EP 66 DI 10.1038/nrclinonc.2010.217 PG 2 WC Oncology SC Oncology GA 713GF UT WOS:000286722400001 PM 21278769 ER PT J AU Riggio, S AF Riggio, Silvana TI Psychiatry for the Neurologist Preface SO NEUROLOGIC CLINICS LA English DT Editorial Material C1 [Riggio, Silvana] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Riggio, Silvana] James J Peters VA Med Ctr, Bronx, NY USA. RP Riggio, S (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Pl,Box 1230, New York, NY 10029 USA. EM silvana.riggio@mssm.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 J9 NEUROL CLIN JI Neurol. Clin. PD FEB PY 2011 VL 29 IS 1 BP XI EP XII DI 10.1016/j.ncl.2010.11.003 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 714BA UT WOS:000286780700001 PM 21172566 ER PT J AU Riggio, S AF Riggio, Silvana TI Traumatic Brain Injury and Its Neurobehavioral Sequelae SO NEUROLOGIC CLINICS LA English DT Article DE Traumatic brain injury; Postconcussive syndrome; Neuropsychiatric disorders; Frontal lobe seizures ID POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; CHRONIC PAIN; PSYCHIATRIC-DISORDERS; SYMPTOMS; FATIGUE; ASSOCIATION; PREVALENCE; CONCUSSION; DISABILITY AB The neurobehavioral sequelae of TBI consist of a spectrum of somatic, neurologic, and psychiatric symptoms. The challenge for clinicians lies in understanding the interface of the various symptoms and how they interrelate with other entities. Specifically, the challenge is differentiating post-TBI-related symptoms from preexisting or de novo psychiatric, neurologic, and/or systemic disorders. A comprehensive evaluation and a multidisciplinary approach to evaluating patients are essential to be able to develop the differential diagnosis needed to design a management plan that maximizes recovery. C1 [Riggio, Silvana] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Riggio, Silvana] James J Peters VA Med Ctr, Bronx, NY USA. RP Riggio, S (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM silvana.riggio@mssm.edu NR 46 TC 13 Z9 14 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 J9 NEUROL CLIN JI Neurol. Clin. PD FEB PY 2011 VL 29 IS 1 BP 35 EP + DI 10.1016/j.ncl.2010.10.008 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 714BA UT WOS:000286780700004 PM 21172569 ER PT J AU Filley, CM AF Filley, Christopher M. TI White Matter: Beyond Focal Disconnection SO NEUROLOGIC CLINICS LA English DT Article DE Disconnection; Neural networks; Diffusion tensor imaging; White matter dementia; Depression; Schizophrenia ID CENTRAL-NERVOUS-SYSTEM; CHRONIC TOLUENE ABUSE; MULTIPLE-SCLEROSIS; METACHROMATIC LEUKODYSTROPHY; DISCONNEXION SYNDROMES; PSYCHIATRIC-DISORDERS; COGNITIVE DYSFUNCTION; BEHAVIORAL NEUROLOGY; HUNTINGTONS-DISEASE; BIPOLAR DISORDER AB The complex phenomenology of white matter dementia and many neuropsychiatric disorders implies that they originate from involvement of distributed neural networks, and white matter neuropathology is increasingly implicated in the pathogenesis of these network disconnection syndromes. White matter disorders produce functional asynchrony of interdependent cerebral regions subserving normal cognitive and emotional functions. Accumulating evidence suggests that white matter dementia primarily reflects disturbed frontal systems connectivity, whereas disruption of frontal and temporal lobe systems is implicated in the pathogenesis of neuropsychiatric disorders. Continued study of normal and abnormal white matter promises to help resolve challenging problems in behavioral neurology and neuropsychiatry. C1 [Filley, Christopher M.] Univ Colorado, Sch Med, Behav Neurol Sect, Aurora, CO 80045 USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Filley, CM (reprint author), Univ Colorado, Sch Med, Behav Neurol Sect, 12631 E 17th Ave,MS B185, Aurora, CO 80045 USA. EM christopher.filley@ucdenver.edu NR 103 TC 12 Z9 12 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 J9 NEUROL CLIN JI Neurol. Clin. PD FEB PY 2011 VL 29 IS 1 BP 81 EP + DI 10.1016/j.ncl.2010.10.003 PG 18 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 714BA UT WOS:000286780700007 PM 21172572 ER PT J AU Soleimani, L Lapidus, KAB Iosifescu, DV AF Soleimani, Laili Lapidus, Kyle A. B. Iosifescu, Dan V. TI Diagnosis and Treatment of Major Depressive Disorder SO NEUROLOGIC CLINICS LA English DT Article DE Major depressive disorder; Comorbid medical illness; Comorbid neurologic illness; Antidepressant treatments; Pharmacotherapies; Psychotherapies; Somatic treatments ID TREATMENT-RESISTANT-DEPRESSION; STAR-ASTERISK-D; RANDOMIZED CLINICAL-TRIAL; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; PSYCHIATRIC-DISORDERS; POSTSTROKE DEPRESSION; DOUBLE-BLIND; MOOD DISORDERS; OLDER-ADULTS AB Major depressive disorder is a common illness, particularly in patients with medical and neurologic conditions. This article summarizes current data on the epidemiology, diagnosis, and treatment of major depression, with special emphasis on the diagnosis and treatment of depression in medical and neurologic patients. We reviewed the role of pharmacotherapies, psychotherapies, somatic treatments, and alternative remedies and we included practical advice for clinician regarding the timing and sequence of these treatments, the role of standardized depression scales, and the criteria for referrals to specialty consultants. C1 [Iosifescu, Dan V.] Mt Sinai Sch Med, Mood & Anxiety Disorders Program, New York, NY 10029 USA. [Soleimani, Laili; Lapidus, Kyle A. B.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Iosifescu, Dan V.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Iosifescu, Dan V.] Harvard Univ, Sch Med, Boston, MA USA. RP Iosifescu, DV (reprint author), Mt Sinai Sch Med, Mood & Anxiety Disorders Program, New York, NY 10029 USA. EM dan.iosifescu@mssm.edu NR 87 TC 16 Z9 16 U1 9 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 J9 NEUROL CLIN JI Neurol. Clin. PD FEB PY 2011 VL 29 IS 1 BP 177 EP + DI 10.1016/j.ncl.2010.10.010 PG 18 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 714BA UT WOS:000286780700013 PM 21172578 ER PT J AU Boyce, JA Assa'a, A Burks, AW Jones, SM Sampson, HA Wood, RA Plaut, M Cooper, SE Fenton, MJ Arshad, SH Bahna, SL Beck, LA Byrd-Bredbenner, C Camargo, CA Eichenfield, L Furuta, GT Hanifin, JM Jones, C Kraft, M Levy, BD Lieberman, P Luccioli, S McCall, KM Schneider, LC Simon, RA Simons, FER Teach, SJ Yawn, BP Schwaninger, JM AF Boyce, Joshua A. Assa'a, Amal Burks, A. Wesley Jones, Stacie M. Sampson, Hugh A. Wood, Robert A. Plaut, Marshall Cooper, Susan E. Fenton, Matthew J. Arshad, S. Hasan Bahna, Sami L. Beck, Lisa A. Byrd-Bredbenner, Carol Camargo, Carlos A., Jr. Eichenfield, Lawrence Furuta, Glenn T. Hanifin, Jon M. Jones, Carol Kraft, Monica Levy, Bruce D. Lieberman, Phil Luccioli, Stefano McCall, Kathleen M. Schneider, Lynda C. Simon, Ronald A. Simons, F. Estelle R. Teach, Stephen J. Yawn, Barbara P. Schwaninger, Julie M. TI Guidelines for the diagnosis and management of food allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report SO NUTRITION LA English DT Article C1 [Plaut, Marshall; Cooper, Susan E.; Fenton, Matthew J.; Schwaninger, Julie M.] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA. [Boyce, Joshua A.] Harvard Univ, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Dept Med,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Camargo, Carlos A., Jr.] Harvard Univ, Brigham & Womens Hosp, Dept Emergency Med,Div Rheumatol Allergy & Immuno, Massachusetts Gen Hosp,Dept Med, Boston, MA 02115 USA. [Levy, Bruce D.] Brigham & Womens Hosp, Partners Asthma Ctr, Pulm & Crit Med Div, Boston, MA 02115 USA. [Assa'a, Amal] Univ Cincinnati, Div Allergy & Immunol, Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45221 USA. [Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27706 USA. [Kraft, Monica] Duke Univ, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Durham, NC 27706 USA. [Jones, Stacie M.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Div Allergy & Immunol, Dept Pediat, Little Rock, AR 72205 USA. [Sampson, Hugh A.] Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Dept Pediat, New York, NY USA. [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA. [Arshad, S. Hasan] Univ Southampton, Southampton SO9 5NH, Hants, England. [Arshad, S. Hasan] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Isle Of Wight, England. [Arshad, S. Hasan] Southampton Univ Hosp NHS Trust, Southampton SO16 6YD, Hants, England. [Bahna, Sami L.] Louisiana State Univ, Hlth Sci Ctr, Allergy & Immunol Sect, Dept Pediat, Baton Rouge, LA 70803 USA. [Beck, Lisa A.] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14642 USA. [Byrd-Bredbenner, Carol] Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08903 USA. [Eichenfield, Lawrence] Rady Childrens Hosp, Div Pediat & Adolescent Dermatol, San Diego, CA USA. [Eichenfield, Lawrence] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA. [Eichenfield, Lawrence] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Furuta, Glenn T.] Childrens Hosp Denver, Sect Pediat Gastroenterol Hepatol & Nutr, Digest Hlth Inst, Aurora, CO USA. [Furuta, Glenn T.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA. Univ Colorado, Denver Sch Med, Dept Pediat, Aurora, CO USA. Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA. Allergy & Asthma Network Mothers Asthmat, Mclean, VA USA. Univ Tennessee, Coll Med, Dept Med, Div Allergy & Immunol, Knoxville, TN 37996 USA. US FDA, Off Food Addit Safety, College Pk, MD USA. Childrens Hosp Orange Cty, Orange, CA USA. Childrens Hosp Boston, Div Immunol, Boston, MA USA. Scripps Clin, Div Allergy Asthma & Immunol, San Diego, CA USA. Univ Manitoba, Fac Med, Dept Pediat, Winnipeg, MB R3T 2N2, Canada. Univ Manitoba, Fac Med, Dept Child Hlth & Immunol, Winnipeg, MB R3T 2N2, Canada. Childrens Natl Med Ctr, Div Emergency Med, Washington, DC 20010 USA. Olmsted Med Ctr, Dept Res, Rochester, MN USA. Univ Minnesota, Sch Med, Dept Family & Community Hlth, Minneapolis, MN 55455 USA. RP Fenton, MJ (reprint author), NIAID, Div Allergy Immunol & Transplantat, NIH, 6610 Rockledge Dr,Room 6503, Bethesda, MD 20892 USA. EM fentonm@niaid.nih.gov RI Byrd-Bredbenner, Carol/F-8064-2015 OI Byrd-Bredbenner, Carol/0000-0002-8010-3987 FU NIAID; GlaxoSmithKline; Food Allergy and Anaphylaxis Network; Gerber; Mead Johnson; National Institutes of Health; Food Allergy Initiative; National Institutes of Health (Division of Receipt and Referral, National Institute of Allergy and Infectious Diseases, National Center for Complementary and Alternative Medicine); Phadia AB; Genentech; National Institutes of Health (National Institute of Allergy and Infectious Diseases); National Institute of Health Research, UK; American Academy of Allergy, Asthma, and Immunology; National Eczema Association; US Department of Agriculture; Canned Food Alliance; New Jersey Department of Health and Senior Services; Dey; Novartis; Astellas; Astellas, Ferndale; Johnson Johnson; Sinclair; Stiefel; Therapeutics Inc.; American Gastrointestinal Association; ALZA; Astellas Pharma US, Inc; Asubio Pharmaceuticals, Inc.; Centocor, Inc; Corgentech; Nucryst Pharmaceuticals; Seattle Genetics; Shionogi USA; AllerGen; Canadian Allergy, Asthma and Immunology Foundation/Anaphylaxis Canada; Canadian Institutes of Health, Research; AstraZeneca Foundation; Aventis; Child Health Center Board; CNMC Research Advisory Council; National Association of Chain Drug Stores Foundation; National Institutes of Health (National Institute of Allergy and Infectious, Diseases: National Heart, Lung, and Blood Institute); Novartis/Genentech; Robert Woods Johnson Foundation; US Centers for Disease Control and Prevention; US Public Health Service; Washington, DC, Department of Health FX NIAID-sponsored Expert Panel; A. Assa'ad holds, or is listed as an inventor on, US patent application #10/566903, entitled "Genetic markers of food allergy." She has served as a consultant for GlaxoSmithKline and as a speaker for the American College of Allergy, Asthma, and, Immunology, the North East Allergy Society, the Virginia Allergy Society, the New, England Allergy Society, and the American Academy of Pediatrics. Dr Assa'ad has, received funding/grant support from GlaxoSmithKline.; A. W. Burks holds, or is listed as an inventor on, multiple US patents related to food allergy. He owns stock in Allertein and MastCell, Inc, and is a minority stockholder in Dannon Co Probiotics. He has served as a consultant for ActoGeniX NV, McNeil Nutritionals, Mead Johnson, and Novartis. He has served on the speaker's bureau for EpiPen/Dey, LP, and has served on the data monitoring committee for Genentech. He has served on an expert panel for Nutricia. Dr Burks has received funding/grant support from the Food Allergy and Anaphylaxis Network, Gerber, Mead Johnson, and the National Institutes of Health.; H. A. Sampson holds, or is listed as an inventor on, multiple US patents related to food allergy. He owns stock in Allertein Therapeutics. He is the immediate past president of the American Academy of Allergy, Asthma, and Immunology. He has served as a consultant for Allertein Therapeutics, the American Academy of Allergy, Asthma, and Immunology, the Food Allergy Initiative, and Schering Plough. He has received, funding/grant support for research projects from the Food Allergy Initiative, the National Institutes of Health (Division of Receipt and Referral, National Institute of Allergy and Infectious Diseases, National Center for Complementary and Alternative Medicine), and Phadia AB. He is a co-owner of Herbal Spring, LLC.; R. A. Wood has served as a speaker/advisory board member for GlaxoSmithKline, Merck, and Dey. He has received funding/grant support from Genentech and the, National Institutes of Health (National Institute of Allergy and Infectious Diseases).; S. H. Arshad has received funding/grant support from the National Institutes of Health and the National Institute of Health Research, UK.; L. A. Beck has received funding/grant support from the American Academy of Allergy, Asthma, and Immunology, the National Eczema Association, and the National Institutes of Health.; C. Byrd-Bredbenner owns stock in Johnson & Johnson. She has received funding/grant support from the US Department of Agriculture, the Canned Food Alliance, and the New Jersey Department of Health and Senior Services.; C. A. Camargo Jr has consulted for Dey and Novartis. He has received funding/grant support from a variety of government agencies and not-for-profit research foundations, as well as Dey and Novartis.; L. Eichenfield has received funding/grant support from a variety of not-for-profit foundations, as well as Astellas, Ferndale, Johnson & Johnson, Novartis, Sinclair, Stiefel, and Therapeutics Inc.; G. T. Furuta has served as a consultant and/or speaker to Caption Therapeutics and TAP. He has received funding/grant support from the American Gastrointestinal Association and the National Institutes of Health.; J. M. Hanifin has served as served as a consultant for ALZA, Anesiva, Inc, Barrier Therapeutics, Inc, Milliken & Company, Nordic Biotech, Novartis Pharmaceuticals Corporation, Shionogi USA, Taisho Pharmaceutical R&D, Inc, Teikoku Pharma USA, Inc, UCB, York Pharma, ZARS, Inc, and ZymoGenetics. He has served as an investigator or received research funding from ALZA, Astellas Pharma US, Inc, Asubio Pharmaceuticals, Inc. Centocor, Inc, Corgentech, Novartis, Nucryst Pharmaceuticals, Seattle Genetics, and Shionogi USA.; F. E. R. Simons holds a patent on "Fast-disintegrating epinephrine tablets for sublingual administration." She is a past-president of the American Academy of Allergy, Asthma and Immunology and of the Canadian Society of Allergy and Clinical Immunology. She is a member of the advisory boards of Dey, Intelliject, and ALK-Abello. She has received funding/grant support from AllerGen, the Canadian Allergy, Asthma and Immunology Foundation/Anaphylaxis Canada, and the Canadian Institutes of Health, Research.; S.J. Teach has served as a speaker for AstraZeneca. He has received funding/grant support from the AstraZeneca Foundation, Aventis, the Child Health Center Board, the CNMC Research Advisory Council, the National Association of Chain Drug Stores Foundation, the National Institutes of Health (National Institute of Allergy and Infectious, Diseases: National Heart, Lung, and Blood Institute), Novartis/Genentech, the Robert Woods Johnson Foundation, the US Centers for Disease Control and Prevention, the US Public Health Service, and the Washington, DC, Department of Health. NR 0 TC 18 Z9 18 U1 1 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-9007 EI 1873-1244 J9 NUTRITION JI Nutrition PD FEB PY 2011 VL 27 IS 2 BP 253 EP 267 DI 10.1016/j.nut.2010.12.001 PG 15 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 710UL UT WOS:000286542400022 PM 21215925 ER PT J AU Flaherty, KT AF Flaherty, Keith T. TI Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress SO PIGMENT CELL & MELANOMA RESEARCH LA English DT Editorial Material ID METASTATIC MELANOMA; ACTIVATED BRAF; INHIBITION; CELLS; SENESCENCE; MUTATIONS; ONCOGENE; NEVI; MICE C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Flaherty, KT (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. EM ktflaherty@aol.com NR 23 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1755-1471 EI 1755-148X J9 PIGM CELL MELANOMA R JI Pigment Cell Melanoma Res. PD FEB PY 2011 VL 24 IS 1 BP 107 EP 109 DI 10.1111/j.1755-148X.2010.00816.x PG 3 WC Oncology; Cell Biology; Dermatology SC Oncology; Cell Biology; Dermatology GA 706IA UT WOS:000286210400018 PM 21232025 ER PT J AU Guidi, J Fava, GA Fava, M Papakostas, GI AF Guidi, J. Fava, G. A. Fava, M. Papakostas, G. I. TI Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Major depressive disorder; meta-analysis; psychotherapy; recurrence; sequential treatment ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; TERM ANTIDEPRESSANT TREATMENT; WELL-BEING THERAPY; RECURRENT DEPRESSION; RESIDUAL SYMPTOMS; RELAPSE PREVENTION; INTERPERSONAL PSYCHOTHERAPY; MAINTENANCE TREATMENT; FOLLOW-UP AB Background. Prevention of relapse and recurrence represents an important task in the successful treatment of major depressive disorder (MDD). The aim of this meta-analysis was to examine the efficacy of the sequential integration of psychotherapy and pharmacotherapy in reducing the risk of relapse and recurrence in MDD. Method. Keyword searches were conducted in Medline, EMBASE, PsycINFO and the Cochrane Library from inception of each database to December 2008. Randomized controlled trials examining the efficacy of the administration of psychotherapy after successful response to acute-phase pharmacotherapy in the treatment of adults with MDD were considered for inclusion in the meta-analysis. Results. Eight high-quality studies with 442 patients in a sequential treatment arm and 433 in a control treatment arm were included. The pooled risk ratio (RR) for relapse/recurrence was 0.797 [95% confidence interval (CI) 0.659-0.964] according to the random-effects model, suggesting a relative advantage in preventing relapse/recurrence for the sequential administration of treatments compared with control conditions. Performing subgroup analyses, we found a trend favoring psychotherapy during continuation of antidepressant drugs compared to antidepressants or treatment as usual (RR 0.842, 95% CI 0.674-1.051). Patients randomized to psychotherapy while antidepressants were discontinued were significantly less likely to experience relapse/recurrence compared to controls (RR 0.650, 95% CI 0.463-0.912). Conclusions. We found evidence that the sequential integration of psychotherapy and pharmacotherapy is a viable strategy for preventing relapse and recurrence in MDD. In addition, our findings suggest that discontinuation of antidepressant drugs may be feasible when psychotherapy is provided. C1 [Guidi, J.; Fava, G. A.] Univ Bologna, Dept Psychol, Affect Disorders Program, I-40127 Bologna, Italy. [Fava, G. A.] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14260 USA. [Fava, M.; Papakostas, G. I.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Fava, M.; Papakostas, G. I.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Guidi, J (reprint author), Univ Bologna, Dept Psychol, Affect Disorders Program, Viale Berti Pichat 5, I-40127 Bologna, Italy. EM jenny.guidi2@unibo.it RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU Abbott Laboratories; Alkermes; Aspect Medical Systems; AstraZeneca; Bio Research; BrainCells Inc.; Bristol-Myers Squibb Company; Cephalon; Clinical Trial Solutions; Eli Lilly Company; Forest Pharmaceuticals Inc.; Ganeden; GlaxoSmithKline; J & J Pharmaceuticals; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; NARSAD; NCCAM; NIDA; NIMH; Novartis; Organon Inc.; PamLab, LLC; Pfizer Inc.; Pharmavite; Roche; Sanofi-Aventis; Shire; Solvay Pharmaceuticals Inc.; Synthelabo; Wyeth-Ayerst Laboratories; Forest Pharmaceuticals; National Institute of Mental Health; PAMLAB LLC; Precision Human Biolaboratories FX M. Fava has received research support from Abbott Laboratories, Alkermes, Aspect Medical Systems, AstraZeneca, Bio Research, BrainCells Inc., Bristol-Myers Squibb Company, Cephalon, Clinical Trial Solutions, Eli Lilly & Company, Forest Pharmaceuticals Inc., Ganeden, GlaxoSmithKline, J & J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, NARSAD, NCCAM, NIDA, NIMH, Novartis, Organon Inc., PamLab, LLC, Pfizer Inc., Pharmavite, Roche, Sanofi-Aventis, Shire, Solvay Pharmaceuticals Inc., Synthelabo, and Wyeth-Ayerst Laboratories; has served on advisory boards for and has been a consultant to Abbott Laboratories, Amarin, Aspect Medical Systems, Astra-Zeneca, Auspex Pharmaceuticals, Bayer AG, Best Practice Project Management Inc., Biovail Pharmaceuticals Inc., BrainCells Inc., Bristol-Myers Squibb Company, Cephalon, Clinical Trials Solutions, CNS Response, Compellis, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eli Lilly & Company, EPIX Pharmaceuticals, Fabre-Kramer Pharmaceuticals Inc., Forest Pharmaceuticals Inc., GlaxoSmithKline, Grunenthal GmBH, Janssen Pharmaceuticals, Jazz Pharmaceuticals, J & J Pharmaceuticals, Knoll Pharmaceutical Company, Labopharm, Lorex Pharmaceuticals, Lundbeck, MedAvante Inc., Merck, Methylation Sciences, Neuronetics, Novartis, Nutrition 21, Organon Inc., PamLab LLC, Pfizer Inc., PharmaStar, Pharmavite, Precision Human Biolaboratory, Roche, SanofiAventis, Sepracor, Schering-Plough, Solvay Pharmaceuticals Inc., Somaxon, Somerset Pharmaceuticals, Synthelabo, Takeda, Tetragenex, Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc., and WyethAyerst Laboratories; has served on speakers' boards for Advanced Meeting Partners, American Psychiatric Association, AstraZeneca, Belvoir, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Cephalon, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, Imedex, Novartis, Organon Inc., Pfizer Inc., PharmaStar, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed-Elsevier, UBC, Wyeth-Ayerst Laboratories; has equity holdings in Compellis; has patent applications for SPCD and for a combination of azapirones and bupropion in MDD; and receives copyright royalties for the MGH Cognitive and Physical Functioning Questionnaire, Sexual Functioning Inventory, Antidepressant Treatment Response Questionnaire, Discontinuation-Emergent Signs and Symptoms, and SAFER. G. I. Papakostas has served as a consultant for AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly & Company, GlaxoSmithKline, Evotec AG, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer Inc., Pierre Fabre Laboratories, Shire Pharmaceuticals, and Wyeth Inc.; has received honoraria from AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly & Company, Evotec AG, GlaxoSmithKline, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, Lundbeck, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer, Pierre Fabre Laboratories, Shire Pharmaceuticals, Titan Pharmaceuticals, and Wyeth Inc.; has received research support from Bristol-Myers Squibb Company, Forest Pharmaceuticals, the National Institute of Mental Health, PAMLAB LLC, Pfizer Inc., and Precision Human Biolaboratories; and has served on the speakers' bureau for Bristol-Myers Squibb Company, and Pfizer Inc. NR 75 TC 40 Z9 40 U1 2 U2 11 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD FEB PY 2011 VL 41 IS 2 BP 321 EP 331 DI 10.1017/S0033291710000826 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 704SO UT WOS:000286072900009 PM 20444307 ER PT J AU Bradley, WG Golding, SG Herold, CJ Hricak, H Krestin, GP Lewin, JS Miller, JC Ringertz, HG Thrall, JH AF Bradley, William G. Golding, Stephen G. Herold, Christian J. Hricak, Hedvig Krestin, Gabriel P. Lewin, Jonathan S. Miller, Janet C. Ringertz, Hans G. Thrall, James H. TI Globalization of P4 Medicine: Predictive, Personalized, Preemptive, and Participatory-Summary of the Proceedings of the Eighth International Symposium of the International Society for Strategic Studies in Radiology, August 27-29, 2009 SO RADIOLOGY LA English DT Article ID ATHEROSCLEROTIC CAROTID PLAQUE; POSITRON-EMISSION-TOMOGRAPHY; COMPUTED-TOMOGRAPHY; PROSTATE-CANCER; CT COLONOGRAPHY; HIGH-RESOLUTION; LUNG-CANCER; QUANTITATIVE-EVALUATION; FOCUSED ULTRASOUND; RADIATION-WORKERS AB In August 2009, the International Society for Strategic Studies in Radiology held its eighth biennial meeting. The program focused on the globalization of predictive medicine-or P4 medicine-as it relates to the practice of radiology and radiology research. P4 medicine refers to predictive, personalized, preemptive, and participatory medicine and was the inspiration of Elias Zerhouni, MD, former director of the National Institutes of Health. This article is a summary of some of the key concepts presented at the meeting by an international group of radiologists, imaging scientists, and leaders of industry. In predictive medicine, imaging and imaging-related technologies will likely play an increasing role in the early detection of disease and, thus, the preemption of the development of advanced, hard-to-treat disease. Research into systems biology and molecular imaging promises to personalize medicine, facilitating the provision of the right care to the right patient at the right time. In participatory medicine, increasing interactions with referring physicians and patients will be helpful in raising awareness and recognition of the role of radiologists and will have a positive effect on professionalism. There is also a need to increase awareness of the vital role of radiologists as imaging and radiation safety experts who evaluate the necessity and appropriateness of examinations, monitor performance quality, and are available for postexamination consultations. (c) RSNA, 2011 C1 [Bradley, William G.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. [Golding, Stephen G.] Univ Oxford, Dept Radiol, Oxford MRI Ctr, Oxford, England. [Herold, Christian J.] Med Univ Vienna, Dept Radiol, Vienna, Austria. [Hricak, Hedvig] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA. [Krestin, Gabriel P.] Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol, Rotterdam, Netherlands. [Lewin, Jonathan S.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA. [Miller, Janet C.; Thrall, James H.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Ringertz, Hans G.] Linkoping Univ Hosp, Dept Radiol, S-58185 Linkoping, Sweden. RP Bradley, WG (reprint author), Univ Calif San Diego, Dept Radiol, 200 W Arbor Dr, San Diego, CA 92103 USA. EM wgbradley@ucsd.edu NR 84 TC 4 Z9 4 U1 0 U2 2 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD FEB PY 2011 VL 258 IS 2 BP 571 EP 582 DI 10.1148/radiol.10100568 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 712GH UT WOS:000286653700028 PM 21273521 ER PT J AU Snyder, CW Vandromme, MJ Tyra, SL Porterfield, JR Clements, RH Hawn, MT AF Snyder, Christopher W. Vandromme, Marianne J. Tyra, Sharon L. Porterfield, John R., Jr. Clements, Ronald H. Hawn, Mary T. TI Effects of Virtual Reality Simulator Training Method and Observational Learning on Surgical Performance SO WORLD JOURNAL OF SURGERY LA English DT Article ID OPERATING-ROOM; SKILLS; SURGERY; INSTRUCTION; PRINCIPLES; EDUCATION; PARADIGM; FEEDBACK; FUTURE; EXPERT AB Virtual reality (VR) simulators and Web-based instructional videos are valuable supplemental training resources in surgical programs, but it is unclear how to optimally integrate them into minimally invasive surgical training. Medical students were randomized to proficiency-based training on VR laparoscopy and endoscopy simulators by two different methods: proctored training (automated simulator feedback plus human expert feedback) or independent training (simulator feedback alone). After achieving simulator proficiency, trainees performed a series of laparoscopic and endoscopic tasks in a live porcine model. Prior to their entry into the animal lab, all trainees watched an instructional video of the procedure and were randomly assigned to either observe or not observe the actual procedure before performing it themselves. The joint effects of VR training method and procedure observation on time to successful task completion were evaluated with Cox regression models. Thirty-two students (16 proctored, 16 independent) completed VR training. Cox regression modeling with adjustment for relevant covariates demonstrated no significant difference in the likelihood of successful task completion for independent versus proctored training [Hazard Ratio (HR) 1.28; 95% Confidence Interval (CI) 0.96-1.72; p = 0.09]. Trainees who observed the actual procedure were more likely to be successful than those who watched the instructional video alone (HR 1.47; 95% CI 1.09-1.98; p = 0.01). Proctored VR training is no more effective than independent training with respect to surgical performance. Therefore, time-consuming human expert feedback during VR training may be unnecessary. Instructional videos, while useful, may not be adequate substitutes for actual observation when trainees are learning minimally invasive surgical procedures. C1 [Tyra, Sharon L.; Porterfield, John R., Jr.; Clements, Ronald H.; Hawn, Mary T.] Univ Alabama Birmingham, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA. [Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. RP Hawn, MT (reprint author), Univ Alabama Birmingham, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA. EM mhawn@uab.edu FU Olympus America Inc. FX The authors acknowledge Joshua L. Argo and Wai M. A. Yeung for their assistance with data acquisition. They are also grateful to Olympus of America and Covidien for equipment donation and technical assistance. The study received no external funding, although Christopher W. Snyder received salary support under an educational grant from Olympus America Inc. NR 32 TC 18 Z9 19 U1 3 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD FEB PY 2011 VL 35 IS 2 BP 245 EP 252 DI 10.1007/s00268-010-0861-1 PG 8 WC Surgery SC Surgery GA 703RG UT WOS:000285998400001 PM 21086125 ER PT J AU Obstein, KL Patil, VD Jayender, J Estepar, RSJ Spofford, IS Lengyel, BI Vosburgh, KG Thompson, CC AF Obstein, Keith L. Patil, Vaibhav D. Jayender, Jagadeesan Estepar, Raul San Jose Spofford, Inbar S. Lengyel, Balazs I. Vosburgh, Kirby G. Thompson, Christopher C. TI Evaluation of colonoscopy technical skill levels by use of an objective kinematic-based system SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID LAPAROSCOPIC SURGERY; SIMULATION; FEASIBILITY; VALIDATION AB Background: Colonoscopy requires training and experience to ensure accuracy and safety. Currently, no objective, validated process exists to determine when an endoscopist has attained technical competence. Kinematics data describing movements of laparoscopic instruments have been used in surgical skill assessment to define expert surgical technique. We have developed a novel system to record kinematics data during colonoscopy and quantitatively assess colonoscopist performance. Objective: To use kinematic analysis of colonoscopy to quantitatively assess endoscopic technical performance. Design: Prospective cohort study. Setting: Tertiary-care academic medical center. Population: This study involved physicians who perform colonoscopy. Intervention: Application of a kinematics data collection system to colonoscopy evaluation. Main Outcome Measurements: Kinematics data, validated task load assessment instrument, and technical difficulty visual analog scale. Results: All 13 participants completed the colonoscopy to the terminal ileum on the standard colon model. Attending physicians reached the terminal ileum quicker than fellows (median time, 150.19 seconds vs 299.86 seconds; p< .01) with reduced path lengths for all 4 sensors, decreased flex (1.75 m vs 3.14 m; P = .03), smaller tip angulation, reduced absolute roll, and lower curvature of the endoscope. With performance of attending physicians serving as the expert reference standard, the mean kinematic score increased by 19.89 for each decrease in postgraduate year (P < .01.). Overall, fellows experienced greater mental, physical, and temporal demand than did attending physicians. Limitation: Small cohort size. Conclusion: Kinematic data and score calculation appear useful in the evaluation of colonoscopy technical skill levels. The kinematic score appears to consistently vary by year of training. Because this assessment is nonsubjective, it may be an improvement over current methods for determination of competence. Ongoing studies are establishing benchmarks and characteristic profiles of skill groups based on kinematics data. (Gastrointest Endosc 2011;73:315-21.) C1 [Obstein, Keith L.; Thompson, Christopher C.] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA. [Patil, Vaibhav D.; Jayender, Jagadeesan; Estepar, Raul San Jose; Lengyel, Balazs I.; Vosburgh, Kirby G.] Massachusetts Gen Hosp, Innovat Technol Image Guidance Lab, Boston, MA 02114 USA. [Patil, Vaibhav D.; Jayender, Jagadeesan; Estepar, Raul San Jose; Lengyel, Balazs I.; Vosburgh, Kirby G.] Massachusetts Gen Hosp, Ctr Integrat Med, Boston, MA 02114 USA. [Estepar, Raul San Jose; Lengyel, Balazs I.; Vosburgh, Kirby G.] Brigham & Womens Hosp, Surg Planning Lab, Boston, MA 02115 USA. [Spofford, Inbar S.] Massachusetts Gen Hosp, Div Pediat Gastroenterol, Boston, MA 02114 USA. RP Thompson, CC (reprint author), Brigham & Womens Hosp, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA. FU Center for Integration of Medicine and Innovative Technology; National Center for Image Guided Therapy [U41 RR019703, W81XWH-07-2-011] FX Grant support was received from the Center for Integration of Medicine and Innovative Technology and the National Center for Image Guided Therapy under award U41 RR019703 (K.G.V) and Cooperative Agreement W81XWH-07-2-011 (C.C.T). Olympus Inc provided equipment support (C.C.T.). No other financial relationships relevant to this publication were disclosed. NR 14 TC 22 Z9 22 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD FEB PY 2011 VL 73 IS 2 BP 315 EP 321 DI 10.1016/j.gie.2010.09.005 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 716VP UT WOS:000287001900018 PM 21111413 ER PT J AU Lai, JS Zelko, F Butt, Z Cella, D Kieran, MW Krull, KR Magasi, S Goldman, S AF Lai, Jin-Shei Zelko, Frank Butt, Zeeshan Cella, David Kieran, Mark W. Krull, Kevin R. Magasi, Susan Goldman, Stewart TI Parent-perceived child cognitive function: results from a sample drawn from the US general population SO CHILDS NERVOUS SYSTEM LA English DT Article DE Perceived cognitive function; Children; Brain tumor; Neuro-oncology; Item bank ID EVERYDAY MEMORY; SELF-REPORT; ECOLOGICAL VALIDITY; PERFORMANCE; CANCER; COMPLAINTS; SURVIVORS; EPILEPSY; OUTCOMES; RATINGS AB This paper reports the development and evaluation of a perceived cognitive function (pedsPCF) item bank reported by parents of the pediatric US general population. Based on feedback from clinicians, parents, and children, we developed a scale sampling concerns related to children's cognitive functioning. We administered the scale to 1,409 parents of children aged 7-17 years; of them, 319 had a neurological diagnosis. Dimensionality of the pedsPCF was evaluated via factor analyses and its clinical utility studied by comparing parent ratings in patient groups and symptom cluster defined by the Child Behavior Checklist (CBCL). Forty-four of 45 items met criteria for unidimensionality. The pedsPCF significantly differentiated samples defined by medication use, repeated grades, special education status, neurologic diagnosis, and relevant symptom clusters with large effect sizes (> 0.8). It can predicted children symptoms with the correction rates ranging 79-89%. We have provided empirical support for the unidimensionality of the pedsPCF item bank and evidence for its potential clinical utility. The pedsPCF is a promising measurement tool to screen children for further comprehensive cognitive tests. C1 [Lai, Jin-Shei; Butt, Zeeshan; Cella, David; Magasi, Susan] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA. [Zelko, Frank; Goldman, Stewart] Childrens Mem Hosp, Chicago, IL 60614 USA. [Butt, Zeeshan] Northwestern Univ, Comprehens Transplant Ctr, Chicago, IL 60611 USA. [Kieran, Mark W.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Kieran, Mark W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Krull, Kevin R.] St Jude Childrens Hosp, Memphis, TN 38105 USA. RP Lai, JS (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, 710 N Lake Shore Dr,724, Chicago, IL 60611 USA. EM js-lai@northwestern.edu OI Kieran, Mark/0000-0003-2184-7692 FU National Cancer Institute [R01CA125671]; National Center for Research Resources, National Institutes of Health [KL2RR0254740] FX This project is supported by the National Cancer Institute (Grant number: R01CA125671; PI: Jin-Shei Lai). Dr. Butt's time is supported in part by grant KL2RR0254740 from the National Center for Research Resources, National Institutes of Health. NR 36 TC 5 Z9 5 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0256-7040 J9 CHILD NERV SYST JI Childs Nerv. Syst. PD FEB PY 2011 VL 27 IS 2 BP 285 EP 293 DI 10.1007/s00381-010-1230-y PG 9 WC Clinical Neurology; Pediatrics; Surgery SC Neurosciences & Neurology; Pediatrics; Surgery GA 707XL UT WOS:000286324500015 PM 20652814 ER PT J AU Horberg, MA Aberg, JA Cheever, LW Renner, P Kaleba, EO Asch, SM AF Horberg, Michael A. Aberg, Judith A. Cheever, Laura W. Renner, Philip Kaleba, Erin O'Brien Asch, Steven M. TI Development of National and Multiagency HIV Care Quality Measures Response SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Horberg, Michael A.] Kaiser Permanente, HIV Interreg Initiat, Oakland, CA 94612 USA. [Aberg, Judith A.] NYU, Sch Med, Dept Med, New York, NY USA. [Cheever, Laura W.] HIV AIDS Bur, Hlth Resources & Serv Adm, Rockville, MD USA. [Renner, Philip] Natl Comm Qual Assurance, Washington, DC USA. [Kaleba, Erin O'Brien] Alliance Chicago Community Hlth Serv, Chicago, IL USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, RAND Corp, Los Angeles, CA 90095 USA. RP Horberg, MA (reprint author), Kaiser Permanente, HIV Interreg Initiat, 2000 Broadway, Oakland, CA 94612 USA. EM michael.horberg@kp.org NR 2 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB PY 2011 VL 52 IS 4 DI 10.1093/cid/ciq181 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 712PD UT WOS:000286677800024 ER PT J AU Dhanani, NM Caruso, TJ Carinci, AJ AF Dhanani, Nadya M. Caruso, Thomas J. Carinci, Adam J. TI Complementary and Alternative Medicine for Pain: An Evidence-based Review SO CURRENT PAIN AND HEADACHE REPORTS LA English DT Review DE Complementary medicine; Alternative medicine; Holistic; Mind-Body; Pain; Pain treatment; Acupuncture; Herbal therapy; Hypnosis; Tai chi; Massage therapy; Biofeedback; Evidence ID LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; WILLOW BARK EXTRACT; TAI CHI; KNEE OSTEOARTHRITIS; HUMAN BRAIN; ACUPUNCTURE; ELECTROACUPUNCTURE; FIBROMYALGIA; CARE AB Pain is one of the most prevalent conditions for which patients seek medical attention. Additionally, the number of patients who utilize complementary and alternative medicine as a treatment of pain either in lieu of, or concurrent with, standard conventional treatments continues to grow. While research into the mechanisms, side effect profiles, and efficacies of these alternative therapies has increased in recent years, much more remains unknown and untested. Herein, we review the literature on complementary and alternative medicine for pain, with particular emphasis on evidence-based assessments pertinent to the most common alternative therapies, including acupuncture, herbal therapy, massage therapy, hypnosis, tai chi, and biofeedback. C1 [Dhanani, Nadya M.; Caruso, Thomas J.; Carinci, Adam J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP Carinci, AJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, 15 Parkman St, Boston, MA 02114 USA. EM acarinci@partners.org NR 53 TC 9 Z9 9 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1531-3433 EI 1534-3081 J9 CURR PAIN HEADACHE R JI Curr. Pain Headache Rep. PD FEB PY 2011 VL 15 IS 1 BP 39 EP 46 DI 10.1007/s11916-010-0158-y PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 706PN UT WOS:000286230400007 PM 21063917 ER PT J AU Styer, AK Toth, TL AF Styer, Aaron K. Toth, Thomas L. TI Antral follicle count in clinical practice: building the bridge from ovarian reserve to in vitro fertilization outcome SO FERTILITY AND STERILITY LA English DT Article DE Antral follicle count; AFC; IVF; ovarian response; pregnancy; IVF cancellation rate; miscarriage; low responder ID STIMULATION RESPONSE; PREDICTION; HORMONE; BASAL; ULTRASONOGRAPHY; METAANALYSIS; PREGNANCY; PROGRAM AB Antral follicle count provides a useful assessment of ovarian reserve to predict ovarian response, estimate risk for cycle cancellation, optimize stimulation protocol selection, and confidently select suitable candidates for IVF. (Fertil Steril (R) 2011;95:480-1. (C)2011 by American Society for Reproductive Medicine.) C1 [Styer, Aaron K.; Toth, Thomas L.] Massachusetts Gen Hosp, Fertil Ctr, Boston, MA 02114 USA. RP Toth, TL (reprint author), Massachusetts Gen Hosp, Fertil Ctr, Boston, MA 02114 USA. EM tltoth@partners.org NR 15 TC 3 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD FEB PY 2011 VL 95 IS 2 BP 480 EP 481 DI 10.1016/j.fertnstert.2010.11.054 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 709EA UT WOS:000286419000009 PM 21183169 ER PT J AU Lee, BY McGlone, SM Bailey, RR Wettstein, ZS Umscheid, CA Muder, RR AF Lee, Bruce Y. McGlone, Sarah M. Bailey, Rachel R. Wettstein, Zachary S. Umscheid, Craig A. Muder, Robert R. TI Economic Impact of Outbreaks of Norovirus Infection in Hospitals SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material ID NORWALK VIRUS; GASTROENTERITIS; VOLUNTEERS C1 [Lee, Bruce Y.] Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, Pittsburgh, PA 15213 USA. [Lee, Bruce Y.; McGlone, Sarah M.; Bailey, Rachel R.; Wettstein, Zachary S.] Univ Pittsburgh, Sch Med, Publ Hlth Computat & Operat Res, Pittsburgh, PA USA. [Lee, Bruce Y.; McGlone, Sarah M.; Bailey, Rachel R.; Wettstein, Zachary S.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA USA. [Lee, Bruce Y.; McGlone, Sarah M.; Bailey, Rachel R.; Wettstein, Zachary S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Umscheid, Craig A.] Univ Penn, Ctr Evidence Based Practice, Philadelphia, PA 19104 USA. [Muder, Robert R.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Lee, BY (reprint author), Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM BYL1@pitt.edu OI Slayton, Rachel/0000-0003-4699-8040 FU NIGMS NIH HHS [U54 GM088491, 1U54GM088491-0109]; NLM NIH HHS [R01 LM009132, 5R01LM009132-02] NR 10 TC 14 Z9 14 U1 0 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD FEB PY 2011 VL 32 IS 2 BP 191 EP 193 DI 10.1086/657910 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 709QT UT WOS:000286457200016 PM 21460478 ER PT J AU Bhatia, V Dean, P Iqbal, F Mundkur, M Heo, J Iskandrian, AE Hage, FG AF Bhatia, V Dean, P. Iqbal, F. Mundkur, M. Heo, J. Iskandrian, A. E. Hage, F. G. TI A BLUNTED HEART RATE RESPONSE TO ADENOSINE IS AN INDEPENDENT PROGNOSTIC INDICATOR IN PATIENTS WITH DIABETES MELLITUS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting CY FEB 17-19, 2011 CL New Orleans, LA C1 [Bhatia, V; Dean, P.; Iqbal, F.; Mundkur, M.; Heo, J.; Iskandrian, A. E.; Hage, F. G.] Univ Alabama, Birmingham, AL USA. [Hage, F. G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 117 BP 405 EP 405 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500128 ER PT J AU Bains, SS Egede, LE AF Bains, S. S. Egede, L. E. TI ASSOCIATION OF HEALTH LITERACY WITH CAM USE IN ADULT PRIMARY CARE PATIENTS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting CY FEB 17-19, 2011 CL New Orleans, LA C1 [Bains, S. S.; Egede, L. E.] Med Univ S Carolina, Charleston, SC 29425 USA. [Bains, S. S.; Egede, L. E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 171 BP 420 EP 420 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500182 ER PT J AU Katz, L Choueiri, T Bellmunt, J AF Katz, L. Choueiri, T. Bellmunt, J. TI C-11 METHIONINE PET-CT IN EVALUATING METASTATIC TRANSITIONAL CELL CARCINOMA RESPONSE TO SUNITINIB THERAPY SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting CY FEB 17-19, 2011 CL New Orleans, LA C1 [Katz, L.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Choueiri, T.; Bellmunt, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 198 BP 428 EP 428 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500209 ER PT J AU Dean, PJ Bhatia, V Iqbal, F McLarry, J Heo, J Iskandrian, AE Hage, FG AF Dean, P. J. Bhatia, V Iqbal, F. McLarry, J. Heo, J. Iskandrian, A. E. Hage, F. G. TI A BLUNTED HEART RATE RESPONSE TO ADENOSINE IS AN INDEPENDENT PREDICTOR OF MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting CY FEB 17-19, 2011 CL New Orleans, LA C1 [Dean, P. J.; Bhatia, V; Iqbal, F.; McLarry, J.; Heo, J.; Iskandrian, A. E.; Hage, F. G.] Univ Alabama, Birmingham, AL USA. [Hage, F. G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 358 BP 472 EP 472 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500368 ER PT J AU Hage, FG Pierce, C Zhang, W Xing, D Chen, Y McCrory, MA Oparil, S Szalai, AJ AF Hage, F. G. Pierce, C. Zhang, W. Xing, D. Chen, Y. McCrory, M. A. Oparil, S. Szalai, A. J. TI ALISKIREN INHIBITS THE VASCULAR INJURY RESPONSE ATTRIBUTABLE TO C-REACTIVE PROTEIN SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting CY FEB 17-19, 2011 CL New Orleans, LA C1 [Hage, F. G.; Pierce, C.; Zhang, W.; Xing, D.; Chen, Y.; McCrory, M. A.; Oparil, S.; Szalai, A. J.] Univ Alabama, Birmingham, AL USA. [Hage, F. G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 385 BP 480 EP 480 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500395 ER PT J AU Kertesz, S Steward, J Johnson, K Borden, A Young, J Stringfellow, E Holt, C Pollio, D AF Kertesz, S. Steward, J. Johnson, K. Borden, A. Young, J. Stringfellow, E. Holt, C. Pollio, D. TI CROSSING THE PRIMARY CARE QUALITY CHASM FOR HOMELESS PATIENTS: UNDERSTANDING THE PERSPECTIVES OF PATIENTS AND THEIR PROVIDERS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting CY FEB 17-19, 2011 CL New Orleans, LA C1 [Kertesz, S.; Steward, J.; Johnson, K.; Borden, A.; Young, J.] Birmingham VA Med Ctr, Birmingham, AL USA. [Stringfellow, E.] Boston Hlth Care, Homeless Program, Boston, MA USA. [Pollio, D.] Univ Alabama, Tuscaloosa, AL USA. [Holt, C.] Univ Maryland, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 575 BP 534 EP 534 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500584 ER PT J AU Huff, NG Castiglioni, A Snyder, E Estrada, C Kim, Y Kertesz, S Schumacher, J AF Huff, N. G. Castiglioni, A. Snyder, E. Estrada, C. Kim, Y. Kertesz, S. Schumacher, J. TI PRESCRIBING OPIATES FOR CHRONIC PAIN - EXPERIENCE MAY NOT ASSURE ADEQUATE KNOWLEDGE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting CY FEB 17-19, 2011 CL New Orleans, LA C1 [Huff, N. G.; Castiglioni, A.; Snyder, E.; Estrada, C.; Kim, Y.; Kertesz, S.; Schumacher, J.] Univ Alabama, Birmingham, AL USA. [Castiglioni, A.; Snyder, E.; Estrada, C.; Kertesz, S.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 587 BP 537 EP 538 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500596 ER PT J AU Huff, NG Roy, B Estrada, C Castiglioni, A Centor, R Willett, L Cohen, S AF Huff, N. G. Roy, B. Estrada, C. Castiglioni, A. Centor, R. Willett, L. Cohen, S. TI NOMINAL GROUP TECHNIQUE TO IDENTIFY ATTRIBUTES OF TOP ATTENDING PHYSICIANS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting CY FEB 17-19, 2011 CL New Orleans, LA C1 [Huff, N. G.; Roy, B.; Estrada, C.; Castiglioni, A.; Centor, R.; Willett, L.; Cohen, S.] Univ Alabama, Birmingham, AL USA. [Estrada, C.; Castiglioni, A.; Centor, R.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 586 BP 537 EP 537 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500595 ER PT J AU Tarbox, LE Wagner, B AF Tarbox, L. E. Wagner, B. TI EFFECTS OF GADOLINIUM-BASED MRI CONTRAST ON ORGAN FIBROSIS IN PARTIALLY NEPHRECTOMIZED RATS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting CY FEB 17-19, 2011 CL New Orleans, LA C1 [Tarbox, L. E.; Wagner, B.] UTHSCSA, San Antonio, TX USA. [Wagner, B.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 599 BP 541 EP 541 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500608 ER PT J AU Little, BP Fintelmann, FJ Mino-Kenudson, M Lanuti, M Shepard, JAO Digumarthy, SR AF Little, Brent P. Fintelmann, Florian J. Mino-Kenudson, Mari Lanuti, Michael Shepard, Jo-Anne O. Digumarthy, Subba R. TI Intrathoracic Hibernoma A Case With Multimodality Imaging Correlation SO JOURNAL OF THORACIC IMAGING LA English DT Article DE hibernoma; fatty tumor; thoracic tumor AB Hibernomas are rare heterogeneous fatty tumors arising from brown fat precursors. Intrathoracic hibernomas are extremely rare. We detail a case of pathologically proven intrathoracic hibernoma in a 67-year-old woman. Chest radiography, computed tomography, fluorodeoxyglucose positron emission tomography, and angiography are presented. A short review of the literature and discussion of imaging and histologic diagnosis of hibernomas are provided. C1 [Little, Brent P.; Fintelmann, Florian J.; Shepard, Jo-Anne O.; Digumarthy, Subba R.] Massachusetts Gen Hosp, Dept Radiol, Div Thorac Radiol, Boston, MA 02114 USA. [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Lanuti, Michael] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Little, BP (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Thorac Radiol, 55 Fruit St, Boston, MA 02114 USA. EM blittle@partners.org NR 10 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0883-5993 J9 J THORAC IMAG JI J. Thorac. Imaging PD FEB PY 2011 VL 26 IS 1 BP W20 EP W22 DI 10.1097/RTI.0b013e3181e35acd PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 709QB UT WOS:000286454900023 PM 20871421 ER PT J AU Guinan, EC Hewett, EK Domaney, NM Margossian, R AF Guinan, Eva C. Hewett, Elizabeth K. Domaney, Nicholas M. Margossian, Renee TI Outcome of hematopoietic stem cell transplant in children with congenital heart disease SO PEDIATRIC TRANSPLANTATION LA English DT Article DE congenital heart disease; stem cell transplant; toxicity; children ID BONE-MARROW TRANSPLANTATION; VENTRICULAR EJECTION FRACTION; HIGH-DOSE CHEMOTHERAPY; PREDICTIVE-VALUE; CARDIAC TOXICITY; LIVER-TRANSPLANTATION; CYCLOPHOSPHAMIDE CARDIOTOXICITY; FAILURE; CYCLOSPORINE; RISK AB CHD is the most commonly occurring birth defect in the United States. Improvements in supportive care for CHD result in increasing numbers of survivors who may develop benign or malignant conditions for which HSCT is indicated. However, the ability of individuals with CHD to tolerate HSCT is unknown. Retrospective medical record review of 1031 patients who underwent HSCT at Children's Hospital Boston between 1989 and 2007 identified those with CHD. Ten patients with CHD that required repair or palliation before or after HSCT, or with CHD that would have required repair had they survived HSCT, were identified. These patients tolerated chemotherapy and/or radiation therapy uneventfully. Although half experienced febrile neutropenia and two had documented bacteremia, no endocarditis was observed. During the first 100 days post-HSCT, combined rates of grade 3, 4, and 5 cardiac, renal, and pulmonary toxicity for these patients were 10%, 0%, and 10%, respectively. In children with underlying CHD, there was no clinical evidence of impaired ability to tolerate febrile neutropenia, volume challenge, or other regimen-related toxicities that might require significant cardiac reserve. CHD alone should not be considered an absolute contraindication for indicated HSCT. C1 [Guinan, Eva C.; Hewett, Elizabeth K.; Domaney, Nicholas M.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Guinan, Eva C.] Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA. [Margossian, Renee] Childrens Hosp Boston, Dept Cardiol, Boston, MA USA. RP Guinan, EC (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Smith Bldg Rm 346,44 Binney St, Boston, MA 02115 USA. EM eva_guinan@dfci.harvard.edu NR 32 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1397-3142 J9 PEDIATR TRANSPLANT JI Pediatr. Transplant. PD FEB PY 2011 VL 15 IS 1 BP 75 EP 80 DI 10.1111/j.1399-3046.2010.01317.x PG 6 WC Pediatrics; Transplantation SC Pediatrics; Transplantation GA 707ZF UT WOS:000286329400019 PM 20345610 ER PT J AU Susa, M Milane, L Amiji, MM Hornicek, FJ Duan, ZF AF Susa, Michiro Milane, Lara Amiji, Mansoor M. Hornicek, Francis J. Duan, Zhenfeng TI Nanoparticles: A Promising Modality in the Treatment of Sarcomas SO PHARMACEUTICAL RESEARCH LA English DT Review DE nanoparticle; sarcoma; tyrosine kinase; drug resistance; cancer-initiating cell ID PRECLINICAL TESTING PROGRAM; SQUAMOUS-CELL CARCINOMA; NEUTRON-CAPTURE THERAPY; ACUTE MYELOID-LEUKEMIA; RANDOMIZED PHASE-III; BREAST-CANCER CELLS; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; EWING SARCOMA; QUANTUM DOTS AB Improvements in surgical technique, chemotherapy, and radiotherapy have enhanced the prognosis of sarcoma patients, but have since reached a plateau in recent years. Novel approaches have been sought but with limited results. Nanomedicine offers solutions in diverse areas of sarcoma therapy including diagnosis and treatment. Several varieties of nanoparticles, including multifunctional nanoparticles, are available that localize the biodistribution of conventional chemotherapeutics to the tumor site. Also, nanoparticles loaded with chemotherapeutic drugs have the ability to overcome drug resistance which is a major obstacle impeding the progress of the treatment. Multifunctional nanoparticles, which have the potential to further augment the bioavailability of drugs, are being actively investigated. In this review, we will discuss the application of nanoparticles for improving the treatment of sarcoma patients. C1 [Susa, Michiro; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA. [Susa, Michiro; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Milane, Lara; Amiji, Mansoor M.] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA. RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, 70 Blossom St,MGR J1115, Boston, MA 02114 USA. EM zduan@partners.org RI Susa, Michiro/L-2291-2013; Amiji, Mansoor/A-4365-2014; OI Amiji, Mansoor/0000-0001-6170-881X; Duan, Zhenfeng/0000-0002-8543-083X FU National Cancer Institute, NIH [R01-CA119617]; Sarcoma Foundation of America; Gattegno and Wechsler funds FX This project was supported, in part, by a grant from the National Cancer Institute, NIH (Nanotechnology Platform Partnership), R01-CA119617. Dr. Duan is supported, in part, through a grant from the Sarcoma Foundation of America. Support has also been provided by the Gattegno and Wechsler funds. NR 135 TC 4 Z9 4 U1 0 U2 14 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0724-8741 J9 PHARM RES-DORDR JI Pharm. Res. PD FEB PY 2011 VL 28 IS 2 BP 260 EP 272 DI 10.1007/s11095-010-0173-z PG 13 WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Chemistry; Pharmacology & Pharmacy GA 711OT UT WOS:000286602000006 PM 20505985 ER PT J AU Iyer, VR Cohen, GL AF Iyer, Veena R. Cohen, George L. TI Palindromic Rheumatism SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE palindromic rheumatism; recurrent arthritis; relapsing arthritis ID CONNECTIVE-TISSUE DISEASES; ARTHRITIS; PROGRESSION AB We present the case of a 56-year-old woman with a one-month history of recurrent, migratory oligoarthritis. Laboratory tests were normal except for positive antinuclear antibody (ANA) titers. Imaging studies were normal. Palindromic rheumatism (PR) was considered as a diagnosis. In this brief report, we discuss the etiopathogenesis, clinical presentation, prognosis and treatment of this entity. We also elaborate on the factors associated with progression to chronic joint disease. It is important for the primary care physician to be aware of this relatively uncommon diagnosis in patients presenting with joint pains and to distinguish it from other causes of recurrent arthritis, especially rheumatoid arthritis (RA). C1 [Iyer, Veena R.; Cohen, George L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol & Rheumatol, Boston, MA 02114 USA. RP Iyer, VR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol & Rheumatol, 55 Fruit St,White 270, Boston, MA 02114 USA. EM vee.iyer@gmail.com NR 12 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD FEB PY 2011 VL 104 IS 2 BP 147 EP 149 DI 10.1097/SMJ.0b013e318200c4cc PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 709RY UT WOS:000286460300018 PM 21206416 ER PT J AU Yu, J Xu, YM Khaoustov, V Yoffe, B AF Yu, Jing Xu, Yumin Khaoustov, Vladimir Yoffe, Boris TI Identification of components of grape powder with anti-apoptotic effects SO TOXICOLOGY AND INDUSTRIAL HEALTH LA English DT Article DE Freeze-dried grape powder; reactive oxygen species; phenolics; anti-apoptosis ID SEED PROANTHOCYANIDIN EXTRACT; PERMEABILITY TRANSITION; CELL-DEATH; MITOCHONDRIA; ANTIOXIDANT; FLAVONOIDS; INDUCTION; (-)-EPICATECHIN; ACTIVATION; MECHANISMS AB This study is to investigate the mechanism underlying the anti-apoptotic effects of freeze-dried grape powder (FDGP) and identify the polyphenolic compounds involved. We examined apoptotic signaling pathways affected by FDGP and by its active components, including epicatechin, cyanidin, quercetin, and resveratrol, in human Huh7 hepatoma cells by assaying cell viability assays, the activities of caspase 3 and caspase 7, and the expression of endoplasmic reticulum stress-associated proteins. FDGP dramatically decreased taurodeoxycholic acid (TDCA)-induced production of reactive oxygen species (ROS). Assessment of individual active components revealed that at concentrations corresponding to 300 mu g/mL FDGP, only quercetin demonstrated cytoprotective effects against mitochondrial-mediated apoptosis. In contrast, increased concentrations of other individual polyphenolic compounds were required to produce measurable cytoprotective effect. Only combinations of all four polyphenolic compounds (epicatechin, cyanidin, quercetin, and resveratrol) restored a degree of the antiapoptotic effects seen with FDGP. The pretreatment of FDGP at 30 mu g/mL concentration could reverse the thapsigargin-induced effects on the expression of endoplasmic reticulum stress-associated proteins. In conclusion, FDGP reduced oxidative stress, endoplasmic reticulum stress, and apoptosis. The mechanisms involved in the anti-apoptotic effects of FDGP included reduced generation of ROS, and reduced processing of certain caspases. We demonstrated that quercetin, epicatechin, and cyanidin are active compounds within FDGP that attenuate apoptosis. These findings contribute to our understanding of the molecular mechanisms of antiapoptotic and anti-oxidant effects of grape and are expected to assist in developing clinical protocols to treat a variety of stress-mediated conditions. C1 [Yu, Jing] Guangxi Tradit Chinese Med Univ, Dept Hepatol, Nanning 530023, Guangxi, Peoples R China. [Xu, Yumin] Shanghai Jiao Tong Univ, Dept Infect Dis, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China. [Khaoustov, Vladimir; Yoffe, Boris] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Yu, J (reprint author), Guangxi Tradit Chinese Med Univ, Dept Hepatol, 2 Ruan Hu St, Nanning 530023, Guangxi, Peoples R China. EM jingy1237@126.com FU Guangxi Scholarship; Texas Medical Center, Houston FX This research was supported by the Guangxi Scholarship Fund and Dr Boris Yoffe's Lab at the Texas Medical Center, Houston. NR 34 TC 6 Z9 6 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0748-2337 J9 TOXICOL IND HEALTH JI Toxicol. Ind. Health PD FEB PY 2011 VL 27 IS 1 BP 19 EP 28 DI 10.1177/0748233710380220 PG 10 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 706FX UT WOS:000286204500003 ER PT J AU Yigit, MV Zhu, LY Ifediba, MA Zhang, Y Carr, K Moore, A Medarova, Z AF Yigit, Mehmet V. Zhu, Leyun Ifediba, Marytheresa A. Zhang, Yong Carr, Kevin Moore, Anna Medarova, Zdravka TI Noninvasive MRI-SERS Imaging in Living Mice Using an Innately Bimodal Nanomaterial SO ACS NANO LA English DT Article DE MRI; SEM; gold nanoparticle; bimodal; Raman; iron oxide nanoparticle; imaging ID ENHANCED RAMAN-SCATTERING; IRON-OXIDE NANOPARTICLES; GOLD NANOPARTICLES; MAGNETIC NANOPARTICLES; CONTRAST AGENTS; DRUG-DELIVERY; CANCER; DNA; NANOCRYSTALS; SPECTROSCOPY AB We report a novel nanomaterial (AuMN-DTTC) that can be used as a bimodal contrast agent for in vivo magnetic resonance imaging (MRI) and Raman spectroscopy. The probe consists of MRI-active superparamagnetic iron oxide nanoparticles, stably complexed with gold nanostructures. The gold component serves as a substrate for a Raman active dye molecule to generate a surface-enhanced Raman scattering (SERS) effect. The synthesized probe produces T2 weighted contrast and can be used as a SERS active material both in silica (in aqueous solution) and in vivo. A quantitative assessment of T2 relaxation times was obtained using multiecho MRI analysis. The T2 relaxation times of AuMN-DTTC and MN (dextran-coated Iron oxide nanoparticles) were 29.23 + 1.45 and 31.58 + 1.7 ms, respectively. The SERS signature of AuMN-DTTC revealed peaks at 508, 629, 782, 844, 1080, 1108, 1135, and 1242 cm(-1). Intramuscular administration of the probe resulted in a decrease of the 12 relaxation time of muscle from 33.4 + 2.5 to 20.3 + 2.2 ms. SERS peaks were observed at 508, 629, 782, 844, 1080, 1108, 1135, and 1242 cm(-1), consistent with the in silica results. Our studies illustrate for the first time the design and in vivo application of a contrast agent, whose component modalities include MRI and SERS. The value of this agent lies in its Innately bimodal nature and its application in vivo for molecular imaging applications. C1 [Yigit, Mehmet V.; Ifediba, Marytheresa A.; Moore, Anna; Medarova, Zdravka] Massachusetts Gen Hosp, Mol Imaging Lab, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA. [Yigit, Mehmet V.; Ifediba, Marytheresa A.; Moore, Anna; Medarova, Zdravka] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Ifediba, Marytheresa A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Ifediba, Marytheresa A.] Harvard MIT Div Hlth Sci & Technol HST, Cambridge, MA 02139 USA. [Zhang, Yong] MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA. [Zhu, Leyun; Carr, Kevin] Agilton Inc, Woburn, MA 01801 USA. RP Medarova, Z (reprint author), Massachusetts Gen Hosp, Mol Imaging Lab, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA. EM zmedarova@partners.org FU National Cancer Institute [R00CA129070]; NSF FX We thank P. Pantazopoulos (Martinos Center for Biomedical Imaging, MGH) for help with the in silico assays, R. Uppal and P. Caravan (Martinos Center for Biomedical Imaging, MGH) for help with ICP-MS, and R. M. Papaleo for his helpful discussions on TEM images. Work at the Martinos Center for Biomedical Imaging was supported under grant R00CA129070 from the National Cancer Institute. TEM work made use of the MIT EM shared facilities of the Material Research Science and Engineering Center (MRSEC) supported by NSF. NR 49 TC 47 Z9 47 U1 3 U2 52 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1936-0851 J9 ACS NANO JI ACS Nano PD FEB PY 2011 VL 5 IS 2 BP 1056 EP 1066 DI 10.1021/nn102587h PG 11 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA 724CN UT WOS:000287553800043 PM 21194236 ER PT J AU Mao, YD Wang, WL Wei, DG Kaxiras, E Sodroski, JG AF Mao, Youdong Wang, Wei L. Wei, Dongguang Kaxiras, Efthimios Sodroski, Joseph G. TI Graphene Structures at an Extreme Degree of Buckling SO ACS NANO LA English DT Article DE graphene; aberration-corrected transmission electron microscopy; Euler buckling Instability; electronic structure; density functional theory ID MASSLESS DIRAC FERMIONS; SUSPENDED GRAPHENE; BILAYER GRAPHENE; SHEETS; GRAPHITE; FILMS AB The distinctive properties of graphene sheets may be significantly influenced by the presence of corrugation structures. Our understanding of these graphene structures has been limited to the mesoscopic scale. Here we characterize angstrom-scale periodic buckling structures in freestanding graphene Mayers produced by liquid-phase processing in the absence of specific substrates. Monochromated, aberration-corrected transmission electron microscopy with sub-angstrom resolution revealed that the unit structures in the major buckling direction consist of only two and three unit cells of graphene's honeycomb lattice, resulting In buckling wavelengths of 3.6 +/- 0.5 and 6.4 +/- 0.8 angstrom, respectively. The buckling shows a strong preference of chiral direction and spontaneously chooses the orientation of the lowest deformation energy, governed by simple geometry rules agreeing with Euler buckling theory. Unexpectedly, the overall buckled structures demonstrate geometric complexity with cascaded features. First-principles calculations suggest that significant anisotropic changes in the electronic structure of graphene are induced by the buckling. C1 [Mao, Youdong; Sodroski, Joseph G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA. [Wang, Wei L.; Kaxiras, Efthimios] Harvard Univ, Sch Engn & Appl Sci, Dept Phys, Cambridge, MA 02138 USA. [Wei, Dongguang] Carl Zeiss NTS LLC, Peabody, MA 01960 USA. [Sodroski, Joseph G.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. RP Mao, YD (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA. EM youdong_mao@dfci.harvard.edu; joseph_sodroskl@dfcl.harvard.edu RI Wang, Wei/B-8061-2009 OI Wang, Wei/0000-0002-5064-8097 FU National Institute of Health (NIH) [AI67854]; Ragon Institute of MGH, MIT, and Harvard; National Science Foundation under NSF [ECS-0335765] FX The authors thank D. C. Bell for assistance and coordination in TEM imaging and maintenance and M. Lemme and Q. Ouyang for insightful discussion and comments. This work was supported by the National Institute of Health (NIH) (AI67854) and the Ragon Institute of MGH, MIT, and Harvard. The experiment was performed in part at the Center for Nanoscale Systems (CNS), a member of National Nanotechnology Infrastructure Network (NNIN), which is supported by the National Science Foundation under NSF award no. ECS-0335765. C.N.S. is part of the Faculty of Arts and Sciences at Harvard University. NR 30 TC 26 Z9 27 U1 3 U2 34 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1936-0851 J9 ACS NANO JI ACS Nano PD FEB PY 2011 VL 5 IS 2 BP 1395 EP 1400 DI 10.1021/nn103153x PG 6 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA 724CN UT WOS:000287553800081 PM 21222462 ER PT J AU Gheorghiade, M Pang, PS O'Connor, CM Prasad, K McMurray, J Teerlink, JR Fiuzat, M Sabbah, H Komajda, M AF Gheorghiade, Mihai Pang, Peter S. O'Connor, Christopher M. Prasad, Krishna McMurray, John Teerlink, John R. Fiuzat, Mona Sabbah, Hani Komajda, Michel TI Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase SO AMERICAN HEART JOURNAL LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; A(1) RECEPTOR ANTAGONIST; COLLEGE-OF-CARDIOLOGY; DOUBLE-BLIND; RENAL IMPAIRMENT; INTRAVENOUS LEVOSIMENDAN; VASOPRESSIN ANTAGONIST; SYSTOLIC DYSFUNCTION; ORAL TOLVAPTAN; TEZOSENTAN AB Hospitalization for acute heart failure syndromes (AHFS) predicts a poor prognosis, with postdischarge mortality and rehospitalization rates reaching 45% within 60 to 90 days. Despite the use of evidence-based therapies and adherence to national process measures, these event rates have largely remained the same over the past decade. Given the current and growing burden of AHFS, there exists a substantial unmet need for novel therapies that improve outcomes. However, attempts to improve symptoms and/or reduce postdischarge events have failed to produce positive results, either because of safety and/or efficacy. These negative results may be related to the drug itself, the protocol in terms of patient selection and/or end points, and/or the trial execution. Although experts may not agree on the exact reasons to explain the lack of success to date of phase III trials in AHFS, there is agreement that clinical benefits observed in phase II trials were not reproduced in phase III trials. A different approach may be needed. In November of 2009, a meeting was held at the Food and Drug Administration with the primary purpose of identifying the reasons why benefits observed during phase II did not translate into benefits in phase III to improve future trial design. Although multiple domains of trial design were discussed, the participants identified a lack of in-depth understanding of novel molecules before pivotal trials in AHFS as a possible contributor to the disappointing results of recent large trials. In this brief report, we outline the T1 or translational phase of research for AHFS clinical development as an important first step toward greater success in AHFS clinical trials. (Am Heart J 2011;161:224-32.) C1 [Gheorghiade, Mihai; Pang, Peter S.] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA. [Pang, Peter S.] Northwestern Univ, Feinberg Sch Med, Dept Emergency Med, Chicago, IL 60611 USA. [O'Connor, Christopher M.; Fiuzat, Mona] Duke Univ, Med Ctr, Durham, NC USA. [Prasad, Krishna] MHRA St Thomas Hosp, London, England. [McMurray, John] Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland. [McMurray, John] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Teerlink, John R.] Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Sabbah, Hani] Wayne State Univ, Div Cardiol, Henry Ford Hosp, Detroit, MI USA. [Komajda, Michel] Hop La Pitie Salpetriere, Dept Cardiol, Paris, France. RP Gheorghiade, M (reprint author), Northwestern Univ, Feinberg Sch Med, Div Cardiol, Ctr Cardiovasc Innovat, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA. EM m-gheorghiade@northwestern.edu RI Teerlink, John/D-2986-2012; OI mcmurray, john/0000-0002-6317-3975 NR 45 TC 25 Z9 26 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD FEB PY 2011 VL 161 IS 2 BP 224 EP 232 DI 10.1016/j.ahj.2010.10.023 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 719FX UT WOS:000287188000004 PM 21315202 ER PT J AU Chiuve, SE Korngold, EC Januzzi, JL Gantzer, ML Albert, CM AF Chiuve, Stephanie E. Korngold, Ethan C. Januzzi, James L., Jr. Gantzer, Mary Lou Albert, Christine M. TI Plasma and dietary magnesium and risk of sudden cardiac death in women SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; C-REACTIVE PROTEIN; ATHEROSCLEROSIS-RISK; VENTRICULAR-ARRHYTHMIAS; CARDIOVASCULAR-DISEASE; SERUM MAGNESIUM; UNITED-STATES; MEN; SUPPLEMENTATION AB Background: Magnesium has antiarrhythmic properties in cellular and experimental models; however, its relation to sudden cardiac death (SCD) risk is unclear. Objective: We prospectively examined the association between magnesium, as measured in diet and plasma, and risk of SCD. Design: The analysis was conducted within the Nurses' Health Study. The association for magnesium intake was examined prospectively in 88,375 women who were free of disease in 1980. Information on magnesium intake, other nutrients, and lifestyle factors was updated every 2-4 y through questionnaires, and 505 cases of sudden or arrhythmic death were documented over 26 y of follow-up. For plasma magnesium, a nested case-control analysis including 99 SCD cases and 291 controls matched for age, ethnicity, smoking, and presence of cardiovascular disease was performed. Results: After multivariable adjustment for confounders and potential intermediaries, the relative risk of SCD was significantly lower in women in the highest quartile compared with those in the lowest quartile of dietary (relative risk: 0.63; 95% CI: 0.44, 0.91) and plasma (relative risk: 0.23; 95% CI: 0.09, 0.60) magnesium. The linear inverse relation with SCD was strongest for plasma magnesium (P for trend = 0.003), in which each 0.25-mg/dL (1 SD) increment in plasma magnesium was associated with a 41% (95% CI: 15%, 58%) lower risk of SCD. Conclusions: In this prospective cohort of women, higher plasma concentrations and dietary magnesium intakes were associated with lower risks of SCD. If the observed association is causal, interventions directed at increasing dietary or plasma magnesium might lower the risk of SCD. Am J Clin Nutr 2011;93:253-60. C1 [Chiuve, Stephanie E.; Albert, Christine M.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02215 USA. [Chiuve, Stephanie E.; Albert, Christine M.] Brigham & Womens Hosp, Dept Med, Ctr Arrhythmia Prevent, Boston, MA 02215 USA. [Albert, Christine M.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. [Chiuve, Stephanie E.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Korngold, Ethan C.; Januzzi, James L., Jr.] Massachusetts Gen Hosp, Dept Med, Div Cardiovasc, Boston, MA 02114 USA. [Gantzer, Mary Lou] Siemens Healthcare Diagnost Inc, Newark, DE USA. RP Chiuve, SE (reprint author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave, Boston, MA 02215 USA. EM schiuve@hsph.harvard.edu FU Siemens Healthcare Diagnostics; American Heart Association; National Institutes of Health [CA-87969, HL-34594, HL-03783, HL-068070]; Balson Cardiac Scholar Fund FX Supported by a research grant from Siemens Healthcare Diagnostics, an Established Investigator Award from the American Heart Association to CMA, and grants CA-87969, HL-34594, HL-03783, and HL-068070 from the National Institutes of Health. JLJ was supported in part by the Balson Cardiac Scholar Fund. NR 45 TC 51 Z9 55 U1 0 U2 9 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD FEB PY 2011 VL 93 IS 2 BP 253 EP 260 DI 10.3945/ajcn.110.002253 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 709DQ UT WOS:000286417900005 PM 21106914 ER PT J AU Shen, JA Johnson, VM Sullivan, LM Jacques, PF Magnani, JW Lubitz, SA Pandey, S Levy, D Vasan, RS Quatromoni, PA Junyent, M Ordovas, JM Benjamin, EJ AF Shen, Jian Johnson, Victor M. Sullivan, Lisa M. Jacques, Paul F. Magnani, Jared W. Lubitz, Steven A. Pandey, Shivda Levy, Daniel Vasan, Ramachandran S. Quatromoni, Paula A. Junyent, Mireia Ordovas, Jose M. Benjamin, Emelia J. TI Dietary factors and incident atrial fibrillation: the Framingham Heart Study SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID POLYUNSATURATED-FATTY-ACIDS; ALCOHOL-CONSUMPTION; FISH-OIL; BLOOD INSTITUTE; NATIONAL HEART; RISK-FACTORS; DANISH DIET; WHOLE-GRAIN; DISEASE; HEALTH AB Background: There have been conflicting reported associations between dietary factors and incident atrial fibrillation (AF). Objective: We evaluated associations between consumption of alcohol, caffeine, fiber, and polyunsaturated fatty acids (PUFAs) and incident AF in the Framingham Heart Study. Design: Participants without AF (n = 4526; 9640 examinations; mean age: 62 y; 56% women) from the original and offspring cohorts completed food-frequency questionnaires and were followed prospectively for 4 y. We examined the associations between dietary exposures and AF with Cox proportional hazards regression. Results: A total of 296 individuals developed AF (177 men, 119 women). In multivariable analyses, there were no significant associations between examined dietary exposures and AF risk. Hazard ratios (HRs) for increasing quartiles of dietary factors were as follows: for alcohol, 0.73 (95% CI: 0.5, 1.05), 0.85 (95% CI: 0.61, 1.18), and 1.12 (95% CI: 0.83, 1.51) (P for trend = 0.48); for caffeine, 0.84 (95% CI: 0.62, 1.15), 0.87 (95% CI: 0.64, 1.2), and 0.98 (95% CI: 0.7, 1.39) (P for trend = 0.84); for total fiber, 0.86 (95% CI: 0.61, 1.2), 0.64 (95% CI: 0.44, 0.92), and 0.81 (95% CI: 0.54, 1.2) (P for trend = 0.16); and for n-3 (omega-3) PUFAs, 1.11 (95% CI: 0.81, 1.54), 0.92 (95% CI: 0.65, 1.29), and 1.18 (95% CI: 0.85, 1.64) (P for trend = 0.57; quartile 1 was the reference group). In exploratory analyses, consumption of >4 servings of dark fish/wk (5 cases and 21 individuals at risk) was significantly associated with AF risk compared with the consumption of,1 serving of dark fish/wk (HR: 6.53; 95% CI: 2.65, 16.06; P < 0.0001). Conclusions: Consumption of alcohol, caffeine, fiber, and fish-derived PUFAs was not significantly associated with AF risk. The observed adverse association between the consumption of dark fish and AF merits further investigation. Our findings suggest that the dietary exposures examined convey limited attributable risk of AF in the general population. Am J Clin Nutr 2011;93:261-6. C1 [Magnani, Jared W.; Levy, Daniel; Benjamin, Emelia J.] NHLBI, Farmingham Heart Study, Framingham, MA 01702 USA. [Shen, Jian; Jacques, Paul F.; Junyent, Mireia; Ordovas, Jose M.] Tufts Univ, Human Nutr Res Ctr Aging, Jean Mayer US Dept Agr, Boston, MA 02111 USA. [Johnson, Victor M.; Sullivan, Lisa M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Quatromoni, Paula A.; Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Magnani, Jared W.; Pandey, Shivda; Levy, Daniel; Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Evans Mem Dept Med, Cardiol Sect, Boston, MA 02215 USA. [Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Evans Mem Dept Med, Sect Prevent Med, Boston, MA 02215 USA. [Quatromoni, Paula A.] Boston Univ, Sargent Coll Hlth & Rehabil Sci, Dept Hlth Sci, Boston, MA 02215 USA. [Lubitz, Steven A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. RP Benjamin, EJ (reprint author), NHLBI, Farmingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. EM emelia@bu.edu OI Ramachandran, Vasan/0000-0001-7357-5970; Sullivan, Lisa/0000-0003-0726-7149; Benjamin, Emelia/0000-0003-4076-2336 FU Heart, Lung, and Blood Institute [HL-54776]; National Institute of Diabetes and Digestive and Kidney Diseases [DK075030]; US Department of Agriculture Research [53-K06-5-10, 58-1950-9-001]; American Heart Association [09FTF2190028]; National Institutes of Health [N01-HC 25195, 6R01-NS 17950, RC1HL101056, HL092577, 1R01HL102214] FX Supported by the National Heart, Lung, and Blood Institute (grants HL-54776; to JS and JMO), the National Institute of Diabetes and Digestive and Kidney Diseases (grant DK075030; to JMO), the US Department of Agriculture Research (contracts 53-K06-5-10 and 58-1950-9-001; to JS and JMO), the American Heart Association (award 09FTF2190028; to JWM), and the National Institutes of Health (grants N01-HC 25195, 6R01-NS 17950, RC1HL101056, HL092577, and 1R01HL102214; to EJB). NR 47 TC 44 Z9 44 U1 0 U2 14 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD FEB PY 2011 VL 93 IS 2 BP 261 EP 266 DI 10.3945/ajcn.110.001305 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 709DQ UT WOS:000286417900006 PM 21106919 ER PT J AU Liu, XL Jakubowski, M Hunt, JL AF Liu, Xiuli Jakubowski, Maureen Hunt, Jennifer L. TI KRAS Gene Mutation in Colorectal Cancer Is Correlated With Increased Proliferation and Spontaneous Apoptosis SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Article DE Colorectal cancer; KRAS; Proliferation; Apoptosis; Microsatellite instability high; Polymerase chain reaction; Cycling sequencing ID K-RAS ONCOGENE; CARCINOMAS; CELLS; PATHWAYS; ADENOCARCINOMA; INSTABILITY; PROGRESSION; ACTIVATION; CETUXIMAB; ADENOMAS AB KRAS mutation occurs in 30% to 50% of colorectal cancers (CRCs) and has been suggested to be associated with proliferation and decreased apoptosis. In this study, we analyzed KRAS in 198 CRCs and compared the clinicopathologic variables between KRAS-mutated and wild-type CRCs. Also, a subset of 90 and 66 CRCs from this cohort underwent microsatellite instability testing and histomorphologic evaluation, and the frequency of microsatellite instability-high (MSI-H) and histomorphologic variables were compared between KRAS-mutated and wild-type CRCs. Clinicopathologic features (age, sex, and tumor site, depth, size, grade, and metastasis) were not different between KRAS-mutated and wild-type CRCs. Compared with wild-type KRAS CRCs, KRAS-mutated CRCs had a lower frequency of MSI-H (15% vs 42%; P = .015), a higher chance of having brisk mitosis (77% vs 43%, P = .022) and apoptosis (77% vs 28%; P = .00012), and a greater mean of mitotic figures (P = .0002) and apoptotic cells (P = .0008). KRAS mutation was associated with higher tumor cell turnover. C1 [Hunt, Jennifer L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Liu, Xiuli; Jakubowski, Maureen] Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA. RP Hunt, JL (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 202,55 Fruit St, Boston, MA 02114 USA. NR 32 TC 21 Z9 22 U1 1 U2 10 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD FEB PY 2011 VL 135 IS 2 BP 245 EP 252 DI 10.1309/AJCP7FO2VAXIVSTP PG 8 WC Pathology SC Pathology GA 709PO UT WOS:000286452800008 PM 21228365 ER PT J AU D'Haens, GR Panaccione, R Higgins, PDR Vermeire, S Gassull, M Chowers, Y Hanauer, SB Herfarth, H Hommes, DW Kamm, M Lofberg, R Quary, A Sands, B Sood, A Watermayer, G Lashner, B Lemann, M Plevy, S Reinisch, W Schreiber, S Siegel, C Targan, S Watanabe, M Feagan, B Sandborn, WJ Colombel, JF Travis, S AF D'Haens, Geert R. Panaccione, Remo Higgins, Peter D. R. Vermeire, Severine Gassull, Miquel Chowers, Yehuda Hanauer, Stephen B. Herfarth, Hans Hommes, Daan W. Kamm, Michael Lofberg, Robert Quary, A. Sands, Bruce Sood, A. Watermayer, G. Lashner, Bret Lemann, Marc Plevy, Scott Reinisch, Walter Schreiber, Stefan Siegel, Corey Targan, Stephen Watanabe, M. Feagan, Brian Sandborn, William J. Colombel, Jean Frederic Travis, Simon TI The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; POPULATION-BASED COHORT; SCHEDULED MAINTENANCE TREATMENT; MONOCLONAL-ANTIBODY ADALIMUMAB; PLACEBO-CONTROLLED TRIALS; SINGLE-CENTER EXPERIENCE; EVIDENCE-BASED CONSENSUS; QUALITY-OF-LIFE; TERM-FOLLOW-UP AB The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but other biological agents (adalimumab (ADA), certolizumab pegol (CZP), and natalizumab (NAT)) appear to have similar benefits in CD. Steroid-refractory, steroid-dependent, or complex fistulizing CD are indications for starting biological therapy, after surgical drainage of any sepsis. For fistulizing CD, the efficacy of IFX for inducing fistula closure is best documented. Unique risks of NAT account for its labeling as a second-line biological agent in some countries. Patients who respond to induction therapy benefit from systematic re-treatment. The combination of IFX with azathioprine is better than monotherapy for induction of remission and mucosal healing up to 1 year in patients who are naive to both agents. Whether this applies to other agents remains unknown. IFX is also effective for treatment-refractory, moderate, or severely active ulcerative colitis. Patients who have a diminished or loss of response to anti-tumor necrosis factor (TNF) therapy may respond to dose adjustment of the same agent or switching to another agent. Careful consideration should be given to the reasons for loss of response. There are insufficient data to make recommendations on when to stop anti-TNF therapy. Preliminary evidence suggests that a substantial proportion of patients in clinical remission for > 1 year, without signs of active inflammation can remain in remission after stopping treatment. C1 [D'Haens, Geert R.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands. [Panaccione, Remo] Univ Calgary, Inflammatory Bowel Dis Clin, Calgary, AB, Canada. [Higgins, Peter D. R.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Vermeire, Severine] Univ Hosp Gasthuisberg, Dept Gastroenterol, B-3000 Louvain, Belgium. [Gassull, Miquel] Germans Trias & Pujol Fdn, Hlth Sci Res Inst, Badalona, Spain. [Chowers, Yehuda] Rambam Hlth Care Campus, Dept Gastroenterol, Haifa, Israel. [Hanauer, Stephen B.] Univ Chicago, Med Ctr, Sect Gastroenter Hepatol & Nutr, Chicago, IL 60637 USA. [Herfarth, Hans] Univ N Carolina, Div Gastroenterol & Hepatol, Chapel Hill, NC USA. [Hommes, Daan W.] Leiden Univ, Med Ctr, Dept Gastroenterol, Leiden, Netherlands. [Kamm, Michael] St Vincents Hosp, Dept Med, Melbourne, Vic, Australia. [Kamm, Michael] Univ London Imperial Coll Sci Technol & Med, London, England. [Lofberg, Robert] IBD Unit, Stockholm, Sweden. [Quary, A.] King Abdulaziz Univ Hosp, Jeddah, Saudi Arabia. [Sands, Bruce] Massachusetts Gen Hosp, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA. [Sood, A.] Dayanand Med Coll & Hosp, Dept Gastroenterol, Ludhiana, Punjab, India. [Watermayer, G.] Groote Schuur Hosp, Div Gastroenterol, ZA-7925 Cape Town, South Africa. [Watermayer, G.] Groote Schuur Hosp, Dept Med, ZA-7925 Cape Town, South Africa. [Lashner, Bret] Cleveland Clin, Dept Gastroenterol, Cleveland, OH 44106 USA. [Lemann, Marc] Hosp St Louis, Dept Gastroenterol, Paris, France. [Plevy, Scott] UNC Sch Med, Chapel Hill, NC USA. [Reinisch, Walter] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria. [Schreiber, Stefan] Univ Hosp Schleswig Holstein UKSH, Dept Gen Internal Med, Kiel, Germany. [Siegel, Corey] Dartmouth Hitchcock Med Ctr, Sect Gastroenterol & Hepatol, Lebanon, NH 03766 USA. [Targan, Stephen] Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90048 USA. [Watanabe, M.] Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan. [Feagan, Brian] Univ Western Ontario, London, ON, Canada. [Sandborn, William J.] Mayo Clin, Rochester, MN USA. [Colombel, Jean Frederic] Hosp Huriez, Dept Hepatogastroenterol, Lille, France. [Travis, Simon] John Radcliffe Hosp, Gastroenterol Unit, Oxford OX3 9DU, England. RP D'Haens, GR (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands. EM g.dhaens@amc.uva.nl RI Schreiber, Stefan/B-6748-2008; Feagan, Brian/M-4283-2015; Higgins, Peter/A-3511-2009; OI Schreiber, Stefan/0000-0003-2254-7771; Higgins, Peter/0000-0003-1602-4341; Vermeire, Severine/0000-0001-9942-3019 FU World Congress of Gastroenterology FX We are grateful to Nicole Eichinger and Sonja Rosensweig, secretariat of the European Crohn's and Colitis Organisation, for their help with the logistics of the meetings and to Christine Mazziotta for technical assistance in preparing the manuscript. Financial support for administration was provided by a standard grant for Position Statements from the World Congress of Gastroenterology. The Pharmaceutical Industry was excluded from all stages of the process. NR 133 TC 214 Z9 231 U1 2 U2 22 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2011 VL 106 IS 2 BP 199 EP 212 DI 10.1038/ajg.2010.392 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 717CX UT WOS:000287021700005 PM 21045814 ER PT J AU Cryer, B Bhatt, DL Lanza, FL Dong, JF Lichtenberger, LM Marathi, UK AF Cryer, Byron Bhatt, Deepak L. Lanza, Frank L. Dong, Jing-fei Lichtenberger, Lenard M. Marathi, Upendra K. TI Low-Dose Aspirin-Induced Ulceration Is Attenuated by Aspirin-Phosphatidylcholine: A Randomized Clinical Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROINTESTINAL INJURY; GASTRODUODENAL ULCERS; MUCOSAL INJURY; RISK; CLOPIDOGREL; INHIBITION; PREVENTION; NSAIDS; PHOSPHOLIPIDS AB OBJECTIVES: Relative contributions of local and systemic mechanisms of upper gastrointestinal (GI) injury following aspirin are unknown. Studies suggest that aspirin's GI risk is age related and that gastro-protection may be needed at therapy initiation. We determined acute gastroduodenal erosion and ulceration following low-dose aspirin and aspirin-phosphatidylcholine complex (PL2200) in subjects at risk of aspirin ulcers. METHODS: In a randomized, single blind, multicenter active-controlled study, we compared upper GI damage of aspirin and PL2200 in healthy subjects (n = 204, ages 50-74 years) following 7 days of oral 325 mg once daily, immediate release aspirin or PL2200. RESULTS: Overall, 42.2% of aspirin-treated subjects developed multiple erosions and/or ulcers, whereas 22.2% treated with PL2200 developed such damage (P = 0.0027). Gastroduodenal ulcers were observed in 17.6% of aspirin-treated compared with 5.1% of subjects treated with PL2200 (P = 0.0069). CONCLUSIONS: Low-dose aspirin induced a surprisingly high incidence of acute gastroduodenal ulcers in at risk subjects, highlighting that aspirin's upper GI risk begins early and may require gastroprotection. Local mechanisms of GI protection are important as aspirin's preassociation with surface-active phospholipids significantly reduced mucosal damage. PL2200 may be an attractive alternative or complement to proton pump inhibitors in older patients who are at risk of aspirin-induced ulceration. Longer-term studies assessing clinical GI events are desirable to confirm the clinical GI safety profile of PL2200. C1 [Cryer, Byron] Univ Texas SW, VA N Texas Hlth Care Syst, Dallas, TX 75216 USA. [Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA. [Lanza, Frank L.; Dong, Jing-fei] Baylor Coll Med, Houston, TX 77030 USA. [Lichtenberger, Lenard M.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA. [Lichtenberger, Lenard M.; Marathi, Upendra K.] PLx Pharma Inc, Houston, TX USA. RP Cryer, B (reprint author), Univ Texas SW, VA N Texas Hlth Care Syst, 4500 S Lancaster RD 111B1, Dallas, TX 75216 USA. EM Byron.Cryer@UTSouthwestern.edu FU Astra Zeneca Bristol-Myers Squibb; Eisai; Sanofi Aventis; Medicines Company; PLx Pharma; TAP Pharmaceuticals; Sucampo Pharmaceuticals; Eisai Pharmaceuticals; Wyeth and Cogentus Pharmaceuticals; PLx Pharma Inc.; National Institute of Diabetes and Digestive and Kidney Diseases [R42 DK063882]; Houston, TX FX Deepak Bhatt has had research grants for studies in which he served as principal investigator from Astra Zeneca Bristol-Myers Squibb, Eisai, Sanofi Aventis, The Medicines Company; Frank Lanza has received research support from PLx Pharma, TAP Pharmaceuticals, Sucampo Pharmaceuticals, Eisai Pharmaceuticals, Wyeth and Cogentus Pharmaceuticals. Lenard Lichtenberger has received research support and is a consultant and equity holder in PLx Pharma Inc. The trial was conducted with grant support from the National Institute of Diabetes and Digestive and Kidney Diseases R42 DK063882 (which provided the resources for part of the study) and from PLx Pharma Inc., Houston, TX (which provided the remaining funds that covered most of the costs of the study). NR 33 TC 38 Z9 39 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2011 VL 106 IS 2 BP 272 EP 277 DI 10.1038/ajg.2010.436 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 717CX UT WOS:000287021700013 PM 21081908 ER PT J AU Gellad, WF Grenard, JL Marcum, ZA AF Gellad, Walid F. Grenard, Jerry L. Marcum, Zachary A. TI A Systematic Review of Barriers to Medication Adherence in the Elderly: Looking Beyond Cost and Regimen Complexity SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Review DE barriers; elderly; medication adherence; systematic review ID PRIMARY-CARE PATIENTS; OLDER-ADULTS; LONGITUDINAL COHORT; PART-D; HEALTH; NONADHERENCE; PREDICTORS; SENIORS; ASSOCIATIONS; METAANALYSIS AB Background: Medication nonadherence is a common problem among the elderly. Objective: To conduct a systematic review of the published literature describing potential nonfinancial barriers to medication adherence among the elderly. Methods: The PubMed and PsychINFO databases were searched for articles published in English between January 1998 and January 2010 that (1) described "predictors," "facilitators," or "determinants" of medication adherence or that (2) examined the "relationship" between a specific barrier and adherence for elderly patients (ie, years of age) in the United States. A manual search of the reference lists of identified articles and the authors' files and recent review articles was conducted. The search included articles that (1) reviewed specific barriers to medication adherence and did not solely describe nonmodifiable predictors of adherence (eg, demographics, marital status), (2) were not interventions designed to address adherence, (3) defined adherence or compliance and specified its method of measurement, and (4) involved US participants only. Nonsystematic reviews were excluded, as were studies that focused specifically on people who were homeless or substance abusers, or patients with psychotic disorders, tuberculosis, or HIV infection, because of the unique circumstances that surround medication adherence for each of these populations. Results: Nine studies met inclusion criteria for this review. Four studies used pharmacy records or claims data to assess adherence, 2 studies used pill count or electronic monitoring, and 3 studies used other methods to assess adherence. Substantial heterogeneity existed among the populations studied as well as among the measures of adherence, barriers addressed, and significant findings. Some potential barriers (ie, factors associated with nonadherence) were identified from the studies, including patient-related factors such as disease-related knowledge, health literacy, and cognitive function; drug-related factors such as adverse effects and polypharmacy; and other factors including the patient-provider relationship and various logistical barriers to obtaining medications. None of the reviewed studies examined primary nonadherence or nonpersistence. Conclusion: Medication nonadherence in the elderly is not well described in the literature, despite being a major cause of morbidity, and thus it is difficult to draw a systematic conclusion on potential barriers based on the current literature. Future research should focus on standardizing medication adherence measurements among the elderly to gain a better understanding of this important issue. (Am J Geriatr Pharmacother. 2011;9:11-23) Published by Elsevier HS Journals, Inc. C1 [Gellad, Walid F.] RAND Hlth, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med Gen Med, Pittsburgh, PA USA. [Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Grenard, Jerry L.] Claremont Grad Univ, Sch Community & Global Hlth, San Dimas, CA USA. [Marcum, Zachary A.] Univ Pittsburgh, Sch Med, Dept Geriatr Med, Pittsburgh, PA USA. RP Gellad, WF (reprint author), RAND Hlth, 4570 5th Ave,Suite 600, Pittsburgh, PA 15213 USA. EM wgellad@rand.org FU Agency for Healthcare Research and Quality [T32 HS00046-14]; National Institute of Aging [T32 AG021885]; Mehlman Vogel Castagnetti FX This study was supported by an Agency for Healthcare Research and Quality grant (T32 HS00046-14), a National Institute of Aging Grant (T32 AG021885), and Mehlman Vogel Castagnetti. Dr. Gellad is additionally supported by a VA HSR&D Career Development Award. The authors would like to thank Joseph T. Hanlon, PharmD, MS, for his assistance with earlier drafts of this manuscript. NR 32 TC 128 Z9 132 U1 7 U2 42 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2011 VL 9 IS 1 BP 11 EP 23 DI 10.1016/j.amjopharm.2011.02.004 PG 13 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 754PA UT WOS:000289866600002 PM 21459305 ER PT J AU Emanuel, JE Lopez, OL Houck, PR Becker, JT Weamer, EA DeMichele-Sweet, MAA Kuller, L Sweet, RA AF Emanuel, James E. Lopez, Oscar L. Houck, Patricia R. Becker, James T. Weamer, Elise A. DeMichele-Sweet, Mary Ann A. Kuller, Lewis Sweet, Robert A. TI Trajectory of Cognitive Decline as a Predictor of Psychosis in Early Alzheimer Disease in the Cardiovascular Health Study SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY MAY 01-03, 2008 CL Washington, DC SP Soc Biol Psychiat DE Alzheimer disease; MCI (mild cognitive impairment); psychosis ID INCREASED FAMILIAL RISK; NEUROPSYCHIATRIC INVENTORY; IMPAIRMENT; SYMPTOMS; DEMENTIA; HALLUCINATIONS; DELUSIONS; PHENOTYPE AB Objective: To compare the trajectories of cognitive decline between groups with, and without, the later development of psychotic symptoms during Alzheimer disease (AD) or mild cognitive impairment (MCI). Design: The authors examined cognitive function in a new analysis of an existing data set, the Cardiovascular Health Study, an epidemiologic, longitudinal follow-up study. Our analyses examined 9 years of follow-up data. Setting: Community. Participants: The authors examined subjects who were without dementia at study entry, received a diagnosis of AD or MCI during follow-up, and had been rated on the Neuropsychiatric Inventory for the presence of psychosis; 362 participants for the modified Mini-Mental State Examination (3MS) analysis and 350 participants for the digit symbol substitution test (DSST) analysis had sufficient follow-up data and apolipoprotein-epsilon (APOE) genotyping. Measurements: The 3MS and DSST were administered annually and analyzed using mixed-effects models including APOE4 status. Results: Mean 3MS and DSST scores did not differ between AD with psychosis (AD + P) and without psychosis groups at baseline. The 3MS and DSST scores decreased more rapidly in subjects who ultimately developed psychosis. Conclusions: Individuals who ultimately develop psychosis have more rapid cognitive deterioration during the earliest phases of AD than individuals with AD not developing psychosis. The genetic and other neurobiologic factors leading to the expression of AD + P may exert their effects by acceleration of the neurodegenerative process. (Am J Geriatr Psychiatry 2011; 19: 160-168) C1 [Emanuel, James E.; Lopez, Oscar L.; Houck, Patricia R.; Becker, James T.; Weamer, Elise A.; DeMichele-Sweet, Mary Ann A.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Lopez, Oscar L.; Becker, James T.; Weamer, Elise A.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA USA. [Kuller, Lewis] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. RP Sweet, RA (reprint author), 3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu OI Becker, James/0000-0003-4425-4726 FU NHLBI NIH HHS [N01 HC075150, N01 HC-55222, N01 HC015103, N01 HC035129, N01 HC045133, N01 HC055222, N01 HC085079, N01 HC085080, N01 HC085081, N01 HC085082, N01 HC085083, N01 HC085084, N01 HC085085, N01 HC085086, N01-HC-75150, N01-HC-85079, N01-HC-85086, N01HC55222, N01HC75150, N01HC85079, N01HC85086, U01 HL080295, U01 HL080295-04]; NIA NIH HHS [AG027224, AG05133, AG15928, P50 AG005133, P50 AG005133-210020, R01 AG015928, R01 AG015928-02, R01 AG020098, R01 AG027224, R01 AG027224-04] NR 29 TC 22 Z9 22 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD FEB PY 2011 VL 19 IS 2 BP 160 EP 168 DI 10.1097/JGP.0b013e3181e446c8 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 709PU UT WOS:000286453700008 PM 20808116 ER PT J AU Glasser, SP Judd, S Basile, J Lackland, D Halanych, J Cushman, M Prineas, R Howard, V Howard, G AF Glasser, Stephen P. Judd, Suzanne Basile, Jan Lackland, Dan Halanych, Jewell Cushman, Mary Prineas, Ronald Howard, Virginia Howard, George TI Prehypertension, Racial Prevalence and Its Association With Risk Factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; cardiovascular disease; hypertension; prehypertension; risk factors ID HIGH BLOOD-PRESSURE; JOINT NATIONAL COMMITTEE; 7TH REPORT; HYPERTENSION; PROGRESSION; PREVENTION; PREDICTORS; ADULTS; HEALTH AB BACKGROUND There are few available data on the epidemiology of prehypertension (preHTN). To determine racial, clinical, and demographic differences in the prevalence of preHTN and its cross-sectional association with vascular risk factors. METHODS Cross-sectional analysis of 5,553 prehypertensives, 20,351 hypertensive's, and 4,246 nonhypertensive participants (age 45), from a population-based national cohort study (REasons for Geographic And Racial Differences in Stroke (REGARDS) total population 30,239, of whom 30,150 had adequate blood pressure (BP) measurements) enrolled from January 2003-October 2007 with oversampling from the southeastern stroke belt, and black individuals. Baseline data were collected using a combination of telephone interview and in-home evaluation. preHTN was defined according to The Seventh Report of the Joint national Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines. RESULTS The prevalence of preHTN was associated with age and black race (62.9% in blacks compared to 54.1% in whites). A higher prevalence of preHTN was observed in obese individuals, self-reported heart disease; and, those with elevated high-sensitivity C reactive protein (hsCRP), diabetes, and microalbuminuria compared to those without these factors. Heavy alcohol consumption in white participants was associated with increased odds of preHTN (odds ratio (OR) = 1.32) but was even greater in black participants (OR = 2.27). CONCLUSION The prevalence of preHTN increased by age and African American race. In addition, a higher prevalence of preHTN was observed with elevated hsCRP, diabetes, microalbuminuria, and those with heavy alcohol consumption compared to those without these factors. C1 [Glasser, Stephen P.; Halanych, Jewell] Univ Alabama, Dept Internal Med, Div Prevent Med, Birmingham, AL USA. [Judd, Suzanne; Howard, Virginia; Howard, George] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Basile, Jan] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Cushman, Mary] Univ Vermont, Burlington, VT USA. [Prineas, Ronald] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. RP Glasser, SP (reprint author), Univ Alabama, Dept Internal Med, Div Prevent Med, Birmingham, AL USA. EM sglasser@uab.edu OI Glasser, Stephen/0000-0001-9620-6406 FU National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services [U01 NS041588]; National Institute of Neurological Disorders and Stroke, National Institutes of Health FX This research project is supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health. Representatives of the funding agency have been involved in the review of the manuscript but not directly involved in the collection, management, analysis or interpretation of the data. The authors acknowledge the participating investigators and institutions for their valuable contributions: The University of Alabama at Birmingham, Birmingham, AL (Study PI, Statistical and Data Coordinating Center, Survey Research Unit): G.H. DrPH, Leslie McClure PhD, V.H.PhD, Libby Wagner MA, Virginia Wadley PhD, Rodney Go PhD, Monika Safford MD, Ella Temple PhD, Margaret Stewart MSPH, J.David Rhodes BSN; University of Vermont (Central Laboratory): M.C. MD; Wake Forest University (ECG Reading Center): R.P. MD, PhD; Alabama Neurological Institute (Stroke Validation Center, Medical Monitoring):Camilo Gomez MD, Susana Bowling MD; University of Arkansas for Medical Sciences (Survey Methodology): LeaVonne Pulley PhD; University of Cincinnati (Clinical Neuroepidemiology): Brett Kissela MD, Dawn Kleindorfer MD; Examination Management Services, Incorporated (In-Person Visits): Andra Graham; Medical University of South Carolina (Migration Analysis Center): D.L. DrPH; Indiana University School of Medicine (Neuropsychology Center): Frederick Unverzagt PhD; National Institute of Neurological Disorders and Stroke, National Institutes of Health (funding agency): Claudia Moy PhD. NR 20 TC 28 Z9 33 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD FEB PY 2011 VL 24 IS 2 BP 194 EP 199 DI 10.1038/ajh.2010.204 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 709PC UT WOS:000286451600012 PM 20864944 ER PT J AU Plantinga, LC Johansen, K Crews, DC Shahinian, VB Robinson, BM Saran, R Burrows, NR Williams, DE Powe, NR AF Plantinga, Laura C. Johansen, Kirsten Crews, Deidra C. Shahinian, Vahakn B. Robinson, Bruce M. Saran, Rajiv Burrows, Nilka Rios Williams, Desmond E. Powe, Neil R. CA CDC CKD Surveillance Team TI Association of CKD With Disability in the United States SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Chronic kidney disease; disability; activities of daily living; limitations; employment; physical functioning; cognitive functioning ID CHRONIC KIDNEY-DISEASE; CHRONIC RENAL-INSUFFICIENCY; GLOMERULAR-FILTRATION-RATE; COGNITIVE FUNCTION; SERUM CREATININE; NATIONAL-HEALTH; DIALYSIS; EQUATION; FRAILTY AB Background: Little is known about disability in early-stage chronic kidney disease (CKD). Study Design: Cross-sectional national survey (National Health and Nutrition Examination Survey 19992006). Setting & Participants: Community-based survey of 16,011 noninstitutionalized US civilian adults (aged >20 years). Predictor: CKD, categorized as no CKD, stages 1 and 2 (albuminuria and estimated glomerular filtration rate [eGFR] >= 60 mL/min/1.73 m(2)), and stages 3 and 4 (eGFR, 15-59 mL/min/1.73 m(2)). Outcome: Self-reported disability, defined by limitations in working, walking, and cognition and difficulties in activities of daily living (ADL), instrumental ADL, leisure and social activities, lower-extremity mobility, and general physical activity. Measurements: Albuminuria and eGFR assessed from urine and blood samples; disability, demographics, access to care, and comorbid conditions assessed using a standardized questionnaire. Results: Age-adjusted prevalence of reported limitations generally was significantly greater with CKD: for example, difficulty with ADL was reported by 17.6%, 24.7%, and 23.9% of older (>= 65 years) and 6.8%, 11.9%, and 11.0% of younger (20-64 years) adults with no CKD, stages 1 and 2, and stages 3 and 4, respectively. CKD also was associated with greater reported limitations and difficulty in other activities after age adjustment, including instrumental ADL, leisure and social activities, lower-extremity mobility, and general physical activity. Other demographics, socioeconomic status, and access to care generally only slightly attenuated the observed associations, particularly in older individuals; adjustment for cardiovascular disease, arthritis, and cancer attenuated most associations such that statistical significance no longer was achieved. Limitations: Inability to establish causality and possible unmeasured confounding. Conclusion: CKD is associated with a higher prevalence of disability in the United States. Age and other comorbid conditions account for most, but not all, of this association. Am J Kidney Dis. 57(2):212-227. (C) 2011 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Plantinga, Laura C.; Powe, Neil R.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Plantinga, Laura C.; Johansen, Kirsten; Powe, Neil R.] Univ Calif San Francisco, San Francisco, CA 94110 USA. [Johansen, Kirsten] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Crews, Deidra C.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Shahinian, Vahakn B.; Saran, Rajiv] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Robinson, Bruce M.; Saran, Rajiv] Arbor Res Collaborat Hlth, Ann Arbor, MI USA. [Burrows, Nilka Rios; Williams, Desmond E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. RP Plantinga, LC (reprint author), San Francisco Gen Hosp, Dept Med, 1001 Potrero Ave,Bldg 10,Fl 3, San Francisco, CA 94110 USA. EM plantingal@medsfgh.ucsf.edu FU Centers for Disease Control and Prevention (CDC) through the Association of American Medical Colleges (AAMC) [U36/CCU319276, MM-0997-07/07, MM-1143-10/10]; Robert Wood Johnson Foundation; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD [K24DK02643] FX This project was supported under a cooperative agreement from the Centers for Disease Control and Prevention (CDC) through the Association of American Medical Colleges (AAMC), grant number U36/CCU319276, AAMC ID numbers MM-0997-07/07 and MM-1143-10/10. Report contents are solely the responsibility of the authors and do not necessarily represent the official views of the AAMC or CDC. Dr Crews is supported by the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Dr Powe is partially supported by grant K24DK02643 from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. NR 26 TC 24 Z9 24 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD FEB PY 2011 VL 57 IS 2 BP 212 EP 227 DI 10.1053/j.ajkd.2010.08.016 PG 16 WC Urology & Nephrology SC Urology & Nephrology GA 708OK UT WOS:000286372700008 PM 21036441 ER PT J AU Huson, SM Acosta, MT Belzberg, AJ Bernards, A Chernoff, J Cichowski, K Evans, DG Ferner, RE Giovannini, M Korf, BR Listernick, R North, KN Packer, RJ Parada, LF Peltonen, J Ramesh, V Reilly, KM Risner, JW Schorry, EK Upadhyaya, M Viskochil, DH Zhu, YA Hunter-Schaedle, K Giancotti, FG AF Huson, Susan M. Acosta, Maria T. Belzberg, Allan J. Bernards, Andre Chernoff, Jonathan Cichowski, Karen Evans, D. Gareth Ferner, Rosalie E. Giovannini, Marco Korf, Bruce R. Listernick, Robert North, Kathryn N. Packer, Roger J. Parada, Luis F. Peltonen, Juha Ramesh, Vijaya Reilly, Karlyne M. Risner, John W. Schorry, Elizabeth K. Upadhyaya, Meena Viskochil, David H. Zhu, Yuan Hunter-Schaedle, Kim Giancotti, Filippo G. TI Back to the Future: Proceedings From the 2010 NF Conference SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE neurofibromatosis; schwannomatosis; NF1; NF2; neurofibroma; learning disabilities; bone dysplasia; MPNST ID GROWTH-FACTOR RECEPTOR; PERIPHERAL-NERVE; NEUROFIBROMATOSIS TYPE-2; PHENOTYPE; TUMORIGENESIS; EXPRESSION; PLEXIFORM; MUTATIONS; SPRED1; TUMORS AB The neurofibromatoses (NF) encompass the rare diseases NF1, NF2, and schwannomatosis. The NFs affect 100,000 Americans; over 2 million persons worldwide; and are caused by mutation of tumor suppressor genes. Individuals with NF1 in particular may develop tumors anywhere in the nervous system; additional manifestations can include learning disabilities, bone dysplasia, cardiovascular defects, unmanageable pain, and physical disfigurement. Ultimately, the NFs can cause blindness, deafness, severe morbidity, and increased mortality and NF1 includes a risk of malignant cancer. Today there is no treatment for the NFs (other than symptomatic); however, research efforts to understand these genetic conditions have made tremendous strides in the past few years. Progress is being made on all fronts, from discovery studies-understanding the molecular signaling deficits that cause the manifestations of NF-to the growth of preclinical drug screening initiatives and the emergence of a number of clinical trials. An important element in fuelling this progress is the sharing of knowledge, and to this end, for over 20 years the Children's Tumor Foundation has convened an annual NF Conference, bringing together NF professionals to share ideas and build collaborations. The 2010 NF Conference held in Baltimore, MD June 5-8, 2010 hosted over 300 NF researchers and clinicians. This paper provides a synthesis of the highlights presented at the Conference and as such, is a "state-of-the-field" for NF research in 2010. (C) 2010 Wiley-Liss, Inc. C1 [Risner, John W.; Hunter-Schaedle, Kim] Childrens Tumor Fdn, New York, NY 10005 USA. [Huson, Susan M.; Evans, D. Gareth] Univ Manchester, St Marys Hosp, Manchester M13 0JH, Lancs, England. [Acosta, Maria T.; Packer, Roger J.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Belzberg, Allan J.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Bernards, Andre; Ramesh, Vijaya] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Chernoff, Jonathan] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Cichowski, Karen] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Ferner, Rosalie E.] Guys & St Thomas NHS Hosp Trust, London, England. [Giovannini, Marco] House Ear Res Inst, Los Angeles, CA USA. [Korf, Bruce R.] Univ Alabama, Birmingham, AL USA. [Listernick, Robert] Childrens Mem Hosp, Chicago, IL 60614 USA. [North, Kathryn N.] Univ Sydney, Sydney, NSW 2006, Australia. [Parada, Luis F.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Peltonen, Juha] Inst Biomed, Helsinki, Finland. [Reilly, Karlyne M.] NCI, NIH, Frederick, MD 21701 USA. [Schorry, Elizabeth K.] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Upadhyaya, Meena] Cardiff Univ, Cardiff, S Glam, Wales. [Viskochil, David H.] Univ Utah, Salt Lake City, UT USA. [Zhu, Yuan] Univ Michigan, Ann Arbor, MI 48109 USA. [Giancotti, Filippo G.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Hunter-Schaedle, K (reprint author), Childrens Tumor Fdn, 95 Pine St, New York, NY 10005 USA. EM khs@ctf.org RI Peltonen, Juha/C-2817-2008; Parada, luis/B-9400-2014; Chernoff, Jonathan/I-7631-2014; North, Kathryn/K-6476-2012; OI Peltonen, Juha/0000-0002-5732-4167; Chernoff, Jonathan/0000-0002-4803-7836; North, Kathryn/0000-0003-0841-8009; Evans, Gareth/0000-0002-8482-5784 FU National Institutes of Health [1R13NS070505-01] FX Grant sponsor: National Institutes of Health; Grant number: 1R13NS070505-01. NR 31 TC 11 Z9 11 U1 1 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4825 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD FEB PY 2011 VL 155A IS 2 BP 307 EP 321 DI 10.1002/ajmg.a.33804 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA 718VE UT WOS:000287153700009 PM 21271647 ER PT J AU Keenan, RT O'Brien, WR Lee, KH Crittenden, DB Fisher, MC Goldfarb, DS Krasnokutsky, S Oh, C Pillinger, MH AF Keenan, Robert T. O'Brien, William R. Lee, Kristen H. Crittenden, Daria B. Fisher, Mark C. Goldfarb, David S. Krasnokutsky, Svetlana Oh, Cheongeun Pillinger, Michael H. TI Prevalence of Contraindications and Prescription of Pharmacologic Therapies for Gout SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Comorbidity; Drug contraindication; Gout; Quality of care; Treatment ID NUTRITION EXAMINATION SURVEY; METABOLIC SYNDROME; NATIONAL-HEALTH; OLDER-ADULTS; HYPERURICEMIA; MANAGEMENT; CARE; ALLOPURINOL; POPULATION; CLASSIFICATION AB BACKGROUND: Patients with gout have comorbidities, but the impact of these comorbidities on treatment has not been studied. METHODS: A total of 575 patients with gout were stratified according to certainty of diagnosis according to International Classification of Diseases, 9th Revision, Clinical Modification code alone (cohort I), American College of Radiology criteria (cohort II), and crystal diagnosis (cohort III). Comorbid conditions were defined according to International Classification of Diseases, 9th Revision, Clinical Modification codes, and stratified as either moderate or severe. Drug contraindications were defined as moderate or strong, based on Food and Drug Administration criteria and severity of disease. RESULTS: The most common comorbidity was hypertension (prevalence 0.89). The presence of comorbidities resulted in a high frequency of contraindications to approved gout medications. More than 90% of patients had at least 1 contraindication to nonsteroidal anti-inflammatory drugs. Many patients demonstrated multiple contraindications to 1 or more gout medications. Frequently, patients were prescribed medications to which they harbored contraindications. The prevalence of patients prescribed colchicine despite having at least 1 strong contraindication was 30% (cohort I), 37% (cohort II), and 39.6% (cohort III). CONCLUSION: Patients with gout typically harbor multiple comorbidities that result in contraindications to many of the medications available to treat gout. Frequently, despite contraindications to gout therapies, patients are frequently prescribed these medications. (C) 2011 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2011) 124, 155-163 C1 [Keenan, Robert T.; O'Brien, William R.; Lee, Kristen H.; Crittenden, Daria B.; Fisher, Mark C.; Krasnokutsky, Svetlana; Pillinger, Michael H.] New York Harbor Hlth Care Syst, Rheumatol Sect, US Dept Vet Affairs, New York, NY USA. [Goldfarb, David S.] New York Harbor Hlth Care Syst, Nephrol Sect, US Dept Vet Affairs, New York, NY USA. [Keenan, Robert T.; O'Brien, William R.; Lee, Kristen H.; Crittenden, Daria B.; Fisher, Mark C.; Krasnokutsky, Svetlana; Pillinger, Michael H.] NYU, Sch Med, Div Rheumatol, New York, NY USA. [Goldfarb, David S.] NYU, Sch Med, Div Nephrol, New York, NY USA. [Oh, Cheongeun] NYU, Sch Med, Div Biostat, New York, NY USA. RP Keenan, RT (reprint author), Duke Univ, Med Ctr, Div Rheumatol, 200 Trent Dr,DUMC 3544, Durham, NC 27710 USA. EM robert.keenan@duke.edu OI Goldfarb, David/0000-0002-9215-1273; Pillinger, Michael/0000-0003-3168-1542 FU National Institutes of Health [5T32AR007176]; Arthritis Foundation New York Chapter FX Drs Keenan and Fisher were supported by National Institutes of Health T32 Training Grant 5T32AR007176. Dr Fisher also was the recipient of Fellowship Training Award from the Arthritis Foundation New York Chapter. No other external funding was used. NR 39 TC 67 Z9 68 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD FEB PY 2011 VL 124 IS 2 BP 155 EP 163 DI 10.1016/j.amjmed.2010.09.012 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 725PO UT WOS:000287658100022 PM 21295195 ER PT J AU Ruhnke, GW Coca-Perraillon, M Kitch, BT Cutler, DM AF Ruhnke, Gregory W. Coca-Perraillon, Marcelo Kitch, Barrett T. Cutler, David M. TI Marked Reduction in 30-Day Mortality Among Elderly Patients with Community-acquired Pneumonia SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Community-acquired pneumonia; Mortality; Trends ID PNEUMOCOCCAL POLYSACCHARIDE VACCINE; INITIAL ANTIMICROBIAL THERAPY; POPULATION-BASED COHORT; UNITED-STATES; ANTIBIOTIC-THERAPY; SEX-DIFFERENCES; OUTCOMES; CARE; ADULTS; GUIDELINES AB BACKGROUND: Community-acquired pneumonia is the most common infectious cause of death in the US. Over the last 2 decades, patient characteristics and clinical care have changed. To understand the impact of these changes, we quantified incidence and mortality trends among elderly adults. METHODS: We used Medicare claims to identify episodes of pneumonia, based on a validated combination of diagnosis codes. Comorbidities were ascertained using the diagnosis codes located on a 1-year look back. Trends in patient characteristics and site of care were compared. The association between year of pneumonia episode and 30-day mortality was then evaluated by logistic regression, with adjustment for age, sex, and comorbidities. RESULTS: We identified 2,654,955 cases of pneumonia from 1987-2005. During this period, the proportion treated as inpatients decreased, the proportion aged >= 80 years increased, and the frequency of many comorbidities rose. Adjusted incidence increased to 3096 episodes per 100,000 population in 1999, with some decrease thereafter. Age/sex-adjusted mortality decreased from 13.5% to 9.7%, a relative reduction of 28.1%. Compared with 1987, the risk of mortality decreased through 2005 (adjusted odds ratio, 0.46; 95% confidence interval, 0.44-0.47). This result was robust to a restriction on comorbid diagnoses assessing for the results' sensitivity to increased coding. CONCLUSIONS: These findings show a marked mortality reduction over time in community-acquired pneumonia patients. We hypothesize that increased pneumococcal and influenza vaccination rates as well as wider use of guideline-concordant antibiotics explain a large portion of this trend. (C) 2011 Elsevier Inc. All rights reserved. (C) 2011 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2011) 124, 171-178 C1 [Ruhnke, Gregory W.] Univ Chicago, Sect Hosp Med, Chicago, IL 60637 USA. [Coca-Perraillon, Marcelo; Cutler, David M.] Natl Bur Econ Res, Cambridge, MA 02138 USA. [Kitch, Barrett T.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Kitch, Barrett T.] N Shore Med Ctr, Salem, MA USA. [Cutler, David M.] Harvard Univ, Cambridge, MA 02138 USA. RP Ruhnke, GW (reprint author), Univ Chicago, Sect Hosp Med, 5841 S Maryland Ave,MC 5000, Chicago, IL 60637 USA. EM gruhnke@medicine.bsd.uchicago.edu FU National Institute on Aging [P01 AG31098, P30 AG12810, P01AG005842]; Health Resources and Services Administration of the Department of Health and Human Services, the Division of General Internal Medicine at the Massachusetts General Hospital [T32 HP11001]; Agency for Healthcare Research and Quality [F32 HS016948-01] FX This work was supported by unrestricted grants P01 AG31098, P30 AG12810, and P01AG005842 from the National Institute on Aging. It also was supported by an institutional Ruth L. Kirschstein National Research Service Award (T32 HP11001) from the Health Resources and Services Administration of the Department of Health and Human Services, the Division of General Internal Medicine at the Massachusetts General Hospital, and grant F32 HS016948-01 from the Agency for Healthcare Research and Quality. The supporters had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 44 TC 42 Z9 44 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD FEB PY 2011 VL 124 IS 2 BP 171 EP U117 DI 10.1016/j.amjmed.2010.08.019 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 725PO UT WOS:000287658100024 PM 21295197 ER PT J AU Kaimal, AJ Little, SE Odibo, AO Stamilio, DM Grobman, WA Long, EF Owens, DK Caughey, AB AF Kaimal, Anjali J. Little, Sarah E. Odibo, Anthony O. Stamilio, David M. Grobman, William A. Long, Elisa F. Owens, Douglas K. Caughey, Aaron B. TI Cost-effectiveness of elective induction of labor at 41 weeks in nulliparous women SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE elective induction; induction of labor; postterm pregnancy ID CESAREAN DELIVERY; GESTATIONAL-AGE; POSTTERM PREGNANCY; EXPECTANT MANAGEMENT; TERM PREGNANCY; RISK-FACTORS; OUTCOMES; BIRTHS; COMPLICATIONS; INFANTS AB OBJECTIVE: To investigate the cost-effectiveness of elective induction of labor at 41 weeks in nulliparous women. STUDY DESIGN: A decision analytic model comparing induction of labor at 41 weeks vs expectant management with antenatal testing until 42 weeks in nulliparas was designed. Baseline assumptions were derived from the literature as well as from analysis of the National Birth Cohort dataset and included an intrauterine fetal demise rate of 0.12% in the 41st week and a cesarean rate of 27% in women induced at 41 weeks. One-way and multiway sensitivity analyses were conducted to examine the robustness of the findings. RESULTS: Compared with expectant management, induction of labor is cost-effective with an incremental cost of $10,945 per quality-adjusted life year gained. Induction of labor at 41 weeks also resulted in a lower rate of adverse obstetric outcomes, including neonatal demise, shoulder dystocia, meconium aspiration syndrome, and severe perineal lacerations. CONCLUSION: Elective induction of labor at 41 weeks is cost-effective and improves outcomes. C1 [Kaimal, Anjali J.; Little, Sarah E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02115 USA. [Odibo, Anthony O.; Stamilio, David M.] Washington Univ, Dept Obstet & Gynecol, St Louis, MO USA. [Grobman, William A.] Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA. [Long, Elisa F.] Yale Univ, Sch Management, New Haven, CT USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Caughey, Aaron B.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA. RP Kaimal, AJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02115 USA. FU Agency for Healthcare Research and Quality, US Department of Health and Human Services [290-02-0017]; Robert Wood Johnson Foundation [RWJF-61535] FX This study was supported in part by contract 290-02-0017 from the Agency for Healthcare Research and Quality, US Department of Health and Human Services. A.B.C. is supported by the Robert Wood Johnson Foundation as a Physician Faculty Scholar Grant RWJF-61535. NR 38 TC 4 Z9 4 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD FEB PY 2011 VL 204 IS 2 AR 137.e1 DI 10.1016/j.ajog.2010.08.012 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 715HV UT WOS:000286874900018 PM 20965482 ER PT J AU Sobrin, L Reynolds, R Yu, Y Fagerness, J Leveziel, N Bernstein, PS Souied, EH Daly, MJ Seddon, JM AF Sobrin, Lucia Reynolds, Robyn Yu, Yi Fagerness, Jesen Leveziel, Nicolas Bernstein, Paul S. Souied, Eric H. Daly, Mark J. Seddon, Johanna M. TI ARMS2/HTRA1 Locus Can Confer Differential Susceptibility to the Advanced Subtypes of Age-Related Macular Degeneration SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID COMPLEMENT FACTOR-H; FAMILIAL AGGREGATION; RISK; VARIANT; HTRA1; MACULOPATHY; GENES; POLYMORPHISM; ASSOCIATION; POPULATION AB PURPOSE: To determine if genetic variants that have been associated with age-related macular degeneration (AMD) have a differential effect on the risk of choroidal neovascularization (CNV) and geographic atrophy. DESIGN: Genetic association study. METHODS: SETTING: Multicenter study. STUDY POPULATION: Seven hundred forty-nine participants with geographic atrophy and 3209 participants with CNV were derived from 4 AMD studies with similar procedures from Tufts Medical Center, the Age-Related Eye Disease Study, University of Utah, and Hopital Intercommunal de Creteil. PROCEDURES: AMD grade was assigned based on fundus photography and examination using the clinical age-related maculopathy staging system. All samples were genotyped for single nucleotide polymorphisms (SNPs) previously associated with AMD. Allele frequencies were compared between participants with CNV and geographic atrophy using PLINK within each cohort and Mantel-Haenszel meta-analysis was performed to combine odds ratios (OR). MAIN OUTCOME MEASURES: Differences in allele frequencies between participants with geographic atrophy and CNV. RESULTS: The frequency of the T allele of ARMS2/HTRA1 rs10490924 was significantly higher in participants with CNV than in those with geographic atrophy (OR, 1.37; 95% confidence interval, 1.21-1.54; P value = 4.2 x 10(-7)). This result remained statistically significant when excluding individuals who had geographic atrophy in 1 eye and CNV in the contralateral eye (P = 2.2 x 10(-4)). None of the other SNPs showed a significant differential effect for CNV vs geographic atrophy, including CFH, C2/CFB, C3, CFI, LIPC, and TIMP3. CONCLUSIONS: Genetic variation at the ARMS2/HTRA1 locus confers a differential risk for CNV vs geographic atrophy in a well-powered sample. (Am J Ophthalmol 2011;151:345-352. (C) 2011 by Elsevier Inc. All rights reserved.) C1 [Seddon, Johanna M.] Tufts Med Ctr, Dept Ophthalmol, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, Boston, MA 02111 USA. [Sobrin, Lucia] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. [Fagerness, Jesen; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Program Med & Populat Genet, Boston, MA 02114 USA. [Fagerness, Jesen; Daly, Mark J.] Broad Inst, Cambridge, MA USA. [Leveziel, Nicolas; Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Hop Intercommunal Creteil, Creteil, France. [Bernstein, Paul S.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA. [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA. RP Seddon, JM (reprint author), Tufts Med Ctr, Dept Ophthalmol, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, 800 Washington St,450, Boston, MA 02111 USA. EM jseddon@tuftsmedicalcenter.org FU National Institutes of Health, Bethesda, Maryland [RO1-EY11309, RO1-EY13435, R24-EY017404, K12-EY16335, EY-11600]; Massachusetts Lions Eye Research Fund, Inc, New Bedford, Massachusetts; Research to Prevent Blindness, Inc, New York, New York; Pfizer; Genentech FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED IN PART BY GRANTS RO1-EY11309, RO1-EY13435, R24-EY017404, K12-EY16335, and EY-11600 from the National Institutes of Health, Bethesda, Maryland; Massachusetts Lions Eye Research Fund, Inc, New Bedford, Massachusetts; unrestricted grants and Career Development Award from Research to Prevent Blindness, Inc, New York, New York; National Center for Research Resources, Bethesda, Maryland; The Macula Vision Research Foundation, West Conshohocken, Pennsylvania; and the Macular Degeneration Research Fund of the Ophthalmic Epidemiology and Generics Service, New England Eye Center, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts. Dr Sobrin has been a consultant for Alcon Laboratories. Dr Souied has been a consultant for Novartis and Bausch & Lomb and received lecture fees from Bausch & Lomb. Dr Seddon has a patent application with Tufts Medical Center and has received grant funding from Pfizer and Genentech. Involved in design of the study (L.S., M.J.D.,.J.M.S.); conduct of the study (L.S., R.R., J.F., J.M.S.); collection, management, analysis, and interpretation of the data (L.S., R.R., Y.Y., J.F., N.L., P.S.B., E.H.S., M.J.D., J.M.S.); and preparation, review, or approval of the manuscript (L.S., Y.Y., J.F., N.L., P.S.B., El-IS., M.J.D., J.M.S.). This study was approved by the Tufts Medical Center Institutional Review Board prospectively. The study is HIPAA compliant and proper informed consent for participation in the research was obtained. NR 30 TC 34 Z9 35 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD FEB PY 2011 VL 151 IS 2 BP 345 EP 352 DI 10.1016/j.ajo.2010.08.015 PG 8 WC Ophthalmology SC Ophthalmology GA 712ZX UT WOS:000286705900024 PM 21122828 ER PT J AU Garcia, AM Dicianno, BE AF Garcia, Angela M. Dicianno, Brad E. TI The Frequency of Lymphedema in an Adult Spina Bifida Population SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Meningomyelocele; Lymphedema; Hypertension; Obesity ID PHYSICAL-ACTIVITY; HUMAN-DISEASE; YOUNG-ADULTS; LIFE-SPAN; BODY-FAT; LYMPHANGIOGENESIS; OBESITY; ADOLESCENTS; PREVENTION; FITNESS AB Garcia AM, Dicianno BE: The frequency of lymphedema in an adult spina bifida population. Am J Phys Med Rehabil 2011;90:89Y96. Objective: In the United States, there are more than 100,000 people with spina bifida. There have been very few studies to date documenting the occurrence of lymphedema in the spina bifida population, despite a case series in 2001 that suggested that the occurrence may be higher than in the general population. Currently, approximately 1 million people have lymphedema in the United States. The purpose of this study was to document the occurrence of lymphedema and associated medical factors in a regional adult spina bifida population. Design: A total of 240 electronic medical records from the Adult Spina Bifida Clinic from January 2005 to August 2008 were retrospectively reviewed. Subjects were divided into two groups based on the presence or absence of lymphedema. chi(2) analyses were used to compare lymphedema groups with respect to history of medical comorbidities and ethnicity. Fisher exact tests were used to compare groups with respect to mobility status and the presence of power wheelchair seat functions. Mann-Whitney U tests were used to compare groups with respect to age, anatomic lesion level, employment level, and income. Results: Twenty-two (9.2%) patients had lymphedema. Mean T SD population age was 35.1 +/- 11.1 yrs. Lymphedema was associated with a history of trauma (P = 0.044), cellulitis (P < 0.001), cancer (P = 0.038), obesity (P < 0.001), wounds (P < 0.001), hypertension (P = 0.036), higher lesion level spina bifida (P = 0.049), and mobility status (P = 0.007). Hypertension and obesity were present in 38.3% and 37.5% of the total study population, respectively. Conclusions: This is the first study to document the occurrence of lymphedema in a spina bifida patient population, which was almost 100 times higher than that in the general patient population. We also documented a high occurrence of hypertension and obesity in the total study population. These findings may help guide further prospective studies to more clearly delineate the risk factors for the development of lymphedema and to determine the appropriate therapies. Better screening, prevention and treatment algorithms are needed for hypertension and obesity in the spina bifida population. C1 [Garcia, Angela M.; Dicianno, Brad E.] UPMC, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. [Dicianno, Brad E.] UPMC, Adult Outpatient Spina Bifida Clin, Pittsburgh, PA 15213 USA. [Dicianno, Brad E.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. RP Dicianno, BE (reprint author), UPMC, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA. OI Dicianno, Brad/0000-0003-0738-0192 FU UPMC Department of Physical Medicine and Rehabilitation FX Funded by the UPMC Department of Physical Medicine and Rehabilitation. Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article. NR 36 TC 6 Z9 6 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD FEB PY 2011 VL 90 IS 2 BP 89 EP 96 DI 10.1097/PHM.0b013e318201753e PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 703QM UT WOS:000285994800001 PM 21173682 ER PT J AU Hurley, BP Pirzai, W Mumy, KL Gronert, K McCormick, BA AF Hurley, Bryan P. Pirzai, Waheed Mumy, Karen L. Gronert, Karsten McCormick, Beth A. TI Selective eicosanoid-generating capacity of cytoplasmic phospholipase A(2) in Pseudomonas aeruginosa-infected epithelial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE lung inflammation; neutrophils; arachidonic acid; prostaglandin E-2; hepoxilin A(3) ID TRANSEPITHELIAL MIGRATION; ACUTE-INFLAMMATION; CYSTIC-FIBROSIS; HEPOXILIN A(3); LUNG; EXPRESSION; PNEUMONIA; PGE(2); RESOLUTION; MEDIATOR AB Hurley BP, Pirzai W, Mumy KL, Gronert K, McCormick BA. Selective eicosanoid-generating capacity of cytoplasmic phospholipase A(2) in Pseudomonas aeruginosa-infected epithelial cells. Am J Physiol Lung Cell Mol Physiol 300: L286-L294, 2011. First published November 19, 2010; doi:10.1152/ajplung.00147.2010.-Airway neutrophil infiltration is a pathological hallmark observed in multiple lung diseases including pneumonia and cystic fibrosis. Bacterial pathogens such as Pseudomonas aeruginosa instigate neutrophil recruitment to the air space. Excessive accumulation of neutrophils in the lung often contributes to tissue destruction. Previous studies have unveiled hepoxilin A(3) as the key molecular signal driving neutrophils across epithelial barriers. The eicosanoid hepoxilin A(3) is a potent neutrophil chemoattractant produced by epithelial cells in response to infection with P. aeruginosa. The enzyme phospholipase A(2) liberates arachidonic acid from membrane phospholipids, the rate-limiting step in the synthesis of all eicosanoids, including hepoxilin A(3). Once generated, aracidonic acid is acted upon by multiple cyclooxygenases and lipoxygenases producing an array of functionally diverse eicosanoids. Although there are numerous phospholipase A(2) isoforms capable of generating arachidonic acid, the isoform most often associated with eicosanoid generation is cytoplasmic phospholipase A(2)alpha. In the current study, we observed that the cytoplasmic phospholipase A(2)alpha isoform is required for mediating P. aeruginosa-induced production of certain eicosanoids such as prostaglandin E-2. However, we found that neutrophil transepithelial migration induced by P. aeruginosa does not require cytoplasmic phospholipase A(2)alpha. Furthermore, P. aeruginosa-induced hepoxilin A(3) production persists despite cytoplasmic phospholipase A(2)alpha suppression and generation of the 12-lipoxygenase metabolite 12-HETE is actually enhanced in this context. These results suggest that alterative phospholipase A(2) isoforms are utilized to synthesize 12-lipoxygenase metabolites. The therapeutic implications of these findings are significant when considering anti-inflammatory therapies based on targeting eicosanoid synthesis pathways. C1 [Hurley, Bryan P.; Pirzai, Waheed; Mumy, Karen L.] Massachusetts Gen Hosp, Mucosal Immunol Lab, Charlestown, MA 02129 USA. [Hurley, Bryan P.; Mumy, Karen L.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Gronert, Karsten] Univ Calif Berkeley, Sch Optometry, Vis Sci Program, Berkeley, CA 94720 USA. [McCormick, Beth A.] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA USA. RP Hurley, BP (reprint author), Massachusetts Gen Hosp, Mucosal Immunol Lab, CNY 114 114-3503, Charlestown, MA 02129 USA. EM bphurley@partners.org FU Research Scholarship Development Award [K22 AI065425]; Cystic Fibrosis Foundation; National Institute of Diabetes and Digestive and Kidney Diseases [DK-56754]; National Eye Institute [EY-016136] FX This work was supported by Research Scholarship Development Award K22 AI065425 (to B. P. Hurley) and a Cystic Fibrosis Foundation Research Grant (to B. P. Hurley). B. A. McCormick is supported by National Institute of Diabetes and Digestive and Kidney Diseases DK-56754. K. Gronert is supported by National Eye Institute Grant EY-016136. NR 37 TC 13 Z9 13 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD FEB PY 2011 VL 300 IS 2 BP L286 EP L294 DI 10.1152/ajplung.00147.2010 PG 9 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 714HW UT WOS:000286800300015 PM 21097525 ER PT J AU Strom, BL Eng, SM Faich, G Reynolds, RF D'Agostino, RB Ruskin, J Kane, JM AF Strom, Brian L. Eng, Sybil M. Faich, Gerald Reynolds, Robert F. D'Agostino, Ralph B. Ruskin, Jeremy Kane, John M. TI Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID SCHIZOAFFECTIVE DISORDER; DOUBLE-BLIND; ANTIPSYCHOTIC-DRUGS; CLINICAL-TRIALS; TOLERABILITY; MORTALITY; EFFICACY; DEATH; RISK; QTC AB Objective: The authors compared 1-year mortality rates associated with ziprasidone and olanzapine in real-world use. Method: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) was an open-label, randomized, postmarketing large simple trial that enrolled patients with schizophrenia (N=18,154) in naturalistic practice in 18 countries. The primary outcome measure was nonsuicide mortality in the year after initiation of assigned treatment. Patients were randomly assigned to receive treatment with either ziprasidone or olanzapine and followed for 1 year by unblinded investigators providing usual care. A physician-administered questionnaire was used to collect baseline demographic information, medical and psychiatric history, and concomitant medication use. Followup information on hospitalizations and emergency department visits, patients' vital status, and current antipsychotic drug status was collected and reported by treating psychiatrists. Post hoc analyses of sudden death, a secondary endpoint, were also conducted. Results: The incidence of nonsuicide mortality within 1 year of initiating pharmacotherapy was 0.91 for ziprasidone (N=9,077) and 0.90 for olanzapine (N=9,077). The relative risk was 1.02 (95% CI=0.76-1.39). This finding was confirmed in numerous secondary and sensitivity analyses. Conclusions: Despite the known risk of QTc prolongation with ziprasidone treatment, the findings of this study failed to show that ziprasidone is associated with an elevated risk of nonsuicidal mortality relative to olanzapine in real-world use; the study excludes a relative risk larger than 1.39 with a high probability. However, the study was neither powered nor designed to examine the risk of rare events like torsade de pointes. C1 [Strom, Brian L.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Pfizer Inc, Dept Epidemiol Safety & Risk Management, New York, NY USA. United BioSource Corp, Safety & Risk Management Unit, Blue Bell, PA USA. Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA. Boston Univ, Dept Math, Boston, MA 02215 USA. Massachusetts Gen Hosp, Ctr Heart, Boston, MA 02114 USA. Zucker Hillside Hosp, Dept Psychiat, Glen Oaks, NY USA. RP Strom, BL (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, 824 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM bstrom@mail.med.upenn.edu FU Pfizer, Inc.; Pfizer FX This study was supported in full by funding from Pfizer, Inc. Dr. Strom is an employee of the University of Pennsylvania, which received financial support from Pfizer in connection with the scientific oversight of the study and the development of this manuscript. He also served as consultant to Pfizer on topics not related to this study and has consulted for Abbott Laboratories, American College of Neuropsychopharmacology, American Medical Association, Astra-Zeneca, Berlex, Biogen, Blue Cross Blue Shield, Bristol-Myers Squibb, Boehringer Ingelheim, Centocor, Cephalon, CV Therapeutics, Cygnus Corporation, Daichii, Eli Lilly, Forest, GlaxoSmithKline, Hoyle Consulting, Johnson & Johnson, Medco, Mediwound, Novartis, NPS Pharma, NUVO Research, Ocient, Pfizer, Pharm Research, PhRMA Foundation, Sanofi-Aventis, Shire, TAP Pharmaceuticals, Teva Neuroscience, and Wyeth. Dr. Kane served as a consultant to Pfizer in connection with the scientific oversight of the study and served as a consultant or speaker for Abbott, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Cephalon, Dainippon Sumitomo, Eisai, Eli Lilly, Intracellular Therapeutics, Janssen, Johnson & Johnson, Lundbeck, Merck, Myriad, Novartis, Otsuka, Pfizer, Proteus Biomedical, Rules Based Medicine, Takeda, Targacept, Vanda, and Wyeth and is a MedAvante shareholder. Dr. Ruskin served as a consultant to Pfizer in connection with the scientific oversight of the study and has served as a consultant or scientific advisory board member for Astellas, AstraZeneca, Bristol-Myers Squibb, Cardiome, Epix, Forest Labs, Genzyme, Javelin, Lundbeck, Millennium, Myriad, Novartis, NovoNordisk, Portola, Purdue, Sanofi-Aventis, Sequel, Sunesis, and Theravance. Dr. Faich is an employee of United BioSource Corporation, which received financial support from Pfizer in connection with the scientific oversight of the study and the development of this manuscript. Dr. Reynolds is an employee and shareholder of Pfizer, as was Dr. Eng when the study was conducted. NR 23 TC 45 Z9 48 U1 0 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD FEB PY 2011 VL 168 IS 2 BP 193 EP 201 DI 10.1176/appi.ajp.2010.08040484 PG 9 WC Psychiatry SC Psychiatry GA 716MI UT WOS:000286972800013 PM 21041245 ER PT J AU Wick, MJ Buesing, EJ Wehling, CA Loomis, ZL Cool, CD Zamora, MR Miller, YE Colgan, SP Hersh, LB Voelkel, NF Dempsey, EC AF Wick, Marilee J. Buesing, Erica J. Wehling, Carol A. Loomis, Zoe L. Cool, Carlyne D. Zamora, Martin R. Miller, York E. Colgan, Sean P. Hersh, Louis B. Voelkel, Norbert F. Dempsey, Edward C. TI Decreased Neprilysin and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE pulmonary hypertension; smooth muscle cell; smoking; oxidative stress; protein degradation ID SMOOTH-MUSCLE-CELLS; NEUTRAL ENDOPEPTIDASE; ARTERIAL-HYPERTENSION; SEVERE EMPHYSEMA; OXIDATIVE STRESS; CIGARETTE-SMOKE; CHRONIC HYPOXIA; LUNG-DISEASES; COPD; INACTIVATION AB Rationale: Studies with genetically engineered mice showed that decreased expression of the transmembrane peptidase neprilysin (NEP) increases susceptibility to hypoxic pulmonary vascular remodeling and hypertension; in hypoxic wild-type mice, expression is decreased early in distal pulmonary arteries, where prominent vascular remodeling occurs. Therefore, in humans with smoke- and hypoxia-induced vascular remodeling, as in chronic obstructive pulmonary disease (COPD), pulmonary activity/expression of NEP may likewise be decreased. Objectives: To test whether NEP activity and expression are reduced in COPD lungs and pulmonary arterial smooth muscle cells (SMCs) exposed to cigarette smoke extract or hypoxia and begin to investigate mechanisms involved. Methods: Control and advanced COPD lung lysates (n = 13-14) were analyzed for NEP activity and protein and mRNA expression. As a control, dipeptidyl peptidase IV activity was analyzed. Lung sections were assessed for vascular remodeling and oxidant damage. Human pulmonary arterial SMCs were exposed to cigarette smoke extract, hypoxia, or H2O2, and incubated with antioxidants or lysosomal/proteasomal inhibitors. Measurements and Main Results: COPD lungs demonstrated areas of vascular rarification, distal muscularization, and variable intimal and prominent medial/adventitial thickening. NEP activity was reduced by 76%; NEP protein expression was decreased in alveolar walls and distal vessels; mRNA expression was also decreased. In SMCs exposed to cigarette smoke extract, hypoxia, and H2O2, NEP activity and expression were also reduced. Reactive oxygen species inactivated NEP activity; NEP protein degradation appeared to be substantially induced. Conclusions: Mechanisms responsible for reduced NEP activity and protein expression include oxidative reactions and protein degradation. Maintaining or increasing lung NEP may protect against pulmonary vascular remodeling in response to chronic smoke and hypoxia. C1 [Wick, Marilee J.; Buesing, Erica J.; Loomis, Zoe L.; Dempsey, Edward C.] Univ Colorado Denver, Cardiovasc Pulm Res Lab, Aurora, CO 80045 USA. [Wick, Marilee J.; Buesing, Erica J.; Loomis, Zoe L.; Zamora, Martin R.; Miller, York E.; Voelkel, Norbert F.; Dempsey, Edward C.] Univ Colorado Denver, Div Pulm Sci & Crit Care, Aurora, CO 80045 USA. [Colgan, Sean P.] Univ Colorado Denver, Div Gastroenterol, Dept Med, Aurora, CO 80045 USA. [Cool, Carlyne D.] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA. [Wick, Marilee J.; Wehling, Carol A.; Miller, York E.; Dempsey, Edward C.] Denver VA Med Ctr, Denver, CO USA. [Cool, Carlyne D.] Natl Jewish Hlth, Dept Med, Denver, CO USA. [Hersh, Louis B.] Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, Lexington, KY USA. RP Dempsey, EC (reprint author), Univ Colorado Denver, Cardiovasc Pulm Res Lab, Box B-133,12700 E 19th Ave, Aurora, CO 80045 USA. EM edward.dempsey@ucdenver.edu FU NIH/NHLBI [RO3 HL095439, RO1 HL078929, PPG HL14985]; National Cancer Institute [CA58187]; Department of Veterans' Affairs; National Institutes of Health (NIH) [NCI CA58187, NCI CA046934]; University of Colorado Denver (UCD); DOM; State of CO; UCD Technology Transfer Office (TTO); Alnylam Pharmaceuticals; Department of Veterans Affairs; Chemicon Inter; Novartis FX M.J.W. received more than $100,001 from the National Institutes of Health (NIH) in sponsored grant support, $10,001-$50,000 from the University of Colorado Denver (UCD) as a DOM small grant, and $10,001-$50,000 from a State of CO and UCD Technology Transfer Office (TTO) for a bioscience discovery grant. E.J.B. received $10,001-$50,000 from the NIH in sponsored grant support and $10,001-$50,000 from a State of CO and UCD TTO for a bioscience discovery grant. C.A.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.L.L. received $10,001-550,000 from the NIH in sponsored grant support and $10,001-$50,000 from a State of CO and UCD ITO for a bioscience discovery grant. C.D.C. received up to $1,000 from UpToDate in royaltiesand more than $100,001 from the NIH/NHLBI in sponsored grants for the Lung Tissue Research Consortium. M.R.Z. received $10,001-$50,000 from CSL Behring in consultancy fees, $10,001-$50,000 from CSL Behring, and $5,001-$10,000 from Roche in lecture fees, and more than $100,001 from APT Pharmaceuticals and $10,001-$50,000 from Alnylam Pharmaceuticals in industry-sponsored grants for clinical trials. Y.E.M. received 51,001-55,000 in lecture fees for an online CME course regarding lung cancer, received 550,001-$100,000 from Soma Logic, Inc. in industry-sponsored grants for plasma-based lung cancer diagnostic tests, and holds a patent with UCD for prostacyclin analogs for the prevention of cancer, and more than $100,001 from the NIH in sponsored grants (NCI CA58187; NCI CA046934) and more than $100,001 from the Department of Veterans Affairs in merit review grants. S.P.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. L.B.H. received more than $100,001 from Chemicon Inter, for the sale of antisera. N.F.V. received $1,001-55,000 from Novartis in lecture fees and a $100,000 grant from the NIH. E.C.D. received more than $100,001 from the NIH and more than $100,001 from the State of CO and UCD TTO for sponsored grants, and more than $100,001 in other support from the Department of Veterans' Affairs. Supported by NIH/NHLBI grants RO3 HL095439, RO1 HL078929, and PPG HL14985 (E.C.D.), National Cancer Institute SPORE in Lung Cancer grant CA58187 (Y.E.M.), and the Department of Veterans' Affairs. NR 60 TC 12 Z9 13 U1 0 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2011 VL 183 IS 3 BP 330 EP 340 DI 10.1164/rccm.201002-0154OC PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 720QD UT WOS:000287294300009 PM 20813891 ER PT J AU Crothers, K Huang, L Goulet, JL Goetz, MB Brown, ST Rodriguez-Barradas, MC Oursler, KK Rimland, D Gibert, CL Butt, AA Justice, AC AF Crothers, Kristina Huang, Laurence Goulet, Joseph L. Goetz, Matthew Bidwell Brown, Sheldon T. Rodriguez-Barradas, Maria C. Oursler, Krisann K. Rimland, David Gibert, Cynthia L. Butt, Adeel A. Justice, Amy C. TI HIV Infection and Risk for Incident Pulmonary Diseases in the Combination Antiretroviral Therapy Era SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE HIV; respiratory tract diseases; lung diseases; obstructive; pneumonia; pneumonia; bacterial ID HUMAN-IMMUNODEFICIENCY-VIRUS; VETERANS AGING COHORT; BACTERIAL PNEUMONIA; CIGARETTE-SMOKING; ADMINISTRATIVE DATA; NEGATIVE VETERANS; MORTALITY-RATES; INDIVIDUALS; COMORBIDITY; PROGRESSION AB Rationale In aging HIV-infected populations comorbid diseases are important determinants of morbidity and mortality. Pulmonary diseases have not been systematically assessed in the combination antiretroviral therapy (ART) era. Objectives: To determine the incidence of pulmonary diseases in HIV-infected persons compared with HIV-uninfected persons. Methods: We analyzed data from the Veterans Aging Cohort Study Virtual Cohort, consisting of 33,420 HIV-infected veterans and 66,840 age, sex, race and ethnicity, and site-matched HIV-uninfected veterans. Using Poisson regression, incidence rates and adjusted incidence rate ratios were calculated to determine the association of HIV with pulmonary disease. The Virtual Cohort was merged with the 1999 Veterans Large Health Survey to adjust for self-reported smoking in a nested sample (14%). Measurements and Main Results: Incident chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, and pulmonary fibrosis, as well as pulmonary infections, were significantly more likely among HIV-infected patients compared with uninfected patients in adjusted analyses, although rates of asthma did not differ by HIV status. Bacterial pneumonia and chronic obstructive pulmonary disease were the two most common incident pulmonary diseases, whereas opportunistic pneumonias were less common. Absolute rates of most pulmonary diseases increased with age, although the relative differences between those with and without HIV infection were greatest in younger persons. Chronic obstructive pulmonary disease and asthma, as well as pulmonary infections, were less likely in those with lower HIV RNA levels and use of ART at baseline. Conclusions: Pulmonary diseases among HIV-infected patients receiving care within the Veterans Affairs Healthcare System in the combination ART era reflect a substantial burden of non AIDS-defining and chronic conditions, many of which are associated with aging. C1 [Crothers, Kristina] Univ Washington, Harborview Med Ctr, Sch Med, Div Pulm & Crit Care Med,Dept Med, Seattle, WA 98104 USA. [Crothers, Kristina; Goulet, Joseph L.; Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, Dept Med, West Haven, CT USA. [Huang, Laurence] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA. [Huang, Laurence] Univ Calif San Francisco, Dept Med, Div HIV AIDS, San Francisco, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Infect Dis Sect, Dept Med, Los Angeles, CA 90095 USA. [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. [Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Med Serv, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Oursler, Krisann K.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Oursler, Krisann K.] Ctr Geriatr Res Educ & Clin, Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA. [Rimland, David] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA. [Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Gibert, Cynthia L.] George Washington Univ, Vet Affairs Med Ctr, Infect Dis Sect, Washington, DC 20052 USA. [Gibert, Cynthia L.] George Washington Univ, Dept Med, Washington, DC 20052 USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Dept Internal Med, Pittsburgh, PA USA. [Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Justice, Amy C.] Yale Univ, Sch Publ Hlth, Dept Internal Med, New Haven, CT 06510 USA. RP Crothers, K (reprint author), Univ Washington, Harborview Med Ctr, Sch Med, Div Pulm & Crit Care Med,Dept Med, 325 9th Ave,Box 359762, Seattle, WA 98104 USA. EM crothk@uw.edu OI Goetz, Matthew/0000-0003-4542-992X; Goulet, Joseph/0000-0002-0842-804X; Crothers, Kristina/0000-0001-9702-0371 FU National Institutes of Health (NIH); Merck; Pfizer; Johns Hopkins University; Valeant Pharma FX K.C. received grant support from the National Institutes of Health (NIH) (more than $100,001). L.H. received grant support from the NIH (more than $100,001). J.L.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.B.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.T.B. received grant support (institutional) from Merck ($10,001-$50,000) and the NIH (more than $100,001). He owns stocks or options of Pfizer ($5,001-$10,000). M.C.R.-B. received grant support (institutional) from Pfizer ($1,001-$5,000). K.K.O. received lecture fees from Johns Hopkins University (up to $1,000) and grant support from the NIH ($50,001-$100,000 and $10,001-$50,000). D.R. received grant support from Pfizer ($1,00145,000) and the CDC (more than $100,001). C.L.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.A.B. received grant support from Valeant Pharma ($10,001-$50,000). A.C.J. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. NR 58 TC 132 Z9 133 U1 1 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2011 VL 183 IS 3 BP 388 EP 395 DI 10.1164/rccm.201006-0836OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 720QD UT WOS:000287294300016 PM 20851926 ER PT J AU Ramadas, RA Ewart, SL Medoff, BD LeVine, AM AF Ramadas, Ravisankar A. Ewart, Susan L. Medoff, Benjamin D. LeVine, Ann Marie TI Interleukin-1 Family Member 9 Stimulates Chemokine Production and Neutrophil Influx in Mouse Lungs SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE IL-1F9; chemokines; lung diseases; inflammation; neutrophil ID NF-KAPPA-B; CHEMOATTRACTANT PROTEIN-1 GENE; EPITHELIAL-CELLS; RECEPTOR ANTAGONIST; MURINE MODEL; AIRWAY HYPERRESPONSIVENESS; PULMONARY INFLAMMATION; IL-1; EXPRESSION; ACTIVATION AB Interleukin-1 (IL-1) is a proinflammatory cytokine that signals through the Type I IL-1 receptor (IL-1RI). Novel IL-1-like cytokines were recently identified. Their functions in lung disease remain unclear. Interleukin-1 family member-9 (IL-1F9) is one such IL-1-like cytokine, expressed in the lungs of humans and mice. IL-1F9 signals through IL-1 receptor-related protein 2 (IL-1Rrp2/IL-1RL2), which is distinct from IL-1RI. We sought to determine if IL-1F9 acts as a proinflammatory cytokine in lung disease. IL-1F9 protein was increased in lung homogenates of house dust mite-challenged A/J mice compared with controls, and expression was seen in airway epithelial cells. The intratracheal administration of recombinant mouse IL-1F9 increased airway hyperresponsiveness and induced neutrophil influx and mucus production, but not eosinophilic infiltration in the lungs of mice. In addition, IL-1 alpha protein levels in bronchoalveolar lavage fluid, chemokines, and chemokine-receptor mRNA expression in the lungs were increased after the instillation of intratracheal IL-1F9. Consistent with these changes, NF-kappa B transcription factor activity was increased in the lungs of mice challenged with IL-1F9 and in a macrophage cell line treated with IL-1F9. These data suggest that IL-1F9 is upregulated during inflammation, and acts as a proinflammatory cytokine in the lungs. C1 [Ramadas, Ravisankar A.; LeVine, Ann Marie] Univ Florida, Dept Pediat, Gainesville, FL USA. [Ewart, Susan L.] Michigan State Univ, Dept Large Anim Clin Sci, Lansing, MI USA. [Medoff, Benjamin D.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Pulm & Crit Care Unit, Charlestown, MA USA. [Medoff, Benjamin D.] Harvard Univ, Sch Med, Charlestown, MA USA. RP LeVine, AM (reprint author), Univ Michigan, Sch Med, CS Mott Childrens Hosp,Div Pediat Crit Care Med, Dept Pediat & Communicable Dis, Mott F-6882 Box 0243,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM anlevine@med.umich.edu FU National Institute of Health [RO1-HL-71522, 5T32HL007874-14] FX This work was supported by National Institute of Health grants RO1-HL-71522 (A.M.L.) and 5T32HL007874-14 (B.D.M). NR 42 TC 40 Z9 42 U1 0 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1044-1549 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD FEB PY 2011 VL 44 IS 2 BP 134 EP 145 DI 10.1165/rcmb.2009-0315OC PG 12 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA 753KJ UT WOS:000289771700002 PM 20299540 ER PT J AU Nese, N Martignoni, G Fletcher, CD Gupta, R Pan, CC Kim, HU Ro, JY Hwang, IS Sato, K Bonetti, F Pea, M Amin, MB Hes, O Svec, A Kida, M Vankalakunti, M Berel, D Rogatko, A Gown, AM Amin, MB AF Nese, Nalan Martignoni, Guido Fletcher, Christopher D. Gupta, Ruta Pan, Chin-Chan Kim, Hyung Ro, Jae Y. Hwang, Il S. Sato, Katsuaki Bonetti, Franco Pea, Maurizio Amin, Mitual B. Hes, Ondrej Svec, Alexandr Kida, Masatoshi Vankalakunti, Mahesha Berel, Dror Rogatko, Andre Gown, Allen M. Amin, Mahul B. TI Pure Epithelioid PEComas (So-Called Epithelioid Angiomyolipoma) of the Kidney: A Clinicopathologic Study of 41 Cases: Detailed Assessment of Morphology and Risk Stratification SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE kidney; PEComa; pure PEComa; epithelioid angiomyolipoma; angiomyolipoma; prognosis; tuberous sclerosis complex; morphology; outcome ID RENAL-CELL CARCINOMA; GENE MUTATION ANALYSIS; AUTOPSY CASE-REPORT; OF-THE-LITERATURE; TUBEROUS SCLEROSIS; SUGAR TUMOR; SARCOMATOUS TRANSFORMATION; MALIGNANT-TRANSFORMATION; ATYPICAL ANGIOMYOLIPOMA; SMOOTH-MUSCLE AB Epithelioid angiomyolipomas (perivascular epithelioid cell tumors) of the kidney are defined as potentially malignant mesenchymal lesions that are closely related to classic angiomyolipoma. Although approximately 120 cases are published, mostly as case reports with variably used diagnostic criteria, the pathologic prognostic predictors of outcome are unknown. We analyzed the clinicopathologic parameters in a large series of 41 cases of pure epithelioid angiomyolipomas of the kidney, which we designate as pure (monotypic) epithelioid PEComas to contrast them from classic angiomyolipomas that are regarded by some as PEComas. We use the terminology "pure" to separate these cases from those that may have variable epithelioid components. The mean age of the patients was 40.7 years (range, 14 to 68 y). The male-to-female ratio was 1:1. Seventy-nine percent of patients were symptomatic at presentation with metastatic disease at onset in 12 cases. Follow-up and/or disease progression information were available for 33 of 41 cases (mean, 44.5mo and median, 24.5mo; range, 4 to 240); 9 patients had a history of associated tuberous sclerosis. Recurrence and metastasis were seen in 17% and 49% of patients; 33% of patients died of disease. Lymph node involvement was seen in 24% of patients; the liver (63%), lung (25%), and mesentery (18.8%) were the most common metastatic sites. Clinicopathologic parameters associated with disease progression (recurrence, metastasis, or death due to disease) in univariate analysis included associated tuberous sclerosis complex or concurrent angiomyolipoma (any metastasis, P = 0.046), necrosis (metastasis at diagnosis, P = 0.012), tumor size >7 cm (progression, P = 0.021), extrarenal extension and/or renal vein involvement (progression, P = 0.023), and carcinoma-like growth pattern (progression, P = 0.040) (the 5 adverse prognostic parameters for pure epithelioid PEComas). Tumors with <2 adverse prognostic parameters (13 cases) were considered to be low risk for progression tumor, with 15% having disease progression. Tumors with 2 to 3 adverse prognostic parameters (14 cases) were considered to be "intermediate risk," with 64% having disease progression. Tumors with more than 4 or more adverse prognostic parameters (6 cases) were considered to be high risk, with all patients having disease progression. Of tumors with 3 or more adverse prognostic parameters, 80% had disease progression. An exact logistic regression analytic model showed that only carcinoma-like growth pattern and extrarenal extension and/or renal vein involvement were significant predictors of outcome (P = 0.009 and 0.033, respectively). Our data of a large series with uniform definitional criteria confirm the malignant potential for pure epithelioid PEComas and provide adverse prognostic parameters for risk stratification in these patients. C1 [Nese, Nalan; Gupta, Ruta; Vankalakunti, Mahesha; Amin, Mahul B.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA. [Berel, Dror; Rogatko, Andre] Cedars Sinai Med Ctr, Biostat & Bioinformat, Los Angeles, CA 90048 USA. [Fletcher, Christopher D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Fletcher, Christopher D.] Harvard Univ, Sch Med, Dana Farber, Boston, MA USA. [Kim, Hyung] Roswell Pk Canc Inst, Buffalo, NY USA. [Amin, Mitual B.] William Beaumont Hosp, Detroit, MI USA. [Kida, Masatoshi] Univ Vermont, Coll Med, Fletcher Allen Hlth Care, Burlington, VT USA. [Gown, Allen M.] Pheno Path Labs, Seattle, WA USA. [Nese, Nalan] Celal Bayar Univ, Manisa, Turkey. [Martignoni, Guido; Bonetti, Franco; Pea, Maurizio] Univ Verona, I-37100 Verona, Italy. [Pan, Chin-Chan] Taipei Vet Gen Hosp, Taipei, Taiwan. [Ro, Jae Y.; Hwang, Il S.; Sato, Katsuaki] Univ Ulsan, Asan Med Ctr, Seoul, South Korea. [Bonetti, Franco] Kanazawa Univ, Kanazawa, Ishikawa 9201192, Japan. [Hes, Ondrej] Univ Hosp Plzen, Plzen, Czech Republic. [Svec, Alexandr; Kida, Masatoshi] Charles Univ Prague, Prague, Czech Republic. RP Amin, MB (reprint author), Cedars Sinai Med Ctr, Dept Pathol & Lab Med, 8700 Beverly Blvd,Suite 8728, Los Angeles, CA 90048 USA. EM aminm@cshs.org NR 83 TC 70 Z9 81 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD FEB PY 2011 VL 35 IS 2 BP 161 EP 176 DI 10.1097/PAS.0b013e318206f2a9 PG 16 WC Pathology; Surgery SC Pathology; Surgery GA 711IC UT WOS:000286581700001 PM 21263237 ER PT J AU Oates, JC Halushka, PV Hutchison, FN Ruiz, P Gilkeson, GS AF Oates, Jim C. Halushka, Perry V. Hutchison, Florence N. Ruiz, Philip Gilkeson, Gary S. TI Selective Cyclooxygenase-2 Inhibitor Suppresses Renal Thromboxane Production but Not Proliferative Lesions in the MRL/lpr Murine Model of Lupus Nephritis SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Lupus nephritis; Animal models; Cyclooxygenase-2; Nitric oxide; Glomerular filtration rate; Thromboxane A(2) ID SYNTHASE INHIBITOR; MICE; ERYTHEMATOSUS; INDOMETHACIN; ANTIBODIES; THERAPY; RISK; GENE AB Introduction: Proliferative lupus nephritis (LN) is marked by increased renal thromboxane (TX) A(2) production. Targeting the TXA(2) receptor or TXA(2) synthase effectively improves renal function in humans with LN and improves glomerular pathology in murine LN. This study was designed to address the following hypotheses: (1) TXA(2) production in the MRL/MpJ-Tnfrsf6(lpr)/J (MRL/lpr) model of proliferative LN is cyclooxygenase (COX)-2 dependent and (2) COX2 inhibitor therapy improves glomerular filtration rate (GFR), proteinuria, markers of innate immune response and glomerular pathology. Methods: Twenty female MRL/lpr and 20 BALB/cJ mice were divided into 2 equal treatment groups: (1) SC-236, a moderately selective COX2 inhibitor or (2) vehicle. After treatment from the age of 10 to 20 weeks, the effectiveness of inhibition of TXA(2) was determined by measuring urine TXB2. Response endpoints measured at the age of 20 weeks were renal function (GFR), proteinuria, urine nitrate + nitrite (NOx) and glomerular histopathology. Results: SC-236 therapy reduced surrogate markers of renal TXA(2) production during early, active glomerulonephritis. When this pharmacodynamic endpoint was reached, therapy improved GFR. Parallel reductions in markers of the innate immune response (urine NOx) during therapy were observed. However, the beneficial effect of SC-236 therapy on GFR was only transient, and renal histopathology was not improved in late disease. Conclusions: These data demonstrate that renal TXA(2) production is COX2 dependent in murine LN and suggest that NO production is directly or indirectly COX2 dependent. However, COX2 inhibitor therapy in this model failed to improve renal pathology, making COX2 inhibition a less attractive approach for treating LN. C1 [Oates, Jim C.; Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol, Dept Med, Charleston, SC 29425 USA. [Oates, Jim C.; Hutchison, Florence N.; Gilkeson, Gary S.] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA. [Hutchison, Florence N.] Med Univ S Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA. [Halushka, Perry V.] Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA. [Ruiz, Philip] Univ Miami, Leonard M Miller Sch Med, Dept Surg, Miami, FL USA. [Ruiz, Philip] Univ Miami, Leonard M Miller Sch Med, Dept Pathol, Miami, FL USA. RP Oates, JC (reprint author), Med Univ S Carolina, Div Rheumatol, Dept Med, 96 Jonathan Lucas St,Suite 912,MSC 637, Charleston, SC 29425 USA. EM oatesjc@musc.edu FU Searle-Monsanto; National Institutes of Health, Bethesda, MD [K08AR002193, R01AR045476]; Medical Research Service, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC FX This study was supported by Searle-Monsanto; the National Institutes of Health, Bethesda, MD, grants K08AR002193 and R01AR045476 (to JCO and GSG); and Career Development, Research Enhancement Award Program, and Merit Review grants from the Medical Research Service, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC. NR 30 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD FEB PY 2011 VL 341 IS 2 BP 101 EP 105 DI 10.1097/MAJ.0b013e3181f56d2c PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 714SD UT WOS:000286828400005 PM 20924284 ER PT J AU Niers, JM Chen, JW Weissleder, R Tannous, BA AF Niers, Johanna M. Chen, John W. Weissleder, Ralph Tannous, Bakhos A. TI Enhanced in Vivo Imaging of Metabolically Biotinylated Cell Surface Reporters SO ANALYTICAL CHEMISTRY LA English DT Article ID MAMMALIAN-CELLS; PROTEINS; PURIFICATION; LIGASE; EXPRESSION; SKELETAL; RECEPTOR; THERAPY; MUSCLE AB Metabolic biotinylation of intracellular and secreted proteins as well as surface receptors in mammalian cells provides a versatile way to monitor gene expression; to purify and target viral vectors; to monitor cell and tumor distribution in real time in vivo; to label cells for isolation; and to tag proteins for purification, localization, and trafficking. Here, we show that metabolic biotinylation of proteins fused to the bacterial biotin acceptor peptides (BAP) varies among different mammalian cell types and can be enhanced by over 10-fold upon overexpression Of the bacterial biotin ligase directed to the same cellular compartment as the fusion protein. We also show that in vivo imaging of metabolically biotinylated cell surface receptors using streptavidin conjugates is significantly enhanced upon coexpression of bacterial biotin ligase in the secretory pathway. These findings have practical applications in designing more efficient targeting and imaging strategies. C1 [Niers, Johanna M.; Tannous, Bakhos A.] Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA. [Niers, Johanna M.; Tannous, Bakhos A.] Massachusetts Gen Hosp, Mol Neurogenet Unit, Dept Neurol, Charlestown, MA 02129 USA. [Chen, John W.; Weissleder, Ralph; Tannous, Bakhos A.] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Dept Radiol, Charlestown, MA 02129 USA. [Chen, John W.; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA 02129 USA. [Niers, Johanna M.; Tannous, Bakhos A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA. RP Tannous, BA (reprint author), Massachusetts Gen Hosp E, Ctr Neurosci, Bldg 149,13th St, Charlestown, MA 02129 USA. EM btannous@hms.harvard.edu FU NIH/NCI [4R00CA126839, P50CA86355]; NIH/NHLBI [K08HL081170]; NIH/NINDS [P30NS045776] FX This work was supported partly by grants from NIH/NCI 4R00CA126839 (B.A.T.), and P50CA86355 (R.W. and B.A.T.) as well as NIH/NHLBI K08HL081170 (J.W.C.) and NIH/NINDS P30NS045776 (B.A.T). The authors would like to acknowledge Miss Lisa Pike, Miss Nicole Lewandrowski, and Mr. Peter Waterman for technical help; Prof. Xandra Breakefield for advice and critical reading of the manuscript; Dr. Vasily Ogryzko (Institut Andre Lwoff, France), and Dr. Darell D. Bigner (Duke University Medical Center) for providing the humanized BirA cDNA and MR1, respectively. NR 28 TC 8 Z9 8 U1 1 U2 12 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 J9 ANAL CHEM JI Anal. Chem. PD FEB 1 PY 2011 VL 83 IS 3 BP 994 EP 999 DI 10.1021/ac102758m PG 6 WC Chemistry, Analytical SC Chemistry GA 712TR UT WOS:000286689600052 PM 21214190 ER PT J AU Owens, DK Qaseem, A Chou, R Shekelle, P AF Owens, Douglas K. Qaseem, Amir Chou, Roger Shekelle, Paul CA Clinical Guidelines Comm Amer Coll TI High-Value, Cost-Conscious Health Care: Concepts for Clinicians to Evaluate the Benefits, Harms, and Costs of Medical Interventions SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID NONVALVULAR ATRIAL-FIBRILLATION; ADJUSTED LIFE-YEAR; LOW-BACK-PAIN; PRACTICE GUIDELINES; AMERICAN-COLLEGE; GRADING QUALITY; UNITED-STATES; ANTIRETROVIRAL THERAPY; DIAGNOSTIC-TESTS; HIV AB Health care costs in the United States are increasing unsustainably, and further efforts to control costs are inevitable and essential. Efforts to control expenditures should focus on the value, in addition to the costs, of health care interventions. Whether an intervention provides high value depends on assessing whether its health benefits justify its costs. High-cost interventions may provide good value because they are highly beneficial; conversely, low-cost interventions may have little or no value if they provide little benefit. Thus, the challenge becomes determining how to slow the rate of increase in costs while preserving high-value, high-quality care. A first step is to decrease or eliminate care that provides no benefit and may even be harmful. A second step is to provide medical interventions that provide good value: medical benefits that are commensurate with their costs. This article discusses 3 key concepts for understanding how to assess the value of health care interventions. First, assessing the benefits, harms, and costs of an intervention is essential to understand whether it provides good value. Second, assessing the cost of an intervention should include not only the cost of the intervention itself but also any downstream costs that occur because the intervention was performed. Third, the incremental cost-effectiveness ratio estimates the additional cost required to obtain additional health benefits and provides a key measure of the value of a health care intervention. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Stanford Univ, Stanford, CA 94305 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org NR 49 TC 126 Z9 128 U1 0 U2 14 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 1 PY 2011 VL 154 IS 3 BP 174 EP + DI 10.7326/0003-4819-154-3-201102010-00007 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 713HY UT WOS:000286729200005 PM 21282697 ER PT J AU Chou, R Qaseem, A Owens, DK Shekelle, P AF Chou, Roger Qaseem, Amir Owens, Douglas K. Shekelle, Paul CA Clinical Guidelines Comm Amer Coll TI Diagnostic Imaging for Low Back Pain: Advice for High-Value Health Care From the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; LUMBAR SPINE; PATIENT EXPECTATIONS; CLINICAL-EVALUATION; PRACTICE PATTERNS; NATIONAL-SURVEY; UNITED-STATES; STRATEGIES; GUIDELINES; US AB Diagnostic imaging is indicated for patients with low back pain only if they have severe progressive neurologic deficits or signs or symptoms that suggest a serious or specific underlying condition. In other patients, evidence indicates that routine imaging is not associated with clinically meaningful benefits but can lead to harms. Addressing inefficiencies in diagnostic testing could minimize potential harms to patients and have a large effect on use of resources by reducing both direct and downstream costs. In this area, more testing does not equate to better care. Implementing a selective approach to low back imaging, as suggested by the American College of Physicians and American Pain Society guideline on low back pain, would provide better care to patients, improve outcomes, and reduce costs. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA. Stanford Univ, Palo Alto, CA 94304 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU Wellpoint; Palladian Health; Consumers Union; Blue Cross Blue Shield Association; American Pain Society; Agency for Healthcare Research and Quality FX Dr. Chou: Consulting fee or honorarium: Wellpoint, Palladian Health, Consumers Union, Blue Cross Blue Shield Association; Grants/grants pending: American Pain Society; Payment for manuscript preparation: American College of Physicians. Dr. Owens: Support for travel to meetings for the study or other purposes: American College of Physicians; Consultancy: Anthem/Wellpoint. Dr. Shekelle: Grants/grants pending: Agency for Healthcare Research and Quality; Royalties: UptoDate; Other: Unpaid advisor for a Wellpoint project that seeks to identify and certify high-quality back pain centers of excellence. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOflnterestForms.do?msNum=M10-139 4. Any conflict of interest of the Clinical Guidelines Committee members was declared, discussed, and resolved. NR 82 TC 125 Z9 126 U1 4 U2 17 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 1 PY 2011 VL 154 IS 3 BP 181 EP + DI 10.7326/0003-4819-154-3-201102010-00008 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 713HY UT WOS:000286729200006 PM 21282698 ER PT J AU Kanwal, F Bacon, BR Asch, SM AF Kanwal, Fasiha Bacon, Bruce R. Asch, Steven M. TI Quality of Care in Patients With Chronic Hepatitis C Virus Infection RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID ANTIVIRAL THERAPY; VETERANS; ELIGIBILITY C1 [Kanwal, Fasiha] John Cochran Vet Affairs Med Ctr, St Louis, MO 63106 USA. [Bacon, Bruce R.] St Louis Univ, Sch Med, St Louis, MO 63110 USA. [Asch, Steven M.] Vet Affairs Greater Los Angeles Med Ctr, Los Angeles, CA 90073 USA. RP Kanwal, F (reprint author), John Cochran Vet Affairs Med Ctr, St Louis, MO 63106 USA. NR 5 TC 0 Z9 0 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 1 PY 2011 VL 154 IS 3 BP 214 EP + DI 10.7326/0003-4819-154-3-201102010-00019 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 713HY UT WOS:000286729200016 ER PT J AU Eikermann-Haerter, K Yuzawa, I Dilekoz, E Joutel, A Moskowitz, MA Ayata, C AF Eikermann-Haerter, Katharina Yuzawa, Izumi Dilekoz, Ergin Joutel, Anne Moskowitz, Michael A. Ayata, Cenk TI Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Syndrome Mutations Increase Susceptibility to Spreading Depression SO ANNALS OF NEUROLOGY LA English DT Article ID TRANSGENIC MOUSE MODEL; CADASIL; NOTCH3; MIGRAINE; PRESSURE; SPECTRUM; STROKE; COMA; AURA AB Migraine with aura is often the first manifestation of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome (CADASIL), a disorder caused by NOTCH3 gene mutations expressed predominantly in vascular smooth muscle. Here, we report that cortical spreading depression (CSD), the electrophysiological substrate of migraine aura, is enhanced in mice expressing a vascular Notch 3 CADASIL mutation (R90C) or a Notch 3 knockout mutation. The phenotype was stronger in Notch 3 knockout mice, implicating both loss of function and neomorphic mutations in its pathogenesis. Our results link vascular smooth muscle Notch 3 mutations to enhanced spreading depression susceptibility, implicating the neurovascular unit in the development of migraine aura. ANN NEUROL 2011;69:413-418 C1 [Eikermann-Haerter, Katharina; Yuzawa, Izumi; Dilekoz, Ergin; Moskowitz, Michael A.; Ayata, Cenk] Harvard Univ, Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab, Dept Radiol,Sch Med, Boston, MA 02129 USA. [Ayata, Cenk] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, Boston, MA 02129 USA. [Ayata, Cenk] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Neurosci Intens Care Unit, Boston, MA 02129 USA. [Joutel, Anne] INSERM, U740, Paris, France. [Joutel, Anne] Univ Paris 07, Fac Med, Paris, France. RP Ayata, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab, Dept Radiol,Sch Med, 149 13th St,Room 6403, Boston, MA 02129 USA. EM cayata@partners.org FU American Heart Association [10SDG2610275]; National Institutes of Health (NIH) [NS061505, NS35611, NS054122] FX This research was supported by grants from the American Heart Association (10SDG2610275 to K.E.-H.) and the National Institutes of Health (NIH) (NS061505 to C.A.; NS35611 to M.M; NS054122 to A.J.). NR 25 TC 39 Z9 42 U1 2 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD FEB PY 2011 VL 69 IS 2 BP 413 EP 418 DI 10.1002/ana.22281 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 733TD UT WOS:000288284900024 PM 21387384 ER PT J AU Patil, S Figlin, RA Hutson, TE Michaelson, MD Negrier, S Kim, ST Huang, X Motzer, RJ AF Patil, S. Figlin, R. A. Hutson, T. E. Michaelson, M. D. Negrier, S. Kim, S. T. Huang, X. Motzer, R. J. TI Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma SO ANNALS OF ONCOLOGY LA English DT Article DE interferon-alpha; Memorial Sloan-Kettering Cancer Center risk groups; prognostic factors; renal cell carcinoma; sunitinib ID INTERFERON-ALPHA; MODEL AB Background: Analysis of prognostic factors for progression-free survival (PFS) and overall survival (OS) was performed using final data from a randomized phase III trial of sunitinib versus interferon-alpha (IFN-alpha) as first-line metastatic renal cell carcinoma (RCC) therapy. Design: A multivariate Cox regression model analyzed baseline variables for prognostic significance. Each variable was investigated univariately and then multivariately using a stepwise algorithm. Results: Each treatment arm comprised 375 patients. For sunitinib, multivariate analysis of PFS identified five independent predictors, including serum lactate dehydrogenase (LDH) level, presence of >= 2 metastatic sites, no prior nephrectomy, Eastern Cooperative Oncology Group (ECOG) performance status, and baseline platelet count, while multivariate analysis of OS identified serum LDH level, corrected serum calcium level, time from diagnosis to treatment, hemoglobin level, ECOG performance status, and presence of bone metastasis as predictors. For IFN-alpha, LDH level and presence of >= 2 metastatic sites were common predictors of PFS to those for sunitinib, as were all predictors of OS except ECOG status. Conclusions: This analysis identified prognostic factors for PFS and OS with sunitinib as first-line metastatic RCC therapy and confirmed that the Memorial Sloan-Kettering Cancer Center model is applicable in the era of targeted therapy. C1 [Patil, S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Figlin, R. A.] City Hope Comprehens Canc Ctr, Div Med Oncol & Therapeut Res, Duarte, CA USA. [Hutson, T. E.] Baylor Sammons Canc Ctr Texas Oncol PA, Genitourinary Oncol Program, Dallas, TX USA. [Michaelson, M. D.] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA 02114 USA. [Negrier, S.] Ctr Leon Berard, Dept Med Oncol & Cytokines, Lyon, France. [Negrier, S.] Ctr Leon Berard, Canc Res Unit, Lyon, France. [Kim, S. T.; Huang, X.] Pfizer Oncol, Clin Dev, La Jolla, CA USA. [Motzer, R. J.] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, Dept Med, New York, NY 10021 USA. RP Patil, S (reprint author), Mem Sloan Kettering Canc Ctr, Dept Biostat Epidemiol & Stat, 1275 York Ave, New York, NY 10021 USA. EM patils@mskcc.org OI Michaelson, Dror/0000-0001-9249-6338 FU Pfizer Inc.; Pfizer FX Pfizer Inc.; SP and MDM have reported no potential conflicts of interest. RAF has received consultant fees and research funding from Pfizer. TEH has received consultant fees, speaker honoraria, and research funding from Pfizer. SN and RJM have received research funding from Pfizer. STK and XH are full-time employees of Pfizer with stock ownership. NR 13 TC 81 Z9 87 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2011 VL 22 IS 2 BP 295 EP 300 DI 10.1093/annonc/mdq342 PG 6 WC Oncology SC Oncology GA 712NL UT WOS:000286673400008 PM 20657034 ER PT J AU Desitter, I Guerrouahen, BS Benali-Furet, N Wechsler, J Janne, PA Kuang, YA Yanagita, M Wang, LL Berkowitz, JA Distel, RJ Cayre, YE AF Desitter, Isabelle Guerrouahen, Bella S. Benali-Furet, Naoual Wechsler, Janine Jaenne, Pasi A. Kuang, Yanan Yanagita, Masahiko Wang, Lilin Berkowitz, Jillian A. Distel, Robert J. Cayre, Yvon E. TI A New Device for Rapid Isolation by Size and Characterization of Rare Circulating Tumor Cells SO ANTICANCER RESEARCH LA English DT Article DE Circulating tumor cells; CTCs; microfiltration by size; real-time quantitative reverse transcriptase-polymerase chain reaction; qRT-PCR; molecular biology; cytomorphology; FISH; cell culture; lung cancer ID METASTATIC BREAST-CANCER; PERIPHERAL-BLOOD; CARCINOMA-CELLS; COLORECTAL-CANCER; LUNG-CANCER; BONE-MARROW; RT-PCR; ENRICHMENT; PROGRESSION; ARRAY AB Background: Circulating tumor cells (CTCs) likely derive from clones in the primary tumor, suggesting that they can be used for all biological tests applying to the primary cells. Materials and Methods: The ScreenCell (R) devices are single-use and low-cost innovative devices that use a filter to isolate and sort tumor cells by size. Results: The ScreenCell (R) Cyto device is able to isolate rare, fixed, tumor cells, with a high recovery rate. Cells are well preserved morphologically. Immunocytochemistry and FISH assays can be performed directly on the filter. The ScreenCell (R) CC device allows isolation of live cells able to grow in culture. High quality genetic materials can be obtained directly from tumor cells isolated on the ScreenCell (R) MB device filter. Conclusion: Due to their reduced size, versatility, and capacity to isolate CTCs within minutes, the ScreenCell (R) devices may be able to simplify and improve non-invasive access to tumor cells. C1 [Cayre, Yvon E.] Hop Robert Debre, F-75019 Paris, France. [Cayre, Yvon E.] Univ Paris 06, F-75019 Paris, France. [Desitter, Isabelle; Guerrouahen, Bella S.; Benali-Furet, Naoual; Wechsler, Janine; Cayre, Yvon E.] ScreenCell, F-75012 Paris, France. [Kuang, Yanan; Yanagita, Masahiko; Wang, Lilin; Berkowitz, Jillian A.; Distel, Robert J.] Dana Farber Canc Inst, Ctr Clin & Translat Res, Translat Res Lab, Boston, MA 02115 USA. RP Cayre, YE (reprint author), Hop Robert Debre, 46 Bd Serurier, F-75019 Paris, France. EM cayreinserm@yahoo.com NR 40 TC 127 Z9 136 U1 3 U2 27 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 J9 ANTICANCER RES JI Anticancer Res. PD FEB PY 2011 VL 31 IS 2 BP 427 EP 441 PG 15 WC Oncology SC Oncology GA 739AR UT WOS:000288684800007 PM 21378321 ER PT J AU Tariman, JD Berry, DL Halpenny, B Wolpin, S Schepp, K AF Tariman, Joseph D. Berry, Donna L. Halpenny, Barbara Wolpin, Seth Schepp, Karen TI Validation and testing of the Acceptability E-scale for Web-based patient-reported outcomes in cancer care SO APPLIED NURSING RESEARCH LA English DT Article ID SELF-REPORT ASSESSMENT; SYSTEM; CHEMOTHERAPY; QOL AB The performance of the Acceptability E-scale was tested in a sample of 627 adult and older adult patients from various oncology clinics who completed an electronic symptoms survey. The revised Acceptability E-scale has strong psychometric properties and can be useful in assessing the acceptability and usability of computerized health-related programs in oncology and other health population. (C) 2011 Published by Elsevier Inc. C1 [Tariman, Joseph D.; Wolpin, Seth; Schepp, Karen] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Berry, Donna L.; Halpenny, Barbara] Dana Farber Canc Inst, Phyllis Cantor Canc Res Ctr, Boston, MA 02445 USA. RP Tariman, JD (reprint author), Univ Washington, Sch Nursing, Seattle, WA 98195 USA. EM jtariman@u.washington.edu FU NINR NIH HHS [T32 NR007106, T32 NR007106-08] NR 18 TC 13 Z9 13 U1 2 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0897-1897 J9 APPL NURS RES JI Appl. Nurs. Res. PD FEB PY 2011 VL 24 IS 1 BP 53 EP 58 DI 10.1016/j.apnr.2009.04.003 PG 6 WC Nursing SC Nursing GA 722WG UT WOS:000287465400008 PM 20974066 ER PT J AU Schjeide, BMM Schnack, C Lambert, JC Lill, CM Kirchheiner, J Tumani, H Otto, M Tanzi, RE Lehrach, H Amouyel, P von Arnim, CAF Bertram, L AF Schjeide, Brit-Maren M. Schnack, Cathrin Lambert, Jean-Charles Lill, Christina M. Kirchheiner, Julia Tumani, Hayrettin Otto, Markus Tanzi, Rudolph E. Lehrach, Hans Amouyel, Philippe von Arnim, Christine A. F. Bertram, Lars TI The Role of Clusterin, Complement Receptor 1, and Phosphatidylinositol Binding Clathrin Assembly Protein in Alzheimer Disease Risk and Cerebrospinal Fluid Biomarker Levels SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID GENOME-WIDE ASSOCIATION; CREUTZFELDT-JAKOB-DISEASE; NINCDS-ADRDA CRITERIA; AMYLOID-BETA-PROTEIN; SYSTEMATIC METAANALYSES; GENETIC ASSOCIATION; IDENTIFIES VARIANTS; FAMILY; DIAGNOSIS; EPSILON-4 AB Context: Two recent and simultaneously published genome-wide association studies independently implicated clusterin (CLU), complement receptor 1 (CR1), and phosphatidylinositol binding clathrin assembly protein (PICALM) as putative novel Alzheimer disease (AD) risk loci. Despite their strong statistical support, all 3 signals emerged from heterogeneous case-control populations and lack replication in different settings. Objective: To determine whether genetic variants in CLU, CR1, and PICALM confer risk for AD in independent data sets (n=4254) and to test the impact of these markers on cerebrospinal fluid (CSF)-A beta 42 and total-tau protein levels (n=425). Design: Genetic association study using family-based and case-control designs. Setting: Ambulatory or hospitalized care. Participants: Family samples originate from mostly multiplex pedigrees recruited at different centers in the United States (1245 families, 2654 individuals with AD, and 1175 unaffected relatives). Unrelated case-control subjects originate from 1 clinical center in Germany(214 individuals with AD and 211 controls). All subjects were of European descent. Main Outcome Measures: The association between 5 genetic variants in CLU, CR1, and PICALM and risk for AD, and the correlation between these 5 genetic variants and CSF-A beta 42 and tau levels. Results: All 3 investigated loci showed significant associations between risk for AD(1-tailed P values ranging from <.001 to .02) and consistent effect sizes and direction. For each locus, the overall evidence of association was substantially strengthened on meta-analysis of all available data (2-tailed P values ranging from 1.1 x 10(-16) to 4.1 x 10(-7)). Of all markers tested, only rs541458 in PICALM was shown to have an effect on CSF protein levels, suggesting that the AD risk allele is associated with decreased CSF A beta 42 levels (2-tailed P=.002). Conclusions: This study provides compelling independent evidence that genetic variants in CLU, CR1, and PICALM are genetically associated with risk for AD. Furthermore, the CSF biomarker analyses provide a first insight into the potentially predominant pathogenetic mechanism(s) underlying the association between AD risk and PICALM. C1 [Bertram, Lars] Max Planck Inst Mol Genet, Neuropsychiat Genet Grp, Dept Vertebrate Genom, D-14195 Berlin, Germany. [Schnack, Cathrin; Kirchheiner, Julia; Tumani, Hayrettin; Otto, Markus; von Arnim, Christine A. F.] Univ Hosp, Dept Neurol, Ulm, Germany. [Lill, Christina M.] Johannes Gutenberg Univ Mainz, Dept Neurol, Univ Med, Mainz, Germany. [Lambert, Jean-Charles; Amouyel, Philippe] INSERM, F-59045 Lille, France. [Lambert, Jean-Charles; Amouyel, Philippe] Inst Pasteur, F-59019 Lille, France. [Amouyel, Philippe] Univ Lille, Lille, France. [Tanzi, Rudolph E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit, Boston, MA USA. RP Bertram, L (reprint author), Max Planck Inst Mol Genet, Neuropsychiat Genet Grp, Dept Vertebrate Genom, Ihnestr 63,Rm 204-1, D-14195 Berlin, Germany. EM bertram@molgen.mpg.de RI lambert, jean-charles/F-8787-2013; Otto, Markus/F-4304-2015; LICEND, CEMND/F-1296-2015; Lill, Christina/J-9449-2015; Bertram, Lars/K-3889-2015; Lambert, jean-charles/A-9553-2014 OI Otto, Markus/0000-0003-4273-4267; Lill, Christina/0000-0002-2805-1307; Bertram, Lars/0000-0002-0108-124X; Lambert, jean-charles/0000-0003-0829-7817 FU Institut Pasteur Lille; Fondation Plan Alzheimer; Cure Alzheimer's Fund; German Federal Ministry of Research and Education; WIN-Kolleg of the Heidelberg Academy of Sciences and Humanities; Anteprion; cNeupro; NeuoTAS; Landesstiftung Baden-Wurtemberg; National Institute on Aging [U24 AG21886] FX The project was funded by grants from the Institut Pasteur Lille, the Fondation Plan Alzheimer, the Cure Alzheimer's Fund (Dr Bertram), and the German Federal Ministry of Research and Education (Dr Bertram). Dr von Arnim was supported by the WIN-Kolleg of the Heidelberg Academy of Sciences and Humanities. Dr Otto was supported by Anteprion, cNeupro, NeuoTAS, and Landesstiftung Baden-Wurtemberg.; Samples from the National Cell Repository for Alzheimer's Disease, which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging, were used in this study. Since the submission of our manuscript, a number of studies have been published that, like our study, independently confirm the association between AD risk and genetic polymorphisms in CLU, CR1, and PICALM. Please see http://www.alzhene.org for up-to-date results. NR 31 TC 47 Z9 48 U1 1 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD FEB PY 2011 VL 68 IS 2 BP 207 EP 213 DI 10.1001/archgenpsychiatry.2010.196 PG 7 WC Psychiatry SC Psychiatry GA 717KC UT WOS:000287041500013 PM 21300948 ER PT J AU Bangalore, S Kumar, S Wetterslev, J Bavry, AA Gluud, C Cutlip, DE Bhatt, DL AF Bangalore, Sripal Kumar, Sunil Wetterslev, Jorn Bavry, Anthony A. Gluud, Christian Cutlip, Donald E. Bhatt, Deepak L. TI Carotid Artery Stenting vs Carotid Endarterectomy Meta-analysis and Diversity-Adjusted Trial Sequential Analysis of Randomized Trials SO ARCHIVES OF NEUROLOGY LA English DT Article ID STENOSIS EVA-3S TRIAL; ANGIOPLASTY; METAANALYSIS; STATEMENT; RISK AB Background: The role of carotid artery stenting (CAS) when compared with carotid endarterectomy (CEA) is controversial, with recent trials showing an increased risk of harm with CAS. Objective: To evaluate the periprocedural and intermediate to long-term benefits and harms of CAS compared with CEA. Data Sources and Study Selection: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials searches for randomized clinical trials until June 2010 of CAS compared with CEA for carotid artery disease. Periprocedural (<= 30-day) outcomes (death, myocardial infarction [MI], or stroke; death or any stroke; any stroke; and MI) and intermediate to long-term outcomes (outcomes as in the Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy [SAPPHIRE] trial: composite of periprocedural death, MI, or stroke plus ipsilateral stroke or death thereafter; periprocedural death or stroke plus ipsilateral stroke thereafter; death or any stroke; and any stroke) were evaluated. Data Extraction: Two of us independently extracted data in duplicate. Baseline characteristics, inclusion and exclusion criteria, use of an embolic protection device, US vs non-US study, and the earlier-mentioned outcomes of interest were extracted from each trial. Data Synthesis: We identified 13 randomized clinical trials randomizing 7477 participants. Carotid artery stenting was associated with an increased risk of periprocedural outcomes of death, MI, or stroke (odds ratio = 1.31; 95% confidence interval, 1.08-1.59), 65% and 67% increases in death or stroke and any stroke, respectively, but with 55% and 85% reductions in the risk of MI and cranial nerve injury, respectively, when compared with CEA. The trial sequential monitoring boundary was crossed by the cumulative z curve, suggesting firm evidence for at least a 20% relative risk increase of periprocedural death or stroke and any stroke and at least a 15% reduction in MI with CAS compared with CEA. Similarly, CAS was associated with 19%, 38%, 24%, and 48% increases in the intermediate to long-term outcomes of SAPPHIRE-like outcome, periprocedural death or stroke and ipsilateral stroke thereafter, death or any stroke, and any stroke, respectively. The trial sequential monitoring boundary was crossed by the cumulative z curve, suggesting firm evidence for at least a 20% relative risk increase of any stroke. Conclusions: In this largest and most comprehensive meta-analysis to date using outcomes that are standard in contemporary studies, CAS was associated with an increased risk of both periprocedural and intermediate to long-term outcomes, but with a reduction in periprocedural MI and cranial nerve injury. Strategies are urgently needed to identify patients who are best served by CAS vs CEA. Arch Neurol. 2011; 68(2):172-184. Published online October 11, 2010. doi:10.1001/archneurol.2010.262 C1 [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA 02132 USA. [Bangalore, Sripal] NYU, Sch Med, New York, NY USA. [Cutlip, Donald E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA. [Kumar, Sunil] Univ Nebraska Med Ctr, Omaha, NE USA. [Wetterslev, Jorn; Gluud, Christian] Copenhagen Univ Hosp, Copenhagen Trial Unit, Ctr Clin Intervent Res, Rigshosp, Copenhagen, Denmark. [Bavry, Anthony A.] Univ Florida, Coll Med, Gainesville, FL USA. RP Bhatt, DL (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy, Boston, MA 02132 USA. EM dlbhattmd@post.harvard.edu RI Bangalore, Sripal/B-6246-2013; Gluud, Christian/K-2561-2013; OI Bangalore, Sripal/0000-0001-9485-0652; Wetterslev, Jorn/0000-0001-7778-1771 FU AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Heartscape; Sanofi Aventis; Medicines Company FX Dr Bhatt has received research grants from AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi Aventis, and The Medicines Company. NR 39 TC 46 Z9 47 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD FEB PY 2011 VL 68 IS 2 BP 172 EP 184 DI 10.1001/archneurol.2010.262 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA 721CY UT WOS:000287330300004 PM 20937941 ER PT J AU Silva, PS Cavallerano, JD Aiello, LM Aiello, LP AF Silva, Paolo S. Cavallerano, Jerry D. Aiello, Lloyd M. Aiello, Lloyd Paul TI Telemedicine and Diabetic Retinopathy Moving Beyond Retinal Screening SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID EYE CARE; PROGRAM; PREVALENCE; DURATION; DISEASE; RISK AB Current projections estimate that diabetes mellitus will afflict over 439 million individuals worldwide by 2030. The task of detecting and evaluating for the presence and severity of retinopathy in the populations with diabetes mellitus is enormous. Although current methods of treatment are effective in reducing the risk for vision loss, a substantial proportion of patients still do not receive appropriate eye care. The use of an ocular telemedicine-based approach has the potential to expand the reach of these highly effective treatments to virtually any location. Novel methods of image acquisition and analysis, as well as the identification of predictive biomarkers, will need to be developed to further enhance this approach of eye care delivery. In addition, such programs will allow the rapid transfer of clinically relevant discoveries and will allow a considerably larger benefit to a broader patient population. Arch Ophthalmol. 2011;129(2):236-242 C1 [Aiello, Lloyd Paul] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA. Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. RP Aiello, LP (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, 1 Joslin Pl, Boston, MA 02215 USA. EM lpaiello@joslin.harvard.edu NR 28 TC 18 Z9 18 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD FEB PY 2011 VL 129 IS 2 BP 236 EP 242 DI 10.1001/archophthalmol.2010.365 PG 7 WC Ophthalmology SC Ophthalmology GA 721CQ UT WOS:000287329500021 PM 21320974 ER PT J AU Cunningham, MT Olson, JD Chandler, WL Van Cott, EM Eby, CS Teruya, J Hollensead, SC Adcock, DM Allison, PM Kottke-Marchant, KK Smith, MD AF Cunningham, Mark T. Olson, John D. Chandler, Wayne L. Van Cott, Elizabeth M. Eby, Charles S. Teruya, Jun Hollensead, Sandra C. Adcock, Dorothy M. Allison, Paul M. Kottke-Marchant, Kandice K. Smith, Marc D. TI External Quality Assurance of Antithrombin, Protein C, and Protein S Assays Results of the College of American Pathologists Proficiency Testing Program in Thrombophilia SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID DEEP-VEIN THROMBOSIS; LABORATORY DIAGNOSIS; PULMONARY-EMBOLISM; PERSPECTIVE; POPULATION; HEMOSTASIS; DEFICIENCY; ISSUES AB Context.-Hereditary and acquired deficiencies of antithrombin (AT), protein C (PC), and protein S (PS) are risk factors for venous thromboembolism. Proper diagnosis requires high-quality assays for these proteins. Objective.-To determine the accuracy and interlaboratory precision of AT, PC, and PS assays used by laboratories participating in the United States College of American Pathologists proficiency testing program in thrombophilia and to grade the performance of laboratories. Design.-Standardized normal plasma with assigned analyte values was sent in 2 separate challenges to participating laboratories. Participants measured AT, PC, and PS levels using local methods. Results.-When compared with the assigned values for the international standard, the order of assay accuracy from highest to lowest was AT activity, PC antigen, AT antigen, total PS antigen, PC activity, PS activity, and free PS antigen (range of assay bias, 2.6%-8.8%). The order of assay precision from highest to lowest was PC activity, AT activity, AT antigen, total PS antigen, PS activity, free PS antigen, and PC antigen (range of assay coefficient of variation, 6.1%-20.0%). Most testing events (87.8%) could be graded as pass or fail using a target range of +/- 3 standard deviations from the method-specific mean. The pass rate was 98.2% for all AT, PC, and PS testing events combined. Conclusions.-Accuracy and precision were higher for AT assays and lower for PC and PS assays. It was feasible to grade individual laboratory performance. (Arch Pathol Lab Med. 2011;135:227-232) C1 [Cunningham, Mark T.] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66223 USA. [Olson, John D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Chandler, Wayne L.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Van Cott, Elizabeth M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Eby, Charles S.] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA. [Teruya, Jun] Texas Childrens Hosp, Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Hollensead, Sandra C.] Univ Louisville Hosp, Dept Pathol, Louisville, KY USA. [Adcock, Dorothy M.] Esoterix Inc, Englewood, CO USA. [Allison, Paul M.] St Lukes Episcopal Hosp, Dept Pathol, Houston, TX 77030 USA. [Kottke-Marchant, Kandice K.] Cleveland Clin, Dept Pathol & Lab Med, Cleveland, OH 44106 USA. [Smith, Marc D.] William Beaumont Hosp, Dept Clin Pathol, Royal Oak, MI 48072 USA. RP Cunningham, MT (reprint author), Univ Kansas, Med Ctr, Dept Pathol, Mail Stop 4049,3901 Rainbow Blvd, Kansas City, KS 66223 USA. EM mcunningham@kumc.edu NR 14 TC 5 Z9 5 U1 0 U2 3 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD FEB PY 2011 VL 135 IS 2 BP 227 EP 232 PG 6 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 722KG UT WOS:000287430500016 PM 21284443 ER PT J AU Teitelbaum, SL Seton, MP Saag, KG AF Teitelbaum, Steven L. Seton, Margaret P. Saag, Kenneth G. TI Should Bisphosphonates Be Used for Long-Term Treatment of Glucocorticoid-Induced Osteoporosis? SO ARTHRITIS AND RHEUMATISM LA English DT Editorial Material ID BONE TURNOVER; POSTMENOPAUSAL WOMEN; ALENDRONATE THERAPY; PATHOGENESIS; TERIPARATIDE; MECHANISMS; DENSITY; DISEASE; OSTEOCLAST; PREVENTION C1 [Teitelbaum, Steven L.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA. [Seton, Margaret P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Seton, Margaret P.] Harvard Univ, Sch Med, Boston, MA USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA. RP Teitelbaum, SL (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA. EM teitelbs@wustl.edu OI Teitelbaum, Steven/0000-0002-4054-6679 FU NIAMS NIH HHS [R01 AR032788, R01 AR032788-17] NR 40 TC 23 Z9 23 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD FEB PY 2011 VL 63 IS 2 BP 325 EP 328 DI 10.1002/art.30135 PG 4 WC Rheumatology SC Rheumatology GA 719KC UT WOS:000287202600003 PM 21279986 ER PT J AU De Caterina, R Talmud, PJ Merlini, PA Foco, L Pastorino, R Altshuler, D Mauri, F Peyvandi, F Lina, D Kathiresan, S Bernardinelli, L Ardissino, D AF De Caterina, Raffaele Talmud, Philippa J. Merlini, Piera Angelica Foco, Luisa Pastorino, Roberta Altshuler, David Mauri, Francesco Peyvandi, Flora Lina, Daniela Kathiresan, Sekar Bernardinelli, Luisa Ardissino, Diego CA Grp Italiano Aterosclerosi TI Strong association of the APOA5-1131T > C gene variant and early-onset acute myocardial infarction SO ATHEROSCLEROSIS LA English DT Article DE Myocardial infarction; Genetics; Association studies; Single nucleotide polymorphisms; APOA5-1131T > C gene variant ID APOLIPOPROTEIN-A-V; CORONARY-ARTERY-DISEASE; HEART-DISEASE; PLASMA TRIGLYCERIDE; LIPOPROTEIN-LIPASE; HAPLOTYPE ANALYSIS; EPIC-NORFOLK; APOA5 LOCUS; HEALTHY-MEN; RISK AB Background: Epidemiological studies support the role for a strong genetic component in the occurrence of early-onset myocardial infarction (MI), although the specific genetic variants responsible for familial clustering remain largely unknown. Methods: The Italian study of early-onset MI is a nationwide case-control study involving 1864 case patients <45 years old who were hospitalized for a first MI, and age/sex/place of origin-matched controls (n = 1864). We investigated the association between early-onset MI, lipid levels and 20 single nucleotide polymorphisms (SNPs) in the candidate genes ADIPOQ, APOA5, ALOX5AP, CYBA, IL6, LPL, PECAM1, PLA2G2A and PLA2G7, chosen because of previously reported associations with Coronary Heart Disease (CHD) or with CHD risk factors. Results: Of all the SNPs investigated, APOA5-1131T>C [(rs662799), minor allele frequency 0.084 (95% confidence interval (CI) 0.07-0.09)] alone showed a statistically significant association with risk of early-onset MI (p = 6.7 x 10(-5)), after Bonferroni correction, with a per C allele odds ratio of 1.44 (95% CI 1.23-1.69). In controls, APOA5-1131T>C was significantly associated with raised plasma triglyceride levels (p = 0.001), compared with non-carriers, the per C allele increase being 11.4% (95% CI 4-19%), equivalent to 0.15 mmol/L (95% CI 0.11-0.20 mmol/L). In cases, the association with early MI risk remained statistically significant after adjustment for triglycerides (p = 0.006). Conclusions: The APOA5-1131C allele, associated with higher fasting triglyceride levels, strongly affects the risk for early-onset MI, even after adjusting for triglycerides. This raises the possibility that APOA5-1131T>C may affect the risk of early MI over and above effects mediated by triglycerides. (C) 2010 Published by Elsevier Ireland Ltd. C1 [De Caterina, Raffaele] Univ G dAnnunzio, Inst Cardiol, Pisa, Italy. [De Caterina, Raffaele] Univ G dAnnunzio, Ctr Excellence Aging, Pisa, Italy. [De Caterina, Raffaele] Fdn G Monasterio, Pisa, Italy. [Talmud, Philippa J.] UCL, Dept Med, Ctr Cardiovasc Genet, London, England. [Merlini, Piera Angelica; Mauri, Francesco] Azienda Osped Niguarda Ca Granda, Div Cardiol, Milan, Italy. [Foco, Luisa; Pastorino, Roberta; Bernardinelli, Luisa] Univ Pavia, Dipartimento Sci Sanit Applicate & Psicocomportam, I-27100 Pavia, Italy. [Altshuler, David; Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Altshuler, David] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Altshuler, David] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Altshuler, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Peyvandi, Flora] IRCCS Maggiore Hosp Fdn, Milan, Italy. [Peyvandi, Flora] Univ Milan, Milan, Italy. [Lina, Daniela; Ardissino, Diego] Univ Parma, Azienda Osped, Div Cardiol, I-43100 Parma, Italy. [Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Kathiresan, Sekar] MIT, Program Med & Populat Genet, Broad Inst, Cambridge, MA 02139 USA. [Kathiresan, Sekar] Harvard Univ, Cambridge, MA 02138 USA. RP De Caterina, R (reprint author), Univ G DAnnunzio, Inst Cardiol, Osped SS Annunziata, Via Vestini, I-66013 Chieti, Italy. EM rdecater@unich.it RI Altshuler, David/A-4476-2009; De Caterina, Raffaele/K-3857-2016; OI Altshuler, David/0000-0002-7250-4107; De Caterina, Raffaele/0000-0003-1637-574X; Talmud, Philippa/0000-0002-5560-1933; Peyvandi, Flora/0000-0001-7423-9864 FU Ministero della Salute [715/2005]; National Institutes of Health [R01 HL087676]; British Heart Foundation [RG08/008] FX This study was supported by a grant from Ministero della Salute 715/2005 and a grant from the National Institutes of Health R01 HL087676. The entire study was conceived and performed within the Gruppo Italiano Aterosclerosi, Trombosi e Biologia Vascolare (ATBV). PJT is funded by the British Heart Foundation (RG08/008). NR 40 TC 27 Z9 27 U1 3 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD FEB PY 2011 VL 214 IS 2 BP 397 EP 403 DI 10.1016/j.atherosclerosis.2010.11.011 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 712FV UT WOS:000286651100026 PM 21130994 ER PT J AU Lopes-Virella, MF Baker, NL Hunt, KJ Lachin, J Nathan, D Virell, G AF Lopes-Virella, Maria F. Baker, Nathaniel L. Hunt, Kelly J. Lachin, John Nathan, David Virell, G. CA DCCT EDIC Res Grp TI Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes SO ATHEROSCLEROSIS LA English DT Article DE Type 1 diabetes; Coronary artery calcification; Coronary artery disease; Oxidized LDL; Oxidized LDL antibodies; Immune complexes; Vascular inflammation; Macrovascular disease; Immunology of atherosclerosis ID LOW-DENSITY-LIPOPROTEIN; INTIMA-MEDIA THICKNESS; HUMAN MACROPHAGES; PITTSBURGH EPIDEMIOLOGY; COMPLICATIONS TRIAL; RISK-FACTORS; ANTIBODIES; DISEASE; INTERVENTIONS; NEPHROPATHY AB Objective: Oxidized LDL (oxLDL) and oxLDL antibodies form immune complexes (IC) that reflect essential components in the development of atherosclerosis: dyslipidemia, oxidative stress and induction of a pro-inflammatory humoral immune response. We measured oxLDL in IC (oxLDL-IC) isolated from patients with type 1 diabetes to assess the relationship between oxLDL-IC and coronary artery calcification (CAC). Methods: OxLDL was measured in IC isolated from baseline samples from a subgroup of 476 patients of the Diabetes Control and Complications Trial (DCCT). CAC was determined by computed tomography (CT) 11-20 years later. Multivariable log-binomial regression models were used to estimate the risk ratios associated with having a high CAC score with an increase of 1 standard deviation (SD) of the natural logarithm of oxLDL-IC. Results: Multivariable regression models indicate that a 1 SD increase in the levels of oxLDL-IC was associated with a 37% increase in the risk of having high CAC score (RR = 1.36; 95% CI: 1.12-1.67) at follow-up after adjustment for DCCT treatment group, retinopathy/AER groups, gender and CT scanning site as well as baseline age, diabetes duration and HbA1C %. Further adjustment for smoking status, blood pressure and LDL resulted in a risk ratio of 1.23 (95% CI: 1.01-1.50) which remained statistically significant indicating that baseline oxLDL-IC is independently associated with the development of CAC. Discussion: Increased levels of oxLDL-IC are associated with the development of coronary calcification. This observation reinforces previously published clinical and experimental data demonstrating that oxLD-IC has pro-inflammatory and proatherogenic properties. Published by Elsevier Ireland Ltd. C1 [Lopes-Virella, Maria F.; Baker, Nathaniel L.; Hunt, Kelly J.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Ralph A Johnson VA Med Ctr, Charleston, SC USA. [Lachin, John] George Washington Univ, Ctr Biostat, Washington, DC USA. [Nathan, David] Harvard Univ, Sch Med, Boston, MA USA. [Nathan, David] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Virell, G.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Lopes-Virella, MF (reprint author), 114 Doughty St, Charleston, SC 29425 USA. EM virellam@musc.edu OI Lachin, John/0000-0001-9838-2841 FU National Institutes of Health/NHLBI [PO1 HL 55782]; NIH/NIDDK [R01 DK081352, R01 DK088778]; Juvenile Diabetes Foundation [2006-49]; Research Service of the Ralph H. Johnson Department of Veterans Affairs Medical Center; Division of Diabetes, Endocrinology and Metabolic Diseases (NIDDK) of the NIH; Genentech Inc through NIDDK FX This work was supported by a Program Project funded by the National Institutes of Health/NHLBI (PO1 HL 55782), by two RO1 Grant funded by NIH/NIDDK (R01 DK081352 and R01 DK088778) and by a Juvenile Diabetes Foundation Grant (2006-49). The work was also supported by the Research Service of the Ralph H. Johnson Department of Veterans Affairs Medical Center.; The DCCT/EDIC was sponsored through research contracts from the Division of Diabetes, Endocrinology and Metabolic Diseases (NIDDK) of the NIH. Additional support was provided by the National Center for Research Resources through the GCRC program and by Genentech Inc through a Cooperative Research and Development Agreement with the NIDDK. NR 31 TC 21 Z9 21 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD FEB PY 2011 VL 214 IS 2 BP 462 EP 467 DI 10.1016/j.atherosclerosis.2010.11.012 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 712FV UT WOS:000286651100037 PM 21156319 ER PT J AU Sakurai, T Dorr, NP Takahashi, N McInnes, LA Elder, GA Buxbaum, JD AF Sakurai, Takeshi Dorr, Nathan P. Takahashi, Nagahide McInnes, L. Alison Elder, Gregory A. Buxbaum, Joseph D. TI Haploinsufficiency of Gtf2i, a Gene Deleted in Williams Syndrome, Leads to Increases in Social Interactions SO AUTISM RESEARCH LA English DT Article DE social behavior; intellectual disability; autism; mouse model ID BEUREN-SYNDROME; MICE; AUTISM AB Identifying genes involved in social behavior is important for autism research. Williams-Beuren syndrome (WBS) is a developmental syndrome with unique neurocognitive features, including low IQ deficits in visuospatial and visual-motor abilities, hypersensitivity to sounds, hypersociability, and increased general anxiety. The syndrome is caused by a recurrent hemizygous deletion of the 7q11.23 region, containing about 28 genes. One of genes in the region, GTF2I, has been implicated in the hypersociability and visuospatial deficits of WBS based on genotype-phenotype correlation studies of patients with atypical deletions. In order to clarify the involvement of GTF2I in neurocognitive function, especially social behavior, we have developed and characterized Gtf2i-deficient mice. We found that homozygous deletion of Gtf2i causes lethality during embryonic development with neural tube closure defects and exencephaly, consistent with other reports. Gtf2i heterozygous animals show no gross changes in brain structure or development. Furthermore, heterozygous animals show no alterations in learning and memory, including spatial memory as assessed by the Morris water maze, but show alterations in the recognition of novel objects. Interestingly, they show increased social interaction with unfamiliar mice and do not show typical social habituation processes, reminiscent of the hypersociability observed in WBS patients. The mice do not appear to show increased anxiety, supporting a specific effect of Gtf2i on defined domains of the WBS phenotype. These data indicate that Gtf2i is involved in several aspects of embryonic development and the development of social neurocircuitry and that GTF2I haploinsufficiency could be a contributor to the hypersociability in WBS patients. C1 [Sakurai, Takeshi; Dorr, Nathan P.; Takahashi, Nagahide; McInnes, L. Alison; Elder, Gregory A.; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Sakurai, Takeshi; McInnes, L. Alison; Buxbaum, Joseph D.] Mt Sinai Sch Med, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA. [Sakurai, Takeshi] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. [Elder, Gregory A.] Vet Affairs Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY USA. RP Buxbaum, JD (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM joseph.buxbaum@mssm.edu OI Buxbaum, Joseph/0000-0001-8898-8313 FU Seaver Foundation; Office of Mount Sinai School of Medicine FX Grant sponsor: The Seaver Foundation.; This research was supported by the Seaver Foundation. T.S. and L.A.M. are current and prior Seaver Fellows, respectively. The Mount Sinai Rat and Mouse Phenotyping Shared Research Facility was supported in part by the Dean's Office of Mount Sinai School of Medicine. The authors thank Dr. Ananda Roy for the generous gift of an antibody. NR 22 TC 31 Z9 31 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1939-3792 J9 AUTISM RES JI Autism Res. PD FEB PY 2011 VL 4 IS 1 SI SI BP 28 EP 39 DI 10.1002/aur.169 PG 12 WC Behavioral Sciences; Psychology, Developmental SC Behavioral Sciences; Psychology GA 729JP UT WOS:000287945900004 PM 21328569 ER PT J AU Kendrick, AA Choudhury, M Rahman, SM McCurdy, CE Friederich, M Van Hove, JLK Watson, PA Birdsey, N Bao, JJ Gius, D Sack, MN Jing, EX Kahn, CR Friedman, JE Jonscher, KR AF Kendrick, Agnieszka A. Choudhury, Mahua Rahman, Shaikh M. McCurdy, Carrie E. Friederich, Marisa Van Hove, Johan L. K. Watson, Peter A. Birdsey, Nicholas Bao, Jianjun Gius, David Sack, Michael N. Jing, Enxuan Kahn, C. Ronald Friedman, Jacob E. Jonscher, Karen R. TI Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation SO BIOCHEMICAL JOURNAL LA English DT Article DE cellular metabolism; mitochondrial metabolism; NAD; non-alcoholic fatty liver disease; obesity; proteomics; sirtuin ID LYSINE ACETYLATION; INSULIN-RESISTANCE; OXIDATIVE STRESS; PYRUVATE-CARBOXYLASE; DEACETYLASE ACTIVITY; HISTONE DEACETYLASE; GENE-EXPRESSION; ACID OXIDATION; OBESITY; METABOLISM AB Acetylation has recently emerged as an important mechanism for controlling a broad array of proteins mediating cellular adaptation to metabolic fuels. Acetylation is governed, in part, by SIRTs (sirtuins), class III NAD(+)-dependent deacetylases that regulate lipid and glucose metabolism in liver during fasting and aging. However, the role of acetylation or SIRTs in pathogenic hepatic fuel metabolism under nutrient excess is unknown. In the present study, we isolated acetylated proteins from total liver proteome and observed 193 preferentially acetylated proteins in mice fed on an HFD (high-fat diet) compared with controls, including 11 proteins not previously identified in acetylation studies. Exposure to the HFD led to hyperacetylation of proteins involved in gluconeogenesis, mitochondrial oxidative metabolism, methionine metabolism, liver injury and the ER (endoplasmic reticulum) stress response. Livers of mice fed on the HFD had reduced SIRT3 activity, a 3-fold decrease in hepatic NAD(+) levels and increased mitochondrial protein oxidation. In contrast, neither SIRT1 nor histone acetyltransferase activities were altered, implicating SIRT3 as a dominant factor contributing to the observed phenotype. In Sirt3(-/-) mice, exposure to the HFD further increased the acetylation status of liver proteins and reduced the activity of respiratory complexes III and IV. This is the first study to identify acetylation patterns in liver proteins of HFD-fed mice. Our results suggest that SIRT3 is an integral regulator of mitochondrial function and its depletion results in hyperacetylation of critical mitochondrial proteins that protect against hepatic lipotoxicity under conditions of nutrient excess. C1 [Kendrick, Agnieszka A.; Friedman, Jacob E.; Jonscher, Karen R.] Univ Colorado, Sch Med, Dept Anesthesiol, NORC,Mass Spectrometry Core Facil, Aurora, CO 80045 USA. [Choudhury, Mahua; Rahman, Shaikh M.; McCurdy, Carrie E.; Friederich, Marisa; Van Hove, Johan L. K.; Friedman, Jacob E.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA. [Watson, Peter A.; Birdsey, Nicholas] Denver VA Med Ctr, Denver, CO 80220 USA. [Bao, Jianjun; Sack, Michael N.] NHLBI, Translat Med Branch, NIH, Bethesda, MD 20892 USA. [Gius, David] NCI, Radiat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Jing, Enxuan; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Friedman, JE (reprint author), Univ Colorado, Sch Med, Dept Anesthesiol, NORC,Mass Spectrometry Core Facil, Aurora, CO 80045 USA. EM jed.friedman@ucdenver.edu OI Jonscher, Karen/0000-0002-7929-4886 FU National Institutes of Health [DK59767, P30-DK48520, K12 HD057022]; University of Colorado, Center for Human Nutrition [P30-DK048520-09]; American Heart Association [09BGIA2060705]; American Diabetes Mentor-based Post-Doctoral Fellowship [7-08-MN-17]; Veterans Administration; National Heart, Lung, and Blood Institute; Center for Cancer Research, National Cancer Institute FX This work was supported by the National Institutes of Health [grant numbers DK59767, P30-DK48520 (to J.E.F.)]; a Pilot & Feasibility Award from the University of Colorado, Center for Human Nutrition [grant number P30-DK048520-09 to K.R.J.)]; the National Institutes of Health Office of Research in Women's Health BIRCWH Program [grant number K12 HD057022 (to C.E.M.)]; a Beginning Grant in Aid from the American Heart Association [grant number 09BGIA2060705 (to S.M.R.)]; and an American Diabetes Mentor-based Post-Doctoral Fellowship [grant number 7-08-MN-17 (to MC.)]. P.W. was supported by Veterans Administration Merit Awards. J.B. and M.N.S. were funded by the National Heart, Lung, and Blood Institute. D.G. was supported by the Center for Cancer Research, National Cancer Institute. NR 53 TC 122 Z9 129 U1 3 U2 27 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD FEB 1 PY 2011 VL 433 BP 505 EP 514 DI 10.1042/BJ20100791 PN 3 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 757AJ UT WOS:000290055900012 PM 21044047 ER PT J AU Chang, WC Hartshorn, KL White, MR Moyo, P Michelow, IC Koziel, H Kinane, BT Schmidt, EV Fujita, T Takahashi, K AF Chang, Wei-Chuan Hartshorn, Kevan L. White, Mitchell R. Moyo, Patience Michelow, Ian C. Koziel, Henry Kinane, Bernard T. Schmidt, Emmett V. Fujita, Teizo Takahashi, Kazue TI Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin SO BIOCHEMICAL PHARMACOLOGY LA English DT Article DE Innate immunity; Mannose-binding lectin; Ficolin; Influenza A virus; Complement; Coagulation ID SURFACTANT PROTEIN-D; INNATE IMMUNE DEFENSE; COMPLEMENT PATHWAY; SERINE-PROTEASE; ALTERNATIVE PATHWAY; DEFICIENT MICE; ANTIINFLUENZA ACTIVITY; MOUSE SERUM; ACTIVATION; COLLECTINS AB MBL structurally contains a type II-like collagenous domain and a carbohydrate recognition domain (CRD). We have recently generated three novel recombinant chimeric lectins (RCL), in which varying length of collagenous domain of mannose-binding lectin (MBL) is replaced with that of L-ficolin (L-FCN). CRD of MBL is used for target recognition because it has a broad spectrum in pathogen recognition compared with L-FCN. Results of our study demonstrate that these RCLs are potent inhibitors of influenza A virus (IAV). RCLs, against IAV, show dose-dependent activation of the lectin complement pathway, which is significantly higher than that of recombinant human MBL (rMBL). This activity is observed even without MBL-associated serine proteases (MASPs, provided by MBL deficient mouse sera), which have been thought to mediate complement activation. These observations suggest that RCLs are more efficient in associating with MASP-2, which predominantly mediates the activity. Yet, additional serum further increases the activity while RCL-mediated coagulation-like enzyme activities are diminished compared with rMBL, suggesting reduced association with MASP-1, which has been shown to mediate coagulation-like activity. These data suggest that RCLs may interfere less with host coagulation, which is advantageous to be a therapeutic drug. Importantly, these RCLs have surpassed rMBL for anti-viral activities, such as viral aggregation, reduction of viral hemagglutination (HA) and inhibition of virus-mediated HA and neuraminidase (NA) activities. These results are encouraging that novel RCLs could be used as anti-IAV agents with less side effect and that RCLs would be suitable candidates in developing a new anti-IAV therapy. (C) 2010 Elsevier Inc. All rights reserved. C1 [Chang, Wei-Chuan; Moyo, Patience; Michelow, Ian C.; Kinane, Bernard T.; Takahashi, Kazue] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Dev Immunol,Dept Pediat, Boston, MA 02114 USA. [Hartshorn, Kevan L.; White, Mitchell R.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Koziel, Henry] Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm Crit Care & Sleep Med, Boston, MA 02115 USA. [Koziel, Henry] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Schmidt, Emmett V.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Fujita, Teizo] Fukushima Med Univ, Dept Immunol, Fukushima 9601295, Japan. RP Takahashi, K (reprint author), 55 Fruit St,GRJ1402, Boston, MA 02114 USA. EM ktakahashi1@partners.org OI Hartshorn, Kevan/0000-0002-7196-7433 FU NIH [UO1 AI074503-01, R21 AI077081-01A1, UO1 AI070330-01] FX We would like to thank Enzon pharmaceuticals for providing rMBL. We also thank Dr. Gregory Stahl, Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, for providing mouse anti-human MBL monoclonal antibody (2A9). This work was supported by NIH grants UO1 AI074503-01 and R21 AI077081-01A1 (KT) and UO1 AI070330-01 (EVS). NR 52 TC 21 Z9 22 U1 0 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0006-2952 J9 BIOCHEM PHARMACOL JI Biochem. Pharmacol. PD FEB 1 PY 2011 VL 81 IS 3 BP 388 EP 395 DI 10.1016/j.bcp.2010.10.012 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 710BT UT WOS:000286486600007 PM 21035429 ER PT J AU Kraehenbuehl, TP Ferreira, LS Hayward, AM Nahrendorf, M van der Vlies, AJ Vasile, E Weissleder, R Langer, R Hubbell, JA AF Kraehenbuehl, Thomas P. Ferreira, Lino S. Hayward, Alison M. Nahrendorf, Matthias van der Vlies, Andre J. Vasile, Eliza Weissleder, Ralph Langer, Robert Hubbell, Jeffrey A. TI Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction SO BIOMATERIALS LA English DT Article DE Hydrogel; Biomimetic material; Matrix metalloproteinase; Cardiac tissue engineering; Vascular grafts; Stem cell ID LEFT-VENTRICULAR FUNCTION; PROGENITOR CELLS; MATRIX METALLOPROTEINASES; VASCULAR DEVELOPMENT; IN-VIVO; HEART; CYTOKINES; HYDROGEL; THERAPY; RATS AB We present use of a synthetic, injectable matrix metalloproteinase (MMP)- responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin beta 4 (T beta 4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries to the heart in a rat model. The gel was found to substitute the degrading extracellular matrix in the infarcted myocardium of rats and to promote structural organization of native endothelial cells, while some of the delivered hESC-derived vascular cells formed de novo capillaries in the infarct zone. Magnetic resonance imaging (MRI) revealed that the microvascular grafts effectively preserved contractile performance 3 d and 6 wk after myocardial infarction, attenuated left ventricular dilation, and decreased infarct size as compared to infarcted rats treated with PBS injection as a control (3 d ejection fraction, + similar to 7%, P < 0.001; 6 wk ejection faction, + similar to 12%, P < 0.001). Elevation in vessel density was observed in response to treatment, which may be due in part to elevations in human (donor)-derived cytokines EGF, VEGF and HGF (1 d). Thus, a clinically relevant matrix for dual delivery of vascular cells and drugs may be useful in engineering sustained tissue preservation and potentially regenerating ischemic cardiac tissue. (c) 2010 Elsevier Ltd. All rights reserved. C1 [Kraehenbuehl, Thomas P.; van der Vlies, Andre J.; Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Inst Bioengn, CH-1015 Lausanne, Switzerland. [Kraehenbuehl, Thomas P.; van der Vlies, Andre J.; Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Inst Chem Sci & Engn, CH-1015 Lausanne, Switzerland. [Kraehenbuehl, Thomas P.; Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Kraehenbuehl, Thomas P.] Hoffmann La Roche Inc, Translat Res Sci, Nutley, NJ 07110 USA. [Ferreira, Lino S.] Biocant, Ctr Inovacao Biotecnol, P-3060197 Cantanhede, Portugal. [Ferreira, Lino S.] Univ Coimbra, Ctr Neurosci & Cell Biol CNC, P-3004517 Coimbra, Portugal. [Hayward, Alison M.] MIT, Div Comparat Med, Cambridge, MA 02139 USA. [Nahrendorf, Matthias; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Vasile, Eliza; Langer, Robert] MIT, Robert Koch Inst, Cambridge, MA 02139 USA. RP Hubbell, JA (reprint author), Ecole Polytech Fed Lausanne, Inst Bioengn, Batiment AAB 039,Stn 15, CH-1015 Lausanne, Switzerland. EM lino@biocant.pt; rlanger@mit.edu; jeffrey.hubbell@epfl.ch RI Vasile, Eugeniu/F-8276-2010; Hubbell, Jeffrey/A-9266-2008; OI Hubbell, Jeffrey/0000-0003-0276-5456; ferreira, lino/0000-0001-8985-9302 FU NIH [HL060435]; European Union; Swiss National Science Foundation [120938, PBELP3-127902]; Rotary Ambassadorial Scholarship; Marie Curie; MIT-Portugal; FCT [PTDC/SAU-BEB/098468/2008] FX This work was supported in part by NIH (grant HL060435), the European Union's 6th Framework Program Expertissues, and the European Union's 7th Framework Program Angioscaff. TPK was supported by the Swiss National Science Foundation (grant numbers 120938 and PBELP3-127902) and a Rotary Ambassadorial Scholarship. LSF was supported by a Marie Curie-Reintegration Grant, MIT-Portugal program, FCT (PTDC/SAU-BEB/098468/2008) and Crioestaminal. NR 33 TC 67 Z9 68 U1 2 U2 45 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 J9 BIOMATERIALS JI Biomaterials PD FEB PY 2011 VL 32 IS 4 BP 1102 EP 1109 DI 10.1016/j.biomaterials.2010.10.005 PG 8 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 699PL UT WOS:000285675200017 PM 21035182 ER PT J AU Xu, F Celli, J Rizvi, I Moon, S Hasan, T Demirci, U AF Xu, Feng Celli, Jonathan Rizvi, Imran Moon, Sangjun Hasan, Tayyaba Demirci, Utkan TI A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform SO BIOTECHNOLOGY JOURNAL LA English DT Article DE Cell patterning; 3D ovarian coculture cancer model; Drug screening; High throughput ID FIBROBLASTS; SIZE; VITRIFICATION; CARCINOMA; DROPLETS; ADHESION; THERAPY; CULTURE AB In vitro 3D cancer models that provide a more accurate representation of disease in vivo are urgently needed to improve our understanding of cancer pathology and to develop better cancer therapies. However, development of 3D models that are based on manual ejection of cells from micropipettes suffer from inherent limitations such as poor control over cell density, limited repeatability, low throughput, and, in the case of coculture models, lack of reproducible control over spatial distance between cell types (e.g., cancer and stromal cells). In this study, we build on a recently introduced 3D model in which human ovarian cancer (OVCAR-5) cells overlaid on Matrigel (TM) spontaneously form multicellular acini. We introduce a high-throughput automated cell printing system to bioprint a 3D coculture model using cancer cells and normal fibroblasts micropatterned on Matrigel (TM). Two cell types were patterned within a spatially controlled microenvironment (e.g., cell density, cell-cell distance) in a high-throughput and reproducible manner; both cell types remained viable during printing and continued to proliferate following patterning. This approach enables the miniaturization of an established macro-scale 3D culture model and would allow systematic investigation into the multiple unknown regulatory feedback mechanisms between tumor and stromal cells and provide a tool for high-throughput drug screening. C1 [Hasan, Tayyaba; Demirci, Utkan] Harvard MIT Hlth Sci & Technol, Cambridge, MA USA. [Xu, Feng; Moon, Sangjun; Demirci, Utkan] Brigham & Womens Hosp, Dept Med, Ctr Biomed Engn, Demirci Bio Acoustic MEMS Med BAMM Lab, Boston, MA 02115 USA. [Celli, Jonathan; Rizvi, Imran; Hasan, Tayyaba] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. RP Demirci, U (reprint author), Harvard MIT Hlth Sci & Technol, Cambridge, MA USA. EM thasan@partners.org; udemirci@rics.bwh.harvard.edu RI Xu, Feng/H-4468-2011; Xu, Feng/C-7430-2011; OI Xu, Feng/0000-0003-4351-0222; Rizvi, Imran/0000-0001-9673-4700 FU Randolph Hearst Foundation; Department of Medicine, Brigham and Women's Hospital for the Young Investigators in Medicine; Wellman Center for Photomedicine; National Institutes of Health [5R01CA119388-03, P01CA084203-06, R21 (EB007707)]; Center for Integration of Medicine and Innovative Technology (CIMIT) under US Army Medical Research FX U.D. would like to thank the Randolph Hearst Foundation and the Department of Medicine, Brigham and Women's Hospital for the Young Investigators in Medicine Award. We thank Jie (Jenny) Zhao, Director of the Photopathology core of the Wellman Center for Photomedicine for her assistance with multiphoton fluorescence imaging. I.R. gratefully acknowledges support from the Wellman Center for Photomedicine in the form of a Wellman Fellowship. We thank Drs. Conor Evans and Adnan Abu-Yousif of the Wellman Center for several useful discussions of this work. This work was performed at both the Bio-Acoustic MEMS in Medicine (BAMM) Laboratories at the Center for Bioengineering, Brigham and Women's Hospital and Harvard Medical School and at the Wellman Center for Photomedicine at the Massachusetts General Hospital and Harvard Medical School. Funding was provided by the National Institutes of Health, 5R01CA119388-03 (to T.H.), P01CA084203-06 (to T.H.) and R21 (EB007707). UD and FX were partially supported by the Center for Integration of Medicine and Innovative Technology (CIMIT) under US Army Medical Research Acquisition Activity Cooperative Agreement - New Development Grant. NR 35 TC 70 Z9 71 U1 5 U2 71 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY SN 1860-6768 J9 BIOTECHNOL J JI Biotechnol. J. PD FEB PY 2011 VL 6 IS 2 BP 204 EP 212 DI 10.1002/biot.201000340 PG 9 WC Biochemical Research Methods; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA 726JV UT WOS:000287718500009 PM 21298805 ER PT J AU Bischoff, DS Sakamoto, T Ishida, K Makhijani, NS Gruber, HE Yamaguchi, DT AF Bischoff, David S. Sakamoto, Taylor Ishida, Kenji Makhijani, Nalini S. Gruber, Helen E. Yamaguchi, Dean T. TI CXC receptor knockout mice: Characterization of skeletal features and membranous bone healing in the adult mouse SO BONE LA English DT Article DE Murine; CXC Receptor; DXA; MicroCT; Cranial Defect; Bone Repair ID EXPRESSION; PHENOTYPE; HOMOLOG; GROWTH; CELLS; CHEMOKINES; LINEAGE; GENE; IL-8; KC AB The potential role of CXC chemokines bearing the glu-leu-arg (ELR) motif in bone repair was studied using a cranial defect (CD) model in mice lacking the OCC receptor (mCXCR(-/-) knockout mice), which is homologous to knockout of the human CXC receptor 2 (CXCR2) gene. During the inflammatory stage of bone repair, ELR CXC chemokines are released by inflammatory cells and serve as chemotactic and angiogenic factors. mCXCR(-/-) mice were smaller in weight and length from base of tail to nose tip, compared to WT littermates. DE)(A analysis indicated that bone mineral density (BMD), bone mineral content (BMC), total area (TA), bone area (BA), and total tissue mass (TIM) were decreased in the mCXCR(-/-) mice at 6, 12, and 18 weeks of age. Trabecular bone characteristics in mCXCR(-/-) (% bone, connectivity, number, and thickness) were reduced, and trabecular spacing was increased as evidenced by mu CT. There was no difference in bone formation or resorption indices measured by bone histomorphometry. Trabecular BMD was not altered. Cortical bone volume. BMD, and thickness were reduced; whereas, bone marrow volume was increased in mCXCR(-/-). Decreased polar moment of inertia (J) in the tibias/femurs suggested that the mCXCR(-/-) long bones are weaker. This was confirmed by three-point bending testing of the femurs. CDs created in 6-week-old male mCXCR(-/-) and WT littermates were not completely healed at 12 weeks; WT animals, however, had significantly more bone in-growth than mCXCR(-/-). New bone sites were identified using polarized light and assessed for numbers of osteocyte (0Cy) lacunae and blood vessels (BIV) around the original CD. In new bone, the number of BIV in WT was >2x that seen in mCXCR(-/-). Bone histomorphometry parameters in the cranial defect did not show any difference in bone formation or resorption markers. In summary, studies showed that mCXCR(-/-) mice have (1) reduced weight and size; (2) decreased BMD and BMC; (3) decreased amounts of trabecular and cortical long bone; (4) decreased femur bone strength; and (5) significantly reduced intramembranous bone formation and number of BIV in new calvarial bone during bone repair. Published by Elsevier Inc. C1 [Bischoff, David S.; Sakamoto, Taylor; Ishida, Kenji; Makhijani, Nalini S.; Yamaguchi, Dean T.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Gruber, Helen E.] Carolinas Med Ctr, Dept Orthopaed Surg, Charlotte, NC 28203 USA. [Bischoff, David S.; Yamaguchi, Dean T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Yamaguchi, DT (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dean.yamaguchi@med.va.gov FU VA [1I01BX000170-01]; VHA Medical Research Service FX Supported by VA Merit Review 1I01BX000170-01.; Grant Information: VHA Medical Research Service Merit Review. NR 29 TC 7 Z9 8 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD FEB 1 PY 2011 VL 48 IS 2 BP 267 EP 274 DI 10.1016/j.bone.2010.09.026 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 710UY UT WOS:000286543700013 PM 20870046 ER PT J AU Seton, M Moses, AM Bode, RK Schwartz, C AF Seton, M. Moses, A. M. Bode, R. K. Schwartz, C. TI Paget's disease of bone: The skeletal distribution, complications and quality of life as perceived by patients SO BONE LA English DT Article DE Paget's disease of bone; Quality of life; Aging ID MACULAR DEGENERATION AB Context: Paget's disease of bone (PDB) is a focal disorder of bone metabolism with overgrowth of affected bone resulting in the skeletal complications of this disease. Objective: This study examines what patients know about the skeletal distribution of their PDB, and correlates this with their reports of complications and quality of life. Design: The New England Registry for PDB (NRPD) is a voluntary registry with a questionnaire linked to a radiographic database. Data were collected by mail beginning in 2001. Setting: Ambulatory population. Patients: Any patient with PDB living in New England was eligible to enroll; 285 elected to participate, mean age 73.2 years. Main outcome measures: Patients were asked what bones were affected by PDB, and whether they suffered complications from PDB. Radiographic studies were sought to corroborate their responses. An SF-12 was administered. Results: Compared to the general population, they reported substantially lower levels of physical health (Physical Component Score (PCS) mean = 40), and slightly better mental health (Mental Component Score (MCS) mean = 52). There were more instances of agreement on disease presence and fewer instances on disagreement (p = 0.001). Radiographic studies supported the presence of a complication from PDB when deformity, fracture and joint replacement had occurred, but were less correlative when headache or hearing loss was reported. Conclusions: Most patients with PDB are aware of the skeletal distribution of their disease; there is a reasonable correlate between complications ascribed to PDB and the presence of PDB on the radiograph except when headache or hearing loss is reported. (C) 2010 Elsevier Inc. All rights reserved. C1 [Seton, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Moses, A. M.] SUNY Upstate Med Univ, Div Endocrinol, Syracuse, NY USA. RP Seton, M (reprint author), Massachusetts Gen Hosp, Bulfinch 165,55 Fruit St, Boston, MA 02114 USA. EM mseton@partners.org NR 14 TC 8 Z9 8 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD FEB 1 PY 2011 VL 48 IS 2 BP 281 EP 285 DI 10.1016/j.bone.2010.09.021 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 710UY UT WOS:000286543700015 PM 20858558 ER PT J AU Mariot, V Wu, JY Aydin, C Mantovani, G Mahon, MJ Linglart, A Bastepe, M AF Mariot, Virginie Wu, Joy Y. Aydin, Cumhur Mantovani, Giovanna Mahon, Matthew J. Linglart, Agnes Bastepe, Murat TI Potent constitutive cyclic AMP-generating activity of XL alpha s implicates this imprinted GNAS product in the pathogenesis of McCune-Albright Syndrome and fibrous dysplasia of bone SO BONE LA English DT Article DE GNAS; McCune-Albright syndrome; Fibrous dysplasia of bone; gsp oncogene; Stimulatory G protein; XL alpha s ID STIMULATORY G-PROTEIN; ADENYL CYCLASE SYSTEM; GS-ALPHA; PSEUDOHYPOPARATHYROIDISM TYPE-1A; ACTIVATING MUTATIONS; HORMONE RESISTANCE; GUANYL NUCLEOTIDES; SUBUNIT G(S)ALPHA; PLASMA MEMBRANES; RAT LIVER AB Patients with McCune-Albright syndrome (MAS), characterized primarily by hyperpigmented skin lesions, precocious puberty, and fibrous dyslasia of bone, carry postzygotic heterozygous mutations of GNAS causing constitutive cAMP signaling. GNAS encodes the alpha-subunit of the stimulatory G protein (Gs alpha), as well as a large variant (XL alpha s) derived from the paternal allele. The mutations causing MAS affect both GNAS products, but whether XL alpha s, like Gs alpha, can be involved in the pathogenesis remains unknown. Here, we investigated biopsy samples from four previously reported and eight new patients with MAS. Activating mutations of GNAS (Arg201 with respect to the amino acid sequence of Gs alpha) were present in all the previously reported and five of the new cases. The mutation was detected within the paternally expressed XL alpha s transcript in five and the maternally expressed NESP55 transcript in four cases. Tissues carrying paternal mutations appeared to have higher XL alpha s mRNA levels than maternal mutations. The human XL alpha s mutant analogous to Gs alpha-R201 H (XL alpha s-R543H) showed markedly higher basal cAMP accumulation than wild-type XL alpha s in transfected cells. Wild-type XL alpha s demonstrated higher basal and isoproterenol-induced cAMP signaling than Gs alpha and co-purified with G beta 1 gamma 2 in transduced cells. XL alpha s mRNA was measurable in mouse calvarial cells, with its level being significantly higher in undifferentiated cells than those expressing preosteoblastic markers osterix and alkaline phosphatase. XL alpha s mRNA was also expressed in murine bone marrow stromal cells and preosteoblastic MC3T3-E1 cells. Our findings are consistent with the possibility that constitutive XL alpha s activity adds to the molecular pathogenesis of MAS and fibrous dysplasia of bone. (C) 2010 Elsevier Inc. All rights reserved. C1 [Wu, Joy Y.; Aydin, Cumhur; Mahon, Matthew J.; Linglart, Agnes; Bastepe, Murat] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Wu, Joy Y.; Aydin, Cumhur; Mahon, Matthew J.; Linglart, Agnes; Bastepe, Murat] Harvard Univ, Sch Med, Boston, MA USA. [Mariot, Virginie; Linglart, Agnes] Univ Paris 05, INSERM, Hop St Vincent de Paul, U986, F-75014 Paris, France. [Aydin, Cumhur] Gulhane Mil Med Acad, Dept Endodont & Conservat Treatment, Ankara, Turkey. [Linglart, Agnes] Univ Milan, Dept Med Sci, Endocrinol & Diabetol Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy. [Linglart, Agnes] Hop St Vincent de Paul, AP HP, F-75014 Paris, France. [Linglart, Agnes] Hop St Vincent de Paul, Ctr Reference Malad Rares Metab Calcium & Phospho, F-75014 Paris, France. RP Bastepe, M (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St Thier 10, Boston, MA 02114 USA. EM bastepe@helix.mgh.harvard.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [R01DK073911]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K08AR054741]; AIRC (Associazione Italiana Ricerca Cancro, Milan, Italy); Gulhane Military Medical Academy, Turkish General Staff, Ankara, Turkey; French Society of Endocrinology; European Society of Pediatric Endocrinology FX We thank Dr. H. Juppner for helpful discussions and critically reviewing the manuscript. We also thank Drs. S. Rodda and A. McMahon for providing the mice with Osterix driven GFP expression and Dr. M. Horowitz for providing the biotinylated alkaline phosphatase antibody. This work was supported in part by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073911 to M.B.) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08AR054741 to J.Y.W), as well as by an AIRC (Associazione Italiana Ricerca Cancro, Milan, Italy) grant (to G.M.). C.A. received a research fellowship award from Gulhane Military Medical Academy, Turkish General Staff, Ankara, Turkey; V.M. received a grant from the French Society of Endocrinology; A.L. received a research fellowship grant from the European Society of Pediatric Endocrinology. NR 55 TC 18 Z9 18 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 EI 1873-2763 J9 BONE JI Bone PD FEB 1 PY 2011 VL 48 IS 2 BP 312 EP 320 DI 10.1016/j.bone.2010.09.032 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 710UY UT WOS:000286543700019 PM 20887824 ER PT J AU Goodwin, PJ Stambolic, V Lemieux, J Chen, BE Parulekar, WR Gelmon, KA Hershman, DL Hobday, TJ Ligibel, JA Mayer, IA Pritchard, KI Whelan, TJ Rastogi, P Shepherd, LE AF Goodwin, Pamela J. Stambolic, Vuk Lemieux, Julie Chen, Bingshu E. Parulekar, Wendy R. Gelmon, Karen A. Hershman, Dawn L. Hobday, Timothy J. Ligibel, Jennifer A. Mayer, Ingrid A. Pritchard, Kathleen I. Whelan, Timothy J. Rastogi, Priya Shepherd, Lois E. TI Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Breast cancer; Metformin; Adjuvant; Clinical testing ID ANTIDIABETIC DRUG METFORMIN; ACTIVATED PROTEIN-KINASE; DIABETIC-PATIENTS; RISK; INSULIN; RESISTANCE; CELLS; HER2; CHEMOTHERAPY; MECHANISM AB Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated. C1 [Goodwin, Pamela J.] Univ Toronto, Mt Sinai Hosp, Dept Med, Div Clin Epidemiol,Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X4, Canada. [Stambolic, Vuk] Univ Hlth Network, Div Signaling Biol, Ontario Canc Inst, Toronto, ON, Canada. [Lemieux, Julie] Univ Laval, Univ Quebec, Ctr Hosp, Quebec City, PQ, Canada. [Chen, Bingshu E.; Parulekar, Wendy R.; Shepherd, Lois E.] Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada. [Gelmon, Karen A.] Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada. [Hershman, Dawn L.] Columbia Univ, Dept Med, Med Ctr, New York, NY USA. [Hobday, Timothy J.] Mayo Clin, Coll Med, Dept Oncol, Rochester, MN USA. [Ligibel, Jennifer A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mayer, Ingrid A.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Pritchard, Kathleen I.] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. [Whelan, Timothy J.] Juravinski Canc Ctr, Dept Radiat Oncol, Hamilton, ON, Canada. [Rastogi, Priya] Natl Surg Adjuvant Breast & Bowel Project NSABP, Pittsburgh, PA USA. [Rastogi, Priya] Univ Pittsburgh, Univ Pittsburgh Canc Inst UPCI, Pittsburgh, PA USA. RP Goodwin, PJ (reprint author), Univ Toronto, Mt Sinai Hosp, Dept Med, Div Clin Epidemiol,Samuel Lunenfeld Res Inst, 1284-600 Univ Ave, Toronto, ON M5G 1X4, Canada. EM pgoodwin@mtsinai.on.ca RI Goodwin, Pamela/K-1477-2013; Whelan, Timothy/D-3185-2017; Pritchard, Kathleen/I-2184-2014 OI Chen, Bingshu/0000-0001-6139-0696; Pritchard, Kathleen/0000-0003-0758-9666 NR 31 TC 108 Z9 110 U1 1 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD FEB PY 2011 VL 126 IS 1 BP 215 EP 220 DI 10.1007/s10549-010-1224-1 PG 6 WC Oncology SC Oncology GA 709VT UT WOS:000286470200024 PM 20976543 ER PT J AU Phillips, KA Aldridge, J Ribi, K Sun, ZX Thompson, A Harvey, V Thurlimann, B Cardoso, F Pagani, O Coates, AS Goldhirsch, A Price, KN Gelber, RD Bernhard, J AF Phillips, Kelly-Anne Aldridge, Julie Ribi, Karin Sun, Zhuoxin Thompson, Alastair Harvey, Vernon Thuerlimann, Beat Cardoso, Fatima Pagani, Olivia Coates, Alan S. Goldhirsch, Aron Price, Karen N. Gelber, Richard D. Bernhard, Juerg TI Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Cognitive function; Breast cancer; Aromatase inhibitor; Tamoxifen; Letrozole; Quality of life ID D-AMPHETAMINE; IMPAIRMENT; WOMEN; PERFORMANCE AB Endocrine therapy for breast cancer may affect cognition. The purpose of this study was to examine whether cognitive function improves after cessation of adjuvant endocrine therapy. Change in cognitive function was assessed in 100 postmenopausal breast cancer patients in the BIG 1-98 trial, who were randomized to receive 5 years of adjuvant tamoxifen or letrozole alone or in sequence. Cognitive function was evaluated by computerized tests during the fifth year of trial treatment (Y5) and 1 year after treatment completion (Y6). Cognitive test scores were standardized according to age-specific norms and the change assessed using the Wilcoxon signed-rank test. There was significant improvement in the composite cognitive function score from Y5 to Y6 (median of change = 0.22, effect size = 0.53, P < 0.0001). This improvement was consistent in women taking either tamoxifen or letrozole at Y5 (P = 0.0006 and P = 0.0002, respectively). For postmenopausal patients who received either adjuvant letrozole or tamoxifen alone or in sequence, cognitive function improved after cessation of treatment. C1 [Ribi, Karin; Bernhard, Juerg] IBCSG Coordinating Ctr, CH-3008 Bern, Switzerland. [Price, Karen N.; Gelber, Richard D.] Dana Farber Canc Inst, Frontier Sci & Technol Res Fdn, IBCSG Stat Ctr, Boston, MA 02115 USA. [Bernhard, Juerg] Univ Hosp Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland. [Phillips, Kelly-Anne] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Thompson, Alastair] Univ Dundee, Ninewells Hosp, Dundee, Scotland. [Harvey, Vernon] Auckland City Hosp, Auckland, New Zealand. [Harvey, Vernon] Australian New Zealand Breast Canc Trials Grp, Newcastle, NSW, Australia. [Thuerlimann, Beat] Kantonsspital, Breast Ctr, St Gallen, Switzerland. [Thuerlimann, Beat; Pagani, Olivia] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland. [Cardoso, Fatima] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium. [Pagani, Olivia] Osped Italiano, Oncol Inst So Switzerland, Lugano, Switzerland. [Coates, Alan S.] Int Breast Canc Study Grp, Bern, Switzerland. [Coates, Alan S.] Univ Sydney, Sydney, NSW 2006, Australia. [Goldhirsch, Aron] European Inst Oncol, Dept Med, Milan, Italy. [Goldhirsch, Aron] Oncol Inst So Switzerland, Bellinzona, Switzerland. RP Bernhard, J (reprint author), IBCSG Coordinating Ctr, Effingerstr 40, CH-3008 Bern, Switzerland. EM Kelly.Phillips@petermac.org; julie@jimmy.harvard.edu; karin.ribi@ibcsg.org; zhuoxin@jimmy.harvard.edu; a.m.thompson@dundee.ac.uk; VernonH@adhb.govt.nz; beat.thuerlimann@kssg.ch; fatimacardoso@fundacaochampalimaud.pt; olivia.pagani@ibcsg.org; alan.coates@ibcsg.org; aron.goldhirsch@ibcsg.org; price@jimmy.harvard.edu; gelber@jimmy.harvard.edu; juerg.bernhard@ibcsg.org OI Phillips, Kelly-Anne/0000-0002-0475-1771; Cardoso, Fatima/0000-0002-6692-2249 FU Novartis; Swedish Cancer Society; Cancer Council Australia; Australian New Zealand Breast Cancer Trials Group; Frontier Science and Technology Research Foundation; Swiss Group for Clinical Cancer Research (SAKK); National Cancer Institute at the National Institutes of Health [CA-75362]; Cancer Research Switzerland/Oncosuisse; Foundation for Clinical Cancer Research of Eastern Switzerland (OSKK); Cancer Council Victoria; Dr. John Colebatch Clinical Research Fellowship FX We thank the patients who participated in this trial, collaborators, and funding sources. Acknowledgment for respective individuals involved in the various groups is given in the Appendix. This work was supported by Novartis and coordinated by IBCSG. Support for the IBCSG: Swedish Cancer Society; The Cancer Council Australia; Australian New Zealand Breast Cancer Trials Group; Frontier Science and Technology Research Foundation; Swiss Group for Clinical Cancer Research (SAKK); National Cancer Institute at the National Institutes of Health (Grant number CA-75362); Cancer Research Switzerland/Oncosuisse; and the Foundation for Clinical Cancer Research of Eastern Switzerland (OSKK); The Cancer Council Victoria, Dr. John Colebatch Clinical Research Fellowship (to K. A. P). NR 17 TC 33 Z9 34 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD FEB PY 2011 VL 126 IS 1 BP 221 EP 226 DI 10.1007/s10549-010-1235-y PG 6 WC Oncology SC Oncology GA 709VT UT WOS:000286470200025 PM 21046229 ER PT J AU Keating, NL Landrum, MB Brooks, JM Chrischilles, EA Winer, EP Wright, K Volya, R AF Keating, Nancy L. Landrum, Mary Beth Brooks, John M. Chrischilles, Elizabeth A. Winer, Eric P. Wright, Kara Volya, Rita TI Outcomes following local therapy for early-stage breast cancer in non-trial populations SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Breast cancer; Surgery; Outcomes; Mastectomy; Breast conservation ID COMPARING TOTAL MASTECTOMY; CONTRALATERAL PROPHYLACTIC MASTECTOMY; SEER-MEDICARE DATA; CONSERVING SURGERY; RADICAL-MASTECTOMY; RANDOMIZED-TRIALS; CLINICAL-TRIALS; CLAIMS DATA; PROPENSITY SCORE; LINKED MEDICARE AB Recent studies suggest trends toward more mastectomies for primary breast cancer treatment. We assessed survival after mastectomy and breast-conserving surgery (BCS) with radiation for early-stage breast cancer among non-selected populations of women and among women similar to those in clinical trials. Using population-based data from Surveillance Epidemiology, and End Results cancer registries linked with Medicare administrative data from 1992 to 2005, we conducted propensity score analysis of survival following primary therapy for early-stage breast cancer, including BCS with radiation, BCS without radiation, mastectomy with radiation, and mastectomy without radiation. Adjusted survival was greatest among women who had BCS with radiation (median survival = 10.98 years). Compared with this group, mortality was higher among women who had mastectomy without radiation (median survival 10.04 years, adjusted hazard ratio (HR) = 1.19, 95% confidence interval (CI) = 1.14-1.23), mastectomy with radiation (median survival 10.02 years, HR = 1.20, 95% CI = 1.14-1.27), and BCS without radiation (median survival 7.63 years, HR = 1.81, 95% CI = 1.70-1.92). Among women representative of those eligible for clinical trials (age a parts per thousand currency sign70 years, Charlson comorbidity score = 0/1, and stage 1 tumors), there were no differences in survival for women who underwent BCS with radiation or mastectomy. In conclusion, after careful adjustment for differences in patient, physician, and hospital characteristics, we found better survival for BCS with radiation versus mastectomy among older early-stage breast cancer patients, with no difference in survival for BCS with radiation versus mastectomy among women representative of those in clinical trials. These findings are reassuring in light of recent trends towards more aggressive primary breast cancer therapy. C1 [Keating, Nancy L.; Landrum, Mary Beth; Volya, Rita] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Keating, Nancy L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA. [Brooks, John M.] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA. [Chrischilles, Elizabeth A.; Wright, Kara] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA. [Winer, Eric P.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Keating, NL (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM keating@hcp.med.harvard.edu FU National Cancer Institute [R01 CA104118] FX This study was funded by the National Cancer Institute, grant R01 CA104118 to Dr. Keating. The authors would like to thank Joshua Angrist, Ph.D., Amitabh Chandra, Ph.D., Richard Gelber, Ph.D., Douglas Staiger, Ph.D., and Alan Zaslavsky, Ph.D., for their helpful advice on analyses during an Advisory Meeting as well as Rachel Freedman, M.D., for helpful comments on an earlier draft of the manuscript and Garrett Kirk for administrative assistance. The authors also thank Linda C. Harlan, Ph.D. for sharing data from the National Cancer Institute's Patterns of Care study that allowed us to estimate rates of tamoxifen use by treatment group. NR 68 TC 14 Z9 16 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD FEB PY 2011 VL 125 IS 3 BP 803 EP 813 DI 10.1007/s10549-010-0865-4 PG 11 WC Oncology SC Oncology GA 709HZ UT WOS:000286430400022 PM 20376555 ER PT J AU Robinson, BW Germano, G Song, YQ Abrams, J Scott, M Guariento, I Tiso, N Argenton, F Basso, G Rhodes, J Kanki, JP Look, AT Balice-Gordon, RJ Felix, CA AF Robinson, Blaine W. Germano, Giuseppe Song, Yuanquan Abrams, Joshua Scott, Marion Guariento, Ilaria Tiso, Natascia Argenton, Francesco Basso, Giuseppe Rhodes, Jennifer Kanki, John P. Look, A. Thomas Balice-Gordon, Rita J. Felix, Carolyn A. TI mll ortholog containing functional domains of human MLL is expressed throughout the zebrafish lifespan and in haematopoietic tissues SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE zebrafish; MLL; molecular cloning; primitive haematopoiesis; definitive haematopoiesis ID ACUTE LYMPHOBLASTIC-LEUKEMIA; STEM-CELLS; DROSOPHILA-TRITHORAX; GENE-EXPRESSION; DEFINITIVE HEMATOPOIESIS; AMINO-TERMINUS; MUTANT MICE; PROTEIN; ONTOGENY; EMBRYO AB P>Infant leukaemia is an embryonal disease in which the underlying MLL translocations initiate in utero. Zebrafish offer unique potential to understand how MLL impacts haematopoiesis from the earliest embryonic timepoints and how translocations cause leukaemia as an embryonal process. In this study, a zebrafish mll cDNA syntenic to human MLL spanning the 5' to 3' UTRs, was cloned from embryos, and mll expression was characterized over the zebrafish lifespan. The protein encoded by the 35-exon ORF exhibited 46 center dot 4% overall identity to human MLL and 68-100% conservation in functional domains (AT-hooks, SNL, CXXC, PHD, bromodomain, FYRN, taspase1 sites, FYRC, SET). Maternally supplied transcripts were detected at 0-2 hpf. Strong ubiquitous early zygotic expression progressed to a cephalo-caudal gradient during later embryogenesis. mll was expressed in the intermediate cell mass (ICM) where primitive erythrocytes are produced and in the kidney where definitive haematopoiesis occurs in adults. mll exhibits high cross species conservation, is developmentally regulated in haematopoietic and other tissues and is expressed from the earliest embryonic timepoints throughout the zebrafish lifespan. Haematopoietic tissue expression validates using zebrafish for MLL haematopoiesis and leukaemia models. C1 [Robinson, Blaine W.; Felix, Carolyn A.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA. [Germano, Giuseppe; Guariento, Ilaria; Basso, Giuseppe; Felix, Carolyn A.] Hosp Univ Padua, Lab Haematol & Oncol, Padua, Italy. [Song, Yuanquan; Abrams, Joshua; Scott, Marion; Balice-Gordon, Rita J.; Felix, Carolyn A.] Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA. [Tiso, Natascia; Argenton, Francesco; Felix, Carolyn A.] Univ Padua, Dept Biol, Padua, Italy. [Rhodes, Jennifer; Felix, Carolyn A.] Fox Chase Canc Ctr, Immune Cell Dev & Host Def Program, Philadelphia, PA 19111 USA. [Kanki, John P.; Look, A. Thomas; Felix, Carolyn A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Felix, Carolyn A.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. RP Felix, CA (reprint author), Childrens Hosp Philadelphia, Div Oncol, Colket Translat Res Bldg,Room 4006,3501 Civ Ctr B, Philadelphia, PA 19104 USA. EM felix@email.chop.edu RI Tiso, Natascia/E-2182-2011; Song, Yuanquan/E-2603-2012; OI Tiso, Natascia/0000-0002-5444-9853; BASSO, GIUSEPPE/0000-0002-2634-9302 FU Eagles Fly for Leukemia; Fondazione Citta' della Speranza; NIH [NS050524, R01CA153348] FX This work was supported by research funding from Eagles Fly for Leukemia to C.A.F., Fondazione Citta' della Speranza to G.G. and C.A.F., NIH NS050524 to R.B.G., and NIH R01CA153348 to C.A.F. and R.B.G. We thank Amy Kugath for performing zebrafish husbandry and assistance with WISH, Stephen Chester for assistance with literature searches and Michael Pack for the embryo dissociation protocol for cell sorting. NR 56 TC 3 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD FEB PY 2011 VL 152 IS 3 BP 307 EP 321 DI 10.1111/j.1365-2141.2010.08398.x PG 15 WC Hematology SC Hematology GA 705PK UT WOS:000286148200006 PM 21155757 ER PT J AU Richardson, PG Mitsiades, CS Laubach, JP Lonial, S Chanan-Khan, AA Anderson, KC AF Richardson, Paul G. Mitsiades, Constantine S. Laubach, Jacob P. Lonial, Sagar Chanan-Khan, Asher A. Anderson, Kenneth C. TI Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Review DE cancer; heat shock protein 90; myeloma; peripheral neuropathy; tanespimycin ID RELAPSED MULTIPLE-MYELOMA; STEM-CELL TRANSPLANTATION; PHASE-II TRIAL; ENDOPLASMIC-RETICULUM; LEUKEMIA-CELLS; BREAST-CANCER; DIFFERENTIAL EXPRESSION; PROGNOSTIC IMPLICATIONS; HYDROCHLORIDE IPI-504; MOLECULAR CHAPERONES AB P>Heat shock protein 90 (HSP90) is a molecular chaperone that is induced in response to cellular stress and stabilizes client proteins involved in cell cycle control and proliferative/anti-apoptotic signalling. HSP90 is overexpressed in a range of cancers, and may contribute to tumour cell survival by stabilizing aberrant signalling proteins and by interfering with apoptosis. Tanespimycin, an HSP90 inhibitor, reduces tumour cell survival in vitro. In multiple myeloma (MM), HSP90 inhibition affects multiple client proteins that contribute to tumour cell survival, including the IGF1 receptor and the IL-6 receptor, and elements of the PI3/Akt, STAT3, and MAPK signalling pathways. HSP90 inhibition also abrogates the protective effect of bone marrow stromal cells and inhibits angiogenesis and osteoclastogenesis. Tanespimycin acts synergistically with the proteasome inhibitor bortezomib in MM cells and tumour explants, possibly reducing their ability to resist bortezomib-induced stress to the endoplasmic reticulum. The combination of tanespimycin and bortezomib has demonstrated significant and durable responses with acceptable toxicity in a phase I/II study in patients with relapsed and relapsed/refractory MM. HSP90 inhibition is a promising strategy in MM especially in combination with bortezomib; additional studies will further evaluate optimal dosings of candidate drugs and schedules, as well as confirm efficacy in comparative phase III trials. C1 [Richardson, Paul G.; Mitsiades, Constantine S.; Laubach, Jacob P.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Chanan-Khan, Asher A.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. RP Richardson, PG (reprint author), Dana Farber Canc Inst, 44 Binney St,Dana 1B02, Boston, MA 02115 USA. EM paul_richardson@dfci.harvard.edu FU Bristol-Myers Squibb; Rick Corman Multiple Myeloma Research Fund; Millennium Pharmaceuticals; Amgen Inc.; AVEO Pharmaceuticals Inc.; EMD Serono Inc.; Sunesis Pharmaceuticals, Inc.; Gloucester Pharmaceuticals Inc.; Celgene Corporation; Novartis Pharmaceuticals FX We would like to thank Katie Redman for administrative assistance and Stephen Collins, PhD, Mary E. Dominiecki, PhD, Robert O'Beirne, and Andrew Graham for scientific, editorial, and graphics assistance in the preparation of this manuscript funded in part by Bristol-Myers Squibb and the Rick Corman Multiple Myeloma Research Fund.; PGR serves on advisory committees for Millennium Pharmaceuticals, Celgene Corporation, and Bristol-Myers Squibb. He also receives research funding from Millennium Pharmaceuticals. CSM has been a consultant and has received honoraria from Bristol-Myers Squibb, Merck & Co., Inc., Millennium Pharmaceuticals, Novartis Pharmaceuticals, and has received research funding from Amgen Inc., AVEO Pharmaceuticals Inc., EMD Serono Inc., and Sunesis Pharmaceuticals, Inc. Dr CSM has patents with and royalties from PharmaMar. JPL has no conflicts of interest. SL has been on advisory boards of Millennium Pharmaceuticals, Celgene Corporation, and Bristol-Myers Squibb. Dr SL has been a consultant for Celgene Corporation, Millennium Pharmaceuticals, Bristol-Myers Squibb, and Novartis Pharmaceuticals, and has received research funding from Millennium Pharmaceuticals and Gloucester Pharmaceuticals Inc. AAC-K has been on advisory boards of Millennium Pharmaceuticals and Celgene Corporation. KCA has been on advisory boards of Millennium Pharmaceuticals, Celgene Corporation, Bristol-Myers Squibb, Merck & Co. Inc., and Novartis Pharmaceuticals, and has received research funding from Millennium Pharmaceuticals, Celgene Corporation, and Novartis Pharmaceuticals. NR 77 TC 66 Z9 71 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD FEB PY 2011 VL 152 IS 4 BP 367 EP 379 DI 10.1111/j.1365-2141.2010.08360.x PG 13 WC Hematology SC Hematology GA 711PC UT WOS:000286602900001 PM 21219297 ER PT J AU Grace, RF Dahlberg, SE Neuberg, D Sallan, SE Connors, JM Neufeld, EJ DeAngelo, DJ Silverman, LB AF Grace, Rachael F. Dahlberg, Suzanne E. Neuberg, Donna Sallan, Stephen E. Connors, Jean M. Neufeld, Ellis J. DeAngelo, Daniel J. Silverman, Lewis B. TI The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE acute lymphoblastic leukaemia; asparaginase; thrombosis; anticoagulation; management ID ESCHERICHIA-COLI-ASPARAGINASE; ANTITHROMBIN-III DEFICIENCY; MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM; ERWINIA-ASPARAGINASE; RISK-FACTORS; CHILDREN; CHILDHOOD; INDUCTION; THERAPY AB P>The optimal management of asparaginase-associated thrombotic complications is not well-defined. We report the features, management and outcome of paediatric (ages 0-18 years) and adult (18-50 years) patients with acute lymphoblastic leukaemia (ALL) with asparaginase-related venous thromboembolic events (VTE) treated at Dana-Farber Cancer Institute on clinical trials for newly diagnosed ALL between 1991-2008. Of 548 patients, 43 (8%) had VTE, including 27/501 (5%) paediatric and 16/47 (34%) adult patients. Sinus venous thrombosis occurred in 1 center dot 6% of patients. Age was the only significant predictor of VTE, with those aged > 30 years at very high risk (VTE rate 42%). 74% of patients received low molecular weight heparin after VTE. Complications of anticoagulation included epistaxis (9%), bruising (2%) and, in two adult patients, major bleeding. Thirty patients (70%) ultimately received at least 85% of the intended doses of asparaginase. 33% of patients experienced recurrent VTE (paediatric 17% vs. adults 47%, P = 0 center dot 07). The 48-month event-free survival for patients with VTE was 85 +/- 6% compared with 88 +/- 2% for those without VTE (P = 0 center dot 36). This study confirms that, after VTE, asparaginase can be restarted with closely monitored anticoagulation after imaging demonstrates clot stabilization or improvement. With this management strategy, a history of VTE does not appear to adversely impact prognosis. C1 [Grace, Rachael F.; Dahlberg, Suzanne E.; Neuberg, Donna; Sallan, Stephen E.; Connors, Jean M.; Neufeld, Ellis J.; DeAngelo, Daniel J.; Silverman, Lewis B.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Grace, Rachael F.; Dahlberg, Suzanne E.; Neuberg, Donna; Sallan, Stephen E.; Connors, Jean M.; Neufeld, Ellis J.; DeAngelo, Daniel J.; Silverman, Lewis B.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Grace, RF (reprint author), Childrens Hosp, Dana Farber Canc Inst, 300 Longwood Ave,Karp 8, Boston, MA 02115 USA. EM Rachael.Grace@childrens.harvard.edu RI Neufeld, Ellis/F-9331-2011; OI Grace, Fergal/0000-0002-3144-5999 FU Scholars in Clinical Science program of Harvard Catalyst \ The Harvard Clinical and Translational Science Center [UL1 RR 025758]; National Cancer Institute [5P01CA68484, K24HL4818] FX This work was conducted with support from the Scholars in Clinical Science program of Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (Award #UL1 RR 025758 to RG and financial contributions from Harvard University and its affiliated academic health care centres). This work was also conducted with support of the National Cancer Institute; Grant numbers: 5P01CA68484 and K24HL4818 (EJN). NR 36 TC 56 Z9 56 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD FEB PY 2011 VL 152 IS 4 BP 452 EP 459 DI 10.1111/j.1365-2141.2010.08524.x PG 8 WC Hematology SC Hematology GA 711PC UT WOS:000286602900009 PM 21210774 ER PT J AU Galka, A Wong, KFK Ozaki, T Muhle, H Stephani, U Siniatchkin, M AF Galka, Andreas Wong, Kin Foon Kevin Ozaki, Tohru Muhle, Hiltrud Stephani, Ulrich Siniatchkin, Michael TI Decomposition of Neurological Multivariate Time Series by State Space Modelling SO BULLETIN OF MATHEMATICAL BIOLOGY LA English DT Article DE Time series analysis; Kalman filtering; Independent Component Analysis; Artifact removal; Electroencephalogram; EEG/FMRI fusion ID INDEPENDENT COMPONENT ANALYSIS; LEAST-SQUARES ESTIMATION; BLIND SOURCE SEPARATION; LINEAR DYNAMIC SYSTEMS; EEG DATA; MAXIMUM-LIKELIHOOD; IDENTIFICATION; SIGNALS; ARTIFACTS; FMRI AB Decomposition of multivariate time series data into independent source components forms an important part of preprocessing and analysis of time-resolved data in neuroscience. We briefly review the available tools for this purpose, such as Factor Analysis (FA) and Independent Component Analysis (ICA), then we show how linear state space modelling, a methodology from statistical time series analysis, can be employed for the same purpose. State space modelling, a generalization of classical ARMA modelling, is well suited for exploiting the dynamical information encoded in the temporal ordering of time series data, while this information remains inaccessible to FA and most ICA algorithms. As a result, much more detailed decompositions become possible, and both components with sharp power spectrum, such as alpha components, sinusoidal artifacts, or sleep spindles, and with broad power spectrum, such as FMRI scanner artifacts or epileptic spiking components, can be separated, even in the absence of prior information. In addition, three generalizations are discussed, the first relaxing the independence assumption, the second introducing non-stationarity of the covariance of the noise driving the dynamics, and the third allowing for non-Gaussianity of the data through a non-linear observation function. Three application examples are presented, one electrocardigram time series and two electroencephalogram (EEG) time series. The two EEG examples, both from epilepsy patients, demonstrate the separation and removal of various artifacts, including hum noise and FMRI scanner artifacts, and the identification of sleep spindles, epileptic foci, and spiking components. Decompositions obtained by two ICA algorithms are shown for comparison. C1 [Galka, Andreas; Muhle, Hiltrud; Stephani, Ulrich; Siniatchkin, Michael] Univ Kiel, Dept Neuropediat, D-24098 Kiel, Germany. [Galka, Andreas] Univ Kiel, Inst Expt & Appl Phys, D-24098 Kiel, Germany. [Galka, Andreas] Univ Kiel, Fac Engn, Informat & Coding Theory Lab, D-24098 Kiel, Germany. [Wong, Kin Foon Kevin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ozaki, Tohru] Tohoku Univ, Aoba Ku, Sendai, Miyagi 9808576, Japan. RP Galka, A (reprint author), Univ Kiel, Dept Neuropediat, D-24098 Kiel, Germany. EM a.galka@neurologie.uni-kiel.de RI Stephani, Ulrich/D-1004-2010; Wong, Kin Foon Kevin/C-7896-2014 FU German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) [SFB 855]; Japanese Society for the Promotion of Science (JSPS) [P 03059, 173000922301, 197002710002] FX This work was supported by the by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) through project SFB 855 "Biomagnetic Sensing" and by the Japanese Society for the Promotion of Science (JSPS) through fellowship ID No. P 03059 and grants KIBAN B No. 173000922301 and WAKATE B No. 197002710002. NR 69 TC 8 Z9 8 U1 4 U2 23 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0092-8240 EI 1522-9602 J9 B MATH BIOL JI Bull. Math. Biol. PD FEB PY 2011 VL 73 IS 2 BP 285 EP 324 DI 10.1007/s11538-010-9563-y PG 40 WC Biology; Mathematical & Computational Biology SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology GA 726UL UT WOS:000287751800003 PM 20821065 ER PT J AU Forman, SA Miller, KW AF Forman, Stuart A. Miller, Keith W. TI Anesthetic sites and allosteric mechanisms of action on Cys-loop ligand-gated ion channels SO CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE LA English DT Article ID NICOTINIC ACETYLCHOLINE-RECEPTOR; GABA(A) RECEPTOR; A RECEPTOR; GENERAL-ANESTHETICS; BINDING-SITES; RICH MEMBRANES; OPEN-STATE; RAT-BRAIN; ETOMIDATE; ACID AB Purpose The Cys-loop ligand-gated ion channel superfamily is a major group of neurotransmitter-activated receptors in the central and peripheral nervous system. The superfamily includes inhibitory receptors stimulated by gamma-aminobutyric acid (GABA) and glycine and excitatory receptors stimulated by acetylcholine and serotonin. The first part of this review presents current evidence on the location of the anesthetic binding sites on these channels and the mechanism by which binding to these sites alters their function. The second part of the review addresses the basis for this selectivity, and the third part describes the predictive power of a quantitative allosteric model showing the actions of etomidate on gamma-aminobutyric acid type A receptors (GABA(A)Rs). Principal findings General anesthetics at clinical concentrations inhibit the excitatory receptors and enhance the inhibitory receptors. The location of general anesthetic binding sites on these receptors is being defined by photoactivable analogues of general anesthetics. The receptor studied most extensively is the muscle-type nicotinic acetylcholine receptor (nAChR), and progress is now being made with GABA(A)Rs. There are three categories of sites that are all in the transmembrane domain: 1) within a single subunit's four-helix bundle (intrasubunit site; halothane and etomidate on the delta subunit of AChRs); 2) between five subunits in the transmembrane conduction pore (channel lumen sites; etomidate and alcohols on nAChR); and 3) between two subunits (subunit interface sites; etomidate between the alpha 1 and beta 2/3 subunits of the GABA(A)R). Conclusions These binding sites function allosterically. Certain conformations of a receptor bind the anesthetic with greater affinity than others. Time-resolved photolabelling of some sites occurs within milliseconds of channel opening on the nAChR but not before. In GABA(A)Rs, electrophysiological data fit an allosteric model in which etomidate binds to and stabilizes the open state, increasing both the fraction of open channels and their lifetime. As predicted by the model, the channel-stabilizing action of etomidate is so strong that higher concentrations open the channel in the absence of agonist. The formal functional paradigm presented for etomidate may apply to other potent general anesthetic drugs. Combining photolabelling with structure-function mutational studies in the context of allosteric mechanisms should lead us to a more detailed understanding of how and where these important drugs act. C1 [Forman, Stuart A.; Miller, Keith W.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Miller, Keith W.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP Forman, SA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Jackson 444, Boston, MA 02114 USA. EM saforman@partners.org FU NIGMS NIH HHS [P01 GM058448, GM 58448, P01 GM058448-12, R01 GM066724, R01 GM066724-07, R01 GM089745, R01 GM089745-01A1] NR 74 TC 48 Z9 48 U1 0 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0832-610X J9 CAN J ANESTH JI Can. J. Anesth. PD FEB PY 2011 VL 58 IS 2 BP 191 EP 205 DI 10.1007/s12630-010-9419-9 PG 15 WC Anesthesiology SC Anesthesiology GA 726XR UT WOS:000287760900008 PM 21213095 ER PT J AU Bittner, EA Yue, Y Xie, ZC AF Bittner, Edward A. Yue, Yun Xie, Zhongcong TI Brief review: Anesthetic neurotoxicity in the elderly, cognitive dysfunction and Alzheimer's disease SO CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE LA English DT Article ID ISOFLURANE INDUCES APOPTOSIS; TERM NEUROCOGNITIVE FUNCTION; NITROUS OXIDE ANESTHESIA; AMYLOID PROTEIN-LEVELS; GENERAL-ANESTHESIA; AGED RATS; MEMORY IMPAIRMENT; CRITICAL ILLNESS; TAU HYPERPHOSPHORYLATION; CALCIUM HOMEOSTASIS AB Purpose Postoperative cognitive decline in the elderly has emerged as a major health concern. In addition, there is a growing interest in the potential relationship between general anesthetic exposure and the onset and progression of Alzheimer's disease (AD). The available evidence of a possible association between anesthesia, surgery, and long-term cognitive effects, including AD, deserves consideration. In this review, we summarize the evidence for anesthesia-induced neurotoxicity in the elderly, while highlighting the limitations of existing data, and we put the literature into perspective for the clinician. Principal findings A growing body of evidence suggests that general anesthetics may be neurotoxic to both young and aging brains. Much of the evidence originates from in vitro and in vivo studies with cells, rodents, and nonhuman primates. Despite the animal data suggesting a relationship between anesthesia and neurotoxicity in the elderly, a definitive link remains elusive in humans. Conclusions The possible relation between anesthetic neurotoxicity, postoperative cognitive dysfunction, and AD remains elusive. It remains unclear whether postoperative cognitive decline in the elderly is related more to perioperative stress and related medical co-morbidities. C1 [Xie, Zhongcong] Massachusetts Gen Hosp, Geriatr Anesthesia Res Unit, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA. [Xie, Zhongcong] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Bittner, Edward A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Bittner, Edward A.] Harvard Univ, Sch Med, Boston, MA USA. [Yue, Yun] Capital Med Univ, Beijing Chaoyang Hosp, Dept Anesthesia, Beijing, Peoples R China. RP Xie, ZC (reprint author), Massachusetts Gen Hosp, Geriatr Anesthesia Res Unit, Dept Anesthesia Crit Care & Pain Med, 114 16th St,3750, Charlestown, MA 02129 USA. EM zxie@partners.org FU NIA NIH HHS [R21 AG029856]; NIGMS NIH HHS [R01 GM088801]; NINDS NIH HHS [K08 NS048140] NR 67 TC 26 Z9 32 U1 1 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0832-610X J9 CAN J ANESTH JI Can. J. Anesth. PD FEB PY 2011 VL 58 IS 2 BP 216 EP 223 DI 10.1007/s12630-010-9418-x PG 8 WC Anesthesiology SC Anesthesiology GA 726XR UT WOS:000287760900010 PM 21174183 ER PT J AU Hurwitz, MD Hansen, JL Prokopios-Davos, S Manola, J Wang, QA Bornstein, BA Hynynen, K Kaplan, ID AF Hurwitz, Mark D. Hansen, Jorgen L. Prokopios-Davos, Savina Manola, Judith Wang, Qian Bornstein, Bruce A. Hynynen, Kullervo Kaplan, Irving D. TI Hyperthermia Combined With Radiation for the Treatment of Locally Advanced Prostate Cancer Long-Term Results From Dana-Farber Cancer Institute Study 94-153 SO CANCER LA English DT Article DE hyperthermia; thermometry; prostate cancer; radiation therapy; androgen deprivation ID THERAPY ONCOLOGY GROUP; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; PHASE-III TRIAL; ANDROGEN DEPRIVATION; DEFINITIVE RADIOTHERAPY; ADVANCED ADENOCARCINOMA; REGIONAL HYPERTHERMIA; CARCINOMA; GOSERELIN AB BACKGROUND: The authors present long-term results from a phase 2 study that assessed the efficacy of transrectal ultrasound hyperthermia plus radiation with or without androgen suppression for the treatment of locally advanced prostate cancer. METHODS: Patients with clinical T2b-T3bN0M0 disease (according to 1992 American Joint Committee on Cancer [AJCC] criteria) received radiation plus 2 transrectal ultrasound hyperthermia treatments. After the first 4 patients, 6 months of androgen suppression were allowed. The study was designed to assess absolute improvement in the 2-year disease-free survival rate compared with the short-term androgen suppression arm in Radiation Therapy Oncology Group (RTOG) study 92-02. RESULTS: Thirty-seven patients received a total of 72 hyperthermia treatments. The mean cumulative equivalent minutes (CEM) T(90)43 degrees C was 8.4 minutes. According to the 1992 AJCC classification, there were 19 patients with T2b tumors, 8 patients with T2c tumors, 5 patients with T3a tumors, and 5 patients with T3b tumors. The median Gleason score was 7 (range, 6-9), and the median prostate-specific antigen (PSA) level was 13.3 ng/mL (range, 2-65 ng/mL). Thirty-three patients received androgen suppression. At a median follow-up of 70 months (range, 18-110 months), the 7-year overall survival rate was 94%, and 61% of patients remained failure free (according to the American Society for Therapeutic Radiology and Oncology definition for failure free survival). The absolute rate of disease-free survival at 2 years, which was the primary study endpoint, improved significantly (84%) compared with a rate of 64% for similar patients on the 4-month androgen suppression arm of RTOG 92-02. When Phoenix criteria (PSA nadir + 2 ng/mL) were used to define biochemical failure, 89% of patients were failure free at 2 years. CONCLUSIONS: Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer appeared to be promising. The current results indicated that further study of hyperthermia for the treatment of prostate cancer with optimal radiation and systemic therapy is warranted. Cancer 2011;117:510-6. (C) 2010 American Cancer Society C1 [Hurwitz, Mark D.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. [Manola, Judith; Wang, Qian] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Hynynen, Kullervo] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Hynynen, Kullervo] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Hynynen, Kullervo] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada. [Kaplan, Irving D.] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. RP Hurwitz, MD (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, 75 Francis St,ASB1,L2, Boston, MA 02115 USA. EM mhurwitz@lroc.harvard.edu FU National Cancer Institute [P-01 CA31303] FX Supported by National Cancer Institute grant P-01 CA31303. NR 23 TC 29 Z9 31 U1 0 U2 9 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2011 VL 117 IS 3 BP 510 EP 516 DI 10.1002/cncr.25619 PG 7 WC Oncology SC Oncology GA 709JC UT WOS:000286433300015 PM 20886629 ER PT J AU Shima, K Morikawa, T Baba, Y Nosho, K Suzuki, M Yamauchi, M Hayashi, M Giovannucci, E Fuchs, CS Ogino, S AF Shima, Kaori Morikawa, Teppei Baba, Yoshifumi Nosho, Katsuhiko Suzuki, Maiko Yamauchi, Mai Hayashi, Marika Giovannucci, Edward Fuchs, Charles S. Ogino, Shuji TI MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers SO CANCER CAUSES & CONTROL LA English DT Article DE Colon cancer; MGMT; Hypermethylation; Epigenetics; Clinical outcome ID O-6-METHYLGUANINE DNA METHYLTRANSFERASE; NORMAL COLONIC-MUCOSA; LOW CIMP-LOW; MICROSATELLITE INSTABILITY; MOLECULAR-FEATURES; PHENOTYPE CIMP; KRAS MUTATION; G-C; GENE; HYPERMETHYLATION AB O (6)-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme. MGMT promoter hypermethylation and epigenetic silencing often occur as early events in carcinogenesis. However, prognostic significance of MGMT alterations in colorectal cancer remains uncertain. Utilizing a database of 855 colon and rectal cancers in two prospective cohort studies (the Nurses' Health Study and the Health Professionals Follow-up Study), we detected MGMT promoter hypermethylation in 325 tumors (38%) by MethyLight and loss of MGMT expression in 37% (247/672) of tumors by immunohistochemistry. We assessed the CpG island methylator phenotype (CIMP) using eight methylation markers [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1], and LINE-1 (L1) hypomethylation, TP53 (p53), and microsatellite instability (MSI). MGMT hypermethylation was not associated with colorectal cancer-specific mortality in univariate or multivariate Cox regression analysis [adjusted hazard ratio (HR) = 1.03; 95% confidence interval (CI), 0.79-1.36] that adjusted for clinical and tumor features, including CIMP, MSI, and BRAF mutation. Similarly, MGMT loss was not associated with patient survival. MGMT loss was associated with G > A mutations in KRAS (p = 0.019) and PIK3CA (p = 0.0031). Despite a well-established role of MGMT aberrations in carcinogenesis, neither MGMT promoter methylation nor MGMT loss serves as a prognostic biomarker in colorectal cancer. C1 [Ogino, Shuji] Harvard Univ, Sch Med, Ctr Mol Oncol Pathol, Dana Farber Canc Inst,Brigham & Womens Hosp, Boston, MA 02115 USA. [Shima, Kaori; Morikawa, Teppei; Baba, Yoshifumi; Nosho, Katsuhiko; Suzuki, Maiko; Yamauchi, Mai; Hayashi, Marika; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Giovannucci, Edward; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA. [Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Ogino, S (reprint author), Harvard Univ, Sch Med, Ctr Mol Oncol Pathol, Dana Farber Canc Inst,Brigham & Womens Hosp, 44 Binney St,Room JF 215C, Boston, MA 02115 USA. EM shuji_ogino@dfci.harvard.edu FU U.S. National Institute of Health (NIH) [P01 CA87969, P01 CA55075, P50 CA127003, K07 CA122826, R01 CA151993]; Bennett Family Fund; Entertainment Industry Foundation National Colorectal Cancer Research Alliance; Uehara Memorial Foundation; Japan Society for Promotion of Science FX We deeply thank the Nurses' Health Study and Health Professionals Follow-up Study cohort participants who have generously agreed to provide us with biological specimens and information through responses to questionnaires, and hospitals and pathology departments throughout the United States for providing us with medical records and tumor tissue specimens. This work was supported by U.S. National Institute of Health (NIH) grants P01 CA87969 (to SE Hankinson), P01 CA55075 (to WC Willett), P50 CA127003 (to CSF), K07 CA122826 (to SO), and R01 CA151993 (to SO), and in part by grants from the Bennett Family Fund and from the Entertainment Industry Foundation National Colorectal Cancer Research Alliance. Y.B. was supported by a fellowship grant from the Uehara Memorial Foundation. K.N. and M.S. were supported by fellowship grants from the Japan Society for Promotion of Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of NCI or NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 35 Z9 38 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD FEB PY 2011 VL 22 IS 2 BP 301 EP 309 DI 10.1007/s10552-010-9698-z PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 709TT UT WOS:000286465000015 PM 21140203 ER PT J AU Yang, C Choy, E Hornicek, FJ Wood, KB Schwab, JH Liu, XZ Mankin, H Duan, ZF AF Yang, Cao Choy, Edwin Hornicek, Francis J. Wood, Kirkham B. Schwab, Joseph H. Liu, Xianzhe Mankin, Henry Duan, Zhenfeng TI Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells SO CANCER CHEMOTHERAPY AND PHARMACOLOGY LA English DT Article DE Histone deacetylase inhibitor; Chemotherapy; Bone sarcoma; Apoptosis ID SUBEROYLANILIDE HYDROXAMIC ACID; HUMAN RAD51 PROTEIN; INDUCED APOPTOSIS; CARCINOMA-CELLS; DNA-REPAIR; IN-VITRO; CANCER; MECHANISMS; RESISTANCE; DEATH AB To better understand the mechanisms of cytotoxicity and cell death induced by HDACI PCI-24781 in bone sarcoma cells. Four bone sarcoma cell lines were treated with PCI-24781, and the cytotoxicity was investigated. Further, accumulation of acetylated histones, p21, and PARP cleavage were evaluated in PCI-24781-treated cells. The synergistic effect of PCI-24781 to doxorubicin and its mechanism was investigated in bone sarcoma cells. MTT assay demonstrated that the growth of bone sarcoma cells was inhibited after treatment with PCI-24781. Accumulation of acetylated histones, p21, and PARP cleavage were found in PCI-24781-treated cells. Expression of DNA repair protein RAD51 was inhibited, and the expression of apoptosis protein GADD45 alpha was induced by PCI-24781 in bone sarcoma cells. Bone sarcoma cells treated with PCI-24781 become more sensitive to doxorubicin. The caspase-3/7 activity was increased with doxorubicin and PCI-24781 treatment in these cells. HDACI PCI-24781 has a synergistic effect on doxorubicin-induced apoptosis in bone sarcoma cells. C1 [Yang, Cao; Hornicek, Francis J.; Wood, Kirkham B.; Schwab, Joseph H.; Liu, Xianzhe; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Yang, Cao; Choy, Edwin; Hornicek, Francis J.; Wood, Kirkham B.; Schwab, Joseph H.; Liu, Xianzhe; Mankin, Henry; Duan, Zhenfeng] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Yang, Cao; Choy, Edwin; Hornicek, Francis J.; Schwab, Joseph H.; Liu, Xianzhe; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA. [Yang, Cao; Liu, Xianzhe] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed Surg, Wuhan 430022, Peoples R China. [Choy, Edwin] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. EM zduan@partners.org OI Choy, Edwin/0000-0001-9896-8084 FU Kenneth Stanton Fund; Gattegno and Wechsler funds; Sarcoma Foundation of America; National Cancer Institute, NIH [R01-CA119617] FX This project was supported, in part, by a grant from the Gattegno and Wechsler funds. Support has also been provided by the Kenneth Stanton Fund. Dr. Duan is supported, in part, through a grant from Sarcoma Foundation of America, and a grant from the National Cancer Institute, NIH (Nanotechnology Platform Partnership), R01-CA119617. NR 36 TC 21 Z9 24 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0344-5704 J9 CANCER CHEMOTH PHARM JI Cancer Chemother. Pharmacol. PD FEB PY 2011 VL 67 IS 2 BP 439 EP 446 DI 10.1007/s00280-010-1344-7 PG 8 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA 711YE UT WOS:000286627400021 PM 20461381 ER PT J AU Hall, MJ Manne, SL Winkel, G Chung, DS Weinberg, DS Meropol, NJ AF Hall, Michael J. Manne, Sharon L. Winkel, Gary Chung, Daniel S. Weinberg, David S. Meropol, Neal J. TI Effects of a Decision Support Intervention on Decisional Conflict Associated with Microsatellite Instability Testing SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; COLORECTAL-CANCER; AID; KNOWLEDGE; SUSCEPTIBILITY; SURGERY; MODEL AB Background: Decision support to facilitate informed consent is increasingly important for complicated medical tests. Here, we test a theoretical model of factors influencing decisional conflict in a study examining the effects of a decision support aid that was designed to assist patients at high risk for hereditary nonpolyposis colorectal cancer (CRC) deciding whether to pursue the microsatellite instability (MSI) test. Methods: Participants were 239 CRC patients at high familial risk for a genetic mutation who completed surveys before and after exposure to the intervention. Half of the sample was assigned to the CD-ROM aid and half received a brief description of the test. Structural equation modeling was employed to examine associations among the intervention, knowledge, pros and cons to having MSI testing, self-efficacy, preparedness, and decisional conflict. Results: The goodness of fit for the model was acceptable [FIML, full information maximum likelihood, chi(2) (df = 280) = 392.24; P = 0.00]. As expected, the paths to decisional conflict were significant for postintervention pros of MSI testing (t = -2.43; P < 0.05), cons of MSI testing (t = 2.78; P < 0.05), and preparedness (t = -7.27; P < 0.01). The intervention impacted decisional conflict by increasing knowledge about the MSI test and knowledge exerted its effects on decisional conflict by increasing preparedness to make a decision about the test and by increases in perceived benefits of having the test. Conclusion: Increasing knowledge, preparedness, and perceived benefits of undergoing the MSI test facilitate informed decision making for this test. Impact: Understanding mechanisms underlying health decisions is critical for improving decisional support. Individuals with Lynch syndrome have an elevated lifetime risk of CRC. Risk of Lynch syndrome may be assessed with a tumor-based screening test (MSI testing or immunohistochemical tissue staining). Cancer Epidemiol Biomarkers Prev; 20(2); 249-54. (C)2011 AACR. C1 [Hall, Michael J.; Manne, Sharon L.; Weinberg, David S.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Winkel, Gary] CUNY, New York, NY 10021 USA. [Chung, Daniel S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Meropol, Neal J.] Case Western Reserve Univ, Univ Hosp, Case Med Ctr, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA. RP Hall, MJ (reprint author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA. EM michael.hall@fccc.edu FU National Cancer Institute [CA109332, K05 CA109008]; [P30 CA006927] FX Funded by grant CA109332 from the National Cancer Institute and P30 CA006927 to Fox Chase Cancer Center, and by an Established Investigator in Cancer Prevention and Control Award to S. L. Manne by the National Cancer Institute (K05 CA109008). NR 25 TC 9 Z9 9 U1 0 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD FEB PY 2011 VL 20 IS 2 BP 249 EP 254 DI 10.1158/1055-9965.EPI-10-0685 PG 6 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 717CU UT WOS:000287021400006 PM 21212064 ER PT J AU Poitras, JL Costa, D Kluk, MJ Amrein, PC Stone, RM Lee, C Dal Cin, P Morton, CC AF Poitras, Jennifer L. Costa, Dolors Kluk, Michael J. Amrein, Philip C. Stone, Richard M. Lee, Charles Dal Cin, Paola Morton, Cynthia C. TI Genomic alterations in myeloid neoplasms with novel, apparently balanced translocations SO CANCER GENETICS LA English DT Article DE Cytogenetics; array CGH; chromosomal rearrangement; hematologic malignancy ID CHRONIC LYMPHOCYTIC-LEUKEMIA; IN-SITU HYBRIDIZATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL REARRANGEMENTS; SUBMICROSCOPIC DELETIONS; TRANSCRIPTION FACTOR; POOR-PROGNOSIS; MESSENGER-RNA; D13S25 LOCUS; ARRAY CGH AB Characterization of gross chromosomal rearrangements, particularly translocations in neoplasms, has proven to be valuable in patient management by aiding in diagnosis, defining prognosis, and leading to new therapeutic interventions. In this report, we investigate two apparently balanced translocations, t(6;17)(q23.3;p13.3) and t(2;13)(p21;q14.11), in patients with myeloid neoplasms and uncover concomitant microdeletions associated with the breakpoints. Breakpoint mapping by fluorescence in situ hybridization (FISH) detected deletions at or adjacent to all breakpoints. Subsequently, array comparative genomic hybridization on the 244 K Agilent platform refined the deletion boundaries, revealing a 1.7 Mb deletion directly adjacent to the 6q23.3 breakpoint, and a 562 kb deletion at 17p13.3 in the first case. The second case was found to harbor a 195 kb deletion at 2p21 and a 1.4 Mb deletion distal to the 13q breakpoint at 13q14.3. Additionally, a 133 kb deletion within the breakpoint region at 13q14.11 and a 265 kb deletion proximal to the breakpoint were discovered, neither of which was detected by FISH. Although a gene fusion resulting from either novel rearrangement cannot be determined from these data, formation of a fusion transcript cannot be excluded because the resolution of the techniques used does not allow definite delineation of the breakpoint locations. Although the incidence and clinical relevance of these focal imbalances remains to be evaluated, the cases presented here support high resolution evaluation of presumably balanced rearrangements in neoplasms. Such imbalances may portend important hitherto unrecognized prognostic and diagnostic categories. C1 [Poitras, Jennifer L.; Lee, Charles; Dal Cin, Paola; Morton, Cynthia C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Costa, Dolors; Morton, Cynthia C.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Costa, Dolors; Kluk, Michael J.; Amrein, Philip C.; Stone, Richard M.; Lee, Charles; Dal Cin, Paola; Morton, Cynthia C.] Harvard Univ, Sch Med, Boston, MA USA. [Kluk, Michael J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Amrein, Philip C.] Massachusetts Gen Hosp, Hematol Oncol Unit, Boston, MA 02114 USA. [Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Morton, CC (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM cmorton@partners.org FU Department of Pathology at Brigham; Women's Hospital FX We thank the Harvard-Partners Center for Genetics and Genomics for kindly providing BAC clones for these experiments. This research was supported in part with institutional funding from the Department of Pathology at Brigham and Women's Hospital. NR 52 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2210-7762 J9 CANCER GENET-NY JI Cancer Genet. PD FEB PY 2011 VL 204 IS 2 BP 68 EP 76 DI 10.1016/j.cancergen.2010.12.005 PG 9 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA 752QP UT WOS:000289707800002 PM 21504705 ER PT J AU Vaid, M Singh, T Li, A Katiyar, N Sharma, S Elmets, CA Xu, H Katiyar, SK AF Vaid, Mudit Singh, Tripti Li, Anna Katiyar, Nandan Sharma, Samriti Elmets, Craig A. Xu, Hui Katiyar, Santosh K. TI Proanthocyanidins Inhibit UV-Induced Immunosuppression Through IL-12-Dependent Stimulation of CD8(+) Effector T Cells and Inactivation of CD4(+) T Cells SO CANCER PREVENTION RESEARCH LA English DT Article ID RADIATION-INDUCED IMMUNOSUPPRESSION; INDUCED OXIDATIVE STRESS; SKH-1 HAIRLESS MICE; CONTACT HYPERSENSITIVITY; ULTRAVIOLET-RADIATION; IN-VIVO; SKIN CANCERS; GRAPE SEEDS; INTERLEUKIN-12; INDUCTION AB The inhibition of UVB-induced immunosuppression by dietary grape seed proanthocyanidins (GSP) has been associated with the induction of interleukin (IL)-12 in mice, and we now confirm that GSPs do not inhibit UVB-induced immunosuppression in IL-12p40 knockout (IL-12 KO) mice and that treatment of these mice with recombinant IL-12 restores the inhibitory effect. To characterize the cell population responsible for the GSP-mediated inhibition of UVB-induced immunosuppression and the role of IL-12 in this process, we used an adoptive transfer approach. Splenocytes and draining lymph nodes were harvested from mice that had been administered dietary GSPs (0.5%-1.0%, w/w), exposed to UVB, and sensitized by the application of 2,4-dinitrofluorobenzene (DNFB) onto the UVB-exposed skin. CD8(+) and CD4(+) T cells were positively selected and transferred into naive mice that were subsequently challenged by application of DNFB on the ear skin. Naive recipients that received CD8(+) T cells from GSP-treated, UVB-irradiated donors exhibited full contact hypersensitivity (CHS) response. Naive mice that received CD4(+) suppressor T cells from GSP-treated, UVB-exposed mice could mount a CHS response after sensitization and subsequent challenge with DNFB. On culture, the CD8(+) T cells from GSP-treated, UVB-exposed mice secreted higher levels (5- to 8-fold) of Th1 cytokines than CD8(+) T cells from UVB-irradiated mice not treated with GSPs. CD4(+) T cells from GSP-treated, UVB-exposed mice secreted significantly lower levels (80%-100%) of Th2 cytokines than CD4(+) T cells from UVB-exposed mice not treated with GSPs. These data suggest that GSPs inhibit UVB-induced immunosuppression by stimulating CD8(+) effector T cells and diminishing regulatory CD4(+) T cells. Cancer Prev Res; 4(2); 238-47. (C)2010 AACR. C1 [Vaid, Mudit; Singh, Tripti; Li, Anna; Katiyar, Nandan; Sharma, Samriti; Elmets, Craig A.; Xu, Hui; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Elmets, Craig A.; Xu, Hui; Katiyar, Santosh K.] Univ Alabama, Skin Dis Res Ctr, Birmingham, AL 35294 USA. [Elmets, Craig A.; Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration; UAB Skin Diseases Research Center [AR050948-01] FX This work was financially supported by the Veterans Administration Merit Review Award (S.K. Katiyar, C.A. Elmets), and the UAB Skin Diseases Research Center (AR050948-01). NR 39 TC 12 Z9 12 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 J9 CANCER PREV RES JI Cancer Prev. Res. PD FEB PY 2011 VL 4 IS 2 BP 238 EP 247 DI 10.1158/1940-6207.CAPR-10-0224 PG 10 WC Oncology SC Oncology GA 715KH UT WOS:000286882900008 PM 21075976 ER PT J AU Saydam, O Senol, O Wurdinger, T Mizrak, A Ozdener, GB Stemmer-Rachamimov, AO Yi, M Stephens, RM Krichevsky, AM Saydam, N Brenner, GJ Breakefield, XO AF Saydam, Okay Senol, Ozlem Wuerdinger, Thomas Mizrak, Arda Ozdener, Gokhan Baris Stemmer-Rachamimov, Anat O. Yi, Ming Stephens, Robert M. Krichevsky, Anna M. Saydam, Nurten Brenner, Gary J. Breakefield, Xandra O. TI miRNA-7 Attenuation in Schwannoma Tumors Stimulates Growth by Upregulating Three Oncogenic Signaling Pathways SO CANCER RESEARCH LA English DT Article ID P21-ACTIVATED KINASES; CANCER-CELLS; PROSTATE-CANCER; SUPPRESSOR GENE; FACTOR RECEPTOR; NEUROFIBROMATOSIS; MICRORNAS; EXPRESSION; MERLIN; INHIBITOR AB Micro RNAs (miRNA) negatively regulate protein-coding genes at the posttranscriptional level and are critical in tumorigenesis. Schwannomas develop from proliferation of dedifferentiated Schwann cells, which normally wrap nerve fibers to help support and insulate nerves. In this study, we carried out high-throughput miRNA expression profiling of human vestibular schwannomas by using an array representing 407 known miRNAs to explore the role of miRNAs in tumor growth. Twelve miRNAs were found to be significantly deregulated in tumor samples as compared with control nerve tissue, defining a schwannoma-typical signature. Among these miRNAs, we focused on miR-7, which was one of the most downregulated in these tumors and has several known oncogene targets, including mRNAs for epidermal growth factor receptor (EGFR) and p21-activated kinase 1 (Pak1). We found that overexpression of miR-7 inhibited schwannoma cell growth both in culture and in xenograft tumor models in vivo, which correlated with downregulation of these signaling pathways. Furthermore, we identified a novel direct target of miR-7, the mRNA for associated cdc42 kinase 1 (Ack1), with the expression levels of miR-7 and Ack1 being inversely correlated in human schwannoma samples. These results represent the first miRNA profiling of schwannomas and the first report of a tumor suppressor function for miR-7 in these tumors that is mediated by targeting the EGFR, Pak1, and Ack1 oncogenes. Our findings suggest miR-7 as a potential therapeutic molecule for schwannoma treatment, and they prompt clinical evaluation of drugs that can inhibit the EGFR, Pak1, and Ack1 signaling pathways to treat this tumor type. Cancer Res; 71(3); 852-61. (C) 2010 AACR. C1 [Saydam, Okay; Saydam, Nurten] Med Univ Vienna, Dept Pediat, A-1090 Vienna, Austria. [Stemmer-Rachamimov, Anat O.] Harvard Univ, Sch Med, Dept Pathol, Mol Neurooncol Lab,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Brenner, Gary J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA 02115 USA. [Krichevsky, Anna M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Yi, Ming; Stephens, Robert M.] NCI, Adv Biomed Comp Ctr, Bethesda, MD 20892 USA. [Saydam, Okay; Senol, Ozlem; Wuerdinger, Thomas; Mizrak, Arda; Ozdener, Gokhan Baris; Breakefield, Xandra O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Saydam, Okay; Senol, Ozlem; Wuerdinger, Thomas; Mizrak, Arda; Ozdener, Gokhan Baris; Breakefield, Xandra O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. RP Saydam, O (reprint author), Med Univ Vienna, Dept Pediat, A-1090 Vienna, Austria. EM okay.saydam@meduniwien.ac.at FU NIH/NINDS [P01 NS24279]; DOD [W81XWH-091-0476]; Children's Tumor Foundation [2007-01-043] FX NIH/NINDS P01 NS24279 (X.O. Breakefield/O. Saydam), DOD W81XWH-091-0476 (X.O. Breakefield/O. Saydam), and Children's Tumor Foundation 2007-01-043 (O. Saydam). NR 38 TC 80 Z9 91 U1 0 U2 11 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD FEB 1 PY 2011 VL 71 IS 3 BP 852 EP 861 DI 10.1158/0008-5472.CAN-10-1219 PG 10 WC Oncology SC Oncology GA 714SW UT WOS:000286830300025 PM 21156648 ER PT J AU Yang, CW Hayashida, T Forster, N Li, CQ Shen, DJ Maheswaran, S Chen, L Anderson, KS Ellisen, LW Sgroi, D Schmidt, EV AF Yang, Chuanwei Hayashida, Tetsu Forster, Nicole Li, Cuiqi Shen, Dejun Maheswaran, Shyamala Chen, Li Anderson, Karen S. Ellisen, Leif W. Sgroi, Dennis Schmidt, Emmett V. TI The Integrin alpha(v)beta(3-5) Ligand MFG-E8 Is a p63/p73 Target Gene in Triple-Negative Breast Cancers but Exhibits Suppressive Functions in ER+ and erbB2(+) Breast Cancers SO CANCER RESEARCH LA English DT Article ID MILK-FAT GLOBULE; DISCOIDIN-DOMAIN PROTEIN; MONOCLONAL-ANTIBODIES; EGF FACTOR-8; IDENTIFICATION; CARCINOMA; APOPTOSIS; CELLS; CHEMOSENSITIVITY; LACTADHERIN AB The progression from preinvasive lesion to invasive carcinoma is a critical step contributing to breast cancer lethality. We identified downregulation of milk fat globule-EGF factor 8 (MFG-E8) as a contributor to breast cancer progression using microarray analysis of laser capture microdissected (LCM) tissues. We first identified MFG-E8 downregulation in invasive lesions in transgenic mammary tumor models, which were confirmed in LCM-isolated human invasive ductal carcinomas compared with patient-matched normal tissues. In situ analyses of MFG-E8 expression in estrogen receptor (ER) positive cases confirmed its downregulation during breast cancer progression and small inhibitory MFG-E8 RNAs accelerated ER+ breast cancer cell proliferation. MFG-E8 also decreased in erbB2(+) human cancers and erbB2 transgenic mice lacking MFG-E8 showed accelerated tumor formation. In contrast, MFG-E8 expression was present at high levels in triple-negative (ER-, PgR(-), erbB2(-)) breast cancers, cell lines, and patient sera. Knockdown, chromatin immunoprecipitation, and reporter assays all showed that p63 regulates MFG-E8 expression, and MFG-E8 knockdowns sensitized triple-negative breast cancers to cisplatin treatment. Taken together, our results show that MFG-E8 is expressed in triple-negative breast cancers as a target gene of the p63 pathway, but may serve a suppressive function in ER+ and erbB2(+) breast cancers. Its potential use as a serum biomarker that contributes to the pathogenesis of triple-negative breast cancers urges continued evaluation of its differential functions. Cancer Res; 71(3); 937-45. (C)2010 AACR. C1 [Schmidt, Emmett V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Res Ctr,Pediat Serv, Boston, MA 02114 USA. [Yang, Chuanwei; Hayashida, Tetsu; Forster, Nicole; Li, Cuiqi; Maheswaran, Shyamala; Chen, Li; Ellisen, Leif W.; Schmidt, Emmett V.] Massachusetts Gen Hosp, Canc Res Ctr, Charlestown, MA USA. [Shen, Dejun] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA. [Anderson, Karen S.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Sgroi, Dennis] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA USA. RP Schmidt, EV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Res Ctr,Pediat Serv, 55 Fruit St,GRJ 904, Boston, MA 02114 USA. EM schmidt@helix.mgh.harvard.edu FU National Cancer Institute of the National Institutes of Health [RO1 CA69069]; Harvard Breast Cancer SPORE grant [P50 CA89393]; NIH [RO1 CA112021]; NIH/National Cancer Institute [CA89138]; NCI [U01 CA117374]; Avon foundation; [U01 AI07033] FX This work, C. Yang, L. Chen, and E. V. Schmidt were supported by a grant from the National Cancer Institute of the National Institutes of HealthRO1 CA69069 and by the Harvard Breast Cancer SPORE grant P50 CA89393. C. Yang received additional support from R01 CA112021, and E. V. Schmidt received support from U01 AI07033. D. Sgroi and C. Li were supported by the Harvard Breast Cancer SPORE grant P50 CA89393 and NIH RO1 CA112021. NIH/National Cancer Institute grant CA89138 supported S. Maheswaran and T. Hayashida. K. S. Anderson was supported by NCI U01 CA117374. The Tracey Davis Memorial Fund supported Nicole Forster and Leif Ellisen received support from the Avon foundation. NR 25 TC 15 Z9 16 U1 0 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD FEB 1 PY 2011 VL 71 IS 3 BP 937 EP 945 DI 10.1158/0008-5472.CAN-10-1471 PG 9 WC Oncology SC Oncology GA 714SW UT WOS:000286830300033 PM 21127199 ER PT J AU Qi, J McTigue, MA Rogers, A Lifshits, E Christensen, JG Janne, PA Engelman, JA AF Qi, Jie McTigue, Michele A. Rogers, Andrew Lifshits, Eugene Christensen, James G. Jaenne, Pasi A. Engelman, Jeffrey A. TI Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors SO CANCER RESEARCH LA English DT Article ID TYROSINE KINASE INHIBITORS; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; C-MET; GEFITINIB RESISTANCE; ACTIVATING MUTATIONS; IMATINIB STI571; RECEPTOR; AMPLIFICATION; GROWTH AB Therapies targeting receptor tyrosine kinases have shown efficacy in molecularly defined subsets of cancers. Unfortunately, cancers invariably develop resistance, and overcoming or preventing resistance will ultimately be key to unleashing their full therapeutic potential. In this study, we examined how cancers become resistant to MET inhibitors, a class of drugs currently under clinical development. We utilized the highly sensitive gastric carcinoma cell line, SNU638, and two related MET inhibitors PHA-665752 and PF-2341066. To our surprise, we observed at least two mechanisms of resistance that arose simultaneously. Both resulted in maintenance of downstream PI3K (phosphoinositide 3-kinase)-AKT and MEK (MAP/ERK kinase)-ERK signaling in the presence of inhibitor. One mechanism, observed by modeling resistance both in vitro and in vivo, involved the acquisition of a mutation in the MET activation loop (Y1230). Structural analysis indicates that this mutation destabilizes the autoinhibitory conformation of MET and abrogates an important aromatic stacking interaction with the inhibitor. The other cause of resistance was activation of the epidermal growth factor receptor (EGFR) pathway due to increased expression of transforming growth factor a. Activation of EGFR bypassed the need for MET signaling to activate downstream signaling in these cells. This resistance could be overcome by combined EGFR and MET inhibition. Thus, therapeutic strategies that combine MET inhibitors capable of inhibiting Y1230 mutant MET in combination with anti-EGFR-based therapies may enhance clinical benefit for patients with MET-addicted cancers. Importantly, these results also underscore the notion that a single cancer can simultaneously develop resistance induced by several mechanisms and highlight the daunting challenges associated with preventing or overcoming resistance. Cancer Res; 71(3); 1081-91. (C)2011 AACR. C1 [Qi, Jie; Lifshits, Eugene; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA. [Qi, Jie; Rogers, Andrew; Lifshits, Eugene; Jaenne, Pasi A.; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA. [Rogers, Andrew; Jaenne, Pasi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [McTigue, Michele A.] Pfizer Inc, Dept Canc Chem, New York, NY USA. [Christensen, James G.] Pfizer, Translat Res, Oncol, La Jolla, CA USA. RP Engelman, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Boston, MA 02129 USA. EM jengelman@partners.org FU NIH [K08 CA120060-01, R01CA137008-01, R01CA140594, RO1CA114465-03, R01CA135257-01]; National Cancer Institute [P50CA090578, P50 CA127003]; AACR; V Foundation; ACS [RSG-06-102-01-CCE]; Hazel and Samuel Bellin research fund; Ellison Foundation FX This study is supported by NIH K08 CA120060-01 (JAE), R01CA137008-01 (J.A. Engelman, P. A. Janne), R01CA140594 (J.A. Engelman), RO1CA114465-03 (P. A. Janne), R01CA135257-01 (P. A. Janne, J.A. Engelman), National Cancer Institute Lung SPORE P50CA090578 (J.A. Engelman, P. A. Janne), P50 CA127003 (J.A. Engelman), AACR (J.A. Engelman), the V Foundation (J.A. Engelman), ACS RSG-06-102-01-CCE (P. A. Janne, J.A. Engelman), Hazel and Samuel Bellin research fund (P. A. Janne), and the Ellison Foundation Scholar (J.A. Engelman). NR 34 TC 88 Z9 93 U1 1 U2 8 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD FEB 1 PY 2011 VL 71 IS 3 BP 1081 EP 1091 DI 10.1158/0008-5472.CAN-10-1623 PG 11 WC Oncology SC Oncology GA 714SW UT WOS:000286830300047 PM 21266357 ER PT J AU Lecomte, J Louis, K Detry, B Blacher, S Lambert, V Bekaert, S Munaut, C Paupert, J Blaise, P Foidart, JM Rakic, JM Krane, SM Noel, A AF Lecomte, Julie Louis, Krystel Detry, Benoit Blacher, Silvia Lambert, Vincent Bekaert, Sandrine Munaut, Carine Paupert, Jenny Blaise, Pierre Foidart, Jean-Michel Rakic, Jean-Marie Krane, Stephen M. Noel, Agnes TI Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization SO CELLULAR AND MOLECULAR LIFE SCIENCES LA English DT Article DE CNV; MMP13; Angiogenesis; Bone marrow; Mesenchymal stem cells ID ACTIVATOR INHIBITOR TYPE-1; MATRIX METALLOPROTEINASES; MACULAR DEGENERATION; GROWTH-FACTOR; COLLAGENASE-3 MMP-13; CELLULAR MECHANISMS; GELATINASE-A; STEM-CELLS; ANGIOGENESIS; MICE AB In this study, we evaluate the potential involvement of collagenase-3 (MMP13), a matrix metalloproteinase (MMP) family member, in the exudative form of age-related macular degeneration characterized by a neovascularisation into the choroid. RT-PCR analysis revealed that human neovascular membranes issued from patients with AMD expressed high levels of Mmp13. The contribution of MMP13 in choroidal neovascularization (CNV) formation was explored by using a murine model of laser-induced CNV and applying it to wild-type mice (WT) and Mmp13-deficient mice (Mmp13 (-/-) mice). Angiogenic and inflammatory reactions were explored by immunohistochemistry. The implication of bone marrow (BM)-derived cells was determined by BM engraftment into irradiated mice and by injecting mesenchymal stem cells (MSC) isolated from WT BM. The deficiency of Mmp13 impaired CNV formation which was fully restored by WT BM engraftment and partially rescued by several injections of WT MSC. The present study sheds light on a novel function of MMP13 during BM-dependent choroidal vascularization and provides evidence for a role for MSC in the pathogenesis of CNV. C1 [Lecomte, Julie; Louis, Krystel; Detry, Benoit; Blacher, Silvia; Lambert, Vincent; Bekaert, Sandrine; Munaut, Carine; Paupert, Jenny; Foidart, Jean-Michel; Noel, Agnes] Univ Liege, Lab Tumor & Dev Biol, Grp Interdisciplinaire Genoprote Appl Res GIGA Ca, CHU B23, B-4000 Liege, Belgium. [Lambert, Vincent; Blaise, Pierre; Rakic, Jean-Marie] CHU, Dept Ophthalmol, B-4000 Liege, Belgium. [Krane, Stephen M.] Harvard Univ, Sch Med, Dept Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA. [Krane, Stephen M.] Massachusetts Gen Hosp, Boston, MA 02129 USA. RP Noel, A (reprint author), Univ Liege, Lab Tumor & Dev Biol, Grp Interdisciplinaire Genoprote Appl Res GIGA Ca, CHU B23, B-4000 Liege, Belgium. EM agnes.noel@ulg.ac.be OI Noel, Agnes/0000-0002-7670-6179 FU European Union; Fonds de la Recherche Scientifique Medicale; Fonds National de la Recherche Scientifique (F.N.R.S., Belgium); Federation belge contre le Cancer; Fonds speciaux de la Recherche (University of Liege); Centre Anti-cancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege); D.G.T.R.E. from the "Region Wallonne" the Interuniversity Attraction Poles Program-Belgian Science Policy (Brussels, Belgium); Televie-FNRS; US National Institutes of Health FX The authors acknowledge P. Gavitelli, F. Olivier, M.-R. Pignon, E. Feyereisen, L. Poma, G. Roland and N. Lefin for collaboration and technical assistance. They thank the GIGA imaging and flow cytometry platform for their help. This work was supported by grants from the European Union Framework Program projects (FP7, MICROENVIMET), the Fonds de la Recherche Scientifique Medicale, the Fonds National de la Recherche Scientifique (F.N.R.S., Belgium), the Federation belge contre le Cancer, the Fonds speciaux de la Recherche (University of Liege), the Centre Anti-cancereux pres l'Universite de Liege, the Fonds Leon Fredericq (University of Liege), the D.G.T.R.E. from the "Region Wallonne" the Interuniversity Attraction Poles Program-Belgian Science Policy (Brussels, Belgium). JL is recipient of a Televie-FNRS grant. SMK was supported by a grant from the US National Institutes of Health. NR 40 TC 18 Z9 22 U1 1 U2 5 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1420-682X J9 CELL MOL LIFE SCI JI Cell. Mol. Life Sci. PD FEB PY 2011 VL 68 IS 4 BP 677 EP 686 DI 10.1007/s00018-010-0476-6 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 712JK UT WOS:000286662700009 PM 20700625 ER PT J AU Lee, AKC Hamalainen, MS Dyckman, KA Barton, JJS Manoach, DS AF Lee, Adrian K. C. Haemaelaeinen, Matti S. Dyckman, Kara A. Barton, Jason J. S. Manoach, Dara S. TI Saccadic Preparation in the Frontal Eye Field Is Modulated by Distinct Trial History Effects as Revealed by Magnetoencephalography SO CEREBRAL CORTEX LA English DT Article DE antisaccade; frontal eye field; magnetoencephalography; saccade; task-switching ID POSITRON-EMISSION-TOMOGRAPHY; FUNCTIONAL NEUROANATOMY; ANTERIOR CINGULATE; CORTICAL ACTIVITY; MACAQUE MONKEYS; CEREBRAL-CORTEX; ANTI-SACCADES; PRO-SACCADES; FMRI; BEHAVIOR AB Optimizing outcomes involves rapidly and continuously adjusting behavior based on context. While most behavioral studies focus on immediate task conditions, responses to events are also influenced by recent history. We used magnetoencephalography and a saccadic paradigm to investigate the neural bases of 2 trial history effects that are well characterized in the behavioral eye movement literature: task-switching and the prior-antisaccade effect. We found that switched trials were associated with increased errors and transient increases in activity in the frontal eye field (FEF) and anterior cingulate cortex early in the preparatory period. These activity changes are consistent with active reconfiguration of the task set, a time-limited process that is triggered by the instructional cue. Following an antisaccade versus prosaccade, there was increased activity in the FEF and prefrontal cortex that persisted into the preparatory period of the subsequent trial, and saccadic latencies were prolonged. We attribute these effects to persistent inhibition of the ocular motor response system from the prior antisaccade. These findings refine our understanding of how trial history interacts with current task demands to adjust responses. Such dynamic modulations of neural activity and behavior by recent experience are at the heart of adaptive flexible behavior. C1 [Manoach, Dara S.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Psychiat, Charlestown, MA 02129 USA. [Lee, Adrian K. C.; Dyckman, Kara A.; Manoach, Dara S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Haemaelaeinen, Matti S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02215 USA. [Barton, Jason J. S.] Univ British Columbia, Dept Neurol, Vancouver, BC V6T 1Z4, Canada. [Barton, Jason J. S.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V6T 1Z4, Canada. RP Manoach, DS (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Psychiat, 149 13th St,Room 1-111, Charlestown, MA 02129 USA. EM dara@nmr.mgh.harvard.edu RI Barton, Jason/A-6362-2012; Hamalainen, Matti/C-8507-2013; OI Lee, Adrian KC/0000-0002-7611-0500 FU MGH-ECOR; Advanced Multimodal Neuroimaging Training Program [1-R90 DA023427-02]; National Institute for Mental Health [R01 MH67720]; Mental Illness Neuroscience Discovery Institute (DOE) [DOE DE-FG02-99ER62764]; National Center for Research Resources [P41RR14075]; Canadian Institutes for Health Research [MOP-81720] FX Postdoctoral Fellowship Award, MGH-ECOR Fund for Medical Discovery to A. K. C. L.; Advanced Multimodal Neuroimaging Training Program (1-R90 DA023427-02 to A. K. C. L.); National Institute for Mental Health (R01 MH67720 to D. S. M.); Mental Illness Neuroscience Discovery Institute (DOE DE-FG02-99ER62764); National Center for Research Resources (P41RR14075); Canadian Institutes for Health Research (MOP-81720 to J.J.S.B. NR 56 TC 11 Z9 11 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 J9 CEREB CORTEX JI Cereb. Cortex PD FEB PY 2011 VL 21 IS 2 BP 245 EP 253 DI 10.1093/cercor/bhq057 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 706KK UT WOS:000286217100001 PM 20522539 ER PT J AU Moulton, EA Becerra, L Maleki, N Pendse, G Tully, S Hargreaves, R Burstein, R Borsook, D AF Moulton, E. A. Becerra, L. Maleki, N. Pendse, G. Tully, S. Hargreaves, R. Burstein, R. Borsook, D. TI Painful Heat Reveals Hyperexcitability of the Temporal Pole in Interictal and Ictal Migraine States SO CEREBRAL CORTEX LA English DT Article DE DTI; fMRI; headache; pain; temporal lobe ID FAMILIAL HEMIPLEGIC MIGRAINE; BRAIN-STEM ACTIVATION; PRIMARY SOMATOSENSORY CORTEX; EVOKED CORTICAL POTENTIALS; NOCICEPTIVE BLINK REFLEX; PREFRONTAL CORTEX; RHESUS-MONKEY; INTENSITY DEPENDENCE; THALAMIC NUCLEUS; MEDIAL PULVINAR AB During migraine attacks, alterations in sensation accompanying headache may manifest as allodynia and enhanced sensitivity to light, sound, and odors. Our objective was to identify physiological changes in cortical regions in migraine patients using painful heat and functional magnetic resonance imaging (fMRI) and the structural basis for such changes using diffusion tensor imaging (DTI). In 11 interictal patients, painful heat threshold + 1 degrees C was applied unilaterally to the forehead during fMRI scanning. Significantly greater activation was identified in the medial temporal lobe in patients relative to healthy subjects, specifically in the anterior temporal pole (TP). In patients, TP showed significantly increased functional connectivity in several brain regions relative to controls, suggesting that TP hyperexcitability may contribute to functional abnormalities in migraine. In 9 healthy subjects, DTI identified white matter connectivity between TP and pulvinar nucleus, which has been related to migraine. In 8 patients, fMRI activation in TP with painful heat was exacerbated during migraine, suggesting that repeated migraines may sensitize TP. This article investigates a nonclassical role of TP in migraineurs. Observed temporal lobe abnormalities may provide a basis for many of the perceptual changes in migraineurs and may serve as a potential interictal biomarker for drug efficacy. C1 [Moulton, E. A.; Becerra, L.; Maleki, N.; Pendse, G.; Tully, S.; Borsook, D.] Harvard Univ, Pain Analgesia Imaging Neurosci Grp, McLean Hosp, Dept Psychiat,Brain Imaging Ctr,Med Sch, Belmont, MA 02478 USA. [Becerra, L.; Borsook, D.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Hargreaves, R.] Merck & Co Inc, Imaging, West Point, PA 19486 USA. [Burstein, R.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Borsook, D (reprint author), Harvard Univ, Pain Analgesia Imaging Neurosci Grp, McLean Hosp, Dept Psychiat,Brain Imaging Ctr,Med Sch, 115 Mill St, Belmont, MA 02478 USA. EM dborsook@partners.org FU National Institutes of Health [R01NS056195, K24NS0624050, R01NS051484, K01DA025289]; Merck and Co.; L Herlands fund FX National Institutes of Health (R01NS056195 to D.B., K24NS0624050 to D.B., R01NS051484 to R.B., and K01DA025289 to E.M.); Merck and Co.; and the L Herlands fund to the Pain/Analgesia Imaging Neuroscience Group (D.B., L.B.). NR 114 TC 75 Z9 78 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 J9 CEREB CORTEX JI Cereb. Cortex PD FEB PY 2011 VL 21 IS 2 BP 435 EP 448 DI 10.1093/cercor/bhq109 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 706KK UT WOS:000286217100021 PM 20562317 ER PT J AU Wirka, RC Gore, S Van Wagoner, DR Arking, DE Lubitz, SA Lunetta, KL Benjamin, EJ Alonso, A Ellinor, PT Barnard, J Chung, MK Smith, JD AF Wirka, Robert C. Gore, Shamone Van Wagoner, David R. Arking, Dan E. Lubitz, Steven A. Lunetta, Kathryn L. Benjamin, Emelia J. Alonso, Alvaro Ellinor, Patrick T. Barnard, John Chung, Mina K. Smith, Jonathan D. TI A Common Connexin-40 Gene Promoter Variant Affects Connexin-40 Expression in Human Atria and Is Associated With Atrial Fibrillation SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY LA English DT Article DE atrial fibrillation; ion channels; genetics; allelic expression imbalance ID HAPLOTYPE RECONSTRUCTION; HEART-DISEASE; GENOTYPE; RISK; MICE AB Background-A common single-nucleotide polymorphism (SNP) in the promoter of the Connexin-40 (Cx40) gene GJA5 was suggested to affect Cx40 promoter activity and the risk of atrial fibrillation (AF), but the role of other common Cx40 polymorphisms is unknown. Methods and Results-Eight SNPs within the Cx40 gene region were tested for association with Cx40 levels measured in atrial tissue from 61 individuals. The previously described Cx40 promoter SNP (rs35594137, -44G -> A) was not associated with Cx40 mRNA levels. However, a common SNP (rs10465885) located in the TATA box of an alternative Cx40 promoter was strongly associated with Cx40 mRNA expression (P < 0.0001) and displayed strong and consistent allelic expression imbalance in human atrial tissue. A promoter-luciferase assay in cultured murine cardiomyocytes demonstrated reduced activity of the promoter containing the minor allele of this SNP (P < 0.0001). Both rs35594137 and rs10465885 were tested for association with early-onset lone AF (<= 60 years of age) in 384 cases and 3010 population control subjects. rs10465885 was associated with the AF phenotype (odds ratio, 1.18; P=0.046). This result was confirmed in a meta-analysis including 2 additional early-onset lone AF case-control cohorts (odds ratio, 1.16, P=0.022). rs35594137 was not associated with the lone AF phenotype in any of the cohorts studied or in a combined analysis. Conclusions-A previously described Cx40 promoter SNP was not found to influence Cx40 expression or risk of AF. We describe an alternate promoter polymorphism that directly affects levels of Cx40 mRNA in vivo and is associated with early-onset lone AF. (Circ Arrhythm Electrophysiol. 2011;4:87-93.) C1 [Wirka, Robert C.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA. [Smith, Jonathan D.] Cleveland Clin, Dept Cell Biol & Cardiovasc Med, Cleveland, OH 44195 USA. [Gore, Shamone] Cleveland Clin, Dept Cell Biol, Cleveland, OH 44195 USA. [Van Wagoner, David R.] Cleveland Clin, Dept Mol Cardiol & Cardiovasc Med, Cleveland, OH 44195 USA. [Barnard, John] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA. [Chung, Mina K.] Cleveland Clin, Dept Cardiovasc Med & Mol Cardiol, Cleveland, OH 44195 USA. [Arking, Dan E.] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Lubitz, Steven A.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Lunetta, Kathryn L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Benjamin, Emelia J.] NHLBI, Framingham, MA USA. [Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Cardiol Sect, Dept Med, Boston, MA 02118 USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Prevent Med Sect, Dept Med, Boston, MA 02118 USA. [Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Alonso, Alvaro] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. RP Smith, JD (reprint author), Cleveland Clin, Dept Cell Biol & Cardiovasc Med, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA. EM barnarj@ccf.org; chungm@ccf.org; smithj4@ccf.org RI Alonso, Alvaro/A-4917-2010; OI Alonso, Alvaro/0000-0002-2225-8323; Lunetta, Kathryn/0000-0002-9268-810X; Benjamin, Emelia/0000-0003-4076-2336 FU CCR NIH HHS [RC1 HL099452-02]; Howard Hughes Medical Institute; NCRR NIH HHS [1UL-RR024989, UL1 RR024989, UL1 RR024989-05, UL1 RR025005, UL1 RR025005-05, UL1RR025005]; NHGRI NIH HHS [U01 HG004402, U01 HG004402-01, U01HG004402]; NHLBI NIH HHS [RC1 HL101056, 1RC1HL099452, HL090620, HL092577, N01 HC055015, N01 HC055016, N01 HC055018, N01 HC055019, N01 HC055020, N01 HC055021, N01 HC055022, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, N01HC55015, N01HC55016, N01HC55018, N01HC55019, N01HC55020, N01HC55021, N01HC55022, R01 HL059367, R01 HL059367-10, R01 HL086694, R01 HL086694-03, R01 HL087641, R01 HL087641-03, R01 HL090620, R01 HL090620-04, R01 HL092577, R01 HL092577-03, R01 HL104156, R01HL086694, R01HL087641, R01HL59367, RC1 HL099452, RC1 HL099452-02, RC1 HL101056-02, T32 HL007575, T32 HL007575-26A1, T32HL007575]; NIDA NIH HHS [DA027021, R21 DA027021, R21 DA027021-02]; PHS HHS [HHSN268200625226C] NR 26 TC 41 Z9 44 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3149 J9 CIRC-ARRHYTHMIA ELEC JI Circ.-Arrhythmia Electrophysiol. PD FEB PY 2011 VL 4 IS 1 BP 87 EP + DI 10.1161/CIRCEP.110.959726 PG 21 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 721LL UT WOS:000287356000015 PM 21076161 ER PT J AU Ling, M Hamilos, DL AF Ling, M. Hamilos, D. L. TI Are we closer to understanding the pathophysiology of chronic rhinosinusitis? SO CLINICAL AND EXPERIMENTAL ALLERGY LA English DT Editorial Material ID CHRONIC HYPERPLASTIC SINUSITIS; MESSENGER-RNA EXPRESSION; AUREUS ENTEROTOXIN-B; NASAL POLYPOSIS; AMPHOTERICIN-B; ANTIFUNGAL TREATMENT; PROSTAGLANDIN; SUPERANTIGENS; RANTES; FUNGI C1 [Ling, M.; Hamilos, D. L.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. RP Hamilos, DL (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St, Boston, MA 02114 USA. EM dhamilos@partners.org OI Ling, Morris/0000-0002-9657-8960 NR 31 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0954-7894 J9 CLIN EXP ALLERGY JI Clin. Exp. Allergy PD FEB PY 2011 VL 41 IS 2 BP 144 EP 146 DI 10.1111/j.1365-2222.2010.03637.x PG 3 WC Allergy; Immunology SC Allergy; Immunology GA 706JE UT WOS:000286213600001 PM 21231974 ER PT J AU Sacks, DB Fonseca, V Goldfine, AB AF Sacks, David B. Fonseca, Vivian Goldfine, Allison B. TI Diabetes: Advances and Controversies SO CLINICAL CHEMISTRY LA English DT Editorial Material ID US POPULATION; PREVALENCE C1 [Sacks, David B.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Sacks, David B.; Goldfine, Allison B.] Harvard Univ, Sch Med, Boston, MA USA. [Fonseca, Vivian] Tulane Univ, Endocrinol Sect, Hlth Sci Ctr, New Orleans, LA 70118 USA. [Goldfine, Allison B.] Joslin Diabet Ctr, Boston, MA 02215 USA. RP Sacks, DB (reprint author), Dept Lab Med, 10 Ctr Dr,Bldg 10,Room 2C427, Bethesda, MD 20892 USA. OI Sacks, David/0000-0003-3100-0735 NR 7 TC 4 Z9 4 U1 0 U2 2 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD FEB PY 2011 VL 57 IS 2 BP 147 EP 149 DI 10.1373/clinchem.2010.159087 PG 3 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 712GD UT WOS:000286653000001 PM 21149500 ER PT J AU Goldfine, AB Fonseca, V Shoelson, SE AF Goldfine, Allison B. Fonseca, Vivian Shoelson, Steven E. TI Therapeutic Approaches to Target Inflammation in Type 2 Diabetes SO CLINICAL CHEMISTRY LA English DT Review ID C-REACTIVE PROTEIN; NF-KAPPA-B; INDUCED INSULIN-RESISTANCE; SODIUM-SALICYLATE; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; IKK-BETA; RANDOMIZED-TRIAL; STATIN THERAPY; OBESE SUBJECTS AB BACKGROUND: Chronic inflammation may participate in the pathogenesis of insulin resistance, type 2 diabetes, and cardiovascular disease and may be a common denominator that links obesity to these disease states. CONTENT: Epidemiologic studies have linked inflammatory biomarkers to incident diabetes and cardiovascular disease risk. Cellular and animal studies have provided support to the idea that inflammation mediates these disease processes, providing impetus to pharmacologically target these pathways for disease treatment and prevention. We review clinical strategies to target inflammation, with a focus on the antiinflammatory and antihyperglycemic effects of salicylates. SUMMARY: The evolving concept of diet-induced obesity driving insulin resistance, type 2 diabetes, and cardiovascular disease through immunologic processes provides new opportunities for the use of antiinflammatory strategies to correct the metabolic consequences of excess adiposity. (C) 2010 American Association for Clinical Chemistry C1 [Goldfine, Allison B.; Shoelson, Steven E.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. [Goldfine, Allison B.; Shoelson, Steven E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA. [Fonseca, Vivian] Tulane Univ, Dept Med, Endocrinol Sect, New Orleans, LA 70118 USA. RP Goldfine, AB (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM allison.goldfine@joslin.harvard.edu FU NIH [U01DK074556, R01HL091750, P50HL083813, P30DK036836]; Joslin Diabetes Center FX A.B. Goldfine, NIH grants (U01DK074556, R01HL091750, P50HL083813, and P30DK036836); V. Fonseca, NIH grants (U01DK074556 and R01HL091750) and Joslin Diabetes Center; S. E. Shoelson, NIH grants (U01DK074556, R01HL091750, P50HL083813, and P30DK036836). NR 46 TC 52 Z9 52 U1 0 U2 9 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD FEB PY 2011 VL 57 IS 2 BP 162 EP 167 DI 10.1373/clinchem.2010.148833 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 712GD UT WOS:000286653000007 PM 21098138 ER PT J AU Nagami, EH Kim, AY Birch, CE Bowen, MJ McGovern, BH AF Nagami, Ellen H. Kim, Arthur Y. Birch, Christopher E. Bowen, Melinda J. McGovern, Barbara H. TI A "One-Two Punch" Leading to Hepatitis C Seroconversion SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID VIRUS-INFECTION; TRANSMISSION; HIV; HCV AB We report a case of acute hepatitis C virus infection that occurred after a traumatic altercation among prison inmates. This report has significant implications for infection control policies and procedures in prisons and jails, where the estimated prevalence of hepatitis C virus infection is similar to 20 times that of the general population. C1 [Nagami, Ellen H.; Kim, Arthur Y.; Birch, Christopher E.; McGovern, Barbara H.] Lemuel Shattuck Hosp, Div Infect Dis, Jamaica Plain, MA 02130 USA. [Nagami, Ellen H.; Kim, Arthur Y.; Birch, Christopher E.; Bowen, Melinda J.] Massachusetts Gen Hosp, Ragon Inst, MIT, Boston, MA 02114 USA. [Kim, Arthur Y.] Harvard Univ, Sch Med, Boston, MA USA. [Kim, Arthur Y.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Nagami, Ellen H.; Birch, Christopher E.; McGovern, Barbara H.] Harvard Univ, Ctr AIDS Res, Boston, MA 02115 USA. [McGovern, Barbara H.] Tufts Med Sch, Div Infect Dis, Boston, MA USA. [Bowen, Melinda J.] Univ Massachusetts, Sch Med, Worcester, MA USA. RP Nagami, EH (reprint author), Lemuel Shattuck Hosp, Div Infect Dis, 7 South,170 Morton St, Jamaica Plain, MA 02130 USA. EM enagami@partners.org FU National Institutes of Health/National Institute of Allergy and Infectious Diseases [U19 AI066345, K23 AI054379, P30 AI060354] FX National Institutes of Health/National Institute of Allergy and Infectious Diseases (Hepatitis C Cooperative Center U19 AI066345, K23 AI054379 to AYK, Harvard University Center for AIDS Research P30 AI060354). NR 12 TC 2 Z9 2 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 IS 3 BP 361 EP 363 DI 10.1093/cid/ciq159 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KD UT WOS:000286216400012 PM 21189425 ER PT J AU Gonzalez, A Certain, L Bhattacharyya, RP AF Gonzalez, Alejandro Certain, Laura Bhattacharyya, Roby P. TI A 52-year-old Cuban Immigrant with Weight Loss, Dyspnea, and Fever SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID SPLENIC TUBERCULOSIS; SPLEEN; ABSCESS; TUMORS C1 [Certain, Laura] Massachusetts Gen Hosp, Internal Med Residency Program, Boston, MA 02114 USA. [Gonzalez, Alejandro] Tufts Univ, Sch Med, Boston, MA 02111 USA. RP Gonzalez, A (reprint author), Tufts Univ, Sch Med, Boston, MA 02111 USA. FU NIAID NIH HHS [T32 AI007061] NR 20 TC 2 Z9 2 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 IS 3 BP 368 EP + DI 10.1093/cid/ciq162 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KD UT WOS:000286216400014 PM 21217183 ER PT J AU Nellore, A Fishman, JA AF Nellore, Anoma Fishman, Jay A. TI NK Cells, Innate Immunity and Hepatitis C Infection after Liver Transplantation SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID NATURAL-KILLER-CELL; REGULATORY T-CELLS; LINKED LYMPHOPROLIFERATIVE SYNDROME; MURINE CYTOMEGALOVIRUS-INFECTION; PLASMACYTOID DENDRITIC CELLS; INHIBITORY RECEPTOR GENES; VIRUS ENVELOPE PROTEIN; COMPLEX CLASS-I; VIRAL CLEARANCE; HCV-INFECTION AB Liver transplantation in patients with active hepatitis C virus (HCV) infection is followed by almost universal recurrence of viral infection. The control of HCV infection has been characterized largely in terms of the HCV-specific function of T-lymphocytes and the adaptive immune response. Emerging data suggest that components of the innate immune system, including natural killer cells, have a central role in determining the nature of posttransplant HCV infection and the likelihood of response to antiviral therapy. This review examines the emerging evidence implicating innate immunity in the pathogenesis of posttransplant HCV infections and the potential therapeutic implications of these observations. C1 [Fishman, Jay A.] Massachusetts Gen Hosp, Transplant Infect Dis Program, Div Infect Dis, Boston, MA 02114 USA. Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Fishman, JA (reprint author), Massachusetts Gen Hosp, Transplant Infect Dis Program, Div Infect Dis, 55 Fruit St,GRJ 504, Boston, MA 02114 USA. EM jfishman@partners.org FU National Institutes of Health [5T32AI007529] FX This work was supported by the National Institutes of Health (training grant 5T32AI007529) to A.N. NR 127 TC 14 Z9 14 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 IS 3 BP 369 EP 377 DI 10.1093/cid/ciq156 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KD UT WOS:000286216400015 PM 21217184 ER PT J AU Baddley, JW Schain, DC Gupte, AA Lodhi, SA Kayler, LK Frade, JP Lockhart, SR Chiller, T Bynon, JS Bower, WA AF Baddley, John W. Schain, Denise C. Gupte, Asmita A. Lodhi, Sundus A. Kayler, Liise K. Frade, Joao P. Lockhart, Shawn R. Chiller, Tom Bynon, J. Steve, Jr. Bower, William A. TI Transmission of Cryptococcus neoformans by Organ Transplantation SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID CORNEAL TRANSPLANTATION; FUNGAL-INFECTIONS; RECIPIENTS; DONOR; PATIENT AB Background. This article describes transmission of Cryptococcus neoformans by solid organ transplantation. Methods. We reviewed medical records and performed molecular genotyping of isolates to determine potential for donor transmission of Cryptococcus. Results. Cryptococcosis was diagnosed in 3 recipients of organs from a common donor with an undifferentiated neurologic condition at the time of death. Cryptococcal meningoencephalitis was later diagnosed in the donor at autopsy. The liver and 1 kidney recipient developed cryptococcemia and pneumonia and the other kidney recipient developed cryptococcemia and meningitis; 2 patients recovered with prolonged antifungal therapy. We tested 4 recipient isolates with multilocus sequence typing and found they had identical alleles. Conclusions. Our investigation documents the transmission of Cryptococcus neoformans by organ transplantation. Evaluation for cryptococcosis in donors with unexplained neurologic symptoms should be strongly considered. C1 [Baddley, John W.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Schain, Denise C.; Gupte, Asmita A.; Lodhi, Sundus A.; Kayler, Liise K.] Univ Florida, Dept Med, Sch Med, Gainesville, FL USA. [Frade, Joao P.; Lockhart, Shawn R.; Chiller, Tom; Bower, William A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Baddley, JW (reprint author), Univ Alabama, Dept Med, Div Infect Dis, 1900 Univ Blvd,229 Tinsley Harrison Tower, Birmingham, AL 35294 USA. EM jbad-dley@uab.edu FU Pfizer FX J.W.B. is an advisory board member at Merck and Co., a consultant for Pfizer, and a Pfizer research grant recipient. All other authors: no conflicts. NR 26 TC 25 Z9 25 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB PY 2011 VL 52 IS 4 BP E94 EP E98 DI 10.1093/cid/ciq216 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 712PD UT WOS:000286677800002 PM 21220771 ER PT J AU Steere, AC Drouin, EE Glickstein, LJ AF Steere, Allen C. Drouin, Elise E. Glickstein, Lisa J. TI Relationship between Immunity to Borrelia burgdorferi Outer-surface Protein A (OspA) and Lyme Arthritis SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ANTIBIOTIC-REFRACTORY ARTHRITIS; HLA-DR MOLECULES; TREATMENT-RESISTANT; T-CELL; ANTIBODY-RESPONSES; DISEASE; VACCINATION; ASSOCIATION; MICE; IMMUNOGENICITY AB Antibiotic-refractory Lyme arthritis may result from Borrelia burgdorferi-induced autoimmunity in affected joints. Such patients usually have certain HLA-DRB1 molecules that bind an epitope of B. burgdorferi outer-surface protein A (OspA(163-175)), and cellular and humoral immune responses to OspA are greater in patients with antibiotic-refractory arthritis than in those with antibiotic-responsive arthritis. Recent work in a mouse model suggests that, during B. burgdorferi infection, OspA in genetically susceptible individuals stimulates a particularly strong T(H)1 response, which may be one of several factors that can help set the stage for a putative autoimmune response in affected joints. However, vaccination with OspA did not induce arthritis in this mouse model, and case and control comparisons in human vaccine trials did not show an increased frequency of arthritis among OspA-vaccinated individuals. Thus, a vaccine-induced immune response to OspA does not replicate the sequence of events needed in the natural infection to induce antibiotic-refractory Lyme arthritis. C1 [Steere, Allen C.; Drouin, Elise E.; Glickstein, Lisa J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02114 USA. RP Steere, AC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, CNY 149-8301,55 Fruit St, Boston, MA 02114 USA. EM asteere@partners.org FU National Institutes of Health [AR-20358]; English, Bonter, Mitchell Foundation; Eshe Fund; Massachusetts General Hospital; Baxter Laboratories, the Centers for Disease Control, Fort Collins, CO FX The National Institutes of Health (AR-20358), the English, Bonter, Mitchell Foundation, the Eshe Fund, and the Lyme/Arthritis Research Fund at Massachusetts General Hospital.; This article was published as part of a supplement entitled "The Need for a New Lyme Disease Vaccine," sponsored by Baxter Laboratories, the Centers for Disease Control, Fort Collins, CO, and Stanley Plotkin. NR 45 TC 24 Z9 26 U1 0 U2 9 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 SU 3 BP S259 EP S265 DI 10.1093/cid/ciq117 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KG UT WOS:000286216700003 PM 21217173 ER PT J AU Tamura, MK Xie, DW Yaffe, K Cohen, DL Teal, V Kasner, SE Messe, SR Sehgal, AR Kusek, J DeSalvo, KB Cornish-Zirker, D Cohan, J Seliger, SL Chertow, GM Go, AS AF Tamura, Manjula Kurella Xie, Dawei Yaffe, Kristine Cohen, Debbie L. Teal, Valerie Kasner, Scott E. Messe, Steven R. Sehgal, Ashwini R. Kusek, John DeSalvo, Karen B. Cornish-Zirker, Denise Cohan, Janet Seliger, Stephen L. Chertow, Glenn M. Go, Alan S. TI Vascular Risk Factors and Cognitive Impairment in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CARDIOVASCULAR HEALTH COGNITION; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; DEMENTIA; BRAIN; ANEMIA; ADULTS; PERFORMANCE; COMMUNITY; OUTCOMES AB Background and objectives Cognitive impairment is common among persons with chronic kidney disease, but the extent to which nontraditional vascular risk factors mediate this association is unclear. Design, setting, participants, & measurements We conducted cross-sectional analyses of baseline data collected from adults with chronic kidney disease participating in the Chronic Renal Insufficiency Cohort study. Cognitive impairment was defined as a Modified Mini-Mental State Exam score >1 SD below the mean score. Results Among 3591 participants, the mean age was 58.2 +/- 11.0 years, and the mean estimated GFR (eGFR) was 43.4 +/- 13.5 ml/min per 1.73 m(2). Cognitive impairment was present in 13%. After adjustment for demographic characteristics, prevalent vascular disease (stroke, coronary artery disease, and peripheral arterial disease) and traditional vascular risk factors (diabetes, hypertension, smoking, and elevated cholesterol), an eGFR <30 ml /min per 1.73 m(2) was associated with a 47% increased odds of cognitive impairment (odds ratio 1.47, 95% confidence interval 1.05, 2.05) relative to those with an eGFR 45 to 59 ml/min per 1.73 m(2). This association was attenuated and no longer significant after adjustment for hemoglobin concentration. While other nontraditional vascular risk factors including C-reactive protein, homocysteine, serum albumin, and albuminuria were correlated with cognitive impairment in unadjusted analyses, they were not significantly associated with cognitive impairment after adjustment for eGFR and other confounders. Conclusions The prevalence of cognitive impairment was higher among those with lower eGFR, independent of traditional vascular risk factors. This association may be explained in part by anemia. Clin J Am Soc Nephrol 6: 248-256, 2011. doi: 10.2215/CJN.02660310 C1 [Tamura, Manjula Kurella; Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA. [Tamura, Manjula Kurella] Vet Affairs Palo Alto Geriatr Res & Educ Clin Ctr, Palo Alto, CA USA. [Xie, Dawei; Teal, Valerie; Kasner, Scott E.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] San Francisco VA Med Ctr, Dept Epidemiol, San Francisco, CA USA. [Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Cohen, Debbie L.] Univ Penn, Renal Electrolyte Div, Philadelphia, PA 19104 USA. [Kasner, Scott E.; Messe, Steven R.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Sehgal, Ashwini R.] Case Western Reserve Univ, Div Nephrol, Cleveland, OH 44106 USA. [Kusek, John] NIDDK, Div Kidney Urol & Hematol Dis, NIH, Bethesda, MD USA. [DeSalvo, Karen B.] Tulane Univ, Sect Gen Internal Med & Geriatr, New Orleans, LA 70118 USA. [Cornish-Zirker, Denise] Univ Michigan, Div Cardiovasc Med & Hypertens, Ann Arbor, MI 48109 USA. [Cohan, Janet] Univ Illinois, Dept Med, Chicago, IL USA. [Seliger, Stephen L.] Univ Maryland, Div Nephrol, Baltimore, MD 21201 USA. [Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, Dept Biostat, San Francisco, CA USA. RP Tamura, MK (reprint author), Stanford Univ, Sch Med, Div Nephrol, 780 Welch Rd,Suite 106, Palo Alto, CA 94304 USA. EM mktamura@stanford.edu RI Kasner, Scott/C-6109-2011; Kurella Tamura, Manjula/C-8284-2014 OI Kurella Tamura, Manjula/0000-0001-5227-2479 FU National Institute of Diabetes and Digestive and Kidney Diseases [5U01DK060990, 5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028, 5U01DK60980, 5U01DK060963, 5U01DK060902, R01DK069406]; National Institutes of Health [UL1RR024134, UL1RR025005, M01RR16500, UL1RR024989, M01RR000042, UL1RR024986, UL1RR029879, RR05096, UL1RR024131]; National Institute of Aging [K23AG028952]; Amgen FX The CRIC Study is supported by cooperative agreement project grants 5U01DK060990, 5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028, 5U01DK60980, 5U01DK060963, and 5U01DK060902 from the National Institute of Diabetes and Digestive and Kidney Diseases and by grants UL1RR024134, UL1RR025005, M01RR16500, UL1RR024989, M01RR000042, UL1RR024986, UL1RR029879, RR05096, and UL1RR024131 from the National Institutes of Health. Dr. Kurella Tamura received support from the National Institute of Aging (grant K23AG028952). Dr. Yaffe was supported by R01DK069406, also from the National Institute of Diabetes and Digestive and Kidney Diseases. These results were presented in abstract form at the American Society of Nephrology Meeting.; Dr. Kurella Tamura has previously received grant support from Amgen. NR 36 TC 41 Z9 47 U1 1 U2 9 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD FEB PY 2011 VL 6 IS 2 BP 248 EP 256 DI 10.2215/CJN.02660310 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 722KJ UT WOS:000287430800004 ER PT J AU Hanzis, C Ojha, RP Hunter, Z Manning, R Lewicki, M Brodsky, P Ioakimidis, L Tripsas, C Patterson, CJ Sheehy, P Treon, SP AF Hanzis, Christina Ojha, Rohit P. Hunter, Zachary Manning, Robert Lewicki, Megan Brodsky, Philip Ioakimidis, Leukothea Tripsas, Christina Patterson, Christopher J. Sheehy, Patricia Treon, Steven P. TI Associated Malignancies in Patients with Waldenstrom's Macroglobulinemia and Their Kin SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Article; Proceedings Paper CT 6th International Workshop on Waldenstroms Macroglobulinemia CY OCT 06-10, 2010 CL Venice, ITALY ID UNDETERMINED SIGNIFICANCE; MONOCLONAL GAMMOPATHY; 1ST-DEGREE RELATIVES; MULTIPLE-MYELOMA; SOLID TUMORS; CANCER; RISK; DELETIONS; NEOPLASMS; PATTERNS AB We examined the incidence of other malignancies in 924 Waldenstrom's Macroglobulinemia (WM) patients and their kin. A total of 225 (24.3%) patients had >= 1 additional malignancy, with 63% predating the WM diagnosis. The most common gender-adjusted malignancies were prostate (9.4%), breast (8.0%), non-melanoma skin (7.1%), hematologic (2.8%), melanoma (2.2%), lung (1.4%) and thyroid 1.1%). Among hematologic malignancies, all 13 cases of diffuse large B-cell lymphoma and 4 cases of acute myelogenous leukemia were diagnosed after WM, and were therapy-related. Familial WM subgroup analysis showed a higher incidence of prostate cancer (P = .046) in sporadic WM patients, while patients with familial WM had a higher incidence of lung cancer (P = .0043). An increased incidence of myeloid leukemias (P < .0001) was reported among kin of familial WM patients. These data reveal specific cancer associations with WM, and provide a basis for exploratory studies aimed at delineating a common genetic basis. Additionally, these studies suggest specific cancer clustering based on familial predisposition to WM. C1 [Treon, Steven P.] Harvard Univ, Sch Med, Bing Ctr Waldenstroms Macroglobulinemia, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Treon, SP (reprint author), Harvard Univ, Sch Med, Bing Ctr Waldenstroms Macroglobulinemia, Dana Farber Canc Inst, M547,44 Binney St, Boston, MA 02115 USA. EM steven_treon@dfci.harvard.edu RI Hunter, Zachary/H-3018-2013; OI Hunter, Zachary/0000-0002-1689-1691; Ojha, Rohit/0000-0003-0595-8990 NR 25 TC 16 Z9 17 U1 0 U2 2 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 88 EP 92 DI 10.3816/CLML.2011.n.016 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600017 PM 21454200 ER PT J AU Zhou, YS Liu, X Xu, LA Tseng, HY Cao, Y Jiang, JR Ciccarelli, BT Yang, GA Patterson, CJ Hunter, ZR Treon, SP AF Zhou, Yangsheng Liu, Xia Xu, Lian Tseng, Hsiuyi Cao, Yang Jiang, Jingrui Ciccarelli, Bryan T. Yang, Guang Patterson, Christopher J. Hunter, Zachary R. Treon, Steven P. TI Matrix Metalloproteinase-8 Is Overexpressed in Waldenstrom's Macroglobulinemia Cells, and Specific Inhibition of this Metalloproteinase Blocks Release of Soluble CD27 SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Article; Proceedings Paper CT 6th International Workshop on Waldenstroms Macroglobulinemia CY OCT 06-10, 2010 CL Venice, ITALY ID MEMORY B-CELLS; CD27-CD70 INTERACTIONS; CD27/CD70 INTERACTION; PLASMA-CELLS; DIFFERENTIATION; RESPONSES; CANCER; ALPHA AB Soluble CD27 (sCD27) is produced by Waldenstrom's macroglobulinemia (WM) cells, with high levels found in WM patients which may facilitate disease expansion. Matrix metalloproteinases (MMP) may facilitate sCD27 release by cleavage of CD27. By gene expression analysis, we observed significantly higher transcription levels of MMP-8 and MMP-9, with 58.5 and 16.7 fold increase in mean transcription levels in WM cells relative to healthy donor peripheral blood B cells (P = .04, and .05, respectively). We developed a model for study of sCD27 release by transfecting BCWM.1 WM cells and BL2126 lymphoblastic B cells, both of which express MMP-8 and MMP-9 with a vector expressing FLAG-tagged CD27 (pFLAG-CD27) which in the presence of phorbol myristate acetate resulted in >= 10-fold increase in sCD27 release. MMP inhibitors against MMP-8, but not MMP 2, 3, or 9 blocked release of sCD27. The results suggest that MMP-8 may play a role in the pathogenesis of WM, and that its inhibition may be of therapeutic value in WM. C1 [Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Treon, SP (reprint author), Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, M547,44 Binney St, Boston, MA 02115 USA. EM steven_treon@dfci.harvard.edu RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 20 TC 4 Z9 4 U1 0 U2 0 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 172 EP 175 DI 10.3816/CLML.2011.n.041 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600042 PM 21856553 ER PT J AU Ly, KI Fintelmann, F Forghani, R Schaefer, PW Hochberg, EP Hochberg, FH AF Ly, K. Ina Fintelmann, Florian Forghani, Reza Schaefer, Pamela W. Hochberg, Ephraim P. Hochberg, Fred H. TI Novel Diagnostic Approaches in Bing-Neel Syndrome SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA LA English DT Article; Proceedings Paper CT 6th International Workshop on Waldenstroms Macroglobulinemia CY OCT 06-10, 2010 CL Venice, ITALY ID CENTRAL-NERVOUS-SYSTEM; WALDENSTROMS MACROGLOBULINEMIA; NEUROPATHIES; INFILTRATION; INVOLVEMENT; PATIENT; FLUID AB The central nervous system (CNS) manifestations of Waldenstrom's macroglobulinemia (WM) are known as the Bing-Neel syndrome (BNS). Patients with BNS can be classified into Group A and Group B based on the presence of lymphoplasmacytoid (LMP) cells within the brain parenchyma, leptomeninges, dura, and/or cerebrospinal fluid (CSF). To identify characteristic imaging findings for both Group A and Group B patients, we reviewed all 36 cases (26 referenced, 10 unreported) of proven WM with CNS symptoms, CSF analysis and/or biopsy, and magnetic resonance imaging (MRI) of the brain and/or spinal cord. Enhancement on MRI suggests invasion of the central neuraxis by LMP cells, and can help distinguish between Group A and Group B patients. In addition to differentiating true WM lesions in the CNS from ischemia, hyperviscosity events, and demyelinating lesions, evaluation of brain and spinal cord with gadolinium-enhanced MRI has the potential to guide management. C1 [Ly, K. Ina; Hochberg, Ephraim P.; Hochberg, Fred H.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Fintelmann, Florian; Forghani, Reza; Schaefer, Pamela W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Ly, KI (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. OI Forghani, Reza/0000-0002-8572-1864 NR 20 TC 16 Z9 16 U1 0 U2 1 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 2152-2650 EI 2152-2669 J9 CL LYMPH MYELOM LEUK JI Clin. Lymphoma Myeloma Leuk. PD FEB PY 2011 VL 11 IS 1 BP 180 EP 183 DI 10.3816/CLML.2011.n.043 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA 748IF UT WOS:000289383600044 PM 21856555 ER PT J AU Dehghani, N Cash, SS Halgren, E AF Dehghani, Nima Cash, Sydney S. Halgren, Eric TI Topographical frequency dynamics within EEG and MEG sleep spindles SO CLINICAL NEUROPHYSIOLOGY LA English DT Article DE Spindle; Synchrony; MEG; EEG; Cortex; Thalamus; Inverse solution ID DEPTH-RECORDED POTENTIALS; SLOW-WAVE SLEEP; SPATIOTEMPORAL STAGES; OSCILLATIONS; MECHANISMS; PATTERNS; CHILDREN; HUMANS; MODELS; CORTEX AB Objective: Spindles are rhythmic bursts of 10-16 Hz activity, lasting similar to 1 s, occur during normal stage 2 sleep. Spindles are slower in frontal EEG and possibly MEG. The posterior-fast EEG pattern may predominate early in the spindle, and the anterior-slow pattern late. We aimed to determine the proportion of spindles showing this spatio-spectro-temporal interaction for EEG, and whether it occurs in MEG. Methods: We recorded high density EEG and MEG from seven healthy subjects during normal stage 2 sleep. High vs. low frequency (12 vs. 14 Hz) power was measured early vs. late (25th-45th vs. 55th-75th duration percentile) in 183 spindle discharges. Results: The predicted spatio-spectro-temporal interaction was shown by 48% of EEG and 34% of MEG spindles (chance = 25%). Topographically, high frequency EEG power was greatest at midline central contacts, and low frequency power at midline frontal. This frequency-specific topography was fixed over the course of the spindle. Conclusions: An evolution from posterior-fast to anterior-slow generators commonly occurs during spindles, and this is visible with EEG and to a lesser extent, MEG. Significance: The spatio-spectral-temporal evolution of spindles may reflect their possible involvement in coordinating cortical activity during consolidation. (C) 2010 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved. C1 [Dehghani, Nima; Halgren, Eric] Univ Calif San Diego, Dept Radiol, Multimodal Imaging Lab, La Jolla, CA 92093 USA. [Halgren, Eric] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Dehghani, Nima; Cash, Sydney S.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,Martinos Ctr Biomed Imagin, Boston, MA 02115 USA. [Dehghani, Nima] Unite Neurosci Informat & Complexite UNIC CNRS, Lab Computat Neurosci, Gif Sur Yvette, France. RP Halgren, E (reprint author), Univ Calif San Diego, Dept Radiol, Multimodal Imaging Lab, 9500 Gilman Dr,Mail Code 0841, La Jolla, CA 92093 USA. EM ehalgren@ucsd.edu OI Dehghani, Nima/0000-0003-2032-8903 FU NIH [NS18741, EB009282, NS44623] FX This research was supported by NIH Grants NS18741, EB009282, and NS44623. We thank Andrea Rossetti, Chin Chuan Chen, Robert Thomas, Ken Kwong, Maxim Bazhenov, and Terry Sejnowski for valuable collaborations. Equivalent contributions were made by the three authors to the work reported here. NR 43 TC 24 Z9 24 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1388-2457 J9 CLIN NEUROPHYSIOL JI Clin. Neurophysiol. PD FEB PY 2011 VL 122 IS 2 BP 229 EP 235 DI 10.1016/j.clinph.2010.06.018 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 703QP UT WOS:000285995400006 PM 20637689 ER PT J AU Callanan, MC Jarrett, B Bragdon, CR Zurakowski, D Rubash, HE Freiberg, AA Malchau, H AF Callanan, Mark C. Jarrett, Bryan Bragdon, Charles R. Zurakowski, David Rubash, Harry E. Freiberg, Andrew A. Malchau, Henrik TI The John Charnley Award Risk Factors for Cup Malpositioning Quality Improvement Through a Joint Registry at a Tertiary Hospital SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article; Proceedings Paper CT 77th Annual Meeting of the American-Academy-of-Orthopaedic-Surgeons CY MAR 09-13, 2010 CL New Orleans, LA SP Amer Acad Orthopaed Surg ID TOTAL HIP-ARTHROPLASTY; MOLECULAR-WEIGHT POLYETHYLENE; ACETABULAR COMPONENT; FEMORAL-HEAD; DISLOCATION; REPLACEMENT; WEAR; IMPINGEMENT; NAVIGATION; ACCURACY AB Background Few studies have examined factors that affect acetabular cup positioning. Since cup positioning has been linked to dislocation and increased bearing surface wear, these factors affecting cup position are important considerations. Question/purposes We determined the percent of optimally positioned acetabular cups and whether patient and surgical factors affected acetabular component position. Methods We obtained postoperative AP pelvis and cross-table lateral radiographs on 2061 consecutive patients who received a THA or hip resurfacing from 2004 to 2008. One thousand nine hundred and fifty-two hips had AP pelvic radiographs with correct position of the hip center, and 1823 had both version and abduction angles measured. The AP radiograph was measured using Hip Analysis Suite (TM) to calculate the cup inclination and version angles, using the lateral film to determine version direction. Acceptable ranges were defined for abduction (30 degrees-45 degrees) and version (5 degrees-25 degrees). Results From the 1823 hips, 1144 (63%) acetabular cups were within the abduction range, 1441 (79%) were within the version range, and 917 (50%) were within the range for both. Surgical approach, surgeon volume, and obesity (body mass index > 30) independently predicted malpositioned cups. Comparison of low versus high volume surgeons, minimally invasive surgical versus posterolateral approach, and obesity versus all other body mass index groups showed a twofold (1.5-2.8), sixfold (3.5-10.7), and 1.3-fold (1.1-1.7) increased risk for malpositioned cups, respectively. Conclusions Factors correlated to malpositioned cups included surgical approach, surgeon volume, and body mass index with increased risk of malpositioning for minimally invasive surgical approach, low volume surgeons, and obese patients. Further analyses on patient and surgical factors' influence on cup position at a lower volume medical center would provide a valuable comparison. C1 [Callanan, Mark C.; Jarrett, Bryan; Bragdon, Charles R.; Rubash, Harry E.; Freiberg, Andrew A.; Malchau, Henrik] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA. [Zurakowski, David] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Anesthesiol, Boston, MA USA. [Zurakowski, David] Harvard Univ, Sch Med, Dept Surg, Childrens Hosp Boston, Boston, MA 02115 USA. RP Malchau, H (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Lab, 55 Fruit St,GRJ 1206, Boston, MA 02114 USA. EM hmalchau@partners.org NR 57 TC 103 Z9 106 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD FEB PY 2011 VL 469 IS 2 BP 319 EP 329 DI 10.1007/s11999-010-1487-1 PG 11 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 716BG UT WOS:000286939300002 PM 20717858 ER PT J AU McCarthy, JC Jarrett, BT Ojeifo, O Lee, JA Bragdon, CR AF McCarthy, Joseph C. Jarrett, Bryan T. Ojeifo, Olumide Lee, Jo Ann Bragdon, Charles R. TI What Factors Influence Long-term Survivorship After Hip Arthroscopy? SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article; Proceedings Paper CT 77th Annual Meeting of the American-Academy-of-Orthopaedic-Surgeons CY MAR 09-13, 2010 CL New Orleans, LA SP Amer Acad Orthopaed Surg ID OF-THE-LITERATURE; FEMOROACETABULAR IMPINGEMENT; PARTIAL MENISCECTOMY; FOLLOW-UP; OUTCOMES; REPAIR; OSTEOARTHRITIS; MENISCUS AB Background Hip arthroscopy is an evolving procedure. One small study suggested that a low modified Harris hip score and arthritis at the time of surgery were predictors of poor prognosis. Questions/purposes We therefore intended to confirm those findings with a large patient cohort to (1) determine the long-term nonarthritic hip score; (2) determine survivorship; (3) identify risk factors that increase the likelihood of THA; and (4) use those factors to create a usable risk assessment algorithm. Patients and Methods We retrospectively reviewed 324 patients (340 hips) who underwent arthroscopy for pain and/or catching. Of these, 106 patients (111 hips or 33%) had a minimum followup of 10 years (mean, 13 years; range, 10-20 years). The average age was 39 years (+/- 13) with 47 men and 59 women. We recorded patient age, gender, acetabular and femoral Outerbridge grade at surgery, and the presence of a labral tear. Followup consisted of a nonarthritic hip score or the date of a subsequent THA. We determined survivorship with the end point of THA for the acetabular and femoral Outerbridge grades. Results Overall survivorship among the 111 hips was 63% at 10 years. The average nonarthritic hip score for non-THA patients was 87.3 (+/- 12.1). Survivorship was greater for acetabular and femoral Outerbridge grades normal through II. Age at arthroscopy and Outerbridge grades independently predicted eventual THA. Gender and the presence of a labral tear did not influence long-term survivorship. Conclusions The long-term survivorship of labral tears with low-grade cartilage damage indicates hip arthroscopy is reasonable for treating labral tears. C1 [McCarthy, Joseph C.; Jarrett, Bryan T.; Ojeifo, Olumide; Lee, Jo Ann; Bragdon, Charles R.] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02115 USA. [McCarthy, Joseph C.; Jarrett, Bryan T.; Ojeifo, Olumide; Lee, Jo Ann; Bragdon, Charles R.] Harvard Univ, Sch Med, Boston, MA USA. RP McCarthy, JC (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Lab, 55 Fruit St,Yawkey 3B, Boston, MA 02115 USA. EM jcmccarthy1@partners.org NR 32 TC 45 Z9 46 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD FEB PY 2011 VL 469 IS 2 BP 362 EP 371 DI 10.1007/s11999-010-1559-2 PG 10 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 716BG UT WOS:000286939300007 PM 20872105 ER PT J AU Cunningham, M Gilkeson, G AF Cunningham, Melissa Gilkeson, Gary TI Estrogen Receptors in Immunity and Autoimmunity SO CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY LA English DT Review DE Estrogen receptors; Autoimmunity; Gender prevalence ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; DENDRITIC CELL-DIFFERENTIATION; PERIPHERAL-BLOOD MONOCYTES; ANTIGEN-PRESENTING CELLS; MRL LPR/LPR MICE; B-LYMPHOPOIESIS; BONE-MARROW; T-CELLS; LYMPHOCYTE PRECURSORS; NEGATIVE REGULATORS AB Due to the female predominance of autoimmune diseases, the role of gender and sex hormones in the immune system is of long-term interest. Estrogen's primary effects are mediated via estrogen receptors alpha and beta (ER alpha/beta) that are expressed on most immune cells. ERs are nuclear hormone receptors that can either directly bind to estrogen response elements in gene promoters or serve as cofactors with other transcription factors (i.e., NFkB/AP1). Cytoplasmic ER and membrane associated ER impact specific kinase signaling pathways. ERs have prominent effects on immune function in both the innate and adaptive immune responses. Genetic deficiency of ER alpha in murine models of lupus resulted in significantly decreased disease and prolonged survival, while ER beta deficiency had minimal to no effect in autoimmune models. The protective effect of ER alpha in lupus is multifactoral. In arthritis models, ER alpha agonists appears to mediate a protective effect. The modulation of ER alpha function appears to be a potential target for therapy in autoimmunity. C1 [Cunningham, Melissa; Gilkeson, Gary] Med Univ S Carolina, Med Res Serv, Ralph H Johnson VAMC, Charleston, SC 29425 USA. [Cunningham, Melissa; Gilkeson, Gary] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. RP Cunningham, M (reprint author), Med Univ S Carolina, Med Res Serv, Ralph H Johnson VAMC, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA. EM gilkeson@musc.edu OI Cunningham, Melissa/0000-0002-9207-1986 FU Veterans Administration Medical Research Service FX This work was supported by a Merit Review Award and a REAP award from the Veterans Administration Medical Research Service. NR 93 TC 91 Z9 94 U1 2 U2 18 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1080-0549 J9 CLIN REV ALLERG IMMU JI Clin. Rev. Allergy Immunol. PD FEB PY 2011 VL 40 IS 1 BP 66 EP 73 DI 10.1007/s12016-010-8203-5 PG 8 WC Allergy; Immunology SC Allergy; Immunology GA 712CH UT WOS:000286639700008 PM 20352526 ER PT J AU Fredman, SJ Monson, CM Adair, KC AF Fredman, Steffany J. Monson, Candice M. Adair, Kathryn C. TI Implementing Cognitive-Behavioral Conjoint Therapy for PTSD With the Newest Generation of Veterans and Their Partners SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; ADJUSTMENT; MARRIAGE; SCALES; IRAQ AB As the newest generation of veterans returns home from the fronts in Afghanistan and Iraq, increased attention is being paid to their postdeployment mental health adjustment as well as the interpersonal sequelae of posttraumatic stress disorder (PTSD) and other mental health conditions. The Department of Defense has begun to invest in relationship-enhancement programs to ease the burden on both service members and their families across the deployment cycle. However, when there is the presence of PTSD, a disorder-specific conjoint treatment may be needed to address both PTSD and associated relationship difficulties. Cognitive-behavioral conjoint therapy (CBCT) for PTSD is a disorder-specific, manualized conjoint therapy designed to simultaneously improve PTSD symptoms and intimate relationship functioning. This article reviews knowledge on the association between PTSD and relationship problems in recently returned veterans and provides an overview of CBCT for PTSD. We then present a case study to illustrate the application of CBCT for PTSD to an Operation Iraqi Freedom (OIF) veteran and his wife and conclude with recommendations for how mental health providers can apply the treatment to recently returned veterans and their loved ones. C1 [Fredman, Steffany J.; Monson, Candice M.; Adair, Kathryn C.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA. [Fredman, Steffany J.; Monson, Candice M.] Boston Univ, Sch Med, Boston, MA 02215 USA. RP Fredman, SJ (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, 150 S Huntington Ave 116B-3, Boston, MA 02130 USA. EM Steffany.Fredman@va.gov NR 25 TC 17 Z9 17 U1 4 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD FEB PY 2011 VL 18 IS 1 BP 120 EP 130 DI 10.1016/j.cbpra.2009.06.007 PG 11 WC Psychology, Clinical SC Psychology GA 712EV UT WOS:000286648400014 ER PT J AU Beier, K Eppanapally, S Bazick, HS Chang, D Mahadevappa, K Gibbons, FK Christopher, KB AF Beier, Kevin Eppanapally, Sabitha Bazick, Heidi S. Chang, Domingo Mahadevappa, Karthik Gibbons, Fiona K. Christopher, Kenneth B. TI Elevation of blood urea nitrogen is predictive of long-term mortality in critically ill patients independent of "normal" creatinine SO CRITICAL CARE MEDICINE LA English DT Article DE blood urea nitrogen; intensive care; mortality; gastrointestinal bleed; creatinine ID DECOMPENSATED HEART-FAILURE; ACUTE MYOCARDIAL-INFARCTION; GLOMERULAR-FILTRATION-RATE; BRAIN NATRIURETIC PEPTIDE; ACUTE CORONARY SYNDROMES; INTENSIVE-CARE-UNIT; ACUTE-RENAL-FAILURE; ADMINISTRATIVE DATABASES; RISK STRATIFICATION; HOSPITAL MORTALITY AB Objective: We hypothesized that elevated blood urea nitrogen can be associated with all-cause mortality independent of creatinine in a heterogeneous critically ill population. Design: Multicenter observational study of patients treated in medical and surgical intensive care units. Setting: Twenty intensive care units in two teaching hospitals in Boston, MA. Patients: A total of 26,288 patients, age >= 18 yrs, hospitalized between 1997 and 2007 with creatinine of 0.80-1.30 mg/dL. Interventions: None. Measurements: Blood urea nitrogen at intensive care unit admission was categorized as 10-20, 20-40, and >40 mg/dL. Logistic regression examined death at days 30, 90, and 365 after intensive care unit admission as well as in-hospital mortality. Adjusted odds ratios were estimated by multivariable logistic regression models. Main Results: Blood urea nitrogen at intensive care unit admission was predictive for short-and long-term mortality independent of creatinine. Thirty days following intensive care unit admission, patients with blood urea nitrogen of >40 mg/dL had an odds ratio for mortality of 5.12 (95% confidence interval, 4.30-6.09; p<.0001) relative to patients with blood urea nitrogen of 10-20 mg/dL. Blood urea nitrogen remained a significant predictor of mortality at 30 days after intensive care unit admission following multivariable adjustment for confounders; patients with blood urea nitrogen of >40 mg/dL had an odds ratio for mortality of 2.78 (95% confidence interval, 2.27-3.39; p<.0001) relative to patients with blood urea nitrogen of 10-20 mg/dL. Thirty days following intensive care unit admission, patients with blood urea nitrogen of 20-40 mg/dL had an odds ratio of 2.15 (95% confidence interval, 1.98-2.33; <.0001) and a multivariable odds ratio of 1.53 (95% confidence interval, 1.40-1.68; p <.0001) relative to patients with blood urea nitrogen of 10-20 mg/dL. Results were similar at 90 and 365 days following intensive care unit admission as well as for in-hospital mortality. A subanalysis of patients with blood cultures (n = 7,482) demonstrated that blood urea nitrogen at intensive care unit admission was associated with the risk of blood culture positivity. Conclusion: Among critically ill patients with creatinine of 0.8-1.3 mg/dL, an elevated blood urea nitrogen was associated with increased mortality, independent of serum creatinine. (Crit Care Med 2011; 39: 305-313) C1 [Beier, Kevin] Harvard Univ, Sch Med, Dept Genet, Cambridge, MA 02138 USA. [Eppanapally, Sabitha; Chang, Domingo; Mahadevappa, Karthik; Christopher, Kenneth B.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Bazick, Heidi S.] Massachusetts Gen Hosp, Dept Anesthesiol, Boston, MA 02114 USA. [Gibbons, Fiona K.] Massachusetts Gen Hosp, Div Pulm, Boston, MA 02114 USA. RP Beier, K (reprint author), Harvard Univ, Sch Med, Dept Genet, Cambridge, MA 02138 USA. EM kbchristopher@partners.org FU National Institutes of Health [5K08AI060881] FX Supported, in part, by the National Institutes of Health (5K08AI060881 to KC). NR 73 TC 33 Z9 35 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2011 VL 39 IS 2 BP 305 EP 313 DI 10.1097/CCM.0b013e3181ffe22a PG 9 WC Critical Care Medicine SC General & Internal Medicine GA 709GN UT WOS:000286426400010 PM 21099426 ER PT J AU Rosenbach, AE Koria, P Goverman, J Kotz, KT Gupta, A Yu, M Fagan, SP Irimia, D Tompkins, RG AF Rosenbach, Alan E. Koria, Piyush Goverman, Jeremy Kotz, Kenneth T. Gupta, Amit Yu, Ming Fagan, Shawn P. Irimia, Daniel Tompkins, Ronald G. TI Microfluidics for T-Lymphocyte Cell Separation and Inflammation Monitoring in Burn Patients SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE LA English DT Article DE antibodies; cytokines; immune system; immunocompromised hosts; lymphocytes; translational research ID CYTOKINE GENE-EXPRESSION; RHEUMATOID-ARTHRITIS; TRAUMA; DISEASE; PCR AB Severe burns result in T lymphocyte specific immunologic changes. In addition to decreased levels of circulating lymphocytes, changes in cytokine secretion and receptor expression also take place. Our finer understanding of the inflammatory response has led to the development of immune-targeted therapeutics, requiring specialized gene-expression monitoring. The emerging field of bio-micro-electromechanical systems can be used to isolate highly pure T lymphocytes in a clinically relevant and timely manner for downstream genomic analysis. Blood samples from healthy volunteers and burn-injured patients were introduced into microfluidic devices developed in our laboratory. Utilizing cell-affinity chromatography for positive selection of T lymphocytes, the devices served as a platform for RNA extraction and downstream cytokine analysis via quantitative real-time polymerase chain reaction (PCR). From a 0.5-mL whole blood sample, the microfluidic devices captured highly pure T lymphocytes from healthy volunteers and burn-injured patients. Cell capture was of sufficient quantity, and extracted RNA was of sufficient quality, for evaluating the gene expression of cytokines: interferon-gamma, interleukin-2, interleukin-4, and interleukin-10. Microfluidics is a useful tool in processing blood from burn-injured patients. Though in its very early stages of development, cell-specific information obtained by this platform/technology will likely be an important component of near-patient molecular diagnostics and personalized medicine. Clin Trans Sci 2011; Volume 4: 63-68 C1 [Rosenbach, Alan E.; Koria, Piyush; Goverman, Jeremy; Kotz, Kenneth T.; Gupta, Amit; Yu, Ming; Fagan, Shawn P.; Irimia, Daniel; Tompkins, Ronald G.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Shriners Hosp Children, Boston, MA 02115 USA. RP Rosenbach, AE (reprint author), Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Shriners Hosp Children, Boston, MA 02115 USA. EM alanrosenbach@hotmail.com OI Irimia, Daniel/0000-0001-7347-2082 FU NIH [T32 GM-007035]; US NIH [U54 GM-062119]; BioMEMS Resource Center [P41 EB-002503] FX AER was supported by a NIH training grant T32 GM-007035. These studies were supported by the US NIH Inflammation and the Host Response to Injury Large scale Collaborative Project, U54 GM-062119, BioMEMS Resource Center P41 EB-002503. Technical assistance from Octavio Hurtado and Dr. Charles Vanderburg was greatly appreciated. NR 20 TC 5 Z9 5 U1 2 U2 20 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1752-8054 J9 CTS-CLIN TRANSL SCI JI CTS-Clin. Transl. Sci. PD FEB PY 2011 VL 4 IS 1 BP 63 EP 68 DI 10.1111/j.1752-8062.2010.00255.x PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 725RB UT WOS:000287662500017 PM 21348958 ER PT J AU Quant, EC Wen, PY AF Quant, Eudocia C. Wen, Patrick Y. TI Response Assessment in Neuro-Oncology SO CURRENT ONCOLOGY REPORTS LA English DT Article DE Response criteria; Response assessment; Radiographic response; Macdonald criteria; RANO criteria; High-grade glioma; Low-grade glioma; Meningioma; Brain metastases; Vestibular schwannomas ID BEVACIZUMAB PLUS IRINOTECAN; PHASE-II TRIAL; RECURRENT MALIGNANT GLIOMA; BRAIN METASTASES; NEUROFIBROMATOSIS TYPE-2; BREAST-CANCER; CONCOMITANT RADIOCHEMOTHERAPY; DISEASE PROGRESSION; RADIATION-THERAPY; CLINICAL-TRIALS AB Accuracy and reproducibility in determining response to therapy and tumor progression can be difficult to achieve for nervous system tumors. Current response criteria vary depending on the pathology and have several limitations. Until recently, the most widely used criteria for gliomas were "Macdonald criteria," based on two-dimensional tumor measurements on neuroimaging studies. However, the Response Assessment in Neuro-Oncology (RANO) Working Group has published new recommendations in high-grade gliomas and is working on recommendations for other nervous system tumors. This article reviews current response criteria for high-grade glioma, low-grade glioma, brain metastasis, meningioma, and schwannoma. C1 [Quant, Eudocia C.; Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Dept Med Oncol, Ctr Neurooncol, Boston, MA 02115 USA. RP Wen, PY (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Med Oncol, Ctr Neurooncol, SW430D,44 Binney St, Boston, MA 02115 USA. EM equant@partners.org; pwen@partners.org NR 51 TC 45 Z9 45 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3790 J9 CURR ONCOL REP JI Curr. Oncol. Rep. PD FEB PY 2011 VL 13 IS 1 BP 50 EP 56 DI 10.1007/s11912-010-0143-y PG 7 WC Oncology SC Oncology GA 723JG UT WOS:000287502100008 PM 21086192 ER PT J AU Musch, G AF Musch, Guido TI Positron emission tomography: a tool for better understanding of ventilator-induced and acute lung injury SO CURRENT OPINION IN CRITICAL CARE LA English DT Review DE acute lung injury; adult respiratory distress syndrome; artificial respiration; mechanical ventilators; positive-pressure respiration; positron emission tomography ID RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; PULMONARY PERFUSION; PRONE POSITION; REGIONAL VENTILATION; NITRIC-OXIDE; FDG-PET; INFLAMMATION; KINETICS; ENDOTOXIN AB Purpose of review PET has recently gained traction among several groups of investigators as an imaging tool to study lung pathophysiology in vivo noninvasively on a regional basis. This review aims to present the major findings of PET studies on acute lung injury (ALI) and ventilator-induced lung injury (VILI) with a perspective relevant to the physiologist-intensivist. Recent findings Using various tracers, PET has been used to investigate the relationship between the distributions of pulmonary perfusion, ventilation and aeration, and the effect of positive end-expiratory pressure, recruitment maneuvers, prone positioning, and endotoxin on these distributions in ALI. More recently, PET with 2-[(18)F]fluoro-2-deoxy-D-glucose has been used to measure regional neutrophil metabolic activation in ALI and VILI. Because gas exchange impairment and inflammation are two hallmarks of ALI and VILI, these studies have provided significant insights into the pathophysiology of these conditions. Summary PET is a versatile imaging tool for physiologic investigation. By imaging the regional effects of interventions commonly performed in critically ill patients with ALI, PET has improved our understanding of the mechanism by which such interventions can exert their positive or negative effects as well as of the pathophysiology of ALI and VILI. C1 [Musch, Guido] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Musch, Guido] Harvard Univ, Sch Med, Boston, MA USA. RP Musch, G (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, GRJ-418,55 Fruit St, Boston, MA 02114 USA. EM guido.musch@gmail.com FU National Institutes of Health [5K08HL076464, 1R01HL094639]; Foundation for Anesthesia Education and Research; American Society of Critical Care Anesthesiologists; Harvard Medical School; Shriners Hospitals for Children; Shriners Burns Institute, Boston FX The present work was supported by National Institutes of Health Grants 5K08HL076464 and 1R01HL094639, by a Research Grant from the Foundation for Anesthesia Education and Research and the American Society of Critical Care Anesthesiologists, by Harvard Medical School's Eleanor and Miles Shore 50th Anniversary Fellowship, and by a grant from Shriners Hospitals for Children and Shriners Burns Institute, Boston. NR 38 TC 6 Z9 6 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-5295 J9 CURR OPIN CRIT CARE JI Curr. Opin. Crit. Care PD FEB PY 2011 VL 17 IS 1 BP 7 EP 12 DI 10.1097/MCC.0b013e32834272ab PG 6 WC Critical Care Medicine SC General & Internal Medicine GA 700GM UT WOS:000285726000002 PM 21169828 ER PT J AU Villar, J Blanco, J Kacmarek, RM AF Villar, Jesus Blanco, Jesus Kacmarek, Robert M. TI Acute respiratory distress syndrome definition: do we need a change? SO CURRENT OPINION IN CRITICAL CARE LA English DT Review DE acute lung injury; acute respiratory distress syndrome; biomarker; lung inflammation; PaO(2)/FiO(2) ratio; positive end-expiratory pressure ID ACUTE LUNG INJURY; ARDS; METAANALYSIS; PRESSURE; OUTCOMES AB Purpose of review Since the first description of the acute respiratory distress syndrome (ARDS) in 1967, no specific clinical sign or diagnostic test has yet been described that identifies ARDS. Its diagnosis is based on a combination of clinical, hemodynamic, and oxygenation criteria. The purpose of this review is to examine the current definition for ARDS and to discuss why this definition may not be the most appropriate definition for this syndrome. Recent findings We will briefly review our current understanding of ARDS, discuss the problems with its current diagnosis, and present clinical, pathological, and biochemical evidences supporting a more appropriate definition for ARDS. In addition, we will discuss recent efforts to identify biological markers for lung injury in pulmonary edema fluid and blood collected from critically ill patients. Summary On the basis of current evidence, it is time for a change in the ARDS definition. A newer classification system that recognizes different severities of pulmonary dysfunction is needed. Such a system should be able to identify patients that would be most responsive to supportive therapies and those unlikely to benefit because of the severity of their disease. C1 [Villar, Jesus] Hosp Univ Dr Negrin, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Res Unit, Las Palmas Gran Canaria 35010, Canary Islands, Spain. [Villar, Jesus; Blanco, Jesus] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain. [Villar, Jesus] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada. [Blanco, Jesus] Hosp Univ Rio Hortega, Intens Care Unit, Valladolid, Spain. [Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Kacmarek, Robert M.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. RP Villar, J (reprint author), Hosp Univ Dr Negrin, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Res Unit, Barranco de la Ballena S-N,4th Floor,South Wing, Las Palmas Gran Canaria 35010, Canary Islands, Spain. EM jesus.villar54@gmail.com FU Fondo de Investigaciones Sanitarias, Spain [07/0113]; CIBERES [CB06/06/1088] FX Funding of this review is supported in part by grants from Fondo de Investigaciones Sanitarias, Spain (07/0113) and from CIBERES (CB06/06/1088). NR 22 TC 13 Z9 19 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-5295 J9 CURR OPIN CRIT CARE JI Curr. Opin. Crit. Care PD FEB PY 2011 VL 17 IS 1 BP 13 EP 17 DI 10.1097/MCC.0b013e32834271fb PG 5 WC Critical Care Medicine SC General & Internal Medicine GA 700GM UT WOS:000285726000003 PM 21150586 ER PT J AU Levitsky, LL AF Levitsky, Lynne L. TI Auxology and obesity SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY LA English DT Editorial Material C1 MassGen Hosp Children, Pediat Endocrine Unit, Boston, MA 02111 USA. RP Levitsky, LL (reprint author), MassGen Hosp Children, Pediat Endocrine Unit, 5th Floor,175 Cambridge St, Boston, MA 02111 USA. EM LLevitsky@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1752-296X J9 CURR OPIN ENDOCRINOL JI Curr. Opin. Endocrinol. Diabetes Obes. PD FEB PY 2011 VL 18 IS 1 BP 1 EP 2 DI 10.1097/MED.0b013e3283427bd4 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 697TW UT WOS:000285542100001 PM 21178690 ER PT J AU Marino, R AF Marino, Rose TI Growth plate biology: new insights SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY LA English DT Article DE chondrocytes; endochondrial bone growth; growth plate ID ENDOCHONDRAL BONE-FORMATION; CHONDROCYTE DIFFERENTIATION; THYROID-HORMONE; EXPRESSION; STIMULATION; HYPERTROPHY; MODULATION; POLARITY; PTHRP AB Purpose of review To discuss the most recent findings of growth plate regulation and physiology. The mechanism of endochondrial bone growth is incompletely understood and continues to be an active area of research. Recent findings In this review, new understandings of growth plate chondrocyte regulation of proliferation, differentiation and ossification are discussed. Through genetic studies potential signaling pathways are proposed and new insights into hormonal influences on growth are offered. New potential genetic pathways regulating growth are suggested and finally skeletal dysplasia and potential emerging treatment are considered. Summary The findings discussed here continue to build the understanding of the mechanisms of growth. As our knowledge increases potential treatments for growth inhibiting conditions can be developed. C1 Massachusetts Gen Hosp, Div Pediat Endocrinol, Boston, MA 02114 USA. RP Marino, R (reprint author), Massachusetts Gen Hosp, Div Pediat Endocrinol, 55 Fruit St, Boston, MA 02114 USA. EM rmarino1@partners.org NR 30 TC 2 Z9 3 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1752-296X J9 CURR OPIN ENDOCRINOL JI Curr. Opin. Endocrinol. Diabetes Obes. PD FEB PY 2011 VL 18 IS 1 BP 9 EP 13 DI 10.1097/MED.0b013e3283423df9 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 697TW UT WOS:000285542100003 PM 21157322 ER PT J AU Yan, N Lieberman, J AF Yan, Nan Lieberman, Judy TI Gaining a foothold: how HIV avoids innate immune recognition SO CURRENT OPINION IN IMMUNOLOGY LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMACYTOID DENDRITIC CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AICARDI-GOUTIERES-SYNDROME; CD4(+) T-CELLS; VAGINAL TRANSMISSION; EXONUCLEASE TREX1; LANGERHANS CELLS; RHESUS MACAQUES; DC-SIGN AB During the first week after sexual exposure to HIV, HIV infection does not appear to trigger a strong innate immune response. Here we describe some recent studies that show that HIV may avoid triggering antiviral innate immune responses by not replicating efficiently in dendritic cells and by avoiding detection in infected CD4 T cells and macrophages by harnessing a host cytoplasmic DNase TREX1 to digest nonproductive HIV reverse transcripts. C1 [Lieberman, Judy] Childrens Hosp Boston, Immune Dis Inst, Boston, MA 02115 USA. Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Lieberman, J (reprint author), Childrens Hosp Boston, Immune Dis Inst, Boston, MA 02115 USA. EM lieberman@idi.harvard.edu RI Lieberman, Judy/A-2717-2015 FU NIH [AI045587] FX This work was supported by NIH AI045587 (JL) and an NIH training grant (NY). NR 89 TC 20 Z9 20 U1 1 U2 3 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0952-7915 J9 CURR OPIN IMMUNOL JI Curr. Opin. Immunol. PD FEB PY 2011 VL 23 IS 1 BP 21 EP 28 DI 10.1016/j.coi.2010.11.004 PG 8 WC Immunology SC Immunology GA 736CN UT WOS:000288467700004 PM 21123040 ER PT J AU Shapira, SD Hacohen, N AF Shapira, Sagi D. Hacohen, Nir TI Systems biology approaches to dissect mammalian innate immunity SO CURRENT OPINION IN IMMUNOLOGY LA English DT Review ID NF-KAPPA-B; GENOME-WIDE ASSOCIATION; TRANSCRIPTIONAL NETWORK; INFLUENZA-VIRUS; TUBERCULOSIS; INFECTION; DISEASES; PATHOGEN; CELLS; MAP AB Advances in experimental tools have allowed for the systematic identification of components and biological processes as well as quantification of their activities over time. Together with computational analysis, these measurement and perturbation technologies have given rise to the field of systems biology, which seeks to discover, analyze and model the interactions of physical components in a biological system. Although in its infancy, recent application of this approach has resulted in novel insights into the machinery that regulates and modifies innate immune cell functions. Here, we summarize contributions that have been made through the unbiased interrogation of the mammalian innate immune system, emphasizing the importance of integrating orthogonal datasets into models. To enable application of approaches more broadly, however, a concerted effort across the immunology community to develop reagent and tool platforms will be required. C1 [Shapira, Sagi D.; Hacohen, Nir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA. [Shapira, Sagi D.; Hacohen, Nir] 7 Cambridge Ctr, Broad Inst, Cambridge, MA 02142 USA. [Shapira, Sagi D.; Hacohen, Nir] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Hacohen, N (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, 149 13th St, Charlestown, MA 02129 USA. EM nhacohen@partners.org FU National Institutes of Health [AI074575, OD002230, AI057159] FX We would like to thank members of the lab for discussions and the National Institutes of Health grants AI074575, OD002230 and AI057159 for support of our work. NR 47 TC 24 Z9 25 U1 0 U2 10 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0952-7915 J9 CURR OPIN IMMUNOL JI Curr. Opin. Immunol. PD FEB PY 2011 VL 23 IS 1 BP 71 EP 77 DI 10.1016/j.coi.2010.10.022 PG 7 WC Immunology SC Immunology GA 736CN UT WOS:000288467700011 PM 21111589 ER PT J AU Lukacs-Kornek, V Turley, SJ AF Lukacs-Kornek, Veronika Turley, Shannon J. TI Self-antigen presentation by dendritic cells and lymphoid stroma and its implications for autoimmunity SO CURRENT OPINION IN IMMUNOLOGY LA English DT Review ID FIBROBLASTIC RETICULAR CELLS; REGULATORY T-CELLS; TOLERANCE IN-VIVO; CUTTING EDGE; STEADY-STATE; PERIPHERAL TOLERANCE; CROSS-PRESENTATION; TISSUE ANTIGENS; TGF-BETA; NODE AB The induction and maintenance of T cell tolerance is essential to prevent autoimmunity. A combination of central and peripheral mechanisms acts to control autoreactive T cells. In secondary lymphoid organs, dendritic cells (DCs) presenting self-antigen were thought to play a major role in the induction of peripheral T cell tolerance. Multiple recent studies have demonstrated that DCs are not absolutely essential to induce and maintain tolerance. Furthermore, it has also been recently shown that non-hematopoietic stromal cells expressing peripheral tissue-restricted antigens can induce T cell tolerance, independently of DCs. Together these studies imply that peripheral tolerance is more complex than previously thought and a consequence of the tolerogenic functions of the hematopoietic and non-hematopoietic compartments within secondary lymphoid organs. C1 [Lukacs-Kornek, Veronika; Turley, Shannon J.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Turley, Shannon J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Turley, SJ (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. EM Shannon_Turley@dfci.harvard.edu FU National Institutes of Health [R01 DK074500, P01 AI045757]; Baruj Benaceraff Postdoctoral Fellowship FX This work was supported by National Institutes of Health Grants (R01 DK074500 and P01 AI045757) (to S.J.T.), and Baruj Benaceraff Postdoctoral Fellowship (to V.L.-K). The authors thank Miroslaw Kornek for helping to design the figure. NR 57 TC 12 Z9 12 U1 0 U2 5 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0952-7915 J9 CURR OPIN IMMUNOL JI Curr. Opin. Immunol. PD FEB PY 2011 VL 23 IS 1 BP 138 EP 145 DI 10.1016/j.coi.2010.11.012 PG 8 WC Immunology SC Immunology GA 736CN UT WOS:000288467700021 PM 21168318 ER PT J AU Tucker, JD Cohen, MS AF Tucker, Joseph D. Cohen, Myron S. TI China's syphilis epidemic: epidemiology, proximate determinants of spread, and control responses SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE China; MSM; sex worker; social; syphilis ID FEMALE SEX WORKERS; SEXUALLY-TRANSMITTED-DISEASES; REPUBLIC-OF-CHINA; CONGENITAL-SYPHILIS; SOCIAL UPHEAVAL; RISK BEHAVIORS; RURAL MIGRANTS; HIV; MEN; PREVALENCE AB Purpose of review China has experienced an increase in the incidence and prevalence of syphilis that is especially remarkable since this infection was virtually eradicated in the country 50 years ago. The purpose of this analysis is to provide an overview of recent literature on syphilis proximate determinants and potential public health responses. Recent findings Per capita syphilis burden is greatest in coastal urban China. There are a number of biological, demographic, geographic, and behavioral/social proximate determinants of syphilis spread that distinguish the Chinese syphilis epidemic. These determinants portend the need for intensified syphilis control efforts, including: comprehensive testing and treatment; integration with HIV, sexually transmitted infection, and antenatal services; scale-up of novel rapid syphilis test technology, and multisectorial support. Summary The Chinese central government recently announced a 10-year syphilis plan to provide clear expectations for evaluating the success of local syphilis control programs and integration with HIV testing programs. Further research is needed to understand the social and behavioral determinants driving the spread of syphilis. C1 [Tucker, Joseph D.] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02139 USA. [Tucker, Joseph D.; Cohen, Myron S.] UNC Chapel Hill Sch Med, Div Infect Dis, Chapel Hill, NC USA. [Tucker, Joseph D.] Guangdong Prov Ctr STI & Skin Dis Control, STD Control Dept, Guangzhou, Guangdong, Peoples R China. RP Tucker, JD (reprint author), Massachusetts Gen Hosp, Infect Dis Unit, GRJ-504, Boston, MA 02139 USA. EM jtucker4@partners.org FU National Institutes of Health (NIH) [US NIH 1K01TW008200-01A1]; University of North Carolina (UNC) [NIH FIC D43 TW01039]; UNC Social Science Research on HIV/AIDS in China [R24 HD056670-01]; UNC Center for AIDS Research; Harvard Institute for Global Health FX The authors would like to thank Brian Vicini for administrative help and Professor Xiang-Sheng Chen (National Center for STD Control, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology, Nanjing, China) for comments on an earlier draft of this manuscript. We acknowledge a National Institutes of Health (NIH) Fogarty K01 Award (US NIH 1K01TW008200-01A1), the University of North Carolina (UNC) Fogarty AIDS International Research and Training Program (NIH FIC D43 TW01039), the UNC Social Science Research on HIV/AIDS in China (NIH NICHD R24 HD056670-01), the UNC Center for AIDS Research, and the Harvard Institute for Global Health. NR 47 TC 37 Z9 46 U1 6 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD FEB PY 2011 VL 24 IS 1 BP 50 EP 55 DI 10.1097/QCO.0b013e32834204bf PG 6 WC Infectious Diseases SC Infectious Diseases GA 698FY UT WOS:000285580500008 PM 21150594 ER EF